molregno,hit_paper,hit_title,drug_paper,drug_title,pattern_count
21716,10.1016/j.bmcl.2015.10.100,Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.,10.1016/j.bmcl.2019.03.021,Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.,5
365189,10.1021/acs.jmedchem.7b01347,Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.,10.1021/acs.jmedchem.4c00441,"Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-<i>d</i>]pyrimidine-4, 7(<i>3H</i>, <i>8H</i>)-dione Compounds.",4
316347,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/jm5019719,Prodrugs of reverse fosmidomycin analogues.,4
316347,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.1c00659,Novel Antiplasmodial Compounds Leveraged with Multistage Potency against the Parasite <i>Plasmodium falciparum</i>: <i>In Vitro</i> and <i>In Vivo</i> Evaluations and Pharmacokinetic Studies.,4
365189,10.1021/acs.jmedchem.7b01347,Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.,10.1021/acs.jmedchem.0c01727,Antitubercular 2-Pyrazolylpyrimidinones: Structure-Activity Relationship and Mode-of-Action Studies.,4
316347,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1039/C8MD00382C,Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.,4
316347,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/jm500811p,Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.,4
316347,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/acs.jmedchem.5b01605,A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.,4
316347,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",4
316347,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/acs.jmedchem.7b00140,3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.,4
419032,10.1016/j.bmcl.2014.03.100,Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization.,10.1016/j.ejmech.2014.09.065,Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.,4
316347,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",4
29890,10.1021/jm400305d,Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.,10.1021/acs.jmedchem.0c01023,From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.,4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/jm500811p,Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.,4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1039/C8MD00382C,Antiplasmodial imidazopyridazines: structure-activity relationship studies lead to the identification of analogues with improved solubility and hERG profiles.,4
6579,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1039/d3md00490b,Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of <i>Plasmodial</i> cysteine protease inhibitors for the treatment of malaria.,4
6579,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/acs.jmedchem.0c00858,"Synthesis, Structure-Activity Relationship, and Antimalarial Efficacy of 6-Chloro-2-arylvinylquinolines.",4
6579,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/acs.jmedchem.5b01605,A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.,4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1016/j.ejmech.2018.03.024,Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.,4
6579,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/acs.jmedchem.7b00140,3-Hydroxy-N'-arylidenepropanehydrazonamides with Halo-Substituted Phenanthrene Scaffolds Cure P. berghei Infected Mice When Administered Perorally.,4
6579,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,10.1021/jm5019719,Prodrugs of reverse fosmidomycin analogues.,4
6579,10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,10.1021/acs.jmedchem.0c01411,"Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model.",4
4941,10.1021/acs.jmedchem.7b01347,Novel Antitubercular 6-Dialkylaminopyrimidine Carboxamides from Phenotypic Whole-Cell High Throughput Screening of a SoftFocus Library: Structure-Activity Relationship and Target Identification Studies.,10.1021/acs.jmedchem.4c00441,"Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-<i>d</i>]pyrimidine-4, 7(<i>3H</i>, <i>8H</i>)-dione Compounds.",4
250483,10.1021/jm0301641,"A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.",10.1016/j.bmcl.2008.02.069,"TIE-2/VEGF-R2 SAR and in vitro activity of C3-acyl dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs.",3
686684,10.1016/j.ejmech.2014.03.061,"Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.",10.1021/acs.jmedchem.6b00912,"Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.",3
686684,10.1016/j.ejmech.2014.03.061,"Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.",10.1016/j.ejmech.2017.07.080,Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.,3
444750,10.1016/j.bmcl.2011.04.027,The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening.,10.1016/j.bmcl.2011.10.116,"3-mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors.",3
444750,10.1016/j.bmcl.2011.04.027,The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening.,10.1016/j.bmc.2022.116964,"1,2,4-Triazole-3-thione analogues with an arylakyl group at position 4 as metallo-β-lactamase inhibitors.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.bmcl.2016.11.003,Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.,3
1447148,10.1021/jm300952s,"Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.",10.1021/acs.jmedchem.0c01851,FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.,3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",3
1281325,10.1021/jm3001289,Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.,10.1021/acs.jmedchem.3c01802,Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.,3
1281325,10.1021/jm3001289,Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.,10.1021/jm3009234,Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.,3
1281325,10.1021/jm3001289,Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.,10.1021/acsmedchemlett.6b00518,Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.,3
365189,10.1021/jm400485e,Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.,10.1021/acs.jmedchem.0c00520,Discovery of Antibacterials That Inhibit Bacterial RNA Polymerase Interactions with Sigma Factors.,3
250604,10.1021/jm0301641,"A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.",10.1021/jm201449n,"Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.",3
2220139,10.1021/acs.jmedchem.7b01375,"Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497).",10.1016/j.bmc.2022.116614,Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,3
717,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,3
717,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1021/acsmedchemlett.5b00173,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",3
122252,10.1016/j.bmcl.2010.06.138,Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.,10.1021/jm4011669,Adenosine A2A receptor as a drug discovery target.,3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.bmcl.2016.09.043,Identification and optimization of a new series of anti-tubercular quinazolinones.,3
365189,10.1016/j.bmcl.2016.09.043,Identification and optimization of a new series of anti-tubercular quinazolinones.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.3c00570,Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",3
2013100,10.1016/j.ejmech.2022.114233,Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification.,10.1016/j.ejmech.2022.115014,"Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.",3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2019.07.062,"Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.",3
2013100,10.1016/j.ejmech.2022.114233,Metabolomics-assisted discovery of a new anticancer GLS-1 inhibitor chemotype from a nortopsentin-inspired library: From phenotype screening to target identification.,10.1016/j.ejmech.2023.115306,Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,3
122252,10.1016/j.bmcl.2010.06.138,Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.,10.1021/jm1008659,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",3
2095675,10.1016/j.ejmech.2023.115130,"""Hit"" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.",10.1016/j.ejmech.2023.115762,"Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.",3
2122083,10.1021/acs.jmedchem.1c01356,"Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders.",10.1016/j.bmcl.2023.129362,Discovery of novel pyridinones as MGAT2 inhibitors for the treatment of metabolic disorders.,3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2022.114947,"Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors.",3
365189,10.1021/jm400485e,Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.,10.1016/j.ejmech.2020.112671,Benzyl and benzoyl benzoic acid inhibitors of bacterial RNA polymerase-sigma factor interaction.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2014.01.058,"Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors.",3
1817650,10.1021/jm5012885,Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic.,10.1021/acs.jmedchem.8b00855,Discovery of a Potent Thiazolidine Free Fatty Acid Receptor 2 Agonist with Favorable Pharmacokinetic Properties.,3
1821836,10.1021/jm500809c,Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis.,10.1016/j.ejmech.2023.115550,Exploring N-myristoyltransferase as a promising drug target against parasitic neglected tropical diseases.,3
1823118,10.1021/ml500387y,Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidate.,10.1021/acs.jmedchem.7b01690,Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile.,3
1926957,10.1021/acs.jmedchem.7b00408,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",10.1021/acs.jmedchem.0c02249,Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139.,3
1926957,10.1021/acs.jmedchem.7b00408,"4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.",10.1016/j.ejmech.2023.115234,From lead to clinic: A review of the structural design of P2X7R antagonists.,3
1173912,10.1016/j.bmcl.2011.04.077,"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.",10.1016/j.bmcl.2011.06.117,"Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.",3
1173912,10.1016/j.bmcl.2011.04.077,"Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.",10.1021/acs.jmedchem.0c02249,Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139.,3
717,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1021/jm201059s,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,3
103658,10.1016/j.bmc.2010.09.041,Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.,10.1016/j.bmcl.2011.05.022,Flavonoids as inhibitors of human CD38.,3
410123,10.1016/j.bmcl.2010.06.138,Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.,10.1021/jm4011669,Adenosine A2A receptor as a drug discovery target.,3
410123,10.1016/j.bmcl.2010.06.138,Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.,10.1021/jm1008659,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1039/d3md00316g,"Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.",3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2017.04.031,"Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acs.jmedchem.5b01542,"Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A Novel Antimycobacterial Class Targeting Mycobacterial Respiration.",3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.3c00570,Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.,3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.5b00176,"Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.",3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2019.111883,Synthesis and bioevaluation of 1-phenylimidazole-4-carboxylic acid derivatives as novel xanthine oxidoreductase inhibitors.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2022.114101,Identification of novel xanthine oxidase inhibitors via virtual screening with enhanced characterization of molybdopterin binding groups.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2012.10.029,"Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2016.07.068,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,3
647206,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,3
218011,10.1016/j.bmcl.2007.10.100,Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation.,10.1016/j.bmcl.2008.12.086,Discovery of novel small molecule cell type-specific enhancers of NF-kappaB nuclear translocation.,3
99024,10.1016/j.ejmech.2021.113823,Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.,10.1021/acs.jmedchem.3c01321,"Small Molecule Ligands of the BET-like Bromodomain, <i>Sm</i>BRD3, Affect <i>Schistosoma mansoni</i> Survival, Oviposition, and Development.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",3
365189,10.1016/j.ejmech.2013.04.060,"Novel small molecule inhibitors targeting the ""switch region"" of bacterial RNAP: structure-based optimization of a virtual screening hit.",10.1021/jm400485e,Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.,3
514159,10.1016/j.bmcl.2008.09.009,"Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor.",10.1016/j.bmcl.2010.09.087,"Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2017.05.044,"Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives.",3
365679,10.1021/jm060631p,"2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists.",10.1021/jm9013696,"Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",3
419032,10.1016/j.bmc.2014.05.056,Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.,10.1016/j.ejmech.2014.09.065,Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2019.07.062,"Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2012.10.029,"Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2017.06.059,"Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors.",3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2022.114896,Discovery of 1-hydroxy-2-methylquinolin-4(1H)-one derivatives as new cytochrome bd oxidase inhibitors for tuberculosis therapy.,3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2024.116785,Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.,3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acs.jmedchem.8b00172,"Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.",3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.bmcl.2016.11.003,Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.,3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2018.03.020,Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.,3
1763252,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2017.05.021,Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.,3
365189,10.1016/j.ejmech.2013.04.060,"Novel small molecule inhibitors targeting the ""switch region"" of bacterial RNAP: structure-based optimization of a virtual screening hit.",10.1021/acs.jmedchem.5b00050,X-ray crystal structures of Escherichia coli RNA polymerase with switch region binding inhibitors enable rational design of squaramides with an improved fraction unbound to human plasma protein.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2018.01.096,"Design, synthesis and biological evaluation of novel xanthine oxidase inhibitors bearing a 2-arylbenzo[b]furan scaffold.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2017.04.031,"Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.5b00176,"Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.",3
717,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1021/jm501995n,Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1039/d3md00316g,"Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2020.112077,"Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2014.06.014,"Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.",3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmcl.2011.06.113,4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum.,3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2015.03.011,Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.,3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2016.04.059,Looking for new antiplasmodial quinazolines: DMAP-catalyzed synthesis of 4-benzyloxy- and 4-aryloxy-2-trichloromethylquinazolines and their in vitro evaluation toward Plasmodium falciparum.,3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2012.07.034,"Tandem synthesis and in vitro antiplasmodial evaluation of new naphtho[2,1-d]thiazole derivatives.",3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmc.2024.117654,Target fishing reveals PfPYK-1 and PfRab6 as potential targets of an antiplasmodial 4-anilino-2-trichloromethylquinazoline hit compound.,3
78759,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,3
71516,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1021/jm8003653,"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.",3
78169,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,3
71516,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.03.121,Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay.,3
71516,10.1016/j.bmcl.2009.04.009,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group.,10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",3
71516,10.1016/j.bmcl.2009.04.009,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
71516,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
71516,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmc.2009.02.029,Discovery and structure-activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.04.009,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.05.012,"Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2: Structure-activity relationships of the 4-, 5-, 6-, 7- and 8-positions.",3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm070528f,Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.,3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm8003653,"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.",3
71516,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.05.012,"Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2: Structure-activity relationships of the 4-, 5-, 6-, 7- and 8-positions.",3
71516,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm400711t,Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.,3
67617,10.1016/j.bmcl.2016.09.043,Identification and optimization of a new series of anti-tubercular quinazolinones.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/acsmedchemlett.5b00266,Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmcl.2008.11.102,DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/jm300395d,"Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.",3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmc.2008.12.034,"Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.",3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmcl.2012.05.128,Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmc.2015.11.039,Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1039/C8MD00148K,Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmcl.2006.12.065,"Design, synthesis, and structure-activity relationship studies of new phenolic DNA gyrase inhibitors.",3
47209,10.1016/j.bmc.2010.09.041,Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.,10.1016/j.bmcl.2011.05.022,Flavonoids as inhibitors of human CD38.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/jm101121s,ATP-binding site of bacterial enzymes as a target for antibacterial drug design.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmc.2012.02.052,In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/jm1014023,A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.ejmech.2013.09.025,Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmcl.2009.12.060,"In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B.",3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.bmcl.2004.03.044,"Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity.",3
48697,10.1021/jm000017s,"Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening.",10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1021/acs.jmedchem.6b01758,Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1021/jm301538e,"Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.",3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1016/j.ejmech.2015.12.013,Imidazole-based pinanamine derivatives: Discovery of dual inhibitors of the wild-type and drug-resistant mutant of the influenza A virus.,3
717,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1016/j.bmcl.2010.06.034,"Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists.",3
31312,10.1016/j.ejmech.2018.08.026,Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.,10.1016/j.ejmech.2019.05.078,"Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism.",3
36237,10.1021/jm3011838,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,10.1016/j.ejmech.2020.112291,Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1021/jm101334y,Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1021/acs.jmedchem.8b00042,Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1021/acs.jmedchem.5b01910,Discovery of Highly Potent Inhibitors Targeting the Predominant Drug-Resistant S31N Mutant of the Influenza A Virus M2 Proton Channel.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1016/j.ejmech.2010.10.010,Discovery of highly potent agents against influenza A virus.,3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1016/j.bmc.2013.08.014,"New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.",3
27647,10.1021/jm901664a,Identification of hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library.,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,3
26280,10.1021/jm500462x,Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,3
26280,10.1021/jm500462x,Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).,10.1016/j.bmc.2020.115776,"Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.",3
396101,10.1021/acs.jmedchem.1c00466,Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.,10.1021/acs.jmedchem.3c02031,"Development of Potent MALT1 Inhibitors Featuring a Novel ""2-Thioxo-2,3-dihydrothiazolo[4,5-<i>d</i>]pyrimidin-7(6<i>H</i>)-one"" Scaffold for the Treatment of B Cell Lymphoma.",3
23466,10.1021/jm8000289,Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library.,10.1039/C2MD20268A,The advantage of biosensor analysis over enzyme inhibition studies for slow dissociating inhibitors  characterization of hydroxamate-based matrix metalloproteinase-12 inhibitors,3
25047,10.1021/acs.jmedchem.0c00705,Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent <i>In Vitro</i> Antileishmanial Activity: Initial SAR and Assessment of <i>In Vivo</i> Activity.,10.1016/j.ejmech.2021.113458,"Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents.",3
15890,10.1016/j.ejmech.2017.12.052,"Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.",10.1016/j.bmc.2019.115185,"Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.",3
16088,10.1016/j.bmcl.2010.07.091,Identification and hit-to-lead optimization of a novel class of CB1 antagonists.,10.1021/jm4010835,Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.,3
15890,10.1016/j.ejmech.2017.12.052,"Efficacy of 2-hydroxy-3-phenylsulfanylmethyl-[1,4]-naphthoquinone derivatives against different Trypanosoma cruzi discrete type units: Identification of a promising hit compound.",10.1016/j.ejmech.2019.111610,"Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.",3
15890,10.1021/acs.jmedchem.3c01322,High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents.,10.1016/j.bmc.2024.117736,"Optimization of benzenesulfonyl derivatives as anti-Trypanosomatidae agents: Structural design, synthesis, and pharmacological assessment against Trypanosoma cruzi and Leishmania infantum.",3
15890,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,10.1016/j.ejmech.2023.115310,"Structural design, synthesis, and anti-Trypanosomatidae profile of new Pyridyl-thiazolidinones.",3
15890,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm8003653,"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.",3
14440,10.1021/acs.jmedchem.9b01100,"Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells.",10.1021/acs.jnatprod.3c00384,Modified Podophyllotoxin Phenoxyacetamide Phenylacetate Derivatives: Tubulin/AKT1 Dual-Targeting and Potential Anticancer Agents for Human NSCLC.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm070528f,Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.,3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmc.2009.02.029,Discovery and structure-activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2012.04.074,New substituted 4H-chromenes as anticancer agents.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2007.05.004,"Antiproliferative and apoptosis inducing properties of pyrano[3,2-c]pyridones accessible by a one-step multicomponent synthesis.",3
14440,10.1016/j.bmcl.2009.04.009,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.ejmech.2012.11.011,Synthesis of novel chromene derivatives of expected antitumor activity.,3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.04.009,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the carboxamide group.,3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1021/jm8003653,"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.",3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.ejmech.2012.11.011,Synthesis of novel chromene derivatives of expected antitumor activity.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm200410r,Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2012.04.074,New substituted 4H-chromenes as anticancer agents.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.03.121,Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay.,3
14440,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.04.145,"Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers.",3
14440,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.04.145,"Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers.",3
13494,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,10.1021/jm301749y,Colloidal aggregation causes inhibition of G protein-coupled receptors.,3
13494,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,3
13494,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,10.1021/jm901613f,Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs.,3
13494,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,3
12428,10.1021/jm500462x,Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099).,10.1016/j.bmc.2020.115776,"Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.",3
11305,10.1021/jm3011838,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,3
11305,10.1021/jm3011838,Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.,10.1016/j.ejmech.2020.112291,Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.,3
11305,10.1016/j.bmcl.2006.10.045,Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,3
11305,10.1016/j.bmcl.2006.10.048,Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.,10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,3
8873,10.1016/j.ejmech.2023.115445,Hit-to-lead optimization of a pyrazinylpiperazine series against Leishmania infantum and Leishmania braziliensis.,10.1016/j.bmc.2024.117736,"Optimization of benzenesulfonyl derivatives as anti-Trypanosomatidae agents: Structural design, synthesis, and pharmacological assessment against Trypanosoma cruzi and Leishmania infantum.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2007.05.098,"Discovery of 5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-7-phenyl-(E)-2,3,6,7-tetrahydro-1,4-thiazepines as a new series of apoptosis inducers using a cell- and caspase-based HTS assay.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm200410r,Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.,3
8062,10.1021/acs.jmedchem.9b01100,"Identification of 2,6-Disubstituted 3H-Imidazo[4,5-b]pyridines as Therapeutic Agents for Dysferlinopathies through Phenotypic Screening on Patient-Derived Induced Pluripotent Stem Cells.",10.1021/acs.jnatprod.3c00384,Modified Podophyllotoxin Phenoxyacetamide Phenylacetate Derivatives: Tubulin/AKT1 Dual-Targeting and Potential Anticancer Agents for Human NSCLC.,3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2012.04.074,New substituted 4H-chromenes as anticancer agents.,3
8062,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmc.2017.05.057,"Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents.",3
8062,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2012.04.074,New substituted 4H-chromenes as anticancer agents.,3
8062,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmc.2009.02.029,Discovery and structure-activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers.,3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.05.012,"Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2: Structure-activity relationships of the 4-, 5-, 6-, 7- and 8-positions.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",3
8062,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,3
8062,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",10.1016/j.bmcl.2009.05.012,"Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2: Structure-activity relationships of the 4-, 5-, 6-, 7- and 8-positions.",3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm400711t,Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids.,3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,3
8062,10.1021/jm049640t,Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.,10.1021/jm701499n,"Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones.",3
6936,10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,10.1016/j.bmc.2017.10.017,Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.bmcl.2010.08.043,Bis-alkylamine quindolone derivatives as new antimalarial leads.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.bmc.2010.08.001,"Synthesis, antimalarial activity, and cellular toxicity of new arylpyrrolylaminoquinolines.",3
6787,10.1016/j.bmcl.2008.02.006,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmc.2024.117654,Target fishing reveals PfPYK-1 and PfRab6 as potential targets of an antiplasmodial 4-anilino-2-trichloromethylquinazoline hit compound.,3
365189,10.1016/j.ejmech.2013.04.060,"Novel small molecule inhibitors targeting the ""switch region"" of bacterial RNAP: structure-based optimization of a virtual screening hit.",10.1016/j.bmcl.2020.127146,"Design, synthesis and biological evaluation of novel hybrids of N-aryl pyrrothine-base α-pyrone as bacterial RNA polymerase inhibitors.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2017.09.051,"Design, synthesis and biological evaluation of N-(4-alkoxy-3-cyanophenyl)isonicotinamide/nicotinamide derivatives as novel xanthine oxidase inhibitors.",3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2014.06.014,"Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.",3
6579,10.1016/j.ejmech.2015.08.044,Discovery and optimisation studies of antimalarial phenotypic hits.,10.1016/j.ejmech.2020.112889,Discovery of fast-acting dual-stage antimalarial agents by profiling pyridylvinylquinoline chemical space via copper catalyzed azide-alkyne cycloadditions.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1021/acsmedchemlett.8b00496,Hybridization of Fluoro-amodiaquine (FAQ) with Pyrimidines: Synthesis and Antimalarial Efficacy of FAQ-Pyrimidines.,3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acs.jmedchem.8b00172,"Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.",3
1567700,10.1016/j.bmcl.2015.06.067,"Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.",10.1016/j.bmcl.2015.06.078,"Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.",3
6579,10.1021/ml400015f,Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties.,10.1021/acsmedchemlett.7b00391,Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.ejmech.2017.10.051,"Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent.",3
1567700,10.1016/j.bmcl.2015.06.078,"Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.",10.1016/j.bmcl.2015.06.067,"Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.",3
365189,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",3
365189,10.1021/jm400485e,Discovery of novel bacterial RNA polymerase inhibitors: pharmacophore-based virtual screening and hit optimization.,10.1021/acs.jmedchem.5b00050,X-ray crystal structures of Escherichia coli RNA polymerase with switch region binding inhibitors enable rational design of squaramides with an improved fraction unbound to human plasma protein.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,3
444750,10.1016/j.bmcl.2011.04.027,The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening.,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,3
6579,10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,10.1039/d3md00490b,Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of <i>Plasmodial</i> cysteine protease inhibitors for the treatment of malaria.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2012.07.034,"Tandem synthesis and in vitro antiplasmodial evaluation of new naphtho[2,1-d]thiazole derivatives.",3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmcl.2011.06.113,4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.ejmech.2010.12.003,4-anilinoquinoline triazines: a novel class of hybrid antimalarial agents.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2016.04.059,Looking for new antiplasmodial quinazolines: DMAP-catalyzed synthesis of 4-benzyloxy- and 4-aryloxy-2-trichloromethylquinazolines and their in vitro evaluation toward Plasmodium falciparum.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.bmcl.2012.06.010,Benzoheterocyclic amodiaquine analogues with potent antiplasmodial activity: synthesis and pharmacological evaluation.,3
6579,10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1039/C0MD00267D,"Extended side chain analogues of 8-aminoquinolines: Synthesis and evaluation of antiprotozoal, antimicrobial, -hematin inhibition, and cytotoxic activities",3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.bmc.2011.06.025,Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1016/j.bmc.2015.04.017,From hybrid compounds to targeted drug delivery in antimalarial therapy.,3
6579,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2015.03.011,Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.,3
2080,10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,10.1016/j.bmc.2017.10.017,Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.,3
2080,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.ejmech.2015.03.011,Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.,3
6579,10.1021/jm8012757,"Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable ""back-up"" compound for N-tert-butyl isoquine.",10.1021/jm101383f,Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.,3
395607,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,3
2080,10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,10.1039/d3md00490b,Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of <i>Plasmodial</i> cysteine protease inhibitors for the treatment of malaria.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2017.05.044,"Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives.",3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1016/j.bmcl.2017.03.039,"Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors.",3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1021/jm300605m,New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.,3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1016/j.ejmech.2022.114304,"Topoisomerase I inhibitors: Challenges, progress and the road ahead.",3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1021/acs.jmedchem.5b00910,Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents.,3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1016/j.ejmech.2023.116061,"Design, synthesis, and biological evaluation of harmine derivatives as topoisomerase I inhibitors for cancer treatment.",3
5985,10.1021/jm100387d,Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents.,10.1016/j.ejmech.2022.114610,"Design, synthesis, and biological evaluation of novel 7-substituted 10,11-methylenedioxy-camptothecin derivatives against drug-resistant small-cell lung cancer in vitro and in vivo.",3
2080,10.1016/j.ejmech.2011.06.021,Targeting the human malaria parasite Plasmodium falciparum: in vitro identification of a new antiplasmodial hit in 4-phenoxy-2-trichloromethylquinazoline series.,10.1016/j.bmcl.2011.06.113,4-Thiophenoxy-2-trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human malaria parasite Plasmodium falciparum.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.3c00570,Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2016.07.068,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1021/acsmedchemlett.5b00176,"Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2016.09.082,"Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.bmcl.2016.04.088,"Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2020.112659,Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents.,3
444750,10.1016/j.bmcl.2011.04.027,The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening.,10.1016/j.ejmech.2018.01.032,"((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.bmcl.2016.11.003,Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2017.05.021,Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents.,3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",3
4941,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,3
3965,10.1021/acs.jmedchem.3c01322,High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents.,10.1016/j.ejmech.2023.115946,The discovery of aryl-2-nitroethyl triamino pyrimidines as anti-Trypanosoma brucei agents.,3
3666,10.1016/j.bmc.2010.09.041,Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.,10.1016/j.bmcl.2011.05.022,Flavonoids as inhibitors of human CD38.,3
694811,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,10.1021/acs.jmedchem.5b00613,Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.,2
694811,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,2
694811,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,10.1021/acs.jmedchem.5b01514,Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.,2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1021/acs.jmedchem.6b00438,Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.,2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1016/j.bmcl.2019.03.014,Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/acs.jmedchem.0c00456,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.,2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.ejmech.2018.11.018,Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/acs.jmedchem.1c00855,"Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1016/j.bmcl.2018.04.016,"Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.",2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1021/acs.jmedchem.0c00456,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1016/j.bmc.2018.11.020,"Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.",2
650126,10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,10.1021/acs.jmedchem.3c02302,"Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.",2
674799,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
682523,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
691867,10.1021/jm500007h,Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.,10.1021/acsmedchemlett.5b00039,"N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors.",2
691867,10.1021/acs.jmedchem.6b01055,Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.,10.1021/acsmedchemlett.8b00364,Privileged Structures and Polypharmacology within and between Protein Families.,2
691867,10.1021/jm500007h,Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib.,10.1016/j.bmcl.2016.04.076,Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.,2
692515,10.1016/j.ejmech.2020.112770,"Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.",10.1021/acs.jmedchem.3c00884,"Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B.",2
692515,10.1016/j.ejmech.2020.112770,"Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.",10.1021/acsmedchemlett.2c00530,Discovery of a Potent and Selective Naphthyridine-Based Chemical Probe for Casein Kinase 2.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/acs.jmedchem.5b00613,Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.,2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/ml300221t,Bromodomains: are readers right for epigenetic therapy?,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/acs.jmedchem.7b00193,"Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.",2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1016/j.ejmech.2018.11.018,Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.,2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1016/j.ejmech.2019.111633,"Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2017.04.031,"Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2022.114101,Identification of novel xanthine oxidase inhibitors via virtual screening with enhanced characterization of molybdopterin binding groups.,2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2019.07.062,"Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",2
650126,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/acs.jmedchem.9b00722,Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.,2
650126,10.1016/j.bmcl.2012.09.043,Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.,10.1016/j.ejmech.2017.04.039,The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.,2
650126,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/jm3003203,Irreversible protein kinase inhibitors: balancing the benefits and risks.,2
630886,10.1016/j.ejmech.2020.112156,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",10.1021/acs.jmedchem.1c01287,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,2
641547,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/jm030266r,A specific mechanism of nonspecific inhibition.,2
641547,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/acs.jmedchem.9b01019,Protein Stability Effects in Aggregate-Based Enzyme Inhibition.,2
641547,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/jm020427b,Kinase inhibitors: not just for kinases anymore.,2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2021.113928,"Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2015.08.056,Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors.,2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmcl.2015.01.055,Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.,2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",2
647206,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmcl.2015.12.055,Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.,2
598402,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1021/acs.jmedchem.8b01971,Optimization of P2Y<sub>12</sub> Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.,2
241,10.1021/acs.jmedchem.1c01250,"Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with <i>In Vivo</i> Efficacy against MRSA.",10.1021/acsmedchemlett.4c00162,Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening.,2
602271,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1016/j.ejmech.2015.11.042,Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.,2
602271,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1016/j.bmc.2013.07.032,Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.,2
602271,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1021/ml5004876,"Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.",2
602271,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1021/ml400203d,"Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors.",2
619400,10.1021/jm9004779,p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.,10.1021/jm9012906,Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.,2
623658,10.1016/j.bmcl.2016.02.075,Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.,10.1039/d2md00139j,4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry.,2
626453,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,2
626453,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1016/j.bmcl.2016.04.052,Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.,2
626453,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,2
626453,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,2
630322,10.1021/jm4007627,Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.,10.1016/j.bmc.2014.08.034,"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.",2
630322,10.1021/jm4007627,Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.,10.1016/j.bmcl.2014.12.081,Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.,2
630322,10.1021/jm4007627,Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.,10.1016/j.bmcl.2015.05.012,Recent trends in orexin research--2010 to 2015.,2
630553,10.1016/j.bmcl.2009.04.108,Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.,10.1016/j.bmcl.2011.12.026,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.",2
582954,10.1021/jm500669m,Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.,10.1016/j.bmcl.2024.129630,Discovery of a novel series of selective macrocyclic PKCTheta inhibitors.,2
582954,10.1021/jm500669m,Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.,10.1016/j.bmcl.2017.01.038,Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β.,2
582954,10.1021/jm500669m,Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.,10.1021/acs.jmedchem.0c01271,"Identification, Structure-Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy.",2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm901421c,The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
583322,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm9810102,Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.,2
585527,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
586457,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
587797,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
592384,10.1016/j.bmcl.2009.10.118,Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.,10.1016/j.ejmech.2018.12.039,Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.,2
598402,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1016/j.ejmech.2021.113924,"P2Y<sub>12</sub> antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies.",2
598402,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1016/j.bmcl.2022.128837,Strategies for targeting the P2Y<sub>12</sub> receptor in the central nervous system.,2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1021/acs.jmedchem.6b00697,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1021/acs.jmedchem.6b00324,Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.,2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1021/acs.jmedchem.6b01392,Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.,2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1016/j.bmcl.2017.12.023,Fragment-based discovery of a potent NAMPT inhibitor.,2
574221,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1016/j.ejmech.2023.115307,Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.,2
574221,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1016/j.ejmech.2022.114903,Structural optimization and biological evaluation of 1-adamantylcarbonyl-4-phenylpiperazine derivatives as FXR agonists for NAFLD.,2
574221,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1021/acs.jmedchem.1c01017,Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.,2
574221,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1021/acs.jmedchem.2c01918,Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease.,2
581569,10.1016/j.bmc.2017.11.022,"Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.",10.1016/j.ejmech.2024.116386,Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.,2
581569,10.1016/j.bmc.2017.11.022,"Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.",10.1016/j.ejmech.2023.115244,"Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.",2
581814,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.ejmech.2022.114311,"Discovery, optimization and evaluation of 1-(indolin-1-yl)ethan-1-ones as novel selective TRIM24/BRPF1 bromodomain inhibitors.",2
581814,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/jm5010682,Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.,2
241,10.1021/acs.jmedchem.1c01250,"Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with <i>In Vivo</i> Efficacy against MRSA.",10.1021/acsmedchemlett.2c00111,"1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.",2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/acs.jmedchem.6b01834,Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmc.2014.03.028,Radiosyntheses and in vivo evaluation of carbon-11 PET tracers for PDE10A in the brain of rodent and nonhuman primate.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.ejmech.2022.114170,Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,2
556755,10.1021/jm9015334,Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.,10.1016/j.ejmech.2022.114170,Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmc.2013.07.030,N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmcl.2011.04.067,Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmcl.2012.07.072,Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm500073h,"Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.",2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmc.2015.06.019,BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm1002793,"Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.",2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmcl.2015.11.013,Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/acs.jmedchem.9b00224,Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.,2
561520,10.1039/C5MD00479A,Discovery of AZD8165  a clinical candidate from a novel series of neutral thrombin inhibitors,10.1021/acs.jmedchem.0c01035,"Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics.",2
561520,10.1039/C5MD00479A,Discovery of AZD8165  a clinical candidate from a novel series of neutral thrombin inhibitors,10.1021/acs.jmedchem.7b00772,Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.,2
568340,10.1021/acs.jmedchem.6b01055,Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.,10.1021/acsmedchemlett.8b00364,Privileged Structures and Polypharmacology within and between Protein Families.,2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1016/j.ejmech.2019.111576,"Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.",2
573927,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1016/j.bmcl.2016.04.039,Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.6b00150,Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2021.113281,"Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.",2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2019.111952,Development of selective mono or dual PROTAC degrader probe of CDK isoforms.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.bmc.2023.117158,"2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation.",2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.1c02064,From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.8b01469,Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.,2
555972,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,2
555972,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm200536d,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm3002372,Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm9015334,Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/jm3004976,Current landscape of phosphodiesterase 10A (PDE10A) inhibition.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.bmcl.2014.03.054,"Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I.",2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1021/acsmedchemlett.0c00330,Quinoline-Pyrazole Scaffold as a Novel Ligand of Galectin-3 and Suppressor of TREM2 Signaling.,2
556755,10.1021/jm900521k,Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.,10.1016/j.ejmech.2011.05.072,Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.,2
457398,10.1016/j.bmcl.2008.08.077,Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.,10.1016/j.bmcl.2009.01.032,The identification of orally bioavailable thrombopoietin agonists.,2
457398,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
458773,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jnatprod.9b01269,Diterpenoids from the Root Bark of <i>Pinus massoniana</i> and Evaluation of Their Phosphodiesterase Type 4D Inhibitory Activity.,2
458773,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,2
458773,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1016/j.ejmech.2023.115893,Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.,2
467361,10.1016/j.bmc.2017.11.022,"Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.",10.1016/j.ejmech.2023.115244,"Design, synthesis and biological evaluation of Nucleosidic CD99 inhibitors that selectively reduce Ewing sarcoma viability.",2
478003,10.1039/C5MD00479A,Discovery of AZD8165  a clinical candidate from a novel series of neutral thrombin inhibitors,10.1021/acs.jmedchem.7b00772,Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.,2
486594,10.1016/j.bmcl.2009.09.096,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,10.1021/jm501913a,Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.,2
486594,10.1016/j.bmcl.2009.09.096,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,10.1016/j.ejmech.2017.08.044,Recent advances in the discovery of small molecule c-Met Kinase inhibitors.,2
490644,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,10.1016/j.bmc.2019.05.006,"Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as potential BRD4 inhibitors.",2
490644,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,10.1021/acs.jmedchem.9b01094,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,2
495109,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
508147,10.1016/j.bmcl.2012.04.103,Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.,10.1016/j.bmcl.2016.03.032,Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.bmcl.2019.05.024,Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2023.115140,Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.,2
511261,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.8b00669,Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.,2
436277,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.bmc.2020.115902,Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.,2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.ejmech.2018.01.032,"((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies.",2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.bmc.2022.116964,"1,2,4-Triazole-3-thione analogues with an arylakyl group at position 4 as metallo-β-lactamase inhibitors.",2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1021/acs.jmedchem.3c00171,"Kinetics, Thermodynamics, and Structural Effects of Quinoline-2-Carboxylates, Zinc-Binding Inhibitors of New Delhi Metallo-β-lactamase-1 Re-sensitizing Multidrug-Resistant Bacteria for Carbapenems.",2
444750,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1021/acs.jmedchem.7b00407,Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.,2
444750,10.1016/j.bmc.2013.03.031,An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening.,10.1021/acs.jmedchem.3c00171,"Kinetics, Thermodynamics, and Structural Effects of Quinoline-2-Carboxylates, Zinc-Binding Inhibitors of New Delhi Metallo-β-lactamase-1 Re-sensitizing Multidrug-Resistant Bacteria for Carbapenems.",2
449724,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,2
452688,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jnatprod.5b00911,17β-Hydroxy-18-acetoxywithanolides from Aeroponically Grown Physalis crassifolia and Their Potent and Selective Cytotoxicity for Prostate Cancer Cells.,2
452688,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jmedchem.2c01770,"Physachenolide C is a Potent, Selective BET Inhibitor.",2
452688,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jmedchem.7b00069,17β-Hydroxywithanolides as Sensitizers of Renal Carcinoma Cells to Tumor Necrosis Factor-α Related Apoptosis Inducing Ligand (TRAIL) Mediated Apoptosis: Structure-Activity Relationships.,2
419601,10.1021/jm00084a010,"(H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.",10.1021/jm950610n,"2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.",2
322,10.1021/acs.jmedchem.5b00098,Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.,10.1021/acs.jmedchem.6b01840,Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.,2
322,10.1021/acs.jmedchem.5b00098,Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.,10.1016/j.bmcl.2017.03.037,Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.,2
421346,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
422253,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1016/j.ejmech.2010.12.012,"HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.",2
422253,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1128/aac.00210-08,Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.,2
422253,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",2
422253,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1016/j.bmc.2010.06.063,"New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.",2
430012,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101470k,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",2
430253,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.bmcl.2010.01.049,"Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.",2
430253,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.bmcl.2009.05.114,Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.,2
436277,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/jm4006059,Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.,2
436277,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1038/nchembio.345,Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.,2
436277,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1021/jm901808w,"A type-II kinase inhibitor capable of inhibiting the T315I ""gatekeeper"" mutant of Bcr-Abl.",2
436277,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1016/j.ejmech.2016.08.026,Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.,2
436277,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1016/j.bmcl.2012.04.066,"Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.",2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
408410,10.1016/j.bmcl.2010.04.075,Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs.,10.1016/j.bmcl.2016.01.024,4-Aryl-3-arylsulfonyl-quinolines as negative allosteric modulators of metabotropic GluR5 receptors: From HTS hit to development candidate.,2
410802,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01093,"Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.",2
410802,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c00983,Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.,2
410802,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01120,From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.,2
410802,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1016/j.ejmech.2023.115893,Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.,2
416772,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1021/acs.jmedchem.0c01524,Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor.,2
416772,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1016/j.bmcl.2022.128837,Strategies for targeting the P2Y<sub>12</sub> receptor in the central nervous system.,2
416772,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1039/D1MD00128K,Synthesis and biological evaluation of <i>N</i> <sup>6</sup> derivatives of 8-azapurine as novel antiplatelet agents.,2
416772,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1016/j.bmcl.2013.11.055,Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.,2
416772,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,10.1016/j.bmcl.2016.04.030,State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.,2
419508,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2020.112077,"Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmcl.2015.12.055,Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.,2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2017.04.031,"Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmcl.2017.01.049,"Discovery and biological evaluation of some (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors.",2
408410,10.1016/j.bmcl.2010.04.075,Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs.,10.1016/j.bmcl.2010.06.075,Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists.,2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2019.07.062,"Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.bmcl.2017.06.059,"Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2017.09.051,"Design, synthesis and biological evaluation of N-(4-alkoxy-3-cyanophenyl)isonicotinamide/nicotinamide derivatives as novel xanthine oxidase inhibitors.",2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
605,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
666,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1021/ml200196p,Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.,2
382857,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,2
387585,10.1016/j.ejmech.2008.06.005,Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors.,10.1016/j.ejmech.2017.04.059,Synthesis of selective 11β-HSD1 inhibitors based on dammarane scaffold.,2
387585,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1016/j.bmcl.2017.05.005,Phenylbenzenesulfonates and -sulfonamides as 17β-hydroxysteroid dehydrogenase type 2 inhibitors: Synthesis and SAR-analysis.,2
387585,10.1016/j.ejmech.2008.06.005,Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors.,10.1021/np500896n,"Hupehenols A-E, selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors from Viburnum hupehense.",2
394165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,2
394165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
394165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,2
394165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",2
395607,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,10.1016/j.ejmech.2021.113928,"Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",2
666,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1016/j.bmcl.2022.128994,"Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.",2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.04.010,"1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.",2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acsmedchemlett.5b00254,"Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.",2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,2
374719,10.1016/j.ejmech.2012.01.056,"Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.",10.1016/j.ejmech.2018.10.029,Novel natural non-nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques.,2
374719,10.1016/j.ejmech.2012.01.056,"Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.",10.1016/j.ejmech.2015.02.032,"(3Z)-3-(2-[4-(aryl)-1,3-thiazol-2-yl]hydrazin-1-ylidene)-2,3-dihydro-1H-indol-2-one derivatives as dual inhibitors of HIV-1 reverse transcriptase.",2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,2
378218,10.1016/j.ejmech.2013.01.023,"Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.",10.1016/j.ejmech.2019.111922,Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?,2
378218,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
378218,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1016/j.bmcl.2021.127906,Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.,2
382857,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,10.1021/jm7014638,Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.,2
382857,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,10.1016/j.bmcl.2007.09.080,Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.,2
382857,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,10.1016/j.bmcl.2008.07.112,Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.,2
382857,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,10.1016/j.bmcl.2008.02.022,4-Aminopyrimidine tetrahydronaphthols: a series of novel vanilloid receptor-1 antagonists with improved solubility properties.,2
721,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.035998,Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,2
721,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
374052,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2012.12.027,"N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.",2
374719,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2016.06.065,"Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.",2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmcl.2017.05.043,Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.3c00554,Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.,2
721,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm901036q,Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.,2
721,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.9b01439,Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c00359,Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.8b00667,Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c00450,Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmcl.2015.09.020,"Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.",2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c01026,"Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.",2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c01952,"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.",2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acsmedchemlett.8b00508,Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.,2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,2
370906,10.1021/jm060747l,"1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate.",10.1128/aac.00211-07,"RSV604, a novel inhibitor of respiratory syncytial virus replication.",2
721,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmc.2019.03.048,"Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.",2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.3c00554,Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.0c01026,"Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.",2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acsmedchemlett.8b00508,Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmc.2018.01.021,"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.",2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2022.114551,Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.7b01135,"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.",2
367860,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.8b00667,Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.,2
367860,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.3c01712,Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.,2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1039/d3md00115f,"Design, synthesis and biological evaluation of phenanthridine amide and 1,2,3-triazole analogues against <i>Mycobacterium tuberculosis</i>.",2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,2
365281,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
365281,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
365281,10.1021/jm901452y,Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators.,10.1016/j.ejmech.2022.114382,"Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation.",2
365281,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
365281,10.1021/jm901452y,Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators.,10.1021/acs.jmedchem.2c01082,Discovery and Optimization of <i>N</i>-Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators.,2
365281,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,2
365281,10.1016/j.ejmech.2021.113693,"Structure-based screening for the discovery of 1,2,4-oxadiazoles as promising hits for the development of new anti-inflammatory agents interfering with eicosanoid biosynthesis pathways.",10.1021/acsmedchemlett.2c00343,"Identification of 2-Aminoacyl-1,3,4-thiadiazoles as Prostaglandin E<sub>2</sub> and Leukotriene Biosynthesis Inhibitors.",2
365281,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
365281,10.1016/j.ejmech.2022.114382,"Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation.",10.1021/acs.jmedchem.2c01082,Discovery and Optimization of <i>N</i>-Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
789,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b00286,"Nε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling.",2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
365189,10.1016/j.bmc.2010.07.010,Identification of novel antitubercular compounds through hybrid virtual screening approach.,10.1016/j.ejmech.2011.06.014,"Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction.",2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2017.01.009,Hybrids of thienopyrimidinones and thiouracils as anti-tubercular agents: SAR and docking studies.,2
365189,10.1016/j.bmc.2017.11.031,Lead identification and optimization of bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.112010,"Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.",2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.bmcl.2019.03.020,Thiazolyl-pyrazole derivatives as potential antimycobacterial agents.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
365189,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",10.1016/j.ejmech.2015.10.054,Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.,2
365189,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",10.1021/acs.jnatprod.9b00062,"Antibacterial Salinaphthoquinones from a Strain of the Bacterium <i>Salinispora arenicola</i> Recovered from the Marine Sediments of St. Peter and St. Paul Archipelago, Brazil.",2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,2
365189,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",10.1039/C9MD00161A,"Novel antimycobacterial C-21 amide derivatives of the antibiotic fusidic acid: synthesis, pharmacological evaluation and rationalization of media-dependent activity using molecular docking studies in the binding site of human serum albumin.",2
365189,10.1021/acs.jmedchem.5b01078,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,10.1021/acs.jmedchem.9b01032,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,2
365189,10.1021/acs.jmedchem.5b01078,Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity.,10.1021/acs.jmedchem.0c02245,"Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.",2
365189,10.1128/aac.00055-06,Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.,10.1021/acs.jmedchem.1c00837,"1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>.",2
364520,10.1021/jm060961+,Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.,10.1021/jm7011485,An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.0c02042,Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture.,2
365189,10.1016/j.bmc.2010.07.010,Identification of novel antitubercular compounds through hybrid virtual screening approach.,10.1016/j.bmcl.2012.12.069,A facile three-component [3+2]-cycloaddition for the regioselective synthesis of highly functionalised dispiropyrrolidines acting as antimycobacterial agents.,2
365189,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
822,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
340684,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1128/aac.00210-08,Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.,2
340684,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",2
340684,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1016/j.bmc.2010.06.063,"New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action.",2
340684,10.1016/j.bmcl.2008.03.089,A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series.,10.1016/j.ejmech.2010.12.012,"HIV-1 integrase strand-transfer inhibitors: design, synthesis and molecular modeling investigation.",2
363589,10.1021/jm300310c,Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.,10.1021/jm5011012,Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.,2
364141,10.1073/pnas.0709695104,Small molecule regulators of autophagy identified by an image-based high-throughput screen.,10.1039/C0MD00236D,"Diphenylbutylpiperidine-based cell autophagy inducers: Design, synthesis and SAR studies",2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm701044r,Multiple N-methylation by a designed approach enhances receptor selectivity.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.5b01441,Discovery of Nanomolar Dengue and West Nile Virus Protease Inhibitors Containing a 4-Benzyloxyphenylglycine Residue.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
364520,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.0c00841,"Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.",2
316347,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
321696,10.1021/jm300459a,Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.,10.1016/j.bmcl.2013.05.099,"Discovery of triazines as potent, selective and orally active PDE4 inhibitors.",2
321696,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1016/j.ejmech.2023.115893,Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.,2
321696,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.1c02058,Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.,2
321696,10.1021/jm300459a,Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.,10.1021/acs.jmedchem.9b02170,Advances in the Development of Phosphodiesterase-4 Inhibitors.,2
321696,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1016/j.ejmech.2023.115195,Advances in the development of phosphodiesterase-4 inhibitors.,2
321696,10.1021/jm300459a,Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.,10.1021/acs.jmedchem.0c01901,Furazans in Medicinal Chemistry.,2
321696,10.1021/jm300459a,Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.,10.1016/j.ejmech.2023.115195,Advances in the development of phosphodiesterase-4 inhibitors.,2
321696,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,2
321696,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,2
328201,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,2
328201,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,2
328201,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,2
328201,10.1016/j.bmcl.2014.02.057,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,10.1016/j.bmcl.2016.04.052,Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.,2
335628,10.1021/acs.jmedchem.5b00197,Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.,10.1016/j.bmcl.2019.126809,"Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.",2
316347,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,2
316347,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,2
316347,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.5b01605,A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.3c01186,Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,2
304798,10.1016/j.bmcl.2007.02.002,Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.,10.1021/jm3013773,Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1016/j.bmcl.2018.12.042,Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.0c01163,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acsmedchemlett.8b00106,New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.,2
304798,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,2
305519,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.ejmech.2018.11.025,"Benzofuran derivatives and their anti-tubercular, anti-bacterial activities.",2
305519,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,2
305519,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",2
308422,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
312899,10.1021/jm030605g,Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.,10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,2
312994,10.1016/j.bmcl.2018.01.003,Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase.,10.1016/j.bmc.2021.116507,Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors.,2
316347,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acsmedchemlett.7b00030,Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2019.06.047,Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acsmedchemlett.0c00612,Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.,2
299120,10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,10.1021/acs.jmedchem.3c02302,"Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.",2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.7b00584,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.6b01194,Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.,2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.8b00401,"Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT2C Receptor.",2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.5b01153,"Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.",2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1016/j.ejmech.2019.111626,Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.,2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1016/j.ejmech.2018.12.070,Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT<sub>2C</sub> and negative allosteric modulator of 5-HT<sub>2B</sub> receptors.,2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1016/j.bmcl.2010.11.120,"Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.",2
301194,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/ml100071j,First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.bmcl.2019.06.040,Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.ejmech.2014.10.021,Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.bmcl.2010.11.040,N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).,2
255947,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
255947,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1038/nchembio.215,Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.,2
276734,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.bmc.2014.11.029,"Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAF(V⁶⁰⁰E) inhibitors.",2
276734,10.1021/jm800539g,Identification of BRAF inhibitors through in silico screening.,10.1016/j.bmcl.2012.09.004,"Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents.",2
276734,10.1021/jm800539g,Identification of BRAF inhibitors through in silico screening.,10.1016/j.ejmech.2014.11.008,"Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.",2
276734,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.bmc.2012.04.047,"Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors.",2
276734,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.ejmech.2014.11.008,"Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.",2
276734,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.bmc.2020.115493,"Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting <sup>V600E</sup>BRAF.",2
276734,10.1021/jm800539g,Identification of BRAF inhibitors through in silico screening.,10.1016/j.ejmech.2012.02.007,"Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.",2
278534,10.1016/j.bmc.2010.09.063,Virtual screening against nuclear factor κB (NF-κB) of a focus library: Identification of bioactive furocoumarin derivatives inhibiting NF-κB dependent biological functions involved in cystic fibrosis.,10.1016/j.ejmech.2011.07.032,"Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: design, synthesis and biological effects.",2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,2
296388,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acsmedchemlett.5b00254,"Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance.",2
230249,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
230249,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
231062,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
250328,10.1021/acs.jmedchem.0c02047,Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,2
255477,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
255477,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101470k,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101470k,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101120u,"Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.",2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm401430e,Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.,2
255904,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.bmcl.2019.126869,"Design, synthesis and bio-evaluation of C-1 alkylated tetrahydro-β-carboline derivatives as novel antifungal lead compounds.",2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.ejmech.2014.12.022,"Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.",2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm100400a,Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm100317b,Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.,2
255904,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1021/acs.jmedchem.9b00363,Improvement of Asparagine Ethylenediamines as Anti-malarial <i>Plasmodium</i>-Selective Proteasome Inhibitors.,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1016/j.ejmech.2019.111646,Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1039/C2MD20060K,Optimization of a series of dipeptides with a P3 -neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1016/j.ejmech.2022.114211,Metabolism guided optimization of peptidomimetics as non-covalent proteasome inhibitors for cancer treatment.,2
187372,10.1016/j.ejmech.2014.01.022,Identification of a new series of amides as non-covalent proteasome inhibitors.,10.1016/j.ejmech.2014.06.017,Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1021/jm200460q,Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors.,2
190484,10.1021/jm034122o,Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor.,10.1021/acs.jmedchem.0c00242,Fragment Linking Strategies for Structure-Based Drug Design.,2
191172,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2015.08.051,"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.",2
191172,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1021/acs.jmedchem.1c00703,"Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.",2
191172,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1021/acs.jmedchem.8b00457,"Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.",2
198677,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",2
198677,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
198677,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,2
228121,10.1021/jm049276y,Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.,10.1016/j.bmcl.2008.01.048,Synthesis of potent pyrrolidine influenza neuraminidase inhibitors.,2
228121,10.1021/jm049276y,Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.,10.1016/j.ejmech.2017.10.004,Synthesis and biological evaluation of NH2-acyl oseltamivir analogues as potent neuraminidase inhibitors.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2012.05.095,Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2010.06.102,Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1039/C6MD00262E,,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2008.02.033,The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.,2
182165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2016.03.023,Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment.,2
182165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
182165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,2
182165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
182165,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
182814,10.1021/jm030605g,Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.,10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,2
183934,10.1021/jm801569z,Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.,10.1016/j.bmc.2016.12.050,"Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.",2
183934,10.1021/jm801569z,Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.,10.1021/jm4002023,"Synthesis and biological activities of a new class of heat shock protein 90 inhibitors, designed by energy-based pharmacophore virtual screening.",2
183934,10.1016/j.bmcl.2011.08.001,"Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.",10.1021/jm500823a,Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.,2
183934,10.1021/jm801569z,Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin.,10.1016/j.bmc.2011.08.048,Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.,2
187372,10.1039/C2MD20060K,Optimization of a series of dipeptides with a P3 -neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome,10.1016/j.ejmech.2018.12.072,Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.,2
187372,10.1016/j.bmcl.2010.09.032,Optimization of a series of dipeptides with a P3 threonine residue as non-covalent inhibitors of the chymotrypsin-like activity of the human 20S proteasome.,10.1021/jm4002296,"Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1074/jbc.m809038200,Structural characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique (DFG-out) conformation and enables inhibitor design.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/jm901297e,Displacement assay for the detection of stabilizers of inactive kinase conformations.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1038/nchembio799,Rational design of inhibitors that bind to inactive kinase conformations.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/jm300411k,"Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2) as an antiinflammatory target: discovery and in vivo activity of selective pyrazolo[1,5-a]pyrimidine inhibitors using a focused library and structure-based optimization approach.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/jm061072p,"Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: novel p38 MAP kinase inhibitors.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2006.09.014,Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2007.11.064,Novel heterocycle-substituted pyrimidines as inhibitors of NF-kappaB transcription regulation related to TNF-alpha cytokine release.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2006.10.044,Trimethylsilylpyrazoles as novel inhibitors of p38 MAP kinase: a new use of silicon bioisosteres in medicinal chemistry.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/jm030120s,"Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.ejmech.2011.11.019,"Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/jm030121k,Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2011.09.078,Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2008.04.043,"Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2008.06.028,Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2007.05.042,New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.bmcl.2009.03.104,Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.,2
139099,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
1125,10.1016/j.bmcl.2011.02.059,"Virtual screening-driven identification of human carbonic anhydrase inhibitors incorporating an original, new pharmacophore.",10.1016/j.ejmech.2020.112875,Ninhydrins inhibit carbonic anhydrases directly binding to the metal ion.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1021/acs.jmedchem.6b00089,Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1021/acs.jmedchem.1c01979,Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1016/j.bmcl.2011.10.085,Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1016/j.bmcl.2006.04.084,Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1016/j.bmcl.2013.09.058,Modulators of the Sphingosine 1-phosphate receptor 1.,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1016/j.bmcl.2012.11.053,"Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1.",2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1021/acs.jmedchem.6b00373,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1021/jm901776q,"Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate.",2
144940,10.1021/jm0492507,"A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.",10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,2
153330,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101470k,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1021/acs.jmedchem.6b01439,Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1042/bj20070797,The selectivity of protein kinase inhibitors: a further update.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/s0960-894x(03)00656-5,The kinetics of binding to p38MAP kinase by analogues of BIRB 796.,2
167995,10.1021/jm020057r,Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.,10.1016/j.ejmech.2020.112721,Selective targeting of the αC and DFG-out pocket in p38 MAPK.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.04.010,"1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.",2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2019.06.047,Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,2
119288,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
120086,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,2
120086,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.ejmech.2022.114361,Spiral molecules with antimalarial activities: A review.,2
120086,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
120086,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,2
120086,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
120086,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
127116,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",2
127116,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",2
136161,10.1021/acsmedchemlett.5b00059,Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.,10.1039/C7MD00131B,The discovery of a potent Na<sub>v</sub>1.3 inhibitor with good oral pharmacokinetics.,2
88232,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/jm400072p,Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors.,2
88232,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/acs.jmedchem.9b00722,Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.,2
88232,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/jm201591k,"Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.",2
88232,10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,10.1021/acs.jmedchem.3c02302,"Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.",2
93617,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01093,"Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.",2
96021,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
98346,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2017.09.047,"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.",2
99024,10.1021/acs.jmedchem.5b02038,Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.,10.1039/D0MD00062K,Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?,2
104250,10.1021/jm2005018,Identification of the binding modes of N-phenylphthalimides inhibiting bacterial thymidylate synthase through X-ray crystallography screening.,10.1021/jm4014086,"2'-Deoxyuridine 5'-monophosphate substrate displacement in thymidylate synthase through 6-hydroxy-2H-naphtho[1,8-bc]furan-2-one derivatives.",2
111060,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,2
113138,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,2
1125,10.1016/j.bmcl.2011.02.059,"Virtual screening-driven identification of human carbonic anhydrase inhibitors incorporating an original, new pharmacophore.",10.1016/j.bmcl.2012.07.094,"Inhibition of α-class cytosolic human carbonic anhydrases I, II, IX and XII, and β-class fungal enzymes by carboxylic acids and their derivatives: new isoform-I selective nanomolar inhibitors.",2
78759,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jnatprod.6b01129,Withanolides from Aeroponically Grown Physalis peruviana and Their Selective Cytotoxicity to Prostate Cancer and Renal Carcinoma Cells.,2
78759,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,2
78759,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,2
2658,10.1016/j.bmc.2017.05.009,Screening for bioactive natural products from a 67-compound library of Glycyrrhiza inflata.,10.1016/j.ejmech.2023.115791,Discovery of anti-inflammatory natural flavonoids: Diverse scaffolds and promising leads for drug discovery.,2
78759,10.1021/acs.jmedchem.3c01708,"Lead Optimization of BIBR1591 To Improve Its Telomerase Inhibitory Activity: Design and Synthesis of Novel Four Chemical Series with In Silico, In Vitro, and In Vivo Preclinical Assessments.",10.1016/j.ejmech.2024.116527,"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments.",2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c02129,An Improved PDE6D Inhibitor Combines with Sildenafil To Inhibit &lt;i&gt;KRAS&lt;/i&gt; Mutant Cancer Cell Growth.,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.2c01120,"Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRAS<sup>G12C</sup> Inhibitor.",2
80965,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
83724,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2023.117381,Synthesis of novobiocin derivatives and evaluation of their antigonococcal activity and pharmacokinetics.,2
83724,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
83724,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
83724,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
84251,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
88232,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/jm100607r,"Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.",2
88232,10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",2
78303,10.1021/acs.jmedchem.0c02047,Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,2
78759,10.1021/np800184g,Marine natural product libraries for high-throughput screening and rapid drug discovery.,10.1021/np200673b,Natural product libraries to accelerate the high-throughput discovery of therapeutic leads.,2
78759,10.1007/s00044-012-0272-y,"Synthesis and antitumor screening of new series of pyrimido-[4,5-b]quinolines and [1,2,4]triazolo[2,3:3,4]pyrimido[6,5-b]quinolines",10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.2c00099,Drugging the Next Undruggable KRAS Allele-Gly12Asp.,2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.2c00741,"Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.",2
78759,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,2
78759,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jnatprod.5b00911,17β-Hydroxy-18-acetoxywithanolides from Aeroponically Grown Physalis crassifolia and Their Potent and Selective Cytotoxicity for Prostate Cancer Cells.,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c02403,Targeting KRAS Diversity: Covalent Modulation of G12X and Beyond in Cancer Therapy.,2
78759,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jnatprod.1c00662,"Strobiloscyphones A-F, 6-Isopentylsphaeropsidones and Other Metabolites from <i>Strobiloscypha</i> sp. AZ0266, a Leaf-Associated Fungus of Douglas Fir.",2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2020.113082,"Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS inhibitors.",2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2021.113816,Targeting mutated GTPase KRAS in tumor therapies.,2
78759,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",2
2277005,10.1021/acs.jmedchem.8b00900,"A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).",10.1021/acs.jmedchem.2c01882,E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology.,2
78759,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jnatprod.1c00724,Ring A/B-Modified 17β-Hydroxywithanolide Analogues as Antiproliferative Agents for Prostate Cancer and Potentiators of Immunotherapy for Renal Carcinoma and Melanoma.,2
78759,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",2
78759,10.1021/acs.jmedchem.5b00867,Discovery of Potent 17β-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors.,10.1021/acs.jmedchem.2c01770,"Physachenolide C is a Potent, Selective BET Inhibitor.",2
2739670,10.1021/acs.jmedchem.1c00047,Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.,10.1039/d1md00362c,Current leishmaniasis drug discovery.,2
72505,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
73547,10.1021/jm501940y,"Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.",10.1021/acsmedchemlett.7b00549,Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents.,2
75258,10.1016/j.bmc.2018.06.027,Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.,10.1016/j.ejmech.2018.10.050,"Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.",2
75258,10.1021/jm980398y,"Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2021.113252,"Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling.",2
75507,10.1016/j.bmc.2020.115437,"A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.",10.1016/j.ejmech.2021.113747,Efforts towards the inhibitor design for New Delhi metallo-beta-lactamase (NDM-1).,2
75507,10.1016/j.ejmech.2019.06.057,Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.,10.1021/acs.jmedchem.2c01799,Optimized Ebselen-Based Inhibitors of Bacterial Ureases with Nontypical Mode of Action.,2
76361,10.1021/jm501021n,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,10.1021/acs.jmedchem.6b01183,Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists.,2
76361,10.1021/jm501021n,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,10.1021/acs.jmedchem.5b01998,Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists.,2
76361,10.1021/jm501021n,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,10.1021/acs.jmedchem.7b00291,"Exploring the Role of N6-Substituents in Potent Dual Acting 5'-C-Ethyltetrazolyladenosine Derivatives: Synthesis, Binding, Functional Assays, and Antinociceptive Effects in Mice ∇.",2
76361,10.1021/jm501021n,In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists.,10.1021/acsmedchemlett.9b00637,Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A Receptor Agonists.,2
77129,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
77459,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
77459,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
77857,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/s0960-894x(98)00111-5,"Preparation of 9-deoxo-4""-deoxy-6,9-epoxyerythromycin lactams ""motilactides"": potent and orally active prokinetic agents.",2
2739670,10.1021/acs.jmedchem.1c00047,Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis.,10.1016/j.ejmech.2023.115471,Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds.,2
70140,10.1016/j.bmc.2012.10.002,Optimization and structure-activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents.,10.1016/j.bmc.2014.01.020,Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections.,2
2434246,10.1021/acs.jmedchem.8b01218,Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.,10.1039/d1md00362c,Current leishmaniasis drug discovery.,2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.bmc.2023.117153,"Design, synthesis and biological evaluation of KRAS<sup>G12C</sup>-PROTACs.",2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c00746,"Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS<sup>G12C</sup> with Demonstrable CNS Penetration.",2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2022.114907,"Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects.",2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c00737,Expanding the Chemistry of Dihaloacetamides as Tunable Electrophiles for Reversible Covalent Targeting of Cysteines.,2
2464781,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2023.115698,Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.,2
2261,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1016/j.ejmech.2019.111643,Practical approaches to evaluating and optimizing brain exposure in early drug discovery.,2
2261,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
2262,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
2262,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
2262,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
2355,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.2c00099,Drugging the Next Undruggable KRAS Allele-Gly12Asp.,2
2211775,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,10.1016/j.bmcl.2024.129643,"Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors.",2
148,10.1021/jm060112m,Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.,10.1016/j.bmc.2012.02.017,"Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.",2
56480,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,2
56480,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1039/C9MD00064J,"Synthesis of bicyclic 1,4-thiazepines as novel anti-<i>Trypanosoma brucei brucei</i> agents.",2
61680,10.1016/j.bmcl.2018.01.006,Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.,10.1016/j.bmc.2021.116343,A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.,2
61682,10.1016/j.bmcl.2018.01.006,Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.,10.1016/j.bmc.2021.116343,A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.,2
62111,10.1016/j.bmc.2018.06.027,Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.,10.1016/j.ejmech.2018.10.050,"Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.",2
62259,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
65044,10.1016/j.ejmech.2017.04.052,"Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity.",10.1016/j.ejmech.2018.09.055,"l,8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017.",2
65605,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,2
65605,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,2
65648,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
66238,10.1073/pnas.0709695104,Small molecule regulators of autophagy identified by an image-based high-throughput screen.,10.1021/jm2011657,Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.,2
66238,10.1073/pnas.0709695104,Small molecule regulators of autophagy identified by an image-based high-throughput screen.,10.1016/j.bmcl.2010.11.029,Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers.,2
154,10.1021/acs.jmedchem.6b00212,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.,10.1021/acs.jmedchem.7b01530,"Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.",2
67617,10.1016/j.bmc.2017.11.031,Lead identification and optimization of bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.112010,"Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.",2
70140,10.1021/acs.jmedchem.1c01250,"Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with <i>In Vivo</i> Efficacy against MRSA.",10.1021/acsmedchemlett.2c00111,"1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.",2
70140,10.1021/acs.jmedchem.8b01287,"Application of Virtual Screening to the Identification of New LpxC Inhibitor Chemotypes, Oxazolidinone and Isoxazoline.",10.1039/d2md00415a,Oxazolidinones as versatile scaffolds in medicinal chemistry.,2
51162,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm100938u,"A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.",2
51162,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
51162,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,2
51162,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,2
51162,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2010.05.095,"Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials.",2
51162,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",2
52874,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.bmc.2018.02.014,"Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.",2
53686,10.1021/jm901775y,"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.",10.1016/j.bmc.2012.06.021,Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.,2
53686,10.1021/jm901775y,"Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.",10.1021/acs.jmedchem.0c01346,"Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.",2
54722,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
54722,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
56095,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
56133,10.1016/j.bmcl.2022.128567,Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.,10.1016/j.bmc.2023.117215,Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.,2
56133,10.1016/j.bmcl.2022.128567,Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.,10.1021/acs.jmedchem.3c00932,"Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure.",2
56480,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1039/d3md00243h,Optimization of the 2-arylquinazoline-4(3<i>H</i>)one scaffold for a selective and potent antitrypanosomal agent: modulation of the mechanism of action through chemical functionalization.,2
56480,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",10.1016/j.bmcl.2018.04.064,Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.bmc.2016.10.038,"Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors.",2
154,10.1021/acs.jmedchem.6b00212,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.,10.1021/acs.jmedchem.6b01427,Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).,2
154,10.1021/acs.jmedchem.6b00212,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.,10.1016/j.bmcl.2017.12.052,Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.,2
2218011,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1021/acs.jmedchem.0c00456,Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.,2
2218011,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1021/acsmedchemlett.3c00242,"Design and Characterization of 1,3-Dihydro-2<i>H</i>-benzo[<i>d</i>]azepin-2-ones as Rule-of-5 Compliant Bivalent BET Inhibitors.",2
48697,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.bmcl.2017.02.031,"Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.",2
48697,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/jm501174m,Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.ejmech.2017.02.046,Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.,2
2218011,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,2
2221622,10.1021/acs.jmedchem.7b00231,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",10.1021/acsmedchemlett.9b00219,Targeting IRAK4 for Degradation with PROTACs.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.bmc.2014.09.008,Structure-guided design and development of novel benzimidazole class of compounds targeting DNA gyraseB enzyme of Staphylococcus aureus.,2
2221622,10.1021/acs.jmedchem.7b00231,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",10.1021/acsmedchemlett.4c00036,In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833).,2
2221622,10.1021/acs.jmedchem.7b00231,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",10.1016/j.bmc.2020.115815,Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.,2
49842,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
51003,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
2221622,10.1021/acs.jmedchem.7b00231,"Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.",10.1021/acs.jmedchem.4c00202,Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury.,2
2231285,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1016/j.ejmech.2024.116344,"Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis.",2
2231285,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1021/acs.jmedchem.1c02002,"Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.",2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/acs.jmedchem.6b01834,Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,2
2272109,10.1021/acs.jmedchem.5b01938,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,10.1016/j.ejmech.2018.03.075,"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.",2
2013100,10.1021/acs.jmedchem.9b01035,Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.,10.1016/j.ejmech.2023.115306,Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics.,2
2013100,10.1021/acs.jmedchem.9b01035,Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.,10.1021/acsmedchemlett.2c00302,Synthesis of Novel Kidney-Type Glutaminase Allosteric Inhibitors Targeting the Critical Lys-320 Residue.,2
2013100,10.1021/acs.jmedchem.9b01035,Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.,10.1021/acs.jmedchem.0c02044,Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1039/C9MD00224C,"New <i>N</i>-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors.",2
48697,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2017.02.046,Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors.,2
2013100,10.1021/acs.jmedchem.9b01035,Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.,10.1016/j.ejmech.2022.114337,Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.,2
2056751,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1021/acs.jmedchem.3c02304,Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease.,2
2087700,10.1021/acs.jmedchem.7b01605,Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.,10.1016/j.ejmech.2024.116475,Recent discovery and development of AXL inhibitors as antitumor agents.,2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/acs.jmedchem.5b00489,"Discovery of 4,5,6,7-Tetrahydrobenzo[1,2-d]thiazoles as Novel DNA Gyrase Inhibitors Targeting the ATP-Binding Site.",2
48697,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,2
37716,10.1021/jm020311f,Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.,10.1016/j.bmcl.2005.03.110,P2 pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold.,2
37716,10.1021/jm020311f,Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.,10.1016/j.ejmech.2018.01.067,The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.,2
37716,10.1021/jm020311f,Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.,10.1016/s0960-894x(03)00099-4,Pharmacokinetic optimization of 3-amino-6-chloropyrazinone acetamide thrombin inhibitors. Implementation of P3 pyridine N-oxides to deliver an orally bioavailable series containing P1 N-benzylamides.,2
38727,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.035998,Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,2
38727,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm901036q,Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.,2
38727,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
38898,10.1021/jm1010572,"Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.",10.1021/acs.jmedchem.8b02021,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,2
40702,10.1016/j.ejmech.2020.113053,Modulators of hERAP2 discovered by high-throughput screening.,10.1021/acs.jmedchem.2c00904,Discovery of Selective Nanomolar Inhibitors for Insulin-Regulated Aminopeptidase Based on α-Hydroxy-β-amino Acid Derivatives of Bestatin.,2
40702,10.1016/j.ejmech.2020.113053,Modulators of hERAP2 discovered by high-throughput screening.,10.1021/acs.jmedchem.4c00840,ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights.,2
41764,10.1021/acs.jmedchem.9b00631,Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.,10.1016/j.ejmech.2021.113818,Cathepsin C inhibitors as anti-inflammatory drug discovery: Challenges and opportunities.,2
43934,10.1016/j.bmc.2009.05.070,Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.,10.1128/aac.00409-10,High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides.,2
43934,10.1016/j.bmc.2009.05.070,Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.,10.1021/ml500534c,Azolylthioacetamide: A Highly Promising Scaffold for the Development of Metallo-β-lactamase Inhibitors.,2
44920,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01093,"Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives.",2
44920,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1016/j.ejmech.2020.113123,The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,2
44920,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01120,From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.,2
46884,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
2155099,10.1021/acs.jmedchem.8b00951,"Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.",10.1021/acs.jmedchem.1c01806,Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.,2
2205527,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
2211775,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,10.1021/acs.jmedchem.2c01518,Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.,2
27912,10.1016/j.ejmech.2012.06.052,"Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors.",10.1016/j.ejmech.2016.08.053,"Synthesis, antiamoebic and molecular docking studies of furan-thiazolidinone hybrids.",2
27912,10.1016/j.ejmech.2012.06.052,"Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors.",10.1016/j.bmcl.2020.127549,Synthesis of metronidazole based thiazolidinone analogs as promising antiamoebic agents.,2
28119,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
28119,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
29097,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
2211775,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,10.1016/j.ejmech.2021.113484,Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors.,2
29890,10.1021/acsmedchemlett.2c00051,Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.,10.1021/acs.jmedchem.2c00283,"Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.",2
2211775,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,10.1016/j.ejmech.2022.114345,Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.,2
33216,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,10.1021/acs.jmedchem.3c02304,Discovery and Optimization of Novel Nonbile Acid FXR Agonists as Preclinical Candidates for the Treatment of Inflammatory Bowel Disease.,2
34933,10.1016/j.ejmech.2020.112156,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",10.1021/acs.jmedchem.1c01287,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,2
2211775,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,10.1021/acs.jmedchem.2c02067,Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.,2
37316,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
37716,10.1021/jm020311f,Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.,10.1021/jm030303e,Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.,2
1202,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1202,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1202,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1216,10.1021/jm020495y,Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.,10.1021/jm300644g,Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.,2
27611,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
27611,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
27626,10.1021/jm060961+,Progressive docking: a hybrid QSAR/docking approach for accelerating in silico high throughput screening.,10.1021/jm7011485,An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.,2
27626,10.1021/jm201556r,Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.,10.1021/jm400157e,Thiophene-core estrogen receptor ligands having superagonist activity.,2
27626,10.1021/jm201556r,Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.,10.1021/jm500670d,β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand.,2
27626,10.1021/jm201556r,Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.,10.1021/acs.jmedchem.5b01276,Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.,2
1927006,10.1021/acs.jmedchem.5b01208,Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.,10.1021/acs.jmedchem.0c01511,Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.,2
1927006,10.1021/acs.jmedchem.5b01208,Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.,10.1016/j.bmcl.2017.11.036,Discovery of new GSK-3β inhibitors through structure-based virtual screening.,2
1927156,10.1021/acs.jmedchem.9b01582,Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.,10.1016/j.ejmech.2021.113420,Progress in developing MNK inhibitors.,2
1927218,10.1016/j.ejmech.2019.111750,Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.,10.1016/j.ejmech.2023.115217,"Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.",2
1927218,10.1016/j.ejmech.2019.111750,Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.,10.1016/j.ejmech.2021.113163,"A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy.",2
1927218,10.1016/j.ejmech.2019.111750,Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.,10.1016/j.ejmech.2020.112703,"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).",2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/j.ejmech.2017.04.003,Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view.,2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/j.bmcl.2016.11.030,"Design, synthesis and anti-HIV-1 RT evaluation of 2-(benzyl(4-chlorophenyl)amino)-1-(piperazin-1-yl)ethanone derivatives.",2
1216,10.1021/jm020495y,Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.,10.1016/j.bmc.2010.03.031,"Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens.",2
1216,10.1021/jm020495y,Novel dihydrofolate reductase inhibitors. Structure-based versus diversity-based library design and high-throughput synthesis and screening.,10.1016/j.bmcl.2012.02.019,Structure aided design of chimeric antibiotics.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b00619,Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.2c00283,"Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.",2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
27340,10.1021/acsmedchemlett.2c00051,Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.,10.1021/acs.jmedchem.2c00283,"Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.",2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
27340,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.0c01477,Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.,2
27611,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
27611,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.035998,Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,2
1202,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm061045z,"Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.",2
26386,10.1016/j.bmcl.2018.01.006,Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.,10.1016/j.bmc.2021.116343,A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.,2
26386,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1021/acs.jmedchem.6b00660,Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.,2
26386,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,2
26401,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
26401,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
26401,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
27278,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
27278,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm501535r,CNS drug design: balancing physicochemical properties for optimal brain exposure.,2
27278,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,2
27307,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115812,Bivalent HIV-1 fusion inhibitors based on peptidomimetics.,2
27307,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/s0960-894x(98)00384-9,Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.,2
27307,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/s0960-894x(98)00250-9,5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.,2
27307,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.2c00203,"4,5-Dihydroxypyrimidine Methyl Carboxylates, Carboxylic Acids, and Carboxamides as Inhibitors of Human Cytomegalovirus pUL89 Endonuclease.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b00286,"Nε-Acryloyllysine Piperazides as Irreversible Inhibitors of Transglutaminase 2: Synthesis, Structure-Activity Relationships, and Pharmacokinetic Profiling.",2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,2
25047,10.1016/j.ejmech.2022.114577,Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani.,10.1016/j.ejmech.2024.116256,Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani.,2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,2
1927218,10.1016/j.ejmech.2019.111750,Effective Virtual Screening Strategy toward heme-containing proteins: Identification of novel IDO1 inhibitors.,10.1016/j.ejmech.2023.115349,"Discovery of novel sulfonamide chromone-oxime derivatives as potent indoleamine 2,3-dioxygenase 1 inhibitors.",2
1947752,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,2
26386,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1021/acs.jmedchem.2c01257,"Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2019.03.017,Small structural alterations greatly influence the membrane affinity of lipophilic ligands: Membrane interactions of bafilomycin A1 and its desmethyl derivative bearing 19F-labeling.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.7b01809,Combined Approach of Backbone Amide Linking and On-Resin N-Methylation for the Synthesis of Bioactive and Metabolically Stable Peptides.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
26386,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1016/j.bmc.2020.115598,Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.,2
26386,10.1021/acs.jmedchem.5b01289,Discovery of Novel Inhibitor Scaffolds against the Metallo-β-lactamase VIM-2 by Surface Plasmon Resonance (SPR) Based Fragment Screening.,10.1021/acs.jmedchem.3c00171,"Kinetics, Thermodynamics, and Structural Effects of Quinoline-2-Carboxylates, Zinc-Binding Inhibitors of New Delhi Metallo-β-lactamase-1 Re-sensitizing Multidrug-Resistant Bacteria for Carbapenems.",2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2017.08.027,An update on small molecules targeting CXCR4 as starting points for the development of anti-cancer therapeutics.,2
20346,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2018.02.043,The chemical diversity and structure-based evolution of non-peptide CXCR4 antagonists with diverse therapeutic potential.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2022.116698,Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.,2
1947752,10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,10.1016/j.bmcl.2018.12.042,Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.,2
21936,10.1021/jm301580n,"Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.",10.1016/j.bmcl.2013.08.112,"Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding.",2
21936,10.1021/jm301580n,"Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.",10.1021/acs.jmedchem.2c01229,"Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.",2
23466,10.1021/acsmedchemlett.7b00483,HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes.,10.1021/acs.jmedchem.0c01285,Therapeutic Targeting of MMP-12 for the Treatment of Chronic Obstructive Pulmonary Disease.,2
1987927,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c00359,Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,2
24969,10.1016/j.ejmech.2016.10.019,Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.,10.1021/acs.jmedchem.9b00387,Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.,2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2018.10.022,Leishmania treatment and prevention: Natural and synthesized drugs.,2
1987927,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2024.116759,A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.,2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2013.12.030,Novel hybrid selenosulfonamides as potent antileishmanial agents.,2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,2
25047,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2013.04.063,Anti-leishmanial evaluation of C2-aryl quinolines: mechanistic insight on bioenergetics and sterol biosynthetic pathway of Leishmania braziliensis.,2
20027,10.1021/jm300068n,Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.,10.1021/acs.jmedchem.5b00849,"Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmcl.2009.06.091,Dihydroxy-pyrimidine and N-methylpyrimidone HIV-integrase inhibitors: improving cell based activity by the quaternarization of a chiral center.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
20027,10.1021/jm300068n,Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.,10.1021/acsmedchemlett.1c00715,Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.,2
20027,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1021/ml200196p,Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.,2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1021/acs.jmedchem.1c02002,"Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.",2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1016/j.ejmech.2024.116344,"Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis.",2
20027,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1016/j.bmcl.2022.128994,"Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.",2
20346,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2017.05.030,"Novel anti-inflammatory agents targeting CXCR4: Design, synthesis, biological evaluation and preliminary pharmacokinetic study.",2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2018.02.085,Anti-inflammatory hybrids of secondary amines and amide-sulfamide derivatives.,2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2019.03.065,Development of CXCR4 modulators based on the lead compound RB-108.,2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1016/j.ejmech.2019.111823,Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.,2
20346,10.1016/j.ejmech.2016.11.026,Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.,10.1021/acs.jmedchem.4c00184,Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4.,2
18145,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
18694,10.1016/j.bmcl.2016.08.034,"Structure-activity relationship of novel series of 1,5-disubstituted tetrazoles as cyclooxygenase-2 inhibitors: Design, synthesis, bioassay screening and molecular docking studies.",10.1039/C6MD00569A,Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).,2
18696,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1021/acs.jmedchem.6b00697,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,2
18696,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,10.1016/j.ejmech.2019.111576,"Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
19573,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,2
19573,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,2
19737,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1016/j.bmcl.2022.128994,"Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.",2
19737,10.1016/j.bmcl.2018.12.043,Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.,10.1016/j.bmcl.2019.06.027,"Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.",2
19737,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1021/ml200196p,Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.,2
19737,10.1016/j.ejmech.2016.07.072,Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.,10.1016/j.ejmech.2017.02.031,"Therapeutic journey of 2,4-thiazolidinediones as a versatile scaffold: An insight into structure activity relationship.",2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1016/j.ejmech.2022.114240,A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.,2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1021/acs.jmedchem.2c02123,Discovery of the First Subnanomolar PPARα/δ Dual Agonist for the Treatment of Cholestatic Liver Diseases.,2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1016/j.ejmech.2024.116567,A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.,2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1021/acsmedchemlett.8b00574,Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.,2
20027,10.1021/acs.jmedchem.7b01285,"Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.",10.1016/j.ejmech.2021.114061,Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.,2
15890,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,2
15890,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2016.05.050,"New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.",2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmcl.2020.127225,"Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.",2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1219,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
16088,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.ejmech.2012.12.056,Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.,2
16088,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.bmcl.2009.11.075,Diaryl piperidines as CB1 receptor antagonists.,2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.3c01712,Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.,2
16088,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.bmcl.2010.03.068,"Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.",2
16088,10.1021/jm701519h,Identification of novel cannabinoid CB1 receptor antagonists by using virtual screening with a pharmacophore model.,10.1016/j.bmcl.2009.05.114,Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.,2
16303,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",10.1007/s00044-013-0512-9,Synthesis and antimicrobial screening of 5-(benzylidene)-3-phenylthiazolidin-4-one derivatives incorporating thiazole ring,2
16303,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,2
16303,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",2
16417,10.1016/j.bmcl.2022.129008,Identification of a new and diverse set of Mycobacterium tuberculosis uracil-DNA glycosylase (MtUng) inhibitors using structure-based virtual screening: Experimental validation and molecular dynamics studies.,10.1016/j.ejmech.2023.115604,Crystal structures of non-uracil ring fragments in complex with Mycobacterium tuberculosis uracil DNA glycosylase (MtUng) as a starting point for novel inhibitor design: A case study with the barbituric acid fragment.,2
16485,10.1016/j.ejmech.2018.11.045,Novel non-xanthine antagonist of the A<sub>2B</sub> adenosine receptor: From HTS hit to lead structure.,10.1016/j.ejmech.2021.113907,Adenosine receptor antagonists: Recent advances and therapeutic perspective.,2
16591,10.1021/acs.jmedchem.5b00170,"Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structure-Activity Relationship Study.",10.1016/j.ejmech.2017.06.028,"2-Substituted 3,7,8-trimethylnaphtho[1,2-b]furan-4,5-diones as specific L-shaped NQO1-mediated redox modulators for the treatment of non-small cell lung cancer.",2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
15890,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",10.1016/j.bmcl.2018.04.064,Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.,2
15890,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,2
15890,10.1016/j.bmcl.2013.12.071,In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.,10.1016/j.ejmech.2016.03.036,Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.,2
15890,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2017.09.047,"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.",2
15890,10.1016/j.bmc.2012.08.047,Optimization of anti-Trypanosoma cruzi oxadiazoles leads to identification of compounds with efficacy in infected mice.,10.1016/j.ejmech.2020.112418,Discovery of highly potent and selective antiparasitic new oxadiazole and hydroxy-oxindole small molecule hybrids.,2
15890,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",10.1021/acs.jmedchem.8b00999,Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.,2
15890,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,2
15890,10.1016/j.ejmech.2022.114421,Identification and development of a series of disubstituted piperazines for the treatment of Chagas disease.,10.1021/acs.jmedchem.3c00582,Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors.,2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1039/C7MD00568G,"Design, synthesis and evaluation of (<i>R</i>)-3-(7-(methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.",2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.0c01026,"Discovery and Biological Evaluation of N-Methyl-pyrrolo[2,3-b]pyridine-5-carboxamide Derivatives as JAK1-Selective Inhibitors.",2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acsmedchemlett.7b00154,JAK2 JH2 Fluorescence Polarization Assay and Crystal Structures for Complexes with Three Small Molecules.,2
1278,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1016/j.ejmech.2017.07.023,How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.,2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1021/jm901132v,Selectively nonselective kinase inhibition: striking the right balance.,2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1016/j.bmcl.2011.04.096,Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.,2
14805,10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,10.1021/acs.jmedchem.3c02302,"Discovery of Novel 5,6-Dihydro-4<i>H</i>-pyrido[2,3,4-<i>de</i>]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.",2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1016/j.ejmech.2019.05.029,"Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy.",2
14805,10.1016/j.bmcl.2006.05.090,Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",2
15086,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
15086,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
15086,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
15086,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.bmc.2018.01.021,"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.",2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
1223,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b00619,Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.,2
14440,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1021/jm8003653,"Discovery of 2-chloro-N-(4-methoxyphenyl)-N-methylquinazolin-4-amine (EP128265, MPI-0441138) as a potent inducer of apoptosis with high in vivo activity.",2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,2
14785,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.bmc.2012.08.043,"Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase.",2
14785,10.1073/pnas.0707498104,Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.,10.1016/j.bmc.2012.08.020,"Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.",2
14785,10.1016/j.bmcl.2007.10.084,Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.,10.1016/j.ejmech.2018.12.011,"Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors.",2
1256,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
1256,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
1256,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1256,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
1256,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
1278,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1278,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm9810102,Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm701044r,Multiple N-methylation by a designed approach enhances receptor selectivity.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2022.116698,Synthesis and evaluation of dual fatty acid amide hydrolase-monoacylglycerol lipase inhibition and antinociceptive activities of 4-methylsulfonylaniline-derived semicarbazones.,2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
1763569,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.2c01550,Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.,2
1763572,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
1782495,10.1021/acs.jmedchem.1c01250,"Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with <i>In Vivo</i> Efficacy against MRSA.",10.1016/j.bmcl.2022.128808,"Structure activity relationship of N-1 substituted 1,5-naphthyrid-2-one analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-9).",2
1782495,10.1021/acs.jmedchem.1c01250,"Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with <i>In Vivo</i> Efficacy against MRSA.",10.1021/acsmedchemlett.4c00162,Development of Novel Bacterial Topoisomerase Inhibitors Assisted by Computational Screening.,2
1817518,10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,10.1021/acs.jmedchem.1c00848,"Design of a ""Two-in-One"" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites.",2
1817518,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
1579887,10.1021/jm400815m,Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.,10.1021/acs.jmedchem.4c00489,"Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants.",2
1579887,10.1021/jm400815m,Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.,10.1016/j.bmcl.2018.01.014,"Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.",2
1579887,10.1021/jm400815m,Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.,10.1021/acs.jmedchem.4c00464,Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist.,2
1583828,10.1021/acs.jmedchem.8b00900,"A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).",10.1021/acs.jmedchem.8b01668,Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.,2
14367,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
14367,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
1279,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
1280,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1280,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2016.10.014,"Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation.",2
1606934,10.1021/acs.jmedchem.7b01466,"Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.",10.1016/j.ejmech.2022.114170,Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,2
1624674,10.1021/acsmedchemlett.5b00102,Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.,10.1021/acs.jmedchem.6b00638,Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.,2
1624674,10.1021/acsmedchemlett.5b00102,Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.,10.1016/j.ejmech.2020.112220,"Design, synthesis and biological evaluation of 1H-pyrazolo [3,4-d]pyrimidine derivatives as PAK1 inhibitors that trigger apoptosis, ER stress and anti-migration effect in MDA-MB-231 cells.",2
1624674,10.1021/acsmedchemlett.5b00102,Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.,10.1016/j.ejmech.2020.112517,Design and synthesis of 1H-indazole-3-carboxamide derivatives as potent and selective PAK1 inhibitors with anti-tumour migration and invasion activities.,2
14440,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",2
1519188,10.1021/acs.jmedchem.7b00598,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",10.1021/acs.jmedchem.8b01906,Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na<sub>V</sub>1.7.,2
14440,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.04.145,"Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers.",2
1519188,10.1021/acs.jmedchem.7b00598,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",10.1021/acs.jmedchem.0c00259,"Discovery of DS-1971a, a Potent, Selective Na<sub>V</sub>1.7 Inhibitor.",2
14440,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",2
14440,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.03.121,Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay.,2
1519188,10.1021/acs.jmedchem.7b00598,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",10.1016/j.bmcl.2017.09.056,Highly potent and selective NaV1.7 inhibitors for use as intravenous agents and chemical probes.,2
1333,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.bmc.2011.08.051,"Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/jm100732t,"A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/jm100080z,"5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.6b00618,Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.,2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2013.07.003,"Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2021.113281,"Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.bmcl.2012.08.117,"Design, synthesis and anticancer activity of 1-acyl-3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/jm301475f,"Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.",2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1021/acs.jmedchem.1c02064,From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.,2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2021.113389,Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.,2
14221,10.1021/jm800382h,"Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.",10.1016/j.ejmech.2019.01.003,Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.,2
14366,10.1016/j.ejmech.2020.112355,Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.,10.1021/acs.jmedchem.4c00312,Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.,2
14366,10.1016/j.ejmech.2020.112355,Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.,10.1021/acs.jmedchem.0c00744,Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.,2
14366,10.1016/j.ejmech.2020.112355,Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.,10.1039/d2md00040g,CDK9 inhibitors in cancer research.,2
14367,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/s0960-894x(98)00111-5,"Preparation of 9-deoxo-4""-deoxy-6,9-epoxyerythromycin lactams ""motilactides"": potent and orally active prokinetic agents.",2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/j.bmc.2010.08.035,9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety.,2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/j.bmcl.2011.04.078,The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.,2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1021/jm0304865,Discovery of a potent and novel motilin agonist.,2
13048,10.1016/j.bmcl.2012.09.043,Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.,10.1016/j.ejmech.2017.04.039,The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.,2
1519188,10.1021/acs.jmedchem.7b00598,"Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.",10.1039/d2md00081d,Inhibition of Na<sub>V</sub>1.7: the possibility of ideal analgesics.,2
13494,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,2
1528018,10.1021/acsmedchemlett.5b00394,Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.,10.1021/acs.jmedchem.9b00688,Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.,2
1528018,10.1021/acsmedchemlett.5b00394,Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.,10.1016/j.bmcl.2022.129007,Synthesis and biological evaluation of (4-hydroxy-2-(substitued sulfonamido)pyrimidine-5-carbonyl)glycines as oral erythropoietin secretagogues.,2
1528018,10.1021/acsmedchemlett.5b00394,Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.,10.1016/j.ejmech.2022.114115,Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.,2
13494,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
13494,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1038/nchembio.215,Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.,2
1280,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1280,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,2
1369,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1370,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.035998,Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b02008,"Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.",2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm5019687,"A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.",2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,2
1528018,10.1021/acsmedchemlett.5b00394,Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.,10.1021/acs.jmedchem.8b00549,"Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.",2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/j.bmcl.2006.08.076,"Design, synthesis and in vivo activity of 9-(S)-dihydroerythromycin derivatives as potent anti-inflammatory agents.",2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1016/j.bmcl.2010.08.030,9-Dihydroerythromycins as non-antibiotic motilin receptor agonists.,2
12506,10.1021/jm00010a024,"Synthesis of 4""-deoxy motilides: identification of a potent and orally active prokinetic drug candidate.",10.1021/jm901107f,Structure-activity relationships of 9-substituted-9-dihydroerythromycin-based motilin agonists: optimizing for potency and safety.,2
1333,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1333,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1333,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
1333,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1370,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm901036q,Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.,2
1370,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm991156g,SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans.,2
11305,10.1016/j.bmcl.2008.09.003,Optimization of a series of potent and selective ketone histone deacetylase inhibitors.,10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,2
11305,10.1016/j.bmcl.2008.09.003,Optimization of a series of potent and selective ketone histone deacetylase inhibitors.,10.1016/j.bmcl.2009.04.011,Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.,2
1528018,10.1021/acsmedchemlett.5b00394,Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors.,10.1021/acs.jmedchem.0c01161,"Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.",2
11305,10.1016/j.ejmech.2020.112189,"Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.",10.1016/j.ejmech.2021.113946,Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).,2
11305,10.1016/j.bmcl.2013.07.001,Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.,10.1021/acs.jmedchem.8b00209,"Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.",2
11501,10.1016/j.bmcl.2020.126952,Screening for tyrosinase inhibitors from actinomycetes; identification of trichostatin derivatives from Streptomyces sp. CA-129531 and scale up production in bioreactor.,10.1021/acs.jnatprod.1c00324,"Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from <i>Streptomyces</i> sp. 13F051.",2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.1c00910,Strategies for Structural Modification of Small Molecules to Improve Blood-Brain Barrier Penetration: A Recent Perspective.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1362,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,2
1369,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,2
1369,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,2
10661,10.1021/jm2011589,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,10.1021/acs.jmedchem.6b00981,Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment Optimization.,2
10747,10.1016/j.ejmech.2018.12.061,Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.,10.1021/acsmedchemlett.3c00063,"Discovery of Potent, Dual-Inhibitors of Diacylglycerol Kinases Alpha and Zeta Guided by Phenotypic Optimization.",2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.8b00619,Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/acs.jmedchem.5b00128,Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm901654x,N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttles.,2
11005,10.1021/acs.jmedchem.5b01154,"Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening.",10.1021/acs.jmedchem.5b01732,Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.,2
11005,10.1021/acs.jmedchem.5b01154,"Discovery and Optimization of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Pharmacophore- and Docking-Based Virtual Screening.",10.1016/j.bmc.2016.07.024,Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.,2
11305,10.1016/j.ejmech.2020.112189,"Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.",10.1016/j.bmc.2021.116251,Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.,2
11305,10.1016/j.bmcl.2009.04.102,Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.,10.1016/j.bmc.2011.11.041,"Synthesis and biochemical analysis of 2,2,3,3,4,4,5,5,6,6,7,7-dodecafluoro-N-hydroxy-octanediamides as inhibitors of human histone deacetylases.",2
11305,10.1016/j.bmcl.2013.07.001,Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.,10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,2
1566719,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1021/acs.jmedchem.6b01761,Drug Discovery Targeting Bromodomain-Containing Protein 4.,2
1566719,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.ejmech.2018.11.018,Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.,2
11305,10.1016/j.bmcl.2013.07.001,Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,2
11305,10.1016/j.ejmech.2020.112189,"Design, synthesis and biological evaluation of novel indazole-based derivatives as potent HDAC inhibitors via fragment-based virtual screening.",10.1016/j.ejmech.2023.115303,"Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs.",2
1566719,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1021/acs.jmedchem.9b01010,"Discovery of Benzo[<i>cd</i>]indol-2(1<i>H</i>)-ones and Pyrrolo[4,3,2-<i>de</i>]quinolin-2(1<i>H</i>)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.",2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,2
8873,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,2
1370,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
1566719,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.ejmech.2021.113853,Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.,2
8873,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,2
8873,10.1021/acsmedchemlett.5b00029,Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.,10.1021/acs.jnatprod.3c00382,Persephacin Is a Broad-Spectrum Antifungal Aureobasidin Metabolite That Overcomes Intrinsic Resistance in <i>Aspergillus fumigatus</i>.,2
8873,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,2
8873,10.1016/j.ejmech.2022.114577,Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against Leishmania donovani.,10.1016/j.ejmech.2023.115445,Hit-to-lead optimization of a pyrazinylpiperazine series against Leishmania infantum and Leishmania braziliensis.,2
8873,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",2
8873,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,2
8873,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1021/jm060156v,Activity of and initial mechanistic studies on a novel antileishmanial agent identified through in silico pharmacophore development and database searching.,2
8917,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.bmc.2018.02.014,"Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.",2
9097,10.1021/acs.jmedchem.7b01223,The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen.,10.1021/acs.jmedchem.8b01869,Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.,2
9372,10.1016/j.ejmech.2021.113779,From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.,10.1016/j.ejmech.2022.114825,In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease.,2
10389,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1021/jm800156z,Toward an optimal blood-brain barrier shuttle by synthesis and evaluation of peptide libraries.,2
1370,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
1529,10.1016/j.bmcl.2010.06.128,Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening.,10.1016/j.bmcl.2022.128994,"Design, synthesis, in-vitro, in-vivo and ex-vivo pharmacology of thiazolidine-2,4-dione derivatives as selective and reversible monoamine oxidase-B inhibitors.",2
1570706,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.05.012,"Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2: Structure-activity relationships of the 4-, 5-, 6-, 7- and 8-positions.",2
1331852,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
1340894,10.1021/acs.jmedchem.6b01055,Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen.,10.1021/acsmedchemlett.8b00364,Privileged Structures and Polypharmacology within and between Protein Families.,2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmc.2011.09.060,"2-Anilinonicotinyl linked 2-aminobenzothiazoles and [1,2,4]triazolo[1,5-b] [1,2,4]benzothiadiazine conjugates as potential mitochondrial apoptotic inducers.",2
1347273,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
1348407,10.1021/acs.jmedchem.8b00648,"Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.",10.1021/acs.jmedchem.4c01154,"2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of &lt;i&gt;Plasmodium falciparum&lt;/i&gt; Phosphatidylinositol-4-kinase and Hemozoin Formation with &lt;i&gt;In Vivo&lt;/i&gt; Efficacy.",2
1348407,10.1021/acs.jmedchem.8b00648,"Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,2
8167,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
8873,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,2
8873,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",2
8062,10.1016/j.ejmech.2021.113930,Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.,10.1016/j.ejmech.2023.115881,"Design, synthesis and biological evaluation of novel dihydroquinolin-4(1H)-one derivatives as novel tubulin polymerization inhibitors.",2
1377720,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2007.05.098,"Discovery of 5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-7-phenyl-(E)-2,3,6,7-tetrahydro-1,4-thiazepines as a new series of apoptosis inducers using a cell- and caspase-based HTS assay.",2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c01952,"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.",2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.3c00050,Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.,2
1378029,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2022.114551,Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.,2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.11.025,Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure-activity relationships of the 9-oxo-9H-fluorene ring.,2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1016/j.bmcl.2009.05.052,"Discovery of 3-aryl-5-aryl-1,2,4-oxadiazoles as a new series of apoptosis inducers. 2. Identification of more aqueous soluble analogs as potential anticancer agents.",2
1423605,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2015.08.051,"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease.",2
8062,10.1021/jm0205200,Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.,10.1021/jm7010657,"Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high throughput screening assay. 4. Structure-activity relationships of N-alkyl substituted pyrrole fused at the 7,8-positions.",2
1423605,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1021/acs.jmedchem.1c00703,"Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease.",2
1423605,10.1021/jm300953p,Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease.,10.1021/acs.jmedchem.8b00457,"Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists.",2
1370,10.1021/jm970530e,Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,2
6936,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,10.1016/j.ejmech.2021.113454,Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2010.05.095,"Discovery of novel 1H-imidazol-2-yl-pyrimidine-4,6-diamines as potential antimalarials.",2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4006077,4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.,2
6936,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,2
6968,10.1073/pnas.0709695104,Small molecule regulators of autophagy identified by an image-based high-throughput screen.,10.1021/jm2011657,Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.,2
6968,10.1021/jm0700262,Target specific virtual screening: optimization of an estrogen receptor screening platform.,10.1021/jm100369g,Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.,2
6968,10.1021/jm0700262,Target specific virtual screening: optimization of an estrogen receptor screening platform.,10.1016/j.bmc.2019.115261,Optimisation of estrogen receptor subtype-selectivity of a 4-Aryl-4H-chromene scaffold previously identified by virtual screening.,2
6968,10.1021/jm0700262,Target specific virtual screening: optimization of an estrogen receptor screening platform.,10.1016/j.ejmech.2013.06.048,3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors.,2
6968,10.1016/j.bmcl.2007.02.002,Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.,10.1021/jm3013773,Synthesis of novel estrogen receptor antagonists using metal-catalyzed coupling reactions and characterization of their biological activity.,2
7714,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
7714,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
7714,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1016/j.ejmech.2019.111643,Practical approaches to evaluating and optimizing brain exposure in early drug discovery.,2
7736,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
7736,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
7736,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
7736,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
6936,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,10.1039/C1MD00129A,"Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors",2
6936,10.1021/jm020142z,"Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.",10.1016/j.ejmech.2018.12.007,Current scenario of artemisinin and its analogues for antimalarial activity.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",2
6936,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,2
6936,10.1021/jm020142z,"Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.",10.1016/j.bmcl.2021.128522,Novel hydrazone derivatives of N-amino-11-azaartemisinin with high order of antimalarial activity against multidrug-resistant Plasmodium yoelii nigeriensis in Swiss mice via intramuscular route.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,2
6936,10.1021/jm020142z,"Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.",10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acsmedchemlett.1c00697,Enantiopure Benzofuran-2-carboxamides of 1-Aryltetrahydro-β-carbolines Are Potent Antimalarials <i>In Vitro</i>.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm100938u,"A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.",2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
6936,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
6936,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,10.1016/j.ejmech.2019.111983,Current progress in antimalarial pharmacotherapy and multi-target drug discovery.,2
6936,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1039/C1MD00129A,"Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors",2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,2
1214046,10.1016/j.bmcl.2018.07.008,"Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.",10.1016/j.ejmech.2022.114940,"Discovery of orally active 1,4,5,6,8-pentaazaacenaphthylens as novel, selective, and potent covalent BTK inhibitors for the treatment of rheumatoid arthritis.",2
6936,10.1016/j.bmcl.2014.01.074,Identification of diverse natural products as falcipain-2 inhibitors through structure-based virtual screening.,10.1021/acs.jmedchem.9b00504,Falcipain Inhibitors Based on the Natural Product Gallinamide A Are Potent in Vitro and in Vivo Antimalarials.,2
1225404,10.1021/acs.jmedchem.0c02047,Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,2
1788,10.1021/acs.jmedchem.9b01561,Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity.,10.1016/j.ejmech.2022.114946,Pyrimidine derivatives with antitubercular activity.,2
1788,10.1016/j.bmc.2017.11.031,Lead identification and optimization of bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.112010,"Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.",2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acs.jmedchem.6b00275,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,2
6643,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
6643,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
6643,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
6643,10.1016/j.bmcl.2020.127602,"Hit-to-lead optimization and discovery of a potent, and orally bioavailable G protein coupled receptor kinase 2 (GRK2) inhibitor.",10.1016/j.ejmech.2022.114668,Targeting GRK2 and GRK5 for treating chronic degenerative diseases: Advances and future perspectives.,2
6643,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
1281805,10.1021/acs.jmedchem.0c00311,Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.,10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,2
6936,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acs.jmedchem.0c00311,Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria.,2
6579,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acs.jmedchem.3c00206,Basic Nitrogen (BaN) Is a Key Property of Antimalarial Chemical Space.,2
6579,10.1016/j.ejmech.2022.115055,"Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents.",10.1016/j.ejmech.2023.115564,Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2020.112652,"An insight on medicinal attributes of 1,2,4-triazoles.",2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2019.111681,Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.,2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,2
6579,10.1016/j.ejmech.2022.115055,"Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents.",10.1039/d3md00490b,Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of <i>Plasmodial</i> cysteine protease inhibitors for the treatment of malaria.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm100410f,Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1038/nchembio.215,Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm3007596,Salicylanilide inhibitors of Toxoplasma gondii.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmcl.2015.01.003,Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.6b00028,Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials.,2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2019.01.027,"1,2,4-Triazolo[1,5-a]pyrimidines in drug design.",2
1281805,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acs.jmedchem.9b00761,The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
6579,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,10.1039/C8MD00608C,Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles.,2
1297331,10.1016/j.bmc.2018.06.027,Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.,10.1021/acs.jmedchem.4c01458,"Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of <i>CCNE1</i>-Amplified Breast Cancer.",2
1322310,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1021/ml5004876,"Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.",2
6579,10.1021/acs.jmedchem.8b01333,"Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.",10.1021/acs.jmedchem.0c01411,"Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model.",2
1322310,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1021/jm400926x,"Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.",2
1322310,10.1021/jm300967g,"Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.",10.1016/j.bmc.2016.07.019,"Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.",2
1153572,10.1021/acs.jmedchem.8b00076,Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.,10.1016/j.bmcl.2019.04.011,"Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.",2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/ml4002858,"Pharmacokinetics, metabolism, and in vivo efficacy of the antimalarial natural product bromophycolide A.",2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.3c00050,Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2022.114551,Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.,2
1153572,10.1021/acsmedchemlett.2c00051,Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.,10.1021/acs.jmedchem.2c00283,"Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.",2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1021/acs.jmedchem.6b00275,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.4c00197,Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.,2
6579,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,10.1021/acs.jmedchem.1c00354,Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and <i>In Vivo</i> Oral Efficacy Studies.,2
1153572,10.1021/acs.jmedchem.8b00076,Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.,10.1021/acs.jmedchem.9b01392,Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/ml2001517,Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).,2
1153572,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1021/acs.jmedchem.3c00050,Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.,2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.8b00076,Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors.,2
6579,10.1016/j.ejmech.2022.115055,"Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents.",10.1039/d3md00423f,"Naphthyl bearing 1,3,4-thiadiazoleacetamides targeting the parasitic folate pathway as anti-infectious agents: <i>in silico</i>, synthesis, and biological approach.",2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.9b01392,Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmc.2015.01.036,Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of Plasmodium falciparum parasites.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2021.113227,Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity.,2
1153572,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm100938u,"A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,2
1214046,10.1016/j.bmcl.2018.07.008,"Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.",10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmc.2022.116830,"New antimalarials identified by a cell-based phenotypic approach: Structure-activity relationships of 2,3,4,9-tetrahydro-1H-β-carboline derivatives possessing a 2-((coumarin-5-yl)oxy)alkanoyl moiety.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.5b01605,A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
1214046,10.1016/j.bmcl.2018.07.008,"Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.",10.1016/j.bmcl.2018.09.018,Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.,2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.ejmech.2019.01.047,Triazole derivatives and their antiplasmodial and antimalarial activities.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",2
1214046,10.1016/j.bmc.2018.01.008,Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.,10.1021/acs.jmedchem.9b01346,Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma.,2
6579,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",2
694811,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,10.1016/j.bmc.2020.115601,"Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors.",2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.bmcl.2017.09.025,"Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.",2
6579,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/acs.jmedchem.3c00206,Basic Nitrogen (BaN) Is a Key Property of Antimalarial Chemical Space.,2
2080,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,2
6579,10.1016/j.ejmech.2022.115055,"Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents.",10.1039/d3md00083d,Is structural hybridization invoking new dimensions for antimalarial drug discovery research?,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acsmedchemlett.6b00416,Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against Plasmodium falciparum.,2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/jm500853v,"Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.",2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1021/jm501174m,Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.,2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/acs.jmedchem.1c00855,"Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.",2
6579,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/ml200135p,An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS.,2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1021/acs.jmedchem.2c01102,Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,2
6579,10.1021/jm020142z,"Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates.",10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,2
6579,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,2
6579,10.1101/2020.03.20.999730,Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs,10.1101/2020.04.21.054387,Identification of potential treatments for COVID-19 through artificial intelligence-enabled phenomic analysis of human cells infected with SARS-CoV-2,2
6579,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1039/C1MD00129A,"Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,2
2080,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
708075,10.1021/acs.jmedchem.9b00091,"Discovery, Optimization, and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors.",10.1021/acs.jmedchem.9b00775,Drugs for the Treatment of Zika Virus Infection.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
2080,10.1021/jm1010572,"Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.",10.1021/acs.jmedchem.8b02021,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,2
6005,10.1021/acs.jmedchem.8b01136,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,10.1021/acs.jmedchem.1c00611,Novel Dual-Target μ-Opioid Receptor and Dopamine D<sub>3</sub> Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management.,2
6216,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1016/j.ejmech.2019.111643,Practical approaches to evaluating and optimizing brain exposure in early drug discovery.,2
6216,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
6216,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
6216,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acsmedchemlett.1c00697,Enantiopure Benzofuran-2-carboxamides of 1-Aryltetrahydro-β-carbolines Are Potent Antimalarials <i>In Vitro</i>.,2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmc.2008.11.009,"Synthesis and antimalarial activity of new 4-amino-7-chloroquinolyl amides, sulfonamides, ureas and thioureas.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm401675a,Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites.,2
712090,10.1016/j.bmcl.2016.03.111,Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.,10.1016/j.ejmech.2021.113652,"Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.",2
6579,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm400656s,Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.,2
712273,10.1021/acs.jmedchem.7b00162,"Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist.",10.1021/acs.jmedchem.8b00743,Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
1051118,10.1021/jm2011589,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,10.1021/acs.jmedchem.6b00981,Identification of Ligand Binding Hot Spots of the Histamine H1 Receptor following Structure-Based Fragment Optimization.,2
2080,10.1021/jm1010572,"Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.",10.1021/jm300563f,Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.,2
2080,10.1021/jm1010572,"Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.",10.1039/d3md00423f,"Naphthyl bearing 1,3,4-thiadiazoleacetamides targeting the parasitic folate pathway as anti-infectious agents: <i>in silico</i>, synthesis, and biological approach.",2
2080,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,2
1052695,10.1016/j.bmcl.2012.06.091,The optimization of pyridazinone series of glucan synthase inhibitors.,10.1021/acs.jmedchem.0c00748,Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall.,2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",2
1153572,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",10.1021/acs.jmedchem.0c01952,"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.",2
1153572,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",2
6005,10.1021/acs.jmedchem.8b01136,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,10.1021/acs.jmedchem.1c01111,Oxidative Metabolism as a Modulator of Kratom's Biological Actions.,2
6005,10.1021/acs.jmedchem.8b01136,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,10.1016/j.ejmech.2019.111701,Progress in the development of more effective and safer analgesics for pain management.,2
6005,10.1021/acs.jmedchem.8b01136,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,10.1021/acs.jmedchem.3c01637,A Novel Bifunctional μOR Agonist and σ<sub>1</sub>R Antagonist with Potent Analgesic Responses and Reduced Adverse Effects.,2
2080,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,2
2080,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1021/acs.jmedchem.5b01605,A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.,2
694811,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",2
241,10.1021/jm401208b,Fragment-to-hit-to-lead discovery of a novel pyridylurea scaffold of ATP competitive dual targeting type II topoisomerase inhibiting antibacterial agents.,10.1016/j.bmc.2016.10.038,"Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors.",2
4941,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1039/d3md00115f,"Design, synthesis and biological evaluation of phenanthridine amide and 1,2,3-triazole analogues against <i>Mycobacterium tuberculosis</i>.",2
694811,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,10.1016/j.ejmech.2018.04.034,"Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",2
4941,10.1016/j.bmcl.2011.07.015,Identification of SQ609 as a lead compound from a library of dipiperidines.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,2
4941,10.1016/j.ejmech.2010.09.063,Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols.,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,2
4941,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,2
4941,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1021/acs.jmedchem.7b01332,"Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity.",2
4941,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,2
4941,10.1128/aac.00055-06,Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.,10.1021/acs.jmedchem.1c00837,"1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in <i>Mycobacterium tuberculosis</i>.",2
2080,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1016/j.ejmech.2018.04.034,"Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.",2
4941,10.1016/j.ejmech.2010.09.063,Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols.,10.1016/j.bmcl.2011.06.040,"Synthesis, molecular modeling and bio-evaluation of cycloalkyl fused 2-aminopyrimidines as antitubercular and antidiabetic agents.",2
4941,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.ejmech.2013.10.082,"Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis.",2
2080,10.1021/jm2003359,Imidazolopiperazines: hit to lead optimization of new antimalarial agents.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
2080,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",2
4941,10.1016/j.bmc.2017.11.031,Lead identification and optimization of bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.112010,"Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/acs.jmedchem.2c01102,Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.,2
694811,10.1021/jm201283q,Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides.,10.1021/jm300915b,Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.,2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1016/j.ejmech.2019.111633,"Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.",2
694811,10.1021/acs.jmedchem.6b00070,"Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).",10.1021/acs.jmedchem.7b00193,"Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.",2
4941,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1016/j.ejmech.2016.07.039,Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.,2
4941,10.1016/j.bmcl.2011.07.015,Identification of SQ609 as a lead compound from a library of dipiperidines.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,2
4941,10.1016/j.bmcl.2011.07.015,Identification of SQ609 as a lead compound from a library of dipiperidines.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,2
2080,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1016/j.bmc.2008.08.046,CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm401430e,Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases.,2
4941,10.1016/j.bmcl.2011.07.015,Identification of SQ609 as a lead compound from a library of dipiperidines.,10.1016/j.ejmech.2016.09.030,"Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: Design, synthesis and evaluation of anti-tubercular activity.",2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.bmc.2018.11.020,"Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.",2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,2
4941,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.ejmech.2018.11.025,"Benzofuran derivatives and their anti-tubercular, anti-bacterial activities.",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,2
4941,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,2
4941,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.bmcl.2013.07.048,"Design, synthesis and antitubercular evaluation of novel 2-substituted-3H-benzofuro benzofurans via palladium-copper catalysed Sonagashira coupling reaction.",2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,2
4941,10.1016/j.ejmech.2011.10.054,"Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.",10.1021/acs.jmedchem.5b00608,"Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis.",2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1021/acsmedchemlett.8b00003,Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.,2
4941,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,2
4941,10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1021/acsmedchemlett.8b00003,Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.,2
4941,10.1016/j.ejmech.2011.02.047,Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.,10.1016/j.ejmech.2012.12.012,Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/acsmedchemlett.5b00048,Discovery of Triazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.ejmech.2014.10.027,1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm301408t,Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm301408t,Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm3003872,"Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.",2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm101120u,"Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.",2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1016/j.bmcl.2010.11.040,N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm0702938,Imidazolylmethylbenzophenones as highly potent aromatase inhibitors.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm3004637,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm3003872,"Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.",2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.ejmech.2014.12.022,"Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.",2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm3004637,Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm301844q,Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11β-hydroxylase inhibition.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101470k,"Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.",2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/acs.jmedchem.5b00079,"Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.",2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1016/j.bmcl.2010.11.040,N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,2
4872,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1016/j.ejmech.2023.115893,Drug repurposing and structure-based discovery of new PDE4 and PDE5 inhibitors.,2
4872,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,2
4872,10.1021/acs.jmedchem.9b00518,Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm100319h,"Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation.",2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1016/j.ejmech.2017.05.041,Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm500140c,Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.,2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.9b01835,Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands.,2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.7b00584,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/acs.jmedchem.6b01194,Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.,2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1021/ml200206z,Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.,2
2214,10.1021/jm801354e,Selective 5-hydroxytryptamine 2C receptor agonists derived from the lead compound tranylcypromine: identification of drugs with antidepressant-like action.,10.1016/j.ejmech.2019.111626,Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.,2
4920,10.1021/jm060186y,Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme.,10.1021/jm800683c,Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm400484p,Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.,2
4920,10.1021/jm800888q,"In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives.",10.1021/jm101120u,"Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.",2
4345,10.1021/jm800473d,"Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.",10.1016/j.bmc.2016.04.018,"Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.",2
4345,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2012.12.027,"N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.",2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2016.06.065,"Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.",2
4345,10.1021/jm00062a027,"Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2011.12.132,Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2019.06.047,Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acsmedchemlett.8b00549,Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.,2
4345,10.1021/jm800473d,"Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.",10.1016/j.bmc.2014.04.018,Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1021/acsmedchemlett.0c00612,Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.04.010,"1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.",2
4345,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/jm020427b,Kinase inhibitors: not just for kinases anymore.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1016/j.ejmech.2018.02.080,Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.,2
3859,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
2223,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
2223,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
3859,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
3859,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1016/j.ejmech.2019.111643,Practical approaches to evaluating and optimizing brain exposure in early drug discovery.,2
3859,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,2
694811,10.1021/jm401088k,Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.,10.1016/j.ejmech.2018.04.034,"Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.",2
3965,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2013.06.040,"Synthesis, antileishmanial activity and structure-activity relationship of 1-N-X-phenyl-3-N'-Y-phenyl-benzamidines.",2
3965,10.1021/jm0493717,Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database.,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,2
3965,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,2
3965,10.1021/jm0505765,Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,2
3965,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,2
3965,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",2
3965,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2021.114088,Efficient targeted oncogenic KRAS<sup>G12C</sup> degradation via first reversible-covalent PROTAC.,2
2286003,10.1016/j.ejmech.2022.114382,"Discovery of novel non-steroidal selective glucocorticoid receptor modulators by structure- and IGN-based virtual screening, structural optimization, and biological evaluation.",10.1021/acs.jmedchem.2c01082,Discovery and Optimization of <i>N</i>-Acyl-6-sulfonamide-tetrahydroquinoline Derivatives as Novel Non-Steroidal Selective Glucocorticoid Receptor Modulators.,2
146,10.1016/j.ejmech.2016.06.042,Engineering another class of anti-tubercular lead: Hit to lead optimization of an intriguing class of gyrase ATPase inhibitors.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,2
148,10.1021/jm060112m,Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.,10.1016/j.bmcl.2009.04.076,Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.,2
148,10.1021/jm060112m,Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application.,10.1021/jm070909t,Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationships.,2
2335154,10.1016/j.bmcl.2020.127417,New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.,10.1021/acs.jmedchem.3c01868,"Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist.",2
2335154,10.1016/j.bmcl.2020.127417,New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.,10.1021/acs.jmedchem.1c00863,Synthesis and Characterization of New V<sub>1A</sub> Antagonist Compounds: The Separation of Four Atropisomeric Stereoisomers.,2
2335325,10.1021/jm301296t,Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).,10.1021/jm4007033,Current status of the research and development of diacylglycerol O-acyltransferase 1 (DGAT1) inhibitors.,2
2335325,10.1021/jm301296t,Design and optimization of pyrazinecarboxamide-based inhibitors of diacylglycerol acyltransferase 1 (DGAT1) leading to a clinical candidate dimethylpyrazinecarboxamide phenylcyclohexylacetic acid (AZD7687).,10.1021/acs.jmedchem.9b01701,The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.,2
2335425,10.1021/acs.jmedchem.1c00365,"Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.",10.1021/acs.jmedchem.1c02168,CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.,2
2335425,10.1021/acs.jmedchem.1c00365,"Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.",10.1021/acs.jmedchem.3c02104,Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.,2
2335425,10.1021/acs.jmedchem.1c00365,"Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors.",10.1021/acs.jmedchem.2c00100,"Structure-Based Discovery and Optimization of Furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.",2
2341275,10.1021/acs.jmedchem.5b01882,Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.,10.1016/j.ejmech.2019.01.084,Clinical candidates modulating protein-protein interactions: The fragment-based experience.,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1016/j.bmc.2023.117153,"Design, synthesis and biological evaluation of KRAS<sup>G12C</sup>-PROTACs.",2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c01773,Discovery of Novel Coumarin-quinolinium Derivatives as Pan-KRAS Translation Inhibitors by Targeting 5'-UTR RNA G-Quadruplexes.,2
3666,10.1021/jm3007245,Evaluation of new scaffolds of myeloperoxidase inhibitors by rational design combined with high-throughput virtual screening.,10.1021/acs.jmedchem.7b00285,Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.,2
2406188,10.1021/acs.jmedchem.9b02052,"Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c00746,"Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRAS<sup>G12C</sup> with Demonstrable CNS Penetration.",2
2658,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
2261,10.1073/pnas.0709695104,Small molecule regulators of autophagy identified by an image-based high-throughput screen.,10.1021/jm2011657,Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.,2
2261,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
3281,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
3599,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,2
3599,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1021/jm801441s,Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.,2
3599,10.1021/jm070375w,High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.,10.1124/dmd.111.038778,Species independence in brain tissue binding using brain homogenates.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1039/C5MD00481K,Focus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature?,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/acs.jmedchem.4c00597,Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/jm301749y,Colloidal aggregation causes inhibition of G protein-coupled receptors.,2
3666,10.1021/jm800054h,Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries.,10.1021/acs.jnatprod.6b00950,Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/acsmedchemlett.9b00093,DMSO-Perturbing Assay for Identifying Promiscuous Enzyme Inhibitors.,2
3666,10.1021/jm010533y,A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.,10.1021/jm030266r,A specific mechanism of nonspecific inhibition.,2
694811,10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",10.1016/j.ejmech.2018.04.034,"Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.",2
2355,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,2
97,10.1016/j.bmcl.2014.02.066,Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.,10.1039/C7MD00629B,Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT<sub>2</sub> and α<sub>1</sub> receptor antagonists.,1
115,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1016/j.bmcl.2011.12.008,"Structure-based design, synthesis and structure-activity relationships of dibenzosuberyl- and benzoate-substituted tropines as ligands for acetylcholine-binding protein.",1
2486781,10.1021/acs.jmedchem.0c01170,"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.2c00063,Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer.,1
2486781,10.1021/acs.jmedchem.0c01170,"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.",10.1021/acs.jmedchem.3c00521,An Analysis of Successful Hit-to-Clinical Candidate Pairs.,1
97,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
97,10.1021/jm00120a003,Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.,10.1016/0960-894X(95)00092-8,"Synthesis, biological in vitro evaluation and stereoselectivity of ondansetron analogues: novel 5-HT2A receptor antagonists",1
2486781,10.1021/acs.jmedchem.0c01170,"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2022.114106,"Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.",1
2537386,10.1016/j.ejmech.2022.114130,In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.,10.1016/j.ejmech.2023.115129,"Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.",1
2537386,10.1016/j.ejmech.2022.114130,In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.,10.1021/acs.jmedchem.3c00818,Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group.,1
2537386,10.1016/j.ejmech.2022.114130,In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.,10.1021/acs.jmedchem.2c01005,Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.,1
2537386,10.1016/j.ejmech.2022.115021,Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.,10.1016/j.ejmech.2023.115721,"Discovery of highly potent covalent SARS-CoV-2 3CL<sup>pro</sup> inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19.",1
2567647,10.1021/acs.jmedchem.0c01878,Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate.,10.1016/j.bmcl.2021.128325,Identification of 6-hydroxy-5-phenyl sulfonylpyrimidin-4(1H)-one APJ receptor agonists.,1
2733861,10.1021/acs.jmedchem.1c02132,"Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain.",10.1021/acs.jmedchem.1c02131,"Discovery of (<i>S</i>)-1-((2',6-Bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain.",1
2753453,10.1021/acs.jmedchem.2c00660,Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,10.1021/acs.jmedchem.3c01787,Discovery of Selective and Orally Available Galectin-1 Inhibitors.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/s0960-894x(02)00298-6,A comparison of the binding of three series of nicotinic ligands.,1
115,10.1016/S0960-894X(97)00347-8,Identification of novel (isoxazole)methylene-1-azabicyclic compounds with high affinity for the central nicotinic cholinergic receptor,10.1016/s0960-894x(99)00477-1,Binding affinities of 3-(3-phenylisoxazol-5-yl)methylidene-1-azabicycles to acetylcholine receptors.,1
115,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1016/j.bmc.2011.08.028,Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors.,1
115,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
115,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1021/jm100834y,Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/j.bmcl.2004.02.007,Epibatidine structure-activity relationships.,1
115,10.1021/acs.jmedchem.5b00904,"Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.",10.1016/j.ejmech.2018.04.026,"Pyridinyl- and pyridazinyl-3,6-diazabicyclo[3.1.1]heptane-anilines: Novel selective ligands with subnanomolar affinity for α4β2 nACh receptors.",1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/j.bmcl.2003.07.035,alpha4beta2 nACh receptor pharmacophore models.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/j.bmcl.2003.10.033,3-(4-Aminobutyn-1-yl)pyridines: binding at alpha 4 beta 2 nicotinic cholinergic receptors.,1
115,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1021/jm300030r,"Synthesis and nicotinic receptor activity of chemical space analogues of N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282,987) and 1,4-diazabicyclo[3.2.2]nonane-4-carboxylic acid 4-bromophenyl ester (SSR180711).",1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/s0960-894x(02)01031-4,Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors.,1
115,10.1016/S0960-894X(97)00347-8,Identification of novel (isoxazole)methylene-1-azabicyclic compounds with high affinity for the central nicotinic cholinergic receptor,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",1
97,10.1021/jm0307842,Alpha1-adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety.,10.1016/j.bmc.2010.11.051,Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to α1-adrenergic receptors among arylpiperazine derivatives of phenytoin.,1
2755078,10.1021/acs.jmedchem.2c00117,"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.",10.1016/j.ejmech.2023.115503,Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.,1
2755078,10.1021/acs.jmedchem.2c00117,"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.",10.1021/acsmedchemlett.2c00349,"Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.",1
2755078,10.1021/acs.jmedchem.2c00117,"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.",10.1021/acsmedchemlett.3c00335,"Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors.",1
2755078,10.1021/acs.jmedchem.2c00117,"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.",10.1021/acs.jmedchem.2c01146,Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.,1
2265,10.1016/j.ejmech.2007.04.009,Computational aqueous solubility prediction for drug-like compounds in congeneric series.,10.1016/j.bmc.2010.08.003,QSAR-based solubility model for drug-like compounds.,1
2261,10.1016/j.bmc.2020.115578,Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT<sub>7A</sub>R ligands.,10.1021/acs.jnatprod.2c00365,Semisynthetic Transformations on (+)-Boldine Reveal a 5-HT<sub>2A/2C</sub>R Antagonist.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/acs.jmedchem.8b01096,Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.,1
2261,10.1021/acs.jmedchem.1c00224,"Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptor Antagonist with Antipsychotic and Procognitive Properties.",10.1021/acs.jmedchem.3c02148,First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT&lt;sub&gt;6&lt;/sub&gt; Agents with a Beneficial Neuroprotective Profile against Alzheimer's Disease.,1
2261,10.1021/jm030480f,Selective optimization of side activities: another way for drug discovery.,10.1021/jm400856t,Polypharmacology - foe or friend?,1
2261,10.1039/C4MD00418C,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,10.1016/j.bmcl.2016.05.079,New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.,1
2261,10.1016/j.bmcl.2010.03.012,The development and validation of a novel virtual screening cascade protocol to identify potential serotonin 5-HT(7)R antagonists.,10.1016/j.ejmech.2012.07.043,"The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists.",1
2261,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1016/s0960-894x(98)00639-8,Butyrophenone analogues in the carbazole series: synthesis and determination of affinities at D2 and 5-HT2A receptors.,1
2261,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1039/C8MD00168E,"The role of aryl-topology in balancing between selective and dual 5-HT<sub>7</sub>R/5-HT<sub>1A</sub> actions of 3,5-substituted hydantoins.",1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1016/j.ejmech.2014.01.012,Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics.,1
2261,10.1016/j.bmcl.2010.03.012,The development and validation of a novel virtual screening cascade protocol to identify potential serotonin 5-HT(7)R antagonists.,10.1016/j.ejmech.2018.01.093,Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT7 receptor agents with antidepressant activity.,1
2261,10.1021/jm00022a004,Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.,10.1021/jm991005d,New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.,1
2261,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1016/j.bmcl.2020.127563,"Synthesis and pharmacological evaluation of 11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepines with clozapine-like receptor occupancy at dopamine D/D receptor.",1
2261,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm400408r,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm501119j,"Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.",1
2261,10.1016/j.ejmech.2012.08.011,Biotransformation of LASSBio-579 and pharmacological evaluation of p-hydroxylated metabolite a N-phenylpiperazine antipsychotic lead compound.,10.1016/j.ejmech.2013.05.027,Synthesis and pharmacological evaluation of new N-phenylpiperazine derivatives designed as homologues of the antipsychotic lead compound LASSBio-579.,1
2658,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
2658,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2007.04.068,"ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands.",1
2580,10.1016/j.ejmech.2015.01.038,Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2.,10.1016/j.bmcl.2016.09.031,Novel benzoquinoline derivatives via unpredicted condensation of ethyl propiolate and naphthylamines: Synthesis and topoisomerase inhibition activity.,1
2580,10.1016/j.ejmech.2016.09.004,Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.,10.1016/j.ejmech.2018.01.010,Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.,1
2580,10.1016/j.ejmech.2016.09.004,Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.,10.1016/j.ejmech.2017.07.050,"Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.",1
2580,10.1016/j.ejmech.2015.01.038,Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2.,10.1016/j.ejmech.2018.01.010,Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.,1
2580,10.1016/j.ejmech.2015.01.038,Boehmeriasin A as new lead compound for the inhibition of topoisomerases and SIRT2.,10.1016/j.ejmech.2018.06.004,"Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.",1
2580,10.1016/j.bmc.2010.04.074,"Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.",10.1016/j.ejmech.2010.08.061,"Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.",1
2451,10.1016/j.bmcl.2013.12.094,"Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.",10.1021/acs.jmedchem.7b00772,Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.,1
2451,10.1016/j.bmcl.2006.01.046,Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety.,10.1016/j.bmcl.2006.02.040,Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.,1
2451,10.1016/j.bmcl.2013.12.094,"Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.",10.1021/acs.jmedchem.9b01060,Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.,1
2431,10.1016/j.bmcl.2009.03.057,Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.,10.1016/j.bmcl.2009.03.031,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,1
2431,10.1016/j.bmcl.2009.03.057,Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.,10.1021/jm9008218,Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough.,1
2355,10.1021/jm9603781,A virtual screening approach applied to the search for trypanothione reductase inhibitors.,10.1016/s0960-894x(01)00528-5,Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine.,1
2355,10.1021/jm9603781,A virtual screening approach applied to the search for trypanothione reductase inhibitors.,10.1021/jm990386s,Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships.,1
2355,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
3012,10.1016/j.ejmech.2011.02.044,Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.,10.1039/C1MD00149C,"2-[(1,3-Dihydro-2H-isoindol-2-yl)methyl]melatonin  a novel MT2-selective melatonin receptor antagonist",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm960653j,1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues.,1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm200221q,"1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm048956y,Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models.,1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1016/j.bmc.2013.12.054,"New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.",1
3012,10.1016/j.ejmech.2011.02.044,Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.,10.1021/jm401343c,"MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm970246n,"Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm980026p,Pharmacophoric search and 3D-QSAR comparative molecular field analysis studies on agonists of melatonin sheep receptors.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.bmcl.2010.12.068,Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands.,1
2724,10.1021/jm9703653,New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.,10.1021/jm901689v,"Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).",1
2724,10.1021/jm00160a017,A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.,10.1021/jm9708700,N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and receptor binding studies.,1
2724,10.1021/jm00160a017,A molecular mechanics approach to the understanding of presynaptic selectivity for centrally acting dopamine receptor agonists of the phenylpiperidine series.,10.1021/jm9703653,New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans.,1
2658,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.11.066,ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.,1
2658,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.09.088,"Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/s0960-894x(98)00601-5,Synthesis of benzocycloalkane derivatives as new conformationally restricted ligands for melatonin receptors.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.bmcl.2010.02.084,Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1039/C8MD00604K,Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm960680+,Three-dimensional quantitative structure-activity relationship of melatonin receptor ligands: a comparative molecular field analysis study.,1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/acs.jmedchem.0c01836,Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm020982d,Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.,1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1021/jm0512544,Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.,1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1021/jm200790v,Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.,1
3012,10.1016/j.ejmech.2011.02.044,Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.,10.1016/j.bmc.2012.10.060,Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability.,1
3012,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",10.1016/j.ejmech.2019.111847,Indole-based melatonin analogues: Synthetic approaches and biological activity.,1
3012,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",10.1016/j.bmc.2013.12.054,"New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.",1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1021/jm200221q,"1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm060850a,"Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm960219h,"Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm980684+,"Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.",1
3012,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",10.1016/j.ejmech.2020.112090,Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.bmc.2012.12.017,N-(Phenoxyalkyl)amides as MT(1) and MT(2) ligands: antioxidant properties and inhibition of Ca(2+)/CaM-dependent kinase II.,1
3012,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",10.1016/j.ejmech.2017.02.034,Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm000922c,Synthesis of phenalene and acenaphthene derivatives as new conformationally restricted ligands for melatonin receptors.,1
3012,10.1021/acs.jmedchem.8b00893,Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit.,10.1016/j.ejmech.2019.111847,Indole-based melatonin analogues: Synthetic approaches and biological activity.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.bmc.2010.06.100,"Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.",1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1016/s0960-894x(03)00090-8,Indanyl piperazines as melatonergic MT2 selective agents.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm7010723,"Design, synthesis, and melatoninergic activity of new azido- and isothiocyanato-substituted indoles.",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1016/j.bmc.2010.06.100,"Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors.",1
3012,10.1016/j.ejmech.2011.02.044,Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.,10.1016/j.ejmech.2016.01.008,"Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity.",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1016/j.ejmech.2011.06.030,"Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm001125h,2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.bmcl.2004.04.082,Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm960651z,"Conformationally restrained melatonin analogues: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study.",1
3012,10.1021/jm020114g,Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",1
3012,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",10.1021/acs.jmedchem.1c01883,Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades.,1
2261,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1016/S0960-894X(97)00392-2,Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm0512544,Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines.,1
3012,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",10.1021/acs.jmedchem.0c01836,Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist.,1
3012,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",10.1016/j.ejmech.2015.09.003,"New coumarin-based fluorescent melatonin ligands. Design, synthesis and pharmacological characterization.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm970721h,"2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm9804937,"Melatonergic properties of the (+)- and (-)-enantiomers of N-(4-methoxy-2,3-dihydro-1H-phenalen-2-yl)amide derivatives.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm001125h,2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT2-selective melatonin antagonists.,1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm7010723,"Design, synthesis, and melatoninergic activity of new azido- and isothiocyanato-substituted indoles.",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm401343c,"MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.",1
3012,10.1021/acs.jmedchem.5b00245,"Novel N-Acetyl Bioisosteres of Melatonin: Melatonergic Receptor Pharmacology, Physicochemical Studies, and Phenotypic Assessment of Their Neurogenic Potential.",10.1016/j.ejmech.2018.07.026,Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1016/s0960-894x(98)00601-5,Synthesis of benzocycloalkane derivatives as new conformationally restricted ligands for melatonin receptors.,1
3012,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",10.1021/jm401343c,"MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm401343c,"MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm200790v,Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.,1
3012,10.1021/jm200385u,"Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.",10.1021/acs.jmedchem.0c00627,Discovery of <b>ACH-000143</b>: A Novel Potent and Peripherally Preferred Melatonin Receptor Agonist that Reduces Liver Triglycerides and Steatosis in Diet-Induced Obese Rats.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm9810093,Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm020982d,Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation.,1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1021/jm9810093,Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study.,1
2261,10.1021/jm960268u,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",10.1016/j.ejmech.2011.07.028,"Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics.",1
2261,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmcl.2015.09.045,Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.,1
2261,10.1021/jm000242+,Behavioral approach to nondyskinetic dopamine antagonists: identification of seroquel.,10.1021/jm0104825,"New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.",1
2261,10.1039/C4MD00418C,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,10.1039/C8MD00204E,Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm100294b,Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.,1
2261,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/acs.jmedchem.9b00864,Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm800689g,"Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.",1
2261,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1016/j.bmcl.2007.06.045,Synthesis and binding affinity of new pyrazole and isoxazole derivatives as potential atypical antipsychotics.,1
2261,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1039/C1MD00202C,"Potential atypical antipsychotics: synthesis, binding affinity and SAR of new heterocyclic bioisosteric butyrophenone analogues as multitarget ligands",1
2261,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1016/j.bmcl.2006.06.022,Hydrazides of clozapine: a new class of D1 dopamine receptor subtype selective antagonists.,1
2261,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2018.01.093,Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT7 receptor agents with antidepressant activity.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm049629t,"Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.",1
2261,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1016/j.bmcl.2006.06.034,Modification of the clozapine structure by parallel synthesis.,1
3666,10.1016/j.bmc.2011.07.005,Biotinylated quercetin as an intrinsic photoaffinity proteomics probe for the identification of quercetin target proteins.,10.1016/j.bmcl.2015.06.052,Regulating the master regulator: Controlling heat shock factor 1 as a chemotherapy approach.,1
3666,10.1016/j.bmc.2013.04.015,Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins.,10.1021/jm400546y,Synthesis and electrochemical and biological studies of novel coumarin-chalcone hybrid compounds.,1
3666,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.bmc.2019.115191,"Design, synthesis and biological evaluation of substituted flavones and aurones as potential anti-influenza agents.",1
3666,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1016/j.bmc.2014.06.010,Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase.,1
3666,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1021/jm200010x,Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.,1
3665,10.1016/j.bmcl.2012.04.081,"Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.",10.1016/j.ejmech.2023.116000,Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2.,1
3665,10.1021/acs.jnatprod.1c00805,Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2.,10.1016/j.ejmech.2023.115772,Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.,1
3599,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1016/j.bmcl.2012.04.045,"Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.",1
3599,10.1021/jm101459g,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",10.1039/C8MD00168E,"The role of aryl-topology in balancing between selective and dual 5-HT<sub>7</sub>R/5-HT<sub>1A</sub> actions of 3,5-substituted hydantoins.",1
3599,10.1016/j.ejmech.2017.12.099,Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.,10.1016/j.ejmech.2019.111736,"Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.",1
3599,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1021/acs.jmedchem.5b00062,Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm980684+,"Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.",1
3012,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm040768k,Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.,1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1016/j.ejmech.2011.06.030,"Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands.",1
3012,10.1021/jm9508189,Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides.,10.1021/jm970246n,"Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles.",1
3012,10.1021/jm00072a008,2-Amido-8-methoxytetralins: a series of nonindolic melatonin-like agents.,10.1016/j.ejmech.2014.03.055,Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum.,1
3683,10.1021/acs.jmedchem.1c02071,Discovery of a Novel Series of Imipridone Compounds as <i>Homo sapiens</i> Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.,10.1021/acs.jmedchem.4c00798,Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.,1
3666,10.1016/j.bmc.2008.07.031,"Identification of SVM-based classification model, synthesis and evaluation of prenylated flavonoids as vasorelaxant agents.",10.1016/j.bmcl.2009.04.120,"Synthesis, biological evaluation of prenylflavonoids as vasorelaxant and neuroprotective agents.",1
3666,10.1021/acs.jnatprod.6b00643,Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs.,10.1016/j.ejmech.2018.01.036,Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.,1
3666,10.1016/j.bmc.2021.116044,The natural-based optimization of kojic acid conjugated to different thio-quinazolinones as potential anti-melanogenesis agents with tyrosinase inhibitory activity.,10.1016/j.ejmech.2023.115672,Catechol-mimicking transition-state analogues as non-oxidizable inhibitors of tyrosinases.,1
3666,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1016/j.ejmech.2018.01.036,Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects.,1
3666,10.1016/j.bmc.2009.02.060,"Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.",10.1021/jm200607g,Low molecular weight phosphotyrosine protein phosphatases as emerging targets for the design of novel therapeutic agents.,1
3666,10.1016/j.ejmech.2010.06.034,"Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.",10.1016/j.ejmech.2014.07.056,Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.,1
3666,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2013.04.064,Superior anticancer activity of halogenated chalcones and flavonols over the natural flavonol quercetin.,1
3666,10.1021/jm801242y,Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.,10.1021/jm3009234,Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.,1
3666,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1021/acs.jmedchem.5b01674,Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.,1
3666,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
3666,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2018.05.004,A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.,1
3666,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1021/acs.jmedchem.9b01012,Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.,1
3666,10.1021/jm00107a023,"Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.",10.1016/j.bmc.2019.06.040,"5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.",1
3666,10.1021/acs.jmedchem.7b00285,Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.,10.1016/j.bmcl.2018.11.031,The development of myeloperoxidase inhibitors.,1
3666,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1016/j.bmc.2014.04.016,Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1039/d1md00105a,Studies on the affinity of 6-[(n-(cyclo)aminoalkyl)oxy]-4H-chromen-4-ones for sigma 1/2 receptors,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.4c00288,"WLB-87848, a Selective σ&lt;sub&gt;1&lt;/sub&gt; Receptor Agonist, with an Unusually Positioned NH Group as Positive Ionizable Moiety and Showing Neuroprotective Activity.",1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmcl.2018.08.016,New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.,1
3859,10.1021/jm030480f,Selective optimization of side activities: another way for drug discovery.,10.1021/jm400856t,Polypharmacology - foe or friend?,1
3859,10.1021/jm500801r,"Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.",10.1021/acs.jmedchem.9b00412,Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs).,1
3859,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1021/acs.jmedchem.3c00976,Discovery of Selective Dopamine Receptor Ligands Derived from (-)-Stepholidine via C-3 Alkoxylation and C-3/C-9 Dialkoxylation.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/acs.jmedchem.4c00288,"WLB-87848, a Selective σ&lt;sub&gt;1&lt;/sub&gt; Receptor Agonist, with an Unusually Positioned NH Group as Positive Ionizable Moiety and Showing Neuroprotective Activity.",1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.ejmech.2014.01.013,Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm300894h,Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1021/jm300894h,Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.,1
3854,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1021/acs.jmedchem.4c00537,Natural Product-Inspired Dopamine Receptor Ligands.,1
3683,10.1021/jm00120a003,Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity.,10.1016/0960-894X(95)00092-8,"Synthesis, biological in vitro evaluation and stereoselectivity of ondansetron analogues: novel 5-HT2A receptor antagonists",1
3683,10.1016/j.ejmech.2016.03.073,"5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.",10.1016/j.bmc.2017.09.018,"New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation.",1
3683,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,10.1021/acs.jmedchem.4c00131,Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.,1
3683,10.1021/jm3003679,Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo.,10.1016/j.ejmech.2019.111705,Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review.,1
2223,10.1016/j.bmc.2010.06.037,"Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.",10.1021/jm200682b,Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.,1
2223,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",1
3859,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1016/j.bmc.2014.09.024,"Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.9b01256,"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2021.113879,Optimization of bifunctional piperidinamide derivatives as σ<sub>1</sub>R Antagonists/MOR agonists for treating neuropathic pain.,1
3859,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1016/s0960-894x(98)00639-8,Butyrophenone analogues in the carbazole series: synthesis and determination of affinities at D2 and 5-HT2A receptors.,1
3859,10.1016/0960-894X(95)00011-H,A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor,10.1016/j.bmcl.2005.02.012,The role of QSAR in dopamine interactions.,1
3859,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1021/jm991005d,New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.,1
3859,10.1021/jm960268u,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",10.1016/j.ejmech.2010.02.060,Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa/thiadiazolylazetidinonyl/thiazolidinonylcarbazoles.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.ejmech.2012.04.018,Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.0c01575,EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,1
3859,10.1021/jm070516u,Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.,10.1016/j.bmcl.2008.10.035,Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmc.2011.04.002,"Design, synthesis and pharmacological evaluation of spirocyclic σ(1) receptor ligands with exocyclic amino moiety (increased distance 1).",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm800689g,"Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.bmc.2017.07.027,"Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands.",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1016/j.ejmech.2014.01.012,Synthesis and evaluation of new coumarin derivatives as potential atypical antipsychotics.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.bmc.2017.07.027,"Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands.",1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1039/C2MD20070H,Homologous piperazine-alcanols: chiral pool synthesis and pharmacological evaluation,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm200585k,Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.,1
2261,10.1021/jm00022a004,Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity.,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,1
2247,10.1021/jm500039e,"Antibacterial activity of a series of N2,N4-disubstituted quinazoline-2,4-diamines.",10.1016/j.ejmech.2021.113979,"The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates.",1
2232,10.1021/acs.jmedchem.9b01404,"Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.",10.1021/acsmedchemlett.3c00566,Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists.,1
2223,10.1021/jm200020a,"Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.",10.1016/j.bmcl.2014.11.036,Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.,1
2223,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",1
2223,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm900888c,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",1
2223,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,1
2223,10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
2223,10.1016/j.bmcl.2006.10.089,Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.,10.1016/j.bmcl.2007.02.006,Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors.,1
2223,10.1021/jm200020a,"Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.",10.1016/j.bmc.2013.11.017,"Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.",1
2223,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
2223,10.1016/j.bmcl.2006.10.089,Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.,10.1016/j.bmcl.2007.06.061,Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.,1
3859,10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,10.1021/acs.jmedchem.8b01096,Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.,1
3859,10.1021/jm990277d,A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.,10.1016/s0960-894x(03)00587-0,"1H-Pyrazolo-[3,4-c]cyclophepta[1,2-c]thiophenes: a unique structural class of dopamine D4 selective ligands.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2022.114113,Synthesis of tropane-based σ<sub>1</sub> receptor antagonists with antiallodynic activity.,1
3859,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1016/j.bmc.2016.03.037,Tetrahydroprotoberberine alkaloids with dopamine and σ receptor affinity.,1
3859,10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",10.1021/acs.jmedchem.5b01416,Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.ejmech.2016.06.001,"Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.5b01416,Synthesis and Biological Evaluation of Novel σ1 Receptor Ligands for Treating Neuropathic Pain: 6-Hydroxypyridazinones.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm400408r,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,1
3859,10.1021/acs.jmedchem.0c01575,EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,10.1016/j.ejmech.2021.114091,"Dual Sigma-1 receptor antagonists and hydrogen sulfide-releasing compounds for pain treatment: Design, synthesis, and pharmacological evaluation.",1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1021/acs.jmedchem.0c01192,Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.,1
3859,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1016/j.bmcl.2007.06.045,Synthesis and binding affinity of new pyrazole and isoxazole derivatives as potential atypical antipsychotics.,1
3859,10.1021/jm990277d,A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.,10.1021/acs.jmedchem.7b00151,Return of D4 Dopamine Receptor Antagonists in Drug Discovery.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmc.2008.12.054,Synthesis and evaluation of ligands for D2-like receptors: the role of common pharmacophoric groups.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm400408r,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmcl.2014.07.018,Further evaluation of the tropane analogs of haloperidol.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1021/jm200585k,Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.,1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1016/j.ejmech.2016.09.008,Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.bmc.2014.05.033,Pyridine analogues of spirocyclic σ₁ receptor ligands.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.ejmech.2016.09.008,Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics.,1
3859,10.1016/S0960-894X(97)00131-5,New cyclic butyrophenone derivatives in the indole series as potential atypical antipsychotics. A simple and practical synthesis of 6-aminomethyl-tetrahydroindol-4-ones and their affinites for D2 and 5-HT2A receptors,10.1039/C1MD00202C,"Potential atypical antipsychotics: synthesis, binding affinity and SAR of new heterocyclic bioisosteric butyrophenone analogues as multitarget ligands",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm100294b,Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1016/j.ejmech.2012.04.018,Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.,1
3859,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmc.2022.117032,Structure-activity relationships of mixed σ<sub>1</sub>R/σ<sub>2</sub>R ligands with antiproliferative and anticancer effects.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/acs.jmedchem.9b00864,Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1021/jm401707t,"Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.",1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,1
3859,10.1021/acs.jmedchem.0c01575,EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,10.1021/acs.jmedchem.3c00959,Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity.,1
3859,10.1021/jm00084a014,"Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.",10.1016/s0960-894x(03)00196-3,Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmc.2010.05.052,"Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1016/j.bmcl.2005.02.012,The role of QSAR in dopamine interactions.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2020.112950,Novel σ antagonists designed for tumor therapy: Structure - activity relationships of aminoethyl substituted cyclohexanes.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/acs.jmedchem.9b01256,"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ1 Receptor Antagonists for the Treatment of Pain.",1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm049629t,"Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.",1
3859,10.1016/0960-894X(95)00011-H,A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor,10.1016/s0960-894x(98)00469-7,NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists.,1
3859,10.1016/j.bmc.2009.05.079,"Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.",10.1021/acs.jmedchem.4c00537,Natural Product-Inspired Dopamine Receptor Ligands.,1
3859,10.1016/j.ejmech.2014.06.054,"Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.",10.1016/j.ejmech.2016.06.001,"Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.",1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmc.2011.12.019,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,1
3859,10.1021/jm00160a050,"Neuroleptics from the 4a,9b-cis- and 4a,9b-trans-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole series. 2.",10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,1
3859,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1021/acs.jmedchem.3c00976,Discovery of Selective Dopamine Receptor Ligands Derived from (-)-Stepholidine via C-3 Alkoxylation and C-3/C-9 Dialkoxylation.,1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1021/acs.jmedchem.6b00585,Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?,1
3859,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
3859,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1021/jm0104825,"New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.",1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmc.2022.117032,Structure-activity relationships of mixed σ<sub>1</sub>R/σ<sub>2</sub>R ligands with antiproliferative and anticancer effects.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2014.10.053,Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.2c02081,Conformationally Restricted σ<sub>1</sub> Receptor Antagonists from (-)-Isopulegol.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.3c00959,Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.bmcl.2018.08.016,New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.,1
3859,10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,10.1016/j.bmcl.2015.09.045,Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.,1
3859,10.1021/jm00388a012,"Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzim idazolone derivatives.",10.1021/jm970217c,"Design of N-acylprolyltyrosine ""tripeptoid"" analogues of neurotensin as potential atypical antipsychotic agents.",1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1016/j.bmc.2022.117032,Structure-activity relationships of mixed σ<sub>1</sub>R/σ<sub>2</sub>R ligands with antiproliferative and anticancer effects.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1021/jm300894h,Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.,1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm501119j,"Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.",1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1016/j.bmc.2017.07.027,"Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands.",1
3859,10.1016/j.ejmech.2021.113879,Optimization of bifunctional piperidinamide derivatives as σ<sub>1</sub>R Antagonists/MOR agonists for treating neuropathic pain.,10.1016/j.ejmech.2022.114649,Benzylaminofentanyl derivates: Discovery of bifunctional μ opioid and σ<sub>1</sub> receptor ligands as novel analgesics with reduced adverse effects.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmc.2017.03.014,"Synthesis of conformationally restricted 1,3-dioxanes to analyze the bioactive conformation of 1,3-dioxane-based σ1 and PCP receptor antagonists.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.bmc.2019.03.030,Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands.,1
3859,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/acs.jmedchem.8b01096,Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.bmc.2016.06.046,Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.ejmech.2014.12.018,Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.8b00848,"Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.",1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.bmc.2017.07.027,"Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ1 receptor ligands.",1
3859,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1016/j.bmc.2011.04.002,"Design, synthesis and pharmacological evaluation of spirocyclic σ(1) receptor ligands with exocyclic amino moiety (increased distance 1).",1
3859,10.1016/j.ejmech.2014.06.054,"Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.",10.1021/acs.jmedchem.6b00585,Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?,1
3859,10.1016/j.ejmech.2014.06.054,"Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.",10.1021/acs.jmedchem.0c01192,Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.,1
3859,10.1016/j.bmc.2009.05.079,"Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.",10.1021/acs.jnatprod.9b00921,"1-(2'-Bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline and 1,2-Demethyl-nuciferine as Agonists in Human D2 Dopamine Receptors.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2014.06.054,"Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.",1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.ejmech.2016.06.001,"Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.",1
3859,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1016/j.bmc.2020.115578,Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT<sub>7A</sub>R ligands.,1
3859,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.ejmech.2014.06.054,"Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.",1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1016/j.ejmech.2014.12.018,Improving selectivity preserving affinity: new piperidine-4-carboxamide derivatives as effective sigma-1-ligands.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2019.05.034,"Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and σ<sub>1</sub> receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2013.09.006,"New combination of pharmacophoric elements of potent σ₁ ligands: design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes.",1
3859,10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,10.1021/jm300302p,Thiophene bioisosteres of spirocyclic σ receptor ligands: relationships between substitution pattern and σ receptor affinity.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1021/ml2001505,Homology Model and Docking-Based Virtual Screening for Ligands of the σ1 Receptor.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1016/j.ejmech.2014.10.053,Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands.,1
3965,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
3965,10.1016/j.bmcl.2008.03.013,Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.,10.1016/j.bmcl.2019.06.048,Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors.,1
3965,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
3965,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,1
3859,10.1021/jm500126s,"Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.",10.1039/D1MD00239B,Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from <i>Mycobacterium tuberculosis</i> to overcome kanamycin resistance.,1
3859,10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",10.1016/j.ejmech.2014.04.019,"Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.",1
3859,10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",10.1021/acs.jmedchem.0c01575,EST64454: a Highly Soluble σ Receptor Antagonist Clinical Candidate for Pain Management.,1
3859,10.1021/jm400181k,"Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.",10.1039/d1md00105a,Studies on the affinity of 6-[(n-(cyclo)aminoalkyl)oxy]-4H-chromen-4-ones for sigma 1/2 receptors,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2014.04.019,"Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.",1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1016/j.ejmech.2021.113443,"Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ<sub>1</sub> receptor affinity, antitumor and analgesic activity.",1
3859,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1021/acs.jmedchem.4c00537,Natural Product-Inspired Dopamine Receptor Ligands.,1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmcl.2015.09.045,Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.,1
3859,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.0c01192,Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.,1
3859,10.1021/jm960268u,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",10.1016/j.ejmech.2011.07.028,"Synthesis, computational studies and preliminary pharmacological evaluation of 2-[4-(aryl substituted) piperazin-1-yl] N, N-diphenylacetamides as potential antipsychotics.",1
3859,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmc.2016.06.011,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,1
3859,10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",10.1039/C2MD20070H,Homologous piperazine-alcanols: chiral pool synthesis and pharmacological evaluation,1
3965,10.1016/j.ejmech.2016.12.017,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,10.1021/acs.jmedchem.3c01322,High-Throughput Phenotypic Screening and Machine Learning Methods Enabled the Selection of Broad-Spectrum Low-Toxicity Antitrypanosomatidic Agents.,1
3965,10.1016/j.ejmech.2016.12.017,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,10.1021/acs.jmedchem.8b02021,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,1
3965,10.1039/C8MD00319J,Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.,10.1016/j.ejmech.2021.113913,Synthesis and in vitro antitrypanosomal evaluation of novel 6-heteroarylidene-substituted quinolone derivatives.,1
3965,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2008.11.031,"Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.",1
3965,10.1021/acs.jmedchem.1c01151,Structure-Based Optimization of Quinazolines as Cruzain and <i>Tbr</i>CATL Inhibitors.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
3965,10.1016/j.bmcl.2004.06.034,Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia.,10.1039/C7MD00445A,Development of highly active anti-<i>Pneumocystis</i> bisbenzamidines: insight into the influence of selected substituents on the <i>in vitro</i> activity.,1
3965,10.1016/j.bmcl.2004.06.034,Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia.,10.1016/j.ejmech.2009.03.014,"Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.",1
3965,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1016/j.ejmech.2021.113861,Synthesis and evaluation of tetrahydroisoquinoline derivatives against Trypanosoma brucei rhodesiense.,1
3965,10.1016/j.bmc.2012.12.042,Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells.,10.1016/j.bmc.2014.02.049,Some non-conventional biomolecular targets for diamidines. A short survey.,1
3965,10.1016/j.bmc.2012.12.042,Identification of small-molecule inhibitors of the human S100B-p53 interaction and evaluation of their activity in human melanoma cells.,10.1021/acs.jmedchem.5b01369,Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations.,1
3965,10.1021/jm301687p,Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).,10.1021/acs.jmedchem.3c01680,Antitrypanosomal Chloronitrobenzamides.,1
3965,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
3965,10.1021/jm0497038,Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.,10.1021/acs.jmedchem.5b01369,Small Molecule Inhibitors of Ca(2+)-S100B Reveal Two Protein Conformations.,1
3965,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
3965,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm0708634,Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.,1
3965,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm301215e,A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1016/s0167-4889(02)00187-8,Role of human organic anion transporter 4 in the transport of ochratoxin A.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1074/jbc.m203803200,Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.,1
3965,10.1016/j.bmcl.2008.03.013,Discovery of novel PRL-3 inhibitors based on the structure-based virtual screening.,10.1016/j.bmc.2014.02.049,Some non-conventional biomolecular targets for diamidines. A short survey.,1
3965,10.1021/jm0497038,Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.,10.1016/j.bmc.2014.02.049,Some non-conventional biomolecular targets for diamidines. A short survey.,1
3965,10.1021/jm0497038,Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.,10.1021/ml300166s,Structure-Based Discovery of a Novel Pentamidine-Related Inhibitor of the Calcium-Binding Protein S100B.,1
3965,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2011.12.018,Quinol derivatives as potential trypanocidal agents.,1
3965,10.1016/j.ejmech.2014.07.113,New series of monoamidoxime derivatives displaying versatile antiparasitic activity.,10.1016/j.ejmech.2018.02.029,Original antileishmanial hits: Variations around amidoximes.,1
3965,10.1016/j.ejmech.2016.12.017,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,10.1021/acsmedchemlett.8b00565,SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-<i>Trypanosoma brucei</i> Agent.,1
3965,10.1016/j.bmc.2013.03.045,Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.,10.1016/j.bmcl.2015.05.072,Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.,1
3965,10.1016/j.bmcl.2004.06.034,Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia.,10.1016/j.bmcl.2009.08.073,Synthesis and SAR of alkanediamide-linked bisbenzamidines with anti-trypanosomal and anti-pneumocystis activity.,1
3965,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2015.09.002,"Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.",1
3965,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
3965,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.8b01578,"Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.",1
3965,10.1021/jm301687p,Optimization of chloronitrobenzamides (CNBs) as therapeutic leads for human African trypanosomiasis (HAT).,10.1016/j.bmc.2016.11.019,Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors.,1
3965,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.bmcl.2009.04.051,Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/jm050670l,"Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1039/C3MD00247K,Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase,1
4345,10.1021/jm0407658,"4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.",10.1021/jm0408621,"4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.",1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmcl.2006.03.080,Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.,1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmc.2010.03.007,Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.,1
4259,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1021/acs.jmedchem.3c00976,Discovery of Selective Dopamine Receptor Ligands Derived from (-)-Stepholidine via C-3 Alkoxylation and C-3/C-9 Dialkoxylation.,1
4259,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1016/j.bmc.2020.115578,Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT<sub>7A</sub>R ligands.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
4011,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1152/ajprenal.00140.2003,Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.61.5.982,Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.,1
4011,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.60.5.1091,Mercapturic acids (N-acetylcysteine S-conjugates) as endogenous substrates for the renal organic anion transporter-1.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1007/s00044-011-9615-3,New antiepileptic agents: structureactivity relationships,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm901563p,Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm100185c,Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm2004305,Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmcl.2010.12.003,Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.,1
4345,10.1021/jm010212m,The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2016.05.010,Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.,1
4345,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2021.116531,Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
4345,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
4345,10.1021/jm990150o,Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.,10.1016/j.bmc.2015.06.016,"Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.",1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
4345,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
4345,10.1016/j.bmc.2011.09.018,Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2012.07.018,One pot efficient diversity oriented synthesis of polyfunctional styryl thiazolopyrimidines and their bio-evaluation as antimalarial and anti-HIV agents.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.11.039,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.",1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2023.115605,Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2022.115042,Development of novel S-N<sub>3</sub>-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity.,1
4345,10.1021/jm960158n,Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.,10.1021/jm400102x,Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.,1
4345,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
4345,10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
2223,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
2217,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
2217,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
2217,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm9012054,Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm020225f,Design and evaluation of affinity labels of functionalized amino acid anticonvulsants.,1
2217,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2011.11.004,Design and synthesis of novel stiripentol analogues as potential anticonvulsants.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm020225f,Design and evaluation of affinity labels of functionalized amino acid anticonvulsants.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm100185c,Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm200759t,"Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain-attenuating properties.",1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1016/j.bmc.2012.04.002,"Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.",1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm200759t,"Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain-attenuating properties.",1
4345,10.1016/j.bmc.2011.09.018,Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.07.021,N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/acs.jmedchem.8b01238,Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01015,"Discovery of Novel Dihydrothiopyrano[4,3-<i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles.",1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2022.114957,"Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation.",1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01885,"Development of Novel Dihydrofuro[3,4-<i>d</i>]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1016/j.bmc.2011.07.023,Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.,1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/jm030255y,Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.,1
4345,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2022.114471,Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
4345,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.ejmech.2022.115042,Development of novel S-N<sub>3</sub>-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity.,1
4345,10.1021/jm010212m,The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmcl.2007.12.015,Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.,1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1016/j.bmc.2013.08.040,"Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.",1
4345,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114939,Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.,1
4345,10.1021/jm00041a023,"Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c00268,"2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
4345,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2013.09.051,"Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.",1
4345,10.1021/jm990150o,Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.,10.1021/jm801395v,Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.,1
4345,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2011.12.132,Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1021/jm200734j,"Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/jm8004493,Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
4345,10.1016/j.bmc.2011.09.018,Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2020.115431,"Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.",1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm101626c,"Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.",1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2022.114939,Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
4345,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
4345,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1016/j.bmc.2011.10.002,"Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.",1
4345,10.1021/jm010212m,The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.,10.1021/jm901167t,Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.,1
4345,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1021/acs.jmedchem.8b01238,Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113868,Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.08.007,Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2018.03.003,The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.,1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2019.111603,Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1016/j.ejmech.2012.10.036,"Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.",1
4345,10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
4345,10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",10.1016/j.bmc.2017.12.033,Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.,1
4345,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2018.01.016,Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
4345,10.1016/j.bmc.2017.12.033,Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.,10.1016/j.bmc.2020.115431,"Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.",1
4345,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmc.2010.03.025,Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
4345,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",1
4345,10.1016/j.bmc.2011.09.018,Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2014.04.018,Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm801330n,Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.,1
4345,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2020.112549,Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
4345,10.1016/j.bmcl.2018.10.010,Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.,10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
4345,10.1021/jm00041a023,"Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1021/jm990580e,Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
4345,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,10.1039/C3MD00337J,Synthesis and biological evaluation of novel quinoxalinone-based HIV-1 reverse transcriptase inhibitors,1
4345,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
4345,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
4345,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm500284x,Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112237,In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.,1
4345,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",1
4345,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/s0960-894x(99)00664-2,1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.,1
4345,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1039/C3MD00225J,Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase,1
4345,10.1016/j.bmc.2020.115431,"Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.",10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
4345,10.1016/j.bmcl.2010.09.034,"Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.",10.1016/j.ejmech.2012.02.019,Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2015.09.020,"A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.",1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/s0960-894x(99)00235-8,"Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.",1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
4345,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
4345,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2011.12.132,Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,1
4345,10.1021/jm0407658,"4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.",10.1021/jm900802y,Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,1
4345,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
4345,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113769,"Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.",1
4345,10.1021/jm00010a010,Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.,10.1021/jm800473d,"Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.",1
4345,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2022.114939,Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.,1
4345,10.1021/jm010212m,The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmcl.2007.11.114,Inhibition of tubulin polymerization by select alkenyldiarylmethanes.,1
4345,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
4381,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2023.115352,"Bioisosteric replacement based on 1,2,4-oxadiazoles in the discovery of 1H-indazole-bearing neuroprotective MAO B inhibitors.",1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
4361,10.1016/j.bmcl.2010.04.095,Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.,10.1016/j.bmc.2016.07.022,The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.,1
4345,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.07.043,Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.,1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.bmc.2010.03.025,Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
4345,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1016/j.bmcl.2010.12.003,Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2021.116239,Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.,1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
4345,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1021/jm500284x,Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.,1
4345,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
4345,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
4345,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
4345,10.1021/jm960158n,Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.,10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,1
4345,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.bmc.2019.03.060,"Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.06.007,Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.,1
4381,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2017.02.027,"Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2018.02.037,"Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1039/C8MD00399H,Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.,1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
4381,10.1016/j.ejmech.2010.07.008,Synthesis of new series of quinoxaline based MAO-inhibitors and docking studies.,10.1016/j.bmc.2015.04.021,Synthesis and evaluation of quinazoline amino acid derivatives as mono amine oxidase (MAO) inhibitors.,1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2016.12.009,"Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.bmcl.2019.02.008,"Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2017.10.050,"Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.12.027,Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.,1
4381,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2016.03.081,(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.,1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1039/C5MD00357A,Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B,1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2020.115400,"Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2016.11.048,Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.,1
4381,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115367,"Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.",1
4381,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.bmc.2016.12.013,"Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.",1
4381,10.1016/j.ejmech.2010.07.008,Synthesis of new series of quinoxaline based MAO-inhibitors and docking studies.,10.1016/j.ejmech.2021.113558,"Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.",1
4381,10.1016/j.ejmech.2010.07.008,Synthesis of new series of quinoxaline based MAO-inhibitors and docking studies.,10.1016/j.bmcl.2014.11.007,α-Ketoamino acid ester derivatives as promising MAO inhibitors.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2018.07.056,Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1039/d0md00150c,"Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.1c00510,Mapping Chromone-3-Phenylcarboxamide Pharmacophore: <i>Quid Est Veritas</i>?,1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2016.09.041,Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.,1
4381,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
4381,10.1016/j.ejmech.2010.07.008,Synthesis of new series of quinoxaline based MAO-inhibitors and docking studies.,10.1016/j.ejmech.2015.02.020,"Exploring new selective 3-benzylquinoxaline-based MAO-A inhibitors: design, synthesis, biological evaluation and docking studies.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm100120s,"Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmcl.2017.01.050,DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.,1
4381,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.bmcl.2016.08.044,"Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.7b00918,Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1039/C6MD00570E,"Pyrazolobenzothiazine-based carbothioamides as new structural leads for the inhibition of monoamine oxidases: design, synthesis, <i>in vitro</i> bioevaluation and molecular docking studies.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
4381,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.bmc.2017.11.036,Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.,1
4381,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.bmc.2019.03.060,"Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.",1
4381,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1021/acs.jmedchem.4c00045,"Dual Inhibitors of Brain Carbonic Anhydrases and Monoamine Oxidase-B Efficiently Protect against Amyloid-β-Induced Neuronal Toxicity, Oxidative Stress, and Mitochondrial Dysfunction.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2018.01.030,"Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.",1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2009.11.003,"Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm801590u,Chalcones: a valid scaffold for monoamine oxidases inhibitors.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acsmedchemlett.3c00532,Benzodioxane Carboxamide Derivatives As Novel Monoamine Oxidase B Inhibitors with Antineuroinflammatory Activity.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.bmc.2017.11.036,Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.,1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.bmc.2016.06.045,"Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors.",1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.4c00045,"Dual Inhibitors of Brain Carbonic Anhydrases and Monoamine Oxidase-B Efficiently Protect against Amyloid-β-Induced Neuronal Toxicity, Oxidative Stress, and Mitochondrial Dysfunction.",1
4381,10.1016/j.bmcl.2019.02.008,"Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.",10.1021/acs.jmedchem.0c01663,Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.,1
4381,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.bmcl.2017.01.050,DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.,1
4381,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2017.08.025,Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.,1
4381,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.10.050,"Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.10.032,Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.,1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.05.070,"Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.",1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1039/C0MD00014K,"Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones",1
4381,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
4381,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.bmc.2016.02.045,"Novel tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one: Design, synthesis, model and use as hMAO-B inhibitors.",1
4381,10.1016/j.bmcl.2019.02.008,"Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.",10.1016/j.bmcl.2021.128051,"Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.0c01663,Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2022.114507,Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties.,1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2021.113183,4-Oxoquinolines and monoamine oxidase: When tautomerism matters.,1
4381,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2013.07.005,Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases.,1
4381,10.1021/acs.jmedchem.0c01663,Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.,10.1016/j.ejmech.2023.115142,Discovery of novel 2-hydroxyl-4-benzyloxybenzyl aniline derivatives as potential multifunctional agents for the treatment of Parkinson's disease.,1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2023.115956,"Discovery of C-3 isoxazole substituted thiochromone S,S-dioxide derivatives as potent and selective inhibitors for monoamine oxidase B (MAO-B).",1
4480,10.1021/jm040222y,"Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.",10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",1
4480,10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",10.1021/acs.jmedchem.3c01811,"Design, Synthesis, Pharmacology, and In Silico Studies of (1<i>S</i>,2<i>S</i>,3<i>S</i>)-2-((<i>S</i>)-Amino(carboxy)methyl)-3-(carboxymethyl)cyclopropane-1-carboxylic Acid (LBG30300): A Picomolar Potency Subtype-Selective mGlu<sub>2</sub> Receptor Agonist.",1
4480,10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",1
4480,10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",10.1021/acs.jmedchem.3c01811,"Design, Synthesis, Pharmacology, and In Silico Studies of (1<i>S</i>,2<i>S</i>,3<i>S</i>)-2-((<i>S</i>)-Amino(carboxy)methyl)-3-(carboxymethyl)cyclopropane-1-carboxylic Acid (LBG30300): A Picomolar Potency Subtype-Selective mGlu<sub>2</sub> Receptor Agonist.",1
4480,10.1021/jm060917u,"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.",10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",1
4480,10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",1
4398,10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",10.1016/j.ejmech.2023.115267,"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.",1
4398,10.1021/jm070130j,Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists.,10.1016/j.bmcl.2008.10.085,Discovery of diacylphloroglucinols as a new class of GPR40 (FFAR1) agonists.,1
4398,10.1016/j.ejmech.2014.11.020,"Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.",10.1016/j.bmc.2016.07.022,The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.,1
4398,10.1016/j.bmcl.2010.04.095,Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.,10.1016/j.ejmech.2014.11.020,"Novel fatty acid binding protein 4 (FABP4) inhibitors: virtual screening, synthesis and crystal structure determination.",1
4398,10.1016/j.bmcl.2010.04.095,Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.,10.1016/j.bmc.2016.07.022,The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.,1
4398,10.1016/j.bmcl.2014.05.012,Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).,10.1021/acs.jmedchem.0c01002,GPR120/FFAR4 Pharmacology: Focus on Agonists in Type 2 Diabetes Mellitus Drug Discovery.,1
4381,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.09.045,"2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2024.116566,Discovery of novel benzimidazole derivatives as selective and reversible monoamine oxidase B inhibitors for Parkinson's disease treatment.,1
4381,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2015.04.009,"Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.",1
4381,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2018.01.029,"Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.",1
4504,10.1021/jm00086a010,"Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.",10.1021/jm9801105,"1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.",1
4504,10.1021/jm00086a010,"Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.",10.1021/jm800160v,"Aminoacyl-anthraquinone conjugates as telomerase inhibitors: synthesis, biophysical and biological evaluation.",1
4504,10.1016/j.bmc.2007.03.003,"Design, synthesis and cell growth inhibitory activity of a series of novel aminosubstituted xantheno[1,2-d]imidazoles in breast cancer cells.",10.1016/j.ejmech.2011.10.059,"Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives.",1
4480,10.1021/jm040222y,"Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.",10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",1
4480,10.1021/jm040222y,"Methyl substitution of 2-aminobicyclo[3.1.0]hexane 2,6-dicarboxylate (LY354740) determines functional activity at metabotropic glutamate receptors: identification of a subtype selective mGlu2 receptor agonist.",10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",1
4480,10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",1
4480,10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",10.1021/acs.jmedchem.3c01811,"Design, Synthesis, Pharmacology, and In Silico Studies of (1<i>S</i>,2<i>S</i>,3<i>S</i>)-2-((<i>S</i>)-Amino(carboxy)methyl)-3-(carboxymethyl)cyclopropane-1-carboxylic Acid (LBG30300): A Picomolar Potency Subtype-Selective mGlu<sub>2</sub> Receptor Agonist.",1
4480,10.1021/jm980616n,"Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.",10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",1
4480,10.1021/jm980616n,"Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.",10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",1
4480,10.1021/jm060917u,"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.",10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",1
4480,10.1021/jm060917u,"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.",10.1021/acs.jmedchem.3c01811,"Design, Synthesis, Pharmacology, and In Silico Studies of (1<i>S</i>,2<i>S</i>,3<i>S</i>)-2-((<i>S</i>)-Amino(carboxy)methyl)-3-(carboxymethyl)cyclopropane-1-carboxylic Acid (LBG30300): A Picomolar Potency Subtype-Selective mGlu<sub>2</sub> Receptor Agonist.",1
4480,10.1021/jm060917u,"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.",10.1021/acs.jmedchem.6b01119,"Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.",1
4480,10.1021/jm980616n,"Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.",10.1021/acs.jmedchem.7b01481,"Synthesis and Pharmacological Characterization of C4β-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu3 Receptor Agonist.",1
4480,10.1021/jm4000165,"Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.",10.1021/acs.jmedchem.6b01119,"Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.",1
4480,10.1021/jm060917u,"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors.",10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",1
4480,10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",10.1021/acs.jmedchem.6b01119,"Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/jm401883v,"Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",1
4504,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
4504,10.1242/jcs.113.11.2011,"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).",10.1016/s0928-0987(03)00204-5,"Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity.",1
4504,10.1016/j.bmc.2007.03.003,"Design, synthesis and cell growth inhibitory activity of a series of novel aminosubstituted xantheno[1,2-d]imidazoles in breast cancer cells.",10.1016/j.bmcl.2011.03.021,"Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.",1
4504,10.1016/j.bmc.2010.04.074,"Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.",10.1016/j.ejmech.2010.08.061,"Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.",1
4504,10.1242/jcs.113.11.2011,"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).",10.1002/ijc.11484,Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.,1
4504,10.1021/jm00086a010,"Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.",10.1021/jm980167r,"Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity.",1
4504,10.1242/jcs.113.11.2011,"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).",10.1021/acs.jmedchem.9b00963,"Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.",1
4504,10.1242/jcs.113.11.2011,"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).",10.1006/bbrc.2001.5130,"Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.",1
4504,10.1016/j.bmc.2007.03.003,"Design, synthesis and cell growth inhibitory activity of a series of novel aminosubstituted xantheno[1,2-d]imidazoles in breast cancer cells.",10.1016/j.bmcl.2015.04.093,"Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.",1
4504,10.1242/jcs.113.11.2011,"The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).",10.1124/mol.105.017988,"Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.",1
4504,10.1021/jm061410m,"Design, synthesis, and evaluation of the antiproliferative activity of a series of novel fused xanthenone aminoderivatives in human breast cancer cells.",10.1016/j.bmcl.2015.04.093,"Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.",1
4504,10.1021/jm061410m,"Design, synthesis, and evaluation of the antiproliferative activity of a series of novel fused xanthenone aminoderivatives in human breast cancer cells.",10.1016/j.bmcl.2011.03.021,"Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.",1
4504,10.1016/j.ejmech.2017.11.101,Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.,10.1016/j.ejmech.2019.111848,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,1
4504,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
4584,10.1021/acs.jmedchem.8b01622,Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.,10.1021/acsmedchemlett.9b00050,Synthesis and Pharmacological Evaluation of Noncatechol G Protein Biased and Unbiased Dopamine D1 Receptor Agonists.,1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/jm901184n,"Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1016/j.bmc.2009.04.031,"Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/jm901184n,"Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease animal models.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1016/j.bmc.2010.06.025,"Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/acs.jmedchem.0c00424,"Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/jm901618d,"Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/jm401883v,"Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1016/j.bmc.2013.03.059,"Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/ml3002117,Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency.,1
4584,10.1021/jm00170a025,Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.,10.1021/jm960318v,"Synthesis, resolution, and preliminary evaluation of trans-2-amino-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes and related derivatives as dopamine receptors ligands.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1016/j.bmc.2013.03.059,"Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/jm300268s,"Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1021/acs.jmedchem.5b01031,"Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/jm300268s,"Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1016/j.bmc.2009.04.031,"Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.",1
4775,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1016/j.bmcl.2023.129258,"Jozibrevine D from Ancistrocladus ileboensis, the fifth alkaloid in a series of six possible atropo-diastereomeric naphthylisoquinoline dimers, showing antiparasitic and antileukemic activities.",1
4775,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2018.02.019,"Conformational mimetics of the α-methyl chalcone TUB091 binding tubulin: Design, synthesis and antiproliferative activity.",1
4775,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2014.03.030,"Synthesis, β-haematin inhibition, and in vitro antimalarial testing of isocryptolepine analogues: SAR study of indolo[3,2-c]quinolines with various substituents at C2, C6, and N11.",1
4775,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.3c01775,"PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin.",1
4775,10.1021/jm5000408,"Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.",10.1016/j.bmc.2021.116018,"Quest for a potent antimalarial drug lead: Synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines.",1
4775,10.1021/acs.jnatprod.9b00755,"Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana Ancistrocladus ealaensis, Targeting Pancreatic Cancer Cells.",10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
4775,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2019.03.045,Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop.,1
4775,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.6b01591,N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.,1
4775,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.08.057,"Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.",1
4730,10.1021/jm00146a022,Optimization of the Schiff bases of N-hydroxy-N'-aminoguanidine as anticancer and antiviral agents.,10.1021/jm010252q,"Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.",1
4634,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2019.111705,Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review.,1
4634,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1016/j.bmcl.2015.07.030,Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.,1
4584,10.1021/jm00170a025,Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.,10.1021/jm9502100,Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping.,1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/jm901618d,"Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease.",1
4584,10.1021/jm070860r,"Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action.",10.1016/j.bmc.2010.06.025,"Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol.",1
4584,10.1021/jm701524h,"Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity.",10.1021/acs.jmedchem.5b01031,"Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.",1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/j.ejmech.2020.112795,Synthesis and bioactivity of phenyl substituted furan and oxazole carboxylic acid derivatives as potential PDE4 inhibitors.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,1
4872,10.1016/0960-894X(95)00336-R,"Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidines",10.1016/s0960-894x(98)00583-6,N-arylrolipram derivatives as potent and selective PDE4 inhibitors.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1016/s0960-894x(00)00449-2,The synthesis and biological evaluation of a novel series of phthalazine PDE4 inhibitors I.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2023.115374,Design and synthesis of a novel class of PDE4 inhibitors with antioxidant properties as bifunctional agents for the potential treatment of COPD.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1021/jm981012m,"Design, synthesis, and biological activities of new thieno[3,2-d] pyrimidines as selective type 4 phosphodiesterase inhibitors.",1
4775,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.bmcl.2012.11.072,"Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.",1
4775,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.ejmech.2017.09.040,Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.,1
4775,10.1016/j.bmc.2012.09.009,Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.,10.1016/j.bmcl.2018.04.019,"Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.",1
4775,10.1021/jm5000408,"Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.",10.1016/j.bmc.2015.02.020,"SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.",1
4775,10.1016/j.bmc.2012.09.009,Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.,10.1016/j.ejmech.2020.112830,"Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).",1
4775,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
4775,10.1016/j.bmc.2012.09.009,Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.,10.1016/j.bmcl.2015.04.053,"Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.",1
4775,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.ejmech.2013.03.072,"Synthesis and antimalarial testing of neocryptolepine analogues: addition of ester function in SAR study of 2,11-disubstituted indolo[2,3-b]quinolines.",1
4775,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1016/s0960-894x(01)00190-1,Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones.,1
4872,10.1021/jm9509096,"Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.",10.1021/jm980314l,"Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.",1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1021/jm970575f,Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(98)00572-1,Orally active indole N-oxide PDE4 inhibitors.,1
4872,10.1016/j.bmcl.2004.03.021,Identification of purine inhibitors of phosphodiesterase 7 (PDE7).,10.1016/j.ejmech.2018.01.068,"Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation.",1
4872,10.1016/j.bmcl.2008.01.028,Identification of a potent new chemotype for the selective inhibition of PDE4.,10.1016/j.bmcl.2009.01.057,Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors.,1
4872,10.1021/jm701635j,"Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.",10.1016/j.bmc.2015.04.027,"Synthesis, biological activities and pharmacokinetic properties of new fluorinated derivatives of selective PDE4D inhibitors.",1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/j.bmc.2017.08.045,"Rational design of conformationally constrained oxazolidinone-fused 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.",1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2022.114631,Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(98)00583-6,N-arylrolipram derivatives as potent and selective PDE4 inhibitors.,1
4872,10.1016/j.bmcl.2004.03.021,Identification of purine inhibitors of phosphodiesterase 7 (PDE7).,10.1016/j.bmcl.2005.02.025,Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.,1
4872,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm300514y,"Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.",1
4872,10.1021/jm000065c,Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl]quinoline (APIIMQ).,10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1016/s0960-894x(01)00817-4,Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.,1
4872,10.1021/jm301059b,"Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.",10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1016/s0960-894x(98)00490-9,Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.,1
4872,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,1
2217,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
2214,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.6b01194,Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.,1
2214,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1016/j.ejmech.2019.111626,Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.,1
4872,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,10.1016/j.ejmech.2024.116386,Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1021/jm970105l,Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1016/s0960-894x(00)00426-1,7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.,1
4872,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,10.1016/j.ejmech.2020.113123,The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,1
4872,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1039/C0MD00215A,Novel indolizine compounds as potent inhibitors of phosphodiesterase IV (PDE4): structureactivity relationship,1
4872,10.1021/jm9509096,"Novel selective PDE IV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans.",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
4872,10.1016/j.bmc.2013.07.007,"Identification of 2,3-disubstituted pyridines as potent, orally active PDE4 inhibitors.",10.1016/j.bmcl.2014.04.052,"Identification of 2,3-disubstituted pyridines as potent, non-emetic PDE4 inhibitors.",1
4872,10.1021/jm980314l,"Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
4872,10.1021/jm980314l,"Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.",10.1016/s0960-894x(03)00438-4,Synthesis and biological activities of 1-pyridylisoquinoline and 1-pyridyldihydroisoquinoline derivatives as PDE4 inhibitors.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,1
4872,10.1016/j.bmcl.2016.11.040,"Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.",10.1016/j.ejmech.2020.113123,The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,1
4872,10.1021/jm701635j,"Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.",10.1021/acs.jmedchem.7b01370,Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.,1
4872,10.1016/0960-894X(95)00336-R,"Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidines",10.1016/s0960-894x(97)10206-2,Quaternary substituted PDE4 inhibitors I: the synthesis and in vitro evaluation of a novel series of oxindoles.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(98)00324-2,The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.1c01085,Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.,1
4872,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1016/j.bmcl.2008.01.028,Identification of a potent new chemotype for the selective inhibition of PDE4.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,1
2217,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.11.004,Design and synthesis of novel stiripentol analogues as potential anticonvulsants.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1007/s00044-011-9615-3,New antiepileptic agents: structureactivity relationships,1
2217,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,10.1016/j.ejmech.2011.07.027,"Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.",1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm9012054,Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm9508705,Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.,1
2217,10.1007/s00044-010-9313-6,"Synthesis, anticonvulsant and toxicity screening of thiazolylthiadiazole derivatives",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm901563p,Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.,1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1016/j.bmc.2012.04.002,"Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.",1
2217,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm100508m,The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm2004305,Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.,1
2217,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm9508705,Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.,1
2214,10.1021/ml200206z,Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.,10.1021/acs.jmedchem.7b00584,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,1
2214,10.1016/j.ejmech.2017.05.047,Synthesis of a new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT1A affinities.,10.1039/C7MD00281E,Development of selective agents targeting serotonin 5HT<sub>1A</sub> receptors with subnanomolar activities based on a coumarin core.,1
2214,10.1021/ml200206z,Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,1
2214,10.1016/j.bmcl.2009.07.063,Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.,10.1021/jm301656h,"Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT(2A)/5-HT(2C) receptor agonists with pro-cognitive properties.",1
2214,10.1021/jm00402a026,Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors.,10.1021/jm030205t,"A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole.",1
2214,10.1021/jm00402a026,Synthesis and serotonin receptor affinities of a series of enantiomers of alpha-methyltryptamines: evidence for the binding conformation of tryptamines at serotonin 5-HT1B receptors.,10.1016/j.bmcl.2013.03.066,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,1
2214,10.1021/ml200206z,Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.,10.1021/acs.jmedchem.6b01194,Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2021.113700,Discovery of novel trimethoxyphenylbenzo[d]oxazoles as dual tubulin/PDE4 inhibitors capable of inducing apoptosis at G2/M phase arrest in glioma and lung cancer cells.,1
4872,10.1021/jm701635j,"Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.",10.1016/j.ejmech.2022.114170,Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1021/jm030603w,8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors.,1
4872,10.1016/0960-894X(95)00336-R,"Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidines",10.1016/s0960-894x(98)00490-9,Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.,1
4872,10.1016/0960-894X(95)00334-P,"Synthesis and in vitro profile of a novel series of catechol benzimidazoles. The discovery of potent, selective phosphodiesterase type IV inhibitors with greatly attenuated affinity for the [3H]rolipram binding site",10.1016/s0960-894x(98)00475-2,Thalidomide analogs and PDE4 inhibition.,1
4872,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jnatprod.4c00422,Discovery of Oxidized &lt;i&gt;p&lt;/i&gt;-Terphenyls as Phosphodiesterase 4 Inhibitors from Marine-Derived Fungi.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(01)00668-0,Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.,1
4872,10.1021/jm701635j,"Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.",10.1016/j.ejmech.2019.04.020,InCl<sub>3</sub> mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis.,1
4872,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.bmcl.2011.07.015,Identification of SQ609 as a lead compound from a library of dipiperidines.,1
4941,10.1016/j.bmcl.2007.09.096,Synthesis and biological evaluation of N-(aryl)-2-thiophen-2-ylacetamides series as a new class of antitubercular agents.,10.1016/j.ejmech.2010.01.024,Novel quinoline and naphthalene derivatives as potent antimycobacterial agents.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2014.05.002,"Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.ejmech.2018.09.049,"Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids.",1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2013.09.061,Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1007/s00044-012-0451-x,"Synthesis, characterization, and SAR studies of new (1H-indol-3-yl)alkyl-3-(1H-indol-3-yl)propanamide derivatives as possible antimicrobial and antitubercular agents",1
4941,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2016.07.068,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.,1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.bmc.2015.03.008,"Novel 2-(2-phenalkyl)-1H-benzo[d]imidazoles as antitubercular agents. Synthesis, biological evaluation and structure-activity relationship.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2008.12.070,"Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents.",1
4920,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.ejmech.2017.05.041,Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.,1
2214,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1016/j.bmc.2014.09.024,"Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles.",1
2214,10.1021/jm9015763,Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist.,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",1
2214,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,1
2214,10.1016/j.ejmech.2017.05.047,Synthesis of a new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT1A affinities.,10.1016/j.bmc.2017.12.016,"5-HT1A and 5-HT2A receptors affinity, docking studies and pharmacological evaluation of a series of 8-acetyl-7-hydroxy-4-methylcoumarin derivatives.",1
4941,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
4941,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.07.033,"Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2015.08.009,"One-pot synthesis of new triazole--Imidazo[2,1-b][1,3,4]thiadiazole hybrids via click chemistry and evaluation of their antitubercular activity.",1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/s0960-894x(98)00526-5,Pyrrolnitrin and related pyrroles endowed with antibacterial activities against Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.ejmech.2020.112699,New one-pot synthesis of anti-tuberculosis compounds inspired on isoniazid.,1
4941,10.1016/j.bmc.2022.117006,Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.,10.1016/j.ejmech.2023.115571,"Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2011.07.033,"Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents.",1
4941,10.1016/j.bmc.2022.117006,Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2013.06.042,"Synthesis and evaluation of α-ketotriazoles and α,β-diketotriazoles as inhibitors of Mycobacterium tuberculosis.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2012.05.004,"New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm201608g,Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis.,1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1021/acs.jmedchem.0c01374,"2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F)-Dependent Nitroreductase (Ddn).",1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.bmcl.2015.02.052,"Synthesis, in vitro anticancer and antimycobacterial evaluation of new 5-(2,5-dimethoxyphenyl)-1,3,4-thiadiazole-2-amino derivatives.",1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.bmcl.2014.07.061,New class of methyl tetrazole based hybrid of (Z)-5-benzylidene-2-(piperazin-1-yl)thiazol-4(%H)-one as potent antitubercular agents.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/j.ejmech.2021.113451,"Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia.",1
2208,10.1021/jm9703911,Identification of highly potent retinoic acid receptor alpha-selective antagonists.,10.1016/j.ejmech.2023.115821,Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1016/s0960-894x(01)00058-0,Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.,1
4941,10.1016/j.bmcl.2005.06.010,Identification of heteroarylenamines as a new class of antituberculosis lead molecules.,10.1016/j.ejmech.2013.06.010,Synthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine.,1
4941,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1016/j.bmcl.2020.127192,"Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.",1
4941,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.3c02061,"Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens.",1
4941,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,10.1016/j.ejmech.2022.114993,Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis.,1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2018.09.049,"Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids.",1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.bmcl.2019.126671,Synthesis and evaluation of a novel quinoline-triazole analogs for antitubercular properties via molecular hybridization approach.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.ejmech.2017.03.015,"Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2-c]pyridine Mannich bases.",1
4941,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2012.05.004,"New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.",1
4941,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
4941,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2020.112772,Synthesis and evaluation of thiophene based small molecules as potent inhibitors of Mycobacterium tuberculosis.,1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2014.05.062,"Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2013.11.002,Synthesis and characterization of new N-(4-(4-chloro-1H-imidazol-1-yl)-3-methoxyphenyl)amide/sulfonamide derivatives as possible antimicrobial and antitubercular agents.,1
4941,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2017.01.024,"Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives.",1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.ejmech.2015.02.062,Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.,1
2214,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.9b01835,Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands.,1
2214,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.7b00584,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/j.bmc.2017.12.015,"Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist.",1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1016/j.ejmech.2023.115821,Strategies for developing retinoic acid receptor alpha-selective antagonists as novel agents for male contraception.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1016/S0960-894X(97)00435-6,"Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid",1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1016/s0960-894x(02)00255-x,"A library construction of 2,5-disubstituted pyrrole compounds by using solid/solution-phase syntheses.",1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1021/jm9703911,Identification of highly potent retinoic acid receptor alpha-selective antagonists.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/S0960-894X(97)00435-6,"Synthesis and biological activity of 1,2,3,4-tetrahydroquinoline and 3,4-(1H)-dihydroquinolin-2-one analogs of retinoic acid",1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/s0960-894x(02)00647-9,Synthesis and biological activity of retinoic acid receptor-alpha specific amides.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1021/jm9704309,Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/s0960-894x(02)00255-x,"A library construction of 2,5-disubstituted pyrrole compounds by using solid/solution-phase syntheses.",1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2013.11.031,"Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.bmc.2013.06.013,Synthesis and bioevaluation of some new isoniazid derivatives.,1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.bmcl.2016.03.059,"Seeking potent anti-tubercular agents: Design, synthesis, anti-tubercular activity and docking study of various ((triazoles/indole)-piperazin-1-yl/1,4-diazepan-1-yl)benzo[d]isoxazole derivatives.",1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
4941,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1016/j.bmcl.2012.10.060,Development of 5-nitrothiazole derivatives: identification of leads against both replicative and latent Mycobacterium tuberculosis.,10.1016/j.bmc.2014.12.019,Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.,1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
4941,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2017.05.026,"QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.bmcl.2011.04.072,"New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2022.114908,"Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation.",1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2023.115539,"Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling.",1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1007/s00044-011-9662-9,"Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies",1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.bmcl.2017.01.026,Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.bmcl.2016.06.082,"Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.",1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2010.07.003,Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.,1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1039/C4MD00288A,"Novel isoniazid-amidoether derivatives: Synthesis, characterization and antimycobacterial activity evaluation",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2022.114742,"A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.",1
4941,10.1007/s00044-011-9646-9,"Synthesis, spectral studies and biological evaluation of a novel series of 2-substituted-5,6-diarylsubstituted imidazo(2,1-b)-1,3,4-thiadiazole derivatives as possible anti-tubercular agents",10.1021/acsmedchemlett.6b00088,Dehydrozingerone Inspired Styryl Hydrazine Thiazole Hybrids as Promising Class of Antimycobacterial Agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00055-06,Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
4941,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.bmcl.2014.05.002,"Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.",1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acsmedchemlett.9b00343,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1016/j.ejmech.2014.05.005,"Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation.",1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2020.127512,Design and synthesis of purine connected piperazine derivatives as novel inhibitors of Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2017.05.044,"Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
4941,10.1016/j.ejmech.2015.07.039,Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.,10.1016/j.ejmech.2015.10.035,Design of new phenothiazine-thiadiazole hybrids via molecular hybridization approach for the development of potent antitubercular agents.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.8b00281,Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.bmcl.2020.127192,"Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors.",1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2018.11.025,"Benzofuran derivatives and their anti-tubercular, anti-bacterial activities.",1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmcl.2011.06.076,Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1016/j.ejmech.2019.05.028,"Synthesis, biological evaluation and computational study of novel isoniazid containing 4H-Pyrimido[2,1-b]benzothiazoles derivatives.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.07.049,"Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.",1
4941,10.1007/s00044-011-9646-9,"Synthesis, spectral studies and biological evaluation of a novel series of 2-substituted-5,6-diarylsubstituted imidazo(2,1-b)-1,3,4-thiadiazole derivatives as possible anti-tubercular agents",10.1039/C5MD00346F,"Ionic liquid-promoted one-pot synthesis of thiazoleimidazo[2,1-b][1,3,4]thiadiazole hybrids and their antitubercular activity",1
4941,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.bmc.2021.116529,"Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.",1
4941,10.1021/acsmedchemlett.8b00410,"Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2019.02.010,"Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.",1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.bmcl.2021.127924,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,1
4941,10.1016/j.ejmech.2020.112175,Repurposed drug candidates for antituberculosis therapy.,10.1016/j.ejmech.2022.114531,Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2012.08.047,"The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm900513a,"Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.",1
4941,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm4003878,Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2017.04.002,Isoniazid derivatives and their anti-tubercular activity.,1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
4941,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.4c00441,"Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-<i>d</i>]pyrimidine-4, 7(<i>3H</i>, <i>8H</i>)-dione Compounds.",1
4941,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
4941,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.bmcl.2018.11.036,"Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents.",1
4941,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmc.2016.01.059,"Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",1
4941,10.1016/j.bmc.2009.04.042,Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.,10.1016/j.bmc.2019.04.032,Insights of synthetic analogues of anti-leprosy agents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.bmcl.2013.06.072,Design and synthesis of positional isomers of 5 and 6-bromo-1-[(phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as possible antimicrobial and antitubercular agents.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",1
4941,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmc.2016.01.011,Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,1
4941,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmcl.2016.04.088,"Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.",1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2015.11.071,Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent.,1
4941,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
4941,10.1016/j.bmcl.2015.11.057,Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents.,10.1016/j.ejmech.2020.112886,Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review.,1
4941,10.1016/j.bmc.2009.04.042,Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.,10.1016/j.bmcl.2021.127924,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2016.06.082,"Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.0c01833,"Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1007/s00044-013-0815-x,"Discovery of new antitubercular agents by combining pyrazoline and benzoxazole pharmacophores: design, synthesis and insights into the binding interactions",1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.0c01833,"Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.",1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.bmc.2014.08.031,Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1016/j.bmcl.2004.09.052,In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.,10.1016/j.ejmech.2007.08.003,Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives.,1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1016/j.ejmech.2021.113668,Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.,1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.ejmech.2014.09.028,Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.bmcl.2015.04.009,"Synthesis and anti-mycobacterial activity of 2-chloronicotinaldehydes based novel 1H-1,2,3-triazolylbenzohydrazides.",1
4941,10.1021/jm050948+,Identification of new diamine scaffolds with activity against Mycobacterium tuberculosis.,10.1016/j.ejmech.2014.07.067,"Design, synthesis and antimycobacterial evaluation of 1-(4-(2-substitutedthiazol-4-yl)phenethyl)-4-(3-(4-substitutedpiperazin-1-yl)alkyl)piperazine hybrid analogues.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2011.10.054,"Identification and development of 2,5-disubstituted oxadiazole as potential candidate for treatment of XDR and MDR tuberculosis.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1021/jm2003624,"Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/acsmedchemlett.5b00324,2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.,1
4941,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
4941,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1016/j.bmc.2022.116938,Drug screening approach against mycobacterial fatty acyl-AMP ligase FAAL32 renews the interest of the salicylanilide pharmacophore in the fight against tuberculosis.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
4941,10.1016/j.bmcl.2021.127924,The optimization and characterization of functionalized sulfonamides derived from sulfaphenazole against Mycobacterium tuberculosis with reduced CYP 2C9 inhibition.,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.4c00441,"Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-<i>d</i>]pyrimidine-4, 7(<i>3H</i>, <i>8H</i>)-dione Compounds.",1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.ejmech.2016.05.025,"Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.",1
4941,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0322-5,"Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of -aryloxyquinoline and their antimicrobial and antituberculosis activities",1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,1
2080,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",10.1016/j.bmc.2017.10.017,Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.,1
4941,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.1c00263,Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.,1
4941,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.bmcl.2017.10.071,"Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.ejmech.2007.08.003,Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2010.08.046,Novel dihydropyrimidines as a potential new class of antitubercular agents.,1
4941,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.bmc.2018.03.004,"Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.",1
4941,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
4941,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2011.12.119,Camphorsulfonic acid catalysed facile tandem double Friedlander annulation protocol for the synthesis of phenoxy linked bisquinoline derivatives and discovery of antitubercular agents.,1
4941,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmc.2012.08.041,"1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.",1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1021/ml400088y,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.bmcl.2012.01.067,Novel N'-benzylidene benzofuran-3-carbohydrazide derivatives as antitubercular and antifungal agents.,1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
4941,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.03.060,"Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1021/jm000098s,Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.,1
2208,10.1021/jm9603532,Identification of a retinoic acid receptor alpha subtype specific agonist.,10.1016/s0960-894x(00)00066-4,Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.,1
2208,10.1021/jm00127a018,Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids.,10.1021/jm9801354,Synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and beta-ionylideneacetamidobenzoates with retinoidal activity.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1021/jm9704309,Regulation of retinoidal actions by diazepinylbenzoic acids. Retinoid synergists which activate the RXR-RAR heterodimers.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1021/jm000098s,Discovery of novel and potent retinoic acid receptor alpha agonists: syntheses and evaluation of benzofuranyl-pyrrole and benzothiophenyl-pyrrole derivatives.,1
2208,10.1021/jm960687r,Identification of retinoic acid receptor beta subtype specific agonists.,10.1016/s0960-894x(00)00066-4,Novel retinoic acid receptor alpha agonists: syntheses and evaluation of pyrazole derivatives.,1
2130,10.1016/j.ejmech.2007.04.009,Computational aqueous solubility prediction for drug-like compounds in congeneric series.,10.1016/j.bmc.2010.08.003,QSAR-based solubility model for drug-like compounds.,1
2124,10.1021/jm00112a029,"Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.",10.1021/jm9802968,"Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.",1
2084,10.1021/jm00112a029,"Syntheses of tolrestat analogues containing additional substituents in the ring and their evaluation as aldose reductase inhibitors. Identification of potent, orally active 2-fluoro derivatives.",10.1021/jm9802968,"Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4- tetrahydropyrrolo[1,2-a]pyrazine -4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners.",1
2084,10.1016/j.bmc.2010.02.050,"Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.",10.1021/acs.jmedchem.7b00830,"Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.",1
2084,10.1016/j.bmc.2010.02.050,"Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.",10.1021/np200118q,Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm5003606,"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2016.06.082,"Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.",1
4941,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
4941,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
4941,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1021/acs.jmedchem.1c00263,Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.,1
4941,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/ml5003458,"Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043.",1
4941,10.1016/j.bmc.2009.04.042,Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.,10.1016/j.bmcl.2020.127576,Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2011.07.049,"Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1007/s00044-011-9948-y,Isoniazid: the magic molecule,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acs.jmedchem.0c01833,"Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1016/j.bmc.2012.03.058,Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2021.113266,Antitubercular properties of thiazolidin-4-ones - A review.,1
4941,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00898-06,Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acsmedchemlett.5b00176,"Design, Synthesis, and Biological Evaluation of Pyrazolo[1,5-a]pyridine-3-carboxamides as Novel Antitubercular Agents.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.bmc.2012.08.041,"1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.",1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acsmedchemlett.4c00114,Design and Synthesis of the Linezolid Bioisosteres to Resolve the Serotonergic Toxicity Associated with Linezolid.,1
4941,10.1016/j.ejmech.2015.07.039,Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.,10.1016/j.ejmech.2019.01.073,"Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors.",1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.ejmech.2015.04.011,"Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.",1
4941,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2014.10.079,"Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.",1
4941,10.1016/j.bmc.2012.03.058,Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.,10.1016/j.ejmech.2018.01.071,New hydrazides derivatives of isoniazid against Mycobacterium tuberculosis: Higher potency and lower hepatocytotoxicity.,1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1021/acsmedchemlett.9b00204,Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm049972y,Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/ml200036r,"Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/ml400088y,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1007/s00044-011-9948-y,Isoniazid: the magic molecule,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2018.03.004,"Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.",1
4941,10.1016/j.bmc.2012.03.058,Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.,10.1016/j.bmcl.2014.02.061,"Design, synthesis and evaluation of 1,2,3-triazole-adamantylacetamide hybrids as potent inhibitors of Mycobacterium tuberculosis.",1
4941,10.1016/j.bmcl.2012.11.097,One pot solvent free synthesis and in vitro antitubercular screening of 3-Aracylphthalides against Mycobacterium tuberculosis.,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
4941,10.1007/s00044-012-0340-3,"Oxadiazolo pyrrolidine carboxamides as enoyl-ACP reductase inhibitors: design, synthesis and antitubercular activity screening",10.1016/j.bmc.2021.116529,"Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.",1
4941,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,10.1016/j.bmcl.2018.01.045,"Synthesis, antimicrobial activity and acid dissociation constants of methyl 5,5-diphenyl-1-(thiazol-2-yl)pyrrolidine-2-carboxylate derivatives.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm300123s,Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.,1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.bmcl.2011.10.048,"Efficient synthesis and in vitro antitubercular activity of 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis.",1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/jm0602662,Antimycobacterial agents. Novel diarylpyrrole derivatives of BM212 endowed with high activity toward Mycobacterium tuberculosis and low cytotoxicity.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.bmcl.2015.12.049,"Synthesis and antituberculosis activity of indole-pyridine derived hydrazides, hydrazide-hydrazones, and thiosemicarbazones.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2009.12.045,Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.03.039,"New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents.",1
4941,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2013.01.017,Synthesis and biological evaluation of a new class of 4-aminoquinoline-rhodanine hybrid as potent anti-infective agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1039/C7MD00350A,"The synthesis, biological evaluation and structure-activity relationship of 2-phenylaminomethylene-cyclohexane-1,3-diones as specific anti-tuberculosis agents.",1
4941,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,10.1016/j.ejmech.2022.114993,Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/s0960-894x(99)00510-7,New pyrrole derivatives as antimycobacterial agents analogs of BM212.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2016.07.068,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2018.11.002,"Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2013.06.013,Synthesis and bioevaluation of some new isoniazid derivatives.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
4941,10.1016/j.bmcl.2004.09.052,In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",1
4941,10.1016/j.bmc.2009.04.042,Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.,10.1016/j.bmc.2012.04.060,Synthesis and antimycobacterial activity of some phthalimide derivatives.,1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.bmcl.2017.05.011,"Synthesis, antimycobacterial activity and docking study of 2-aroyl-[1]benzopyrano[4,3-c]pyrazol-4(1H)-one derivatives and related hydrazide-hydrazones.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2015.05.048,"Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.bmc.2021.116348,"Preparation, biological & cheminformatics-based assessment of N<sup>2</sup>,N<sup>4</sup>-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials.",1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
2080,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm201095h,Targeting the liver stage of malaria parasites: a yet unmet goal.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500715u,"N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.",1
2080,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2023.115534,"Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation.",1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1039/d2md00218c,"Preparation, biological evaluation and QSAR analysis of urea substituted 2,4-diamino-pyrimidine anti-malarials.",1
2080,10.1021/jm030781p,Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.,10.1021/jm040769c,Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1016/j.ejmech.2014.01.024,"Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives.",10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2015.08.006,Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.06.053,"hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents.",1
4941,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
4941,10.1016/j.bmcl.2013.12.080,Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy.,10.1021/jm500432n,Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2014.01.024,"Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives.",10.1016/j.ejmech.2015.01.013,Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors.,1
4941,10.1007/s00044-011-9646-9,"Synthesis, spectral studies and biological evaluation of a novel series of 2-substituted-5,6-diarylsubstituted imidazo(2,1-b)-1,3,4-thiadiazole derivatives as possible anti-tubercular agents",10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",1
4941,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
4941,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1021/acs.jnatprod.9b00475,"Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.",1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1021/acs.jmedchem.9b00912,"Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.",1
4941,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2018.07.047,Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/s0960-894x(98)00248-0,"N-[4-(1,1'-biphenyl)methyl]-4-(4-thiomorpholinylmethyl) benzenamines as non-oxazolidinone analogues of antimycobacterial U-100480.",1
4941,10.1016/j.ejmech.2010.07.016,Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.,10.1016/j.bmc.2011.09.017,"Chemical synthesis, biological evaluation and structure-activity relationship analysis of azaisoindolinones, a novel class of direct enoyl-ACP reductase inhibitors as potential antimycobacterial agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2011.07.068,"Synthesis and biological evaluation of some novel N-aryl-1,4-dihydropyridines as potential antitubercular agents.",1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1021/jm4003878,Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.bmcl.2004.01.010,Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/jm800038g,"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.",1
4941,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2020.112075,"Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis.",1
4941,10.1021/jm300123s,Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2014.05.069,"1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.",1
4941,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2015.07.039,Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.,1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2009.11.036,"New 1,3-oxazolo[4,5-c]quinoline derivatives: synthesis and evaluation of antibacterial and antituberculosis properties.",1
4941,10.1007/s00044-011-9646-9,"Synthesis, spectral studies and biological evaluation of a novel series of 2-substituted-5,6-diarylsubstituted imidazo(2,1-b)-1,3,4-thiadiazole derivatives as possible anti-tubercular agents",10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.",1
4941,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2009.12.055,Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
4941,10.1016/j.bmc.2012.03.058,Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.,10.1021/acs.jmedchem.2c00718,"Design, Synthesis, and Biological Evaluation of Pyrrole-2-carboxamide Derivatives as Mycobacterial Membrane Protein Large 3 Inhibitors for Treating Drug-Resistant Tuberculosis.",1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2022.114993,Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis.,1
4941,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2020.112358,"Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
4941,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,10.1016/j.ejmech.2022.114916,Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm4012774,"Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acsmedchemlett.3c00570,Exploring Scaffold Hopping for Novel 2-(Quinolin-4-yloxy)acetamides with Enhanced Antimycobacterial Activity.,1
4941,10.1016/j.bmc.2009.04.042,Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.,10.1016/j.ejmech.2019.111935,Synthesis and anti-Mycobacterium tuberculosis activity of imide-β-carboline and carbomethoxy-β-carboline derivatives.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
4941,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
4941,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmcl.2015.12.083,"Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases.",1
4941,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2016.04.088,"Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.",1
4941,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2020.112659,Endeavors towards transformation of M. tuberculosis thymidylate kinase (MtbTMPK) inhibitors into potential antimycobacterial agents.,1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1007/s00044-013-0815-x,"Discovery of new antitubercular agents by combining pyrazoline and benzoxazole pharmacophores: design, synthesis and insights into the binding interactions",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.ejmech.2017.07.004,"Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents.",1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.ejmech.2020.112175,Repurposed drug candidates for antituberculosis therapy.,1
4941,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2020.112538,"Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis.",1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2014.06.071,Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2013.11.007,"Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.",1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.bmc.2019.04.017,Benzofuran-isatin hybrids tethered via different length alkyl linkers and their in vitro anti-mycobacterial activities.,1
4941,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,1
4941,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.bmcl.2010.12.082,Synthesis and antitubercular evaluation of novel substituted aryl and thiophenyl tethered dihydro-6H-quinolin-5-ones.,1
4941,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",1
4941,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
4941,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.06.071,Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.,1
4941,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.ejmech.2018.11.025,"Benzofuran derivatives and their anti-tubercular, anti-bacterial activities.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.bmcl.2017.10.071,"Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives.",1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,1
4941,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.bmcl.2020.127655,Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.,1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,1
4941,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2010.01.024,Novel quinoline and naphthalene derivatives as potent antimycobacterial agents.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2008.05.061,"Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.",1
4941,10.1016/j.bmcl.2005.06.010,Identification of heteroarylenamines as a new class of antituberculosis lead molecules.,10.1016/j.bmc.2019.06.002,The synthesis and evaluation of quinolinequinones as anti-mycobacterial agents.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
4941,10.1016/j.bmcl.2016.03.066,Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.,10.1039/d4md00221k,"Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-&lt;i&gt;N&lt;/i&gt;-oxide derivatives as potential antitubercular agents.",1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1016/j.bmcl.2020.127576,Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmcl.2018.07.005,"Design, synthesis and antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties.",1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.ejmech.2023.115633,"Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents.",1
4941,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
4941,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1021/acsmedchemlett.5b00367,Design and Synthesis of a Focused Library of Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors.,1
4941,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",1
4941,10.1016/j.ejmech.2015.07.039,Linked pyridinyl-thiadiazoles: Design and synthesis as potential candidate for treatment of XDR and MDR tuberculosis.,10.1016/j.ejmech.2020.112178,"Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors.",1
4941,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901112f,"Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.",1
4941,10.1016/j.bmcl.2005.03.065,"In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.",10.1016/j.ejmech.2010.08.024,"Synthesis and anti-tubercular and antimicrobial activities of some 2r,4c-diaryl-3-azabicyclo[3.3.1]nonan-9-one N-isonicotinoylhydrazone derivatives.",1
4941,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/jm201095h,Targeting the liver stage of malaria parasites: a yet unmet goal.,1
2080,10.1021/jm300563f,Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.,10.1016/j.ejmech.2023.115534,"Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation.",1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
2080,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2015.03.011,Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2022.115043,Discovery of potent Plasmodium falciparum protein kinase 6 (PfPK6) inhibitors with a type II inhibitor pharmacophore.,1
2080,10.1021/jm00131a009,"Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.",10.1016/j.ejmech.2023.115971,Investigating the anti-cancer potential of pyrimethamine analogues through a modern chemical biology lens.,1
4941,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
4941,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acs.jmedchem.0c00500,Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.,1
4941,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2010.09.063,Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy)phenyl cyclopropyl methanols.,1
5028,10.1016/j.ejmech.2016.03.015,Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.,10.1016/j.ejmech.2021.113353,"In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.",1
5028,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1016/j.ejmech.2018.05.008,Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.,1
5028,10.1021/acs.jmedchem.0c01313,"Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.",10.1039/d2md00347c,Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.,1
5028,10.1021/acs.jmedchem.0c01313,"Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.",10.1021/acsmedchemlett.2c00223,SJPYT-195: A Designed Nuclear Receptor Degrader That Functions as a Molecular Glue Degrader of GSPT1.,1
4941,10.1021/acs.jmedchem.7b00793,Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.,10.1039/C8MD00056E,"Design, synthesis and antimycobacterial activity of hybrid molecules combining pyrazinamide with a 4-phenylthiazol-2-amine scaffold.",1
4941,10.1016/j.ejmech.2011.09.054,New series of isoniazid hydrazones linked with electron-withdrawing substituents.,10.1016/j.ejmech.2017.04.002,Isoniazid derivatives and their anti-tubercular activity.,1
4941,10.1016/j.bmcl.2004.09.052,In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.,10.1007/s00044-011-9948-y,Isoniazid: the magic molecule,1
4941,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
4941,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1039/C3MD00366C,"Synthesis and biological evaluation of substituted N-alkylphenyl-3,5-dinitrobenzamide analogs as anti-TB agents",1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
4941,10.1016/j.bmc.2012.03.058,Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability.,10.1016/j.ejmech.2023.115351,Structure-directed identification of pyridine-2-methylamine derivatives as MmpL3 inhibitors for use as antitubercular agents.,1
4941,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2022.114916,Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
4941,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acsmedchemlett.2c00254,Antitubercular Activity of Novel 2-(Quinoline-4-yloxy)acetamides with Improved Drug-Like Properties.,1
4941,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
5582,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
5582,10.1053/gast.2002.36591,The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.,10.1124/dmd.112.047068,"Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.",1
5575,10.1038/nchembio826,Probing cell-division phenotype space and Polo-like kinase function using small molecules.,10.1016/j.cub.2006.12.046,The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.,1
5575,10.1021/jm300100d,Identification of a class of novel tubulin inhibitors.,10.1021/ml5000564,High content screening of diverse compound libraries identifies potent modulators of tubulin dynamics.,1
5575,10.1021/jm300100d,Identification of a class of novel tubulin inhibitors.,10.1016/j.bmcl.2012.07.023,Identification of selective tubulin inhibitors as potential anti-trypanosomal agents.,1
5575,10.1016/j.ejmech.2018.05.028,"Synthesis, cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain at C2 position.",10.1021/acs.jmedchem.2c00432,"A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62.",1
5575,10.1021/jm300100d,Identification of a class of novel tubulin inhibitors.,10.1021/jm400575x,"Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.",1
5575,10.1038/nchembio826,Probing cell-division phenotype space and Polo-like kinase function using small molecules.,10.1016/j.ejmech.2020.112697,Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.,1
5575,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.6b01591,N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.,1
5528,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
5528,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
5528,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
5467,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1074/jbc.m108472200,Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus.,1
5246,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1021/acs.jnatprod.8b00416,"1,4-Benzodioxane Lignans: An Efficient, Asymmetric Synthesis of Flavonolignans and Study of Neolignan Cytotoxicity and Antiviral Profiles.",1
5028,10.1021/acs.jmedchem.5b01735,A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.,10.1021/acsmedchemlett.0c00440,Sweet and Blind Spots in E3 Ligase Ligand Space Revealed by a Thermophoresis-Based Assay.,1
5028,10.1021/acs.jmedchem.5b01735,A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands.,10.1021/acs.jmedchem.9b00454,De-Novo Design of Cereblon (CRBN) Effectors Guided by Natural Hydrolysis Products of Thalidomide Derivatives.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.ejmech.2013.06.030,Probes for narcotic receptor mediated phenomena. 48. C7- and C8-substituted 5-phenylmorphan opioids from diastereoselective alkylation.,1
5985,10.1021/acsmedchemlett.8b00200,"Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.",10.1021/acsmedchemlett.3c00034,"Discovery of [1,2,3]Triazolo[4,5-<i>c</i>]quinoline Derivatives as a New Class of Ataxia-Telangiectasia Mutated Kinase Inhibitors.",1
5985,10.1021/acsmedchemlett.8b00200,"Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.",10.1016/j.ejmech.2022.114196,"Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study.",1
5985,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
5985,10.1021/acsmedchemlett.8b00200,"Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors.",10.1021/acs.jmedchem.3c00082,"Discovery and Evaluation of 3-Quinoxalin Urea Derivatives as Potent, Selective, and Orally Available ATM Inhibitors Combined with Chemotherapy for the Treatment of Cancer via Goal-Oriented Molecule Generation and Virtual Screening.",1
5985,10.1016/j.bmc.2018.08.008,A series of camptothecin prodrugs exhibit HDAC inhibition activity.,10.1021/acs.jmedchem.0c00305,"Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation.",1
5975,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
5975,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
5970,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
5970,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
5666,10.1021/jm00052a003,"Identification, synthesis, and characterization of a unique class of N-methyl-D-aspartate antagonists. The 6,11-ethanobenzo[b]quinolizinium cation.",10.1016/s0960-894x(98)00541-1,Excellent acceleration of the Diels-Alder reaction by microwave irradiation for the synthesis of new fluorine-substituted ligands of NMDA receptor.,1
5638,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
5582,10.1053/gast.2002.36591,The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.,10.1093/toxsci/kfq269,Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.,1
5582,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
5582,10.1053/gast.2002.36591,The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.,10.1124/dmd.111.040758,In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.,1
5582,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
6005,10.1021/acs.jmedchem.1c00256,Identification of an <i>N</i>-acylated-<sup>D</sup>Arg-Leu-NH<sub>2</sub> Dipeptide as a Highly Selective Neuropeptide FF1 Receptor Antagonist That Potently Prevents Opioid-Induced Hyperalgesia.,10.1021/acs.jmedchem.4c00442,Multitarget μ-Opioid Receptor Agonists─Neuropeptide FF Receptor Antagonists Induce Potent Antinociception with Reduced Adverse Side Effects.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/jm9004225,"Probes for narcotic receptor mediated phenomena. 39. Enantiomeric N-substituted benzofuro[2,3-c]pyridin-6-ols: synthesis and topological relationship to oxide-bridged phenylmorphans.",1
6005,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.4c00333,Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.,1
6005,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1016/j.ejmech.2018.01.066,"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.",1
6005,10.1016/j.bmc.2010.04.069,Identification of the three-dimensional pharmacophore of kappa-opioid receptor agonists.,10.1016/j.ejmech.2011.01.064,"Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.",1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.ejmech.2012.01.025,Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/jm901503e,"Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.",1
6005,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.8b01136,Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias.,1
6005,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1039/d0md00104j,G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.bmc.2011.04.028,Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.,1
6005,10.1021/acs.jmedchem.6b01181,Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.,10.1016/j.bmc.2019.01.003,Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: Synthesis and neuropharmacological evaluation.,1
6005,10.1021/acs.jmedchem.6b01181,Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.,10.1016/j.bmc.2020.115438,"Design, synthesis, and biological activity of new endomorphin analogs with multi-site modifications.",1
6005,10.1021/jm030311v,"Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].",10.1021/jm300686p,14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.,1
6005,10.1021/acs.jmedchem.5b01270,"Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.",10.1021/acs.jmedchem.9b00219,Structural Simplification of a Tetrahydroquinoline-Core Peptidomimetic μ-Opioid Receptor (MOR) Agonist/δ-Opioid Receptor (DOR) Antagonist Produces Improved Metabolic Stability.,1
6005,10.1021/acs.jmedchem.5b01270,"Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.",10.1016/j.ejmech.2016.09.003,"Discovery, structure-activity relationship studies, and anti-nociceptive effects of N-(1,2,3,4-tetrahydro-1-isoquinolinylmethyl)benzamides as novel opioid receptor agonists.",1
6005,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.0c01915,Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/jm701162g,Herkinorin analogues with differential beta-arrestin-2 interactions.,1
6005,10.1021/acs.jmedchem.6b01181,Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.,10.1021/acs.jmedchem.0c01367,Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/acs.jmedchem.1c00611,Novel Dual-Target μ-Opioid Receptor and Dopamine D<sub>3</sub> Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1039/d0md00104j,G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9,1
2080,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
2080,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.6b01733,Target Elucidation by Cocrystal Structures of NADH-Ubiquinone Oxidoreductase of Plasmodium falciparum (PfNDH2) with Small Molecule To Eliminate Drug-Resistant Malaria.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
2080,10.1021/jm00131a009,"Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.",10.1021/jm970050n,Structural studies on bioactive compounds. 28. Selective activity of triazenyl-substituted pyrimethamine derivatives against Pneumocystis carinii dihydrofolate reductase.,1
2080,10.1021/jm300563f,Structure-based selectivity optimization of piperidine-pteridine derivatives as potent Leishmania pteridine reductase inhibitors.,10.1021/acs.jmedchem.8b02021,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
6005,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.7b01363,"Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.",1
6005,10.1021/acs.jmedchem.3c00417,Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D<sub>3</sub> (D<sub>3</sub>R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics.,10.1021/acs.jmedchem.4c00646,Systematic Structure-Activity Relationship Study of Nalfurafine Analogues toward Development of Potentially Nonaddictive Pain Management Treatments.,1
6078,10.1021/jm9811256,Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,10.1016/j.bmcl.2007.08.065,Some new acyclic nucleotide analogues as antiviral prodrugs: synthesis and bioactivities in vitro.,1
6078,10.1021/jm9811256,Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,10.1016/j.ejmech.2011.06.034,Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.,1
6078,10.1021/jm9811256,Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,10.1021/jm011095y,6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity.,1
6078,10.1021/jm9811256,Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,10.1021/jm020036x,"2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents.",1
6078,10.1016/j.ejmech.2007.03.005,Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus.,10.1021/jm901237x,"Design, synthesis, and antihepatitis B virus activities of novel 2-pyridone derivatives.",1
6078,10.1021/jm9811256,Structure-antiviral activity relationship in the series of pyrimidine and purine N-[2-(2-phosphonomethoxy)ethyl] nucleotide analogues. 1. Derivatives substituted at the carbon atoms of the base.,10.1021/jm030932o,"5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity.",1
6012,10.1016/j.bmc.2010.03.041,"Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.",10.1021/acs.jmedchem.7b00416,Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.,1
6012,10.1016/j.bmc.2010.03.041,"Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.",10.1021/acs.jmedchem.6b01260,Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.,1
6012,10.1016/j.bmc.2010.03.041,"Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.",10.1016/j.ejmech.2011.06.034,Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication.,1
6005,10.1016/j.bmcl.2010.10.068,"Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.",10.1021/jm501535r,CNS drug design: balancing physicochemical properties for optimal brain exposure.,1
6005,10.1021/jm030311v,"Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].",10.1016/j.ejmech.2015.11.028,Multitarget opioid ligands in pain relief: New players in an old game.,1
6005,10.1021/acs.jmedchem.5b01270,"Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.",10.1021/acsmedchemlett.9b00549,Novel <i>N</i>-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists.,1
6005,10.1021/acs.jmedchem.5b01270,"Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.",10.1021/acs.jmedchem.9b01818,Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.,1
6005,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1021/acsmedchemlett.6b00381,Hydrazone Linker as a Useful Tool for Preparing Chimeric Peptide/Nonpeptide Bifunctional Compounds.,1
6005,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.ejmech.2015.11.028,Multitarget opioid ligands in pain relief: New players in an old game.,1
6005,10.1021/acs.jmedchem.6b01181,Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities.,10.1021/acs.jmedchem.1c00694,"Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects.",1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2016.09.078,"Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.",1
6216,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1016/j.bmcl.2010.12.079,"Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.",1
6216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.07.058,Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.,1
6216,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",1
6216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.5b01222,"Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.",1
6216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm061045z,"Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.",1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.7b01417,"Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.",1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",1
6216,10.1021/jm070524a,Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.,10.1016/j.ejmech.2017.09.021,NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,1
6167,10.1016/j.bmcl.2009.03.057,Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.,10.1016/j.bmcl.2009.03.031,The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.,1
6167,10.1016/j.bmcl.2009.03.057,Identification of 3-substituted N-benzhydryl-nortropane analogs as nociceptin receptor ligands for the management of cough and anxiety.,10.1021/jm9008218,Discovery of orally active 3-pyridinyl-tropane as a potent nociceptin receptor agonist for the management of cough.,1
6243,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
6243,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm900888c,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",1
6243,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
6243,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,1
6243,10.1021/jm070524a,Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.,10.1016/j.ejmech.2017.09.021,NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.,1
6243,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,1
6243,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
6243,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",1
6243,10.1016/j.bmcl.2009.07.050,Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2011.08.002,Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.,1
6216,10.1021/jm9603781,A virtual screening approach applied to the search for trypanothione reductase inhibitors.,10.1016/j.bmc.2008.05.074,The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.,1
6216,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
6402,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
6402,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,1
6402,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
6402,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1016/j.bmc.2021.116185,Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.,1
6402,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.2c02032,Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer <i>In Vitro</i> and <i>In Vivo</i>.,1
6402,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.9b01580,Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.,1
6402,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.3c00465,Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.,1
6402,10.1021/acs.jmedchem.3c00465,Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
6402,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
6402,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.2c00008,"Discovery of Thieno[2,3-<i>e</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability.",1
6317,10.1021/jm801335z,Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.,10.1021/acs.jmedchem.5b01281,Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.,1
6317,10.1021/jm801335z,Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.,10.1016/j.ejmech.2017.05.041,Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2011.08.002,Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.,1
6243,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",1
6243,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
6243,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
6579,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.1c00748,"Total Synthesis and Antimalarial Activity of 2-(<i>p</i>-Hydroxybenzyl)-prodigiosins, Isoheptylprodigiosin, and Geometric Isomers of Tambjamine MYP1 Isolated from Marine Bacteria.",1
6579,10.1021/acs.jnatprod.9b00755,"Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana Ancistrocladus ealaensis, Targeting Pancreatic Cancer Cells.",10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2018.05.022,Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P2 position of PEXEL peptidomimetics.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1016/j.ejmech.2017.10.051,"Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent.",1
6579,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.ejmech.2020.112652,"An insight on medicinal attributes of 1,2,4-triazoles.",1
6579,10.1021/jm070733v,Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.,10.1021/jm400282d,Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities.,1
6579,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1021/acs.jnatprod.2c01172,Plasmodium-Resistant Indole Diterpenoid Biosynthesis Gene Cluster Derived from <i>Aspergillus oryzae</i> Was Activated by Exogenous P450 Gene <i>Ast B</i>.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.ejmech.2021.113227,Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.ejmech.2022.114653,New structural classes of antimalarials.,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.ejmech.2018.10.035,Quinoline and quinolone dimers and their biological activities: An overview.,1
6579,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.5b00678,"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.",1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jnatprod.7b00917,"Bastimolide B, an Antimalarial 24-Membered Marine Macrolide Possessing a tert-Butyl Group.",1
6480,10.1016/j.ejmech.2009.09.005,"A series of 1, 2-coupled indane dimers with mast cell stabilisation and smooth muscle relaxation properties.",10.1016/j.ejmech.2011.01.073,"Synthesis of novel mast cell-stabilising and anti-allergic 1,2,3,4-tetrahydro-1-naphthalenols and related compounds.",1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1021/acsmedchemlett.8b00222,Potent Antimalarial Activity of Two Arenes Linked with Triamine Designed To Have Multiple Interactions with Heme.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
2080,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
2080,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2016.12.024,"Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.",1
2067,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1021/np900821e,Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
2046,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
2046,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.8b02008,"Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.",1
2046,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
6579,10.1021/jm401675a,Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites.,10.1016/j.ejmech.2023.116117,"Targeting autophagy drug discovery: Targets, indications and development trends.",1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1016/j.bmc.2010.06.008,1-Azaaurones derived from the naturally occurring aurones as potential antimalarial drugs.,1
6579,10.1021/ml100120a,Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria.,10.1016/j.bmcl.2011.07.112,Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.02.050,Antimalarials from nature.,1
6579,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.ejmech.2010.12.003,4-anilinoquinoline triazines: a novel class of hybrid antimalarial agents.,1
6579,10.1016/j.ejmech.2018.03.024,Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.,10.1016/j.ejmech.2021.113227,Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity.,1
6579,10.1016/j.bmcl.2019.06.045,Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.,10.1039/d3md00083d,Is structural hybridization invoking new dimensions for antimalarial drug discovery research?,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1016/j.ejmech.2024.116599,Optimization of diastereomeric dihydropyridines as antimalarials.,1
6579,10.1016/j.bmc.2016.09.013,"Conjugation of N-acylhydrazone and 1,2,4-oxadiazole leads to the identification of active antimalarial agents.",10.1016/j.ejmech.2021.113271,In vitro and in vivo antiplasmodial activity of novel quinoline derivative compounds by molecular hybridization.,1
6579,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/acs.jmedchem.6b00275,Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2014.03.030,"Synthesis, β-haematin inhibition, and in vitro antimalarial testing of isocryptolepine analogues: SAR study of indolo[3,2-c]quinolines with various substituents at C2, C6, and N11.",1
6579,10.1016/j.ejmech.2010.08.049,"Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.",10.1021/ml500211c,Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2015.07.047,Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.,1
6579,10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.ejmech.2013.03.072,"Synthesis and antimalarial testing of neocryptolepine analogues: addition of ester function in SAR study of 2,11-disubstituted indolo[2,3-b]quinolines.",1
6579,10.1021/ml500211c,Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.,10.1016/j.ejmech.2018.06.042,"Synthesis and antiplasmodial activity of glyco-conjugate hybrids of phenylhydrazono-indolinones and glycosylated 1,2,3-triazolyl-methyl-indoline-2,3-diones.",1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2021.113227,Synthesis and biological evaluation of benzhydryl-based antiplasmodial agents possessing Plasmodium falciparum chloroquine resistance transporter (PfCRT) inhibitory activity.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.bmcl.2021.127855,"Design, synthesis and biological evaluation of mono- and bisquinoline methanamine derivatives as potential antiplasmodial agents.",1
6579,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2023.115694,Triazole hybrid compounds: A new frontier in malaria treatment.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.bmc.2021.116018,"Quest for a potent antimalarial drug lead: Synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2018.03.024,Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2017.03.010,Synthesis and antiplasmodial activity of novel indoleamide derivatives bearing sulfonamide and triazole pharmacophores.,1
6579,10.1016/j.ejmech.2010.08.049,"Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.",10.1016/j.ejmech.2020.112215,Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review.,1
6579,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,10.1016/j.ejmech.2023.115564,Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",1
6579,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2024.117734,"Discovery of harmiprims, harmine-primaquine hybrids, as potent and selective anticancer and antimalarial compounds.",1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1021/jm300831b,"Mimicking the intramolecular hydrogen bond: synthesis, biological evaluation, and molecular modeling of benzoxazines and quinazolines as potential antimalarial agents.",1
2029,10.1021/jm101008m,"A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.",10.1016/j.ejmech.2014.04.046,Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors.,1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1016/j.ejmech.2024.116599,Optimization of diastereomeric dihydropyridines as antimalarials.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
6579,10.1021/ml2001517,Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).,10.1016/j.ejmech.2020.112652,"An insight on medicinal attributes of 1,2,4-triazoles.",1
6579,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2023.115458,Recent developments in antimalarial activities of 4-aminoquinoline derivatives.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
6579,10.1016/j.ejmech.2013.08.046,"In vitro antimalarial activity, β-haematin inhibition and structure-activity relationships in a series of quinoline triazoles.",10.1039/d2md00324d,"Expanding the scope of novel 1,2,3-triazole derivatives as new antiparasitic drug candidates.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
6579,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1021/acs.jmedchem.6b00719,Identification and SAR Evaluation of Hemozoin-Inhibiting Benzamides Active against Plasmodium falciparum.,10.1039/c9md00468h,Insights into structural and physicochemical properties required for beta-hematin inhibition of privileged triarylimidazoles,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2015.01.036,Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of Plasmodium falciparum parasites.,1
6579,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
6579,10.1021/acs.jmedchem.6b00719,Identification and SAR Evaluation of Hemozoin-Inhibiting Benzamides Active against Plasmodium falciparum.,10.1016/j.ejmech.2018.09.060,Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.,1
2046,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.2c00252,Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.,1
2046,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajprenal.1999.276.2.f295,Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acsmedchemlett.4c00183,"Synthesis and Evaluation of 1,3-Disubstituted Imidazolidine-2,4,5-triones as Inhibitors of Pyruvate Carboxylase.",1
2046,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm5019687,"A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.",1
2046,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm061045z,"Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.",1
2045,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
2045,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
2045,10.1016/j.bmcl.2016.03.035,Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.,10.1016/j.bmcl.2017.03.086,Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.,1
2045,10.1016/j.bmcl.2016.03.035,Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.,10.1016/j.bmcl.2016.10.032,The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.,1
2045,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.bmc.2012.12.015,Synthesis of derivatives of the keto-pyrrolyl-difluorophenol scaffold: some structural aspects for aldose reductase inhibitory activity and selectivity.,1
2029,10.1021/jm050462t,"A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.",10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2011.10.037,Synthesis and antimalarial evaluation of novel isocryptolepine derivatives.,1
6579,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.ejmech.2017.09.040,Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.,1
6579,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.bmcl.2012.11.072,"Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.",1
6579,10.1021/np000306j,"In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.",10.1128/aac.01175-08,In vitro and in vivo properties of ellagic acid in malaria treatment.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2024.116677,Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3.,1
6579,10.1016/j.ejmech.2010.08.049,"Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.",10.1021/jm201216y,"Stilbene-chalcone hybrids: design, synthesis, and evaluation as a new class of antimalarial scaffolds that trigger cell death through stage specific apoptosis.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2012.03.042,Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2018.03.024,Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2021.113253,Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acsmedchemlett.1c00697,Enantiopure Benzofuran-2-carboxamides of 1-Aryltetrahydro-β-carbolines Are Potent Antimalarials <i>In Vitro</i>.,1
6579,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1016/j.ejmech.2024.116599,Optimization of diastereomeric dihydropyridines as antimalarials.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2015.05.040,"Synthesis, β-hematin inhibition studies and antimalarial evaluation of dehydroxy isotebuquine derivatives against Plasmodium berghei.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2019.01.047,Triazole derivatives and their antiplasmodial and antimalarial activities.,1
6579,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
6579,10.1021/ml2001517,Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).,10.1016/j.ejmech.2019.01.047,Triazole derivatives and their antiplasmodial and antimalarial activities.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
6579,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,10.1016/j.ejmech.2024.116782,Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
6579,10.1016/j.ejmech.2010.08.049,"Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.",10.1016/j.bmc.2013.12.032,"Synthesis, in vitro antimalarial activity and cytotoxicity of novel 4-aminoquinolinyl-chalcone amides.",1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.ejmech.2019.01.047,Triazole derivatives and their antiplasmodial and antimalarial activities.,1
6579,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.ejmech.2021.113685,"Novel halogenated arylvinyl-1,2,4 trioxanes as potent antiplasmodial as well as anticancer agents: Synthesis, bioevaluation, structure-activity relationship and in-silico studies.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.4c01241,Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acsmedchemlett.1c00589,"Indole-Containing Pyrazino[2,1-<i>b</i>]quinazoline-3,6-diones Active against <i>Plasmodium</i> and Trypanosomatids.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2018.06.042,"Synthesis and antiplasmodial activity of glyco-conjugate hybrids of phenylhydrazono-indolinones and glycosylated 1,2,3-triazolyl-methyl-indoline-2,3-diones.",1
6579,10.1016/j.bmcl.2006.11.051,Synthesis and antimalarial evaluation of a series of piperazinyl flavones.,10.1016/j.ejmech.2020.112215,Chalcone hybrids as privileged scaffolds in antimalarial drug discovery: A key review.,1
6579,10.1016/j.ejmech.2010.08.049,"Reinvestigation of structure-activity relationship of methoxylated chalcones as antimalarials: synthesis and evaluation of 2,4,5-trimethoxy substituted patterns as lead candidates derived from abundantly available natural β-asarone.",10.1016/j.ejmech.2014.11.016,Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
6579,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2014.11.022,Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review.,1
6579,10.1016/j.bmc.2012.09.052,Synthesis and antimalarial evaluation of a screening library based on a tetrahydroanthraquinone natural product scaffold.,10.1016/j.ejmech.2020.113084,Antimalarial application of quinones: A recent update.,1
6579,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1016/j.bmc.2012.09.052,Synthesis and antimalarial evaluation of a screening library based on a tetrahydroanthraquinone natural product scaffold.,10.1016/j.bmcl.2017.07.039,"Synthesis of antimalarial amide analogues based on the plant serrulatane diterpenoid 3,7,8-trihydroxyserrulat-14-en-19-oic acid.",1
6579,10.1021/ml100120a,Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria.,10.1016/j.ejmech.2013.10.079,Urea/oxalamide tethered β-lactam-7-chloroquinoline conjugates: synthesis and in vitro antimalarial evaluation.,1
6579,10.1016/j.ejmech.2013.08.046,"In vitro antimalarial activity, β-haematin inhibition and structure-activity relationships in a series of quinoline triazoles.",10.1016/j.bmc.2015.06.044,In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine.,1
6579,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1016/j.ejmech.2016.07.027,Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.,10.1016/j.ejmech.2017.03.007,N-Piperonyl substitution on aminoquinoline-pyrimidine hybrids: Effect on the antiplasmodial potency.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2018.10.035,Quinoline and quinolone dimers and their biological activities: An overview.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.0c01511,Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2022.116830,"New antimalarials identified by a cell-based phenotypic approach: Structure-activity relationships of 2,3,4,9-tetrahydro-1H-β-carboline derivatives possessing a 2-((coumarin-5-yl)oxy)alkanoyl moiety.",1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
2029,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2018.04.061,Current anti-diabetic agents and their molecular targets: A review.,1
2029,10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,10.1021/jm101008m,"A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.",1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.ejmech.2023.115270,Designed multiple ligands for the treatment of type 2 diabetes mellitus and its complications: Discovery of (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)alkanoic acids active as novel dual-targeted PTP1B/AKR1B1 inhibitors.,1
2029,10.1016/j.bmc.2014.02.016,Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.,10.1016/j.ejmech.2018.04.061,Current anti-diabetic agents and their molecular targets: A review.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
6579,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
6579,10.1016/j.bmcl.2006.11.051,Synthesis and antimalarial evaluation of a series of piperazinyl flavones.,10.1016/j.bmc.2010.06.067,Anti-HIV and antiplasmodial activity of original flavonoid derivatives.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
6579,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
6579,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,10.1039/d1md00038a,"Design, synthesis, crystal structure and anti-plasmodial evaluation of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives",1
6579,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
6579,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1021/acs.jmedchem.3c00206,Basic Nitrogen (BaN) Is a Key Property of Antimalarial Chemical Space.,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.bmcl.2021.127855,"Design, synthesis and biological evaluation of mono- and bisquinoline methanamine derivatives as potential antiplasmodial agents.",1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.bmc.2015.01.036,Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of Plasmodium falciparum parasites.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/np200399t,"Antimalarial β-carboline and indolactam alkaloids from Marinactinospora thermotolerans, a deep sea isolate.",1
6579,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2016.08.039,Hybrid molecules: The privileged scaffolds for various pharmaceuticals.,1
6579,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.bmc.2018.05.041,"Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.",1
2029,10.1021/jm960124f,"Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.",10.1016/j.bmcl.2007.04.109,"Evaluation of in vitro aldose redutase inhibitory activity of 5-arylidene-2,4-thiazolidinediones.",1
2029,10.1016/j.bmc.2013.06.062,1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.,10.1016/j.ejmech.2017.02.053,Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.,1
2029,10.1021/jm050462t,"A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.",10.1016/j.bmc.2014.02.016,Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.,1
2029,10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,10.1016/j.ejmech.2017.02.053,Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.,1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.bmcl.2010.11.041,In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors.,1
2029,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2023.115270,Designed multiple ligands for the treatment of type 2 diabetes mellitus and its complications: Discovery of (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)alkanoic acids active as novel dual-targeted PTP1B/AKR1B1 inhibitors.,1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.ejmech.2014.05.003,Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.,1
2029,10.1021/jm960124f,"Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.",10.1016/j.bmc.2008.04.072,"Synthesis, induced-fit docking investigations, and in vitro aldose reductase inhibitory activity of non-carboxylic acid containing 2,4-thiazolidinedione derivatives.",1
2029,10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,10.1016/j.bmc.2013.06.062,1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.,1
2029,10.1021/jm050462t,"A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.",10.1016/j.bmc.2013.06.062,1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.,1
2029,10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,10.1016/j.bmc.2014.02.016,Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.,1
2029,10.1016/j.bmc.2013.06.062,1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors.,10.1016/j.ejmech.2018.04.061,Current anti-diabetic agents and their molecular targets: A review.,1
1994,10.1021/jm8000345,Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.,10.1016/j.bmcl.2008.08.009,Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1016/j.bmcl.2009.06.083,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1021/jm800222k,Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.,1
6579,10.1016/j.ejmech.2018.03.024,Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues.,10.1016/j.ejmech.2020.112275,A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery.,1
6579,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",10.1021/acs.jmedchem.0c01411,"Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1021/jm4011466,Structural optimization of quinolon-4(1H)-imines as dual-stage antimalarials: toward increased potency and metabolic stability.,10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.12.109,"1H-1,2,3-Triazole-tethered isatin-7-chloroquinoline and 3-hydroxy-indole-7-chloroquinoline conjugates: synthesis and antimalarial evaluation.",1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1128/aac.01220-10,Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm200718m,"Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
6579,10.1016/j.bmcl.2017.12.060,"Semisynthesis, cytotoxicity, antimalarial evaluation and structure-activity relationship of two series of triterpene derivatives.",10.1016/j.ejmech.2022.114653,New structural classes of antimalarials.,1
6579,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1021/acs.jmedchem.8b00143,Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1021/acsmedchemlett.4c00323,Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery.,1
6579,10.1016/j.bmcl.2010.10.070,In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,1
6579,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.8b00143,Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.,1
6579,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1016/j.bmcl.2023.129258,"Jozibrevine D from Ancistrocladus ileboensis, the fifth alkaloid in a series of six possible atropo-diastereomeric naphthylisoquinoline dimers, showing antiparasitic and antileukemic activities.",1
2029,10.1016/j.bmc.2010.02.010,Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisosterism between a carboxylic acid moiety and that of a tetrazole.,10.1016/j.bmc.2012.12.015,Synthesis of derivatives of the keto-pyrrolyl-difluorophenol scaffold: some structural aspects for aldose reductase inhibitory activity and selectivity.,1
2029,10.1021/jm050462t,"A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners.",10.1016/j.bmc.2007.08.019,Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.,1
2029,10.1016/j.bmc.2010.04.016,Identification of new non-carboxylic acid containing inhibitors of aldose reductase.,10.1016/j.bmc.2014.02.016,Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.,1
2029,10.1021/jm101008m,"A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activity.",10.1016/j.bmc.2012.12.015,Synthesis of derivatives of the keto-pyrrolyl-difluorophenol scaffold: some structural aspects for aldose reductase inhibitory activity and selectivity.,1
2029,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2014.05.003,Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.,1
2029,10.1016/j.bmc.2014.02.016,Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation.,10.1016/j.ejmech.2017.02.053,Enhancing activity and selectivity in a series of pyrrol-1-yl-1-hydroxypyrazole-based aldose reductase inhibitors: The case of trifluoroacetylation.,1
1994,10.1021/jm8000345,Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.,10.1021/acs.jmedchem.6b01197,Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects.,1
1994,10.1016/j.bmcl.2008.08.009,Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.,10.1021/acs.jmedchem.5b00638,Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.,1
1994,10.1021/jm800222k,Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.,10.1016/j.bmcl.2009.06.083,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.,1
1994,10.1016/j.ejmech.2008.12.016,"Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.",10.1016/j.bmcl.2014.12.077,Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.,1
1994,10.1016/j.bmcl.2008.08.009,Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.,10.1016/j.bmcl.2009.06.083,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.,1
1994,10.1021/jm800222k,Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.,10.1021/acs.jmedchem.5b00638,Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.,1
1994,10.1021/jm8000345,Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.,10.1021/jm9000709,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",10.1039/d3md00490b,Reinvestigation of diphenylmethylpiperazine analogues of pyrazine as new class of <i>Plasmodial</i> cysteine protease inhibitors for the treatment of malaria.,1
6579,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2016.11.057,"Design, synthesis and evaluation of 4-aminoquinoline-purine hybrids as potential antiplasmodial agents.",1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
6579,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,10.1039/d3md00423f,"Naphthyl bearing 1,3,4-thiadiazoleacetamides targeting the parasitic folate pathway as anti-infectious agents: <i>in silico</i>, synthesis, and biological approach.",1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,1
6579,10.1016/j.ejmech.2013.08.046,"In vitro antimalarial activity, β-haematin inhibition and structure-activity relationships in a series of quinoline triazoles.",10.1016/j.ejmech.2019.01.047,Triazole derivatives and their antiplasmodial and antimalarial activities.,1
6579,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
6579,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,10.1016/j.ejmech.2021.113722,Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.,1
6579,10.1021/np000306j,"In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.",10.1016/j.bmc.2009.02.050,Antimalarials from nature.,1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1016/j.ejmech.2011.02.029,Amodiaquine analogues containing NO-donor substructures: synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria.,1
6579,10.1016/j.ejmech.2013.08.046,"In vitro antimalarial activity, β-haematin inhibition and structure-activity relationships in a series of quinoline triazoles.",10.1021/acs.jmedchem.6b00719,Identification and SAR Evaluation of Hemozoin-Inhibiting Benzamides Active against Plasmodium falciparum.,1
6579,10.1021/ml100120a,Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1016/j.bmc.2017.12.022,"Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.",10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
6579,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1016/j.ejmech.2012.04.029,Discovery of a new antileishmanial hit in 8-nitroquinoline series.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.bmcl.2014.10.015,Synthesis of novel triazole-linked mefloquine derivatives: biological evaluation against Plasmodium falciparum.,1
6579,10.1021/np000306j,"In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.",10.1128/aac.00544-08,Compounds structurally related to ellagic acid show improved antiplasmodial activity.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2015.04.017,From hybrid compounds to targeted drug delivery in antimalarial therapy.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2015.06.044,In vitro antiplasmodial activity of triazole-linked chloroquinoline derivatives synthesized from 7-chloro-N-(prop-2-yn-1-yl)quinolin-4-amine.,1
6579,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.ejmech.2016.08.039,Hybrid molecules: The privileged scaffolds for various pharmaceuticals.,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.ejmech.2014.06.014,"Synthesis and in vitro evaluation of 4-trichloromethylpyrrolo[1,2-a]quinoxalines as new antiplasmodial agents.",1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,1
6579,10.1021/jm300286a,Lead optimization of antimalarial propafenone analogues.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
1994,10.1021/jm800222k,Discovery of a novel series of benzoic acid derivatives as potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety.,10.1021/acs.jmedchem.6b01197,Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1021/acs.jmedchem.5b00638,Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1021/acs.jmedchem.6b01197,Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1021/jm9000709,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and evaluation of physical properties as potential overactive bladder therapies: part 5.,1
1994,10.1021/jm8000345,Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.,10.1016/j.bmcl.2009.06.083,Discovery of highly potent and selective biphenylacylsulfonamide-based beta3-adrenergic receptor agonists and molecular modeling based on the solved X-ray structure of the beta2-adrenergic receptor: part 6.,1
1994,10.1016/j.bmcl.2008.08.009,Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.,10.1021/acs.jmedchem.6b01197,Discovery of Novel Indazole Derivatives as Orally Available β3-Adrenergic Receptor Agonists Lacking Off-Target-Based Cardiovascular Side Effects.,1
1994,10.1021/jm701324c,Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I.,10.1016/j.bmcl.2008.08.009,Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV.,1
1991,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
1991,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2012.10.002,"Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.",1
1991,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2016.01.009,The importance of triazole scaffold in the development of anticonvulsant agents.,1
1853,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
1853,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
1853,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
1788,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
1788,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
6579,10.1021/acs.jmedchem.8b01961,Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,1
6579,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,10.1021/acs.jmedchem.2c00585,Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.bmc.2014.12.018,Quinoline-based antimalarial hybrid compounds.,1
6579,10.1016/j.bmcl.2013.09.015,Antimalarial activity of compounds comprising a primary benzene sulfonamide fragment.,10.1016/j.ejmech.2023.115699,"Current development of 1,2,3-triazole derived potential antimalarial scaffolds: Structure- activity relationship (SAR) and bioactive compounds.",1
6579,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2024.116163,Discovery of new piperaquine hybrid analogs linked by triazolopyrimidine and pyrazolopyrimidine scaffolds with antiplasmodial and transmission blocking activities.,1
6579,10.1021/jm300286a,Lead optimization of antimalarial propafenone analogues.,10.1016/j.ejmech.2023.115564,Development of diphenylmethylpiperazine hybrids of chloroquinoline and triazolopyrimidine using Petasis reaction as new cysteine proteases inhibitors for malaria therapeutics.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1021/acs.jmedchem.5b01374,Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.ejmech.2021.113981,"Design, synthesis, and characterization of novel aminoalcohol quinolines with strong in vitro antimalarial activity.",1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2019.111755,Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1016/j.bmcl.2009.08.013,Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates.,10.1016/j.bmcl.2013.12.067,Synthesis of halogenated 4-quinolones and evaluation of their antiplasmodial activity.,1
6579,10.1016/j.bmcl.2006.11.051,Synthesis and antimalarial evaluation of a series of piperazinyl flavones.,10.1016/j.bmc.2009.02.050,Antimalarials from nature.,1
6579,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2018.11.008,Synthesis of isatin based N<sup>1</sup>-alkylated 3-β-C-glycoconjugated-oxopropylidene oxindoles as potent antiplasmodial agents.,1
6579,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.ejmech.2021.113687,"Further investigation of harmicines as novel antiplasmodial agents: Synthesis, structure-activity relationship and insight into the mechanism of action.",1
6579,10.1021/ml500211c,Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.,10.1016/j.ejmech.2015.05.020,"Synthesis, antimalarial and antitubercular activities of meridianin derivatives.",1
1994,10.1021/jm8000345,Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.,10.1021/acs.jmedchem.5b00638,Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.08.057,"Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.",1
6579,10.1021/ml500211c,Identification of novel phenyl butenonyl C-glycosides with ureidyl and sulfonamidyl moieties as antimalarial agents.,10.1016/j.ejmech.2018.11.008,Synthesis of isatin based N<sup>1</sup>-alkylated 3-β-C-glycoconjugated-oxopropylidene oxindoles as potent antiplasmodial agents.,1
6579,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,10.1016/j.ejmech.2022.115055,"Identification, in-vitro anti-plasmodial assessment and docking studies of series of tetrahydrobenzothieno[2,3-d]pyrimidine-acetamide molecular hybrids as potential antimalarial agents.",1
6579,10.1016/j.ejmech.2018.10.041,Identification of novel quinazoline derivatives as potent antiplasmodial agents.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
6579,10.1016/j.bmc.2021.116041,Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.,10.1016/j.ejmech.2023.116117,"Targeting autophagy drug discovery: Targets, indications and development trends.",1
6579,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1128/aac.00439-08,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,1
6579,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmc.2009.10.042,Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2015.07.051,"Antimalarial benzoheterocyclic 4-aminoquinolines: Structure-activity relationship, in vivo evaluation, mechanistic and bioactivation studies.",1
6579,10.1021/jm401278d,"Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity.",10.1021/acs.jmedchem.6b01265,Identification of a Potential Antimalarial Drug Candidate from a Series of 2-Aminopyrazines by Optimization of Aqueous Solubility and Potency across the Parasite Life Cycle.,1
6579,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2010.11.037,"Synthesis of 2-(aminomethyl)aziridines and their microwave-assisted ring opening to 1,2,3-triaminopropanes as novel antimalarial pharmacophores.",1
6579,10.1021/jm070733v,Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.,10.1021/jm301506h,Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/jm031132g,"In vitro antimalarial activity of a series of cationic 2,2'-bipyridyl- and 1,10-phenanthrolineplatinum(II) benzoylthiourea complexes.",10.1016/j.bmc.2015.01.036,Interrogating alkyl and arylalkylpolyamino (bis)urea and (bis)thiourea isosteres as potent antimalarial chemotypes against multiple lifecycle forms of Plasmodium falciparum parasites.,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.ejmech.2013.08.004,"Synthesis, characterization, antiparasitic and cytotoxic evaluation of thioureas conjugated to polyamine scaffolds.",1
6579,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.bmc.2009.02.050,Antimalarials from nature.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/ml4002858,"Pharmacokinetics, metabolism, and in vivo efficacy of the antimalarial natural product bromophycolide A.",1
6579,10.1021/ml2001517,Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.ejmech.2014.11.022,Reemergence of chloroquine (CQ) analogs as multi-targeting antimalarial agents: a review.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2011.06.025,Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds.,1
6579,10.1016/j.ejmech.2013.08.046,"In vitro antimalarial activity, β-haematin inhibition and structure-activity relationships in a series of quinoline triazoles.",10.1039/c9md00468h,Insights into structural and physicochemical properties required for beta-hematin inhibition of privileged triarylimidazoles,1
6579,10.1016/j.bmc.2020.115732,Chemical constituents from Macleaya cordata (Willd) R. Br. and their phenotypic functions against a Parkinson's disease patient-derived cell line.,10.1021/acs.jnatprod.3c00743,Isolation and In Vitro and In Vivo Activity of Secondary Metabolites from &lt;i&gt;Clerodendrum polycephalum&lt;/i&gt; Baker against &lt;i&gt;Plasmodium&lt;/i&gt; Malaria Parasites.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
6579,10.1021/jm300802s,"Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling.",10.1016/j.bmc.2015.02.061,Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.,1
6579,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.bmcl.2020.127514,Structural hybridization as a facile approach to new drug candidates.,1
6579,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
6579,10.1021/ml100120a,Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria.,10.1016/j.bmc.2014.04.066,Novel synthetic route for antimalarial benzo[a]phenoxazine derivative SSJ-183 and two active metabolites.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,1
6579,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,1
6579,10.1016/j.ejmech.2018.10.041,Identification of novel quinazoline derivatives as potent antiplasmodial agents.,10.1021/acs.jnatprod.2c00484,Dactylosporolides: Glycosylated Macrolides from <i>Dactylosporangium fulvum</i>.,1
6579,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1021/jm801490z,Synthesis and antiplasmodial activity of aminoalkylamino-substituted neocryptolepine derivatives.,1
6579,10.1016/j.bmcl.2020.127514,Structural hybridization as a facile approach to new drug candidates.,10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.ejmech.2011.12.028,"Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles.",1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.ejmech.2017.10.051,"Synthesis, β-hematin inhibition studies and antimalarial evaluation of new dehydroxy isoquine derivatives against Plasmodium berghei: A promising antimalarial agent.",1
6579,10.1016/j.bmcl.2009.08.013,Synthesis and biological evaluation of new heterocyclic quinolinones as anti-parasite and anti-HIV drug candidates.,10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500715u,"N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.",1
6579,10.1021/acsmedchemlett.6b00416,Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against Plasmodium falciparum.,10.1016/j.ejmech.2018.09.060,Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.,1
6579,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,10.1016/j.bmc.2024.117654,Target fishing reveals PfPYK-1 and PfRab6 as potential targets of an antiplasmodial 4-anilino-2-trichloromethylquinazoline hit compound.,1
6579,10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
6579,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
6579,10.1021/jm070733v,Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds.,10.1021/acs.jmedchem.8b01310,Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1021/acs.jmedchem.4c01241,Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,1
6579,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
1788,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
1788,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
1788,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.9b01561,Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity.,1
1788,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
1788,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,1
1788,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
1788,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmc.2016.01.011,Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.,1
1788,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,1
1788,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1021/acs.jnatprod.9b00475,"Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.",1
1788,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1128/aac.01315-06,In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.,1
1785,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
1763,10.1016/j.bmc.2022.116672,Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.,10.1021/acs.jnatprod.3c00304,Bifunctionalized Betulinic Acid Conjugates with C-3-Monodesmoside and C-28-Triphenylphosphonium Moieties with Increased Cancer Cell Targetability.,1
1763,10.1016/j.ejmech.2011.02.053,Identification of pentacyclic triterpenes derivatives as potent inhibitors against glycogen phosphorylase based on 3D-QSAR studies.,10.1016/j.ejmech.2019.07.049,2-O-(2-chlorobenzoyl) maslinic acid triggers apoptosis in A2780 human ovarian carcinoma cells.,1
1763,10.1016/j.bmc.2022.116672,Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.,10.1016/j.ejmech.2023.115546,"Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.",1
6579,10.1021/ml100120a,Discovery of Novel Benzo[a]phenoxazine SSJ-183 as a Drug Candidate for Malaria.,10.1039/C2MD20136D,Synthesis of cyanine dyes and investigation of their in vitro antiprotozoal activities,1
6579,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
6579,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1021/acsmedchemlett.6b00416,Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against Plasmodium falciparum.,10.1039/c9md00468h,Insights into structural and physicochemical properties required for beta-hematin inhibition of privileged triarylimidazoles,1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm400246e,Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.,1
6579,10.1021/ml2001517,Cyclopropyl Carboxamides: A New Oral Antimalarial Series Derived from the Tres Cantos Anti-Malarial Set (TCAMS).,10.1021/acs.jmedchem.5b00114,A Developability-Focused Optimization Approach Allows Identification of in Vivo Fast-Acting Antimalarials: N-[3-[(Benzimidazol-2-yl)amino]propyl]amides.,1
6579,10.1021/jm4011466,Structural optimization of quinolon-4(1H)-imines as dual-stage antimalarials: toward increased potency and metabolic stability.,10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
6579,10.1016/j.bmcl.2006.11.051,Synthesis and antimalarial evaluation of a series of piperazinyl flavones.,10.1016/j.ejmech.2013.09.008,Flavones as isosteres of 4(1H)-quinolones: discovery of ligand efficient and dual stage antimalarial lead compounds.,1
6579,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2018.09.060,Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.,1
6579,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.ejmech.2022.114408,"Design and synthesis of harmiquins, harmine and chloroquine hybrids as potent antiplasmodial agents.",1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm200718m,"Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.",1
6579,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",10.1021/acs.jmedchem.8b01333,"Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.",1
6579,10.1021/acs.jmedchem.6b00719,Identification and SAR Evaluation of Hemozoin-Inhibiting Benzamides Active against Plasmodium falciparum.,10.1021/acsmedchemlett.6b00416,Identification and Mechanistic Evaluation of Hemozoin-Inhibiting Triarylimidazoles Active against Plasmodium falciparum.,1
6579,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2023.117468,"Design, synthesis and antiplasmodial evaluation of new amide-, carbamate-, and ureido-type harmicines.",1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400656s,Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.,1
6579,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/jm400656s,Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.,1
6723,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
6723,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1016/j.bmcl.2010.08.145,A practical deuterium-free NMR method for the rapid determination of 1-octanol/water partition coefficients of pharmaceutical agents.,1
6706,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
6706,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,1
6643,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2021.113654,Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.,1
6643,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
6643,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,1
6579,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
6579,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
6579,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2019.126810,"Synthesis, anti-plasmodial and cytotoxic evaluation of 1H-1,2,3-triazole/acyl hydrazide integrated tetrahydro-β-carboline-4-aminoquinoline conjugates.",1
6579,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1021/jm101383f,Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.,1
6579,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6579,10.1021/jm8012618,"Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.",10.1016/j.bmc.2013.06.067,"Tetrazole-based deoxyamodiaquines: synthesis, ADME/PK profiling and pharmacological evaluation as potential antimalarial agents.",1
6772,10.1021/jm980067l,Identification and characterization of m1 selective muscarinic receptor antagonists1.,10.1021/jm301774u,Structural modifications to tetrahydropyridine-3-carboxylate esters en route to the discovery of M5-preferring muscarinic receptor orthosteric antagonists.,1
6772,10.1021/jm00128a008,Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics.,10.1016/0960-894X(96)00107-2,The N4 nitrogen of pirenzepine is responsible for selective binding of the M1 subtype human muscarinic receptor,1
6772,10.1021/jm00391a019,Tricyclic compounds as selective antimuscarinics. 1. Structural requirements for selectivity toward the muscarinic acetylcholine receptor in a series of pirenzepine and imipramine analogues.,10.1016/s0960-894x(99)00528-4,"Quinolizidinyl derivatives of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one as ligands for muscarinic receptors.",1
6772,10.1021/jm00128a008,Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics.,10.1016/s0960-894x(99)00528-4,"Quinolizidinyl derivatives of 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one as ligands for muscarinic receptors.",1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm1010012,Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.,1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,1
6760,10.1021/jm1010012,Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.,10.1016/j.bmcl.2011.10.014,3D-Quantitative structure-activity relationship and docking studies of the tachykinin NK3 receptor.,1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1016/j.bmcl.2006.08.086,"N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists.",1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1016/j.bmcl.2008.12.005,New quinoline NK3 receptor antagonists with CNS activity.,1
6760,10.1021/jm900948q,Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,1
6760,10.1021/jm5017413,Discovery and optimization of novel antagonists to the human neurokinin-3 receptor for the treatment of sex-hormone disorders (Part I).,10.1016/j.bmc.2016.05.054,Development of novel NK3 receptor antagonists with reduced environmental impact.,1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1016/j.bmc.2016.05.054,Development of novel NK3 receptor antagonists with reduced environmental impact.,1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1016/j.bmcl.2011.10.014,3D-Quantitative structure-activity relationship and docking studies of the tachykinin NK3 receptor.,1
6760,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,10.1016/j.bmcl.2013.12.033,Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.,1
6760,10.1021/jm1010012,Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.,10.1016/j.bmc.2016.05.054,Development of novel NK3 receptor antagonists with reduced environmental impact.,1
6760,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm900948q,Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/S0960-894X(97)00142-X,Synthesis and estrogen receptor binding affinities of the major human metabolites of raloxifene (LY139481),1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00050-5,Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.,1
6902,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.ejmech.2012.01.025,Probes for narcotic receptor mediated phenomena. 44. Synthesis of an N-substituted 4-hydroxy-5-(3-hydroxyphenyl)morphan with high affinity and selective μ-antagonist activity.,1
6902,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/jm901503e,"Synthesis and opioid activity of enantiomeric N-substituted 2,3,4,4a,5,6,7,7a-octahydro-1H-benzofuro[3,2-e]isoquinolines.",1
6902,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/acs.jmedchem.1c00611,Novel Dual-Target μ-Opioid Receptor and Dopamine D<sub>3</sub> Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management.,1
6902,10.1021/jm00378a009,Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.,10.1016/j.bmc.2009.07.024,Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence.,1
6902,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1021/jm800913d,"Probes for narcotic receptor mediated phenomena. 37. Synthesis and opioid binding affinity of the final pair of oxide-bridged phenylmorphans, the ortho- and para-b-isomers and their N-phenethyl analogues, and the synthesis of the N-phenethyl analogues of the ortho- and para-d-isomers.",1
6902,10.1021/jm00199a018,Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.,10.1016/j.bmcl.2014.05.033,Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.,1
6902,10.1021/jm061325e,Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.,10.1016/j.bmc.2011.04.028,Probes for narcotic receptor mediated phenomena. Part 42: synthesis and in vitro pharmacological characterization of the N-methyl and N-phenethyl analogues of the racemic ortho-c and para-c oxide-bridged phenylmorphans.,1
6902,10.1021/jm00202a018,Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone.,10.1016/j.bmcl.2014.05.033,Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.,1
6787,10.1021/jm00105a067,Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens.,10.1016/j.ejmech.2008.03.020,"Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities.",1
6787,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1016/j.bmcl.2004.10.085,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",1
6787,10.1021/jm00105a067,Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens.,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",1
6787,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(00)00010-x,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",1
6787,10.1021/jm00105a067,Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens.,10.1016/j.bmc.2007.02.007,"Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha,17beta-diol as antiandrogens.",1
6784,10.1021/jm00392a005,Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.,10.1021/jm021050c,"Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives.",1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.bmcl.2004.03.074,Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs.,1
6914,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2005.05.089,Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.,1
6914,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.05.074,Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/jm401144z,Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.ejmech.2012.02.021,Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.,1
6914,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.10.036,Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/acs.jmedchem.5b01276,Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.bmcl.2004.12.074,Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.,1
6914,10.1021/jm2011657,Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.,10.1039/d4md00364k,Integrating computational and experimental chemical biology revealed variable anticancer activities of phosphodiesterase isoenzyme 5 inhibitors (PDE5i) in lung cancer.,1
6914,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2005.08.084,Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00145-6,"Synthesis and biological activity of trans-2,3-dihydroraloxifene.",1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(02)00985-x,2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(02)00613-3,Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.,1
6914,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.05.073,Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.,1
6914,10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,10.1016/j.ejmech.2012.02.021,Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500715u,"N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.",1
6936,10.1016/j.bmcl.2004.01.024,Crucial role of the peroxyketal function for antimalarial activity in the G-factor series.,10.1021/acsmedchemlett.9b00669,Synthesis of Novel G Factor or Chloroquine-Artemisinin Hybrids and Conjugates with Potent Antiplasmodial Activity.,1
6936,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.bmc.2018.05.041,"Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin.",1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2019.07.019,An insight into the medicinal perspective of synthetic analogs of indole: A review.,1
6936,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.02.050,Antimalarials from nature.,1
6936,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1039/c9md00479c,An epigrammatic status of the azole-based antimalarial drugs,1
6936,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.bmcl.2018.05.035,"Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.",1
6936,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2022.115000,A comprehensive overview of Artemisinin and its derivatives as anticancer agents.,1
6936,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2021.113454,Combating multi-drug resistant malaria parasite by inhibiting falcipain-2 and heme-polymerization: Artemisinin-peptidyl vinyl phosphonate hybrid molecules as new antimalarials.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",1
6936,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6914,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
6936,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2014.03.030,"Synthesis, β-haematin inhibition, and in vitro antimalarial testing of isocryptolepine analogues: SAR study of indolo[3,2-c]quinolines with various substituents at C2, C6, and N11.",1
1712,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmcl.2007.01.038,"Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.",1
1712,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmc.2007.11.050,"Synthesis and antimycobacterial evaluation of newer 1-cyclopropyl-1,4-dihydro-6-fluoro-7-(substituted secondary amino)-8-methoxy-5-(sub)-4-oxoquinoline-3-carboxylic acids.",1
1712,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
1712,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
1712,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm980448z,Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.,1
1712,10.1016/j.ejmech.2011.06.032,Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
1712,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
1712,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
1712,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
1712,10.1016/j.ejmech.2011.06.032,Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
1712,10.1016/j.ejmech.2011.06.032,Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.,10.1016/j.ejmech.2018.01.080,Fluoroquinolone derivatives and their anti-tubercular activities.,1
1712,10.1016/j.ejmech.2011.06.032,Synthesis and in vitro antibacterial activity of a series of novel gatifloxacin derivatives.,10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
1712,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmcl.2004.03.070,Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.61.5.982,Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.,1
1620,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",1
6936,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.bmc.2017.05.018,Synthesis of nοvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.12.109,"1H-1,2,3-Triazole-tethered isatin-7-chloroquinoline and 3-hydroxy-indole-7-chloroquinoline conjugates: synthesis and antimalarial evaluation.",1
6936,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2018.03.010,Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.5b00678,"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.",1
6936,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2024.116354,Activity refinement of aryl amino acetamides that target the P. falciparum STAR-related lipid transfer 1 protein.,1
6936,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1021/acs.jmedchem.5b01380,Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents.,1
6936,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1016/j.bmc.2015.04.017,From hybrid compounds to targeted drug delivery in antimalarial therapy.,1
6936,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1016/j.bmcl.2020.127037,Synthesis and efficacy of pyrvinium-inspired analogs against tuberculosis and malaria pathogens.,1
6936,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.ejmech.2020.112044,Artemisinin-derived hybrids and their anticancer activity.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acsmedchemlett.1c00697,Enantiopure Benzofuran-2-carboxamides of 1-Aryltetrahydro-β-carbolines Are Potent Antimalarials <i>In Vitro</i>.,1
6936,10.1021/jm00113a021,Monoterpenic fragment analogues of aplasmomycin as potential antimalarial.,10.1016/s0960-894x(01)00396-1,Antimalarial t-butylperoxyamines.,1
6936,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.bmc.2017.10.017,Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.,1
6936,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
6936,10.1021/ml300008j,A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
6936,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2017.07.061,Quinoline hybrids and their antiplasmodial and antimalarial activities.,1
1620,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1620,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1620,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1620,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00145-6,"Synthesis and biological activity of trans-2,3-dihydroraloxifene.",1
6968,10.1016/j.bmc.2008.09.035,"Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.",10.1007/s00044-012-0391-5,"Design, synthesis, and cytotoxic activities of new 2,4,5-triarylimidazoles",1
6968,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.bmcl.2022.128668,"Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.",1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
6968,10.1016/j.bmc.2008.09.035,"Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
6968,10.1016/j.bmc.2008.09.035,"Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.",10.1016/j.bmc.2013.05.012,Synthesis and biological evaluation of novel tamoxifen analogues.,1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.bmc.2009.08.011,Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.,1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/jm0700262,Target specific virtual screening: optimization of an estrogen receptor screening platform.,1
6936,10.1039/C4MD00091A,Synthesis and evaluation of artesunateindoloquinoline hybrids as antimalarial drug candidates,10.1016/j.ejmech.2018.12.007,Current scenario of artemisinin and its analogues for antimalarial activity.,1
6936,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.bmcl.2015.05.067,Synthesis of a novel series of fluoroarene derivatives of artemisinin as potent antifungal and anticancer agent.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
6968,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
6968,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1620,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1152/ajprenal.2000.279.3.f449,"Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.",1
1620,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm2001629,Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.,1
1620,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
1620,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1254/jphs.94.197,Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.,1
1620,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1124/dmd.110.035998,Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1152/ajprenal.00290.2002,Transport of cimetidine by flounder and human renal organic anion transporter 1.,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
1620,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
1620,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1016/j.ejphar.2004.09.032,Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).,1
1620,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
1620,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1124/mol.56.1.1,Selective substrates for non-neuronal monoamine transporters.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1016/j.bmcl.2007.02.002,Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1016/j.bmcl.2019.01.036,Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.,1
6968,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
6968,10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,10.1016/j.bmcl.2019.01.036,Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1016/j.bmcl.2019.01.036,Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.,1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/jm040858p,Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.,1
6968,10.1016/j.ejmech.2023.115331,"Application of an ""inhalation by design"" approach to the identification and in-vitro evaluation of novel purine based PI3Kδ inhibitors.",10.1021/acs.jmedchem.4c00610,Discovery and Optimization of Pyridazinones as PI3Kδ Selective Inhibitors for Administration by Inhalation.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
6968,10.1016/j.bmc.2008.09.035,"Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.",10.1016/j.bmc.2010.04.007,"Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazoles and 3-hydroxy ketones as estrogen receptor alpha and beta agonists.",1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
6968,10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
6968,10.1021/np100920q,Using the pER8:GUS reporter system to screen for phytoestrogens from Caesalpinia sappan.,10.1016/j.bmcl.2013.06.022,3-Acyl-5-hydroxybenzofuran derivatives as potential anti-estrogen breast cancer agents: a combined experimental and theoretical investigation.,1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.bmc.2021.116395,"Benzothiophene derivatives as selective estrogen receptor covalent antagonists: Design, synthesis and anti-ERα activities.",1
6968,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2018.10.045,Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1016/j.ejmech.2008.01.001,Synthesis and preliminary biological evaluation of new carbon-11 labeled tetrahydroisoquinoline derivatives as SERM radioligands for PET imaging of ER expression in breast cancer.,1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
6968,10.1021/jm100369g,Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.,10.1016/j.ejmech.2012.04.041,Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.,1
6968,10.1016/j.ejmech.2011.05.054,"Design, synthesis and bioevaluation of novel candidate selective estrogen receptor modulators.",10.1016/j.bmc.2019.115261,Optimisation of estrogen receptor subtype-selectivity of a 4-Aryl-4H-chromene scaffold previously identified by virtual screening.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1039/d3md00157a,"Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents.",1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.7b01682,"Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.",1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.9b01580,Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.,1
6968,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.9b01580,Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,1
6968,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.bmcl.2024.129789,"Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents.",1
6968,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
7501,10.1021/acs.jmedchem.8b00498,Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo.,10.1016/j.ejmech.2021.113555,Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.,1
7501,10.1016/j.bmcl.2007.12.055,Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors.,10.1021/np100935s,Inverse virtual screening of antitumor targets: pilot study on a small database of natural bioactive compounds.,1
7494,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajprenal.00402.2002,Molecular characterization of human and rat organic anion transporter OATP-D.,1
7494,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
7427,10.1021/jm900469e,Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.,10.1016/j.ejmech.2016.06.054,Synthesis and biological evaluation of 6-fluoro-3-phenyl-7-piperazinyl quinolone derivatives as potential topoisomerase I inhibitors.,1
7427,10.1021/jm900469e,Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.,10.1016/j.bmcl.2013.03.037,"Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.",1
7289,10.1021/acs.jmedchem.5b00865,"Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.",10.1021/acs.jmedchem.6b01711,Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.bmcl.2022.128668,"Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.",1
6968,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/jm0700262,Target specific virtual screening: optimization of an estrogen receptor screening platform.,1
6968,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,1
6968,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
6968,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1016/j.bmcl.2021.128335,Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.,1
6968,10.1021/jm900146e,Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.,10.1016/j.bmcl.2017.04.029,"Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.",1
6968,10.1016/j.bmc.2008.09.035,"Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators.",10.1016/j.ejmech.2017.09.015,Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.,1
6968,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1039/d3md00157a,"Design, synthesis, and biological evaluation of indole-modified tamoxifen relatives as potent anticancer agents.",1
6968,10.1021/jm100369g,Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.,10.1016/j.bmcl.2013.03.105,Discovery of natural estrogen receptor modulators with structure-based virtual screening.,1
7736,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
7714,10.1016/j.ejmech.2017.12.099,Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.,10.1016/j.bmcl.2021.127909,Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.,1
7714,10.1021/jm960268u,"Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.",10.1016/j.ejmech.2016.07.038,Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.,1
7714,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmcl.2015.09.045,Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.,1
7714,10.1016/j.bmcl.2016.04.087,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",10.1016/j.bmcl.2018.01.038,Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.,1
7714,10.1021/jm070516u,Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.,10.1016/j.bmcl.2008.10.035,Synthesis and preliminary pharmacological evaluation of N-2-(4-(4-(2-substitutedthiazol-4-yl) piperazin-1-yl)-2-oxoethyl)acetamides as novel atypical antipsychotic agents.,1
7714,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.ejmech.2016.07.038,Synthesis and pharmacological characterization of novel N-(trans-4-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)cyclohexyl)amides as potential multireceptor atypical antipsychotics.,1
7714,10.1021/jm00084a014,"Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.",10.1021/jm300975f,Systematic in vivo screening of a series of 1-propyl-4-arylpiperidines against dopaminergic and serotonergic properties in rat brain: a scaffold-jumping approach.,1
7714,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1021/acs.jmedchem.3c00976,Discovery of Selective Dopamine Receptor Ligands Derived from (-)-Stepholidine via C-3 Alkoxylation and C-3/C-9 Dialkoxylation.,1
7714,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm400408r,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,1
7714,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.ejmech.2016.09.008,Synthesis and biological evaluation of new 6-hydroxypyridazinone benzisoxazoles: Potential multi-receptor-targeting atypical antipsychotics.,1
7502,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1016/j.bmc.2017.10.005,Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.,1
7501,10.1021/acs.jmedchem.8b00498,Structure-Based Drug Design and Identification of H2O-Soluble and Low Toxic Hexacyclic Camptothecin Derivatives with Improved Efficacy in Cancer and Lethal Inflammation Models in Vivo.,10.1021/acs.jmedchem.3c02115,Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements.,1
7501,10.1021/jm900469e,Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification.,10.1021/jm400906z,"A new strategy to improve the metabolic stability of lactone: discovery of (20S,21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors.",1
7501,10.1016/j.bmcl.2007.12.055,Synthesis and cytotoxic activity of a new series of topoisomerase I inhibitors.,10.1021/jm300605m,New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure-activity relationship analysis and biological evaluations.,1
7501,10.1021/jm401471v,Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.,10.1021/acs.jmedchem.5b00303,Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.,1
8062,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115879,Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2017.12.004,"Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.",1
8062,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",10.1021/acsmedchemlett.9b00352,"Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones as Novel Tubulin Inhibitors.",1
8062,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1016/j.ejmech.2020.113023,"Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.",1
8062,10.1016/j.ejmech.2019.06.006,Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.,10.1021/acs.jmedchem.0c00408,Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.,1
8062,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",10.1021/acs.jmedchem.1c01202,"X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2024.116649,"Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.",1
8062,10.1016/j.ejmech.2019.06.006,Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.,10.1016/j.ejmech.2022.114155,Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.,1
8062,10.1016/j.bmc.2012.12.010,"Synthesis of N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells.",10.1016/j.bmc.2016.11.026,"Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.",1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/acs.jnatprod.1c00342,"Taccachatrones A-G, Highly Oxidized Steroids from the Rhizomes of <i>Tacca chantrierii</i> and Their Cytotoxicity Assessment.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2021.113316,Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.,1
8062,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2018.07.044,"Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation.",1
8062,10.1016/j.ejmech.2019.06.006,Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells.,10.1021/acs.jnatprod.0c00064,"Amentotaxins C-V, Structurally Diverse Diterpenoids from the Leaves and Twigs of the Vulnerable Conifer Amentotaxus argotaenia and Their Cytotoxic Effects.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acsmedchemlett.9b00352,"Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones as Novel Tubulin Inhibitors.",1
8062,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",10.1016/j.bmc.2021.116061,Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.,1
8062,10.1021/acs.jmedchem.0c00408,Identification of a Potent Oridonin Analogue for Treatment of Triple-Negative Breast Cancer.,10.1016/j.ejmech.2022.114155,Identification of new potent anticancer derivatives through simplifying the core structure and modification on their 14- hydroxyl group from oridonin.,1
1615,10.1021/acs.jmedchem.6b00660,Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.,10.1016/j.ejmech.2022.114341,Semisynthetic pleuromutilin antimicrobials with therapeutic potential against methicillin-resistant Staphylococcus aureus by targeting 50S ribosomal subunit.,1
1615,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.2133/dmpk.17.253,Transporter-mediated Drug Interactions.,1
1615,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1016/s0167-4889(02)00187-8,Role of human organic anion transporter 4 in the transport of ochratoxin A.,1
1560,10.1016/j.ejmech.2007.08.004,"Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxamides.",10.1016/j.bmcl.2011.06.074,Diversity oriented design of various hydrazides and their in vitro evaluation against Mycobacterium tuberculosis H37Rv strains.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",1
8062,10.1021/np050397q,Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells.,10.1016/j.bmc.2021.116072,Synthesis and biological activity of selenopsammaplin A and its analogues as antitumor agents with DOT1L inhibitory activity.,1
8062,10.1021/acsmedchemlett.9b00352,"Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones as Novel Tubulin Inhibitors.",10.1021/acs.jmedchem.1c01202,"X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2018.11.070,"Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.",1
8062,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1016/j.ejmech.2022.114887,"Design, synthesis and biological evaluation of a new class of 7H-pyrrolo[2,3-d]pyrimidine derivatives as Mps1 inhibitors for the treatment of breast cancer.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2023.115470,Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells.,1
8062,10.1016/j.ejmech.2017.02.025,"The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.",10.1021/acs.jnatprod.9b00659,Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.,1
8062,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1021/acs.jmedchem.5b01380,Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents.,1
8062,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.bmc.2023.117437,"Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.7b00273,"In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents.",1
8062,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2022.114707,Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51.,1
8062,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2018.12.030,A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe.,1
8062,10.1016/j.bmcl.2007.04.058,Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies.,10.1016/j.bmc.2013.11.037,The synthesis of novel taxoids for oral administration.,1
8062,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115281,Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.1c01202,"X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.",1
8062,10.1021/acs.jmedchem.7b01644,Bifidenone: Structure-Activity Relationship and Advanced Preclinical Candidate.,10.1021/acs.jmedchem.1c00790,"Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.",1
1620,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2011.08.002,Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.,1
1620,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
1620,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
1620,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1620,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1615,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1615,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
1615,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.61.5.982,Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.,1
1615,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
1615,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.ejmech.2010.09.045,The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains.,1
1615,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.2133/dmpk.17.253,Transporter-mediated Drug Interactions.,1
1615,10.1016/j.bmc.2006.12.027,N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.,10.1016/j.bmcl.2012.04.056,"Synthesis and antimicrobial activities of structurally novel S,S'-bis(heterosubstituted) disulfides.",1
8062,10.1021/acs.jnatprod.6b00893,Isolation and Identification of the Novel Tubulin Polymerization Inhibitor Bifidenone.,10.1021/acs.jmedchem.7b01644,Bifidenone: Structure-Activity Relationship and Advanced Preclinical Candidate.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.0c01345,"SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2017.08.018,"Synthesis and biological evaluation of N-substituted 3-oxo-1,2,3,4-tetrahydro-quinoxaline-6-carboxylic acid derivatives as tubulin polymerization inhibitors.",1
8062,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,10.1016/j.bmcl.2019.03.020,Thiazolyl-pyrazole derivatives as potential antimycobacterial agents.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.7b01858,Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2016.05.025,"Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.",1
8062,10.1016/j.ejmech.2019.01.011,"Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.",10.1021/acs.jmedchem.1c00100,Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy.,1
8062,10.1038/nchembio.94,Synthesis enables identification of the cellular target of leucascandrolide A and neopeltolide.,10.1016/j.bmc.2020.115792,A look around the West Indies: The spices of life are secondary metabolites.,1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/np500768s,"Melampodium leucanthum, a source of cytotoxic sesquiterpenes with antimitotic activities.",1
8062,10.1021/acsmedchemlett.9b00352,"Scaffold Hopping-Driven Optimization of 4-(Quinazolin-4-yl)-3,4-dihydroquinoxalin-2(1<i>H</i>)-ones as Novel Tubulin Inhibitors.",10.1016/j.ejmech.2023.115470,Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells.,1
8062,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",10.1021/acs.jmedchem.7b00273,"In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2015.04.055,Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.,1
8062,10.1016/j.bmc.2015.12.042,"New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.",10.1016/j.ejmech.2018.07.011,Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131).,1
8062,10.1021/acs.jnatprod.6b00893,Isolation and Identification of the Novel Tubulin Polymerization Inhibitor Bifidenone.,10.1021/acs.jnatprod.9b00724,Anibamine and Its Analogues: Potent Antiplasmodial Agents from <i>Aniba citrifolia</i>.,1
8062,10.1016/j.bmc.2015.07.016,"Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitors.",10.1016/j.bmc.2016.05.025,"Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors.",1
8062,10.1021/ml200195s,Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.,10.1016/j.ejmech.2016.07.002,"Synthesis, anti-cancer evaluation of benzenesulfonamide derivatives as potent tubulin-targeting agents.",1
8062,10.1016/j.ejmech.2019.01.011,"Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.",10.1016/j.ejmech.2024.116766,"Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation.",1
8062,10.1021/acs.jmedchem.2c01208,Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.,10.1016/j.ejmech.2024.116177,Design and synthesis of novel 3-amino-5-phenylpyrazole derivatives as tubulin polymerization inhibitors targeting the colchicine-binding site.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2023.115870,The discovery of water-soluble indazole derivatives as potent microtubule polymerization inhibitors.,1
8062,10.1016/j.ejmech.2017.02.025,"The derivatives of Pulsatilla saponin A, a bioactive compound from Pulsatilla chinensis: Their synthesis, cytotoxicity, haemolytic toxicity and mechanism of action.",10.1021/acs.jnatprod.7b00578,"Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives.",1
1529,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1021/jm010490l,"Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities.",1
1380,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
1380,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
1380,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
1380,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
1380,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
1370,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.08.094,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.",1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.04.066,"Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1016/j.bmcl.2005.06.007,A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.,10.1007/s00044-013-0766-2,2D QSAR of heteroaryl-substituted propanolamines as antihypertensive agents,1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/np4005079,The bat flower: a source of microtubule-destabilizing and -stabilizing compounds with synergistic antiproliferative actions.,1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/np400435t,Hydrolysis reactions of the taccalonolides reveal structure-activity relationships.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm900756t,"Synthesis and in vitro opioid receptor functional antagonism of methyl-substituted analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/acsmedchemlett.7b00115,Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/acs.jmedchem.8b00674,"Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm701344b,"Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).",1
8062,10.1016/j.ejmech.2018.05.028,"Synthesis, cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain at C2 position.",10.1016/j.bmc.2019.02.044,"Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.",1
8062,10.1021/acs.jnatprod.7b00857,A Series of Enthalpically Optimized Docetaxel Analogues Exhibiting Enhanced Antitumor Activity and Water Solubility.,10.1016/j.ejmech.2022.114784,"Design, synthesis, and biological evaluation of ocotillol derivatives fused with 2-aminothiazole via A-ring as modulators of P-glycoprotein-mediated multidrug resistance.",1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/acs.jnatprod.6b00944,Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJ.,1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/jm300564b,Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.,1
8062,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.5b00270,"Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.",1
8062,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
8062,10.1021/ml200195s,Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.,10.1021/acsmedchemlett.1c00219,"Design, Synthesis, and Biological Evaluation of Novel 1,3-Oxazole Sulfonamides as Tubulin Polymerization Inhibitors.",1
8062,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.bmcl.2009.09.075,Histone deacetylase and microtubules as targets for the synthesis of releasable conjugate compounds.,1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.8b01755,Discovery of Novel Quinoline-Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity.,1
8062,10.1021/jm200757g,Identification and biological activities of new taccalonolide microtubule stabilizers.,10.1021/acs.jnatprod.7b00967,Taccalonolide Microtubule Stabilizers Generated Using Semisynthesis Define the Effects of Mono Acyloxy Moieties at C-7 or C-15 and Disubstitutions at C-7 and C-25.,1
8062,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1039/d2md00442a,"Design, synthesis and <i>in vitro</i> cytotoxicity evaluation of indolo-pyrazoles grafted with thiazolidinone as tubulin polymerization inhibitors.",1
8062,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2022.116976,"Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm058264p,"N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm1004978,"Analogues of (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in vitro and in vivo opioid receptor antagonist activity.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1016/j.ejmech.2014.12.016,"Novel fluoroalkyl derivatives of selective kappa opioid receptor antagonist JDTic: Design, synthesis, pharmacology and molecular modeling studies.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/np070194x,Flavonoids as opioid receptor ligands: identification and preliminary structure-activity relationships.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1016/j.ejmech.2017.10.012,"Selective kappa opioid antagonists for treatment of addiction, are we there yet?",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm030467v,Importance of phenolic address groups in opioid kappa receptor selective antagonists.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1016/j.bmc.2016.06.029,"Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1016/j.bmc.2015.08.025,"Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of the 3- and 4-methyl substituents.",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1016/j.bmcl.2014.03.040,Antagonists of the kappa opioid receptor.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm058261c,N-substituted cis-4a-(3-hydroxyphenyl)-8a-methyloctahydroisoquinolines are opioid receptor pure antagonists.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1074/jbc.m705540200,Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm301783x,Development of κ opioid receptor antagonists.,1
8090,10.1021/acs.jmedchem.8b00673,"Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).",10.1021/acs.jmedchem.8b00674,"Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)- N-[1 R)-1-(Cyclohexylmethyl)-2-methylpropyl]-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (CDTic).",1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm200789r,Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/jm400275h,Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2-methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists.,1
8090,10.1021/jm030094y,"Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.",10.1021/acs.jmedchem.8b00673,"Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic).",1
8417,10.1016/j.bmcl.2008.06.097,Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,1
8417,10.1021/jm00188a006,"Synthesis and antitumor activity of cyclophosphamide analogues. 2. Preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems.",10.1007/s00044-011-9737-7,"Antitumor activities of some new 1,3,2-oxaza- and 1,3,2-diazaphosphorinanes against K562, MDA-MB-231, and HepG2 cells",1
8417,10.1021/jm00155a022,"Synthesis and antitumor activity of cyclophosphamide analogues. 4. Preparation, kinetic studies, and anticancer screening of ""phenylketophosphamide"" and similar compounds related to the cyclophosphamide metabolite aldophosphamide.",10.1007/s00044-011-9737-7,"Antitumor activities of some new 1,3,2-oxaza- and 1,3,2-diazaphosphorinanes against K562, MDA-MB-231, and HepG2 cells",1
8209,10.1016/j.ejmech.2015.12.047,"Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.",10.1016/j.ejmech.2023.115888,"The location, physiology, pathology of hippocampus Melatonin MT<sub>2</sub> receptor and MT<sub>2</sub>-selective modulators.",1
8209,10.1016/j.ejmech.2012.01.027,"Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).",10.1016/j.ejmech.2017.10.025,Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.,1
8209,10.1016/j.ejmech.2012.01.027,"Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).",10.1016/j.ejmech.2015.12.047,"Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.",1
8209,10.1016/j.ejmech.2015.12.047,"Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.",10.1016/j.ejmech.2017.10.025,Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.,1
8209,10.1016/j.ejmech.2012.01.027,"Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).",10.1039/C4MD00149D,,1
8209,10.1016/j.ejmech.2015.12.047,"Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.",10.1016/j.ejmech.2020.112078,Quinazoline and phthalazine derivatives as novel melatonin receptor ligands analogues of agomelatine.,1
8209,10.1016/j.ejmech.2012.01.027,"Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).",10.1016/j.ejmech.2020.112078,Quinazoline and phthalazine derivatives as novel melatonin receptor ligands analogues of agomelatine.,1
8209,10.1016/j.ejmech.2012.01.027,"Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).",10.1016/j.ejmech.2023.115888,"The location, physiology, pathology of hippocampus Melatonin MT<sub>2</sub> receptor and MT<sub>2</sub>-selective modulators.",1
8193,10.1021/jm4012164,Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.,10.1021/acs.jmedchem.1c01318,"Novel Antimicrobial 8-Hydroxyquinoline-Based Agents: Current Development, Structure-Activity Relationships, and Perspectives.",1
8167,10.1016/j.bmcl.2019.05.041,A high throughput substrate binding assay reveals hexachlorophene as an inhibitor of the ER-resident HSP70 chaperone GRP78.,10.1016/j.ejmech.2023.115792,Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy.,1
8130,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1073/pnas.1033060100,The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.,1
8130,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
8130,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajprenal.00402.2002,Molecular characterization of human and rat organic anion transporter OATP-D.,1
8810,10.1021/jm00007a004,"Design, synthesis, and structure--activity relationship studies for a new imidazole series of J774 macrophage specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors.",10.1016/j.bmc.2018.06.024,"Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.",1
8810,10.1021/jm00007a004,"Design, synthesis, and structure--activity relationship studies for a new imidazole series of J774 macrophage specific acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors.",10.1021/acs.jmedchem.2c01265,Targeting Sterol <i>O</i>-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,1
8543,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
8543,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
8543,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
8543,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
8543,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
8543,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
8543,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
8543,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
8543,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
8531,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
8531,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
8531,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
8417,10.1021/jm00188a006,"Synthesis and antitumor activity of cyclophosphamide analogues. 2. Preparation, hydrolytic studies, and anticancer screening of 5-bromocyclophosphamide, 3,5-dehydrocyclophosphamide, and related systems.",10.1007/s00044-010-9466-3,"Cyclophosphamide analogues: synthesis, spectroscopic study, and antitumor activity of diazaphosphorinanes",1
8417,10.1021/acs.jmedchem.5b00118,Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity.,10.1016/j.ejmech.2017.12.008,"Synthesis and biological evaluation of novel 2-arylvinyl-substituted naphtho[2,3-d]imidazolium halide derivatives as potent antitumor agents.",1
8873,10.1016/j.bmcl.2013.09.047,Synthesis and anti-parasitic activity of a novel quinolinone-chalcone series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
8873,10.1016/j.bmc.2010.10.065,Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.,10.1016/j.bmc.2013.08.043,CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents.,1
8873,10.1016/j.bmc.2007.03.018,"Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes.",10.1128/aac.00231-10,In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.,1
8873,10.1016/j.ejmech.2018.04.057,Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.,10.1016/j.ejmech.2021.113606,Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.,1
8873,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
8873,10.1016/j.ejmech.2017.01.029,"Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.",10.1016/j.bmcl.2018.08.040,"Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.",1
8873,10.1021/jm0508843,Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.,10.1016/j.ejmech.2020.113048,"Design, synthesis, and biodistribution studies of new analogues of marine alkaloids: Potent in vitro and in vivo fungicidal agents against Candida spp.",1
8873,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
8873,10.1016/j.bmc.2011.03.038,"Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.",10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
8873,10.1016/j.bmc.2013.03.045,Synthesis and biological evaluation against Leishmania amazonensis of a series of alkyl-substituted benzophenones.,10.1016/j.bmcl.2015.05.072,Synthesis and evaluation of novel prenylated chalcone derivatives as anti-leishmanial and anti-trypanosomal compounds.,1
8873,10.1016/j.bmc.2008.05.076,Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.,10.1016/j.ejmech.2015.07.018,"Synthesis, leishmanicidal, trypanocidal and cytotoxic activity of quinoline-hydrazone hybrids.",1
8810,10.1021/jm00047a009,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.,10.1016/0960-894X(95)00001-A,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: ureas bearing heterocyclic groups bioisosteric for an imidazole,1
8810,10.1021/jm00047a009,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.,10.1021/acs.jmedchem.2c01265,Targeting Sterol <i>O</i>-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,1
8810,10.1021/jm00047a009,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.,10.1016/j.bmc.2018.06.024,"Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors.",1
8810,10.1021/jm00047a009,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.,10.1016/0960-894X(95)00002-B,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: ureas bearing two heterocyclic head groups,1
8810,10.1021/jm00047a009,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: synthesis and structure-activity relationship studies of a new series of trisubstituted imidazoles.,10.1016/0960-894X(95)00003-C,Acyl CoA:cholesterol acyltransferase (ACAT) inhibitors: heterocyclic bioisosteres for the urea group in DuP 128,1
8873,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,1
8873,10.1016/j.ejmech.2011.02.034,Optimization of 3-(phenylthio)quinolinium compounds against opportunistic fungal pathogens.,10.1016/j.ejmech.2013.09.044,Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents.,1
8873,10.1016/j.bmc.2010.10.065,Identification of 3-phenylaminoquinolinium and 3-phenylaminopyridinium salts as new agents against opportunistic fungal pathogens.,10.1016/j.ejmech.2011.03.021,δ-Carbolines and their ring-opened analogs: synthesis and evaluation against fungal and bacterial opportunistic pathogens.,1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.05.083,"Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.",1
1370,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112282,N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm5019687,"A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.",1
1370,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.08.094,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.2c00252,Turning Nonselective Inhibitors of Type I Protein Arginine Methyltransferases into Potent and Selective Inhibitors of Protein Arginine Methyltransferase 4 through a Deconstruction-Reconstruction and Fragment-Growing Approach.,1
1370,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
1370,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1370,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.07.014,"4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.8b02008,"Discovery of a Novel Chemotype of Histone Lysine Methyltransferase EHMT1/2 (GLP/G9a) Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Co-crystal Structure.",1
8873,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
8873,10.1021/jm5000408,"Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.",10.1016/j.bmcl.2016.02.044,Individual and combined antiparasitic effect of six plant metabolites against Leishmania amazonensis and Trypanosoma cruzi.,1
8873,10.1016/j.bmc.2009.07.037,"Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes.",10.1128/aac.00231-10,In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.,1
8873,10.1016/j.bmc.2007.03.018,"Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes.",10.1007/s00044-011-9578-4,"Synthesis, characterization and antimicrobial activity of 4-amino-1-alkyl pyridinium salts",1
8873,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
8873,10.1016/j.ejmech.2018.04.057,Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.,10.1016/j.ejmech.2023.115471,Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds.,1
8873,10.1016/j.bmc.2011.03.038,"Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.",10.1016/j.ejmech.2021.113606,Recent advancements in anti-leishmanial research: Synthetic strategies and structural activity relationships.,1
8873,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
8873,10.1021/jm0508843,Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.,10.1016/j.bmc.2007.03.018,"Synthesis, antifungal and haemolytic activity of a series of bis(pyridinium)alkanes.",1
8873,10.1016/j.ejmech.2011.02.034,Optimization of 3-(phenylthio)quinolinium compounds against opportunistic fungal pathogens.,10.1016/j.bmc.2013.08.043,CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents.,1
8873,10.1021/np9002806,"Farinomalein, a maleimide-bearing compound from the entomopathogenic fungus Paecilomyces farinosus.",10.1021/np100568w,"N-hydroxypyridones, phenylhydrazones, and a quinazolinone from Isaria farinosa.",1
8873,10.1016/j.ejmech.2018.04.057,Identification of chalcone-based antileishmanial agents targeting trypanothione reductase.,10.1016/j.bmcl.2021.128289,In vitro anti-Leishmania activity and molecular docking of spiro-acridine compounds as potential multitarget agents against Leishmania infantum.,1
8873,10.1016/j.ejmech.2018.03.083,"Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.",10.1021/acs.jmedchem.3c01105,Discovery of Lead 2-Thiazolylhydrazones with Broad-Spectrum and Potent Antifungal Activity.,1
8873,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
8873,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
8873,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
8873,10.1016/j.bmc.2008.05.076,Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.,10.1016/j.ejmech.2016.08.048,"Synthesis and evaluation against Leishmania amazonensis of novel pyrazolo[3,4-d]pyridazinone-N-acylhydrazone-(bi)thiophene hybrids.",1
8873,10.1021/np50091a008,Screening of marine invertebrates for the presence of ergosterol-sensitive antifungal compounds.,10.1016/j.bmcl.2003.10.018,Differential modulation of the antifungal activity of amphotericin B by natural and ent-cholesterol.,1
8873,10.1021/jm0508843,Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.,10.1007/s00044-011-9578-4,"Synthesis, characterization and antimicrobial activity of 4-amino-1-alkyl pyridinium salts",1
8873,10.1016/j.ejmech.2009.11.029,Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.,10.1016/j.ejmech.2010.03.014,Some new biologically active metal-based sulfonamide.,1
8873,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
8873,10.1021/jm5000408,"Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.",10.1016/j.bmc.2015.02.020,"SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.",1
8873,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
8873,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
8873,10.1007/s00044-010-9427-x,"Synthesis, spectral, theoretical, and antimicrobial screening of some heterocyclic oximes",10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,1
8873,10.1016/j.bmc.2007.10.034,Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.,10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
8873,10.1016/j.bmc.2007.08.009,"Synthesis and evaluation of antifungal properties of a series of the novel 2-amino-5-oxo-4-phenyl-5,6,7,8-tetrahydroquinoline-3-carbonitrile and its analogues.",10.1016/j.bmc.2009.02.019,Exploration of click reaction for the synthesis of modified nucleosides as chitin synthase inhibitors.,1
8873,10.1021/jm0508843,Correlation of antifungal activity with fungal phospholipase inhibition using a series of bisquaternary ammonium salts.,10.1128/aac.00231-10,In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.,1
8873,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
8873,10.1016/j.bmc.2009.07.037,"Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes.",10.1007/s00044-011-9578-4,"Synthesis, characterization and antimicrobial activity of 4-amino-1-alkyl pyridinium salts",1
8873,10.1016/j.bmc.2009.07.037,"Synthesis, antifungal, haemolytic and cytotoxic activities of a series of bis(alkylpyridinium)alkanes.",10.1021/np200644s,"Synthesis and antifungal activity of natural product-based 6-alkyl-2,3,4,5-tetrahydropyridines.",1
8873,10.1016/j.bmc.2011.05.055,"Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.",10.1016/j.bmc.2013.12.020,"Unsymmetrical 1,5-diaryl-3-oxo-1,4-pentadienyls and their evaluation as antiparasitic agents.",1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1021/jm1013488,Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.,1
8910,10.1021/jm00008a007,"Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.",10.1021/jm030936t,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,1
8910,10.1021/jm00008a007,"Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.",10.1016/s0960-894x(98)00461-2,N alpha-alkylated derivatives of 2-phenylhistamines: synthesis and in vitro activity of potent histamine H1-receptor agonists.,1
8910,10.1021/jm7014777,Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.,10.1039/C2MD20212C,Mapping histamine H4receptorligand binding modes,1
8910,10.1016/j.bmc.2009.08.059,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",10.1039/C2MD20212C,Mapping histamine H4receptorligand binding modes,1
8910,10.1021/jm00008a007,"Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.",10.1021/jm0309147,N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.,1
8910,10.1021/jm00008a007,"Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.",10.1021/jm991056a,"Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H(1)-receptor agonists.",1
8910,10.1016/j.bmcl.2010.04.017,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,10.1021/acs.jmedchem.9b01342,"[<sup>3</sup>H]UR-DEBa176: A 2,4-Diaminopyrimidine-Type Radioligand Enabling Binding Studies at the Human, Mouse, and Rat Histamine H<sub>4</sub> Receptors.",1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1016/j.bmc.2009.08.059,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",1
8873,10.1021/jm5000408,"Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.",10.1016/j.ejmech.2018.08.012,An update on small molecule strategies targeting leishmaniasis.,1
8873,10.1016/j.bmc.2011.05.055,"Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.",10.1016/j.ejmech.2015.10.011,2-Amino-thiophene derivatives present antileishmanial activity mediated by apoptosis and immunomodulation in vitro.,1
8873,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112558,8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.,1
8873,10.1016/j.ejmech.2017.01.029,"Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.",10.1016/j.bmc.2018.08.025,Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.,1
8873,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
8873,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,1
8873,10.1016/j.bmc.2011.05.055,"Design, synthesis and antileishmanial in vitro activity of new series of chalcones-like compounds: a molecular hybridization approach.",10.1016/j.bmcl.2014.05.018,Synthesis of novel 4-nitropyrrole-based semicarbazide and thiosemicarbazide hybrids with antimicrobial and anti-tubercular activity.,1
8917,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
8917,10.1016/j.ejmech.2009.11.029,Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.,10.1016/j.ejmech.2010.03.014,Some new biologically active metal-based sulfonamide.,1
8917,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b01019,Protein Stability Effects in Aggregate-Based Enzyme Inhibition.,1
8910,10.1016/j.bmc.2009.08.059,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",10.1016/j.bmcl.2011.10.104,Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.,1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1016/j.bmcl.2011.10.104,Ligand based design of novel histamine H₄ receptor antagonists; fragment optimization and analysis of binding kinetics.,1
8910,10.1016/j.ejmech.2021.113190,Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H<sub>2</sub>R and D<sub>3</sub>R.,10.1021/acs.jmedchem.1c00692,Abolishing Dopamine D<sub>2long</sub>/D<sub>3</sub> Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H<sub>2</sub> Receptor Agonists.,1
8910,10.1021/jm00008a007,"Synthesis and histamine H1 receptor agonist activity of a series of 2-phenylhistamines, 2-heteroarylhistamines, and analogues.",10.1016/j.bmcl.2005.10.030,Side-chain modified analogues of histaprodifen: asymmetric synthesis and histamine H1-receptor activity.,1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1021/jm901379s,Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H4 receptor inverse agonists.,1
8910,10.1021/jm7014777,Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.,10.1039/C5MD00022J,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,1
8910,10.1016/j.bmc.2009.08.059,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",10.1016/j.bmcl.2015.12.035,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",1
8910,10.1016/j.ejmech.2021.113190,Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H<sub>2</sub>R and D<sub>3</sub>R.,10.1016/j.bmcl.2021.128388,Shining light on the histamine H<sub>2</sub> receptor: Synthesis of carbamoylguanidine-type agonists as a pharmacological tool to study internalization.,1
8910,10.1016/j.bmcl.2010.04.017,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,10.1021/jm1013488,Triazole ligands reveal distinct molecular features that induce histamine H4 receptor affinity and subtly govern H4/H3 subtype selectivity.,1
8910,10.1016/j.bmcl.2010.04.017,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,10.1016/j.bmcl.2010.10.041,Histamine H4 receptor agonists.,1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1021/jm800876b,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,1
8910,10.1021/jm7014217,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,10.1021/jm900526h,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,1
8910,10.1016/j.bmcl.2010.04.017,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,10.1039/C5MD00022J,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,1
9217,10.1021/jm00092a010,Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.,10.1021/jm960301c,Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2022.114788,Design and synthesis of functionalized 4-aryl-Catechol derivatives as new antiinflammtory agents with in vivo efficacy.,1
9217,10.1021/jm900212y,Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2015.11.048,Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition.,1
9217,10.1016/j.ejmech.2018.08.098,"Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.",10.1021/acsmedchemlett.9b00193,"Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.",1
9217,10.1016/j.bmcl.2009.12.047,Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.,10.1016/j.ejmech.2013.06.039,"Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase.",1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2022.114788,Design and synthesis of functionalized 4-aryl-Catechol derivatives as new antiinflammtory agents with in vivo efficacy.,1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2020.112620,"Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.",1
9217,10.1021/jm00092a010,Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.,10.1016/j.bmcl.2007.02.038,"Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling.",1
9217,10.1016/j.bmcl.2009.12.047,Pharmacophore modeling and virtual screening for designing potential 5-lipoxygenase inhibitors.,10.1016/j.ejmech.2018.08.098,"Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.",1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.bmc.2018.12.043,"Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.",1
8917,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1021/acs.jmedchem.3c01254,Developing Novel Coumarin-Containing Azoles Antifungal Agents by the Scaffold Merging Strategy for Treating Azole-Resistant Candidiasis.,1
8917,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
8917,10.1021/jm00391a037,"Synthesis and antifungal activity of a series of novel 1,2-disubstituted propenones.",10.1016/j.bmc.2007.07.023,"Synthesis, antifungal and antimycobacterial activities of new bis-imidazole derivatives, and prediction of their binding to P450(14DM) by molecular docking and MM/PBSA method.",1
8917,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
8917,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2023.115436,New miconazole-based azoles derived from eugenol show activity against Candida spp. and Cryptococcus gattii by inhibiting the fungal ergosterol biosynthesis.,1
8917,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.bmcl.2022.129044,"Design, synthesis and antifungal activities of novel triazole derivatives with selenium-containing hydrophobic side chains.",1
9217,10.1021/jm301900x,Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.,10.1021/acs.jmedchem.5b01011,Discovery of Novel 15-Lipoxygenase Activators To Shift the Human Arachidonic Acid Metabolic Network toward Inflammation Resolution.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,1
9217,10.1016/j.ejmech.2018.05.041,Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.,10.1016/j.ejmech.2022.114788,Design and synthesis of functionalized 4-aryl-Catechol derivatives as new antiinflammtory agents with in vivo efficacy.,1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2018.05.041,Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2020.112620,"Synthesis, inhibitory activity and in silico docking of dual COX/5-LOX inhibitors with quinone and resorcinol core.",1
9217,10.1016/j.ejmech.2018.05.041,Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.,10.1016/j.ejmech.2019.07.033,Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors.,1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2019.07.033,Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2015.11.048,Exploring the role of chloro and methyl substitutions in 2-phenylthiomethyl-benzoindole derivatives for 5-LOX enzyme inhibition.,1
9217,10.1016/j.ejmech.2016.10.046,Optimization of benzoquinone and hydroquinone derivatives as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2018.07.031,Discovery of a benzenesulfonamide-based dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase that favorably modulates lipid mediator biosynthesis in inflammation.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2018.08.098,"Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.",1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2018.05.041,Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.,1
9217,10.1016/j.ejmech.2015.02.042,Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes.,10.1016/j.ejmech.2019.07.033,Protective effect of piceatannol and bioactive stilbene derivatives against hypoxia-induced toxicity in H9c2 cardiomyocytes and structural elucidation as 5-LOX inhibitors.,1
9217,10.1021/jm00092a010,Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.,10.1021/jm970046b,"Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.",1
9217,10.1021/jm00092a010,Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors.,10.1021/jm960088k,Modulators of leukotriene biosynthesis and receptor activation.,1
9217,10.1021/jm900212y,Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.,10.1021/jm401740w,Indirubin core structure of glycogen synthase kinase-3 inhibitors as novel chemotype for intervention with 5-lipoxygenase.,1
9217,10.1021/jm900212y,Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2014.05.033,"Further studies on ethyl 5-hydroxy-indole-3-carboxylate scaffold: design, synthesis and evaluation of 2-phenylthiomethyl-indole derivatives as efficient inhibitors of human 5-lipoxygenase.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2011.07.004,"Multi-target strategy to address Alzheimer's disease: design, synthesis and biological evaluation of new tacrine-based dimers.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2017.02.049,"Design, synthesis and biological evaluation of multifunctional tacrine-curcumin hybrids as new cholinesterase inhibitors with metal ions-chelating and neuroprotective property.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2018.01.028,"Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.",1
9333,10.1016/j.ejmech.2011.02.073,New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.,10.1016/j.bmc.2018.08.035,"Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.bmc.2014.08.035,"Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1016/j.bmcl.2010.10.068,"Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.",10.1016/j.ejmech.2024.116289,Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/acs.jmedchem.6b01178,"The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators.",1
9277,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/S0960-894X(00)80547-8,"Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds",1
9277,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1016/j.ejmech.2022.114606,Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.,1
9277,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1016/j.bmc.2014.06.010,Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase.,1
9277,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2014.06.010,Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase.,1
9277,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.ejmech.2022.114606,Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.,1
9277,10.1038/nchembio.307,Rapid behavior-based identification of neuroactive small molecules in the zebrafish.,10.1021/acs.jnatprod.9b00563,Cholinesterase Inhibitory Arisugacins L-Q from a <i>Penicillium</i> sp. Isolate Obtained through a Citizen Science Initiative and Their Activities in a Phenotype-Based Zebrafish Assay.,1
9277,10.1016/j.ejmech.2014.05.002,Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.,10.1021/acs.jmedchem.5b01674,Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode.,1
9217,10.1021/jm900212y,Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.,10.1016/j.ejmech.2018.05.041,Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation.,1
9217,10.1021/jm301900x,Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen.,10.1016/j.bmcl.2014.04.006,"Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2014.03.044,"Design, synthesis and biological evaluation of novel tetrahydroacridine pyridine- aldoxime and -amidoxime hybrids as efficient uncharged reactivators of nerve agent-inhibited human acetylcholinesterase.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.08.035,"Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.",1
9333,10.1021/jm0109356,Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil.,10.1021/jm021055+,Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmcl.2022.129037,Selective butyrylcholinesterase inhibition by isatin dimers and 3-indolyl-3-hydroxy-2-oxindole dimers.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2013.02.095,"Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2018.06.044,"Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1021/acs.jmedchem.1c00048,Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.,1
9333,10.1016/j.ejmech.2007.04.018,"Chemiluminescent high-throughput microassay applied to imidazo[2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors.",10.1016/j.bmc.2016.01.031,"Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmcl.2011.07.091,Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.,1
9333,10.1016/j.ejmech.2018.02.023,Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.,10.1016/j.ejmech.2021.113973,"Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1016/j.ejmech.2020.112743,Rational design of new multitarget histamine H receptor ligands as potential candidates for treatment of Alzheimer's disease.,10.1016/j.ejmech.2023.115832,"Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.07.053,Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d3md00708a,"Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2017.08.013,"Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: Design, synthesis and biological evaluation.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2022.114510,A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement.,1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.bmc.2019.01.025,Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).,1
9333,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/S0960-894X(00)80547-8,"Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds",1
9333,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmcl.2008.08.076,Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity.,1
9333,10.1021/jm070536w,New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.,10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2020.112997,ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/acs.jmedchem.5b00958,Evaluation of Homobivalent Carbolines as Designed Multiple Ligands for the Treatment of Neurodegenerative Disorders.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmc.2012.07.045,"O-Hydroxyl- or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-β aggregation.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/jm300124p,Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2011.09.038,"Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmc.2010.12.034,Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2021.113278,A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease.,1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.bmcl.2022.128602,"Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmcl.2015.07.026,Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1039/C7MD00143F,"5-Methyl-<i>N</i>-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-amine: a highly potent human cholinesterase inhibitor.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2017.08.013,"Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: Design, synthesis and biological evaluation.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1021/jm101299d,Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: a systematic investigation of the influence of linker and cationic heads over affinity and selectivity.,1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.bmc.2018.10.003,"Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2018.02.023,Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.,1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm300246n,Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.,1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm901616h,Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/jm8001313,Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.,1
9333,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.bmc.2012.11.044,"Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors.",1
9333,10.1016/j.ejmech.2017.04.064,"Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.",10.1016/j.bmc.2018.10.003,"Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/acs.jmedchem.1c00534,Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer's Disease Mouse Model.,1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm801131a,NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm901614b,"Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm100329q,"Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115301,"Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1021/acs.jmedchem.0c01129,Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2011.05.068,"Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4-b]quinoline, and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine derivatives.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2013.09.061,"Design, synthesis and evaluation of novel 4-dimethylamine flavonoid derivatives as potential multi-functional anti-Alzheimer agents.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2018.01.028,"Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2017.12.084,"Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2010.08.054,"Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2010.09.039,Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2019.01.025,Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).,1
9333,10.1016/j.ejmech.2011.02.073,New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.,10.1016/j.bmcl.2014.12.071,Iminosugars as a new class of cholinesterase inhibitors.,1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/acs.jmedchem.7b00702,"Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a ""Bio-Oxidizable"" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2019.06.056,"Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo[3,4-b]pyridine hybrids.",1
9333,10.1021/jm070536w,New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.,10.1016/j.ejmech.2011.02.073,New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.,1
9333,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1021/jm049877p,Modulation of binding strength in several classes of active site inhibitors of acetylcholinesterase studied by comparative binding energy analysis.,1
9333,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.ejmech.2017.12.084,"Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm200853t,"Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2012.04.029,"Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2016.06.022,"Design, synthesis and evaluation of 4-dimethylamine flavonoid derivatives as potential multifunctional anti-Alzheimer agents.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2010.09.010,Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2011.09.051,"Synthesis, biological evaluation of 9-N-substituted berberine derivatives as multi-functional agents of antioxidant, inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.bmcl.2015.07.026,Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/acs.jmedchem.6b01178,"The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators.",1
9333,10.1016/j.bmcl.2020.127075,Discovery of 9-phenylacridinediones as highly selective butyrylcholinesterase inhibitors through structure-based virtual screening.,10.1021/acs.jmedchem.0c01129,Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmc.2018.02.014,"Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.",1
9333,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2017.08.013,"Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: Design, synthesis and biological evaluation.",1
9333,10.1016/j.bmcl.2016.01.080,In silico to in vitro screening of hydroxypyridinones as acetylcholinesterase inhibitors.,10.1016/j.ejmech.2020.112350,"New deferiprone derivatives as multi-functional cholinesterase inhibitors: design, synthesis and in vitro evaluation.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.bmc.2019.01.025,Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).,1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1039/D1MD00217A,An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.,1
9333,10.1021/jm070536w,New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.,10.1016/j.bmcl.2014.12.071,Iminosugars as a new class of cholinesterase inhibitors.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2016.11.050,"Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapy.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmc.2014.08.035,"Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2018.05.031,Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2023.117178,"Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2013.09.024,"Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1039/D1MD00217A,An overview on the synthesis of carbohydrate-based molecules with biological activity related to neurodegenerative diseases.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2021.113397,Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.,1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2018.01.014,"Tetrahydroacridine derivatives with dichloronicotinic acid moiety as attractive, multipotent agents for Alzheimer's disease treatment.",1
9333,10.1016/j.ejmech.2011.02.073,New potent human acetylcholinesterase inhibitors in the tetracyclic triterpene series with inhibitory potency on amyloid β aggregation.,10.1016/j.ejmech.2017.07.072,"New racemic annulated pyrazolo[1,2-b]phthalazines as tacrine-like AChE inhibitors with potential use in Alzheimer's disease.",1
9333,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmcl.2021.128316,"Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.bmcl.2008.08.076,Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity.,1
9333,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1039/C7MD00143F,"5-Methyl-<i>N</i>-(8-(5,6,7,8-tetrahydroacridin-9-ylamino)octyl)-5<i>H</i>-indolo[2,3-<i>b</i>]quinolin-11-amine: a highly potent human cholinesterase inhibitor.",1
9333,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2016.06.022,"Design, synthesis and evaluation of 4-dimethylamine flavonoid derivatives as potential multifunctional anti-Alzheimer agents.",1
9333,10.1016/j.bmcl.2019.126754,Discovery of potent and selective butyrylcholinesterase inhibitors through the use of pharmacophore-based screening.,10.1016/j.bmc.2022.117030,Isatoic anhydrides as novel inhibitors of monoamine oxidase.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/jm5010804,Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmc.2008.06.022,"Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2014.02.035,"Design, synthesis and biological evaluation of D-ring opened galantamine analogs as multifunctional anti-Alzheimer agents.",1
9333,10.1016/j.bmcl.2020.127609,Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening.,10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2015.01.058,"Multifunctional tacrine-trolox hybrids for the treatment of Alzheimer's disease with cholinergic, antioxidant, neuroprotective and hepatoprotective properties.",1
9333,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.04.064,"Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2018.02.083,The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmcl.2021.128316,"Design, synthesis and biological evaluation of naringenin carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2013.02.014,"Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2018.01.028,"Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/jm5010804,Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2010.08.054,"Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists.",1
9333,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1039/C3MD00376K,"Multitarget-directed resveratrol derivatives: anti-cholinesterases, anti--amyloid aggregation and monoamine oxidase inhibition properties against Alzheimer's disease",1
9333,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2018.01.028,"Synthesis and activity towards Alzheimer's disease in vitro: Tacrine, phenolic acid and ligustrazine hybrids.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmcl.2012.08.036,"Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm801292b,"Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/acs.jmedchem.1c00048,Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2008.08.076,Tacrine based human cholinesterase inhibitors: synthesis of peptidic-tethered derivatives and their effect on potency and selectivity.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.10.003,"Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.",1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1021/acs.jmedchem.0c00528,Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmcl.2008.05.039,"Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors.",1
9333,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.ejmech.2013.09.024,"Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.",1
9333,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2022.114152,"Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2014.09.081,Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2013.03.051,"Design, synthesis and evaluation of novel tacrine-coumarin hybrids as multifunctional cholinesterase inhibitors against Alzheimer's disease.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm201460y,"New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties.",1
9333,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1016/j.ejmech.2012.06.038,"Synthesis, biological assessment, and molecular modeling of racemic 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chromeno[2,3-b]quinolin-8-amines as potential drugs for the treatment of Alzheimer's disease.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1039/C2MD20063E,Synthesis of dual AChE/5-HT4 receptor multi-target directed ligands,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmcl.2020.127609,Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1021/jm901616h,Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors.,1
9333,10.1016/j.ejmech.2018.02.023,Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.,10.1016/j.ejmech.2019.111916,"1-Benzylpyrrolidine-3-amine-based BuChE inhibitors with anti-aggregating, antioxidant and metal-chelating properties as multifunctional agents against Alzheimer's disease.",1
9333,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2015.04.055,"Design, synthesis and anticholinesterase activity of novel benzylidenechroman-4-ones bearing cyclic amine side chain.",1
9333,10.1016/j.ejmech.2018.02.023,Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.,10.1016/j.ejmech.2021.113827,A tacrine-tetrahydroquinoline heterodimer potently inhibits acetylcholinesterase activity and enhances neurotransmission in mice.,1
9333,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2014.06.057,"Syntheses of coumarin-tacrine hybrids as dual-site acetylcholinesterase inhibitors and their activity against butylcholinesterase, Aβ aggregation, and β-secretase.",1
9333,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2011.02.071,Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.,1
9333,10.1016/j.ejmech.2007.04.018,"Chemiluminescent high-throughput microassay applied to imidazo[2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors.",10.1016/j.ejmech.2010.08.054,"Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2017.12.005,Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmcl.2013.10.034,"Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/jm300246n,Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.,1
9333,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.bmc.2010.12.034,Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.,1
9333,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2012.09.005,Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.,1
9333,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1021/jm200853t,"Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.",1
9333,10.1016/j.ejmech.2018.02.023,Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease.,10.1039/C9MD00337A,Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands.,1
9333,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.08.021,A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.,1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1016/j.ejmech.2017.06.048,New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2018.10.003,"Design, synthesis, cholinesterase inhibition and molecular modelling study of novel tacrine hybrids with carbohydrate derivatives.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2014.06.045,Amine substitution of quinazolinones leads to selective nanomolar AChE inhibitors with 'inverted' binding mode.,1
9333,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2019.01.025,Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2013.02.047,Investigation of the role of linker moieties in bifunctional tacrine hybrids.,1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1039/C0MD00256A,Tacrine-mefenamic acid hybrids for inhibition of acetylcholinesterase,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2023.117178,"Design, synthesis, and biological evaluation of novel N-Benzyl piperidine derivatives as potent HDAC/AChE inhibitors for Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2018.02.002,"Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2021.116385,Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.,1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2022.114152,"Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2019.111707,"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/acs.jmedchem.5b01325,"Tacrine-Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity.",1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2010.12.041,(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.bmcl.2013.10.034,"Novel tacrine-ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1021/jm901614b,"Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.ejmech.2020.112997,ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker.,1
9333,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.02.014,"Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.",1
9333,10.1016/j.bmcl.2008.03.073,Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates.,10.1016/j.bmc.2015.12.031,"Design, synthesis and evaluation of novel 7-aminoalkyl-substituted flavonoid derivatives with improved cholinesterase inhibitory activities.",1
9333,10.1016/j.ejmech.2016.06.025,"Novel series of tacrine-tianeptine hybrids: Synthesis, cholinesterase inhibitory activity, S100B secretion and a molecular modeling approach.",10.1039/C9MD00358D,Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling.,1
9333,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmcl.2019.126880,Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.,1
9333,10.1021/jm701225u,Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.,10.1016/j.ejmech.2016.07.052,Rational modification of donepezil as multifunctional acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.,1
9333,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.ejmech.2014.03.044,"Design, synthesis and biological evaluation of novel tetrahydroacridine pyridine- aldoxime and -amidoxime hybrids as efficient uncharged reactivators of nerve agent-inhibited human acetylcholinesterase.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2018.02.002,"Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2021.113397,Discovery of multifunctional anti-Alzheimer's agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters.,1
9372,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.bmc.2012.11.044,"Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors.",1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2017.07.055,"Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
9372,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2015.04.055,"Design, synthesis and anticholinesterase activity of novel benzylidenechroman-4-ones bearing cyclic amine side chain.",1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2022.114305,Novel inhibitors of AChE and Aβ aggregation with neuroprotective properties as lead compounds for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2022.114806,"Design, synthesis and evaluation of fused hybrids with acetylcholinesterase inhibiting and Nrf2 activating functions for Alzheimer's disease.",1
9372,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1016/j.ejmech.2009.12.038,Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.12.030,"Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.08.035,"Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.",1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1021/acs.jmedchem.1c01784,"Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.ejmech.2021.113964,Research progress in pharmacological activities and structure-activity relationships of tetralone scaffolds as pharmacophore and fluorescent skeleton.,1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.ejmech.2013.06.021,"Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.111958,Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2017.02.039,"Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2024.116289,Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane.,1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2021.113663,Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine.,1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.bmc.2019.07.001,"Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2021.113310,"Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2018.07.033,Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2020.112180,The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.1c01784,"Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2023.117333,Novel drug-like fluorenyl derivatives as selective butyrylcholinesterase and β-amyloid inhibitors for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
9372,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2024.116592,"Novel neuroprotective 5,6-dihydropyrido[2',1':2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation.",1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2019.04.038,"A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmc.2022.117132,"Multitargeting approaches to cognitive impairment: Synthesis of aryl-alkylpiperazines and assessment at cholinesterases, histamine H<sub>3</sub> and dopamine D<sub>3</sub> receptors.",1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.bmc.2019.02.031,"Design and development of novel N-(pyrimidin-2-yl)-1,3,4-oxadiazole hybrids to treat cognitive dysfunctions.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1039/C6MD00053C,Synthesis and evaluation of donepezilferulic acid hybrids as multi-target-directed ligands against Alzheimer's disease,1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2017.07.055,"Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2019.111598,"Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.",1
9372,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2017.07.077,"Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d3md00708a,"Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases.",1
9372,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/S0960-894X(00)80547-8,"Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds",1
9372,10.1016/j.bmc.2007.12.048,Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.,10.1016/j.bmc.2011.09.061,"Searching for the Multi-Target-Directed Ligands against Alzheimer's disease: discovery of quinoxaline-based hybrid compounds with AChE, H₃R and BACE 1 inhibitory activities.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
9372,10.1016/j.bmc.2007.12.048,Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.,10.1016/j.bmc.2008.10.029,Synthesis and structure-activity relationships for biphenyl H3 receptor antagonists with moderate anti-cholinesterase activity.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2022.114729,"Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.",1
9372,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.ejmech.2017.12.084,"Novel donepezil-like N-benzylpyridinium salt derivatives as AChE inhibitors and their corresponding dihydropyridine ""bio-oxidizable"" prodrugs: Synthesis, biological evaluation and structure-activity relationship.",1
9372,10.1016/j.ejmech.2019.111613,Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2021.113973,"Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2017.08.021,A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.,1
9372,10.1021/ml3001769,Identification of aminopyridazine-derived antineuroinflammatory agents effective in an Alzheimer's mouse model.,10.1016/j.ejmech.2021.113224,"Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
9372,10.1016/j.ejmech.2018.01.066,"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.",10.1016/j.bmc.2022.116952,Synthesis and biological evaluation of 4-hydroxy-methylpiperidinyl-N-benzyl-acylarylhydrazone hybrids designed as novel multifunctional drug candidates for Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2022.114510,A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement.,1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmcl.2015.10.051,Synthesis of donepezil-based multifunctional agents for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.7b01417,"Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.07.021,"Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2019.05.055,"Design, synthesis, and biological evaluation of rutacecarpine derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease.",1
9372,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.ejmech.2019.06.026,"Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/s0960-894x(99)00597-1,Synthesis and acetylcholinesterase inhibitory activity of huperzine A-E2020 combined compound.,1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.04.064,"Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.",1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.08.021,A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2018.05.031,Novel tetrahydrocarbazole benzyl pyridine hybrids as potent and selective butryl cholinesterase inhibitors with neuroprotective and β-secretase inhibition activities.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1039/C9MD00030E,"Synthesis, molecular docking, and biological evaluation of novel 2-pyrazoline derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1016/j.bmcl.2010.10.068,"Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.",10.1016/j.ejmech.2024.116289,Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1021/acs.jmedchem.0c01129,Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2023.115135,"Discovery of new, highly potent and selective inhibitors of BuChE - design, synthesis, in vitro and in vivo evaluation and crystallography studies.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112265,"Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.ejmech.2012.09.030,"Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2024.116511,Structure-based design of multitargeting ChEs-MAO B inhibitors based on phenyl ring bioisosteres: AChE/BChE selectivity switch and drug-like characterization.,1
9372,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2021.113973,"Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
9372,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.0c01573,Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors.,1
9372,10.1007/s00044-012-0227-3,New molecular scaffolds for the design of Alzheimers acetylcholinesterase inhibitors identified using ligand- and receptor-based virtual screening,10.1039/d2md00042c,"Design, synthesis and biological evaluation of light-driven on-off multitarget AChE and MAO-B inhibitors.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.bmc.2020.115721,"Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.",1
9372,10.1016/j.ejmech.2019.111613,Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2022.114729,"Design, synthesis, and biological evaluation of aromatic tertiary amine derivatives as selective butyrylcholinesterase inhibitors for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112282,N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1039/C7MD00199A,Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.,1
9372,10.1016/j.bmcl.2010.10.068,"Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.",10.1021/acs.jmedchem.0c00756,MicroRNA-Based Multitarget Approach for Alzheimer's Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis.,1
9372,10.1016/j.ejmech.2011.02.019,Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.,10.1016/j.bmc.2014.02.046,Quinolone-benzylpiperidine derivatives as novel acetylcholinesterase inhibitor and antioxidant hybrids for Alzheimer disease.,1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2018.08.005,"Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.",1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1039/d3md00635b,Amine-containing donepezil analogues as potent acetylcholinesterase inhibitors with increased polarity.,1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2018.08.005,"Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.",1
9372,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,10.1016/j.bmc.2020.115991,"Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation.",1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2021.114044,"Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2024.116353,"Novel 6-alkyl-bridged 4-arylalkylpiperazin-1-yl derivatives of azepino[4,3-b]indol-1(2H)-one as potent BChE-selective inhibitors showing protective effects against neurodegenerative insults.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2021.113224,"Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2020.115940,Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.,1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2024.116450,"Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment.",1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1021/acs.jmedchem.1c00048,Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.,1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmc.2019.01.025,Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).,1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2022.114689,"Design, synthesis and biological evaluation of novel coumarin derivatives as multifunctional ligands for the treatment of Alzheimer's disease.",1
9372,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1016/j.bmc.2014.12.057,"Synthesis, biological evaluation and molecular docking study of novel piperidine and piperazine derivatives as multi-targeted agents to treat Alzheimer's disease.",1
9372,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
9372,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2015.10.001,"Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation.",1
9372,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1016/j.bmc.2008.12.067,"Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115301,"Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2019.111613,Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.,1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmcl.2012.04.029,"Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2016.09.041,Synthesis and evaluation of 7-substituted coumarin derivatives as multimodal monoamine oxidase-B and cholinesterase inhibitors for the treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.bmc.2016.02.023,"Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1021/acs.jmedchem.1c00048,Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease.,1
9372,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2023.117256,Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT<sub>6</sub> receptor interaction.,1
9372,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1021/jm101299d,Homodimeric bis-quaternary heterocyclic ammonium salts as potent acetyl- and butyrylcholinesterase inhibitors: a systematic investigation of the influence of linker and cationic heads over affinity and selectivity.,1
9372,10.1021/jm0109356,Synthesis and screening for antiacetylcholinesterase activity of (1-benzyl-4-oxopiperidin-3-ylidene)methylindoles and -pyrroles related to donepezil.,10.1016/j.bmc.2008.12.067,"Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2024.116409,"Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy.",1
9372,10.1016/j.ejmech.2018.01.066,"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.",10.1016/j.bmc.2020.115991,"Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation.",1
9372,10.1016/j.ejmech.2019.111613,Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2023.115670,Discovery of triazole-bridged aryl adamantane analogs as an intriguing class of multifunctional agents for treatment of Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2020.112180,The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.,1
9372,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.bmc.2023.117333,Novel drug-like fluorenyl derivatives as selective butyrylcholinesterase and β-amyloid inhibitors for the treatment of Alzheimer's disease.,1
9372,10.1016/j.ejmech.2020.112743,Rational design of new multitarget histamine H receptor ligands as potential candidates for treatment of Alzheimer's disease.,10.1016/j.ejmech.2023.115832,"Discovery of novel multifunctional ligands targeting GABA transporters, butyrylcholinesterase, β-secretase, and amyloid β aggregation as potential treatment of Alzheimer's disease.",1
9372,10.1016/j.ejmech.2019.111613,Discovery of novel series of 2-substituted benzo[d]oxazol-5-amine derivatives as multi-target directed ligands for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2024.116409,"Design, synthesis, and biological evaluation of some 2-(3-oxo-5,6-diphenyl-1,2,4-triazin-2(3H)-yl)-N-phenylacetamide hybrids as MTDLs for Alzheimer's disease therapy.",1
9372,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2011.02.071,Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.,1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.ejmech.2014.05.056,Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives.,1
9495,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1124/dmd.104.002477,"Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.",1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.111598,"Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.",1
9372,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1039/C8MD00312B,"New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of <i>N</i>-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl)amines.",1
9372,10.1021/jm00081a022,QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase.,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,1
9372,10.1016/j.bmc.2007.12.048,Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.,10.1021/acs.jmedchem.8b00848,"Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.ejmech.2017.07.077,"Novel cinnamamide-dibenzylamine hybrids: Potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease.",1
9372,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2021.113492,Dual-target compounds for Alzheimer's disease: Natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR).,1
9372,10.1021/ml3001769,Identification of aminopyridazine-derived antineuroinflammatory agents effective in an Alzheimer's mouse model.,10.1016/j.ejmech.2019.111707,"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",1
9372,10.1016/j.bmc.2010.01.071,Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238.,10.1016/j.bmc.2016.04.015,"Biological evaluation of synthetic α,β-unsaturated carbonyl based cyclohexanone derivatives as neuroprotective novel inhibitors of acetylcholinesterase, butyrylcholinesterase and amyloid-β aggregation.",1
9372,10.1021/jm001088u,"Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.",10.1021/jm200853t,"Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.",1
9372,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
9372,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
9372,10.1021/acs.jmedchem.0c01863,Kinetics-Driven Drug Design Strategy for Next-Generation Acetylcholinesterase Inhibitors to Clinical Candidate.,10.1016/j.ejmech.2021.114095,Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.,1
9372,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1021/jm8009684,Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.,1
9372,10.1016/j.ejmech.2007.04.018,"Chemiluminescent high-throughput microassay applied to imidazo[2,1-b]thiazole derivatives as potential acetylcholinesterase and butyrylcholinesterase inhibitors.",10.1016/j.bmc.2016.01.031,"Synthesis, molecular docking and biological evaluation of N,N-disubstituted 2-aminothiazolines as a new class of butyrylcholinesterase and carboxylesterase inhibitors.",1
9372,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.bmc.2018.12.030,"Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease.",1
10389,10.1021/jm00128a010,Antimalarials. 16. Synthesis of 2-substituted analogues of 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3- (trifluoromethyl)phenoxy]quinoline as candidate antimalarials.,10.1016/j.bmcl.2007.09.044,Synthesis and evaluation of naphthyridine compounds as antimalarial agents.,1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1016/s0960-894x(02)00802-8,Isolation and antimalarial activity of peroxydisulfate oxidation products of primaquine.,1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1016/j.bmcl.2007.09.044,Synthesis and evaluation of naphthyridine compounds as antimalarial agents.,1
10389,10.1016/j.bmc.2009.01.013,Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.,10.1016/j.bmc.2012.06.038,Synthesis and evaluation of hybrid drugs for a potential HIV/AIDS-malaria combination therapy.,1
10389,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",10.1021/acs.jmedchem.8b01769,"Structure-Activity Relationship Studies and Plasmodium Life Cycle Profiling Identifies Pan-Active N-Aryl-3-trifluoromethyl Pyrido[1,2- a]benzimidazoles Which Are Efficacious in an in Vivo Mouse Model of Malaria.",1
10389,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2024.117734,"Discovery of harmiprims, harmine-primaquine hybrids, as potent and selective anticancer and antimalarial compounds.",1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1128/aac.00288-07,2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization.,1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1128/aac.00645-07,"Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate.",1
10358,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1016/s0960-894x(98)00626-x,"Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.",1
10276,10.1021/jm201320w,Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.,10.1016/j.bmc.2019.115157,Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition.,1
10276,10.1016/j.bmc.2019.115157,Synthesis and elaboration of N-methylpyrrolidone as an acetamide fragment substitute in bromodomain inhibition.,10.1021/acs.jmedchem.1c00787,From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD).,1
10276,10.1021/jm201320w,Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.,10.1039/C3MD00291H,Discovery of BET bromodomain inhibitors and their role in target validation,1
9988,10.1021/acs.jmedchem.9b01404,"Identification of Psychoplastogenic N,N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies.",10.1021/acs.jmedchem.3c01696,Psychoplastogenic DYRK1A Inhibitors with Therapeutic Effects Relevant to Alzheimer's Disease.,1
9495,10.1021/jm00173a013,"Synthesis, biological profile, and quantitative structure-activity relationship of a series of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.",10.1016/S0960-894X(00)80623-X,Synthesis of tetrazol-1-yl analogs of HMG-COA reductase inhibitor BMS180431 (formerly BMY21950),1
9495,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
9495,10.1016/j.bmc.2010.08.036,Synthesis and biological evaluation of a series of aromatic bisphosphonates.,10.1016/j.bmcl.2015.04.021,N-Oxide derivatives of 3-(3-pyridyl)-2-phosphonopropanoic acids as potential inhibitors of Rab geranylgeranylation.,1
10909,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2011.01.042,Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,1
10909,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2019.02.015,Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.,1
10909,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1021/acs.jmedchem.9b00026,Five-Membered N-Heterocyclic Scaffolds as Novel Amino Bioisosteres at γ-Aminobutyric Acid (GABA) Type A Receptors and GABA Transporters.,1
10909,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1016/j.ejmech.2011.01.042,Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,1
10909,10.1021/jm00017a014,"Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol.",10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",1
10909,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2019.05.001,Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).,1
10813,10.1021/jm00084a014,"Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.",10.1016/j.bmc.2012.10.049,Discovery of novel α₁-adrenoceptor ligands based on the antipsychotic sertindole suitable for labeling as PET ligands.,1
10813,10.1021/jm00084a014,"Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.",10.1016/s0960-894x(03)00196-3,Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.,1
10747,10.1039/C4MD00418C,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,10.1016/j.bmcl.2016.05.079,New halogenated tris-(phenylalkyl)amines as h5-HT2B receptor ligands.,1
10747,10.1039/C4MD00418C,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,10.1039/C8MD00204E,Pharmacophore-based tailoring of biphenyl amide derivatives as selective 5-hydroxytryptamine 2B receptor antagonists.,1
10423,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
10389,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2023.117468,"Design, synthesis and antiplasmodial evaluation of new amide-, carbamate-, and ureido-type harmicines.",1
10389,10.1016/j.bmc.2009.01.013,Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.,10.1039/C5MD00115C,Discovery of oxybisbenzoylamides as a new class of antimalarial agents,1
10389,10.1021/acs.jmedchem.8b01961,Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1021/jm201095h,Targeting the liver stage of malaria parasites: a yet unmet goal.,1
10389,10.1021/jm00351a017,Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents.,10.1016/s0960-894x(00)00436-4,Enhanced pneumocystis carinii activity of new primaquine analogues.,1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2009.09.021,"Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties.",1
11002,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
10989,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/j.bmcl.2008.08.065,Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.,1
10989,10.1021/jm9603781,A virtual screening approach applied to the search for trypanothione reductase inhibitors.,10.1016/j.bmc.2008.05.074,The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.,1
10989,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/jm030008u,Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.,1
10989,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(01)00662-x,"[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.",1
10989,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/jm010146o,"Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.",1
10989,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/j.ejmech.2016.08.067,"Synthesis and biological evaluation of new aryl-alkyl(alkenyl)-4-benzylpiperidines, novel Sigma Receptor (SR) modulators, as potential anticancer-agents.",1
10959,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2014.04.034,Towards the development of 5-HT₇ ligands combining serotonin-like and arylpiperazine moieties.,1
10959,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1021/jm8014553,Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.,1
10959,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1021/jm500880c,The extracellular entrance provides selectivity to serotonin 5-HT7 receptor antagonists with antidepressant-like behavior in vivo.,1
10959,10.1016/j.ejmech.2016.03.073,"5-HT2 receptor affinity, docking studies and pharmacological evaluation of a series of 1,3-disubstituted thiourea derivatives.",10.1016/j.bmc.2017.09.018,"New 5-HT1A, 5HT2A and 5HT2C receptor ligands containing a picolinic nucleus: Synthesis, in vitro and in vivo pharmacological evaluation.",1
10909,10.1021/jm00017a014,"Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol.",10.1016/s0960-894x(01)00184-6,Bioisosteric determinants for subtype selectivity of ligands for heteromeric GABA(A) receptors.,1
10909,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1016/j.ejmech.2014.07.039,Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists.,1
10909,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1021/jm301473k,Synthesis and biological evaluation of 4-(aminomethyl)-1-hydroxypyrazole analogues of muscimol as γ-aminobutyric acid(a) receptor agonists.,1
10909,10.1021/jm00017a014,"Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol.",10.1021/jm701562x,Synthesis of GABAA receptor agonists and evaluation of their alpha-subunit selectivity and orientation in the GABA binding site.,1
11002,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2018.09.047,Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.,1
11002,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2022.114783,Novel nitrogen mustard-artemisinin hybrids with potent anti-leukemia action through DNA damage and activation of GPx.,1
11002,10.1021/ml500141f,Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,1
11002,10.1021/ml500141f,Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.,10.1016/j.ejmech.2018.09.047,Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.,1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.04.066,"Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2009.07.043,Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent.,1
1370,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2018.07.033,Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.,1
1370,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acsmedchemlett.4c00183,"Synthesis and Evaluation of 1,3-Disubstituted Imidazolidine-2,4,5-triones as Inhibitors of Pyruvate Carboxylase.",1
1370,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.7b01537,4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.,1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
1370,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.07.014,"4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2009.04.102,Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/acs.jmedchem.8b00189,Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.,1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.bmc.2020.115639,The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1021/acs.jmedchem.6b00579,Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
11305,10.1016/j.bmcl.2017.06.027,Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cells.,10.1039/C8MD00107C,Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition.,1
11305,10.1021/jm0703136,2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.,10.1016/j.ejmech.2019.111691,Indole: A privileged scaffold for the design of anti-cancer agents.,1
11305,10.1016/j.ejmech.2021.113392,"Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.",10.1016/j.ejmech.2021.113946,Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).,1
11305,10.1021/jm0703136,2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.,10.1021/jm300197a,Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.,1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1039/C5MD00247H,Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.bmc.2009.10.042,Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.,1
11212,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
11005,10.1021/acs.jmedchem.5b01732,Identification of Cyproheptadine as an Inhibitor of SET Domain Containing Lysine Methyltransferase 7/9 (Set7/9) That Regulates Estrogen-Dependent Transcription.,10.1016/j.bmc.2016.07.024,Steric structure-activity relationship of cyproheptadine derivatives as inhibitors of histone methyltransferase Set7/9.,1
11005,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2019.111705,Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review.,1
11002,10.1021/ml500141f,Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.,10.1016/j.ejmech.2022.114783,Novel nitrogen mustard-artemisinin hybrids with potent anti-leukemia action through DNA damage and activation of GPx.,1
11002,10.1021/ml500141f,Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.,10.1016/j.ejmech.2018.02.088,"Novel hybrids of brefeldin A and nitrogen mustards with improved antiproliferative selectivity: Design, synthesis and antitumor biological evaluation.",1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/acs.jmedchem.4c00836,Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2020.112831,Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/ml400175d,Development of a chimeric c-Src kinase and HDAC inhibitor.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmcl.2011.05.098,A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1007/s00044-011-9879-7,"Synthesis, antiproliferation, and docking studies of N-phenyl-lipoamide and 8-mercapto-N-phenyloctanamide derivatives: effects of C6 position thiol moiety",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2008.07.119,"Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.",1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmc.2017.05.062,"Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.",1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2020.112844,"Paradigm shift of ""classical"" HDAC inhibitors to ""hybrid"" HDAC inhibitors in therapeutic interventions.",1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmc.2013.06.009,Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).,1
11305,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,1
11305,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.bmcl.2011.06.015,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm101373a,"Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.",1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmc.2013.11.021,"Synthesis and anticancer activities of thieno[3,2-d]pyrimidines as novel HDAC inhibitors.",1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.ejmech.2020.112844,"Paradigm shift of ""classical"" HDAC inhibitors to ""hybrid"" HDAC inhibitors in therapeutic interventions.",1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.bmc.2018.07.026,Incorporation of histone deacetylase inhibitory activity into the core of tamoxifen - A new hybrid design paradigm.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1021/acs.jmedchem.8b00384,Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.,1
11305,10.1016/j.bmcl.2016.03.116,A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors.,10.1016/j.bmcl.2017.05.004,Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2009.04.011,Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.bmcl.2016.09.058,Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.ejmech.2021.113569,"A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.",1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,1
11305,10.1021/ml1001163,Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2011.08.027,The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.,1
11305,10.1016/j.bmc.2018.02.033,Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.,10.1016/j.bmc.2019.03.008,"Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.",1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2008.09.003,Optimization of a series of potent and selective ketone histone deacetylase inhibitors.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/jm901358y,Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity.,1
11305,10.1021/jm0703136,2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.,10.1016/j.ejmech.2017.03.079,4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2020.113065,Investigation of the in vitro and in vivo efficacy of peptoid-based HDAC inhibitors with dual-stage antiplasmodial activity.,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmc.2009.10.042,Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.bmc.2015.11.005,"Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2009.09.100,Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.,1
11305,10.1021/jm0703136,2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.,10.1021/jm400385r,Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform.,1
11305,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2023.115879,Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1039/C2MD00317A,"Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases",1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.bmcl.2011.01.134,Discovery of histone deacetylase 8 selective inhibitors.,1
11305,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1039/C4MD00211C,Synthesis of hybrid anticancer agents based on kinase and histone deacetylase inhibitors,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.bmc.2022.117085,"Novel bioactive hybrid Celecoxib-HDAC Inhibitor, induces apoptosis in human acute lymphoblastic leukemia cells.",1
11305,10.1021/ml1001163,Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.,10.1016/j.bmc.2023.117444,"2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines.",1
11305,10.1021/ml1001163,Antiproliferative and differentiating activities of a novel series of histone deacetylase inhibitors.,10.1021/ml400158k,Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.bmc.2016.12.032,Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.bmcl.2014.08.060,The antileishmanial activity of isoforms 6- and 8-selective histone deacetylase inhibitors.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1007/s00044-011-9879-7,"Synthesis, antiproliferation, and docking studies of N-phenyl-lipoamide and 8-mercapto-N-phenyloctanamide derivatives: effects of C6 position thiol moiety",1
11305,10.1016/j.bmcl.2003.07.012,A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.,10.1016/j.ejmech.2019.111725,"N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.",1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.bmc.2018.06.016,"Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.",1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.ejmech.2020.112887,Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.,1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.bmcl.2015.12.007,"Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.",1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2019.111725,"N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.",1
11305,10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,10.1021/acs.jmedchem.4c00541,Hydrazides as Inhibitors of Histone Deacetylases.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/acs.jmedchem.9b02161,Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/acsmedchemlett.7b00172,"Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives.",1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1021/jm101373a,"Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.",1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/acs.jmedchem.5b01478,Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1021/acs.jmedchem.0c02111,"Discovery of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.",1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.bmcl.2008.11.081,Sulfamides as novel histone deacetylase inhibitors.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm8005355,Histone deacetylase inhibitors through click chemistry.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/jm9005077,Binding ensemble profiling with photoaffinity labeling (BEProFL) approach: mapping the binding poses of HDAC8 inhibitors.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/jm901667k,Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.,1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.bmcl.2008.10.058,Alpha-mercaptoketone based histone deacetylase inhibitors.,1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1021/acs.jmedchem.0c00491,Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.,1
11305,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,10.1021/acs.jmedchem.5b00062,Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1128/aac.01220-10,Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2014.05.050,Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/acsmedchemlett.1c00074,Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/jm400179b,Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.,1
11305,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.ejmech.2024.116782,Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1021/acs.jmedchem.0c00491,Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.bmc.2021.116185,Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/acs.jmedchem.7b00115,Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/jm900648x,Hydroxamates: relationships between structure and plasma stability.,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2008.11.081,Sulfamides as novel histone deacetylase inhibitors.,1
11305,10.1016/j.ejmech.2016.02.001,Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.,10.1016/j.ejmech.2020.112679,Hydroxamic acid hybrids as the potential anticancer agents: An Overview.,1
11305,10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,10.1021/acs.jmedchem.4c01438,Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer.,1
11305,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1021/jm4008449,Total synthesis and full histone deacetylase inhibitory profiling of Azumamides A-E as well as β²- epi-Azumamide E and β³-epi-Azumamide E.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1016/j.bmc.2022.117028,Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.,10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.ejmech.2020.112831,Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1021/acs.jmedchem.8b00189,Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.,1
11305,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1016/j.ejmech.2013.05.017,"Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.",10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,1
11305,10.1016/j.bmcl.2003.07.012,A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.,10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.bmcl.2007.06.063,Trithiocarbonates: exploration of a new head group for HDAC inhibitors.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1016/j.bmc.2009.12.005,Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/acs.jmedchem.3c01095,"Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation.",1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2018.12.039,Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2009.04.102,Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.,1
11305,10.1016/j.bmc.2018.08.008,A series of camptothecin prodrugs exhibit HDAC inhibition activity.,10.1016/j.ejmech.2020.112628,Histone deacetylase inhibitor based prodrugs.,1
11305,10.1021/jm0613828,Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
11305,10.1016/j.ejmech.2013.05.017,"Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.",10.1016/j.ejmech.2016.12.032,Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/acsmedchemlett.6b00239,Development of a Potent and Selective HDAC8 Inhibitor.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,1
11305,10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,10.1021/acsmedchemlett.1c00713,"The <i>N,N,O</i>-Trisubstituted Hydroxylamine Isostere and Its Influence on Lipophilicity and Related Parameters.",1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1021/acs.jmedchem.5b01342,Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.,1
11305,10.1016/j.bmc.2018.08.008,A series of camptothecin prodrugs exhibit HDAC inhibition activity.,10.1016/j.ejmech.2020.112679,Hydroxamic acid hybrids as the potential anticancer agents: An Overview.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2020.112193,Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2016.10.006,"Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.",1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1021/ml400175d,Development of a chimeric c-Src kinase and HDAC inhibitor.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1128/aac.00439-08,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2013.03.049,The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.,1
11305,10.1021/jm0613828,Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.,10.1016/j.ejmech.2016.11.055,Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.bmcl.2017.06.033,The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2007.01.117,Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2024.116782,Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmcl.2008.09.003,Optimization of a series of potent and selective ketone histone deacetylase inhibitors.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2020.112831,Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.,1
11305,10.1016/j.bmcl.2003.07.012,A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.,10.1016/j.bmcl.2005.07.081,Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates.,1
11305,10.1016/j.bmcl.2003.07.012,A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.,10.1021/acs.jmedchem.3c00226,The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1021/acsmedchemlett.1c00074,Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmcl.2009.08.010,Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/acs.jmedchem.1c01726,<i>N</i>-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/acs.jmedchem.8b00209,"Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer.",1
11305,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1021/acsmedchemlett.9b00071,Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease.,1
11305,10.1016/j.ejmech.2016.02.001,Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.,10.1016/j.ejmech.2020.112291,Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/acs.jmedchem.7b00115,Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).,1
11305,10.1016/j.ejmech.2016.01.013,Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.,10.1021/acs.jmedchem.3c00226,The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs.,1
11305,10.1016/j.bmcl.2013.04.067,"Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,1
11305,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1021/acsmedchemlett.8b00440,"Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.",1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2020.112338,"Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1.",1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2015.12.033,"Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC.",1
11305,10.1016/j.ejmech.2016.02.001,Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.,10.1016/j.ejmech.2017.03.079,4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/jm900125m,"Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2011.07.124,Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
11305,10.1016/j.ejmech.2016.01.013,Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.,10.1021/acsmedchemlett.0c00369,Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm101092u,"Non-natural macrocyclic inhibitors of histone deacetylases: design, synthesis, and activity.",1
11305,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2023.115935,HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents.,1
11305,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1021/acs.jmedchem.5b00062,Discovery of Orally Available Runt-Related Transcription Factor 3 (RUNX3) Modulators for Anticancer Chemotherapy by Epigenetic Activation and Protein Stabilization.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.ejmech.2020.112844,"Paradigm shift of ""classical"" HDAC inhibitors to ""hybrid"" HDAC inhibitors in therapeutic interventions.",1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmcl.2011.01.134,Discovery of histone deacetylase 8 selective inhibitors.,1
11305,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1016/j.bmc.2011.01.013,Modulation of the activity of histone acetyltransferases by long chain alkylidenemalonates (LoCAMs).,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm2016182,Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.,1
11305,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1021/jm200620f,In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).,1
11305,10.1016/j.bmcl.2003.07.012,A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units.,10.1016/j.bmcl.2017.09.036,"Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups.",1
1370,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.9b00525,"(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.8b00619,Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.,1
1370,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.08.017,"Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.8b01578,"Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2018.12.032,Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.,1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.05.083,"Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmcl.2012.09.056,"Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease.",1
1370,10.1021/jm200076a,"Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.",10.1021/jm200825u,"Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.",1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.08.017,"Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1370,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.bmc.2021.116510,From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.,1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2020.112844,"Paradigm shift of ""classical"" HDAC inhibitors to ""hybrid"" HDAC inhibitors in therapeutic interventions.",1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.ejmech.2018.12.039,Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.ejmech.2020.112679,Hydroxamic acid hybrids as the potential anticancer agents: An Overview.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.bmc.2015.11.005,"Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.",1
11305,10.1016/j.ejmech.2016.01.013,Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.,10.1016/j.ejmech.2020.112628,Histone deacetylase inhibitor based prodrugs.,1
11305,10.1016/j.ejmech.2016.02.001,Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.,10.1016/j.ejmech.2017.01.035,"Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.",1
11305,10.1016/j.bmcl.2004.10.074,Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.,10.1021/jm2016182,Defining the mechanism of action and enzymatic selectivity of psammaplin A against its epigenetic targets.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmcl.2012.06.017,"Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.",1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1021/jm2003552,"Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.",1
11305,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1039/C5MD00451A,A potent trifluoromethyl ketone histone deacetylase inhibitor exhibits class-dependent mechanism of action,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2018.12.039,Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2018.03.002,Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.,1
11305,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1016/j.bmc.2017.05.058,Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.,1
11305,10.1016/j.ejmech.2016.01.013,Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.,10.1016/j.ejmech.2021.113569,"A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2008.09.003,Optimization of a series of potent and selective ketone histone deacetylase inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2021.113745,"Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.",1
11305,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,10.1016/j.ejmech.2016.11.055,Improving potency and metabolic stability by introducing an alkenyl linker to pyridine-based histone deacetylase inhibitors for orally available RUNX3 modulators.,1
11305,10.1016/j.bmcl.2013.04.067,"Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.",10.1016/j.ejmech.2020.112844,"Paradigm shift of ""classical"" HDAC inhibitors to ""hybrid"" HDAC inhibitors in therapeutic interventions.",1
11305,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,10.1016/j.ejmech.2023.115759,Rational discovery of dual FLT3/HDAC inhibitors as a potential AML therapy.,1
11305,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1039/C2MD00317A,"Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases",1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2012.05.034,Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC-EGFR dual inhibitors.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1021/acs.jmedchem.1c00491,"Thiazolidinedione ""Magic Bullets"" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their <i>In Vitro</i> and <i>In Vivo</i> Antitumor Effects.",1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1016/j.bmc.2018.06.016,"Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.",1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1016/j.ejmech.2017.04.017,"Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.",1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1016/j.bmc.2016.10.006,"Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.",1
11305,10.1016/j.ejmech.2011.04.027,Structure-based optimization of click-based histone deacetylase inhibitors.,10.1021/jm201496g,Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.,1
11305,10.1016/j.bmcl.2012.06.017,"Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2.",10.1021/acs.jmedchem.7b00115,Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).,1
11305,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2013.11.072,Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/jm200799p,Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.,1
11305,10.1016/j.ejmech.2013.05.017,"Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring.",10.1016/j.ejmech.2018.01.021,"Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.ejmech.2013.10.045,Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.,1
11305,10.1021/jm0613828,Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.,10.1021/jm3009376,Property-based optimization of hydroxamate-based γ-lactam HDAC inhibitors to improve their metabolic stability and pharmacokinetic profiles.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1016/j.ejmech.2017.10.076,The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1021/jm400390r,Discovery of the first histone deacetylase 6/8 dual inhibitors.,1
11305,10.1021/acs.jmedchem.5b00099,Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.,10.1016/j.ejmech.2021.113870,Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.,1
11305,10.1016/j.ejmech.2016.01.013,Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.,10.1016/j.ejmech.2018.08.073,HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.ejmech.2017.10.076,The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1021/acs.jmedchem.8b01090,Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.,1
11305,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2021.113946,Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).,1
11305,10.1016/j.ejmech.2016.02.001,Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.,10.1016/j.ejmech.2017.03.064,"Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.",1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2008.11.081,Sulfamides as novel histone deacetylase inhibitors.,1
11305,10.1021/jm0613828,Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.,10.1016/j.bmcl.2007.09.034,Modification of cap group in delta-lactam-based histone deacetylase (HDAC) inhibitors.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.ejmech.2023.115594,Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
11305,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.bmc.2013.03.049,The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.,1
11305,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2016.05.047,Inside HDACs with more selective HDAC inhibitors.,1
11501,10.1021/jm030222i,Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.,10.1021/jm900850t,Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.,1
11501,10.1016/j.bmcl.2014.12.030,Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.,10.1021/acs.jnatprod.1c00324,"Ulleunganilines A-C, Trichostatin Analogues Bearing a Modified Side Chain from <i>Streptomyces</i> sp. 13F051.",1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmcl.2008.12.045,Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors.,1
11501,10.1021/jm030222i,Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.,10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/acsmedchemlett.7b00012,"Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors.",1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/jm400564j,Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/ja102758v,"Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A.",1
11501,10.1016/j.bmcl.2014.10.019,Aurones as histone deacetylase inhibitors: identification of key features.,10.1016/j.bmcl.2015.11.011,Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/acs.jmedchem.8b00151,5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.,1
11305,10.1021/jm0703136,2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.,10.1021/jm900648x,Hydroxamates: relationships between structure and plasma stability.,1
11305,10.1021/jm300837y,Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.,10.1016/j.bmcl.2017.06.033,The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.,1
11305,10.1021/jm5008962,Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.,10.1021/jm502011f,Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors.,1
11305,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,1
11305,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,1
11305,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1038/nchembio.313,Chemical phylogenetics of histone deacetylases.,1
11501,10.1016/j.bmcl.2014.12.030,Identification of trichostatin derivatives from Streptomyces sp. CPCC 203909.,10.1016/j.bmcl.2020.126952,Screening for tyrosinase inhibitors from actinomycetes; identification of trichostatin derivatives from Streptomyces sp. CA-129531 and scale up production in bioreactor.,1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
11501,10.1021/jm030222i,Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.,10.1128/aac.00439-08,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.,1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2014.05.050,Discovery of HDAC inhibitors with potent activity against multiple malaria parasite life cycle stages.,1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1128/aac.00439-08,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.,1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.bmc.2009.10.042,Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.,1
11501,10.1016/j.bmcl.2014.10.019,Aurones as histone deacetylase inhibitors: identification of key features.,10.1016/j.bmc.2021.116510,From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.,1
11501,10.1016/j.bmcl.2006.12.117,Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor.,10.1016/j.bmcl.2012.03.004,Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.,1
11501,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2023.115935,HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents.,1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1038/nchembio.313,Chemical phylogenetics of histone deacetylases.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1021/jm901667k,Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.,1
11501,10.1016/j.ejmech.2016.03.046,Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.,10.1016/j.bmc.2019.06.036,Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1021/jm900850t,Discovery of potent and selective histone deacetylase inhibitors via focused combinatorial libraries of cyclic alpha3beta-tetrapeptides.,1
11501,10.1021/jm030222i,Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.,10.1128/aac.00757-07,Potent antimalarial activity of histone deacetylase inhibitor analogues.,1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.bmc.2009.10.042,Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group.,1
11674,10.1007/s00044-008-9121-4,Microwave-assisted synthesis and evaluation of anti-inflammatory activity of new series of N-substituted 2-butyl-5-chloro-3H-imidazole-4-carbaldehyde derivatives,10.1007/s00044-010-9410-6,Conventional and microwave-assisted synthesis of imidazole and guanidine derivatives and their biological evaluation,1
11671,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/jm301433m,"Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters.",1
11671,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/jm900565c,"The glutamate receptor GluR5 agonist (S)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic acid and the 8-methyl analogue: synthesis, molecular pharmacology, and biostructural characterization.",1
11671,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.4c01311,Domoic Acid as a Lead for the Discovery of the First Selective Ligand for Kainate Receptor Subtype 5 (GluK5).,1
11671,10.1021/jm800865a,"1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators.",10.1021/jm2004078,"Selective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1H,3H)-dione: synthesis, molecular modeling, and pharmacological and biostructural characterization.",1
11671,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.8b01986,Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands.,1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2018.10.041,Identification of novel quinazoline derivatives as potent antiplasmodial agents.,1
11501,10.1016/j.bmcl.2009.12.054,Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.,10.1016/j.bmc.2014.06.029,"Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.",1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.bmc.2013.06.009,Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).,1
11501,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
11501,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.ejmech.2010.02.030,Inside HDAC with HDAC inhibitors.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.bmcl.2015.11.011,Cross metathesis with hydroxamate and benzamide BOC-protected alkenes to access HDAC inhibitors and their biological evaluation highlighted intrinsic activity of BOC-protected dihydroxamates.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.bmc.2013.04.036,Structural basis for the design and synthesis of selective HDAC inhibitors.,1
11501,10.1021/jm7009217,"Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.",10.1016/j.bmc.2010.03.022,Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1016/s0960-894x(01)00088-9,Water-soluble propofol analogues with intravenous anaesthetic activity.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm010903i,Alpha-amino acid phenolic ester derivatives: novel water-soluble general anesthetic agents which allosterically modulate GABA(A) receptors.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/acs.jmedchem.7b00253,"Design, Synthesis, and Evaluation of a Series of Novel Benzocyclobutene Derivatives as General Anesthetics.",1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/acs.jmedchem.7b00254,"Design, Synthesis, and Evaluation of Novel 2,6-Disubstituted Phenol Derivatives as General Anesthetics.",1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1016/j.bmcl.2012.07.001,ortho Substituent effects on the anticonvulsant properties of 4-hydroxy-trifluoroethyl phenols.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm1004072,m-Azipropofol (AziPm) a photoactive analogue of the intravenous general anesthetic propofol.,1
11762,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
11762,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
11715,10.1021/jm00105a044,"Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones.",10.1016/j.ejmech.2020.112924,An update into the medicinal chemistry of translocator protein (TSPO) ligands.,1
11674,10.1021/np970343j,Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.,10.1021/acsmedchemlett.5b00286,Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.,1
11674,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
11674,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
11674,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
11674,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
11674,10.1021/np970343j,Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.,10.1016/j.bmcl.2003.11.066,Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.,1
11674,10.1021/jm3011146,Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.,10.1016/j.bmc.2016.01.009,"Design, synthesis and biological evaluation of novel analgesic agents targeting both cyclooxygenase and TRPV1.",1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm901421c,The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
11968,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.8b01398,Pyridinium Oximes with Ortho-Positioned Chlorine Moiety Exhibit Improved Physicochemical Properties and Efficient Reactivation of Human Acetylcholinesterase Inhibited by Several Nerve Agents.,1
11968,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
11968,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2016.09.078,"Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.",1
11968,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm9700225,"1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.",1
11968,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acsmedchemlett.6b00451,Systematic Study of Effects of Structural Modifications on the Aqueous Solubility of Drug-like Molecules.,1
11968,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1016/j.ejmech.2020.112261,A potent photoreactive general anesthetic with novel binding site selectivity for GABA receptors.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm970681h,"Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological profile at recombinant human GABAA receptors.",1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1016/s0960-894x(03)00346-9,"Novel water soluble 2,6-dimethoxyphenyl ester derivatives with intravenous anaesthetic activity.",1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm200943f,p-(4-Azipentyl)propofol: a potent photoreactive general anesthetic derivative of propofol.,1
11819,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm010461a,4D-QSAR analysis of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the GABA(A) receptor.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2010.03.038,Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2019.03.037,"Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.",1
12428,10.1021/acs.jmedchem.5b01485,Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.,10.1021/acs.jmedchem.1c00790,"Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.",1
12428,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.bmcl.2021.128330,"Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains.",1
1370,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",1
1370,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1369,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
1362,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
1362,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
1362,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
12428,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmcl.2012.12.070,"Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.",1
12356,10.1021/jm00107a008,"Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols.",10.1021/jm030791q,"Highly potent 1,4-benzothiazine derivatives as K(ATP)-channel openers.",1
12170,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1021/jm301473k,Synthesis and biological evaluation of 4-(aminomethyl)-1-hydroxypyrazole analogues of muscimol as γ-aminobutyric acid(a) receptor agonists.,1
12170,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1016/j.ejmech.2014.07.039,Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABA(A) receptor agonists.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
11968,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.07.058,Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2010.11.035,Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.,1
12428,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1021/ml500279k,Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics.,1
12428,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2019.02.073,"Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.",1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2018.09.012,Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
12428,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.ejmech.2019.03.037,"Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.",1
12428,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.ejmech.2022.114888,"1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.",1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2010.11.079,Discovery of novel ureas and thioureas of 3-decladinosyl-3-hydroxy 15-membered azalides active against efflux-mediated resistant Streptococcus pneumoniae.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2012.01.023,Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2009.11.032,"Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.",1
12428,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2012.11.028,"Synthesis and antibacterial evaluation of novel 11,4″-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria.",1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2012.10.054,"Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides.",1
12428,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.bmcl.2021.128110,"Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives.",1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2009.06.023,"Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.",1
12428,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2020.112222,"Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.",1
1362,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
1362,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
1362,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2008.09.028,In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II.,1
1354,10.1021/jm00389a008,"Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.",10.1021/acs.jmedchem.5b00201,Volume of Distribution in Drug Design.,1
1354,10.1021/jm00389a008,"Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.",10.1021/acs.jmedchem.6b00472,"The ""Cyclopropyl Fragment"" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.",1
1333,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2009.11.039,Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.,1
1333,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1333,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
12506,10.1016/j.bmcl.2006.08.130,"Identification of a novel boron-containing antibacterial agent (AN0128) with anti-inflammatory activity, for the potential treatment of cutaneous diseases.",10.1039/C0MD00119H,"Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications",1
12506,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2005.10.074,Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives.,1
12506,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,1
12506,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2024.116630,"Design, synthesis and structure-activity relationships of novel non-ketolides: 9-Oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH.",1
12506,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2010.11.035,Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.,1
12506,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2004.12.067,"Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes.",1
12428,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
12428,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2012.12.070,"Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.",1
12825,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
12825,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
12825,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
12506,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2005.12.033,Synthesis and biological investigation of new 4''-malonyl tethered derivatives of erythromycin and clarithromycin.,1
12506,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
12506,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2007.04.104,"Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives.",1
12506,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2006.09.036,Synthesis and antibacterial activity of C6-carbazate ketolides.,1
12506,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2005.10.074,Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives.,1
12506,10.1016/j.bmcl.2008.10.071,Identification of small molecule agonists of the motilin receptor.,10.1016/j.bmcl.2008.10.072,The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor.,1
12506,10.1021/acs.jmedchem.8b02032,Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.,10.1021/acs.jmedchem.3c00782,"Potent, Selective, and Membrane Permeable 2-Amino-4-Substituted Pyridine-Based Neuronal Nitric Oxide Synthase Inhibitors.",1
12506,10.1016/j.bmcl.2011.04.004,Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents.,10.1021/acs.jmedchem.5b00175,"Creation of Customized Bioactivity within a 14-Membered Macrolide Scaffold: Design, Synthesis, and Biological Evaluation Using a Family-18 Chitinase.",1
12506,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
12506,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
12506,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2005.12.097,"Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides.",1
12506,10.1016/j.bmcl.2008.07.118,"Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: length optimization and zero carbon linker oximes.",10.1016/j.bmcl.2008.10.109,"Synthesis of 3,6-bicyclolides: a novel class of macrolide antibiotics.",1
12506,10.1016/j.bmcl.2008.10.071,Identification of small molecule agonists of the motilin receptor.,10.1021/jm801332q,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",1
13048,10.1021/jm4004076,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,10.1021/acs.jmedchem.7b00841,Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.,1
13048,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1039/d2md00067a,"FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.",1
13048,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
12911,10.1021/jm9906116,"Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.",10.1016/j.bmcl.2007.01.089,Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.,1
12850,10.1021/jm020985q,New active series of growth hormone secretagogues.,10.1016/j.ejmech.2022.114308,An insight into the multifunctional role of ghrelin and structure activity relationship studies of ghrelin receptor ligands with clinical trials.,1
12850,10.1021/jm960054c,Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor.,10.1016/j.ejmech.2022.114308,An insight into the multifunctional role of ghrelin and structure activity relationship studies of ghrelin receptor ligands with clinical trials.,1
12850,10.1021/jm020985q,New active series of growth hormone secretagogues.,10.1016/j.bmc.2013.06.006,Antiproliferative activity on human prostate carcinoma cell lines of new peptidomimetics containing the spiroazepinoindolinone scaffold.,1
12850,10.1021/jm010207i,"Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues.",10.1016/j.bmc.2007.01.057,Modeling of human ghrelin receptor (hGHS-R1a) in its close state and validation by molecular docking.,1
12825,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
12825,10.1021/jm900712n,Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury.,10.1021/ml200303r,"Water-soluble progesterone analogues are effective, injectable treatments in animal models of traumatic brain injury.",1
12825,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
12825,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm200585k,Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.,1
12825,10.1021/jm900712n,Development and screening of water-soluble analogues of progesterone and allopregnanolone in models of brain injury.,10.1021/jm501676v,Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells.,1
12825,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
12825,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
12825,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
13366,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1016/j.ejmech.2018.12.051,High-throughput screening of novel pyruvate dehydrogenase kinases inhibitors and biological evaluation of their in vitro and in vivo antiproliferative activity.,1
13329,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
13048,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1016/j.ejmech.2019.06.054,"Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.",1
13048,10.1016/j.bmcl.2008.04.009,"Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.",10.1016/j.ejmech.2019.02.050,"Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.",1
13048,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
13048,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1021/acs.jmedchem.7b01091,Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.,1
13048,10.1016/j.bmcl.2009.01.068,"N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2015.12.016,Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.,1
13048,10.1016/j.bmcl.2008.04.009,"Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.",10.1016/j.ejmech.2015.12.016,Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.,1
13048,10.1016/j.bmcl.2009.10.040,"N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2015.12.016,Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.,1
13048,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2016.12.038,"Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).",1
13048,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2011.02.057,"Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.",1
13048,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2014.07.108,Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.,1
13048,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
13048,10.1016/j.bmcl.2008.04.009,"Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.",10.1016/j.bmcl.2009.01.068,"N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",1
13048,10.1016/j.bmcl.2008.04.009,"Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.",10.1016/j.bmcl.2009.10.040,"N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",1
13048,10.1016/j.bmcl.2009.01.068,"N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2009.10.040,"N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.",1
13494,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm061349l,Antibacterial nicotinamide adenine dinucleotide synthetase inhibitors: amide- and ether-linked tethered dimers with alpha-amino acid end groups.,1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00723,"A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.",1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,1
13456,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmcl.2010.07.038,Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV.,1
13456,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1021/jm010461a,4D-QSAR analysis of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the GABA(A) receptor.,1
13456,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
13456,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmcl.2011.05.071,In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.,1
13456,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2011.01.016,"Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site.",1
13429,10.1021/acs.jmedchem.7b00313,Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.,10.1021/acs.jmedchem.0c01686,Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.,1
13429,10.1021/acs.jmedchem.7b00313,Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.,10.1021/acs.jmedchem.2c01433,B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.,1
13366,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1021/acs.jmedchem.6b01245,Development of the First Generation of Disulfide-Based Subtype-Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors.,1
13366,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1021/acs.jmedchem.8b01168,Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases.,1
13366,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1021/acs.jmedchem.9b00565,Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.,1
13366,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1016/j.bmcl.2017.10.073,Identification of pyruvate dehydrogenase kinase 1 inhibitors with anti-osteosarcoma activity.,1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
13756,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
13756,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
13756,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
13756,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
13756,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
13756,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
13590,10.1016/j.bmc.2019.06.025,Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus.,10.1039/d2md00194b,Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage.,1
13590,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1021/acs.jmedchem.5b01380,Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents.,1
13494,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
13494,10.1021/acs.jmedchem.6b00007,Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors.,10.1016/j.ejmech.2022.114105,A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).,1
13494,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,1
13494,10.1007/s00044-010-9328-z,"Synthesis of new series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4-ones for their bacterial and cyclin-dependent kinases (CDKs) inhibitory activities",10.1016/j.bmc.2017.10.012,"An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.",1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm301749y,Colloidal aggregation causes inhibition of G protein-coupled receptors.,1
13494,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm4009357,Fragment-based identification of a locus in the Sec7 domain of Arno for the design of protein-protein interaction inhibitors.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/ml400492t,"Novel carboline derivatives as potent antifungal lead compounds: design, synthesis, and biological evaluation.",1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
13758,10.1016/j.bmc.2007.10.034,Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.,10.1016/j.bmc.2012.10.027,Contribution to investigation of antimicrobial activity of styrylquinolines.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.08.089,"Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.",1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.ejmech.2020.112991,"Novel naphthylamide derivatives as dual-target antifungal inhibitors: Design, synthesis and biological evaluation.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2012.05.070,Synthesis and biological evaluation of vinyl ether-containing azole derivatives as inhibitors of Trichophyton rubrum.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1021/acs.jmedchem.3c01372,Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2020.112082,New azole antifungals with a fused triazinone scaffold.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/jm4016284,"Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.",1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.04.056,Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.,1
13758,10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2010.12.006,"New azoles with antifungal activity: Design, synthesis, and molecular docking.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.05.047,"Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2015.08.023,"Design, synthesis, and structure-activity relationship studies of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates.",1
13758,10.1016/j.ejmech.2014.07.001,"Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.",10.1016/j.ejmech.2017.02.035,New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies.,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,1
13758,10.1021/acs.jmedchem.4c00209,A Unique Hybridization Route to Access Hydrazylnaphthalimidols as Novel Structural Scaffolds of Multitargeting Broad-Spectrum Antifungal Candidates.,10.1016/j.ejmech.2024.116626,Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance.,1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2023.115436,New miconazole-based azoles derived from eugenol show activity against Candida spp. and Cryptococcus gattii by inhibiting the fungal ergosterol biosynthesis.,1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1021/acsmedchemlett.0c00017,Construction and Evaluation of Molecular Models: Guide and Design of Novel SE Inhibitors.,1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.ejmech.2020.112645,"Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors.",1
13758,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.07.144,Discovery of highly potent novel antifungal azoles by structure-based rational design.,1
13758,10.1016/j.ejmech.2012.01.034,Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives.,10.1016/j.ejmech.2017.02.035,New azole derivatives showing antimicrobial effects and their mechanism of antifungal activity by molecular modeling studies.,1
13758,10.1016/j.ejmech.2023.115782,Optimization and antifungal activity of quinoline derivatives linked to chalcone moiety combined with FLC against Candida albicans.,10.1039/d4md00021h,New azole derivatives linked to indole/indoline moieties combined with FLC against drug-resistant <i>Candida albicans</i>.,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",1
13758,10.1021/jm5019093,PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.,10.1016/j.bmc.2018.09.004,"Antifungal benzo[b]thiophene 1,1-dioxide IMPDH inhibitors exhibit pan-assay interference (PAINS) profiles.",1
13758,10.1016/j.ejmech.2014.07.001,"Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.",10.1021/acs.jmedchem.3c01898,Miconazole-like Scaffold is a Promising Lead for <i>Naegleria fowleri</i>-Specific CYP51 Inhibitors.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.bmcl.2019.06.040,Strategies for the development of highly selective cytochrome P450 inhibitors: Several CYP targets in current research.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1039/d2md00196a,Efficient selective targeting of <i>Candida</i> CYP51 by oxadiazole derivatives designed from plant cuminaldehyde.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.04.022,"Design, synthesis and molecular docking studies of novel triazole as antifungal agent.",1
13758,10.1016/j.bmcl.2012.08.073,Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.,10.1016/j.bmcl.2016.06.030,Synthesis and antimicrobial evaluation of novel ethyl 2-(2-(4-substituted)acetamido)-4-subtituted-thiazole-5-carboxylate derivatives.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2023.115506,"Novel antifungal triazoles with alkynyl-methoxyl side chains: Design, synthesis, and biological activity evaluation.",1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2022.114707,Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51.,1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2019.06.083,Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C4MD00505H,Discovery of highly potent triazoleantifungal agents with piperidine-oxadiazole side chains,1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2021.113740,"Design, synthesis and evaluation of novel 5-phenylthiophene derivatives as potent fungicidal of Candida albicans and antifungal reagents of fluconazole-resistant fungi.",1
13758,10.1016/j.ejmech.2014.07.001,"Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.",10.1016/j.ejmech.2019.01.012,"Searching for new agents active against Candida albicans biofilm: A series of indole derivatives, design, synthesis and biological evaluation.",1
13758,10.1016/j.ejmech.2012.01.034,Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives.,10.1016/j.ejmech.2014.07.001,"Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.",1
13758,10.1016/j.ejmech.2010.03.045,"Synthesis and biological evaluation of a novel series of 2,2-bisaminomethylated aurone analogues as anti-inflammatory and antimicrobial agents.",10.1007/s00044-012-9979-z,"Synthesis of new olefin chalcone derivatives as antitumor, antioxidant and antimicrobial agents",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2013.04.025,Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement.,1
13758,10.1016/j.bmc.2011.08.029,"Antifungal activity of a series of 1,2-benzisothiazol-3(2H)-one derivatives.",10.1016/j.bmcl.2017.01.027,Broad spectrum anti-infective properties of benzisothiazolones and the parallels in their anti-bacterial and anti-fungal effects.,1
13758,10.1016/j.ejmech.2014.07.001,"Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as Candida albicans inhibitors.",10.1016/j.bmcl.2016.10.091,Exploring the anti-biofilm activity of cinnamic acid derivatives in Candida albicans.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2014.07.064,Scaffold hopping of sampangine: discovery of potent antifungal lead compound against Aspergillus fumigatus and Cryptococcus neoformans.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2012.04.013,"Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.",1
13758,10.1007/s00044-009-9273-x,Synthesis and evaluation of a series of aminocyanopyridines as antimicrobial agents,10.1007/s00044-012-0066-2,"Synthesis, antimicrobial and antioxidant activities of some new indole derivatives containing pyridopyrimidine and pyrazolopyridine moieties",1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1021/acs.jmedchem.3c01254,Developing Novel Coumarin-Containing Azoles Antifungal Agents by the Scaffold Merging Strategy for Treating Azole-Resistant Candidiasis.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2011.06.008,"Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.",1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2015.03.024,"Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.",1
13758,10.1016/j.bmcl.2014.07.064,Scaffold hopping of sampangine: discovery of potent antifungal lead compound against Aspergillus fumigatus and Cryptococcus neoformans.,10.1016/j.bmc.2019.01.029,Discovery of novel simplified isoxazole derivatives of sampangine as potent anti-cryptococcal agents.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2012.02.042,"New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.02.042,"Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2010.03.014,"Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.11.101,"Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.",1
13758,10.1016/j.ejmech.2012.01.034,Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives.,10.1016/j.ejmech.2019.01.012,"Searching for new agents active against Candida albicans biofilm: A series of indole derivatives, design, synthesis and biological evaluation.",1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2016.04.070,Discovery of novel berberine imidazoles as safe antimicrobial agents by down regulating ROS generation.,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C4MD00281D,Synthesis and biological evaluation of a new class of quinazolinoneazoles as potential antimicrobial agents and their interactions with calf thymus DNA and human serum albumin,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1039/d2md00196a,Efficient selective targeting of <i>Candida</i> CYP51 by oxadiazole derivatives designed from plant cuminaldehyde.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.4c01057,"Design, Synthesis, and Activity Evaluation of Novel Benzazole Bifunctional Antifungal Inhibitors with an LDH Carrier.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.0c00102,Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.,1
13758,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
13758,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.01.048,"Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.",1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.ejmech.2019.06.083,Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening.,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2019.04.043,"Antibacterial activity study of 1,2,4-triazole derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.2c01451,"Novel Aryl Alkamidazole Derivatives as Multifunctional Antifungal Inhibitors: Design, Synthesis, and Biological Evaluation.",1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C7MD00112F,"Discovery of potential antifungal triazoles: design, synthesis, biological evaluation, and preliminary antifungal mechanism exploration.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C3MD20086H,Synthesis and antifungal activity of the novel triazole compounds,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.07.003,"Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.",1
13758,10.1016/j.bmcl.2014.07.064,Scaffold hopping of sampangine: discovery of potent antifungal lead compound against Aspergillus fumigatus and Cryptococcus neoformans.,10.1021/acs.jmedchem.3c02331,Discovery of New Tricyclic Oxime Sampangine Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcosis and Candidiasis.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C2MD20211E,Structureactivity relationships of tetrahydrocarbazole derivatives as antifungal lead compounds,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C1MD00103E,Discovery of highly potent antifungal triazoles by structure-based lead fusion,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2010.09.070,Novel conformationally restricted triazole derivatives with potent antifungal activity.,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
13758,10.1016/j.ejmech.2018.03.083,"Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.",10.1021/acs.jmedchem.3c01105,Discovery of Lead 2-Thiazolylhydrazones with Broad-Spectrum and Potent Antifungal Activity.,1
13758,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1021/acs.jmedchem.1c01991,"Species-Selective Targeting of Fungal Hsp90: Design, Synthesis, and Evaluation of Novel 4,5-Diarylisoxazole Derivatives for the Combination Treatment of Azole-Resistant Candidiasis.",1
13758,10.1016/j.ejmech.2012.01.034,Synthesis and antifungal activity of a new series of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives.,10.1021/acs.jmedchem.3c01898,Miconazole-like Scaffold is a Promising Lead for <i>Naegleria fowleri</i>-Specific CYP51 Inhibitors.,1
13758,10.1016/j.bmcl.2012.08.073,Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.,10.1016/j.ejmech.2019.06.074,"Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.03.020,"Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.",1
13758,10.1016/j.bmc.2023.117543,"Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents.",10.1039/d4md00021h,New azole derivatives linked to indole/indoline moieties combined with FLC against drug-resistant <i>Candida albicans</i>.,1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.ejmech.2021.113950,Construction and activity evaluation of novel benzodioxane derivatives as dual-target antifungal inhibitors.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.02.027,"Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.",1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.111689,Combating fluconazole-resistant fungi with novel β-azole-phenylacetone derivatives.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C3MD00032J,"Berberine azoles as antimicrobial agents: synthesis, biological evaluation and their interactions with human serum albumin",1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C6MD00357E,,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2016.04.036,"Design, synthesis and biological evaluation of 5-fluorouracil-derived benzimidazoles as novel type of potential antimicrobial agents.",1
13758,10.1007/s00044-012-0369-3,Antibacterial and antifungal screening of newly synthesized benzimidazole-clubbed chalcone derivatives,10.1007/s00044-013-0791-1,"Synthesis and antimicrobial evaluation of 1,3,4-oxadiazole-based chalcone derivatives",1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2015.06.041,Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.bmc.2020.115398,Promising antifungal agents: A minireview.,1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2010.11.042,Design and synthesis of 3-(azol-1-yl)phenylpropanes as microbicidal spermicides for prophylactic contraception.,1
13758,10.1016/j.bmcl.2014.07.064,Scaffold hopping of sampangine: discovery of potent antifungal lead compound against Aspergillus fumigatus and Cryptococcus neoformans.,10.1016/j.ejmech.2017.10.043,Discovery of simplified sampangine derivatives as novel fungal biofilm inhibitors.,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C5MD00574D,Synthesis and biological evaluation of Schiff base-linked imidazolyl naphthalimides as novel potential anti-MRSA agents,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.,1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C5MD00186B,"Design, synthesis, and antibacterial evaluation of novel azolylthioether quinolones as MRSA DNA intercalators",1
13758,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1021/acs.jmedchem.4c01057,"Design, Synthesis, and Activity Evaluation of Novel Benzazole Bifunctional Antifungal Inhibitors with an LDH Carrier.",1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1021/acs.jmedchem.3c02426,Selenization of Small Molecule Drugs: A New Player on the Board.,1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1021/acs.jmedchem.2c00878,"Design, Synthesis, and Biological Evaluation of Dual-Target COX-2/CYP51 Inhibitors for the Treatment of Fungal Infectious Diseases.",1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.bmc.2019.02.009,"Design, synthesis and biological evaluation of amide-pyridine derivatives as novel dual-target (SE, CYP51) antifungal inhibitors.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.03.019,Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2017.10.081,"Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives.",1
13758,10.1039/C8MD00230D,Structure-based virtual screening and ADME/T-based prediction analysis for the discovery of novel antifungal CYP51 inhibitors.,10.1016/j.ejmech.2021.113972,Construction and activity evaluation of novel dual-target (SE/CYP51) anti-fungal agents containing amide naphthyl structure.,1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2022.114707,Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.01.075,Design and synthesis of antifungal benzoheterocyclic derivatives by scaffold hopping.,1
13758,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",1
13758,10.1016/j.bmcl.2012.08.073,Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.,10.1016/j.bmcl.2014.05.051,One pot three components microwave assisted and conventional synthesis of new 3-(4-chloro-2-hydroxyphenyl)-2-(substituted) thiazolidin-4-one as antimicrobial agents.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2021.113715,"Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.3c01308,Novel Nitric Oxide Donor-Azole Conjugation Strategy for Efficient Treatment of <i>Cryptococcus neoformans</i> Infections.,1
14125,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,1
14125,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
14125,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1016/s0014-5793(98)00585-7,Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.,1
14125,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1039/C6MD00235H,,1
14125,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2014.05.079,"Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.",1
13758,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2013.10.056,"Synthesis and biological evaluation of novel substituted 1,3,4-thiadiazole and 2,6-di aryl substituted imidazo [2,1-b] [1,3,4] thiadiazole derivatives.",1
13758,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.bmcl.2022.129044,"Design, synthesis and antifungal activities of novel triazole derivatives with selenium-containing hydrophobic side chains.",1
13758,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2022.114195,"Design, synthesis, and evaluation of novel 3-thiophene derivatives as potent fungistatic and fungicidal reagents based on a conformational restriction strategy.",1
13758,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.bmcl.2017.12.040,"Design, synthesis, and structure-activity relationship studies of novel tetrazole antifungal agents with potent activity, broad antifungal spectrum and high selectivity.",1
13758,10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
13758,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2017.11.027,"Novel aminopyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation.",1
1333,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1021/acsmedchemlett.0c00417,In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae.,1
1333,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
1333,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
1333,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
1333,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1333,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
1280,10.1016/j.ejmech.2014.05.017,Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.,10.1016/j.ejmech.2016.01.019,Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.,1
1280,10.1021/np970343j,Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.,10.1021/acsmedchemlett.5b00286,Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.,1
1280,10.1021/np020023m,Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.,10.1021/np100283t,"Ipomotaosides A-D, resin glycosides from the aerial parts of Ipomoea batatas and their inhibitory activity against COX-1 and COX-2.",1
1280,10.1016/j.ejmech.2007.03.032,"Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates.",10.1016/j.bmc.2009.03.053,"Synthesis, antiplatelet and in silico evaluations of novel N-substituted-phenylamino-5-methyl-1H-1,2,3-triazole-4-carbohydrazides.",1
1280,10.1016/j.ejmech.2007.03.032,"Synthesis and anti-platelet activity of novel arylsulfonate--acylhydrazone derivatives, designed as antithrombotic candidates.",10.1016/j.bmcl.2017.04.007,"Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties.",1
1280,10.1016/j.ejmech.2008.09.020,Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.,10.1016/j.bmc.2014.03.043,"Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.",1
1280,10.1021/np020023m,Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.,10.1021/np040130b,Lanostane triterpenoids and triterpene glycosides from the fruit body of Fomitopsis pinicola and their inhibitory activity against COX-1 and COX-2.,1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1124/jpet.301.1.293,Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.,1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajprenal.1999.276.2.f295,Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C.,1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1073/pnas.1033060100,The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.,1
14263,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
14221,10.1021/jm4006884,"A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.",10.1016/j.ejmech.2016.01.011,"5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.",1
14221,10.1021/jm4006884,"A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.",10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",1
14221,10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
14221,10.1016/j.bmc.2010.11.022,"Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25.",10.1016/j.bmcl.2011.05.019,"Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies.",1
14221,10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",10.1016/j.ejmech.2016.01.011,"5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.",1
14221,10.1016/j.bmc.2010.11.022,"Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25.",10.1016/j.bmcl.2012.08.117,"Design, synthesis and anticancer activity of 1-acyl-3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives.",1
14221,10.1021/jm4006884,"A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.",10.1016/j.ejmech.2019.112019,"Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: Design, synthesis, and in vitro biological evaluation.",1
14221,10.1016/j.ejmech.2016.02.072,"Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.",10.1021/acs.jmedchem.3c00566,Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery.,1
14221,10.1016/j.ejmech.2015.06.046,"Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.",10.1021/acs.jmedchem.3c00566,Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery.,1
14221,10.1016/j.ejmech.2015.06.046,"Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
14221,10.1016/j.ejmech.2016.02.072,"Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
14221,10.1016/j.ejmech.2015.06.046,"Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors.",10.1016/j.ejmech.2016.02.072,"Novel optimization of valmerins (tetrahydropyrido[1,2-a]isoindolones) as potent dual CDK5/GSK3 inhibitors.",1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
14125,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1074/jbc.272.30.18526,Expression cloning and characterization of a novel multispecific organic anion transporter.,1
14125,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
14275,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm901621h,A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.,1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm010538v,Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.,1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm500196c,"Highly potent and selective ectonucleotide pyrophosphatase/phosphodiesterase I inhibitors based on an adenosine 5'-(α or γ)-thio-(α,β- or β,γ)-methylenetriphosphate scaffold.",1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm100030u,"2-MeS-beta,gamma-CCl2-ATP is a potent agent for reducing intraocular pressure.",1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm990158y,2-thioether 5'-O-(1-thiotriphosphate)adenosine derivatives as new insulin secretagogues acting through P2Y-Receptors.,1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm000020b,Novel inhibitors of nucleoside triphosphate diphosphohydrolases: chemical synthesis and biochemical and pharmacological characterizations.,1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm400197m,Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists.,1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm990085i,"Characterization of ""mini-nucleotides"" as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study.",1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm3006355,Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.,1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm100597c,"Diadenosine 5',5''-(boranated)polyphosphonate analogues as selective nucleotide pyrophosphatase/phosphodiesterase inhibitors.",1
14264,10.1021/acs.jmedchem.5b01972,Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.,10.1021/acs.jmedchem.7b00854,Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor.,1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm3006355,Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.,1
14264,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm901621h,A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.,1
14264,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm901621h,A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.,1
14263,10.1021/jm200020a,"Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.",10.1016/j.bmc.2013.11.017,"Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.",1
14263,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm900888c,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.08.094,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.",1
14367,10.1021/jm1005034,"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.",10.1021/jm4014136,"Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.",1
14367,10.1021/jm101459g,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",10.1016/j.ejmech.2012.11.042,Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT₁A/5-HT₂A/5-HT₇ and dopamine D₂/D₃ receptors.,1
14367,10.1021/jm1005034,"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.",10.1016/j.bmcl.2012.10.089,A rhodamine-labeled citalopram analogue as a high-affinity fluorescent probe for the serotonin transporter.,1
14367,10.1021/jm901818u,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,10.1021/jm100481d,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",1
14367,10.1021/jm101459g,"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.",10.1021/acs.jmedchem.7b00839,"Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity.",1
14366,10.1021/jm031121n,"Identification, synthesis, and characterization of new glycogen phosphorylase inhibitors binding to the allosteric AMP site.",10.1021/jm201439b,Binding evaluation of fragment-based scaffolds for probing allosteric enzymes.,1
14366,10.1021/jm201439b,Binding evaluation of fragment-based scaffolds for probing allosteric enzymes.,10.1039/C2MD20035J,INPHARMA-based identification of ligand binding site in fragment-based drug design,1
14366,10.1016/j.bmc.2009.12.077,"Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.",10.1016/j.bmc.2010.06.046,"Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.",1
14366,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
14275,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm3006355,Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.,1
14275,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm3006355,Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist.,1
14275,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm000020b,Novel inhibitors of nucleoside triphosphate diphosphohydrolases: chemical synthesis and biochemical and pharmacological characterizations.,1
14275,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm400197m,Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists.,1
14275,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm060485n,Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.,1
14275,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm901621h,A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2017.12.004,"Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.",1
14440,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1021/np900821e,Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.,1
14440,10.1016/j.bmcl.2012.04.007,Bio-inspired synthesis and biological evaluation of a colchicine-related compound library.,10.1016/j.bmc.2021.116014,"Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives.",1
14406,10.1016/S0960-894X(00)80531-4,"Synthesis, biochemical activity and behavioral effects of a series of 1,4,5,6-tetrahydropyrimidines as novel ligands for M1 receptors",10.1021/jm960467d,"Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.",1
1280,10.1007/s00044-013-0580-x,"Novel 1,3-diarylpyrazole acrylamides: synthesis, antiplatelet activity screening, and in silico evaluation studies",10.1039/C8MD00022K,"Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.",1
1280,10.1016/j.ejmech.2008.09.020,Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.,10.1007/s00044-010-9494-z,"Synthesis and evaluation of anti-inflammatory and analgesic activity of 3-[(5-substituted-1,3,4-oxadiazol-2-yl-thio)acetyl]-2H-chromen-2-ones",1
1280,10.1016/j.bmcl.2015.01.010,Schiff's bases of quinazolinone derivatives: Synthesis and SAR studies of a novel series of potential anti-inflammatory and antioxidants.,10.1016/j.ejmech.2018.03.076,An overview of quinazolines: Pharmacological significance and recent developments.,1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2009.09.021,"Pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione derivatives: their cytoprotection effect from rotenone toxicity and preliminary DMPK properties.",1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.08.094,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: Exploration of pyridazinones containing 6-amino-substituents.",1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.05.083,"Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.",1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.04.066,"Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.08.017,"Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1039/C9MD00286C,Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.,1
1279,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2016.09.078,"Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.",1
1279,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1016/j.bmcl.2010.12.079,"Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2017.07.054,"Discovery of 9H-purins as potential tubulin polymerization inhibitors: Synthesis, biological evaluation and structure-activity relationships.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.0c01345,"SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,1
14440,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1016/s0960-894x(01)00190-1,Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2014.09.093,Synthesis and antiproliferative activity of 6-phenylaminopurines.,1
14440,10.1016/j.ejmech.2018.07.060,"Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.",10.1039/d2md00340f,"Synthesis and bioactive evaluation of <i>N</i>-((1-methyl-1<i>H</i>-indol-3-yl)methyl)-<i>N</i>-(3,4,5-trimethoxyphenyl)acetamide derivatives as agents for inhibiting tubulin polymerization.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.5b01086,"Synthesis and Biochemical Evaluation of 3-Phenoxy-1,4-diarylazetidin-2-ones as Tubulin-Targeting Antitumor Agents.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.1c01202,"X-ray Crystallography-Guided Design, Antitumor Efficacy, and QSAR Analysis of Metabolically Stable Cyclopenta-Pyrimidinyl Dihydroquinoxalinone as a Potent Tubulin Polymerization Inhibitor.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1039/d1md00392e,Identification and validation of novel microtubule suppressors with an imidazopyridine scaffold through structure-based virtual screening and docking.,1
14440,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1016/j.bmc.2007.01.016,"Synthesis and biological activity of 2,5-diaryl-3-methylpyrimido[4,5-c]quinolin-1(2H)-one derivatives.",1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.ejmech.2014.07.050,"Novel 9'-substituted-noscapines: synthesis with Suzuki cross-coupling, structure elucidation and biological evaluation.",1
14440,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1039/d4md00210e,"Synthesis, &lt;i&gt;in silico&lt;/i&gt;, &lt;i&gt;in vitro&lt;/i&gt; evaluation of furanyl- and thiophenyl-3-phenyl-1&lt;i&gt;H&lt;/i&gt;-indole-2-carbohydrazide derivatives as tubulin inhibitors and anticancer agents.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2015.04.055,Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.,1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.bmc.2015.08.027,"Synthesis, antiproliferative activity and possible mechanism of action of novel 2-acetamidobenzamides bearing the 2-phenoxy functionality.",1
14440,10.1016/j.bmcl.2012.04.007,Bio-inspired synthesis and biological evaluation of a colchicine-related compound library.,10.1016/j.bmc.2019.115144,"Synthesis, biological evaluation and molecular docking studies of new amides of 4-bromothiocolchicine as anticancer agents.",1
14440,10.1021/acs.jmedchem.2c01208,Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.,10.1016/j.ejmech.2023.116079,Discovery of novel coumarin-based derivatives as inhibitors of tubulin polymerization targeting the colchicine binding site with potent anti-gastric cancer activities.,1
14440,10.1016/j.bmcl.2012.04.007,Bio-inspired synthesis and biological evaluation of a colchicine-related compound library.,10.1016/j.bmcl.2021.128382,Synthesis of thiocolchicine amine derivatives and evaluation of their antiproliferative activity.,1
14440,10.1016/j.bmcl.2009.05.054,"Design, synthesis and identification of novel colchicine-derived immunosuppressant.",10.1016/j.bmc.2019.115144,"Synthesis, biological evaluation and molecular docking studies of new amides of 4-bromothiocolchicine as anticancer agents.",1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2023.115470,Discovery of novel N-aryl-2-trifluoromethyl-quinazoline-4-amine derivatives as the inhibitors of tubulin polymerization in leukemia cells.,1
14440,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.bmc.2011.12.057,"Synthesis, biological evaluation, and molecular docking studies of cinnamic acyl 1,3,4-thiadiazole amide derivatives as novel antitubulin agents.",1
14440,10.1016/j.ejmech.2018.07.060,"Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.",10.1016/j.bmcl.2021.128131,WITHDRAWN: Discovery of indoline derivatives as anticancer agents via inhibition of tubulin polymerization.,1
14440,10.1016/j.bmc.2009.02.029,Discovery and structure-activity relationships of (2-(arylthio)benzylideneamino)guanidines as a novel series of potent apoptosis inducers.,10.1016/j.bmc.2010.10.008,"Synthesis, molecular modeling and biological evaluation of guanidine derivatives as novel antitubulin agents.",1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.ejmech.2013.04.068,"2-cinnamamido, 2-(3-phenylpropiolamido), and 2-(3-phenylpropanamido)benzamides: synthesis, antiproliferative activity, and mechanism of action.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2018.02.019,"Conformational mimetics of the α-methyl chalcone TUB091 binding tubulin: Design, synthesis and antiproliferative activity.",1
14440,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.bmcl.2019.126816,"Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.6b01591,N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.,1
14440,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2018.07.044,"Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation.",1
14440,10.1016/j.bmcl.2012.04.007,Bio-inspired synthesis and biological evaluation of a colchicine-related compound library.,10.1021/acs.jmedchem.0c00222,Colchicine Alkaloids and Synthetic Analogues: Current Progress and Perspectives.,1
14440,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.ejmech.2013.01.006,"(E)-4-aryl-4-oxo-2-butenoic acid amides, chalcone-aroylacrylic acid chimeras: design, antiproliferative activity and inhibition of tubulin polymerization.",1
14440,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1016/j.bmc.2023.117459,"Design, synthesis and anticancer activity of N-aryl indolylsulfoximines: Identification of potent and selective anticancer agents.",1
14440,10.1016/j.bmcl.2009.05.054,"Design, synthesis and identification of novel colchicine-derived immunosuppressant.",10.1016/j.bmcl.2021.128382,Synthesis of thiocolchicine amine derivatives and evaluation of their antiproliferative activity.,1
14440,10.1038/1557,Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.ejmech.2017.03.051,"Anthranilamide-based 2-phenylcyclopropane-1-carboxamides, 1,1'-biphenyl-4-carboxamides and 1,1'-biphenyl-2-carboxamides: Synthesis biological evaluation and mechanism of action.",1
14440,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1279,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2018.12.032,Investigation of stereoisomeric bisarylethenesulfonic acid esters for discovering potent and selective PTP1B inhibitors.,1
1279,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1279,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmcl.2019.126750,"Green chemistry appended synthesis, metabolic stability and pharmacokinetic assessment of medicinally important chromene dihydropyrimidinones.",1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.08.017,"Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.07.058,Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.,1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.8b00619,Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.,1
1279,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
1279,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
14440,10.1021/ml200195s,Identification of Simple Compounds with Microtubule-Binding Activity That Inhibit Cancer Cell Growth with High Potency.,10.1016/j.bmc.2013.03.049,The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.,1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.ejmech.2018.10.066,"1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.",1
14440,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/jm501180v,Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.,1
14440,10.1016/j.bmcl.2012.04.007,Bio-inspired synthesis and biological evaluation of a colchicine-related compound library.,10.1021/acsmedchemlett.5b00418,New Colchicine-Derived Triazoles and Their Influence on Cytotoxicity and Microtubule Morphology.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.bmc.2022.116976,"Synthesis and screening of novel 4-N-heterocyclic-2-aryl-6,7,8-trimethoxyquinazolines as antiproliferative and tubulin polymerization inhibitors.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.bmc.2015.04.055,Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.,1
14440,10.1021/acs.jmedchem.3c00465,Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.,10.1016/j.ejmech.2024.116177,Design and synthesis of novel 3-amino-5-phenylpyrazole derivatives as tubulin polymerization inhibitors targeting the colchicine-binding site.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/ml5004684,Synthesis and Structure-Activity Relationship Study of 1-Phenyl-1-(quinazolin-4-yl)ethanols as Anticancer Agents.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2023.115870,The discovery of water-soluble indazole derivatives as potent microtubule polymerization inhibitors.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.7b01858,Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.,1
14440,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2024.116649,"Discovery and mechanistic insights into thieno[3,2-d]pyrimidine and heterocyclic fused pyrimidines inhibitors targeting tubulin for cancer therapy.",1
14440,10.1016/j.ejmech.2011.03.067,"Synthesis, antiproliferative activity, and mechanism of action of a series of 2-{[(2E)-3-phenylprop-2-enoyl]amino}benzamides.",10.1016/j.bmc.2014.05.029,"Design, synthesis and biological evaluation of (E)-3-(3,4-dihydroxyphenyl)acrylylpiperazine derivatives as a new class of tubulin polymerization inhibitors.",1
14440,10.1016/j.bmc.2020.115674,"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.",10.1016/j.ejmech.2021.113511,"Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.",1
14440,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1039/d3md00600j,"2,3-Dihydroquinazolin-4(1&lt;i&gt;H&lt;/i&gt;)-ones and quinazolin-4(3&lt;i&gt;H&lt;/i&gt;)-ones as broad-spectrum cytotoxic agents and their impact on tubulin polymerisation.",1
14440,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1021/jm1000979,"N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2019.03.045,Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop.,1
14440,10.1016/j.bmcl.2009.05.054,"Design, synthesis and identification of novel colchicine-derived immunosuppressant.",10.1016/j.bmc.2021.116014,"Synthesis, anticancer activity and molecular docking studies of N-deacetylthiocolchicine and 4-iodo-N-deacetylthiocolchicine derivatives.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/acs.jmedchem.3c01775,"PM534, an Optimized Target-Protein Interaction Strategy through the Colchicine Site of Tubulin.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2014.09.093,Synthesis and antiproliferative activity of 6-phenylaminopurines.,1
14440,10.1016/j.ejmech.2018.07.060,"Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.",10.1016/j.ejmech.2021.114069,"Design, synthesis and evaluation of novel bis-substituted aromatic amide dithiocarbamate derivatives as colchicine site tubulin polymerization inhibitors with potent anticancer activities.",1
1279,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1279,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmc.2012.11.041,"Design, synthesis, and structure-activity relationships of a series of 4-benzyl-5-isopropyl-1H-pyrazol-3-yl β-D-glycopyranosides substituted with novel hydrophilic groups as highly potent inhibitors of sodium glucose co-transporter 1 (SGLT1).",1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.07.014,"4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1279,10.1021/acs.jmedchem.8b02032,Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.,10.1021/acs.jmedchem.3c00782,"Potent, Selective, and Membrane Permeable 2-Amino-4-Substituted Pyridine-Based Neuronal Nitric Oxide Synthase Inhibitors.",1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.05.083,"Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.",1
1279,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
1279,10.1016/j.bmcl.2008.02.072,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.",10.1016/j.bmcl.2008.07.014,"4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.",1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
1279,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2009.11.039,Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.,1
1279,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1023/a:1025032511040,pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.,1
14440,10.1021/acs.jmedchem.2c01208,Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.,10.1016/j.ejmech.2023.116118,"Design, synthesis and biological evaluation of 1,2,3-triazole benzothiazole derivatives as tubulin polymerization inhibitors with potent anti-esophageal cancer activities.",1
14785,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acsmedchemlett.9b00599,Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors.,1
14785,10.1016/j.bmc.2014.10.038,Identification of novel 4-anilinoquinazoline derivatives as potent  EGFR inhibitors both under normoxia and hypoxia.,10.1016/j.bmc.2016.01.003,"Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.",1
14785,10.1016/j.bmc.2014.10.038,Identification of novel 4-anilinoquinazoline derivatives as potent  EGFR inhibitors both under normoxia and hypoxia.,10.1016/j.bmcl.2018.10.016,"Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.",1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1016/j.ejmech.2021.113158,"Discovery of 3-phenyl- and 3-N-piperidinyl-isothiazolo[4,3-b]pyridines as highly potent inhibitors of cyclin G-associated kinase.",1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1021/acs.jmedchem.0c01467,Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.,1
14785,10.1016/j.ejmech.2018.06.024,Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.,10.1016/j.ejmech.2021.113300,"Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors.",1
14785,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
14440,10.1016/j.bmcl.2009.05.054,"Design, synthesis and identification of novel colchicine-derived immunosuppressant.",10.1016/j.bmcl.2012.08.068,Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokinetic properties.,1
14440,10.1016/j.ejmech.2018.07.060,"Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.",10.1016/j.bmcl.2021.128095,Discovery of indoline derivatives as anticancer agents via inhibition of tubulin polymerization.,1
14440,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2018.12.030,A class of novel tubulin polymerization inhibitors exert effective anti-tumor activity via mitotic catastrophe.,1
14440,10.1021/jm00061a005,"Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.",10.1016/j.bmc.2017.01.027,"Tubulin-binding dibenz[c,e]oxepines: Part 2. Structural variation and biological evaluation as tumour vasculature disrupting agents.",1
14440,10.1021/acs.jmedchem.2c01208,Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.,10.1016/j.ejmech.2024.116177,Design and synthesis of novel 3-amino-5-phenylpyrazole derivatives as tubulin polymerization inhibitors targeting the colchicine-binding site.,1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1016/j.ejmech.2017.02.049,β-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells.,1
14440,10.1016/j.ejmech.2018.07.060,"Bioactive heterocycles containing a 3,4,5-trimethoxyphenyl fragment exerting potent antiproliferative activity through microtubule destabilization.",10.1016/j.ejmech.2019.01.033,"Molecular diversity of trimethoxyphenyl-1,2,3-triazole hybrids as novel colchicine site tubulin polymerization inhibitors.",1
14440,10.1021/jm401939g,Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.,10.1021/jm500849z,Synthesis and biological evaluation of novel millepachine derivatives as a new class of tubulin polymerization inhibitors.,1
14440,10.1016/j.bmcl.2009.05.054,"Design, synthesis and identification of novel colchicine-derived immunosuppressant.",10.1016/j.ejmech.2019.111788,Recent developments on (-)-colchicine derivatives: Synthesis and structure-activity relationship.,1
14785,10.1021/acs.jmedchem.5b01412,Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study.,10.1021/acs.jmedchem.6b00995,"Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.",1
1279,10.1016/j.bmcl.2008.04.005,"Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.",10.1016/j.bmcl.2008.04.066,"Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.",1
1278,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1278,10.1021/jm800151n,Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.,10.1021/jm801351u,"L-Type calcium channel blockers: from diltiazem to 1,2,4-oxadiazol-5-ones via thiazinooxadiazol-3-one derivatives.",1
1278,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1278,10.1021/jm800151n,Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.,10.1021/jm9008696,"Stereoselective behavior of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a new L-type calcium channel blocker.",1
1278,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1278,10.1021/jm801195k,Inhibition of MDR1 activity in vitro by a novel class of diltiazem analogues: toward new candidates.,10.1016/j.ejmech.2014.12.044,Synthesis and L-type calcium channel blocking activity of new chiral oxadiazolothiazinones.,1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1016/j.ejmech.2019.05.010,Recent update on anti-dengue drug discovery.,1
14785,10.1016/j.ejmech.2018.06.024,Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.,10.1016/j.ejmech.2019.111786,"6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: Design, synthesis and structure-activity relationship studies.",1
14785,10.1016/j.bmc.2020.115674,"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.",10.1016/j.ejmech.2021.113511,"Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.",1
14785,10.1021/acs.jmedchem.6b00680,"Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.",10.1021/acs.jmedchem.0c01170,"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.",1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1016/j.bmcl.2020.127284,Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines.,1
14785,10.1016/j.ejmech.2018.06.024,Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.,10.1016/j.ejmech.2019.04.018,Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR - MAPK pathway.,1
14785,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1016/j.ejmech.2019.03.004,Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.,1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1016/j.bmc.2019.115188,"Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase.",1
14805,10.1016/j.ejmech.2017.10.007,Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
14805,10.1016/j.bmcl.2015.10.003,"Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.",10.1016/j.ejmech.2020.112640,Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).,1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1021/acs.jmedchem.1c01714,Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.,1
14805,10.1016/j.bmcl.2015.10.003,"Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.",10.1016/j.ejmech.2016.12.055,"Design, synthesis and biological evaluation of quinazoline-phosphoramidate mustard conjugates as anticancer drugs.",1
14805,10.1016/j.bmcl.2015.10.003,"Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.",10.1016/j.bmc.2016.05.063,"Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.",1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2015.03.004,Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors.,1
14805,10.1016/j.bmcl.2015.10.003,"Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.",10.1021/acs.jmedchem.0c01647,"HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.",1
14805,10.1021/acsmedchemlett.7b00011,Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
14805,10.1021/acsmedchemlett.7b00011,Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.,10.1021/acsmedchemlett.9b00453,Scaffold and Parasite Hopping: Discovery of New Protozoal Proliferation Inhibitors.,1
14805,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1039/c4md00441h,"EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.",1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2011.11.056,Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.,1
14805,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
14785,10.1016/j.ejmech.2019.111648,"Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.",10.1016/j.bmc.2020.115657,"Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.",1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1021/acs.jmedchem.1c00302,Kinase Inhibitors as Underexplored Antiviral Agents.,1
14785,10.1021/acs.jmedchem.8b00613,"Optimization of Isothiazolo[4,3- b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity.",10.1016/j.bmcl.2021.128407,Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV).,1
15086,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm061431g,Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.,1
15086,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2012.10.002,"Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.",1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2007.02.004,"Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.",1
15086,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm000155h,Medicinal chemistry of neuronal voltage-gated sodium channel blockers.,1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.bmcl.2015.01.004,"Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.",1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm040048d,"Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.",1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2011.07.043,"Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.",1
14882,10.1021/jm049073+,"Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.",10.1021/jm900366z,"Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.",1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2016.10.006,"Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy.",1
14805,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1016/j.ejmech.2017.10.007,Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.,1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.bmc.2011.11.023,"Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.",1
14805,10.1021/jm100665z,"Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
14805,10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",10.1016/j.bmcl.2017.02.027,Synthesis and in vitro biological evaluation of novel quinazoline derivatives.,1
14805,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1021/acsmedchemlett.7b00011,Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites.,1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1016/j.ejmech.2017.03.084,"Oxadiazole-substituted naphtho[2,3-b]thiophene-4,9-diones as potent inhibitors of keratinocyte hyperproliferation. Structure-activity relationships of the tricyclic quinone skeleton and the oxadiazole substituent.",1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1021/acs.jmedchem.3c02031,"Development of Potent MALT1 Inhibitors Featuring a Novel ""2-Thioxo-2,3-dihydrothiazolo[4,5-<i>d</i>]pyrimidin-7(6<i>H</i>)-one"" Scaffold for the Treatment of B Cell Lymphoma.",1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1016/j.ejmech.2020.112962,"A comprehensive review on β-lapachone: Mechanisms, structural modifications, and therapeutic potentials.",1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1016/j.bmc.2023.117331,Synthesis and structure-activity relationship studies of naphthoquinones as STAT3 inhibitors.,1
15472,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1021/acs.jmedchem.4c00238,Cyanomethylquinolones as a New Class of Potential Multitargeting Broad-Spectrum Antibacterial Agents.,1
15472,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm980448z,Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.,1
15423,10.1021/jm00088a011,Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
15423,10.1016/S0960-894X(97)00054-1,"Synthesis and structural optimization of 7-(3,3-disubstituted-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids as antibacterial agents",10.1016/s0960-894x(98)00390-4,Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.,1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm050283b,"Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design.",1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm030498q,3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.,1
15086,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2010.02.063,"Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.",1
15086,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.bmcl.2010.05.059,"Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.",1
15086,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
15086,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
15086,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
15890,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.08.057,"Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.",1
15890,10.1016/j.ejmech.2013.04.022,"Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.",10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,1
15890,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.ejmech.2014.09.045,Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2017.09.047,"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.",1
1223,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
1223,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1223,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1223,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
1223,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
1223,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1223,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2009.11.039,Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.,1
1223,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
1223,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.bmc.2018.08.025,Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.,1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1016/j.ejmech.2019.06.056,Synthesis of quinones with highlighted biological applications: A critical update on the strategies towards bioactive compounds with emphasis on lapachones.,1
15738,10.1021/acs.jmedchem.5b01415,Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.,10.1016/j.ejmech.2020.112594,Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,1
15890,10.1016/j.ejmech.2017.01.029,"Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.",10.1016/j.bmcl.2018.08.040,"Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.",1
15890,10.1016/j.ejmech.2018.02.020,"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.",10.1016/j.ejmech.2018.06.063,Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.,1
15890,10.1016/j.ejmech.2015.01.065,"Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.",10.1016/j.ejmech.2017.03.063,An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.,1
15890,10.1016/j.ejmech.2013.04.022,"Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.",10.1016/j.ejmech.2014.09.027,In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm501568b,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.ejmech.2015.08.042,3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acsmedchemlett.9b00218,Discovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruzi.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2016.05.050,"New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2017.09.047,"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.",1
15890,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm201215n,"Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.",1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2017.02.026,Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.,1
15890,10.1016/j.ejmech.2016.02.028,In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51.,10.1016/j.ejmech.2017.05.011,Rhodium-catalyzed C-H bond activation for the synthesis of quinonoid compounds: Significant Anti-Trypanosoma cruzi activities and electrochemical studies of functionalized quinones.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2014.08.012,"2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation.",1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2018.08.079,Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.,1
15890,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.bmcl.2012.11.072,"Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.",1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2012.03.039,"On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions.",1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",1
15890,10.1016/j.ejmech.2017.08.055,Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.,10.1016/j.ejmech.2019.05.001,Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2016.01.010,Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2019.07.018,"2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.ejmech.2016.04.010,Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.,1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1021/acs.jnatprod.5b00070,Anti-parasitic Guanidine and Pyrimidine Alkaloids from the Marine Sponge Monanchora arbuscula.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.ejmech.2016.08.002,Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.,1
15890,10.1016/j.ejmech.2020.112849,Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.,10.1016/j.ejmech.2023.115451,"Design, synthesis and antitrypanosomatid activity of 2-nitroimidazole-3,5-disubstituted isoxazole compounds based on benznidazole.",1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.bmc.2015.10.048,"Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.",1
15890,10.1016/j.ejmech.2017.01.029,"Design and synthesis of a new series of 3,5-disubstituted isoxazoles active against Trypanosoma cruzi and Leishmania amazonensis.",10.1016/j.bmc.2018.08.025,Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.,1
15890,10.1016/j.ejmech.2018.02.020,"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.",10.1016/j.ejmech.2019.111610,"Synthesis, structure-activity relationship and trypanocidal activity of pyrazole-imidazoline and new pyrazole-tetrahydropyrimidine hybrids as promising chemotherapeutic agents for Chagas disease.",1
15890,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.ejmech.2017.08.055,Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2011.12.028,"Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles.",1
15890,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1016/j.bmcl.2023.129258,"Jozibrevine D from Ancistrocladus ileboensis, the fifth alkaloid in a series of six possible atropo-diastereomeric naphthylisoquinoline dimers, showing antiparasitic and antileukemic activities.",1
15890,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm5015742,Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.,1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2016.09.045,Novel 2-arylazoimidazole derivatives as inhibitors of Trypanosoma cruzi proliferation: Synthesis and evaluation of their biological activity.,1
15890,10.1016/j.ejmech.2020.112849,Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.,10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
15890,10.1016/j.ejmech.2018.02.020,"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.",10.1016/j.bmcl.2018.04.064,Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.,1
15890,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.ejmech.2014.11.018,"Synthesis and biological evaluation of novel 2,3-disubstituted quinoxaline derivatives as antileishmanial and antitrypanosomal agents.",1
15890,10.1128/aac.01617-09,"Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.",10.1021/acs.jmedchem.9b01275,"Discovery of Pyrrolo[2,3-<i>b</i>]pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti-<i>Trypanosoma cruzi</i> Agents.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.ejmech.2014.09.045,Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2014.08.012,"2-Pyridyl thiazoles as novel anti-Trypanosoma cruzi agents: structural design, synthesis and pharmacological evaluation.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,1
15890,10.1021/acs.jmedchem.3c00582,Structure-Guided Design and Synthesis of a Pyridazinone Series of <i>Trypanosoma cruzi</i> Proteasome Inhibitors.,10.1016/j.ejmech.2024.116641,DNA G-quadruplexes in the genome of Trypanosoma cruzi as potential therapeutic targets for Chagas disease: Dithienylethene ligands as effective antiparasitic agents.,1
15890,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
15890,10.1016/j.ejmech.2015.01.065,"Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.",10.1016/j.ejmech.2019.111778,Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.,1
15890,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2013.08.022,"Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2017.02.026,Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2016.01.010,Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.,1
15890,10.1021/acs.jmedchem.1c01151,Structure-Based Optimization of Quinazolines as Cruzain and <i>Tbr</i>CATL Inhibitors.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2023.115508,"1,3-Thiazole derivatives as privileged structures for anti-Trypanosoma cruzi activity: Rational design, synthesis, in silico and in vitro studies.",1
15890,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1016/j.ejmech.2017.02.026,Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.,1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2016.01.010,Phthalimido-thiazoles as building blocks and their effects on the growth and morphology of Trypanosoma cruzi.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm401610c,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,1
15890,10.1016/j.bmcl.2018.04.064,Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.,10.1016/j.bmcl.2018.08.040,"Synthesis and biological evaluation of isoxazolyl-sulfonamides: A non-cytotoxic scaffold active against Trypanosoma cruzi, Leishmania amazonensis and Herpes Simplex Virus.",1
15890,10.1021/acs.jmedchem.1c01151,Structure-Based Optimization of Quinazolines as Cruzain and <i>Tbr</i>CATL Inhibitors.,10.1016/j.ejmech.2023.115622,"Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1021/jm4017015,"Synthesis and biological evaluation of N,N'-squaramides with high in vivo efficacy and low toxicity: toward a low-cost drug against Chagas disease.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.bmc.2013.01.027,α-Selective glycosylation affords mucin-related GalNAc amino acids and diketopiperazines active on Trypanosoma cruzi.,1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2019.07.018,"2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.",1
15890,10.1016/j.ejmech.2010.09.034,Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activity.,10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
15890,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.bmcl.2015.12.070,Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2016.05.050,"New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.bmc.2012.06.027,"New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.",1
15890,10.1016/j.ejmech.2013.04.022,"Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.",10.1016/j.ejmech.2022.114876,From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds.,1
15890,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2014.08.005,From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.bmc.2016.07.013,"Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1021/acs.jmedchem.5b00748,"2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.",1
15890,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.ejmech.2017.04.075,"Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.",1
15890,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1039/C1MD00223F,"Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain",1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2017.09.047,"Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.bmc.2015.10.048,"Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.",1
15890,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2017.02.026,Desing and synthesis of potent anti-Trypanosoma cruzi agents new thiazoles derivatives which induce apoptotic parasite death.,1
15890,10.1016/j.ejmech.2013.04.022,"Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.",10.1016/j.ejmech.2018.01.043,Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.,1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.bmc.2015.10.048,"Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi.",1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2019.07.018,"2-(phenylthio)ethylidene derivatives as anti-Trypanosoma cruzi compounds: Structural design, synthesis and antiparasitic activity.",1
15890,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,10.1016/j.ejmech.2016.05.050,"New 1,3-thiazole derivatives and their biological and ultrastructural effects on Trypanosoma cruzi.",1
15890,10.1016/j.ejmech.2018.02.020,"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.",10.1021/acs.jmedchem.8b01464,"Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.",1
15890,10.1016/j.bmc.2010.09.056,Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents.,10.1016/j.ejmech.2015.01.065,"Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2017.11.075,Novel triazine dimers with potent antitrypanosomal activity.,1
15890,10.1021/acs.jmedchem.1c01151,Structure-Based Optimization of Quinazolines as Cruzain and <i>Tbr</i>CATL Inhibitors.,10.1021/acs.jmedchem.1c02063,Intramolecular Interactions Enhance the Potency of Gallinamide A Analogues against <i>Trypanosoma cruzi</i>.,1
15890,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm300508n,"Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.",1
15890,10.1016/j.ejmech.2016.02.028,In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on Trypanosoma cruzi CYP51.,10.1016/j.ejmech.2020.112146,Synthesis and in vitro evaluation of new 5-substituted 6-nitroimidazooxazoles as antikinetoplastid agents.,1
15890,10.1016/j.ejmech.2013.04.022,"Design, synthesis and biological evaluation of new aryl thiosemicarbazone as antichagasic candidates.",10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,1
15890,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.bmc.2015.08.014,Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.,1
15890,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2023.115508,"1,3-Thiazole derivatives as privileged structures for anti-Trypanosoma cruzi activity: Rational design, synthesis, in silico and in vitro studies.",1
15890,10.1016/j.ejmech.2020.112849,Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.,10.1021/acs.jmedchem.3c01745,"Design and Synthesis of Novel 3-Nitro-1<i>H</i>-1,2,4-triazole-1,2,3-triazole-1,4-disubstituted Analogs as Promising Antitrypanosomatid Agents: Evaluation of In Vitro Activity against Chagas Disease and Leishmaniasis.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1021/acs.jmedchem.8b01464,"Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2018.06.063,Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.,1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1021/jm400508e,"Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2014.07.038,"Synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives against Leishmania donovani and Trypanosoma cruzi.",1
15890,10.1021/acs.jnatprod.9b00755,"Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana Ancistrocladus ealaensis, Targeting Pancreatic Cancer Cells.",10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
15890,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1039/C1MD00223F,"Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain",1
1219,10.1016/j.bmcl.2008.05.034,"1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance.",10.1016/j.bmcl.2012.03.005,"Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents.",1
1219,10.1016/j.bmc.2012.11.019,"New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).",10.1016/j.ejmech.2017.01.019,N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.ejmech.2016.05.015,Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm200924c,Halogenated 2'-benzoylpyridine thiosemicarbazone (XBpT) chelators with potent and selective anti-neoplastic activity: relationship to intracellular redox activity.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.bmc.2011.11.033,Investigation of substituted 6-aminohexanoates as skin penetration enhancers.,1
15938,10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,10.1021/jm9016703,Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.,1
15938,10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,10.1016/j.bmcl.2012.07.030,Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.bmc.2010.10.025,"Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.",1
15938,10.1007/s00044-012-0229-1,"Synthesis, physico-chemical properties, and antimicrobial evaluation of a new series of iron(III) hexadentate chelators",10.1021/acs.jmedchem.0c01480,Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm801585u,"2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.",1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm300768u,Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.bmcl.2012.12.044,Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm301691s,Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.,1
15938,10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,10.1016/j.ejmech.2017.08.021,A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/ml400422a,Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.,1
15938,10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,10.1016/j.bmcl.2012.12.044,Synthesis and biological evaluation of substituted 2-benzoylpyridine thiosemicarbazones: novel structure-activity relationships underpinning their anti-proliferative and chelation efficacy.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm9016703,Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm9014394,A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm900552r,Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.,1
1223,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
1223,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
1219,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1016/j.ejmech.2024.116256,Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani.,1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1021/acs.jmedchem.2c01175,New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.,1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.bmc.2017.11.016,Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).,1
1219,10.1016/j.ejmech.2011.02.026,A series of structurally simple chloroquine chemosensitizing dibemethin derivatives that inhibit chloroquine transport by PfCRT.,10.1021/ml5000228,Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT.,1
1219,10.1016/j.bmc.2015.07.027,Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors.,10.1016/j.bmc.2017.08.003,A novel delocalized lipophilic cation-chlorambucil conjugate inhibits P-glycoprotein in HepG2/ADM cells.,1
1219,10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
1219,10.1021/acs.jmedchem.8b01957,"Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.",10.1021/acsmedchemlett.9b00471,Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.,1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1016/j.bmc.2020.115798,Nitrogen-containing naringenin derivatives for reversing multidrug resistance in cancer.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",1
1219,10.1021/jm011046l,Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.,10.1016/j.ejmech.2011.02.026,A series of structurally simple chloroquine chemosensitizing dibemethin derivatives that inhibit chloroquine transport by PfCRT.,1
16088,10.1021/jm4010708,"6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.",10.1016/j.bmc.2018.07.043,Synthesis and pharmacological characterization of functionalized 6-piperazin-1-yl-purines as cannabinoid receptor 1 (CB1) inverse agonists.,1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1021/jm800843r,"Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.",1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1016/j.ejmech.2008.01.043,"Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.",1
16088,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.ejmech.2023.115633,"Synthesis, biological evaluation and docking studies of silicon incorporated diarylpyrroles as MmpL3 inhibitors: An effective strategy towards development of potent anti-tubercular agents.",1
16088,10.1021/ml3000325,Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.,10.1016/j.bmcl.2013.06.066,Peripherally restricted CB1 receptor blockers.,1
16088,10.1021/jm800416m,"Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.",10.1016/j.bmcl.2009.08.092,Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.,1
16088,10.1021/jm301212u,"Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.",10.1021/jm3017464,"Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.",1
16088,10.1021/jm301212u,"Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.",10.1016/j.ejmech.2013.12.018,"Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.",1
16088,10.1021/jm200476p,Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.,10.1021/jm3003334,"Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists.",1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1016/j.bmcl.2009.05.114,Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.,1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1016/j.ejmech.2013.12.018,"Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.",1
15958,10.1021/jm200018k,"Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.",10.1039/d2md00081d,Inhibition of Na<sub>V</sub>1.7: the possibility of ideal analgesics.,1
15958,10.1021/jm200018k,"Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.",10.1016/j.bmcl.2011.11.111,Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.,1
15958,10.1021/jm201197z,"Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.",10.1016/j.ejmech.2013.05.008,Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.bmcl.2012.07.030,Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy.,1
15938,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1016/j.ejmech.2017.08.021,A novel class of thiosemicarbazones show multi-functional activity for the treatment of Alzheimer's disease.,1
16088,10.1016/j.bmcl.2007.03.011,Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.,10.1016/j.ejmech.2008.01.043,"Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.",1
16088,10.1021/jm3017464,"Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.",10.1016/j.ejmech.2013.12.018,"Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists.",1
16088,10.1021/jm200476p,Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.,10.1021/acs.jmedchem.5b00227,"Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.",1
16088,10.1021/jm301212u,"Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.",10.1021/ml3004236,Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB2 Receptor Inverse Agonists.,1
16088,10.1021/jm200476p,Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.,10.1016/j.ejmech.2012.09.035,Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.,1
16088,10.1021/ml3000325,Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.,10.1016/j.ejmech.2012.09.035,Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.,1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1016/j.bmcl.2009.11.125,Novel thioamide derivatives as neutral CB1 receptor antagonists.,1
16088,10.1021/jm200476p,Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.,10.1021/acs.jmedchem.5b01559,Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility.,1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1016/j.bmcl.2008.04.022,Aminopyrazine CB1 receptor inverse agonists.,1
16088,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
16088,10.1021/jm800066v,"Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.",10.1016/j.bmcl.2009.03.046,Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.,1
16088,10.1021/jm3017464,"Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.",10.1021/acs.jmedchem.5b00227,"Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.",1
16088,10.1021/jm200476p,Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.,10.1021/jm3008213,7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.,1
16088,10.1021/jm800416m,"Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.",10.1021/jm2000536,"N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.",1
16088,10.1016/j.bmcl.2007.03.011,Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.,10.1016/j.bmcl.2010.03.068,"Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.",1
16088,10.1021/jm800329z,"Discovery and labeling of high-affinity 3,4-diarylpyrazolines as candidate radioligands for in vivo imaging of cannabinoid subtype-1 (CB1) receptors.",10.1016/j.bmcl.2009.08.092,Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors.,1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0322-5,"Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of -aryloxyquinoline and their antimicrobial and antituberculosis activities",1
16303,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
16303,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",1
16303,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.06.071,Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.,1
16303,10.1007/s00044-011-9752-8,Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives,10.1007/s00044-011-9833-8,"Synthesis, characterization, and antimicrobial evaluation of novel naphthalene-based 1,2,4-triazoles",1
16303,10.1007/s00044-012-9990-4,"Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,1
16303,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.05.054,"1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.",1
16303,10.1007/s00044-011-9752-8,Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",1
16303,10.1007/s00044-013-0489-4,"Synthesis of a new series of 2-(2-oxo-2H-chromen-3-yl)-5H-chromeno[4,3-b]pyridin-5-ones by two facile methods and evaluation of their antimicrobial activity",10.1016/j.ejmech.2020.113034,"A review: Biologically active 3,4-heterocycle-fused coumarins.",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0301-x,Microwave-induced CAN promoted atom-economic synthesis of 1H-benzo[b]xanthene and 4H-benzo[g]chromene derivatives of N-allyl quinolone and their antimicrobial activity,1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-011-9861-4,Microwave-assisted synthesis of 3-indolyl substituted 4H-chromenes catalyzed by DMAP and their antimicrobial activity,1
16088,10.1021/ml3000325,Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.,10.1021/jm4010708,"6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.",1
16088,10.1016/j.bmc.2007.03.075,"Scaffold hopping, synthesis and structure-activity relationships of 5,6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists.",10.1021/jm900179y,Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.,1
16088,10.1021/acs.jmedchem.1c01836,"Synthesis, Biological Evaluation, and Molecular Modeling Studies of 3,4-Diarylpyrazoline Series of Compounds as Potent, Nonbrain Penetrant Antagonists of Cannabinoid-1 (CB<sub>1</sub>R) Receptor with Reduced Lipophilicity.",10.1021/acs.jmedchem.3c00599,"Cannabinoformins: Designing Biguanide-Embedded, Orally Available, Peripherally Selective Cannabinoid-1 Receptor Antagonists for Metabolic Syndrome Disorders.",1
16088,10.1016/j.bmcl.2008.06.045,"Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist.",10.1016/j.bmcl.2009.03.046,Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.,1
16088,10.1021/jm800066v,"Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.",10.1021/jm900471u,"Discovery of 2-[5-(4-chloro-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazol-3-yl]-1,5,5-trimethyl-1,5-dihydro-imidazol-4-thione (BPR-890) via an active metabolite. A novel, potent and selective cannabinoid-1 receptor inverse agonist with high antiobesity efficacy in DIO mice.",1
16303,10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",10.1007/s00044-013-0512-9,Synthesis and antimicrobial screening of 5-(benzylidene)-3-phenylthiazolidin-4-one derivatives incorporating thiazole ring,1
16303,10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,1
16303,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
16303,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
16303,10.1007/s00044-012-9990-4,"Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus",10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",1
16303,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
16303,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.07.057,"Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.",1
16303,10.1007/s00044-012-9990-4,"Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus",10.1016/j.ejmech.2016.08.039,Hybrid molecules: The privileged scaffolds for various pharmaceuticals.,1
16303,10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,10.1007/s00044-013-0512-9,Synthesis and antimicrobial screening of 5-(benzylidene)-3-phenylthiazolidin-4-one derivatives incorporating thiazole ring,1
16303,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.bmcl.2014.05.002,"Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0292-7,"Synthesis and in vitro antimicrobial evaluation of novel 2-amino-6-(phenylthio)-4-(2-(phenylthio)quinolin-3-yl)pyridine-3,5-dicarbonitriles",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0381-7,Microwave-assisted synthesis of novel 4H-chromene derivatives bearing 2-aryloxyquinoline and their antimicrobial activity assessment,1
16303,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0085-z,"Microwave-assisted CAN-catalyzed solvent-free synthesis of N-allyl quinolone-based pyrano[4,3-b]chromene and benzopyrano[3,2-c]chromene derivatives and their antimicrobial activity",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
16506,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
16506,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
16498,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
16498,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
16485,10.1016/j.ejmech.2020.112743,Rational design of new multitarget histamine H receptor ligands as potential candidates for treatment of Alzheimer's disease.,10.1021/acs.jmedchem.3c00430,Dual Piperidine-Based Histamine H<sub>3</sub> and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain.,1
16485,10.1021/np010464q,Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.,10.1016/j.ejmech.2011.05.023,"Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.",1
16485,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.1c00261,The Medicinal Chemistry of Caffeine.,1
16485,10.1021/jm201439b,Binding evaluation of fragment-based scaffolds for probing allosteric enzymes.,10.1039/C2MD20035J,INPHARMA-based identification of ligand binding site in fragment-based drug design,1
16485,10.1016/j.bmc.2010.07.054,Identification of small molecule compounds with higher binding affinity to guanine deaminase (cypin) than guanine.,10.1021/acs.jmedchem.1c00261,The Medicinal Chemistry of Caffeine.,1
16485,10.1021/np010464q,Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.,10.1016/j.bmc.2015.09.012,"1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.",1
16450,10.1016/j.ejmech.2008.09.020,Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.,10.1016/j.bmc.2014.03.043,"Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.",1
16450,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.ejmech.2009.02.026,Synthesis and pharmacological evaluation of N-phenyl-acetamide sulfonamides designed as novel non-hepatotoxic analgesic candidates.,1
16450,10.1021/jm201320w,Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.,10.1039/C5MD00209E,Fragments in bromodomain drug discovery,1
16450,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
16308,10.1016/j.bmc.2014.03.043,"Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.",10.1016/j.bmc.2016.10.036,"Synthesis, COX-1/2 inhibition activities and molecular docking study of isothiazolopyridine derivatives.",1
16303,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2012.05.004,"New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.",1
16656,10.1021/jm100022r,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,10.1016/j.bmcl.2010.04.013,Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A.,1
16592,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
16592,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
16592,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
16591,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
16591,10.1016/s0014-5793(98)00585-7,Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.,10.1021/acs.jmedchem.2c01079,"Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.",1
16591,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,1
16591,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
16591,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
16591,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
16581,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1016/j.bmcl.2010.08.145,A practical deuterium-free NMR method for the rapid determination of 1-octanol/water partition coefficients of pharmaceutical agents.,1
16581,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
16581,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,10.1021/acs.jmedchem.4c00131,Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.,1
16510,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
16510,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
16506,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
17169,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
17124,10.1021/jm9805081,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.",10.1016/j.bmc.2013.02.033,Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.,1
16973,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
16740,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1021/acs.jmedchem.1c01694,Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.,1
16740,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1016/j.bmc.2019.01.018,Inhibition of a viral prolyl hydroxylase.,1
16716,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/d3md00204g,"Design, synthesis and evaluation of halogenated phenazine antibacterial prodrugs targeting nitroreductase enzymes for activation.",1
16688,10.1016/j.bmcl.2004.07.085,Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.,10.1021/jm050483n,Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.,1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1021/jm800896z,Nicotinic acid receptor agonists.,1
16656,10.1021/jm100022r,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,10.1016/j.bmcl.2020.127105,Discovery of novel pyrrole derivatives as potent agonists for the niacin receptor GPR109A.,1
16656,10.1021/jm100022r,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,10.1016/j.bmcl.2010.04.001,Anthranilic acid replacements in a niacin receptor agonist.,1
16656,10.1021/jm100022r,Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate.,10.1016/j.bmc.2015.02.018,Affinity and kinetics study of anthranilic acids as HCA2 receptor agonists.,1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1016/j.bmcl.2007.07.101,Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.,1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1016/j.bmcl.2020.127105,Discovery of novel pyrrole derivatives as potent agonists for the niacin receptor GPR109A.,1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1016/j.bmcl.2010.03.062,Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).,1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1021/jm800258p,"3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.",1
16656,10.1016/j.bmcl.2007.06.028,Agonist lead identification for the high affinity niacin receptor GPR109a.,10.1021/jm900151e,Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats.,1
17347,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
17347,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b00676,"Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.",1
17347,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.5b00676,"Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.",1
17347,10.1016/j.bmcl.2004.10.029,Optimization of pyrrolidinone based HIV protease inhibitors.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
17347,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
17347,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.6b00639,"Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.",1
17224,10.1016/j.bmcl.2010.12.109,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,10.1016/j.bmc.2011.05.022,"Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.",1
17224,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1016/j.ejmech.2023.115772,Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.,1
17169,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
17169,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.ejmech.2018.09.046,"Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.",1
17169,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
17169,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1128/aac.01766-09,"Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.",1
17169,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
17169,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/jm200649p,"Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.",1
17169,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
17169,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.bmcl.2006.01.011,Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.,1
18694,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmc.2008.04.007,"Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.",1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1021/ml500299q,Synthesis of Deuterated Benzopyran Derivatives as Selective COX-2 Inhibitors with Improved Pharmacokinetic Properties.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2013.02.033,Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2012.10.131,Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2011.08.053,Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2019.03.052,"New pyrazole derivatives: Synthesis, anti-inflammatory activity, cycloxygenase inhibition assay and evaluation of mPGES.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.07.023,"Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm900702b,"Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.04.045,"Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2014.02.032,Structure-activity relationship of celecoxib and rofecoxib for the membrane permeabilizing activity.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.12.023,Structure-based parallel medicinal chemistry approach to improve metabolic stability of benzopyran COX-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",1
18594,10.1021/jm051199z,"Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates.",10.1016/j.bmcl.2008.01.096,"An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs.",1
17347,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1128/aac.01766-09,"Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.",1
17347,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.ejmech.2018.09.046,"Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.",1
17347,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/jm200649p,"Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.",1
18694,10.1016/j.bmc.2014.12.041,"Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors.",10.1016/j.bmc.2018.01.007,"Synthesis, biological evaluation and docking study of a new series of di-substituted benzoxazole derivatives as selective COX-2 inhibitors and anti-inflammatory agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2009.04.125,"Design and synthesis of 3-alkyl-2-aryl-1,3-thiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2015.01.041,"Environmentally benign synthesis, molecular properties prediction and anti-inflammatory activity of novel isoxazolo[5,4-d]isoxazol-3-yl-aryl-methanones via vinylogous Henry nitroaldol adducts as synthons.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2016.09.023,"Synthesis of phenylpiperazine derivatives of 1,4-benzodioxan as selective COX-2 inhibitors and anti-inflammatory agents.",1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.ejmech.2023.115443,"Synthesis of new multitarget-directed ligands containing thienopyrimidine nucleus for inhibition of 15-lipoxygenase, cyclooxygenases, and pro-inflammatory cytokines.",1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmc.2012.09.021,"Synthesis, biological evaluation and molecular modeling of dihydro-pyrazolyl-thiazolinone derivatives as potential COX-2 inhibitors.",1
18694,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1016/j.ejmech.2023.115138,"Development of novel pyrazole, imidazo[1,2-b]pyrazole, and pyrazolo[1,5-a]pyrimidine derivatives as a new class of COX-2 inhibitors with immunomodulatory potential.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm049121q,"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020089e,"Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2006.06.036,Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.,1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm0707525,"Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.02.033,"Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0510474,"Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2003.10.004,"Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.",1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm049121q,"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.",1
18694,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2022.116633,Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity.,1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmc.2013.12.008,Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.,1
18694,10.1016/j.bmcl.2004.02.028,"2,3-diarylpyran-4-ones: a new series of selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
18694,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1016/j.bmcl.2015.03.022,"Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.",1
18694,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1016/j.ejmech.2007.06.022,Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2012.03.044,"Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.12.039,Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2016.08.034,"Structure-activity relationship of novel series of 1,5-disubstituted tetrazoles as cyclooxygenase-2 inhibitors: Design, synthesis, bioassay screening and molecular docking studies.",1
18694,10.1016/j.bmc.2014.12.041,"Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors.",10.1039/C6MD00569A,Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).,1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1016/j.ejmech.2019.111601,"Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities.",1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.bmc.2016.06.026,"Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0705096,CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0707525,"Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2008.07.058,"Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(03)00282-8,"Conformationally restricted 3,4-diarylfuranones (2,3a,4,5-tetrahydronaphthofuranones) as selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(00)00634-x,"2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.",1
18694,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1021/jm030268b,"Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.",1
18694,10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",10.1039/C7MD00390K,Recent development of lipoxygenase inhibitors as anti-inflammatory agents.,1
18694,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.ejmech.2007.06.022,Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.1c00880,"Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents <i>In Vitro</i> and <i>In Vivo</i>.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm990577v,"4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2007.07.084,"Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.",1
18694,10.1007/s00044-012-9975-3,"Synthesis, molecular modeling and anti-inflammatory screening of new 1,2,3-benzotriazinone derivatives",10.1016/j.ejmech.2018.11.027,Anti-inflammatory activity of triazine derivatives: A systematic review.,1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2014.08.062,Synthesis of novel pyrazole–thiadiazole hybrid as potential potent and selective cyclooxygenase-2 (COX-2) inhibitors.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1039/d4md00135d,"New pyrazole-pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, &lt;i&gt;in silico&lt;/i&gt; studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2007.09.038,"Synthesis and biological evaluation of 2-trifluoromethyl/sulfonamido-5,6-diaryl substituted imidazo[2,1-b]-1,3,4-thiadiazoles: a novel class of cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2008.01.021,"Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.01.014,"Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm2001376,Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2012.01.130,N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/C2MD20317K,Metabolism-guided drug design,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2008.08.059,"Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.",1
18694,10.1016/j.bmcl.2020.127173,"Screening of chalcone analogs with anti-depressant, anti-inflammatory, analgesic, and COX-2-inhibiting effects.",10.1039/d1md00280e,Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/C5MD00278H,Targeting microsomal prostaglandin E2synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs),1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2013.04.074,"1,4-Diaryl-substituted triazoles as cyclooxygenase-2 inhibitors: Synthesis, biological evaluation and molecular modeling studies.",1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.ejmech.2016.03.011,"Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2014.08.050,"Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.",1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1021/jm0705096,CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1021/jm050619h,Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.,1
18694,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1016/s0960-894x(02)00952-6,"2,3-Diarylbenzopyran derivatives as a novel class of selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-012-0387-1,Synthesis and biologic evaluation of new 3-phenoxyazetidin-2-one derivatives as selective cyclooxygenase-2 inhibitors,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2011.06.019,"Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-009-9230-8,"Design and synthesis of new 2-aryl, 3-benzyl-(1,3-oxazolidine or 1,3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2006.06.032,Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.,1
18694,10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,10.1016/j.ejmech.2013.10.083,"3D QSAR studies based in silico screening of 4,5,6-triphenyl-1,2,3,4-tetrahydropyrimidine analogs for anti-inflammatory activity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2004.01.053,"Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2007.11.033,Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,1
18694,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1039/d2md00192f,"Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-<i>a</i>]pyrimidine scaffold.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(00)00522-9,Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.,1
18694,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmcl.2017.04.020,"Novel pyrazoles and pyrazolo[1,2-a]pyridazines as selective COX-2 inhibitors; Ultrasound-assisted synthesis, biological evaluation, and DFT calculations.",1
18694,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmc.2014.02.042,Synthesis and biological evaluation of new pyrazolone-pyridazine conjugates as anti-inflammatory and analgesic agents.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0302391,"Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/ml100232q,[I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.05.073,"Synthesis, biological evaluation and docking studies of novel benzopyranone congeners for their expected activity as anti-inflammatory, analgesic and antipyretic agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0101343,Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00559-4,A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmc.2010.01.021,"Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmcl.2004.09.073,"3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.8b00922,"Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.",1
18694,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1021/jm020545z,"In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2021.116344,Discovery of pyrazole N-aryl sulfonate: A novel and highly potent cyclooxygenase-2 (COX-2) selective inhibitors.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2007.06.022,Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.bmc.2008.12.032,"Synthesis and cyclooxygenase inhibition of various (aryl-1,2,3-triazole-1-yl)-methanesulfonylphenyl derivatives.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.04.049,Synthesis of new thiazolo-celecoxib analogues as dual cyclooxygenase-2/15-lipoxygenase inhibitors: Determination of regio-specific different pyrazole cyclization by 2D NMR.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0101287,"Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2003.10.027,"Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2004.09.073,"3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm8015188,"Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmcl.2012.01.130,N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(03)00391-3,"6-Alkyl, alkoxy, or alkylthio-substituted 3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmcl.2010.01.014,"Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm101330h,Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2019.03.036,Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.06.155,Triaryl (Z)-olefins suitable for radiolabeling with carbon-11 or fluorine-18 radionuclides for positron emission tomography imaging of cyclooxygenase-2 expression in pathological disease.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2011.04.027,"Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.",1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.bmc.2006.12.041,"Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1021/jm200715n,Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0582064,3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.,1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.bmc.2015.07.070,"Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents.",1
18694,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm9906015,"Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.05.084,Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-011-9710-5,"Design and synthesis of new 2,4,5-triarylimidazole derivatives as selective cyclooxygenase (COX-2) inhibitors",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00365-0,"SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.",1
18694,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1021/jm0101343,Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm1013693,Synopsis of some recent tactical application of bioisosteres in drug design.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2008.04.007,"Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2006.12.041,"Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.",1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2019.05.051,"Chalcone derivatives bearing chromen or benzo[f]chromen moieties: Design, synthesis, and evaluations of anti-inflammatory, analgesic, selective COX-2 inhibitory activities.",1
18694,10.1016/j.ejmech.2007.08.005,"Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.",10.1016/j.ejmech.2019.03.021,Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm991106b,"Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.08.013,"Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00288-7,"The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.",1
18694,10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",10.1016/j.ejmech.2023.115138,"Development of novel pyrazole, imidazo[1,2-b]pyrazole, and pyrazolo[1,5-a]pyrimidine derivatives as a new class of COX-2 inhibitors with immunomodulatory potential.",1
18694,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.bmc.2022.116633,Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity.,1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.ejmech.2016.05.066,"Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones.",1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.bmcl.2010.05.092,"1,5-Diarylimidazoles with strong inhibitory activity against COX-2 catalyzed PGE2 production from LPS-induced RAW 264.7 cells.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1021/jm0607247,"NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00157-2,"Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2011.02.013,"Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: Molecular docking study.",1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmc.2008.08.059,"Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: a search for novel nitric oxide donor anti-inflammatory agents.",1
18694,10.1021/jm101330h,Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1021/jm300576q,Predicting new indications for approved drugs using a proteochemometric method.,1
18694,10.1016/j.bmcl.2014.03.087,"Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs.",10.1016/j.ejmech.2021.113493,Contemporary advances of cyclic molecules proposed for inflammation.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm049939b,"Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm010153c,Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.,1
18694,10.1016/j.bmcl.2016.12.069,"Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening.",10.1016/j.ejmech.2021.113493,Contemporary advances of cyclic molecules proposed for inflammation.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2012.09.069,"Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.",1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2020.127376,Synthesis and evaluations of selective COX-2 inhibitory effects: Benzo[d]thiazol analogs.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm050619h,Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm070821f,New celecoxib derivatives as anti-inflammatory agents.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2017.08.023,Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids.,1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.ejmech.2014.12.039,Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm800219f,The many roles for fluorine in medicinal chemistry.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm8009876,Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2012.03.013,Synthesis and biological activity of 2-aminothiazoles as novel inhibitors of PGE2 production in cells.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2015.07.070,"Synthesis, biological evaluation and docking study of maleimide derivatives bearing benzenesulfonamide as selective COX-2 inhibitors and anti-inflammatory agents.",1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1021/acs.jmedchem.6b01484,Pentafluorosulfanyl-Substituted Benzopyran Analogues As New Cyclooxygenase-2 Inhibitors with Excellent Pharmacokinetics and Efficacy in Blocking Inflammation.,1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.ejmech.2018.09.007,"Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2006.05.028,N-acylated sulfonamide sodium salt: a prodrug of choice for the bifunctional 2-hydroxymethyl-4-(5-phenyl-3-trifluoromethyl-pyrazol-1-yl) benzenesulfonamide class of COX-2 inhibitors.,1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2017.06.002,"Synthesis, potential anti-inflammatory and analgesic activities study of (S)-N-substituted-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxamides.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.9b00823,Engineered Substrate for Cyclooxygenase-2: A Pentapeptide Isoconformational to Arachidonic Acid for Managing Inflammation.,1
18694,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1016/j.bmc.2018.07.024,"Synthesis, in vitro and in vivo biological evaluation, COX-1/2 inhibition and molecular docking study of indole-N-acylhydrazone derivatives.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2008.10.001,"Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.12.060,"Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.12.008,"Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also inhibits tumor necrosis factor-alpha production.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2011.01.057,"Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors.",1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2010.10.001,Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2020.127743,"Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2016.04.046,"Cyclooxygenase-2 and 15-lipoxygenase inhibition, synthesis, anti-inflammatory activity and ulcer liability of new celecoxib analogues: Determination of region-specific pyrazole ring formation by NOESY.",1
18694,10.1016/j.bmc.2014.12.041,"Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors.",10.1016/j.ejmech.2020.112918,"Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety.",1
18694,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.ejmech.2013.12.023,Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.,1
18694,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.bmcl.2016.09.060,Synthesis and anti-inflammatory activity of paeonol analogues in the murine model of complete Freund's adjuvant induced arthritis.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2015.11.105,"Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,3,5-triarylpyrazoline and 1,5-diarylpyrazole derivatives as selective COX-2 inhibitors.",1
18694,10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,10.1016/j.bmcl.2016.02.029,Design and synthesis of [(125)I]Pyricoxib: A novel (125)I-labeled cyclooxygenase-2 (COX-2) inhibitors.,1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.bmcl.2017.04.020,"Novel pyrazoles and pyrazolo[1,2-a]pyridazines as selective COX-2 inhibitors; Ultrasound-assisted synthesis, biological evaluation, and DFT calculations.",1
18694,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2017.04.020,"Novel pyrazoles and pyrazolo[1,2-a]pyridazines as selective COX-2 inhibitors; Ultrasound-assisted synthesis, biological evaluation, and DFT calculations.",1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2014.03.087,"Design, synthesis, docking and anti-inflammatory evaluation of novel series of benzofuran based prodrugs.",1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm0607247,"NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.",1
18694,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
18694,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2014.02.073,Synthesis of thio-heterocyclic analogues from Baylis-Hillman bromides as potent cyclooxygenase-2 inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.08.048,"Design, synthesis and molecular docking study of novel quinoxalin-2(1H)-ones as anti-tumor active agents with inhibition of tyrosine kinase receptor and studying their cyclooxygenase-2 activity.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.12.030,"Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC.",1
18694,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.ejmech.2017.09.056,Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.,1
18694,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1021/jm030268b,"Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.",1
18694,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2009.04.009,"Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents.",1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1016/j.ejmech.2019.03.042,"Novel benzenesulfonamide and 1,2-benzisothiazol-3(2H)-one-1,1-dioxide derivatives as potential selective COX-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2023.129129,Investigation of mitochondrial targeting ability of sydnones and sydnonimines and mitochondria-targeted delivery of celecoxib.,1
18694,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.bmc.2014.03.043,"Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020545z,"In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2023.115496,"Synthesis and anti-inflammatory activity evaluation of NO-releasing furoxan/1,2,4-triazole hybrid derivatives.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2005.05.107,The molecular basis for coxib inhibition of p38alpha MAP kinase.,1
18694,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1021/jm0611861,"Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors.",1
18694,10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",10.1016/j.ejmech.2016.08.039,Hybrid molecules: The privileged scaffolds for various pharmaceuticals.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2011.05.017,"A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2013.05.029,Synthesis of novel celecoxib analogues by bioisosteric replacement of sulfonamide as potent anti-inflammatory agents and cyclooxygenase inhibitors.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.04.065,Synthesis of N-benzenesulfonamide-1H-pyrazoles bearing arylsulfonyl moiety: novel celecoxib analogs as potent anti-inflammatory agents.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-011-9709-y,"Design and synthesis of new 1,2-diaryl-4,5,6,7-tetrahydro-1H-benzo[d] imidazoles as selective cyclooxygenase (COX-2) inhibitors",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm901269y,"Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2019.115246,Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm701467e,"Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2015.07.036,Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.03.011,"Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: Molecular docking studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm030268b,"Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(00)00329-2,"Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm980642l,"2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.",1
18694,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1016/j.bmcl.2003.10.027,"Polar substitutions in the benzenesulfonamide ring of celecoxib afford a potent 1,5-diarylpyrazole class of COX-2 inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(01)00825-3,Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2018.09.016,Methyl-containing pharmaceuticals: Methylation in drug design.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.06.022,"Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.06.056,"Design and synthesis of new 1,3-benzthiazinan-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2003.11.014,Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride.,1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1016/j.ejmech.2017.06.044,New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity.,1
18694,10.1016/j.bmcl.2010.07.053,The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: the first clinical candidate.,10.1016/j.bmcl.2016.08.034,"Structure-activity relationship of novel series of 1,5-disubstituted tetrazoles as cyclooxygenase-2 inhibitors: Design, synthesis, bioassay screening and molecular docking studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020563g,"Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(03)00046-5,"3,4-Diaryl-5-hydroxyfuranones: highly selective inhibitors of cyclooxygenase-2 with aqueous solubility.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(01)00800-9,Structure-based design of cyclooxygenase-2 selectivity into ketoprofen.,1
18694,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2020.127743,"Molecular docking and synthesis of caffeic acid analogous and its anti-inflammatory, analgesic and ulcerogenic studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1039/C6MD00569A,Structure-activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009-2016).,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/d1md00280e,Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.,1
18694,10.1016/j.bmcl.2013.02.107,"Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2.",10.1016/j.bmc.2017.07.038,"Design, synthesis and bioactivities of Celecoxib analogues or derivatives.",1
18694,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.ejmech.2023.115724,Magic shotgun approach to anti-inflammatory pharmacotherapy: Synthesis of novel thienopyrimidine monomers/heterodimer as dual COX-2 and 15-LOX inhibitors endowed with potent antioxidant activity.,1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2017.01.019,N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.,1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2018.01.092,"Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.",1
1219,10.1016/j.bmc.2012.11.019,"New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).",10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",1
19569,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
19344,10.1021/jm7014155,"Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.",10.1021/acs.jmedchem.9b00942,"Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).",1
18726,10.1021/jm00128a008,Tricyclic compounds as selective muscarinic receptor antagonists. 3. Structure-selectivity relationships in a series of cardioselective (M2) antimuscarinics.,10.1016/0960-894X(96)00107-2,The N4 nitrogen of pirenzepine is responsible for selective binding of the M1 subtype human muscarinic receptor,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.6b00697,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4001049,Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4008664,Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.3c02112,Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.,1
18696,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1016/j.bmcl.2017.06.018,SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2009.05.046,"Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.",1
18694,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2008.10.009,Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.,1
18694,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
19569,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",1
19569,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1021/jm201136z,Structural modifications that alter the P-glycoprotein efflux properties of compounds.,1
19569,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
19569,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1021/acs.jmedchem.2c01175,New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.,1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm960384x,Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.,1
1219,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1016/j.neuropharm.2006.07.038,"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.ejmech.2017.01.019,N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.,1
1219,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acsmedchemlett.1c00328,Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against <i>Plasmodium falciparum</i> In Vitro.,1
1219,10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",10.1016/j.ejmech.2019.111655,"Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.",1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2019.111726,Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.ejmech.2012.02.034,"Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors.",1
1219,10.1016/j.bmc.2018.11.010,Optimization and preclinical evaluation of novel histamine H<sub>3</sub>receptor ligands: Acetyl and propionyl phenoxyalkyl piperazine derivatives.,10.1016/j.bmcl.2020.127522,N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H receptor and cancer resistance proteins.,1
1219,10.1016/j.bmcl.2016.04.064,Identification of selenocompounds with promising properties to reverse cancer multidrug resistance.,10.1016/j.ejmech.2022.114761,Seleno-vs. thioether triazine derivatives in search for new anticancer agents overcoming multidrug resistance in lymphoma.,1
1219,10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",10.1021/acs.jmedchem.2c01175,New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2008.04.072,"New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies.",1
19737,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.bmcl.2018.08.036,"Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.",1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(99)00603-4,Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.,1
19737,10.1016/j.ejmech.2020.112258,Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.,10.1016/j.ejmech.2021.113285,Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2013.02.003,Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(00)00491-1,Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer.,1
19737,10.1016/j.bmcl.2008.08.028,"New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies.",10.1016/j.ejmech.2016.07.072,Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.,1
19737,10.1016/j.bmc.2013.02.003,Design and synthesis of a series of α-benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility.,10.1016/j.bmcl.2017.04.061,Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2018.07.005,"Design, synthesis, and evaluation of novel l-phenylglycine derivatives as potential PPARγ lead compounds.",1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(01)00649-7,Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2010.02.073,Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.,1
19737,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.bmcl.2012.11.088,"Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",1
19573,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
19573,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
19573,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
19569,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1021/jm0491851,A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2010.12.032,Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modification.,1
20027,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,10.1016/j.ejmech.2015.11.030,Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators.,1
20027,10.1021/jm101063h,Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.,10.1016/j.ejmech.2017.07.015,Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2012.06.039,Design and synthesis of marine fungal phthalide derivatives as PPAR-γ agonists.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2004.10.042,2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.,1
20027,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,1
20027,10.1016/j.bmc.2008.03.043,"Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.",10.1016/j.bmc.2010.12.023,Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.,1
20027,10.1016/j.bmc.2008.03.043,"Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.",10.1016/j.bmcl.2012.09.092,"Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2006.11.005,Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators.,1
20027,10.1016/j.bmcl.2016.09.009,Identification of small molecules that bind to the mitochondrial protein mitoNEET.,10.1016/j.bmcl.2019.01.041,Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1.,1
19915,10.1016/j.ejmech.2021.113879,Optimization of bifunctional piperidinamide derivatives as σ<sub>1</sub>R Antagonists/MOR agonists for treating neuropathic pain.,10.1021/acs.jmedchem.3c01637,A Novel Bifunctional μOR Agonist and σ<sub>1</sub>R Antagonist with Potent Analgesic Responses and Reduced Adverse Effects.,1
19915,10.1016/j.ejmech.2021.113879,Optimization of bifunctional piperidinamide derivatives as σ<sub>1</sub>R Antagonists/MOR agonists for treating neuropathic pain.,10.1016/j.ejmech.2022.114649,Benzylaminofentanyl derivates: Discovery of bifunctional μ opioid and σ<sub>1</sub> receptor ligands as novel analgesics with reduced adverse effects.,1
19915,10.1016/j.bmcl.2003.10.048,Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites.,10.1021/jm058225d,Designed multiple ligands. An emerging drug discovery paradigm.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2008.08.028,"New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies.",1
19737,10.1016/j.bmcl.2016.09.009,Identification of small molecules that bind to the mitochondrial protein mitoNEET.,10.1016/j.bmcl.2019.01.041,Binding of thiazolidinediones to the endoplasmic reticulum protein nutrient-deprivation autophagy factor-1.,1
19737,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2005.01.074,"Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2.",1
20027,10.1016/j.bmc.2008.03.043,"Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.",10.1016/j.bmc.2009.09.001,Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2005.01.074,"Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2009.09.001,Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2008.03.043,"Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1021/jm0614432,"Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors.",1
1219,10.1016/j.ejmech.2011.02.026,A series of structurally simple chloroquine chemosensitizing dibemethin derivatives that inhibit chloroquine transport by PfCRT.,10.1021/acs.jmedchem.7b01537,4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.,1
1219,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.ejmech.2017.01.019,N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.,1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm201705f,"Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.",1
1219,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,1
1219,10.1016/j.ejmech.2020.112175,Repurposed drug candidates for antituberculosis therapy.,10.1016/j.ejmech.2021.114066,Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.ejmech.2019.111655,"Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.",1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",1
1219,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1124/dmd.111.042382,"The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.",1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",1
20027,10.1021/acsmedchemlett.1c00715,Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.,10.1016/j.ejmech.2024.116728,"Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis.",1
20027,10.1016/j.ejmech.2008.01.029,Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.,10.1016/j.bmc.2019.115162,Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators.,1
20027,10.1021/jm100242d,"Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221).",10.1021/ml300352x,Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2008.08.112,"Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(03)00401-3,Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2017.01.015,"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.",1
20027,10.1016/j.bmc.2010.12.023,Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.,10.1016/j.bmc.2015.11.013,Identification of dual PPARα/γ agonists and their effects on lipid metabolism.,1
20027,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1021/acs.jmedchem.0c01555,A Novel N-Substituted Valine Derivative with Unique Peroxisome Proliferator-Activated Receptor γ Binding Properties and Biological Activities.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2011.03.020,Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.,1
20027,10.1021/jm048993p,Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.,10.1016/j.ejmech.2015.11.030,Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators.,1
20027,10.1016/j.ejmech.2008.01.029,Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.,10.1016/j.bmcl.2009.04.050,"Design, synthesis and insulin-sensitizing activity of indomethacin and diclofenac derivatives.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2018.08.082,Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1021/jm0502135,Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2010.02.073,Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.,1
20027,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1016/j.bmc.2022.116877,Indazole MRL-871 interacts with PPARγ via a binding mode that induces partial agonism.,1
20027,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1016/j.ejmech.2024.116728,"Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis.",1
20027,10.1021/jm048993p,Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.,10.1016/j.bmcl.2006.08.110,Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(99)00603-4,Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.,1
20027,10.1016/j.ejmech.2009.09.042,Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.,10.1021/jm300068n,Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2006.09.011,Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.,1
20027,10.1021/acsmedchemlett.1c00715,Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.,10.1016/j.bmc.2023.117238,Discovery of FXR/PPARγ dual partial agonist.,1
20027,10.1016/j.ejmech.2009.09.042,Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.,10.1016/j.ejmech.2014.06.013,Synthesis and biological evaluation of new rhodanine analogues bearing 2-chloroquinoline and benzo[h]quinoline scaffolds as anticancer agents.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2009.03.143,"4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.",1
20027,10.1007/s00044-012-0007-0,Identification of ZINC02765569: a potent inhibitor of PTP1B by vHTS,10.1007/s00044-012-0165-0,Molecular modeling and synthesis of ZINC02765569 derivatives as protein tyrosine phosphatase 1B inhibitors: lead optimization study,1
20027,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2007.05.079,Design of a partial PPARdelta agonist.,1
20027,10.1021/jm048993p,Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.,10.1021/jm8003416,"Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2009.02.072,"Selective, potent PPARgamma agonists with cyclopentenone core structure.",1
20027,10.1016/j.ejmech.2009.09.042,Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.,10.1016/j.bmc.2010.09.068,"1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2014.11.044,"Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.",1
20027,10.1016/j.bmc.2010.12.023,Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.,10.1016/j.bmc.2012.01.028,Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2006.06.093,"Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).",1
20027,10.1016/j.bmc.2008.03.043,"Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.",10.1016/j.ejmech.2015.11.030,Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators.,1
20346,10.1016/j.ejmech.2019.03.065,Development of CXCR4 modulators based on the lead compound RB-108.,10.1021/acs.jmedchem.4c00184,Synthetically Feasible De Novo Molecular Design of Leads Based on a Reinforcement Learning Model: AI-Assisted Discovery of an Anti-IBD Lead Targeting CXCR4.,1
20027,10.1016/j.ejmech.2008.01.029,Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.,10.1016/j.bmcl.2015.02.021,"Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity.",1
20027,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1021/acs.jmedchem.0c00048,Insights into PPARγ Phosphorylation and Its Inhibition Mechanism.,1
20027,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1016/j.ejmech.2024.116567,A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2008.06.050,"Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.",1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2010.04.031,Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).,1
20027,10.1016/j.ejmech.2009.09.042,Identification of (beta-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor gamma activity.,10.1016/j.ejmech.2011.03.040,Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2014.10.083,Structural development studies of PPARs ligands based on tyrosine scaffold.,1
20027,10.1021/jm990522t,"Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones.",10.1016/j.bmc.2017.01.015,"Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists.",1
20027,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1021/acs.jmedchem.1c00560,Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2008.01.029,Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2006.09.028,"Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.",1
20027,10.1016/j.bmc.2010.09.068,"1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.",10.1016/j.ejmech.2015.11.030,Design and synthesis of novel Y-shaped barbituric acid derivatives as PPARγ activators.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(01)00649-7,Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmc.2023.117238,Discovery of FXR/PPARγ dual partial agonist.,1
20027,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1021/jm900964r,7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.,1
21523,10.1124/dmd.110.035105,Identification of clinically used drugs that activate pregnane X receptors.,10.1021/acs.jmedchem.6b01287,Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.,1
21459,10.1021/jm030801n,"Opioid binding and in vitro profiles of a series of 4-hdroxy-3-methoxyindolomorphinans. Transformation of a delta-selective ligand into a high affinity kappa-selective ligand by introduction of a 5,14-substituted bridge.",10.1016/j.bmcl.2005.02.032,Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone.,1
21459,10.1021/jm00199a018,Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.,10.1016/j.bmcl.2014.05.033,Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.,1
21459,10.1021/jm030311v,"Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].",10.1016/j.bmc.2014.05.065,Pyrrolo- and pyridomorphinans: non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists.,1
21459,10.1021/jm980511k,"Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.",10.1021/ml100126b,1-Substituted 4-(3-Hydroxyphenyl)piperazines Are Pure Opioid Receptor Antagonists.,1
20346,10.1016/j.ejmech.2018.02.042,"Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.",10.1016/j.ejmech.2019.111823,Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.,1
20346,10.1016/j.ejmech.2019.03.065,Development of CXCR4 modulators based on the lead compound RB-108.,10.1016/j.ejmech.2019.111823,Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.,1
20346,10.1021/jm00019a017,Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.,10.1016/j.bmc.2009.01.014,64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.,1
20346,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",1
20346,10.1021/jm00019a017,Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.,10.1021/jm801065q,Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.,1
20346,10.1016/j.ejmech.2019.111914,Structural optimization of aminopyrimidine-based CXCR4 antagonists.,10.1016/j.ejmech.2020.112537,"Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.",1
20346,10.1016/j.ejmech.2018.02.042,"Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.",10.1016/j.ejmech.2020.112537,"Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.",1
20346,10.1016/j.ejmech.2018.02.042,"Design, synthesis, and structure-activity-relationship of a novel series of CXCR4 antagonists.",10.1016/j.ejmech.2019.111914,Structural optimization of aminopyrimidine-based CXCR4 antagonists.,1
20346,10.1021/jm00019a017,Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors.,10.1074/jbc.m704739200,Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.,1
20346,10.1021/acs.jmedchem.6b00695,"Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.",10.1016/j.ejmech.2019.111823,Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.,1
20346,10.1021/acs.jmedchem.6b00695,"Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.",10.1021/acs.jmedchem.7b01062,"Structure-Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.bmc.2017.11.016,Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).,1
1219,10.1016/j.bmc.2015.07.027,Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors.,10.1016/j.ejmech.2016.03.070,Synthesis and bioevaluation of novel benzodipyranone derivatives as P-glycoprotein inhibitors for multidrug resistance reversal agents.,1
21697,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1021/jm050619h,Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors.,1
21697,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm049121q,"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.",1
21697,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
21697,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2008.10.039,"Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors.",1
21697,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2007.11.010,"1-Toluene-sulfonyl-3-[(3'-hydroxy-5'-substituted)-gamma-butyrolactone]-indoles: synthesis, COX-2 inhibition and anti-cancer activities.",1
21697,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm0607247,"NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.",1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1021/acs.jmedchem.6b01287,Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1039/C9MD00074G,Novel zafirlukast derivatives exhibit selective antibacterial activity against <i>Porphyromonas gingivalis</i>.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/j.bmc.2024.117653,Bioisoteres for carboxylic acids: From ionized isosteres to novel unionized replacements.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/j.ejmech.2018.08.077,Breathing new life into West Nile virus therapeutics; discovery and study of zafirlukast as an NS2B-NS3 protease inhibitor.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/s0960-894x(98)00442-9,N-carbamoyl analogs of Zafirlukast: potent receptor antagonists of leukotriene D4.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/j.bmcl.2003.08.070,Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/s0960-894x(98)00273-x,Development of new chromanol antagonists of leukotriene D4.,1
21523,10.1021/jm00168a037,"Evolution of a series of peptidoleukotriene antagonists: synthesis and structure/activity relationships of 1,3,5-substituted indoles and indazoles.",10.1016/j.bmcl.2009.05.094,Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.,1
21697,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,1
21697,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1016/j.bmcl.2004.09.073,"3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.",1
21697,10.1021/jm030276s,"Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donor-containing pyrazoles.",10.1021/jm0607247,"NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.",1
21697,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
1219,10.1016/j.bmcl.2008.05.034,"1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance.",10.1016/j.bmc.2009.04.021,"2-(3-Aryl-2-propenoyl)-3-methylquinoxaline-1,4-dioxides: a novel cluster of tumor-specific cytotoxins which reverse multidrug resistance.",1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2018.01.019,"Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.",1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1016/j.ejmech.2019.111655,"Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.",1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm980121y,Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1016/j.bmc.2017.11.016,Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR).,1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1016/j.bmc.2009.02.002,"Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.bmc.2012.11.019,"New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).",1
1219,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
1219,10.1021/acs.jmedchem.5b01429,Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.,10.1021/acs.jnatprod.6b00190,Bioactive Dihydro-β-agarofuran Sesquiterpenoids from the Australian Rainforest Plant Maytenus bilocularis.,1
1219,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm060056p,New potent P-glycoprotein inhibitors carrying a polycyclic scaffold.,1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",1
1219,10.1016/j.ejmech.2019.03.054,"Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.",10.1016/j.ejmech.2021.113336,"Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.",1
23466,10.1016/j.bmc.2019.03.043,Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.,10.1021/acs.jmedchem.1c01855,Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.,1
23093,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
23093,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
23093,10.1021/jm990567u,Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).,10.1021/jm000541z,Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.,1
21938,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2019.111705,Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review.,1
21936,10.1016/j.bmcl.2013.08.112,"Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding.",10.1021/acs.jmedchem.2c01229,"Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.",1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1016/j.bmcl.2011.04.067,Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1021/acs.jmedchem.9b00224,Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1021/jm3004976,Current landscape of phosphodiesterase 10A (PDE10A) inhibition.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1016/j.ejmech.2011.05.072,Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1021/jm1002793,"Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.",1
21716,10.1016/j.bmcl.2019.03.021,Benzothiophene derivatives as phosphodiesterase 10A (PDE10A) inhibitors: Hit-to-lead studies.,10.1016/j.ejmech.2024.116386,Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.,1
21716,10.1021/jm060653b,"Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.",10.1016/j.bmc.2013.07.030,N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.,1
21697,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1021/jm030268b,"Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors.",1
21697,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1021/jm020545z,"In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.",1
24420,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1016/s0960-894x(98)00626-x,"Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.ejmech.2011.09.050,"Design, synthesis and biological evaluation of substituted 11H-benzo[a]carbazole-5-carboxamides as novel antitumor agents.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1021/jm0308850,"New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.ejmech.2012.12.039,Oxo-heterocyclic fused naphthalimides as antitumor agents: synthesis and biological evaluation.,1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.bmc.2007.07.008,Highly efficient antitumor agents of heterocycles containing sulfur atom: linear and angular thiazonaphthalimides against human lung cancer cell in vitro.,1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1021/jm070315q,"2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.ejmech.2013.07.027,"Synthesis, in vitro evaluation and molecular modelling of naphthalimide analogue as anticancer agents.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.bmc.2012.02.049,"Selenium-containing naphthalimides as anticancer agents: design, synthesis and bioactivity.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.bmc.2007.05.032,"Molecular design, chemical synthesis, and biological evaluation of '4-1' pentacyclic aryl/heteroaryl-imidazonaphthalimides.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.ejmech.2011.01.050,"The novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA intercalation and photocleavage.",1
23998,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.bmcl.2005.04.012,"Synthesis, antitumor evaluation and DNA photocleaving activity of novel methylthiazonaphthalimides with aminoalkyl side chains.",1
23522,10.1021/jm00085a007,Antimycobacterial activity of a series of pyrazinoic acid esters.,10.1128/aac.01458-06,Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.,1
23522,10.1021/jm00085a007,Antimycobacterial activity of a series of pyrazinoic acid esters.,10.1016/j.bmcl.2006.01.064,Synthesis of pyrazinamide Mannich bases and its antitubercular properties.,1
23522,10.1021/jm00085a007,Antimycobacterial activity of a series of pyrazinoic acid esters.,10.1021/jm9708745,Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids.,1
23522,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2013.11.031,"Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.",1
23466,10.1016/j.bmc.2019.03.043,Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds.,10.1021/acs.jmedchem.2c01698,"Discovery of TP0597850: A Selective, Chemically Stable, and Slow Tight-Binding Matrix Metalloproteinase-2 Inhibitor with a Phenylbenzamide-Pentapeptide Hybrid Scaffold.",1
25047,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
25047,10.1016/j.ejmech.2015.08.013,Aminothiazoles: Hit to lead development to identify antileishmanial agents.,10.1021/acs.jmedchem.5b01456,Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.,1
25047,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.ejmech.2017.08.055,Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.,1
25047,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
25047,10.1021/acs.jmedchem.3c00056,"Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides.",10.1016/j.ejmech.2023.115863,"Design, synthesis, and biological evaluation of quinoline-piperazine/pyrrolidine derivatives as possible antileishmanial agents.",1
24991,10.1016/j.bmc.2007.10.075,Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors.,10.1039/C0MD00119H,"Boronic acids in medicinal chemistry: anticancer, antibacterial and antiviral applications",1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/acs.jmedchem.6b01373,Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.,1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/jm049670w,Novel azido and isothiocyanato analogues of [3-(4-phenylalkylpiperazin-1-yl)propyl]bis(4-fluorophenyl)amines as potential irreversible ligands for the dopamine transporter.,1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(02)00464-x,Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes.,1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/jm030008u,Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.,1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/j.bmc.2014.11.007,"Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.",1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(01)00662-x,"[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.",1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/j.bmcl.2008.08.065,Dual DAT/sigma1 receptor ligands based on 3-(4-(3-(bis(4-fluorophenyl)amino)propyl)piperazin-1-yl)-1-phenylpropan-1-ol.,1
24971,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(02)01051-x,Synthesis of dopamine transporter selective 3-[2-(diarylmethoxyethylidene)]-8-alkylaryl-8-azabicyclo[3.2.1]octanes.,1
24969,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1039/d3md00630a,Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents.,1
24969,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1016/j.ejmech.2024.116690,7-Amino-3-phenyl-2-methyl-pyrazolopyrimidine derivatives inhibit human rhinovirus replication.,1
25047,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.ejmech.2017.01.022,"Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.",1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acs.jmedchem.5b01456,Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity.,1
25047,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1016/j.ejmech.2023.115471,Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds.,1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1039/d1md00362c,Current leishmaniasis drug discovery.,1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
25047,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.bmcl.2012.11.072,"Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.",1
25047,10.1016/j.ejmech.2010.01.061,Computational screening for membrane-directed inhibitors of mast cell activation.,10.1016/j.ejmech.2011.02.068,Lipid-like sulfoxides and amine oxides as inhibitors of mast cell activation.,1
25047,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
25047,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b01581,"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.",1
25047,10.1016/j.ejmech.2017.01.022,"Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.",10.1039/d3md00243h,Optimization of the 2-arylquinazoline-4(3<i>H</i>)one scaffold for a selective and potent antitrypanosomal agent: modulation of the mechanism of action through chemical functionalization.,1
25047,10.1016/j.ejmech.2015.08.013,Aminothiazoles: Hit to lead development to identify antileishmanial agents.,10.1016/j.ejmech.2023.115310,"Structural design, synthesis, and anti-Trypanosomatidae profile of new Pyridyl-thiazolidinones.",1
25047,10.1016/j.ejmech.2017.01.022,"Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.",10.1016/j.ejmech.2019.111742,"Synthesis, biological activity, and mechanism of action of new 2-pyrimidinyl hydrazone and N-acylhydrazone derivatives, a potent and new classes of antileishmanial agents.",1
25047,10.1016/j.ejmech.2017.01.022,"Design, synthesis, structure-activity relationship and mechanism of action studies of a series of 4-chloro-1-phthalazinyl hydrazones as a potent agent against Leishmania braziliensis.",10.1016/j.ejmech.2018.04.003,"Anti-leishmanial click modifiable thiosemicarbazones: Design, synthesis, biological evaluation and in silico studies.",1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.ejmech.2020.112914,Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.,1
25047,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.ejmech.2023.115471,Molecular-level strategic goals and repressors in Leishmaniasis - Integrated data to accelerate target-based heterocyclic scaffolds.,1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b01581,"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.",1
25047,10.1021/acs.jmedchem.1c01437,DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.,10.1021/acs.jmedchem.4c01370,Discovery of a Series of Macrocycles as Potent Inhibitors of <i>Leishmania Infantum</i>.,1
25047,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.08.057,"Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.",1
25047,10.1016/j.ejmech.2016.01.028,Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.,10.1016/j.ejmech.2017.08.030,Eugenol derived immunomodulatory molecules against visceral leishmaniasis.,1
25047,10.1016/j.ejmech.2015.08.013,Aminothiazoles: Hit to lead development to identify antileishmanial agents.,10.1016/j.bmcl.2020.127616,Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds.,1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1021/acs.jmedchem.3c00056,"Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides.",1
25047,10.1016/j.ejmech.2016.12.017,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,10.1021/acs.jmedchem.8b02021,Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.,1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1016/j.ejmech.2021.113458,"Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents.",1
25047,10.1021/acsmedchemlett.7b00039,Synthesis and Activity of a New Series of Antileishmanial Agents.,10.1021/acs.jnatprod.0c00025,Spongian Diterpenoids Derived from the Antarctic Sponge <i>Dendrilla antarctica</i> Are Potent Inhibitors of the <i>Leishmania</i> Parasite.,1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1021/acs.jmedchem.1c00135,"Revisiting Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleosides as Anti-<i>Trypanosoma cruzi</i> and Antileishmanial Agents.",1
25047,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1016/j.bmcl.2023.129258,"Jozibrevine D from Ancistrocladus ileboensis, the fifth alkaloid in a series of six possible atropo-diastereomeric naphthylisoquinoline dimers, showing antiparasitic and antileukemic activities.",1
25047,10.1016/j.ejmech.2016.12.017,Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.,10.1016/j.ejmech.2019.111676,"Discovery of a benzothiophene-flavonol halting miltefosine and antimonial drug resistance in Leishmania parasites through the application of medicinal chemistry, screening and genomics.",1
25047,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1039/d1md00362c,Current leishmaniasis drug discovery.,1
25047,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,1
25047,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
25047,10.1016/j.ejmech.2016.01.028,Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.,10.1016/j.ejmech.2022.114959,"New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies.",1
1219,10.1016/j.ejmech.2019.111857,Virtual screening-driven discovery of dual 5-HT<sub>6</sub>/5-HT<sub>2A</sub> receptor ligands with pro-cognitive properties.,10.1021/acs.jmedchem.0c02009,Imidazopyridine-Based 5-HT Receptor Neutral Antagonists: Impact of N-Benzyl and N-Phenylsulfonyl Fragments on Different Receptor Conformational States.,1
1219,10.1016/j.ejmech.2014.09.084,"Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters.",10.1021/acs.jmedchem.5b01429,Optimization by Molecular Fine Tuning of Dihydro-β-agarofuran Sesquiterpenoids as Reversers of P-Glycoprotein-Mediated Multidrug Resistance.,1
1219,10.1016/j.bmc.2015.07.027,Optimization of permethyl ningalin B analogs as P-glycoprotein inhibitors.,10.1016/j.ejmech.2018.01.019,"Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.",1
1219,10.1016/j.bmcl.2016.04.064,Identification of selenocompounds with promising properties to reverse cancer multidrug resistance.,10.1016/j.bmcl.2017.01.033,Selenoesters and selenoanhydrides as novel multidrug resistance reversing agents: A confirmation study in a colon cancer MDR cell line.,1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1021/acs.jmedchem.2c01175,New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells.,1
1219,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1021/jm8012745,"N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent transporter-dependent multidrug resistance inhibitors.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.ejmech.2019.111655,"Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.",1
1219,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1021/jm0491851,A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.,1
1219,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1219,10.1021/jm9016174,"Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors.",10.1021/acs.jmedchem.6b01879,Exploration of 2-((Pyridin-4-ylmethyl)amino)nicotinamide Derivatives as Potent Reversal Agents against P-Glycoprotein-Mediated Multidrug Resistance.,1
1219,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acsmedchemlett.3c00496,"hERG, <i>Plasmodium</i> Life Cycle, and Cross Resistance Profiling of New Azabenzimidazole Analogues of Astemizole.",1
1219,10.1021/jm050542x,Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models.,10.1016/j.ejmech.2018.01.092,"Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.",1
25047,10.1016/j.ejmech.2016.01.028,Identification of a diverse indole-2-carboxamides as a potent antileishmanial chemotypes.,10.1016/j.ejmech.2017.10.032,"Design, synthesis and evaluation of amino-substituted 1H-phenalen-1-ones as anti-leishmanial agents.",1
25047,10.1016/j.ejmech.2017.08.055,Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.,10.1016/j.ejmech.2021.113516,"Design, synthesis, in vitro and in vivo biological evaluation of pyranone-piperazine analogs as potent antileishmanial agents.",1
25047,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.4c00517,Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents.,1
25047,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.ejmech.2020.112914,Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.,1
25047,10.1021/acs.jnatprod.9b00755,"Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana Ancistrocladus ealaensis, Targeting Pancreatic Cancer Cells.",10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
25047,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",1
25047,10.1021/acs.jmedchem.1c01437,DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.,10.1021/acs.jmedchem.3c00056,"Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides.",1
25047,10.1016/j.ejmech.2020.112956,"In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.",10.1039/d2md00464j,"Antileishmanial evaluation of triazole-butenolide conjugates: design, synthesis, <i>in vitro</i> screening, SAR and <i>in silico</i> ADME predictions.",1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1039/d0md00083c,Antileishmanial assessment of isoxazole derivatives against L. donovani,1
25047,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
25047,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1021/acs.jmedchem.1c01437,DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.,1
25047,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1039/d1md00362c,Current leishmaniasis drug discovery.,1
25047,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.10.022,Leishmania treatment and prevention: Natural and synthesized drugs.,1
25047,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112558,8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.,1
25906,10.1021/np3001738,"Identification of 4,5-dihydro-4-hydroxygeldanamycins as shunt products of geldanamycin biosynthesis.",10.1021/acs.jnatprod.2c01151,"Discovery of Bioactive Metabolites by Acidic Stress to a Geldanamycin Producer, <i>Streptomyces samsunensis</i>.",1
25906,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.ejmech.2016.05.033,"Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.",1
25906,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.ejmech.2016.05.033,"Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.",1
25906,10.1021/np3001738,"Identification of 4,5-dihydro-4-hydroxygeldanamycins as shunt products of geldanamycin biosynthesis.",10.1021/np4000679,"19-[(1'S,4'R)-4'-Hydroxy-1'-methoxy-2'-oxopentyl]geldanamycin, a natural geldanamycin analogue from Streptomyces hygroscopicus 17997.",1
25906,10.1016/j.bmc.2019.115253,Identification of vibsanin A analog as a novel HSP90 inhibitor.,10.1016/j.bmcl.2022.128589,Elucidation of structure-activity relationship of humulanolides and identification of humulanolide analog as a novel HSP90 inhibitor.,1
25906,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.6b00085,Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.,1
25906,10.1016/j.ejmech.2017.11.054,"Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.",10.1016/j.ejmech.2021.113428,Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo.,1
25906,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
25906,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1039/C6MD00340K,,1
25906,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acsmedchemlett.7b00193,Resorcinol-Based Grp94-Selective Inhibitors.,1
25906,10.1016/j.ejmech.2017.11.054,"Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.",10.1016/j.bmcl.2023.129375,Development of VER-50589 analogs as novel Hsp90 inhibitors.,1
25906,10.1016/j.ejmech.2017.11.054,"Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.",10.1016/j.ejmech.2022.114582,"Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay.",1
25906,10.1016/j.bmcl.2007.08.069,A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.,10.1016/j.bmcl.2009.06.040,Identification of new Hsp90 inhibitors by structure-based virtual screening.,1
25047,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.3c00056,"Optimization of Orally Bioavailable Antileishmanial 2,4,5-Trisubstituted Benzamides.",1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
25047,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
26280,10.1021/acsmedchemlett.8b00410,"Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
26280,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.ejmech.2021.113723,Modification of 5-methylphenanthridium from benzothiazoles to indoles as potent FtsZ inhibitors: Broadening the antibacterial spectrum toward vancomycin-resistant enterococci.,1
26280,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,10.1021/acsmedchemlett.3c00032,"Evaluation of 1,3,4-Thiadiazole Carbonic Anhydrase Inhibitors for Gut Decolonization of Vancomycin-Resistant Enterococci.",1
26280,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2019.04.063,Lipophilic efficient phenylthiazoles with potent undecaprenyl pyrophosphatase inhibitory activity.,1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.bmcl.2003.07.017,Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials.,1
26280,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.3c01040,Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs.,1
26280,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1016/j.ejmech.2023.115239,Oxazolidinone: A promising scaffold for the development of antibacterial drugs.,1
26280,10.1016/j.ejmech.2019.111781,Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria.,10.1016/j.ejmech.2023.115239,Oxazolidinone: A promising scaffold for the development of antibacterial drugs.,1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.ejmech.2006.10.005,Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones.,1
25906,10.1016/j.bmcl.2007.08.069,A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.,10.1016/j.bmc.2008.10.087,Discovery and development of heat shock protein 90 inhibitors.,1
25906,10.1021/np3001738,"Identification of 4,5-dihydro-4-hydroxygeldanamycins as shunt products of geldanamycin biosynthesis.",10.1021/np400308w,"Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15.",1
25906,10.1016/j.bmc.2019.115253,Identification of vibsanin A analog as a novel HSP90 inhibitor.,10.1016/j.bmc.2023.117463,Discovery of three-dimensional bicyclo[3.3.1]nonanols as novel heat shock protein 90 inhibitors.,1
25906,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmc.2008.10.087,Discovery and development of heat shock protein 90 inhibitors.,1
25906,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmcl.2007.08.069,A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.,1
25906,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1021/jm9004708,Heat shock protein 90: inhibitors in clinical trials.,1
26280,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/D1MD00230A,"Design, synthesis, and antibacterial activity of <i>N</i>-(trifluoromethyl)phenyl substituted pyrazole derivatives.",1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.bmcl.2009.04.133,Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial.,1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.ejmech.2023.115239,Oxazolidinone: A promising scaffold for the development of antibacterial drugs.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1039/C5MD00101C,"Synthesis and antibacterial activity evaluation of C-5 side chain modified analogues of FYL-66, a potential agent against methicillin-resistant Staphylococcus aureus",1
26280,10.1016/j.bmcl.2004.02.047,DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids.,10.1021/jm900519b,"Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.",1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.bmc.2022.116614,Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1021/acs.jmedchem.4c00558,Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of &lt;i&gt;Clostridioides difficile&lt;/i&gt; Infection.,1
26280,10.1039/C6MD00236F,SAR and identification of 2-(quinolin-4-yloxy)acetamides as <i>Mycobacterium tuberculosis</i> cytochrome <i>bc</i><sub>1</sub> inhibitors.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.bmcl.2013.05.023,Synthesis and biological evaluation of novel benzoxazinyl-oxazolidinones as potential antibacterial agents.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.bmcl.2015.03.053,"Synthesis and structure-activity relationship studies of novel [6,6,5] tricyclic oxazolidinone derivatives as potential antibacterial agents.",1
26280,10.1016/j.bmc.2015.02.016,Identification of Bacillus anthracis PurE inhibitors with antimicrobial activity.,10.1016/j.ejmech.2021.113442,A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies.,1
26280,10.1021/acsmedchemlett.5b00213,"Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.",10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.3c01040,Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives.,1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.bmcl.2005.12.025,"Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.",1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1021/acsmedchemlett.4c00114,Design and Synthesis of the Linezolid Bioisosteres to Resolve the Serotonergic Toxicity Associated with Linezolid.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.0c00500,Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.,1
26280,10.1021/acs.jmedchem.6b01834,Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.,10.1016/j.ejmech.2018.06.023,"N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.",1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1021/acs.jmedchem.3c01040,Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.bmcl.2008.02.052,Synthesis and structure-activity studies of novel homomorpholine oxazolidinone antibacterial agents.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.ejmech.2012.02.002,"Synthesis and preliminary antibacterial evaluation of Linezolid-like 1,2,4-oxadiazole derivatives.",1
26280,10.1021/acsmedchemlett.5b00213,"Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.",10.1021/acsmedchemlett.7b00263,"Design, Synthesis, and Antibacterial Evaluation of Oxazolidinones with Fused Heterocyclic C-Ring Substructure.",1
26280,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.bmc.2020.115729,"Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.",1
26280,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.3c02061,"Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens.",1
26280,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.ejmech.2023.115930,New broad-spectrum and potent antibacterial agents with dual-targeting mechanism: Promoting FtsZ polymerization and disrupting bacterial membranes.,1
26280,10.1016/j.bmcl.2017.10.018,Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity.,10.1016/j.ejmech.2020.113002,Installation of an aryl boronic acid function into the external section of N-aryl-oxazolidinones: Synthesis and antimicrobial evaluation.,1
26280,10.1021/acsmedchemlett.5b00213,"Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.",10.1016/j.ejmech.2024.116326,Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.ejmech.2023.115239,Oxazolidinone: A promising scaffold for the development of antibacterial drugs.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs.,1
26280,10.1016/j.bmcl.2007.10.061,Synthesis and antibacterial activity of potent heterocyclic oxazolidinones and the identification of RBx 8700.,10.1016/j.bmc.2012.11.036,Recent development of potent analogues of oxazolidinone antibacterial agents.,1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.bmcl.2006.10.063,New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics.,1
26280,10.1016/j.ejmech.2019.112022,"N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification.",10.1016/j.ejmech.2022.115026,Current scenario of quinolone hybrids with potential antibacterial activity against ESKAPE pathogens.,1
26280,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs.,1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.bmcl.2009.04.133,Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial.,1
26280,10.1021/acsmedchemlett.5b00213,"Design, Synthesis, and Identification of Silicon Incorporated Oxazolidinone Antibiotics with Improved Brain Exposure.",10.1021/acs.jmedchem.2c01349,Structure-Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens.,1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.bmcl.2004.06.076,Discovery of isoxazolinone antibacterial agents. Nitrogen as a replacement for the stereogenic center found in oxazolidinone antibacterials.,1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.ejmech.2023.115239,Oxazolidinone: A promising scaffold for the development of antibacterial drugs.,1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.ejmech.2016.09.007,"New isoxazolidinone and 3,4-dehydro-β-proline derivatives as antibacterial agents and MAO-inhibitors: A complex balance between two activities.",1
26280,10.1021/acs.jmedchem.6b01834,Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.,10.1016/j.ejmech.2018.08.025,Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.,1
26280,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1016/j.ejmech.2024.116326,Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.,1
26280,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.ejmech.2024.116326,Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.,1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.bmcl.2009.04.133,Synthesis and antibacterial evaluation of isoxazolinyl oxazolidinones: Search for potent antibacterial.,1
26280,10.1021/jm020248u,Identification of phenylisoxazolines as novel and viable antibacterial agents active against Gram-positive pathogens.,10.1016/j.bmc.2012.08.023,Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties.,1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.bmcl.2005.12.025,"Novel 4-N-substituted aryl pent-2-ene-1,4-dione derivatives of piperazinyloxazolidinones as antibacterials.",1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.bmc.2012.11.036,Recent development of potent analogues of oxazolidinone antibacterial agents.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.ejmech.2015.10.025,Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives.,1
26280,10.1016/j.bmcl.2017.10.018,Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity.,10.1021/acs.jmedchem.2c01349,Structure-Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens.,1
26280,10.1016/j.bmcl.2012.10.052,Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.,10.1016/j.bmcl.2013.10.069,Structure-anti-MRSA activity relationship of macrocyclic bis(bibenzyl) derivatives.,1
1219,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1219,10.1016/j.bmc.2012.11.019,"New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).",10.1016/j.ejmech.2018.01.092,"Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents.",1
1219,10.1016/j.bmc.2012.11.019,"New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR).",10.1016/j.ejmech.2018.01.019,"Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.",1
1219,10.1016/j.bmcl.2008.05.034,"1-[4-(2-Aminoethoxy)phenylcarbonyl]-3,5-bis-(benzylidene)-4-oxopiperidines: a novel series of highly potent revertants of P-glycoprotein associated multidrug resistance.",10.1016/j.ejmech.2012.02.042,"Dimeric 3,5-bis(benzylidene)-4-piperidones: a novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.",1
1219,10.1021/acs.jmedchem.8b00834,"Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with ""Click Chemistry"".",10.1021/acs.jmedchem.1c01452,Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors.,1
1216,10.1021/jm00381a008,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1021/jm030599o,"Synthesis of 2,4-diamino-6-[2'-O-(omega-carboxyalkyl)oxydibenz[b,f]azepin-5-yl]methylpteridines as potent and selective inhibitors of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductase.",1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1039/C3MD00104K,Antifolates as effective antimicrobial agents: new generations of trimethoprim analogs,1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1021/jm401204g,"Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.",1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1128/aac.01666-08,Crystal structure of Bacillus anthracis dihydrofolate reductase with the dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural explanation of potency and selectivity.,1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1016/j.bmcl.2011.07.059,"Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines.",1
26386,10.1021/acsmedchemlett.7b00428,Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.,10.1021/acs.jmedchem.2c01257,"Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates.",1
26280,10.1016/j.bmcl.2004.04.037,The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones.,10.1016/j.bmcl.2007.06.075,Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.bmc.2012.11.036,Recent development of potent analogues of oxazolidinone antibacterial agents.,1
26280,10.1021/jm070708p,"Antibacterial oxazolidinones possessing a novel C-5 side chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic acid amide (PF-00422602), a new lead compound.",10.1016/j.ejmech.2016.09.007,"New isoxazolidinone and 3,4-dehydro-β-proline derivatives as antibacterial agents and MAO-inhibitors: A complex balance between two activities.",1
26280,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.bmcl.2007.06.075,Synthesis and in vitro antibacterial activity of novel methylamino piperidinyl oxazolidinones.,1
26280,10.1016/j.ejmech.2019.111781,Optimization of biaryloxazolidinone as promising antibacterial agents against antibiotic-susceptible and antibiotic-resistant gram-positive bacteria.,10.1016/j.ejmech.2024.116493,"Novel biaryloxazolidinone derivatives with broad-spectrum antibacterial activity, favorable drug-like profiles and in vivo efficacy against linezolid-resistant Staphylococcusaureus.",1
26820,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
26820,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2009.11.039,Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.,1
26820,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
26820,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
26820,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
26820,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
26820,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
26732,10.1016/S0960-894X(00)80531-4,"Synthesis, biochemical activity and behavioral effects of a series of 1,4,5,6-tetrahydropyrimidines as novel ligands for M1 receptors",10.1021/jm960467d,"Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.",1
26451,10.1021/jm960628d,Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists.,10.1016/j.bmc.2010.06.047,"Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.",1
26431,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
26386,10.1021/acsmedchemlett.7b00428,Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.,10.1016/j.bmc.2020.115437,"A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.",1
26386,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,10.1016/j.bmc.2020.115598,Structural studies of triazole inhibitors with promising inhibitor effects against antibiotic resistance metallo-β-lactamases.,1
26386,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,10.1016/j.bmc.2020.115437,"A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.",1
1219,10.1016/j.ejmech.2019.111857,Virtual screening-driven discovery of dual 5-HT<sub>6</sub>/5-HT<sub>2A</sub> receptor ligands with pro-cognitive properties.,10.1016/j.ejmech.2020.112765,A dual-acting 5-HT receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties.,1
1219,10.1021/acs.jmedchem.8b00834,"Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with ""Click Chemistry"".",10.1021/acs.jmedchem.1c00779,"Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).",1
1219,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1016/j.cbi.2005.11.002,"Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).",1
27112,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
27111,10.1021/jm400966v,Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.,10.1021/acs.jmedchem.9b01301,Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.,1
27111,10.1021/jm400966v,Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,1
27111,10.1016/j.bmc.2007.12.040,Identification of aquaporin 4 inhibitors using in vitro and in silico methods.,10.1016/j.bmc.2008.06.005,Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.,1
27072,10.1021/jm070524a,Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.,10.1021/acs.jmedchem.9b00739,"Discovery of Potent, Selective, and Direct Acid Sphingomyelinase Inhibitors with Antidepressant Activity.",1
27072,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
27072,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27072,10.1021/jm070524a,Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.,10.1016/j.ejmech.2017.09.021,NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.,1
27072,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
26820,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
26820,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
26820,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
26820,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1002/jps.20373,"Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.",1
26820,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
26820,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112085,"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.",1
27112,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2019.111841,"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.",1
27112,10.1021/jm2005546,Optimization of propafenone analogues as antimalarial leads.,10.1021/jm300286a,Lead optimization of antimalarial propafenone analogues.,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm980121y,Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity.,1
27112,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27112,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1016/j.ejmech.2023.115238,Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma.,1
27112,10.1021/jm300286a,Lead optimization of antimalarial propafenone analogues.,10.1016/j.ejmech.2023.115238,Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma.,1
27112,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
27112,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm2005546,Optimization of propafenone analogues as antimalarial leads.,1
27112,10.1021/jm2005546,Optimization of propafenone analogues as antimalarial leads.,10.1016/j.ejmech.2023.115238,Drug repurposing of propafenone to discover novel anti-tumor agents by impairing homologous recombination to delay DNA damage recovery of rare disease conjunctival melanoma.,1
27112,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
27229,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
27229,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
27190,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
27190,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
27190,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
27185,10.1097/00001813-199607000-00012,Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.,10.1124/jpet.102.037549,Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.,1
27185,10.1124/dmd.110.037671,Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry.,10.1124/dmd.111.043505,Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.,1
27185,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27185,10.1021/jm001126+,Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone.,10.1016/j.ejmech.2006.12.031,Synthesis and cytotoxicity properties of amiodarone analogues.,1
27185,10.1097/00001813-199607000-00012,Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.,10.1021/jm020941h,Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm960384x,Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1016/j.bmc.2009.02.002,"Search for MDR modulators: design, syntheses and evaluations of N-substituted acridones for interactions with p-glycoprotein and Mg2+.",1
27112,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
27112,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
27112,10.1021/jm00014a031,"Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.",10.1021/jm201705f,"Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.",1
27112,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2022.114707,Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51.,1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2016.12.013,"Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.",1
27251,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2024.116450,"Lead optimization based design, synthesis, and pharmacological evaluation of quinazoline derivatives as multi-targeting agents for Alzheimer's disease treatment.",1
27251,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2022.114152,"Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.",1
27251,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2018.07.033,Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.07.021,"Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.",1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2016.12.037,"Synthesis, anticholinesterase activity and molecular modeling study of novel carbamate-substituted thymol/carvacrol derivatives.",1
27251,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1039/d4md00113c,"Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-based derivatives as multitarget anti-Alzheimer agents.",1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115301,"Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.",1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.111598,"Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.",1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2019.111598,"Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.",1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2023.117256,Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT<sub>6</sub> receptor interaction.,1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112265,"Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.",1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
27307,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2018.01.016,Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.,1
27278,10.1016/j.bmcl.2010.10.068,"Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.",10.1021/jm501535r,CNS drug design: balancing physicochemical properties for optimal brain exposure.,1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2020.112273,The structure-based optimization of δ-sultone-fused pyrazoles as selective BuChE inhibitors.,1
27251,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmcl.2022.129037,Selective butyrylcholinesterase inhibition by isatin dimers and 3-indolyl-3-hydroxy-2-oxindole dimers.,1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2013.01.052,Synthesis and in vitro evaluation of new derivatives of 2-substituted-6-fluorobenzo[d]thiazoles as cholinesterase inhibitors.,1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2015.01.005,"Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.",1
27251,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2019.111707,"Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.",1
27251,10.1016/j.ejmech.2019.02.030,Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.,10.1016/j.bmc.2020.115721,"Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.",1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.ejmech.2019.06.026,"Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.",1
27251,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.bmc.2012.09.005,Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.,1
27251,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.111958,Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
27251,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2020.112180,The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.,1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
27307,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/s0960-894x(98)00384-9,Structure-based design of N-[2-(1-piperidinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.,1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1016/j.bmc.2007.02.031,"An efficient synthesis of 3-fluoro-5-thio-xylofuranosyl nucleosides of thymine, uracil, and 5-fluorouracil as potential antitumor or/and antiviral agents.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2021.116239,Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.,1
27307,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113868,Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.,1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
27307,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2022.114939,Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.,1
27307,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2023.115605,Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles.,1
27307,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
27307,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2020.115812,Bivalent HIV-1 fusion inhibitors based on peptidomimetics.,1
27307,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
27307,10.1021/jm00023a007,A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.,10.1016/j.bmc.2009.11.016,Synthesis and anti-HIV evaluation of water-soluble calixarene-based bithiazolyl podands.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.11.039,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.",1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
27307,10.1016/j.bmcl.2010.12.109,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,10.1016/j.bmc.2011.05.022,"Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.",1
27307,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",1
27307,10.1021/jm00023a007,A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.,10.1128/aac.00972-07,Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
27307,10.1021/jm00088a003,Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.,10.1016/S0960-894X(01)80775-7,Novel pseudosymmetric inhibitors of HIV-1 protease,1
27307,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1021/jm0303148,"Synthesis, structure-activity relationships, and mechanism of drug resistance of D- and L-beta-3'-fluoro-2',3'-unsaturated-4'-thionucleosides as anti-HIV agents.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
27307,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/j.ejmech.2022.115042,Development of novel S-N<sub>3</sub>-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity.,1
27307,10.1021/jm00023a007,A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.,10.1016/j.bmc.2011.10.002,"Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.",1
27307,10.1021/jm010212m,The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2016.05.010,Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
27307,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",10.1016/j.bmc.2020.115812,Bivalent HIV-1 fusion inhibitors based on peptidomimetics.,1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1016/j.bmc.2006.10.033,Fluoro-ketopyranosyl nucleosides: synthesis and biological evaluation of 3-fluoro-2-keto-beta-D-glucopyranosyl derivatives of N4-benzoyl cytosine.,1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2018.03.003,The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.,1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1016/j.ejmech.2007.04.001,Unsaturated fluoro-ketopyranosyl nucleosides: synthesis and biological evaluation of 3-fluoro-4-keto-beta-d-glucopyranosyl derivatives of N(4)-benzoyl cytosine and N(6)-benzoyl adenine.,1
27307,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/s0960-894x(98)00250-9,5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
27307,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,1
27307,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
1216,10.1021/jm201645r,"Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.",10.1021/acsmedchemlett.0c00393,Dual-Target Inhibitors of the Folate Pathway Inhibit Intrinsically Trimethoprim-Resistant DfrB Dihydrofolate Reductases.,1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
27307,10.1016/j.ejmech.2018.07.067,"Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.",10.1016/j.ejmech.2019.111699,Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity.,1
27307,10.1021/jm960802y,Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.,10.1016/s0960-894x(99)00235-8,"Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.",1
27307,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",1
27307,10.1016/j.bmcl.2010.12.109,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,10.1016/j.ejmech.2019.111566,Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review.,1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1021/jm0300274,"l-2',3'-Didehydro-2',3'-dideoxy-3'-fluoronucleosides: synthesis, anti-HIV activity, chemical and enzymatic stability, and mechanism of resistance.",1
27307,10.1021/jm00023a007,A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors.,10.1016/j.bmc.2011.07.023,Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.,1
27307,10.1016/j.ejmech.2018.07.067,"Design, synthesis, docking studies and biological screening of 2-thiazolyl substituted -2,3-dihydro-1H-naphtho[1,2-e][1,3]oxazines as potent HIV-1 reverse transcriptase inhibitors.",10.1016/j.ejmech.2019.111566,Synthetic routes and structure-activity relationships (SAR) of anti-HIV agents: A key review.,1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
27307,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
27307,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
27307,10.1016/j.ejmech.2018.07.020,"Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui.",10.1021/acs.jnatprod.9b00088,Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata.,1
27307,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27307,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
27308,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.ejmech.2023.115658,"Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.",1
27307,10.1021/jm00128a013,"3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.",10.1021/jm040027j,"Synthesis, structure-activity relationships, and drug resistance of beta-d-3'-fluoro-2',3'-unsaturated nucleosides as anti-HIV Agents.",1
27307,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1021/jm100727t,Targeted mutations of Bacillus anthracis dihydrofolate reductase condense complex structure−activity relationships.,1
1216,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2022.114959,"New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies.",1
1216,10.1021/jm00352a002,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1021/jm030931w,"Folate-synthesizing enzyme system as target for development of inhibitors and inhibitor combinations against Candida albicans-synthesis and biological activity of new 2,4-diaminopyrimidines and 4'-substituted 4-aminodiphenyl sulfones.",1
1216,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2023.115333,"Modulating leishmanial pteridine metabolism machinery via some new coumarin-1,2,3-triazoles: Design, synthesis and computational studies.",1
1216,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
1216,10.1021/jm201645r,"Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase.",10.1016/j.ejmech.2021.113979,"The discovery of 1, 3-diamino-7H-pyrrol[3, 2-f]quinazoline compounds as potent antimicrobial antifolates.",1
1216,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2018.04.003,"Anti-leishmanial click modifiable thiosemicarbazones: Design, synthesis, biological evaluation and in silico studies.",1
1216,10.1021/jm00381a008,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1021/jm020466n,"Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three major opportunistic pathogens of AIDS.",1
1216,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2019.06.051,"Synthesis, in vitro biological evaluation and in silico studies of certain arylnicotinic acids conjugated with aryl (thio)semicarbazides as a novel class of anti-leishmanial agents.",1
1216,10.1021/jm00381a008,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1021/jm030438k,"New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity.",1
1216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1216,10.1021/jm00105a008,"On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.",10.1016/j.bmcl.2003.07.023,"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.",1
1216,10.1021/jm800776a,Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase.,10.1016/j.bmc.2009.06.021,"In vitro biological activity and structural analysis of 2,4-diamino-5-(2'-arylpropargyl)pyrimidine inhibitors of Candida albicans.",1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2011.09.018,Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores.,1
27347,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
27342,10.1016/j.bmcl.2008.04.025,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",10.1021/jm8009537,"Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",1
27342,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2010.01.056,Structure-activity relationships of norepinephrine reuptake inhibitors with benzothiadiazine dioxide or dihydrosulfostyril cores.,1
27342,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm900888c,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",1
27342,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27340,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
27340,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.05.054,"1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.",1
27340,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",1
27340,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
27340,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
27340,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
27340,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.07.057,"Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.",1
27308,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
27308,10.1021/acs.jmedchem.1c00883,Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.,10.1016/j.bmc.2023.117543,"Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents.",1
27308,10.1021/acs.jmedchem.4c00303,Identification of Potent and Selective Inhibitors of &lt;i&gt;Acanthamoeba&lt;/i&gt;: Structural Insights into Sterol 14α-Demethylase as a Key Drug Target.,10.1021/acs.jmedchem.4c01109,"A First-in-Class Pyrazole-isoxazole Enhanced Antifungal Activity of Voriconazole: Synergy Studies in an Azole-Resistant <i>Candida albicans</i> Strain, Computational Investigation and in Vivo Validation in a <i>Galleria mellonella</i> Fungal Infection Model.",1
27544,10.1021/acs.jmedchem.5b00752,"Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.",10.1021/acs.jmedchem.1c01637,"Design, Synthesis, and Biological Evaluation of 2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV Entry Inhibitors.",1
27417,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
27370,10.1021/acs.jmedchem.6b00211,"The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.",10.1021/acs.jmedchem.9b00575,"Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.",1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm070778w,Nonsteroidal glucocorticoid agonists: tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) efficacy selectivity.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2010.11.047,Tetrahydroquinoline glucocorticoid receptor agonists: discovery of a 3-hydroxyl for improving receptor selectivity.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2010.04.012,5-Functionalized indazoles as glucocorticoid receptor agonists.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2011.01.093,Discovery of orally available tetrahydroquinoline-based glucocorticoid receptor agonists.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2008.05.029,"Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.",1
27370,10.1021/jm4019178,Identification of highly efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects.,10.1016/j.bmcl.2016.12.047,Discovery of new selective glucocorticoid receptor agonist leads.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2007.05.062,"5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.",1
27370,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2007.03.103,"Novel glucocorticoids containing a 6,5-bicyclic core fused to a pyrazole ring: synthesis, in vitro profile, molecular modeling studies, and in vivo experiments.",1
27370,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2011.01.104,"Nonsteroidal 2,3-dihydroquinoline glucocorticoid receptor agonists with reduced PEPCK activation.",1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2011.01.106,Tetrahydroquinolin-3-yl carbamate glucocorticoid receptor agonists with reduced PEPCK activation.,1
27370,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1073/pnas.0705517104,Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.,1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.6b00410,Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator.,1
27624,10.1021/acs.jmedchem.0c01127,"Discovery of EST73502, a Dual μ-Opioid Receptor Agonist and σ Receptor Antagonist Clinical Candidate for the Treatment of Pain.",10.1021/acs.jmedchem.1c00417,Propionamide Derivatives as Dual μ-Opioid Receptor Agonists and σ<sub>1</sub> Receptor Antagonists for the Treatment of Pain.,1
27611,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
1216,10.1021/jm00381a008,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1016/j.bmcl.2003.07.023,"Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.",1
1216,10.1021/jm00105a008,"On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.",10.1021/jm960491r,"Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis.",1
1216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1216,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
1216,10.1016/j.ejmech.2014.12.051,"Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.",10.1016/j.ejmech.2023.115534,"Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation.",1
1216,10.1021/jm00381a008,Receptor-based design of dihydrofolate reductase inhibitors: comparison of crystallographically determined enzyme binding with enzyme affinity in a series of carboxy-substituted trimethoprim analogues.,10.1021/jm010407u,"Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.",1
1202,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm061045z,"Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.",1
1202,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
1159,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2010.12.048,"A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.",1
1159,10.1016/j.bmcl.2004.07.085,Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.,10.1016/j.bmcl.2005.08.048,Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.,1
27609,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
27609,10.1021/jm00392a005,Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.,10.1021/jm021050c,"Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives.",1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/jm049223g,Indazole estrogens: highly selective ligands for the estrogen receptor beta.,1
27626,10.1016/j.ejmech.2015.01.059,"Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.",10.1016/j.bmcl.2016.09.046,Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00648-4,Synthesis and estrogenic activities of novel 7-thiosubstituted estratriene derivatives.,1
27626,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.bmcl.2022.128668,"Rational design, synthesis, antiproliferative activity against MCF-7, MDA-MB-231 cells, estrogen receptors binding affinity, and computational study of indenopyrimidine-2,5-dione analogs for the treatment of breast cancer.",1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.0c02230,Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00143-2,A new anti-tubulin agent containing the benzo[b]thiophene ring system.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.10.036,Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.05.073,Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.,1
27626,10.1016/j.bmcl.2006.11.066,ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.,10.1016/j.ejmech.2011.03.030,Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes.,1
27626,10.1021/jm701561e,Synthesis and screening of mono- and di-aryl technetium and rhenium metallocarboranes. A new class of probes for the estrogen receptor.,10.1021/jm201556r,Identification and structure-activity relationships of a novel series of estrogen receptor ligands based on 7-thiabicyclo[2.2.1]hept-2-ene-7-oxide.,1
27626,10.1016/j.bmcl.2007.04.068,"ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands.",10.1016/j.ejmech.2009.02.006,Bibenzyl- and stilbene-core compounds with non-polar linker atom substituents as selective ligands for estrogen receptor beta.,1
27626,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.2c02032,Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer <i>In Vitro</i> and <i>In Vivo</i>.,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.11.066,ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2005.05.089,Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(02)00613-3,Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/jm049719y,Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/j.ejmech.2012.02.021,Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.,1
27626,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmc.2016.06.050,"Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.",1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2006.05.036,Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere.,1
27626,10.1016/j.bmcl.2007.04.068,"ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands.",10.1021/jm8001795,"Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library.",1
27626,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.1c02037,Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen.,1
27626,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
27626,10.1016/j.bmcl.2006.11.066,ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.,10.1021/jm300860j,"Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles.",1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.03.098,The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.05.103,Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/s0960-894x(99)00050-5,Novel nonsteroidal selective estrogen receptor modulators. Carbon and heteroatom replacement of oxygen in the ethoxypiperidine region of raloxifene.,1
27626,10.1021/jm100369g,Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.,10.1016/j.ejmech.2012.04.041,Discovery and structure-activity analysis of selective estrogen receptor modulators via similarity-based virtual screening.,1
27626,10.1021/jm8001795,"Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library.",10.1016/j.bmc.2010.04.007,"Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazoles and 3-hydroxy ketones as estrogen receptor alpha and beta agonists.",1
27626,10.1038/nchembio775,Virtual and biomolecular screening converge on a selective agonist for GPR30.,10.1038/nchembio.188,Bioactivity-guided mapping and navigation of chemical space.,1
27626,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27626,10.1038/nchembio775,Virtual and biomolecular screening converge on a selective agonist for GPR30.,10.1039/C5MD00455A,Integrating multicomponent flow synthesis and computational approaches for the generation of a tetrahydroquinoline compound based library,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1016/S0960-894X(97)00142-X,Synthesis and estrogen receptor binding affinities of the major human metabolites of raloxifene (LY139481),1
27626,10.1016/j.bmcl.2007.04.068,"ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands.",10.1016/j.bmc.2009.02.064,"Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents.",1
27626,10.1021/jm100369g,Discovery of potent ligands for estrogen receptor beta by structure-based virtual screening.,10.1016/j.bmcl.2013.03.105,Discovery of natural estrogen receptor modulators with structure-based virtual screening.,1
27626,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2013.03.105,Discovery of natural estrogen receptor modulators with structure-based virtual screening.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2006.03.098,The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands.,1
27626,10.1016/j.bmcl.2004.04.081,Lead identification of a potent benzopyranone selective estrogen receptor modulator.,10.1016/j.bmcl.2013.03.105,Discovery of natural estrogen receptor modulators with structure-based virtual screening.,1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2020.112191,Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.,1
27626,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,1
27626,10.1021/jm00374a021,"Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.",10.1021/acs.jmedchem.5b01276,Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.,1
27626,10.1038/nchembio775,Virtual and biomolecular screening converge on a selective agonist for GPR30.,10.1021/acsmedchemlett.8b00212,A Series of Indole-Thiazole Derivatives Act as GPER Agonists and Inhibit Breast Cancer Cell Growth.,1
27626,10.1016/j.ejmech.2015.01.059,"Identification of fused 16β,17β-oxazinone-estradiol derivatives as a new family of non-estrogenic 17β-hydroxysteroid dehydrogenase type 1 inhibitors.",10.1021/acsmedchemlett.7b00265,Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2004.05.074,Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.,1
27626,10.1016/j.bmcl.2004.04.081,Lead identification of a potent benzopyranone selective estrogen receptor modulator.,10.1016/j.bmcl.2017.04.029,"Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.",1
27626,10.1038/nchembio775,Virtual and biomolecular screening converge on a selective agonist for GPR30.,10.1021/jm400132d,Contributions of academic laboratories to the discovery and development of chemical biology tools.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2006.05.103,Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/jm0509389,Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2005.11.014,Androstenediol analogs as ER-beta-selective SERMs.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmcl.2005.08.010,Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.,1
27626,10.1021/jm101063h,Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents.,10.1016/j.ejmech.2017.07.015,Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.,1
27626,10.1016/j.bmcl.2006.11.066,ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives.,10.1021/jm801458t,Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta.,1
27626,10.1038/nchembio775,Virtual and biomolecular screening converge on a selective agonist for GPR30.,10.1021/jm9011802,Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.12.053,Bridged androstenediol analogs as ER-beta selective SERMs.,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1021/jm8001795,"Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library.",1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.05.036,Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere.,1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2007.03.016,"Synthesis, characterization, and estrogen receptor binding affinity of flavone-, indole-, and furan-estradiol conjugates.",1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/jm8001795,"Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library.",1
27626,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2006.09.088,"Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones.",1
27626,10.1016/j.bmcl.2005.07.008,ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives.,10.1016/j.bmcl.2007.04.068,"ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands.",1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/jm058173s,ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity.,1
27639,10.1021/jm049655r,Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.,10.1021/np060268p,Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana.,1
27639,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.bmcl.2014.03.058,"Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease.",1
27639,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmcl.2019.03.050,"Design, synthesis, evaluation and molecular modeling study of 4-N-phenylaminoquinolines for Alzheimer disease treatment.",1
27639,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2019.07.053,Tacrine-O-protected phenolics heterodimers as multitarget-directed ligands against Alzheimer's disease: Selective subnanomolar BuChE inhibitors.,1
27639,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.bmc.2010.12.034,Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors.,1
27639,10.1021/jm070536w,New potent acetylcholinesterase inhibitors in the tetracyclic triterpene series.,10.1016/j.bmcl.2010.08.123,Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities.,1
27639,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
27639,10.1021/jm049655r,Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.,10.1016/j.bmc.2010.05.071,"Morphinans and isoquinolines: acetylcholinesterase inhibition, pharmacophore modeling, and interaction with opioid receptors.",1
27626,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1016/j.bmcl.2005.08.010,Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.,1
27626,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/jm500569h,Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
27626,10.1021/jm020291h,A new series of estrogen receptor modulators that display selectivity for estrogen receptor beta.,10.1016/j.bmc.2010.04.007,"Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazoles and 3-hydroxy ketones as estrogen receptor alpha and beta agonists.",1
27626,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
27626,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
27626,10.1021/jm030086h,Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.,10.1021/jm040858p,Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.,1
27647,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,10.1016/j.ejmech.2016.10.035,Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.,1
27647,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,10.1039/C6MD00657D,Synthesis and <i>in vitro</i> study of novel borneol derivatives as potent inhibitors of the influenza A virus.,1
27647,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,10.1021/acs.jmedchem.8b00042,Discovery of Highly Potent Pinanamine-Based Inhibitors against Amantadine- and Oseltamivir-Resistant Influenza A Viruses.,1
27647,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,10.1021/acs.jmedchem.6b01758,Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.,1
27647,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2013.05.046,Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.,1
27647,10.1021/ml500236n,Identification and synthesis of quinolizidines with anti-influenza a virus activity.,10.1021/ml500533x,Phenolic diterpenoid derivatives as anti-influenza a virus agents.,1
27647,10.1039/C4MD00515E,Identification of camphor derivatives as novel M2 ion channel inhibitors of influenza A virus,10.1016/j.ejmech.2024.116172,Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations.,1
27639,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.06.007,Isosteroidal alkaloids as potent dual-binding site inhibitors of both acetylcholinesterase and butyrylcholinesterase from the bulbs of Fritillaria walujewii.,1
27639,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.ejmech.2018.07.033,Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.,1
27639,10.1021/jm049655r,Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products.,10.1016/j.bmc.2014.01.010,Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors.,1
27639,10.1016/j.bmc.2010.04.063,Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase.,10.1016/j.bmc.2014.08.035,"Design, synthesis and evaluation of novel tacrine-(β-carboline) hybrids as multifunctional agents for the treatment of Alzheimer's disease.",1
27639,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2023.117256,Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT<sub>6</sub> receptor interaction.,1
27639,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.bmc.2018.08.035,"Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors.",1
27639,10.1021/jm701253t,Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely potent inhibitors.,10.1016/j.ejmech.2013.09.024,"Multifunctional tacrine-flavonoid hybrids with cholinergic, β-amyloid-reducing, and metal chelating properties for the treatment of Alzheimer's disease.",1
27639,10.1021/acs.jmedchem.6b00356,Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.,10.1016/j.ejmech.2023.115301,"Highly selective butyrylcholinesterase inhibitors related to Amaryllidaceae alkaloids - Design, synthesis, and biological evaluation.",1
27639,10.1021/acs.jmedchem.7b01086,The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity.,10.1016/j.bmc.2022.116807,Evaluation of chromane derivatives: Promising privileged scaffolds for lead discovery within Alzheimer's disease.,1
27912,10.1016/j.bmc.2014.01.036,"Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.",10.1016/j.ejmech.2015.03.002,"Synthesis and in vitro and in vivo biological evaluation of substituted nitroquinoxalin-2-ones and 2,3-diones as novel trichomonacidal agents.",1
27912,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
27912,10.1016/j.ejmech.2017.05.058,"Synthesis, antiprotozoal activity, and chemoinformatic analysis of 2-(methylthio)-1H-benzimidazole-5-carboxamide derivatives: Identification of new selective giardicidal and trichomonicidal compounds.",10.1021/acs.jmedchem.0c00910,Anti-Giardia Drug Discovery: Current Status and Gut Feelings.,1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
27812,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1016/j.bmc.2011.08.028,Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors.,1
27812,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1021/ml100125f,Exploring α7-Nicotinic Receptor Ligand Diversity by Scaffold Enumeration from the Chemical Universe Database GDB.,1
27812,10.1021/jm300247y,"Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789).",10.1016/j.ejmech.2015.03.025,Structure-activity relationship studies of SEN12333 analogues: determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs.,1
27812,10.1016/j.bmc.2011.08.028,Acetylcholine binding protein (AChBP) as template for hierarchical in silico screening procedures to identify structurally novel ligands for the nicotinic receptors.,10.1016/j.bmc.2012.06.054,Identification of novel α7 nicotinic receptor ligands by in silico screening against the crystal structure of a chimeric α7 receptor ligand binding domain.,1
27812,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1016/j.bmc.2012.06.054,Identification of novel α7 nicotinic receptor ligands by in silico screening against the crystal structure of a chimeric α7 receptor ligand binding domain.,1
27780,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
27780,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
27780,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
27780,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
27713,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
27647,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
27647,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,10.1021/acs.jmedchem.4c00131,Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.,1
1125,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.bmc.2017.02.032,Comparison of the anion inhibition profiles of the β- and γ-carbonic anhydrases from the pathogenic bacterium Burkholderia pseudomallei.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,1
1125,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.bmc.2015.05.019,"Design and synthesis of benzothiazole-6-sulfonamides acting as highly potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII.",1
1125,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.bmc.2015.05.013,New amide derivatives of Probenecid as selective inhibitors of carbonic anhydrase IX and XII: biological evaluation and molecular modelling studies.,1
27912,10.1016/j.bmcl.2015.06.002,Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound.,10.1016/j.bmc.2017.06.026,"Antitrichomonal activity of δ opioid receptor antagonists, 7-benzylidenenaltrexone derivatives.",1
27912,10.1016/j.bmcl.2010.07.094,"Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.",10.1016/j.ejmech.2021.113669,A review on the structures and biological activities of anti-Helicobacter pylori agents.,1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00055-06,Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.,1
27912,10.1016/j.ejmech.2010.07.028,"Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail.",10.1016/j.ejmech.2012.03.049,"Synthesis and in vitro evaluation of novel tetrazole embedded 1,3,5-trisubstituted pyrazoline derivatives as Entamoeba histolytica growth inhibitors.",1
27912,10.1016/j.ejmech.2010.07.028,"Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail.",10.1016/j.ejmech.2012.06.052,"Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors.",1
27912,10.1016/j.ejmech.2011.06.005,"Novel terpene based 1,4,2-dioxazoles: synthesis, characterization, molecular properties and screening against Entamoeba histolytica.",10.1016/j.ejmech.2012.06.052,"Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors.",1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm801246z,Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.,1
27912,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1016/j.ejmech.2019.06.068,Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.,1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",1
27912,10.1016/j.ejmech.2010.07.028,"Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail.",10.1016/j.ejmech.2014.01.023,"Design, synthesis and biological evaluation of 3-[4-(7-chloro-quinolin-4-yl)-piperazin-1-yl]-propionic acid hydrazones as antiprotozoal agents.",1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2020.112994,Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.,1
27912,10.1016/j.ejmech.2010.07.028,"Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail.",10.1016/j.ejmech.2016.08.022,Synthesis and biological evaluation of 4-(2-(dimethylamino)ethoxy)benzohydrazide derivatives as inhibitors of Entamoeba histolyica.,1
27912,10.1016/j.bmcl.2021.127843,Promising hit compounds against resistant trichomoniasis: Synthesis and antiparasitic activity of 3-(ω-aminoalkoxy)-1-benzyl-5-nitroindazoles.,10.1021/acs.jmedchem.3c00697,Synthesis and Biophysical and Biological Studies of <i>N</i>-Phenylbenzamide Derivatives Targeting Kinetoplastid Parasites.,1
27912,10.1007/s00044-012-0224-6,5-Nitro-heteroarylidene analogs of 2-thiazolylimino-4-thiazolidinones as a novel series of antibacterial agents,10.1016/j.ejmech.2021.113669,A review on the structures and biological activities of anti-Helicobacter pylori agents.,1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm300123s,Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.,1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2019.06.068,Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.,1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
1159,10.1016/j.bmcl.2004.07.085,Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.,10.1021/jm050483n,Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.,1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2012.07.024,The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.,1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2015.11.104,"Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.",1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2010.11.064,Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.,1
1159,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2011.06.038,Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.,1
1148,10.1016/j.bmcl.2004.07.085,Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.,10.1021/jm050483n,Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2016.12.040,Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,1
1125,10.1021/jm00394a021,"Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.",10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.11.045,5-Substituted-benzylsulfanyl-thiophene-2-sulfonamides with effective carbonic anhydrase inhibitory activity: Solution and crystallographic investigations.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,1
28331,10.1016/j.bmcl.2015.12.037,"Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents.",10.1016/j.bmcl.2018.10.003,"5-(4-Hydroxyphenyl)-3H-1,2-dithiole-3-thione-based fibrates as potential hypolipidemic and hepatoprotective agents.",1
28331,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
28331,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
28331,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1021/acsmedchemlett.6b00033,"Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist.",1
28310,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
28177,10.1016/j.bmcl.2006.09.015,In silico identification and biochemical characterization of novel inhibitors of NQO1.,10.1016/j.bmcl.2010.10.070,In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).,1
27912,10.1016/j.bmcl.2005.05.124,A linear discrimination analysis based virtual screening of trichomonacidal lead-like compounds: outcomes of in silico studies supported by experimental results.,10.1016/j.ejmech.2015.03.002,"Synthesis and in vitro and in vivo biological evaluation of substituted nitroquinoxalin-2-ones and 2,3-diones as novel trichomonacidal agents.",1
27912,10.1016/j.bmcl.2010.06.133,"Preliminary studies of 3,4-dichloroaniline amides as antiparasitic agents: structure-activity analysis of a compound library in vitro against Trichomonas vaginalis.",10.1016/j.ejmech.2017.11.029,Recent developments in anti-Trichomonas research: An update review.,1
27912,10.1016/j.bmcl.2005.05.124,A linear discrimination analysis based virtual screening of trichomonacidal lead-like compounds: outcomes of in silico studies supported by experimental results.,10.1016/j.bmc.2014.01.036,"Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.",1
27912,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm049972y,Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents.,1
27912,10.1016/j.bmcl.2010.07.094,"Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.",10.1016/j.ejmech.2011.12.021,"Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.",1
27912,10.1016/j.ejmech.2011.06.005,"Novel terpene based 1,4,2-dioxazoles: synthesis, characterization, molecular properties and screening against Entamoeba histolytica.",10.1016/j.bmcl.2016.09.040,Recent progress on the discovery of antiamoebic agents.,1
27912,10.1016/j.ejmech.2010.07.028,"Synthesis, characterization, antiamoebic activity and cytotoxicity of novel series of pyrazoline derivatives bearing quinoline tail.",10.1007/s00044-012-0070-6,"Pyrazolo[3,4-d]pyrimidine analogues: synthesis, characterization and their in vitro antiamoebic activity",1
27912,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1016/j.ejmech.2016.04.064,"Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.",1
27912,10.1016/j.bmcl.2012.02.084,"Thiosemicarbazone fragment embedded within 1,2,4-triazole ring as inhibitors of Entamoeba histolytica.",10.1016/j.bmcl.2016.09.040,Recent progress on the discovery of antiamoebic agents.,1
27912,10.1007/s00044-012-0224-6,5-Nitro-heteroarylidene analogs of 2-thiazolylimino-4-thiazolidinones as a novel series of antibacterial agents,10.1016/j.ejmech.2019.06.068,Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.,1
28477,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.bmc.2016.02.023,"Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1021/acs.jmedchem.1c01784,"Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2017.08.048,"Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.",1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2017.07.055,"Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2017.07.008,"Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.",1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2017.07.008,"Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.bmc.2015.04.009,"Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1039/C5MD00124B,Chromanones: selective and reversible monoamine oxidase B inhibitors with nanomolar potency,1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1039/C7MD00199A,Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.,1
28477,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2008.11.068,"New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.",1
28477,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.1c01784,"Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.",1
28331,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.ejmech.2017.06.033,"A novel structural class of coumarin-chalcone fibrates as PPARα/γ agonists with potent antioxidant activities: Design, synthesis, biological evaluation and molecular docking studies.",1
28331,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2010.12.011,"Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.",1
28331,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
28331,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1021/jm201697v,Indole-based fibrates as potential hypolipidemic and antiobesity agents.,1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.ejmech.2022.115024,Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors.,1
29061,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.bmcl.2015.03.018,A FRET-based assay for screening SIRT5 specific modulators.,1
29061,10.1016/j.ejmech.2022.114623,Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors.,10.1016/j.ejmech.2022.115024,Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors.,1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.ejmech.2020.112201,Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.,1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.bmcl.2012.10.136,Inhibition of the human deacylase Sirtuin 5 by the indole GW5074.,1
29061,10.1016/j.ejmech.2022.114623,Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors.,10.1016/j.bmc.2023.117455,"Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors.",1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1016/j.ejmech.2022.114623,Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors.,1
28699,10.1016/j.ejmech.2008.12.024,Synthesis and evaluation of a novel series of heterocyclic oleanolic acid derivatives with anti-osteoclast formation activity.,10.1039/C5MD00482A,Novel heterocyclic ring-fused oleanolic acid derivatives as osteoclast inhibitors for osteoporosis,1
28477,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2017.07.055,"Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1039/C5MD00357A,Acetophenone derivatives: novel and potent small molecule inhibitors of monoamine oxidase B,1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
28477,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.bmc.2017.08.048,"Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.",1
28477,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
28477,10.1016/j.ejmech.2013.01.039,A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2017.08.025,Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.,1
28477,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",1
29097,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1016/j.ejmech.2024.116599,Optimization of diastereomeric dihydropyridines as antimalarials.,1
29090,10.1021/jm00186a013,"Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents.",10.1016/j.ejmech.2020.112261,A potent photoreactive general anesthetic with novel binding site selectivity for GABA receptors.,1
29061,10.1016/j.bmcl.2015.03.018,A FRET-based assay for screening SIRT5 specific modulators.,10.1016/j.ejmech.2020.112201,Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.,1
29061,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm301424d,Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.,1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1016/j.ejmech.2022.114363,"Overview of SIRT5 as a potential therapeutic target: Structure, function and inhibitors.",1
29061,10.1016/j.ejmech.2012.07.001,Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.,10.1016/j.ejmech.2020.112201,Sensitive fluorogenic substrates for sirtuin deacylase inhibitor discovery.,1
29061,10.1007/s00044-012-0007-0,Identification of ZINC02765569: a potent inhibitor of PTP1B by vHTS,10.1007/s00044-012-0165-0,Molecular modeling and synthesis of ZINC02765569 derivatives as protein tyrosine phosphatase 1B inhibitors: lead optimization study,1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1016/j.ejmech.2022.114623,Identification of 2-hydroxybenzoic acid derivatives as selective SIRT5 inhibitors.,1
29061,10.1021/jm300526r,Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme.,10.1021/ml3002709,Inhibitors of the NAD(+)-Dependent Protein Desuccinylase and Demalonylase Sirt5.,1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1016/j.ejmech.2022.115024,Pyrazolone derivatives as potent and selective small-molecule SIRT5 inhibitors.,1
29061,10.1016/j.bmc.2009.07.073,Identification and characterization of novel sirtuin inhibitor scaffolds.,10.1021/jm400204k,"Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.",1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1016/j.bmc.2023.117455,"Design, synthesis and biological evaluation of 2,4,6- trisubstituted triazine derivatives as new nonpeptide small-molecule SIRT5 inhibitors.",1
29061,10.1016/j.ejmech.2012.07.001,Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2.,10.1021/jm400204k,"Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3.",1
29061,10.1021/acs.jmedchem.5b00515,Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.,10.1021/acsmedchemlett.8b00245,Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.,1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1021/acs.jmedchem.2c00687,Therapeutic Potential and Activity Modulation of the Protein Lysine Deacylase Sirtuin 5.,1
29061,10.1016/j.ejmech.2020.112676,Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.,10.1016/j.ejmech.2021.113803,Discovery of new human Sirtuin 5 inhibitors by mimicking glutaryl-lysine substrates.,1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
29890,10.1021/jm800435s,Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.,10.1021/jm801347s,Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.,1
29890,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
29890,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
29890,10.1016/j.bmcl.2012.06.035,Discovery and optimization of novel purines as potent and selective CB2 agonists.,10.1021/jm400305d,Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.,1
29890,10.1016/j.ejmech.2009.06.035,"Design, synthesis and pharmacological screening of novel nitric oxide donors containing 1,5-diarylpyrazolin-3-one as nontoxic NSAIDs.",10.1007/s00044-010-9389-z,"Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenicity and nitric oxide-releasing studies of novel ibuprofen analogs as nonulcerogenic derivatives",1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112085,"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.",1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
29890,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,1
29890,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
29097,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,10.1021/acs.jmedchem.2c00585,Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.,1
29097,10.1021/acs.jmedchem.6b00752,Hit-to-Lead Studies for the Antimalarial Tetrahydroisoquinolone Carboxanilides.,10.1016/j.ejmech.2024.116599,Optimization of diastereomeric dihydropyridines as antimalarials.,1
29097,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,10.1021/acs.jmedchem.3c00852,Structure-Guided Design of Nurr1 Agonists Derived from the Natural Ligand Dihydroxyindole.,1
29097,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,10.1021/acs.jmedchem.1c01077,Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1.,1
29097,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
30180,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
30180,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
30111,10.1021/acs.jmedchem.9b02107,Exploration of Fragment Binding Poses Leading to Efficient Discovery of Highly Potent and Orally Effective Inhibitors of FABP4 for Anti-inflammation.,10.1021/acs.jmedchem.1c01803,Fragment-to-Lead Medicinal Chemistry Publications in 2020.,1
29989,10.1021/acs.jmedchem.7b00285,Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure.,10.1021/acs.jmedchem.4c00721,Targeting Myeloperoxidase Ameliorates Gouty Arthritis: A Virtual Screening Success Story.,1
29890,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
29890,10.1016/j.ejmech.2008.09.020,Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.,10.1016/j.bmc.2014.03.043,"Synthesis, pharmacological screening and in silico studies of new class of Diclofenac analogues as a promising anti-inflammatory agents.",1
29890,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
29890,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2019.111841,"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.",1
29890,10.1021/jm801347s,Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.,10.1021/acs.jmedchem.5b00544,Enthalpic Forces Correlate with the Selectivity of Transthyretin-Stabilizing Ligands in Human Plasma.,1
29890,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
29890,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
29890,10.1016/j.ejmech.2008.09.020,Synthesis and pharmacological evaluation of a novel series of 5-(substituted)aryl-3-(3-coumarinyl)-1-phenyl-2-pyrazolines as novel anti-inflammatory and analgesic agents.,10.1007/s00044-010-9494-z,"Synthesis and evaluation of anti-inflammatory and analgesic activity of 3-[(5-substituted-1,3,4-oxadiazol-2-yl-thio)acetyl]-2H-chromen-2-ones",1
29890,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
29890,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
29890,10.1007/s00044-011-9901-0,"Pharmacological screening for anti-inflammatory, analgesic activity of pyrazolyl derivatives along with molecular docking studies",10.1016/j.ejmech.2021.113493,Contemporary advances of cyclic molecules proposed for inflammation.,1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1021/acs.jmedchem.5b01502,KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.,1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1021/jm2004046,Curcumin recognizes a unique binding site of tubulin.,1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1016/j.ejmech.2018.08.026,Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.,1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1016/j.ejmech.2017.08.022,Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy.,1
31312,10.1016/j.bmcl.2012.04.081,"Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13.",10.1016/j.ejmech.2023.116000,Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2.,1
31312,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1021/jm5019687,"A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.",1
31312,10.1016/j.bmcl.2015.05.056,"Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid and diarylpentanoid derivatives.",10.1016/j.bmcl.2016.03.092,Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines.,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2019.111704,Insights on the synthesis of asymmetric curcumin derivatives and their biological activities.,1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1016/j.bmc.2010.12.039,"Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.",1
31312,10.1016/j.bmcl.2016.11.047,"Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents.",10.1016/j.bmc.2019.07.008,"X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer.",1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.bmcl.2016.10.080,Synthesis and biological evaluation of allylated mono-carbonyl analogues of curcumin (MACs) as anti-cancer agents for cholangiocarcinoma.,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.bmcl.2017.02.056,Diarylpentadienone derivatives (curcumin analogues): Synthesis and anti-inflammatory activity.,1
31241,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
30180,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
30180,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
30180,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2017.09.072,CureCuma-cationic curcuminoids with improved properties and enhanced antimicrobial photodynamic activity.,1
31312,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2017.04.064,"Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.",1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,1
31312,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1039/C1MD00199J,Development of second generation epigenetic agents,1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1021/acs.jmedchem.5b01203,Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2018.01.088,"Novel dissymmetric 3,5-bis(arylidene)-4-piperidones as potential antitumor agents with biological evaluation in vitro and in vivo.",1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2019.02.042,Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI).,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2019.02.020,"Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation.",1
31312,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1016/j.ejmech.2019.04.038,"A multifunctional therapeutic approach: Synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer's disease.",1
31312,10.1016/j.bmc.2014.01.022,Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors.,10.1021/acs.jmedchem.5b01502,KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.,1
31312,10.1016/j.ejmech.2016.05.041,Synthesis and optimization of novel allylated mono-carbonyl analogs of curcumin (MACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI) in rats.,10.1016/j.ejmech.2018.06.027,"N-phenylsulfonyl-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-κB inhibitors in hepatic carcinoma cell lines.",1
31312,10.1021/jm500521n,"Discovery and optimization of 1,3,5-trisubstituted pyrazolines as potent and highly selective allosteric inhibitors of protein kinase C-ζ.",10.1039/C8MD00100F,"Design and synthesis of novel 1,3,5-triphenyl pyrazolines as potential anti-inflammatory agents through allosteric inhibition of protein kinase Czeta (PKCζ).",1
31312,10.1016/j.bmcl.2015.05.056,"Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid and diarylpentanoid derivatives.",10.1016/j.ejmech.2019.111704,Insights on the synthesis of asymmetric curcumin derivatives and their biological activities.,1
31312,10.1016/j.bmc.2014.01.022,Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors.,10.1016/j.ejmech.2019.05.078,"Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism.",1
31312,10.1016/j.ejmech.2011.01.039,Feruloylacetone as the model compound of half-curcumin: synthesis and antioxidant properties.,10.1016/j.bmc.2015.12.049,An appraisal on recent medicinal perspective of curcumin degradant: Dehydrozingerone (DZG).,1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1016/j.ejmech.2019.05.078,"Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism.",1
31811,10.1007/s00044-010-9313-6,"Synthesis, anticonvulsant and toxicity screening of thiazolylthiadiazole derivatives",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
31811,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,10.1016/j.ejmech.2011.07.027,"Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.",1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1016/j.bmc.2023.117529,4-Arylidene curcumin derivatives in vitro inhibit α-Synuclein aggregation and disaggregate the preformed fibril.,1
31312,10.1016/j.ejmech.2016.04.053,Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.,10.1039/C8MD00312B,"New amyloid beta-disaggregating agents: synthesis, pharmacological evaluation, crystal structure and molecular docking of <i>N</i>-(4-((7-chloroquinolin-4-yl)oxy)-3-ethoxybenzyl)amines.",1
31312,10.1016/j.ejmech.2011.01.039,Feruloylacetone as the model compound of half-curcumin: synthesis and antioxidant properties.,10.1016/j.bmc.2019.07.008,"X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer.",1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1016/j.bmcl.2015.07.088,Synthesis and biological evaluation of new symmetric curcumin derivatives.,1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1021/jm701595q,"epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors.",1
31312,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1021/acs.jmedchem.5b01502,KATching-Up on Small Molecule Modulators of Lysine Acetyltransferases.,1
31312,10.1016/j.ejmech.2020.113096,Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease.,10.1016/j.ejmech.2022.114825,In vitro and in vivo biological evaluation of newly synthesized multi-target 20(R)-panaxadiol derivatives for treating Alzheimer's disease.,1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1039/C4MD00541D,"Synthesis, biological evaluation and QSAR studies of diarylpentanoid analogues as potential nitric oxideinhibitors",1
31312,10.1016/j.bmcl.2008.04.017,Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.,10.1016/j.ejmech.2019.05.078,"Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism.",1
31312,10.1021/jm1004545,Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.,10.1016/j.ejmech.2012.07.039,"Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling.",1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1039/C1MD00199J,Development of second generation epigenetic agents,1
31312,10.1021/jm060601m,Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.,10.1016/j.bmc.2014.01.022,Synthesis of a novel series of thiazole-based histone acetyltransferase inhibitors.,1
31312,10.1016/j.bmcl.2015.05.056,"Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid and diarylpentanoid derivatives.",10.1016/j.ejmech.2018.08.039,"Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro.",1
31312,10.1021/acs.jmedchem.6b00976,A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway.,10.1016/j.ejmech.2019.04.016,Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1021/jm020899q,Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.,1
33373,10.1021/jm990567u,Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).,10.1021/jm000541z,Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.,1
33216,10.1021/acs.jmedchem.9b00995,Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.,10.1021/acs.jmedchem.0c01883,Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.,1
33216,10.1021/jm960311d,"Identification of the first retinoid X, receptor homodimer antagonist.",10.1021/jm030651g,Determinants of retinoid X receptor transcriptional antagonism.,1
33216,10.1021/ml5000405,Identification of a New RXRα Antagonist Targeting the Coregulator-Binding Site.,10.1021/acs.jnatprod.2c00791,"Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus, <i>Daldinia childiae</i>.",1
32408,10.1021/jm00164a052,"Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.",10.1016/0960-894X(95)00038-U,"Synthesis and binding affinity of 2,3,3a,4,9,9a-hexahydro-9,4-(iminomethano)-1H-benz[f]indenes. Ligands for the PCP site of the NMDA receptor",1
32408,10.1021/jm00164a052,"Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists.",10.1021/jm970059p,Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors.,1
32027,10.1021/jm200018k,"Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.",10.1021/jm300623u,"3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.",1
31811,10.1007/s00044-010-9313-6,"Synthesis, anticonvulsant and toxicity screening of thiazolylthiadiazole derivatives",10.1016/j.ejmech.2013.06.026,"Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.",1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.07.043,"Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.",1
31811,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1007/s00044-012-0169-9,Synthesis and anticonvulsant activity of novel quinazolin-4(3H)-one derived pyrazole analogs,1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmcl.2012.11.051,"Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.",1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmcl.2019.05.007,"Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.",1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
31811,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.10.020,"Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.",1
33576,10.1039/C0MD00183J,"[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors",10.1016/j.ejmech.2016.09.039,Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2021.113218,FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.,1
33576,10.1039/C0MD00183J,"[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors",10.1016/j.ejmech.2023.115626,Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.,1
33576,10.1016/j.ejmech.2017.09.018,"Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.",10.1021/acs.jmedchem.3c02319,Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1021/jm049538w,Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2006.06.054,Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.,1
33576,10.1016/j.ejmech.2014.09.023,"Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.",10.1016/j.bmc.2024.117749,"Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors.",1
33576,10.1021/acsmedchemlett.9b00615,Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase.,10.1021/acs.jmedchem.3c02319,Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2005.11.105,2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2005.10.058,N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.,1
33576,10.1016/j.bmcl.2011.01.137,Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,10.1016/j.ejmech.2023.115626,Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2016.09.039,Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2005.12.090,Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1021/jm050559f,"2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.",1
33576,10.1021/acsmedchemlett.9b00615,Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETV804M Kinase.,10.1021/acs.jmedchem.0c02167,Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2005.11.033,Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.,1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
33986,10.1016/j.bmc.2016.12.017,Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).,10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
33986,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
33986,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
33679,10.1021/jm00014a015,Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.,10.1016/j.bmcl.2011.03.004,Inhibition of the M. tuberculosis 3β-hydroxysteroid dehydrogenase by azasteroids.,1
33679,10.1021/jm00014a015,Structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase by 6-azaandrost-4-en-3-ones: optimization of the C17 substituent.,10.1021/acs.jmedchem.7b01788,Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.,1
33667,10.1021/jm990567u,Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).,10.1021/jm000541z,Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.,1
33664,10.1021/jm030480f,Selective optimization of side activities: another way for drug discovery.,10.1021/jm400856t,Polypharmacology - foe or friend?,1
33576,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1021/acs.jmedchem.7b01091,Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2015.10.053,1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2006.11.087,ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.,1
33576,10.1039/C0MD00183J,"[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors",10.1016/j.bmcl.2011.01.137,Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.bmcl.2008.06.083,Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2023.115626,Quinazoline-based VEGFR-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.,1
33576,10.1021/jm011022e,"Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.",10.1016/j.ejmech.2019.07.055,"Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.",1
34094,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.04.135,Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.,1
34094,10.1016/j.ejmech.2008.12.016,"Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.",10.1016/j.bmcl.2014.12.077,Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.,1
34094,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
33986,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
33986,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
33986,10.1016/j.bmc.2016.12.017,Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).,10.1021/acs.jmedchem.3c01022,"Design, Synthesis, and Biological Evaluation of Novel Thioureidobenzamide (TBA) Derivatives as HBV Capsid Assembly Modulators.",1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
33986,10.1016/j.ejmech.2007.03.005,Identification of 1-isopropylsulfonyl-2-amine benzimidazoles as a new class of inhibitors of hepatitis B virus.,10.1016/j.ejmech.2014.01.046,A review of non-nucleoside anti-hepatitis B virus agents.,1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
33986,10.1016/j.bmc.2016.12.017,Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).,10.1016/j.ejmech.2021.113780,"Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors.",1
33986,10.1016/j.bmc.2016.12.017,Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).,10.1039/d3md00461a,Discovery of carboxyl-containing heteroaryldihydropyrimidine derivatives as novel HBV capsid assembly modulators with significantly improved metabolic stability.,1
33986,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",1
33986,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
33986,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
34933,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
34933,10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
34933,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1021/jm061329j,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",1
34933,10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,10.1016/j.bmc.2017.04.018,Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.,1
34933,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
34197,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmcl.2014.07.018,Further evaluation of the tropane analogs of haloperidol.,1
34197,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,1
34197,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm501119j,"Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.",1
34197,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm049629t,"Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.",1
34197,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm800689g,"Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.",1
34197,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm100294b,Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.,1
34094,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.0c01195,Recent Advances in β<sub>2</sub>-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.,1
34094,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.1c02006,Discovery of a Highly Selective β<sub>2</sub>-Adrenoceptor Agonist with a 2-Amino-2-phenylethanol Scaffold as an Oral Antiasthmatic Agent.,1
34094,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.11.072,A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.ejmech.2019.05.038,Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.,1
36237,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2018.10.041,Identification of novel quinazoline derivatives as potent antiplasmodial agents.,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
34933,10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1016/j.bmc.2017.04.018,Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1021/jm061329j,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,1
34933,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
34933,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
34933,10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
34933,10.1021/jm061329j,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",10.1021/jm900280m,Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.,1
34933,10.1021/jm061329j,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
34933,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1021/jm900280m,Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.,1
34933,10.1021/jm061329j,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",10.1016/j.bmcl.2007.07.034,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",1
34933,10.1016/j.bmc.2017.04.018,Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmc.2017.03.036,"Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.",1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmcl.2012.01.053,"Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.",1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2007.01.117,Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.,1
36237,10.1016/j.ejmech.2018.10.041,Identification of novel quinazoline derivatives as potent antiplasmodial agents.,10.1016/j.ejmech.2022.115022,"Novel pyridine-containing histone deacetylase inhibitors strongly arrest proliferation, induce apoptosis and modulate miRNAs in cancer cells.",1
36237,10.1021/acs.jmedchem.3c00525,Discovery of (<i>S</i>)-<i>N</i>-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6<i>H</i>)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.,10.1021/acs.jmedchem.3c01095,"Discovery of Selective Histone Deacetylase 1 and 2 Inhibitors: Screening of a Focused Library Constructed by Click Chemistry, Kinetic Binding Analysis, and Biological Evaluation.",1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm7011408,Histone deacetylase inhibitors: from bench to clinic.,1
36237,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.bmcl.2011.06.015,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2011.08.027,The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.,1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmc.2013.06.009,Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1016/j.bmc.2017.05.062,"Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.",1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2009.04.102,Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.,1
36237,10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,10.1021/acs.jmedchem.7b00115,Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).,1
36237,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1016/j.bmcl.2009.04.102,Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.,1
36237,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1038/nchembio.313,Chemical phylogenetics of histone deacetylases.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2019.02.044,Pyridazinone-substituted benzenesulfonamides display potent inhibition of membrane-bound human carbonic anhydrase IX and promising antiproliferative activity against cancer cell lines.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2014.08.015,Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases.,1
37316,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
37316,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1128/aac.01766-09,"Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.",1
37316,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
37316,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
37095,10.1016/j.bmc.2020.115406,"A new series of aryl sulfamate derivatives: Design, synthesis, and biological evaluation.",10.1016/j.bmc.2024.117645,"Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents.",1
36662,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
36595,10.1021/jm00016a009,Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.,10.1016/s0960-894x(99)00214-0,"trans-2,6-,3,6- and 4,6-diaza-5,6,6a,7,8,12b-hexahydro-benzo[c]phenanthrene-10,11- diols as dopamine agonists.",1
36595,10.1021/jm00016a009,Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.,10.1016/j.ejmech.2011.11.039,Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.,1
36595,10.1021/jm00016a009,Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.,10.1021/jm970038v,Substituted hexahydrobenzo[f]thieno[c]quinolines as dopamine D1-selective agonists: synthesis and biological evaluation in vitro and in vivo.,1
36595,10.1021/jm00016a009,Synthesis and biological evaluation of a series of substituted benzo[a]phenanthridines as agonists at D1 and D2 dopamine receptors.,10.1021/jm200334c,"Probing the steric space at the floor of the D1 dopamine receptor orthosteric binding domain: 7α-, 7β-, 8α-, and 8β-methyl substituted dihydrexidine analogues.",1
36295,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,10.1021/acs.jmedchem.4c00597,Colloidal Aggregation Confounds Cell-Based Covid-19 Antiviral Screens.,1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,1
36237,10.1016/j.bmcl.2006.09.002,"A series of novel, potent, and selective histone deacetylase inhibitors.",10.1016/j.bmcl.2007.11.047,Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).,1
36237,10.1021/jm800079s,A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.,10.1021/jm9004303,Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.,1
37812,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2015.10.014,Inhibition of mammalian carbonic anhydrase isoforms I-XIV with a series of phenolic acid esters.,1
37812,10.1016/j.bmc.2015.10.014,Inhibition of mammalian carbonic anhydrase isoforms I-XIV with a series of phenolic acid esters.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1021/acs.jmedchem.3c00721,"1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities.",1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2024.116527,"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments.",1
1125,10.1021/acsmedchemlett.5b00175,Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series.,10.1016/j.bmcl.2016.07.015,Synthesis and carbonic anhydrase inhibitory effects of new N-glycosylsulfonamides incorporating the phenol moiety.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2015.10.021,"Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2016.01.020,"Synthesis of 4-sulfamoylphenyl-benzylamine derivatives with inhibitory activity against human carbonic anhydrase isoforms I, II, IX and XII.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.01.037,Sulfonamide inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.,1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2018.11.073,Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.10.018,New natural product carbonic anhydrase inhibitors incorporating phenol moieties.,1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2021.114008,Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.,1
1125,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,10.1021/acsmedchemlett.2c00471,Structural Characterization of Thiadiazolesulfonamide Inhibitors Bound to <i>Neisseria gonorrhoeae</i> α-Carbonic Anhydrase.,1
1125,10.1016/j.bmc.2017.03.017,Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.,10.1016/j.bmc.2017.07.056,Synthesis and carbonic anhydrase inhibition of polycyclic imides incorporating N-benzenesulfonamide moieties.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2021.114008,Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.,1
39437,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0101343,Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.,1
39437,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(01)00825-3,Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response.,1
39437,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020089e,"Inhibitory mode of 1,5-diarylpyrazole derivatives against cyclooxygenase-2 and cyclooxygenase-1: molecular docking and 3D QSAR analyses.",1
38985,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0101343,Three-dimensional quantitative structure-activity relationships of cyclo-oxygenase-2 (COX-2) inhibitors: a comparative molecular field analysis.,1
38985,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2003.10.004,"Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine.",1
38898,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.bmcl.2017.12.002,A multifaceted approach to identify non-specific enzyme inhibition: Application to Mycobacterium tuberculosis shikimate kinase.,1
38898,10.1021/jm980202u,"Riluzole series. Synthesis and in vivo ""antiglutamate"" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.",10.1021/acsmedchemlett.8b00103,Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.,1
38898,10.1021/jm980202u,"Riluzole series. Synthesis and in vivo ""antiglutamate"" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.",10.1021/acsmedchemlett.3c00224,Development of Riluzole Analogs with Improved Use-Dependent Inhibition of Skeletal Muscle Sodium Channels.,1
38898,10.1021/jm980202u,"Riluzole series. Synthesis and in vivo ""antiglutamate"" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.",10.1021/jm1010572,"Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.",1
38898,10.1021/jm980202u,"Riluzole series. Synthesis and in vivo ""antiglutamate"" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.",10.1016/j.bmcl.2016.05.087,"Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.",1
38898,10.1021/jm980202u,"Riluzole series. Synthesis and in vivo ""antiglutamate"" activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines.",10.1021/jm901375r,"Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino(6-trifluoromethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases.",1
38727,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
37820,10.1021/jm100340m,Computer-aided optimization of phosphinic inhibitors of bacterial ureases.,10.1021/jm200587f,Remarkable potential of the α-aminophosphonate/phosphinate structural motif in medicinal chemistry.,1
37820,10.1021/jm100340m,Computer-aided optimization of phosphinic inhibitors of bacterial ureases.,10.1016/j.bmcl.2017.02.022,Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.,1
37820,10.1021/jm100340m,Computer-aided optimization of phosphinic inhibitors of bacterial ureases.,10.1021/ml500380f,"Bis(aminomethyl)phosphinic Acid, a Highly Promising Scaffold for the Development of Bacterial Urease Inhibitors.",1
37812,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
39781,10.1021/acs.jmedchem.2c01311,Discovery and Optimization of Quinoline Analogues as Novel Potent Antivirals against Enterovirus D68.,10.1016/j.ejmech.2024.116235,"Design, synthesis, and molecular modeling studies of novel 2-quinolone-1,2,3-triazole-α-aminophosphonates hybrids as dual antiviral and antibacterial agents.",1
39781,10.1016/j.ejmech.2016.03.049,"VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.",10.1021/acs.jmedchem.8b00931,Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.,1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1021/acsmedchemlett.8b00134,"3-Aryl-1,2,4-oxadiazole Derivatives Active Against Human Rhinovirus.",1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1039/d3md00630a,Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents.,1
39781,10.1021/jm701494b,Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein.,10.1016/j.ejmech.2016.03.049,"VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.",1
39781,10.1021/jm701494b,Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein.,10.1021/acs.jnatprod.7b00648,Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders.,1
39781,10.1021/jm030166l,"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.",10.1039/d3md00630a,Highly potent and selective phosphatidylinositol 4-kinase IIIβ inhibitors as broad-spectrum anti-rhinoviral agents.,1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1016/j.ejmech.2019.06.008,Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.,1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1016/j.ejmech.2017.09.036,Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study.,1
39624,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmc.2008.07.036,Monoquaternary pyridinium salts with modified side chain-synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase.,1
39624,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,1
39624,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,10.1016/j.bmc.2008.07.036,Monoquaternary pyridinium salts with modified side chain-synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase.,1
39624,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmcl.2006.08.011,Synthesis of asymmetrical bispyridinium compounds bearing cyano-moiety and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,1
39624,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,10.1016/j.bmc.2007.08.002,Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker: preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase.,1
39624,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmc.2007.08.002,Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker: preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase.,1
39570,10.1021/jm030781p,Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.,10.1021/jm040769c,Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.,1
40702,10.1016/j.bmc.2006.10.010,"A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.",10.1016/j.bmc.2009.04.038,Design and synthesis of novel chloramphenicol amine derivatives as potent aminopeptidase N (APN/CD13) inhibitors.,1
40702,10.1016/j.bmc.2006.10.010,"A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.",10.1016/j.bmc.2010.11.066,"Design, synthesis and biological evaluation of novel L-lysine ureido derivatives as aminopeptidase N inhibitors.",1
40405,10.1021/jm950812j,"Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.",10.1021/jm9905054,4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5.,1
40405,10.1021/jm950812j,"Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.",10.1016/j.ejmech.2019.05.026,Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.,1
39933,10.1021/jm00381a005,"Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids.",10.1016/s0960-894x(02)00186-5,Syntheses and bioactivities of novel carbamates combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).,1
39933,10.1021/jm00381a005,"Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids.",10.1016/s0960-894x(02)00005-7,Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI).,1
39857,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,1
39857,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
39857,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm300112w,"Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors.",1
39857,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.bmc.2011.10.015,"Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors.",1
39857,10.1016/j.bmcl.2015.08.071,"Discovery of benzothiazine derivatives as novel, orally-active anti-epileptic drug candidates with broad anticonvulsant effect.",10.1016/j.bmcl.2016.11.035,"Simple N,N-dimethyl phenylsulfonamides show potent anticonvulsant effect in two standard epilepsy models.",1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1016/j.bmcl.2022.128673,Enteroviral replication inhibition by N-Alkyl triazolopyrimidinone derivatives through a non-capsid binding mode.,1
39781,10.1021/acs.jmedchem.7b00175,A Novel Series of Highly Potent Small Molecule Inhibitors of Rhinovirus Replication.,10.1021/acs.jmedchem.8b00931,Structure-Based Drug Design of Potent Pyrazole Derivatives against Rhinovirus Replication.,1
39781,10.1016/j.ejmech.2016.03.049,"VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.",10.1016/j.ejmech.2017.09.036,Heterocyclic pharmacochemistry of new rhinovirus antiviral agents: A combined computational and experimental study.,1
39781,10.1016/j.ejmech.2016.03.049,"VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.",10.1016/j.ejmech.2019.06.008,Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses.,1
39781,10.1016/j.ejmech.2016.03.049,"VP1 crystal structure-guided exploration and optimization of 4,5-dimethoxybenzene-based inhibitors of rhinovirus 14 infection.",10.1021/acs.jnatprod.7b00648,Phenylpropenoids from Bupleurum fruticosum as Anti-Human Rhinovirus Species A Selective Capsid Binders.,1
42304,10.1021/jm0003283,Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.,10.1016/s0960-894x(02)00156-7,Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens.,1
42304,10.1021/jm0003283,Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",1
42304,10.1021/jm0003283,Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.,10.1021/jm0308850,"New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.",1
42304,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1021/jm0308850,"New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties.",1
42013,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
41569,10.1021/acs.jmedchem.5b01803,Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors.,10.1016/j.ejmech.2020.112310,"Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: In vitro, in vivo, and combination therapy study.",1
40940,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm010538v,Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.,1
40940,10.1021/jm00076a023,"Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate.",10.1021/jm010369e,"Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.",1
40940,10.1016/j.ejmech.2012.08.004,"Ligand-based designing, in silico screening, and biological evaluation of new potent fructose-1,6-bisphosphatase (FBPase) inhibitors.",10.1021/acs.jnatprod.0c00014,"Structural Specificity of Flavonoids in the Inhibition of Human Fructose 1,6-Bisphosphatase.",1
40702,10.1016/j.bmc.2012.06.041,"Rapid and efficient synthesis of a novel series of substituted aminobenzosuberone derivatives as potent, selective, non-peptidic neutral aminopeptidase inhibitors.",10.1021/acs.jmedchem.7b00782,Design of Aminopeptidase N Inhibitors as Anti-cancer Agents.,1
40702,10.1021/acsmedchemlett.6b00084,Screening Identifies Thimerosal as a Selective Inhibitor of Endoplasmic Reticulum Aminopeptidase 1.,10.1021/acs.jmedchem.4c00840,ERAP Inhibitors in Autoimmunity and Immuno-Oncology: Medicinal Chemistry Insights.,1
40702,10.1021/jm00083a013,"Analgesic dipeptide derivatives. 7. 3,7-Diamino-2-hydroxyheptanoic acid (DAHHA) containing dipeptide analogues of the analgesic compound H-Lys-Trp(Nps)-OMe.",10.1016/S0960-894X(01)80519-9,Pseudopeptide inhibitors of aminopeptidases containing the [CH(CN)NH] surrogate as a transition-state MIMIC,1
40702,10.1021/acs.jmedchem.9b00757,Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions.,10.1016/j.ejmech.2020.112679,Hydroxamic acid hybrids as the potential anticancer agents: An Overview.,1
40702,10.1021/jm900259h,Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography.,10.1021/acs.jmedchem.9b00663,Effect of Modifier Structure on the Activation of Leukotriene A<sub>4</sub> Hydrolase Aminopeptidase Activity.,1
40702,10.1016/j.bmc.2012.06.041,"Rapid and efficient synthesis of a novel series of substituted aminobenzosuberone derivatives as potent, selective, non-peptidic neutral aminopeptidase inhibitors.",10.1016/j.bmc.2013.08.044,"Synthesis of amino-hydroxy-benzocycloheptenones as potent, selective, non-peptidic dinuclear zinc metalloaminopeptidase inhibitors.",1
40702,10.1016/j.bmc.2006.10.010,"A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening.",10.1021/jm301506h,Structure-activity relationships and blood distribution of antiplasmodial aminopeptidase-1 inhibitors.,1
43934,10.1016/j.ejmech.2009.11.029,Identification of antibacterial and antifungal pharmacophore sites for potent bacteria and fungi inhibition: indolenyl sulfonamide derivatives.,10.1016/j.ejmech.2010.03.014,Some new biologically active metal-based sulfonamide.,1
43934,10.1016/S0960-894X(01)80596-5,Synthesis and biological properties of a new series of anti-MRSA -lactams; 2-(thiazol-2-ylthio)carbapenems,10.1016/S0960-894X(97)00272-2,Novel dithiocarbamate carbapenems1 with anti-MRSA activity,1
43934,10.1016/S0960-894X(01)80596-5,Synthesis and biological properties of a new series of anti-MRSA -lactams; 2-(thiazol-2-ylthio)carbapenems,10.1016/0960-894X(96)00450-7,Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity,1
43740,10.1021/jm800726b,Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening.,10.1016/j.ejmech.2018.09.067,1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.,1
42756,10.1021/jm2012563,Chemical modification of the multitarget neuroprotective compound fisetin.,10.1016/j.bmc.2021.116456,"Design, synthesis and bioactivity evaluation of fisetin derivatives as potential anti-inflammatory agents against LPS-induced acute lung injury.",1
42577,10.1021/jm101266s,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,10.1021/acs.jmedchem.6b00628,Fragment-Based Identification of Influenza Endonuclease Inhibitors.,1
42531,10.1021/jm00105a008,"On the optimization of hydrophobic and hydrophilic substituent interactions of 2,4-diamino-5-(substituted-benzyl)pyrimidines with dihydrofolate reductase.",10.1021/jm960491r,"Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis.",1
42503,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm991171l,The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.,1
42503,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1016/j.ejmech.2022.114618,Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.,1
42503,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1021/jm981051y,"Synthesis of imidazo[1,2-a]pyridines as antiviral agents.",1
42503,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2007.03.061,"Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).",1
42503,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2008.09.027,"Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.",1
42503,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm980287z,"5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.",1
42304,10.1021/jm0003283,Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.,10.1016/j.bmc.2011.08.016,"Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides.",1
42304,10.1021/jm0003283,Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs.,10.1016/j.bmc.2008.11.024,"Molecular modelling studies, synthesis and biological activity of a series of novel bisnaphthalimides and their development as new DNA topoisomerase II inhibitors.",1
42304,10.1021/jm020950q,"Synthesis, antitumor activity, molecular modeling, and DNA binding properties of a new series of imidazonaphthalimides.",10.1016/j.bmc.2011.08.016,"Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides.",1
45596,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmc.2007.08.002,Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker: preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase.,1
45596,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,10.1016/j.bmc.2007.08.002,Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker: preparation and reactivation of tabun- and paraoxon-inhibited acetylcholinesterase.,1
45596,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,10.1016/j.bmcl.2010.11.051,"Preparation, in vitro screening and molecular modelling of symmetrical 4-tert-butylpyridinium cholinesterase inhibitors--analogues of SAD-128.",1
45596,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,10.1016/j.bmc.2008.07.036,Monoquaternary pyridinium salts with modified side chain-synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase.,1
45596,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmcl.2006.08.011,Synthesis of asymmetrical bispyridinium compounds bearing cyano-moiety and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,1
44920,10.1016/j.bmcl.2005.02.083,Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.,10.1016/j.bmc.2008.07.022,"In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.",1
44920,10.1021/acs.jmedchem.8b01209,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",10.1016/j.ejmech.2020.113123,The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,1
44920,10.1021/acs.jmedchem.8b01209,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01120,From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.,1
44920,10.1021/acs.jmedchem.3c01088,"First Optimization of Novel, Potent, Selective PDE11A4 Inhibitors for Age-Related Cognitive Decline.",10.1016/j.ejmech.2024.116386,Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.,1
44920,10.1021/jm201422e,"Drug-to-genome-to-drug, step 2: reversing selectivity in a series of antiplasmodial compounds.",10.1021/acs.jmedchem.0c01887,β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,1
43952,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
43952,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
43952,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1016/j.ejmech.2015.02.056,Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.,1
43952,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1021/acs.jmedchem.7b00215,Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms.,1
43952,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1021/acs.jmedchem.6b01439,Pharmacophore-Based Repositioning of Approved Drugs as Novel Staphylococcus aureus NorA Efflux Pump Inhibitors.,1
43934,10.1016/S0960-894X(01)80596-5,Synthesis and biological properties of a new series of anti-MRSA -lactams; 2-(thiazol-2-ylthio)carbapenems,10.1016/0960-894X(95)00235-L,Benzothiazolylthio carbapenems: potent anti-MRSA agents,1
47271,10.1021/np970427s,"Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm8009487,"Synthesis, cytotoxic activity, and mechanism of action of furo[2,3-c]acridin-6-one and benzo[b]furo[3,2-h]acridin-6-one analogues of psorospermin and acronycine.",1
47209,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2018.05.004,A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease.,1
47209,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2014.07.013,Flavones: an important scaffold for medicinal chemistry.,1
47209,10.1021/np8004248,Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.,10.1021/np100784t,Cycloartane triterpenes isolated from Combretum quadrangulare in a screening program for death-receptor expression enhancing activity.,1
47209,10.1021/np100784t,Cycloartane triterpenes isolated from Combretum quadrangulare in a screening program for death-receptor expression enhancing activity.,10.1021/np500734t,Prenylated flavonoids and resveratrol derivatives isolated from Artocarpus communis with the ability to overcome TRAIL resistance.,1
47209,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2012.03.051,Structure-based virtual screening of novel inhibitors of the uridyltransferase activity of Xanthomonas oryzae pv. oryzae GlmU.,1
47209,10.1021/np100784t,Cycloartane triterpenes isolated from Combretum quadrangulare in a screening program for death-receptor expression enhancing activity.,10.1021/np300179c,Eudesmane-type sesquiterpenoid and guaianolides from Kandelia candel in a screening program for compounds to overcome TRAIL resistance.,1
47209,10.1021/np8004248,Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.,10.1021/np500734t,Prenylated flavonoids and resveratrol derivatives isolated from Artocarpus communis with the ability to overcome TRAIL resistance.,1
47209,10.1021/np8004248,Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.,10.1021/np900202n,Cardenolide glycosides of Thevetia peruviana and triterpenoid saponins of Sapindus emarginatus as TRAIL resistance-overcoming compounds.,1
47209,10.1021/np300179c,Eudesmane-type sesquiterpenoid and guaianolides from Kandelia candel in a screening program for compounds to overcome TRAIL resistance.,10.1021/np500734t,Prenylated flavonoids and resveratrol derivatives isolated from Artocarpus communis with the ability to overcome TRAIL resistance.,1
47209,10.1021/np8004248,Tyrosine derivatives isolated from Streptomyces sp. IFM 10937 in a screening program for TRAIL-resistance-overcoming activity.,10.1021/np300179c,Eudesmane-type sesquiterpenoid and guaianolides from Kandelia candel in a screening program for compounds to overcome TRAIL resistance.,1
46385,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm900888c,"1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.",1
46385,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2009.07.053,"Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.",1
46041,10.1021/jm100573q,"Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.",10.1016/j.ejmech.2022.114606,Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.,1
45596,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmc.2008.07.036,Monoquaternary pyridinium salts with modified side chain-synthesis and evaluation on model of tabun- and paraoxon-inhibited acetylcholinesterase.,1
45596,10.1016/j.bmcl.2005.10.059,Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpyrifos-inhibited acetylcholinesterase.,10.1016/j.bmcl.2007.03.025,Novel series of bispyridinium compounds bearing a (Z)-but-2-ene linker--synthesis and evaluation of their reactivation activity against tabun and paraoxon-inhibited acetylcholinesterase.,1
47579,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmcl.2012.12.063,Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.,1
47579,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1039/C3MD00125C,3-Formylchromone based topoisomerase II inhibitors: discovery of potent leads,1
47579,10.1016/j.bmc.2010.04.074,"Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.",10.1016/j.ejmech.2010.08.061,"Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.",1
47447,10.1021/jm990387k,Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series.,10.1016/j.bmcl.2009.05.094,Synthesis and structure-activity relationships of gamma-carboline derivatives as potent and selective cysLT(1) antagonists.,1
47447,10.1021/jm990387k,Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series.,10.1016/j.bmc.2010.06.047,"Pharmacophore identification, synthesis, and biological evaluation of carboxylated chalcone derivatives as CysLT1 antagonists.",1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/np980420q,"Chiral dihydroxylation of acronycine: absolute configuration of natural cis-1,2-dihydroxy-1,2-dihydroacronycine and cytotoxicity of (1R,2R)- and (1S,2S)-1,2-diacetoxy-1,2-dihydroacronycine.",1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm8009487,"Synthesis, cytotoxic activity, and mechanism of action of furo[2,3-c]acridin-6-one and benzo[b]furo[3,2-h]acridin-6-one analogues of psorospermin and acronycine.",1
47271,10.1021/np970427s,"Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/np800644y,Antitumor psoropermum xanthones and sarcomelicope acridones: privileged structures implied in DNA alkylation.,1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm500927d,"Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine.",1
47271,10.1021/np970427s,"Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm500927d,"Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine.",1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1016/S0960-894X(97)00117-0,Synthesis and biological activities of truncated acridone: Structure-activity relationship studies of cytotoxic 5-hydroxy-4-quinolone,1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/np970427s,"Synthesis and biological activity of esters in the trans-1,2-dihydroxy-1,2-dihydroacronycine series.",1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1016/j.ejmech.2022.114527,A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships.,1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/np800644y,Antitumor psoropermum xanthones and sarcomelicope acridones: privileged structures implied in DNA alkylation.,1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm0602007,"Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine.",1
47271,10.1021/jm9602975,"Synthesis and cytotoxic and antitumor activity of esters in the 1,2-dihydroxy-1,2-dihydroacronycine series.",10.1021/jm990972l,"Synthesis and cytotoxic and antitumor activity of benzo[b]pyrano[3, 2-h]acridin-7-one analogues of acronycine.",1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.ejmech.2016.10.037,New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.ejmech.2020.112994,Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective.,1
1125,10.1021/jm00394a021,"Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.",10.1021/jm9901879,"Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.",1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
48697,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,10.1016/j.ejmech.2016.04.050,"Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.",1
48697,10.1016/j.bmcl.2010.04.140,Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.,10.1039/d3md00431g,"A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.",1
48697,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1021/acs.jmedchem.2c01905,New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate <i>Staphylococcus aureus</i>.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.ejmech.2016.04.050,"Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/acs.jmedchem.7b01395,"Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.ejmech.2014.10.034,"Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.",1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmcl.2009.12.060,"In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/ml300275g,"3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.",1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.ejmech.2018.07.059,"Novel coumarin-pyrazole carboxamide derivatives as potential topoisomerase II inhibitors: Design, synthesis and antibacterial activity.",1
48697,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1021/acs.jmedchem.2c01905,New Dual Inhibitors of Bacterial Topoisomerases with Broad-Spectrum Antibacterial Activity and In Vivo Efficacy against Vancomycin-Intermediate <i>Staphylococcus aureus</i>.,1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmcl.2009.07.141,"5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are antibacterial agents targeting the ATPase domains of DNA gyrase and topoisomerase IV.",1
47579,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.ejmech.2016.06.024,Scaffold-hopping of bioactive flavonoids: Discovery of aryl-pyridopyrimidinones as potent anticancer agents that inhibit catalytic role of topoisomerase IIα.,1
48697,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
48697,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,1
48697,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.bmc.2013.06.042,Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.,1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.bmc.2016.12.040,Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.ejmech.2019.112021,Pyrrolo and pyrrolopyrimidine sulfonamides act as cytotoxic agents in hypoxia via inhibition of transmembrane carbonic anhydrases.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2019.111698,"Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.",1
1125,10.1016/j.ejmech.2012.08.006,"Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.",10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1021/jm501573b,"Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxybromophenol derivatives incorporating cyclopropane moieties.",1
1125,10.1016/j.bmc.2014.09.021,"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.",10.1016/j.bmc.2016.01.020,"Synthesis of 4-sulfamoylphenyl-benzylamine derivatives with inhibitory activity against human carbonic anhydrase isoforms I, II, IX and XII.",1
1125,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,10.1021/acs.jmedchem.4c00740,Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant &lt;i&gt;Neisseria gonorrhoeae&lt;/i&gt;.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.ejmech.2018.07.019,"Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2016.02.011,Development of 3-(4-aminosulphonyl)-phenyl-2-mercapto-3H-quinazolin-4-ones as inhibitors of carbonic anhydrase isoforms involved in tumorigenesis and glaucoma.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.8b00770,Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.,1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmcl.2008.02.008,"Carbonic anhydrase inhibitors: the very weak inhibitors dithiothreitol, beta-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2016.02.032,Sulfonamide inhibition studies of the β-carbonic anhydrase from the newly discovered bacterium Enterobacter sp. B13.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2015.07.024,"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties.",1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmc.2008.12.034,"Synthesis, structure and antibacterial activity of new 2-(1-(2-(substituted-phenyl)-5-methyloxazol-4-yl)-3-(2-substitued-phenyl)-4,5-dihydro-1H-pyrazol-5-yl)-7-substitued-1,2,3,4-tetrahydroisoquinoline derivatives.",1
48697,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,10.1039/C6MD00377J,A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library.,1
48697,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2021.113200,New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.,1
48697,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
48697,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1016/j.bmcl.2012.11.022,Novobiocin analogues with second-generation noviose surrogates.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/acs.jmedchem.8b00825,Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1039/C6MD00377J,A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library.,1
48697,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,10.1016/j.ejmech.2014.10.034,"Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.bmc.2018.04.028,Exploiting polarity and chirality to probe the Hsp90 C-terminus.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1016/j.ejmech.2014.06.067,Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.,1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmc.2008.11.058,Synthesis and antibacterial property of quinolines with potent DNA gyrase activity.,1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmc.2012.02.052,In silico discovery and biophysical evaluation of novel 5-(2-hydroxybenzylidene) rhodanine inhibitors of DNA gyrase B.,1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.bmcl.2008.11.102,DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: synthesis and antibacterial activity.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.ejmech.2022.114190,Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2016.11.027,"Discovery of 4-sulfamoyl-phenyl-β-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.01.019,"Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.",1
1125,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2018.05.034,"Synthesis, characterization and biological evaluation of tertiary sulfonamide derivatives of pyridyl-indole based heteroaryl chalcone as potential carbonic anhydrase IX inhibitors and anticancer agents.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmcl.2013.10.026,Salen and tetrahydrosalen derivatives act as effective inhibitors of the tumor-associated carbonic anhydrase XII--a new scaffold for designing isoform-selective inhibitors.,1
1125,10.1016/j.bmc.2014.09.021,"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.",10.1016/j.bmc.2017.03.063,"Synthesis and biological evaluation of novel aromatic and heterocyclic bis-sulfonamide Schiff bases as carbonic anhydrase I, II, VII and IX inhibitors.",1
1125,10.1016/j.ejmech.2013.01.030,Optimization of heterocyclic substituted benzenesulfonamides as novel carbonic anhydrase IX inhibitors and their structure activity relationship.,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,1
1125,10.1016/j.bmc.2009.11.031,"Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex.",10.1016/j.bmc.2013.07.014,Synthesis of novel acridine and bis acridine sulfonamides with effective inhibitory activity against the cytosolic carbonic anhydrase isoforms II and VII.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/j.bmc.2012.12.004,Carbonic anhydrase inhibitors: benzenesulfonamides incorporating cyanoacrylamide moieties are low nanomolar/subnanomolar inhibitors of the tumor-associated isoforms IX and XII.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2015.04.019,Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2015.05.073,Synthesis and carbonic anhydrase inhibitory properties of novel uracil derivatives.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmcl.2015.04.037,Sulfonamide inhibition study of the β-class carbonic anhydrase from the caries producing pathogen Streptococcus mutans.,1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.ejmech.2020.112392,"Synthesis, characterization and carbonic anhydrase I and II inhibitory evaluation of new sulfonamide derivatives bearing dithiocarbamate.",1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.bmc.2019.03.001,"Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/jm0501073,Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.,1
48697,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmcl.2017.02.031,"Three-component, one-pot synthesis of anthranilamide Schiff bases bearing 4-aminoquinoline moiety as Mycobacterium tuberculosis gyrase inhibitors.",1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1021/jm300395d,"Structure-based discovery of substituted 4,5'-bithiazoles as novel DNA gyrase inhibitors.",1
48697,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1021/jm200010x,Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.,1
48697,10.1016/j.bmcl.2010.04.140,Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues.,10.1016/j.bmcl.2014.05.020,Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/acs.jmedchem.5b01354,Novobiocin Analogues That Inhibit the MAPK Pathway.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1021/ml5004475,"Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.bmcl.2012.11.022,Novobiocin analogues with second-generation noviose surrogates.,1
48697,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1039/C9MD00224C,"New <i>N</i>-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors.",1
48697,10.1016/j.bmc.2014.02.020,"Computer-aided identification of novel 3,5-substituted rhodanine derivatives with activity against Staphylococcus aureus DNA gyrase.",10.1016/j.bmc.2015.08.004,Dual inhibition of Staphylococcus aureus DNA gyrase and topoisomerase IV activity by phenylalanine-derived (Z)-5-arylmethylidene rhodanines.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1016/j.bmcl.2014.05.020,Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1021/ml300275g,"3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues.",1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1039/d3md00431g,"A silicon-containing aryl/penta-1,4-dien-3-one/amine hybrid exhibits antiproliferative effects on breast cancer cells by targeting the HSP90 C-terminus without inducing heat-shock response.",1
48697,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1039/C9MD00224C,"New <i>N</i>-phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors.",1
48697,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
48697,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2021.113200,New dual ATP-competitive inhibitors of bacterial DNA gyrase and topoisomerase IV active against ESKAPE pathogens.,1
48697,10.1016/j.bmcl.2010.12.088,Identification and initial SAR of silybin: an Hsp90 inhibitor.,10.1021/acs.jmedchem.9b00940,"Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm000255n,Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.,1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm049606e,"Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm201506e,"Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm970443m,"Synthesis and anti-HIV-1 activity of novel 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm980260f,"5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm010580q,Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.,1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1016/s0960-894x(98)00250-9,5-Alkyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-ones as potent non-nucleoside reverse transcriptase inhibitors of S-DABO series.,1
49476,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
49344,10.1016/j.bmc.2007.08.009,"Synthesis and evaluation of antifungal properties of a series of the novel 2-amino-5-oxo-4-phenyl-5,6,7,8-tetrahydroquinoline-3-carbonitrile and its analogues.",10.1016/j.bmc.2009.02.019,Exploration of click reaction for the synthesis of modified nucleosides as chitin synthase inhibitors.,1
49226,10.1021/jm400966v,Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.,10.1021/acs.jmedchem.9b01301,Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.,1
48849,10.1021/jm050027z,Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.,10.1016/j.ejmech.2021.113378,Biguanides: Species with versatile therapeutic applications.,1
48849,10.1021/jm050027z,Inhibitors of Trypanosoma cruzi trypanothione reductase revealed by virtual screening and parallel synthesis.,10.1016/j.ejmech.2024.116303,Biochemical and structural characterization of chlorhexidine as an ATP-assisted inhibitor against type 1 methionyl-tRNA synthetase from Gram-positive bacteria.,1
48697,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmc.2016.01.011,Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.,1
48697,10.1021/jm030394f,Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
48697,10.1021/jm200148p,Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.,10.1016/j.bmcl.2014.05.020,Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines.,1
48697,10.1021/ml400404s,Identification of a new scaffold for hsp90 C-terminal inhibition.,10.1021/acs.jmedchem.8b00825,Allosteric Modulators of HSP90 and HSP70: Dynamics Meets Function through Structure-Based Drug Design.,1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1016/j.ejmech.2017.07.002,"Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.7b01708,"Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
49931,10.1021/jm00131a009,"Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.",10.1021/jm040785+,"Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').",1
49931,10.1016/j.ejmech.2017.01.033,"Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.",10.1016/j.ejmech.2019.06.013,"Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401139z,"Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.",1
49931,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2017.08.032,"Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm990192c,Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.,1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm500139a,Synthesis of novel fluoro analogues of MKC442 as microbicides.,1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1016/j.bmc.2007.09.015,Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.,1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm010853h,"Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm0309856,"Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant.",1
49830,10.1021/jm970110p,A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.,10.1021/jm201506e,"Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm0407658,"4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm040845b,"Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach.",1
49830,10.1021/jm960056x,Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.,10.1021/jm970110p,A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.,1
49931,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm061045z,"Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.",1
49931,10.1021/jm00131a009,"Structural studies on bioactive compounds. 8. Synthesis, crystal structure, and biological properties of a new series of 2,4-diamino-5-aryl-6-ethylpyrimidine dihydrofolate reductase inhibitors with in vivo activity against a methotrexate-resistant tumor cell line.",10.1021/jm970055k,"Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401328u,"Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
49931,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm501113m,"Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
49931,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1016/j.bmc.2020.115544,"Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.",1
49931,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2016.03.032,"Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.3c00763,Structure-Based Design of Transport-Specific Multitargeted One-Carbon Metabolism Inhibitors in Cytosol and Mitochondria.,1
49931,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1016/j.bmc.2021.116093,"Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.",1
49931,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",1
49931,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2017.07.002,"Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.bmc.2021.116093,"Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.",1
49931,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.bmc.2020.115544,"Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.",1
49931,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2019.06.013,"Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.",1
49931,10.1016/j.ejmech.2017.01.033,"Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.",10.1016/j.ejmech.2020.112113,"Design, synthesis and biological activity of N-substituted tetrahydropteroate analogs as non-classical antifolates against cobalamin-dependent methionine synthase and potential anticancer agents.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.7b01708,"Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.",1
49931,10.1016/j.bmc.2018.04.035,"Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.",10.1016/j.ejmech.2019.06.013,"Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.",1
49931,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
49931,10.1016/j.ejmech.2017.01.033,"Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.",10.1016/j.bmc.2018.04.035,"Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.",1
49931,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.3c00763,Structure-Based Design of Transport-Specific Multitargeted One-Carbon Metabolism Inhibitors in Cytosol and Mitochondria.,1
49931,10.1016/0960-894X(96)00053-4,"Synthesis and biological evaluation of a new series of dihydrofolate reductase inhibitors based on the 4-(2,6-diamino-5-pyrimidinyl)alkyl-L-glutamic acid structure",10.1016/s0960-894x(98)00683-0,"The synthesis and biological activity of a series of 2,4-diaminopyrido[2,3-d]pyrimidine based antifolates as antineoplastic and antiarthritic agents.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm501113m,"Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.",1
49931,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
50822,10.1016/j.bmcl.2010.04.070,Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.,10.1021/acs.jmedchem.5b00828,"Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.",1
50822,10.1021/jm9014263,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,10.1039/c2md00320a,Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).,1
50822,10.1016/j.bmcl.2010.04.070,Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.,10.1021/acs.jmedchem.9b01033,Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.,1
50101,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
50101,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
50101,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401139z,"Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.",1
50101,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401328u,"Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.",1
49931,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",1
49931,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
49931,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2017.01.033,"Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.",1
49931,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
51056,10.1021/np970343j,Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.,10.1016/j.bmcl.2003.11.066,Synthesis and evaluation of S-4-(3-thienyl)phenyl-alpha-methylacetic acid.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm991106b,"Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.",1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm8009876,Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0000719,"Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.",1
51056,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm701467e,"Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib.",1
51056,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
51056,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
51056,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm9700225,"1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.",1
51003,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2021.113253,Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.,1
50822,10.1021/jm9014263,Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.,10.1016/j.bmcl.2010.04.070,Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.,1
50822,10.1016/j.bmcl.2010.11.060,Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,10.1021/acs.jmedchem.5b00828,"Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.",1
50822,10.1016/j.bmcl.2010.11.060,Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,10.1021/acs.jmedchem.9b01033,Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye.,1
50822,10.1016/j.bmcl.2010.11.060,Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,10.1016/j.ejmech.2013.10.048,Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.,1
50822,10.1016/j.bmcl.2010.11.060,Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.,10.1039/c2md00320a,Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/acs.jmedchem.6b01804,"Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment.",1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/s0960-894x(02)00252-4,Carbonic anhydrase inhibitors. Preparation of potent sulfonamides inhibitors incorporating bile acid tails.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2016.12.047,Benzenesulfonamide bearing imidazothiadiazole and thiazolotriazole scaffolds as potent tumor associated human carbonic anhydrase IX and XII inhibitors.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2016.06.052,Synthesis 4-[2-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-ethyl]-benzenesulfonamides with subnanomolar carbonic anhydrase II and XII inhibitory properties.,1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2023.115707,Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.bmc.2021.116279,"Design, synthesis and biochemical evaluation of novel carbonic anhydrase inhibitors triggered by structural knowledge on hCA VII.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2010.12.048,"A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.",1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.ejmech.2016.09.035,Synthesis and evaluation of new benzodioxole-based dithiocarbamate derivatives as potential anticancer agents and hCA-I and hCA-II inhibitors.,1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2022.114190,Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.,1
1125,10.1016/j.bmc.2008.11.071,Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors.,10.1016/j.ejmech.2019.111642,From random to rational: A discovery approach to selective subnanomolar inhibitors of human carbonic anhydrase IV based on the Castagnoli-Cushman multicomponent reaction.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2016.11.021,Anion inhibition profiles of the γ-carbonic anhydrase from the pathogenic bacterium Burkholderia pseudomallei responsible of melioidosis and highly drug resistant to common antibiotics.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2015.11.104,"Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2019.111573,"New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2014.07.048,Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: the β-class (PgiCAb) versus the γ-class (PgiCA) enzymes.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/d1md00280e,Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.,1
52141,10.1021/jm8005838,"Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.",10.1016/j.bmcl.2024.129652,"Design, synthesis of new 3H-imidazo[4,5-b]pyridine derivatives and evaluation of their inhibitory properties as mixed lineage kinase 3 inhibitors.",1
52087,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
52087,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
52087,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
52087,10.1021/jm00105a067,Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens.,10.1016/j.bmcl.2020.127507,Synthesis of flutamide-conjugates.,1
52087,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
51182,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
51162,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2010.09.024,Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.,1
51162,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
51162,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
51162,10.1021/jm701606b,"A series of potent and selective, triazolylphenyl-based histone deacetylases inhibitors with activity against pancreatic cancer cells and Plasmodium falciparum.",10.1128/aac.00439-08,Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors.,1
51162,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.2c02092,"Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.",1
51162,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,1
51162,10.1016/j.bmc.2009.01.013,Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.,10.1016/j.ejmech.2010.09.024,Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives.,1
51056,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2012.10.131,Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2015.07.024,"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties.",1
55033,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1006/bbrc.2000.3377,"Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate.",1
55033,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1124/jpet.301.1.293,Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.,1
54658,10.1021/jm00124a015,Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists.,10.1016/S0960-894X(01)81066-0,Excitatory amino acids: 6-phosphonomethyltetrahydro-4-pyrimidinecarboxylic acids and their acyclic analogues are competitive N-methyl-D-aspartic acid receptor antagonists.,1
54658,10.1021/jm00124a015,Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists.,10.1016/S0960-894X(00)80087-6,"Pharmacology of (2R, 4R, 5S)-2-amino-4,5-(1,2-cyclohexyl)-7-phosphonoheptanoic acid (NPC 17742); a selective, systemically active, competitive NMDA antagonist",1
54658,10.1021/jm00124a015,Synthesis and pharmacology of a series of 3- and 4-(phosphonoalkyl)pyridine- and -piperidine-2-carboxylic acids. Potent N-methyl-D-aspartate receptor antagonists.,10.1016/S0960-894X(00)80223-1,Competitive NMDA antagonist that base their activity on a unique conformational effect,1
54404,10.1021/jm0209984,"Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.",10.1007/s00044-009-9192-x,"(Hetero)aroyl esters of 2-(N-phthalimido)ethanol and analogues: parallel synthesis, anti-HIV-1 activity and cytotoxicity",1
54404,10.1021/jm0209984,"Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.",10.1016/j.bmc.2008.05.010,Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.,1
53616,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2020.112726,Monoterpenoid-based inhibitors of filoviruses targeting the glycoprotein-mediated entry process.,1
53616,10.1021/jm201301h,Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,10.1021/ml3002715,From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.,1
53616,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2021.113654,Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.,1
53616,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
52874,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
52874,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
52141,10.1021/jm8005838,"Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.",10.1016/j.ejmech.2023.115511,The emerging role of mixed lineage kinase 3 (MLK3) and its potential as a target for neurodegenerative diseases therapies.,1
52141,10.1021/jm8005838,"Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.",10.1021/acs.jmedchem.8b00370,Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration.,1
52141,10.1021/jm8005838,"Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models.",10.1021/jm401094t,"Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.",1
56133,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2011.02.077,"Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.",1
56133,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,10.1016/j.bmcl.2010.10.117,"Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists.",1
56133,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2007.05.079,Design of a partial PPARdelta agonist.,1
56133,10.1021/jm900464j,"Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.",10.1016/j.ejmech.2015.03.006,"Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618.",1
56095,10.1021/acs.jmedchem.8b01961,Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acs.jmedchem.3c01040,Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/acs.jmedchem.0c00500,Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1128/aac.49.6.2153-2163.2005,New small-molecule synthetic antimycobacterials.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.ejmech.2024.116326,Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.,1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1021/jm800038g,"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.",1
55600,10.1021/jm950956y,Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity.,10.1016/j.bmcl.2004.01.010,Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.,1
55033,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajpregu.1999.277.3.r734,Cloning of mouse prostaglandin transporter PGT cDNA: species-specific substrate affinities.,1
55033,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1152/ajprenal.00402.2002,Molecular characterization of human and rat organic anion transporter OATP-D.,1
55033,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1073/pnas.1033060100,The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.,1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.ejmech.2015.03.066,Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.,1
56480,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
56480,10.1007/s00044-012-0010-5,"Molecular drug design, synthesis and pharmacophore site identification of spiroheterocyclic compounds: Trypanosoma crusi inhibiting studies",10.1007/s00044-013-0781-3,"Computational POM evaluation of experimental in vitro Trypanosoma cruzi and Mycobacterium tuberculosis inhibition of heterocyclic-2-carboxylic acid (3-cyano-1,4-di-noxidequinoxalin-2-yl)amide derivatives",1
56133,10.1021/jm900464j,"Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.",10.1021/acs.jmedchem.9b01882,Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.,1
56133,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1021/jm900464j,"Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.",1
56133,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmc.2011.03.053,Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.,1
56133,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2010.11.030,Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.,1
56133,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,10.1021/jm9007399,Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.,1
56133,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.ejmech.2015.03.006,"Synthesis, biological evaluation and molecular modeling studies of the PPARβ/δ antagonist CC618.",1
56133,10.1021/jm900464j,"Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.",10.1021/acs.jmedchem.7b00805,Polypharmacology of N6-(3-Iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA) and Related A3 Adenosine Receptor Ligands: Peroxisome Proliferator Activated Receptor (PPAR) γ Partial Agonist and PPARδ Antagonist Activity Suggests Their Antidiabetic Potential.,1
56133,10.1016/j.bmcl.2009.04.151,Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.,10.1016/j.bmcl.2011.02.077,"Phenoxyacetic acids as PPARδ partial agonists: synthesis, optimization, and in vivo efficacy.",1
56133,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2008.08.011,Discovery of a novel class of PPARdelta partial agonists.,1
56133,10.1016/j.bmcl.2009.04.151,Identification of a PPARdelta agonist with partial agonistic activity on PPARgamma.,10.1016/j.bmc.2011.10.020,"Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.",1
56133,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,10.1021/acs.jmedchem.9b01882,Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.,1
56133,10.1021/jm061202u,Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.,10.1016/j.bmcl.2007.05.051,Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.,1
56480,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2010.01.052,Naftifine-analogues as anti-Trypanosoma cruzi agents.,1
56480,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1039/C0MD00085J,"Development of second generation amidinohydrazones, thio- and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1,3-dioxide core scaffolds",1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm300508n,"Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.",1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm301215e,A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.,1
56480,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2019.04.052,Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.,1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.ejmech.2009.12.061,Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma.,1
56480,10.1016/j.ejmech.2018.02.020,"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.",10.1016/j.bmcl.2018.04.064,Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.,1
56480,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.ejmech.2017.04.075,"Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.",1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.bmc.2013.06.017,"5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.",1
56480,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2011.03.046,In search of patterns over physicochemical properties and pharmacological activities for a set of [MCl₂(thiosemicarbazone)] complexes (M=Pt/Pd): support for multiple mechanisms of antichagasic action excluding DNA-bonding in vivo?,1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2013.08.022,"Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.",1
56480,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,1
56480,10.1016/j.ejmech.2011.04.057,Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.,10.1016/j.ejmech.2012.10.009,"Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.",1
56480,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1039/C1MD00223F,"Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain",1
56480,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1021/jm500018m,Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.,1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2014.08.005,From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.,1
56831,10.1016/j.bmc.2011.03.038,"Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.",10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
56831,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.04.056,Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.,1
56713,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1016/j.bmcl.2009.10.029,Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.,1
56713,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1039/c2md20299a,Prenyltransferase Inhibitors: Treating Human Ailments from Cancer to Parasitic Infections.,1
56480,10.1021/jm9004835,Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.,10.1016/j.ejmech.2017.11.075,Novel triazine dimers with potent antitrypanosomal activity.,1
56480,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1016/j.ejmech.2013.04.065,"Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.",1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.bmcl.2010.06.101,Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides.,1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.bmcl.2017.06.013,Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.,1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.ejmech.2012.10.047,Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.,1
56480,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2014.07.103,Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity.,1
56480,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm201215n,"Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.",1
56480,10.1016/j.bmc.2008.11.065,"Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.",10.1016/j.ejmech.2015.06.048,Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.,1
56480,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.ejmech.2014.09.045,Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.,1
56480,10.1021/jm2002469,"3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.",10.1039/C1MD00223F,"Amidines bearing benzofuroxan or benzimidazole 1,3-dioxide core scaffolds as Trypanosoma cruzi-inhibitors: structural basis for their interactions with cruzipain",1
56480,10.1021/jm301518v,Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.,10.1016/j.ejmech.2014.02.001,Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.,1
60714,10.1016/S0960-894X(01)80178-5,"Synthesis of RPR 100893, prototype of a new series of potent and selective non peptide NK1 antagonists : the triarylperhydroisoindolols.",10.1016/0960-894X(95)00277-Z,"4,4-Diphenyl-7-perhydrothiapyrano[3,4-c]pyrrolone, a new series of substance P receptors antagonists",1
58841,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
58428,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmcl.2011.05.071,In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.,1
58424,10.1016/j.bmc.2018.12.043,"Design, synthesis and identification of novel coumaperine derivatives for inhibition of human 5-LOX: Antioxidant, pseudoperoxidase and docking studies.",10.1016/j.bmc.2019.06.040,"5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach.",1
57200,10.1016/j.bmcl.2010.01.115,Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.,10.1021/jm301848w,On dihydroorotate dehydrogenases and their inhibitors and uses.,1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1021/acs.jmedchem.8b00373,"Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors.",1
57200,10.1016/j.bmcl.2010.01.115,Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures.,10.1016/j.ejmech.2019.111681,Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.,1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1016/j.ejmech.2019.111681,Dihydroorotate dehydrogenase inhibitors in anti-infective drug research.,1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1021/jm501446r,Original 2-(3-alkoxy-1H-pyrazol-1-yl)pyrimidine derivatives as inhibitors of human dihydroorotate dehydrogenase (DHODH).,1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1021/acs.jmedchem.7b01862,"Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase.",1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1016/j.ejmech.2023.116069,Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses.,1
57200,10.1021/ml300464h,SAR Based Optimization of a 4-Quinoline Carboxylic Acid Analog with Potent Anti-Viral Activity.,10.1039/C6MD00024J,Biological evaluation of quinoline derivatives as inhibitors of human dihydroorotate dehydrogenase,1
57175,10.1021/acs.jmedchem.1c00018,Identification of a Novel TAR RNA-Binding Protein 2 Modulator with Potential Therapeutic Activity against Hepatocellular Carcinoma.,10.1021/acs.jmedchem.2c00189,Discovery of a Novel Small-Molecule Inhibitor Disrupting TRBP-Dicer Interaction against Hepatocellular Carcinoma via the Modulation of microRNA Biogenesis.,1
56831,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.01.048,"Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.",1
56831,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C3MD20086H,Synthesis and antifungal activity of the novel triazole compounds,1
56831,10.1016/j.bmc.2007.10.034,Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.,10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
61337,10.1016/j.bmcl.2014.08.002,Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.,10.1016/j.bmcl.2015.07.020,Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1016/j.bmcl.2015.07.020,Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1128/aac.01452-09,In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1021/jm0400101,Control of hepatitis C: a medicinal chemistry perspective.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1021/jm301887f,Achiral pyrazinone-based inhibitors of the hepatitis C virus NS3 protease and drug-resistant variants with elongated substituents directed toward the S2 pocket.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1021/jm100690x,Discovery of a potent and selective noncovalent linear inhibitor of the hepatitis C virus NS3 protease (BI 201335).,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1021/jm401690f,Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.,1
61315,10.1016/j.bmc.2018.08.008,A series of camptothecin prodrugs exhibit HDAC inhibition activity.,10.1021/acs.jmedchem.0c00305,"Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation.",1
61315,10.1016/j.bmc.2018.08.008,A series of camptothecin prodrugs exhibit HDAC inhibition activity.,10.1016/j.ejmech.2020.112628,Histone deacetylase inhibitor based prodrugs.,1
61181,10.1016/j.bmcl.2004.11.032,Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.,10.1016/j.bmc.2016.09.017,Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α1-adrenergic receptor antagonist with uro-selective activity.,1
61181,10.1021/jm990567u,Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).,10.1016/j.ejmech.2010.09.042,Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.,1
61181,10.1021/jm9905918,"Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.",10.1021/acs.jmedchem.5b01528,"Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities.",1
61181,10.1021/jm9905918,"Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.",10.1016/j.ejmech.2010.09.042,Synthesis and α1-adrenoceptor antagonist activity of tamsulosin analogues.,1
61181,10.1021/jm990567u,Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).,10.1021/jm000541z,Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.,1
61181,10.1021/jm9905918,"Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.",10.1016/j.ejmech.2011.04.032,"Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties.",1
61181,10.1021/jm9905918,"Design, synthesis, and structure-activity relationships of phthalimide-phenylpiperazines: a novel series of potent and selective alpha(1)(a)-adrenergic receptor antagonists.",10.1021/acs.jmedchem.6b01217,"Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α1A-Adrenoceptor Antagonists.",1
61945,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1021/acs.jmedchem.0c02252,Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.,1
61945,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1021/acs.jmedchem.9b00796,Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.,1
61945,10.1021/acs.jmedchem.0c02252,Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.,10.1021/acs.jmedchem.2c00911,"Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity.",1
61945,10.1021/acs.jmedchem.0c02252,Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.,10.1016/j.bmcl.2022.128841,Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.,1
61945,10.1021/acs.jmedchem.0c02252,Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.,10.1021/acs.jmedchem.2c01975,"Advances in Epilepsy: Mechanisms, Clinical Trials, and Drug Therapies.",1
61682,10.1021/jm020002p,Structure-based approach for binding site identification on AmpC beta-lactamase.,10.1128/aac.01762-09,Phenotypic and biochemical comparison of the carbapenem-hydrolyzing activities of five plasmid-borne AmpC β-lactamases.,1
61682,10.1021/jm00074a002,Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.,10.1016/j.ejmech.2021.113436,"A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.",1
61682,10.1016/j.bmc.2007.08.001,A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.,10.1016/j.bmc.2021.116343,A novel tricyclic β-lactam exhibiting potent antibacterial activities against carbapenem-resistant Enterobacterales: Synthesis and structure-activity-relationships.,1
61682,10.1021/jm020002p,Structure-based approach for binding site identification on AmpC beta-lactamase.,10.1128/aac.00608-08,Role of the Ser-287-Asn replacement in the hydrolysis spectrum extension of AmpC beta-lactamases in Escherichia coli.,1
61682,10.1016/j.bmc.2007.08.001,A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.,10.1016/j.bmcl.2018.01.006,Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.,1
61682,10.1021/jm020002p,Structure-based approach for binding site identification on AmpC beta-lactamase.,10.1016/j.bmc.2007.11.074,Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure.,1
61682,10.1021/jm00074a002,Structure-activity relationship within a series of pyrazolidinone antibacterial agents. 2. Effect of side-chain modification on in vitro activity and pharmacokinetic parameters.,10.1021/acs.jmedchem.0c00255,A γ-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli.,1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1016/j.bmcl.2008.02.053,"Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.",1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1021/acs.jmedchem.3c01971,"Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?",1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1128/aac.00677-09,"MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.",1
61337,10.1021/jm0342414,Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.,10.1016/j.bmcl.2008.07.124,Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.,1
1125,10.1016/j.bmc.2014.09.021,"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.",10.1016/j.bmc.2015.06.050,"Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2007.07.019,"Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.",1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmc.2017.05.005,"Potential inhibitors of human carbonic anhydrase isozymes I and II: Design, synthesis and docking studies of new 1,3,4-thiadiazole derivatives.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/s0960-894x(03)00628-0,"Inhibition of Src kinase activity by 4-anilino-5,10-dihydro-pyrimido[4,5-b]quinolines.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2005.07.061,"Inhibition of Src kinase activity by 7-[(2,4-dichloro-5-methoxyphenyl)amino]-2-heteroaryl-thieno[3,2-b]pyridine-6-carbonitriles.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/s0960-894x(02)00302-5,Inhibition of Src kinase activity by 4-anilino-7-thienyl-3-quinolinecarbonitriles.,1
62111,10.1016/j.bmcl.2005.01.004,Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.,10.1016/j.bmcl.2009.07.043,4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.,1
62111,10.1016/j.bmcl.2005.01.004,Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.,10.1021/jm061031t,"Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmc.2009.02.054,Structure-based virtual screening of Src kinase inhibitors.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2008.10.006,"The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2005.01.004,Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2009.07.043,4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2003.07.001,Investigation of the effect of varying the 4-anilino and 7-alkoxy groups of 3-quinolinecarbonitriles on the inhibition of Src kinase activity.,1
62111,10.1016/j.bmcl.2005.01.004,Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor.,10.1016/j.bmcl.2010.03.025,Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.,1
61945,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1021/acs.jmedchem.2c00911,"Beyond Retigabine: Design, Synthesis, and Pharmacological Characterization of a Potent and Chemically Stable Neuronal Kv7 Channel Activator with Anticonvulsant Activity.",1
61945,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1016/j.bmcl.2022.128841,Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2018.03.032,Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.,1
62111,10.1021/jm501929n,Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.,10.1021/acs.jmedchem.1c01030,Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers.,1
62111,10.1021/jm061031t,"Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.",10.1016/j.bmc.2007.09.028,Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2012.01.052,Design and synthesis of thiourea compounds that inhibit transmembrane anchored carbonic anhydrases.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.10.006,"Poly(amidoamine) dendrimers show carbonic anhydrase inhibitory activity against α-, β-, γ- and η-class enzymes.",1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1021/acs.jmedchem.8b01504,4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2016.04.002,Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds.,1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2020.112923,Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.,1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm060807n,"Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1021/jm501573b,"Synthesis and carbonic anhydrase isoenzymes I, II, IX, and XII inhibitory effects of dimethoxybromophenol derivatives incorporating cyclopropane moieties.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2014.09.021,"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.",1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2022.114412,Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.01.005,"Cloning, characterization and anion inhibition studies of a γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.",1
1125,10.1016/j.bmc.2017.03.017,Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.,10.1016/j.ejmech.2019.111702,"Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.12.040,Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa.,1
63252,10.1021/acs.jmedchem.8b00106,Further Developments of the Phenyl-Pyrrolyl Pentane Series of Nonsteroidal Vitamin D Receptor Modulators as Anticancer Agents.,10.1016/j.ejmech.2018.12.024,Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.,1
63252,10.1021/acs.jmedchem.8b00106,Further Developments of the Phenyl-Pyrrolyl Pentane Series of Nonsteroidal Vitamin D Receptor Modulators as Anticancer Agents.,10.1016/j.ejmech.2018.08.085,"Sulfonyl-containing phenyl-pyrrolyl pentane analogues: Novel non-secosteroidal vitamin D receptor modulators with favorable physicochemical properties, pharmacokinetic properties and anti-tumor activity.",1
63252,10.1016/j.bmc.2013.01.042,A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.,10.1016/j.bmc.2015.01.007,Structural development of stapled short helical peptides as vitamin D receptor (VDR)-coactivator interaction inhibitors.,1
62864,10.1016/j.ejmech.2008.01.029,Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.,10.1016/j.bmc.2019.115162,Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators.,1
62864,10.1021/acs.jmedchem.8b00835,Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.,10.1016/j.ejmech.2024.116567,A chemical modification of a peroxisome proliferator-activated receptor pan agonist produced a shift to a new dual alpha/gamma partial agonist endowed with mitochondrial pyruvate carrier inhibition and antidiabetic properties.,1
62864,10.1016/j.bmc.2010.12.023,Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.,10.1016/j.bmc.2015.11.013,Identification of dual PPARα/γ agonists and their effects on lipid metabolism.,1
62259,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
62259,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.ejmech.2024.116364,The role of the methoxy group in approved drugs.,1
62111,10.1021/jm061031t,"Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles.",10.1016/j.bmcl.2009.07.043,4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmc.2007.09.028,Facile preparation of new 4-phenylamino-3-quinolinecarbonitrile Src kinase inhibitors via 7-fluoro intermediates: identification of potent 7-amino analogs.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1021/acs.jmedchem.5b01618,"Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.",1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmc.2008.04.065,Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2010.03.025,Optimization of 7-alkene-3-quinolinecarbonitriles as Src kinase inhibitors.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/s0960-894x(02)00577-2,Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors.,1
62111,10.1021/jm0102250,Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity.,10.1016/j.bmcl.2004.02.035,Synthesis and inhibition of Src kinase activity by 7-ethenyl and 7-ethynyl-4-anilino-3-quinolinecarbonitriles.,1
64200,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.05.025,"Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.",1
64200,10.1016/j.ejmech.2008.12.028,Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase.,10.1016/j.bmcl.2012.12.022,Novel diaryl ureas with efficacy in a mouse model of malaria.,1
64200,10.1021/jm9017724,Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.,10.1016/j.bmcl.2013.02.019,"Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.",1
64102,10.1021/jm00403a025,Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.,10.1021/jm960435q,Repromicin derivatives with potent antibacterial activity against Pasteurella multocida.,1
64102,10.1021/jm00403a025,Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: a new series of orally effective antibiotics.,10.1021/jm0308951,Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues.,1
63649,10.1016/j.ejmech.2016.03.015,Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.,10.1016/j.ejmech.2019.05.035,"Design, synthesis and biological evaluation of the thioether-containing lenalidomide analogs with anti-proliferative activities.",1
63649,10.1021/acs.jmedchem.0c01313,"Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.",10.1021/acs.jmedchem.3c00851,Leveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.,1
63649,10.1021/acs.jmedchem.0c01313,"Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.",10.1039/d2md00347c,Structural rationalization of GSPT1 and IKZF1 degradation by thalidomide molecular glue derivatives.,1
63649,10.1016/j.ejmech.2016.03.015,Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.,10.1016/j.ejmech.2021.113353,"In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.",1
63649,10.1016/j.ejmech.2016.03.015,Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.,10.1016/j.ejmech.2020.112912,"Design, synthesis and biological evaluation of thioether-containing lenalidomide and pomalidomide derivatives with anti-multiple myeloma activity.",1
63401,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(01)00668-0,Phthalazine PDE4 inhibitors. Part 3: the synthesis and in vitro evaluation of derivatives with a hydrogen bond acceptor.,1
63401,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(98)00572-1,Orally active indole N-oxide PDE4 inhibitors.,1
63401,10.1021/jm970685m,Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.,10.1016/s0960-894x(98)00324-2,The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I.,1
63252,10.1021/acs.jmedchem.8b00106,Further Developments of the Phenyl-Pyrrolyl Pentane Series of Nonsteroidal Vitamin D Receptor Modulators as Anticancer Agents.,10.1021/acs.jmedchem.8b01165,"Design, Synthesis, and Antifibrosis Activity in Liver of Nonsecosteroidal Vitamin D Receptor Agonists with Phenyl-pyrrolyl Pentane Skeleton.",1
63252,10.1016/j.bmc.2013.01.042,A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.,10.1016/j.bmc.2018.11.008,Structural development of non-secosteroidal vitamin D receptor (VDR) ligands without any asymmetric carbon.,1
63252,10.1016/j.bmc.2013.01.042,A series of nonsecosteroidal vitamin D receptor agonists for osteoporosis therapy.,10.1016/j.ejmech.2015.10.042,Novel nonsecosteroidal VDR ligands with phenyl-pyrrolyl pentane skeleton for cancer therapy.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1101/2020.04.16.044016,A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acs.jmedchem.2c01516,"Novel 3-Trifluoromethyl-1,2,4-oxadiazole Analogues of Astemizole with Multi-stage Antiplasmodium Activity and <i>In Vivo</i> Efficacy in a <i>Plasmodium berghei</i> Mouse Malaria Infection Model.",1
65605,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1128/aac.00431-10,Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1016/j.bmcl.2008.11.047,Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acs.jmedchem.3c00206,Basic Nitrogen (BaN) Is a Key Property of Antimalarial Chemical Space.,1
65415,10.1016/j.bmcl.2010.09.051,"Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.",10.1016/j.bmcl.2016.01.005,"1-[3-(2-Hydroxyethylsulfanyl)propanoyl]-3,5-bis(benzylidene)-4-piperidones: A novel cluster of P-glycoprotein dependent multidrug resistance modulators.",1
65415,10.1016/j.ejmech.2010.09.058,"Structure-cytotoxicity relationship in a series of N-phosphorus substituted E,E-3,5-bis(3-pyridinylmethylene)- and E,E-3,5-bis(4-pyridinylmethylene)piperid-4-ones.",10.1016/j.bmc.2014.12.042,"Investigation of fatty acid conjugates of 3,5-bisarylmethylene-4-piperidone derivatives as antitumor agents and human topoisomerase-IIα inhibitors.",1
65415,10.1016/j.bmcl.2010.09.051,"Sequential cytotoxicity: a theory examined using a series of 3,5-bis(benzylidene)-1-diethylphosphono-4-oxopiperidines and related phosphonic acids.",10.1016/j.bmc.2016.03.056,"Tumour-specific cytotoxicity and structure-activity relationships of novel 1-[3-(2-methoxyethylthio)propionyl]-3,5-bis(benzylidene)-4-piperidones.",1
65415,10.1021/ml500141f,Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.,10.1016/j.bmc.2021.116341,Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer.,1
65351,10.1021/jm00088a011,Quinolone antibacterial agents. Synthesis and structure-activity relationships of a series of amino acid prodrugs of racemic and chiral 7-(3-amino-1-pyrrolidinyl)quinolones. Highly soluble quinolone prodrugs with in vivo pseudomonas activity.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
65351,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
65351,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmcl.2007.01.038,"Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.",1
65351,10.1016/S0960-894X(97)00054-1,"Synthesis and structural optimization of 7-(3,3-disubstituted-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids as antibacterial agents",10.1016/s0960-894x(98)00390-4,Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.,1
64200,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.11.032,"Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.",1
64200,10.1021/jm9017724,Identification and development of novel inhibitors of Toxoplasma gondii enoyl reductase.,10.1016/j.bmcl.2013.04.035,Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.,1
67617,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,1
67617,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2018.07.047,Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.,1
67617,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.bmcl.2020.127579,"Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents.",1
67617,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
67617,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,1
67617,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2021.113472,"Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis.",1
67010,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.bmcl.2009.02.085,Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.,1
67010,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
66136,10.1021/jm00037a016,Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.,10.1021/acs.jmedchem.2c01265,Targeting Sterol <i>O</i>-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,1
66136,10.1021/jm00037a016,Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-[(1-phenylcyclopentyl)methyl]ureas with enhanced hypocholesterolemic activity.,10.1016/0960-894X(95)00387-9,A series of conformationally and sterically constrained analogs of N-phenyl-N-aralkylurea ACAT inhibitors,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acsmedchemlett.3c00496,"hERG, <i>Plasmodium</i> Life Cycle, and Cross Resistance Profiling of New Azabenzimidazole Analogues of Astemizole.",1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1021/acsmedchemlett.1c00328,Structure-Activity Relationship Studies Reveal New Astemizole Analogues Active against <i>Plasmodium falciparum</i> In Vitro.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1016/j.bmc.2017.10.004,Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds.,1
65605,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
65605,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
67617,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.bmcl.2017.10.071,"Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives.",1
67617,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
67617,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
67617,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmcl.2015.12.083,"Synthesis, in vitro antimycobacterial evaluation and docking studies of some new 5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-one schiff bases.",1
67617,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.11.032,"Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.",1
67617,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
67617,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
67617,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1039/d1md00367d,"Design, synthesis and anti-mycobacterial evaluation of imidazo[1,2-<i>a</i>]pyridine analogues.",1
67617,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
67617,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
67617,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
67617,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
67617,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2018.03.020,Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.,1
67617,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,1
67617,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.bmcl.2018.11.036,"Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents.",1
67617,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
67987,10.1016/j.bmcl.2011.11.043,Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay.,10.1016/j.ejmech.2018.08.093,DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.,1
67987,10.1016/j.bmc.2009.10.063,Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.,10.1016/j.bmcl.2014.05.008,Naturally occurring polyphenolic inhibitors of amyloid beta aggregation.,1
67987,10.1016/j.ejmech.2021.113929,"Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PA<sub>N</sub> inhibitors.",10.1021/acs.jmedchem.2c00857,Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PA<sub>N</sub> Endonuclease Inhibitors.,1
67987,10.1016/j.bmc.2009.10.063,Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.,10.1016/j.ejmech.2019.01.039,On the role of synthesized hydroxylated chalcones as dual functional amyloid-β aggregation and ferroptosis inhibitors for potential treatment of Alzheimer's disease.,1
67617,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2020.127512,Design and synthesis of purine connected piperazine derivatives as novel inhibitors of Mycobacterium tuberculosis.,1
67617,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2018.07.047,Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.,1
67617,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.05.025,"Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.",1
67617,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1021/acs.jnatprod.9b00475,"Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.",1
67617,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmc.2016.01.059,"Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",1
67617,10.1016/j.bmc.2014.05.038,"Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.",10.1016/j.bmcl.2016.04.088,"Synthesis and antitubercular evaluation of novel dibenzo[b,d]thiophene tethered imidazo[1,2-a]pyridine-3-carboxamides.",1
67617,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,1
67617,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.0c01833,"Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.",1
67617,10.1016/j.ejmech.2009.02.013,Synthesis and antitubercular screening of imidazole derivatives.,10.1021/ml4002248,Identification of 1-[4-Benzyloxyphenyl)-but-3-enyl]-1H-azoles as New Class of Antitubercular and Antimicrobial Agents.,1
67617,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2013.11.031,"Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.",1
67617,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,1
67617,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2016.09.043,Identification and optimization of a new series of anti-tubercular quinazolinones.,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.ejmech.2013.07.011,"Design, synthesis and biological evaluation of novel mansonone E derivatives prepared via CuAAC click chemistry as topoisomerase II inhibitors.",1
68607,10.1016/j.ejmech.2016.09.004,Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.,10.1016/j.ejmech.2018.01.010,Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmc.2009.08.064,"Pyranonaphthoquinone derivatives of eleutherin, ventiloquinone L, thysanone and nanaomycin A possessing a diverse topoisomerase II inhibition and cytotoxicity spectrum.",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.ejmech.2016.06.024,Scaffold-hopping of bioactive flavonoids: Discovery of aryl-pyridopyrimidinones as potent anticancer agents that inhibit catalytic role of topoisomerase IIα.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.ejmech.2017.01.001,"Synthesis of 2,3,6,7-tetramethoxyphenanthren-9-amine: An efficient precursor to access new 4-aza-2,3-dihydropyridophenanthrenes as apoptosis inducing agents.",1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.bmc.2013.11.035,"Design, synthesis and cytotoxic activity of novel sulfonylurea derivatives of podophyllotoxin.",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmc.2013.07.016,Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity.,1
68607,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2023.115116,ATP-competitive inhibitors of human DNA topoisomerase IIα with improved antiproliferative activity based on N-phenylpyrrolamide scaffold.,1
68396,10.1021/jm051225t,Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.,10.1016/j.bmc.2011.01.042,Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.,1
68396,10.1021/jm300146f,Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping.,10.1021/acs.jmedchem.5b01653,The Medicinal Chemistry of Dengue Virus.,1
68396,10.1021/jm051225t,Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.,10.1021/jm100424m,Triazole-linked inhibitors of inosine monophosphate dehydrogenase from human and Mycobacterium tuberculosis.,1
68396,10.1021/jm051225t,Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.,10.1016/j.bmcl.2011.11.078,"The design, synthesis and in vitro immunosuppressive evaluation of novel isobenzofuran derivatives.",1
68396,10.1016/j.bmcl.2018.04.045,"Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors.",10.1016/j.ejmech.2018.09.016,Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents.,1
68396,10.1016/j.bmcl.2018.04.045,"Hit discovery of Mycobacterium tuberculosis inosine 5'-monophosphate dehydrogenase, GuaB2, inhibitors.",10.1039/C9MD00179D,Inhibitors of inosine 5'-monophosphate dehydrogenase as emerging new generation antimicrobial agents.,1
68396,10.1021/jm051225t,Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.,10.1021/jm070864w,Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.,1
68396,10.1021/jm051225t,Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target.,10.1016/j.bmc.2008.08.062,Mycophenolic acid analogs with a modified metabolic profile.,1
68607,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
68607,10.1016/j.ejmech.2016.02.050,"A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.",10.1016/j.ejmech.2019.03.034,A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.,1
68607,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,10.1016/j.ejmech.2020.112830,"Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmcl.2012.12.063,Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.ejmech.2013.03.068,"Synthesis and cytotoxic activity on human cancer cells of carbamate derivatives of 4β-(1,2,3-triazol-1-yl)podophyllotoxin.",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmc.2017.02.024,5-Ethynylarylnaphthalimides as antitumor agents: Synthesis and biological evaluation.,1
68607,10.1016/j.ejmech.2016.02.050,"A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.",10.1016/j.bmc.2018.09.019,"Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.",1
68607,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,10.1016/j.ejmech.2014.10.050,"Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.",1
68607,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,10.1016/j.bmcl.2016.07.072,"Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.ejmech.2011.01.011,"Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.",1
68607,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2017.08.032,"Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.",1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1016/j.bmcl.2016.12.040,Synthesis and biological evaluation of naphthoquinone-coumarin conjugates as topoisomerase II inhibitors.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.bmcl.2014.10.082,Synthesis and evaluation of ether-linked demethylepipodophyllotoxin dimers.,1
68607,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
68607,10.1016/j.ejmech.2016.02.050,"A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.",10.1016/j.ejmech.2017.01.003,"Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.",1
68607,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2020.112830,"Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).",1
68607,10.1016/j.ejmech.2013.11.010,"Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties.",10.1016/j.ejmech.2016.07.007,"Amino substituted benzimidazo[1,2-a]quinolines: Antiproliferative potency, 3D QSAR study and DNA binding properties.",1
68607,10.1021/jm020913z,"Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.",10.1016/j.ejmech.2019.111960,"Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.",1
68607,10.1016/j.ejmech.2013.11.010,"Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties.",10.1016/j.ejmech.2019.01.017,Quinolone hybrids and their anti-cancer activities: An overview.,1
68607,10.1016/j.bmc.2011.10.012,"Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.",10.1016/j.bmc.2015.04.022,"Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.",1
68607,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.bmc.2018.02.042,Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.ejmech.2014.01.038,Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions.,1
68607,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,10.1016/j.ejmech.2017.12.050,4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.,1
68607,10.1016/j.ejmech.2021.113916,"Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.",10.1016/j.bmc.2023.117403,"Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.",1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.bmc.2011.03.030,Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents.,1
68607,10.1016/j.bmcl.2021.127899,Multicomponent synthesis and anti-proliferative screening of biaryl triazole-containing cyclophanes.,10.1016/j.bmcl.2022.128628,Expanding the structure-activity relationship of cytotoxic diphenyl macrocycles.,1
68607,10.1016/j.ejmech.2015.03.046,Synthesis and identification of unprecedented selective inhibitors of CK1ε.,10.1016/j.ejmech.2017.11.003,A green multicomponent synthesis of tocopherol analogues with antiproliferative activities.,1
68607,10.1016/j.bmc.2011.10.012,"Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.",10.1016/j.ejmech.2014.09.050,"Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents.",1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.ejmech.2011.06.004,Synthesis and biological evaluation of derivatives of 4-deoxypodophyllotoxin as antitumor agents.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1021/jm200737s,Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.,1
68607,10.1021/np010176u,Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity.,10.1021/np020282b,Triterpenoid constituents isolated from the bark of Abies sachalinensis.,1
68607,10.1016/j.ejmech.2019.04.055,"Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.",10.1016/j.ejmech.2020.112459,Synthesis and biological evaluation of novel pyrazoline derivatives containing indole skeleton as anti-cancer agents targeting topoisomerase II.,1
68607,10.1016/j.ejmech.2016.02.050,"A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.",10.1021/acs.jmedchem.7b01202,Discovery of Novel Topoisomerase II Inhibitors by Medicinal Chemistry Approaches.,1
68607,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2019.03.034,A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1021/acsmedchemlett.5b00040,Switch in Site of Inhibition: A Strategy for Structure-Based Discovery of Human Topoisomerase IIα Catalytic Inhibitors.,1
68607,10.1021/acs.jmedchem.2c00615,Optimization of the Natural Product Calothrixin A to Discover Novel Dual Topoisomerase I and II Inhibitors with Improved Anticancer Activity.,10.1021/acs.jmedchem.4c00982,"Discovery of Indolo[3,2-<i>c</i>]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity.",1
68607,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2023.115116,ATP-competitive inhibitors of human DNA topoisomerase IIα with improved antiproliferative activity based on N-phenylpyrrolamide scaffold.,1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.bmcl.2008.08.050,Synthesis of unsymmetrical biphenyls as potent cytotoxic agents.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.bmcl.2011.10.024,"Carbamates of 4'-demethyl-4-deoxypodophyllotoxin: synthesis, cytotoxicity and cell cycle effects.",1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.bmc.2013.01.069,"Design, synthesis and potent cytotoxic activity of novel podophyllotoxin derivatives.",1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1021/jm200235u,N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.,1
68607,10.1016/j.bmc.2018.09.021,"A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.",10.1016/j.ejmech.2021.113916,"Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.",1
68607,10.1016/j.bmc.2018.09.021,"A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.",10.1016/j.ejmech.2021.113860,"Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison.",1
68607,10.1016/j.ejmech.2021.113916,"Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors.",10.1016/j.ejmech.2022.114999,Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.,1
68607,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.bmcl.2011.04.036,Three new cytotoxic aryltetralin lignans from Sinopodophyllum emodi.,1
68607,10.1016/j.ejmech.2013.09.053,Synthesis and evaluation of the apoptosis inducing and CT DNA interaction properties of a series of 4β-carbamoyl 4'-O-demethylepipodophyllotoxins.,10.1016/j.bmc.2015.02.048,In vitro radical scavenging and cytotoxic activities of novel hybrid selenocarbamates.,1
70140,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,10.1021/acs.jmedchem.2c00134,"Design, Synthesis, and Proof-of-Concept of Triple-Site Inhibitors against Aminoacyl-tRNA Synthetases.",1
70140,10.1039/C8MD00257F,Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.,10.1016/j.bmc.2019.07.023,Natural product derived promising anti-MRSA drug leads: A review.,1
70140,10.1016/j.bmc.2014.01.020,Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections.,10.1016/j.bmcl.2016.08.095,Synthesis and antibacterial evaluation of hamacanthin B analogues.,1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1021/jm500270w,Membrane active vancomycin analogues: a strategy to combat bacterial resistance.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.bmc.2013.09.026,Synthesis and evaluation of the cell cycle arrest and CT DNA interaction properties of 4β-amino-4'-O-demethyl-4-deoxypodophyllotoxins.,1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1021/np900821e,Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.,1
68607,10.1021/jm0495733,Synthesis and biological study of a new series of 4'-demethylepipodophyllotoxin derivatives.,10.1016/j.bmc.2018.02.050,"Sulfamic acid promoted one-pot synthesis of phenanthrene fused-dihydrodibenzo-quinolinones: Anticancer activity, tubulin polymerization inhibition and apoptosis inducing studies.",1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.ejmech.2017.12.050,4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1039/C3MD00125C,3-Formylchromone based topoisomerase II inhibitors: discovery of potent leads,1
68607,10.1021/jm800499x,Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.,10.1021/acs.jmedchem.5b01284,"Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives as Nonintercalative Topoisomerase II Catalytic Inhibitors.",1
68607,10.1021/np030373o,Current developments in the discovery and design of new drug candidates from plant natural product leads.,10.1016/j.ejmech.2012.10.026,Lignopurines: a new family of hybrids between cyclolignans and purines. Synthesis and biological evaluation.,1
68607,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,1
68607,10.1016/j.ejmech.2016.09.004,Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.,10.1016/j.bmcl.2018.03.017,Synthesis and biological evaluation of novel carbazole-rhodanine conjugates as topoisomerase II inhibitors.,1
68607,10.1016/j.bmc.2018.09.021,"A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.",10.1016/j.ejmech.2019.03.034,A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.,1
68607,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1016/j.ejmech.2015.01.011,Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.,1
68607,10.1016/j.ejmech.2019.04.055,"Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.",10.1016/j.bmc.2023.117403,"Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure-activity relationships.",1
70140,10.1021/acs.jmedchem.5b00366,"Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.",10.1021/acs.jmedchem.6b00219,Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action.,1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1021/jm4004494,Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.,1
70140,10.1021/acs.jmedchem.6b00726,Antibacterial and Solubility Optimization of Thiomuracin A.,10.1016/j.bmc.2018.05.031,Facilely accessible quinoline derivatives as potent antibacterial agents.,1
70140,10.1021/acs.jmedchem.9b00394,Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.,10.1021/acsmedchemlett.2c00111,"1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.",1
70140,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.ejmech.2020.112245,Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA).,1
70140,10.1016/j.bmcl.2004.02.047,DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids.,10.1128/aac.01709-08,Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.,1
70140,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
70140,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.bmcl.2017.01.019,Synthesis and in vitro activity of dicationic indolyl diphenyl ethers as novel potent antibiotic agents against drug-resistant bacteria.,1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1016/j.bmcl.2015.12.027,A stepwise dechlorination/cross-coupling strategy to diversify the vancomycin 'in-chloride'.,1
70140,10.1016/0960-894X(96)00154-0,Synthesis and antibacterial activity of new tropone-substituted phenyloxazolidinone antibacterial agents 1. Identification of leads and importance of the tropone substitution pattern,10.1021/jm800038g,"Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.",1
70140,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1021/acs.jmedchem.8b01093,Battle against Vancomycin-Resistant Bacteria: Recent Developments in Chemical Strategies.,1
70140,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1039/d2md00415a,Oxazolidinones as versatile scaffolds in medicinal chemistry.,1
70140,10.1021/acs.jmedchem.5b00366,"Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.",10.1021/acs.jmedchem.3c00181,Structure-Activity Relationship Study of Antimicrobial Peptide PE2 Delivered Novel Linear Derivatives with Potential of Eradicating Biofilms and Low Incidence of Drug Resistance.,1
70140,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,10.1021/acs.jmedchem.2c01496,Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.,1
70140,10.1039/C9MD00044E,Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): antibiotic-resistance and the biofilm phenotype.,10.1016/j.ejmech.2023.115853,"Development of teixobactin analogues containing hydrophobic, non-proteogenic amino acids that are highly potent against multidrug-resistant bacteria and biofilms.",1
70140,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/d3md00204g,"Design, synthesis and evaluation of halogenated phenazine antibacterial prodrugs targeting nitroreductase enzymes for activation.",1
70140,10.1016/j.bmcl.2004.02.047,DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acids.,10.1021/jm900519b,"Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents.",1
70140,10.1016/j.bmcl.2009.06.006,The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2010.03.044,"4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: novel C7 moieties of fluoroquinolones as antibacterial agents.",1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1039/C0MD00230E,New insight into the mode of action of vancomycin dimers in bacterial cell wall synthesis,1
70140,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1021/acs.jmedchem.2c00134,"Design, Synthesis, and Proof-of-Concept of Triple-Site Inhibitors against Aminoacyl-tRNA Synthetases.",1
70140,10.1016/j.ejmech.2016.09.054,Structure-activity relationships and optimization of acyclic acylphloroglucinol analogues as novel antimicrobial agents.,10.1016/j.bmc.2019.07.023,Natural product derived promising anti-MRSA drug leads: A review.,1
70140,10.1016/j.ejmech.2016.09.054,Structure-activity relationships and optimization of acyclic acylphloroglucinol analogues as novel antimicrobial agents.,10.1021/acs.jnatprod.9b00064,"Callistemonols A and B, Potent Antimicrobial Acylphloroglucinol Derivatives with Unusual Carbon Skeletons from <i>Callistemon viminalis</i>.",1
70140,10.1021/acs.jmedchem.6b00726,Antibacterial and Solubility Optimization of Thiomuracin A.,10.1021/acs.jnatprod.2c00120,Micrococcin P2 Targets <i>Clostridioides difficile</i>.,1
70140,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1021/jm200010x,Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.,1
70140,10.1021/jm960207w,Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
70140,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2020.112245,Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA).,1
70140,10.1016/j.ejmech.2019.112022,"N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification.",10.1016/j.ejmech.2022.115026,Current scenario of quinolone hybrids with potential antibacterial activity against ESKAPE pathogens.,1
70140,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.ejmech.2010.09.045,The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains.,1
70140,10.1016/j.bmc.2014.01.020,Discovery and optimization of a new class of pyruvate kinase inhibitors as potential therapeutics for the treatment of methicillin-resistant Staphylococcus aureus infections.,10.1021/acs.jmedchem.0c00826,Nature-Inspired (di)Azine-Bridged Bisindole Alkaloids with Potent Antibacterial In Vitro and In Vivo Efficacy against Methicillin-Resistant Staphylococcus aureus.,1
70140,10.1021/jm9017543,Discovery of a novel series of semisynthetic vancomycin derivatives effective against vancomycin-resistant bacteria.,10.1021/acs.jmedchem.2c01293,Targeting Vancomycin-Resistant <i>Enterococci</i> (VRE) Infections and Van Operon-Mediated Drug Resistance Using Dimeric Cholic Acid-Peptide Conjugates.,1
70140,10.1039/C9MD00044E,Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): antibiotic-resistance and the biofilm phenotype.,10.1021/acs.jmedchem.4c00436,"Development of Membrane-Targeting Fluorescent 2-Phenyl-1&lt;i&gt;H&lt;/i&gt;-phenanthro[9,10-&lt;i&gt;d&lt;/i&gt;]imidazole-Antimicrobial Peptide Mimic Conjugates against Methicillin-Resistant &lt;i&gt;Staphylococcus aureus&lt;/i&gt;.",1
71256,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2019.111691,Indole: A privileged scaffold for the design of anti-cancer agents.,1
71256,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.bmc.2021.116597,Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents.,1
71256,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.bmcl.2019.126816,"Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors.",1
71256,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1039/d2md00442a,"Design, synthesis and <i>in vitro</i> cytotoxicity evaluation of indolo-pyrazoles grafted with thiazolidinone as tubulin polymerization inhibitors.",1
71256,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1016/j.bmc.2021.116597,Indole derivatives as tubulin polymerization inhibitors for the development of promising anticancer agents.,1
71256,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.bmcl.2020.127635,"Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility.",1
70140,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/D1MD00230A,"Design, synthesis, and antibacterial activity of <i>N</i>-(trifluoromethyl)phenyl substituted pyrazole derivatives.",1
70140,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2023.115689,Thiazole-based analogues as potential antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) and their SAR elucidation.,1
70140,10.1039/C9MD00044E,Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): antibiotic-resistance and the biofilm phenotype.,10.1016/j.ejmech.2024.116274,Novel membrane-targeting isoxanthohumol-amine conjugates for combating methicillin-resistant Staphylococcus aureus (MRSA) infections.,1
70140,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1016/j.bmcl.2011.06.081,"Unprecedented C-2 arylation of indole with diazonium salts: Syntheses of 2,3-disubstituted indoles and their antimicrobial activity.",1
70140,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1021/acs.jmedchem.2c01496,Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.,1
70140,10.1021/acs.jmedchem.1c01754,Lysine Stapling Screening Provides Stable and Low Toxic Cationic Antimicrobial Peptides Combating Multidrug-Resistant Bacteria <i>In Vitro</i> and <i>In Vivo</i>.,10.1021/acs.jmedchem.2c00661,Lysine-Tethered Stable Bicyclic Cationic Antimicrobial Peptide Combats Bacterial Infection in Vivo.,1
70140,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1021/acs.jmedchem.7b00108,Triaryl Benzimidazoles as a New Class of Antibacterial Agents against Resistant Pathogenic Microorganisms.,1
70140,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.bmcl.2019.126887,Synthesis and in vitro activity of asymmetric indole-based bisamidine compounds against Gram-positive and Gram-negative pathogens.,1
70140,10.1021/acs.jmedchem.5b00366,"Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.",10.1016/j.ejmech.2023.115638,"A facile and selective derivatization approach on kynurenine-NH<sub>2</sub> in daptomycin, leading to the discovery of hexakynomycin to combat multidrug-resistant Gram-positive pathogens especially daptomycin-resistant bacteria.",1
70140,10.1016/j.ejmech.2016.09.054,Structure-activity relationships and optimization of acyclic acylphloroglucinol analogues as novel antimicrobial agents.,10.1039/C8MD00257F,Structural optimization and antibacterial evaluation of rhodomyrtosone B analogues against MRSA strains.,1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmc.2013.03.068,Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/j.bmc.2013.07.014,Synthesis of novel acridine and bis acridine sulfonamides with effective inhibitory activity against the cytosolic carbonic anhydrase isoforms II and VII.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/acs.jmedchem.5b00523,6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2015.10.018,New natural product carbonic anhydrase inhibitors incorporating phenol moieties.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1021/jm3014376,Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.,1
71516,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1021/jm500530v,One-pot synthesis of vinca alkaloids-phomopsin hybrids.,1
71516,10.1097/00001813-199607000-00012,Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.,10.1021/jm020941h,Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).,1
71516,10.1016/j.bmcl.2018.02.006,High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.,10.1016/j.bmcl.2019.03.036,Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.,1
71516,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1021/ml400281w,Potent Vinblastine C20' Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line.,1
71516,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2019.111691,Indole: A privileged scaffold for the design of anti-cancer agents.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.bmcl.2015.02.045,Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1021/acs.jmedchem.7b00958,Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.,1
71516,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1021/acs.jmedchem.6b00525,Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1021/acs.jmedchem.6b00525,Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.,1
71516,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1016/j.bmcl.2015.02.045,Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1016/j.bmcl.2019.03.036,Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.,1
71516,10.1016/j.bmcl.2009.03.121,Discovery of substituted N'-(2-oxoindolin-3-ylidene)benzohydrazides as new apoptosis inducers using a cell- and caspase-based HTS assay.,10.1007/s00044-010-9361-y,"Design, synthesis, and QSAR study of novel 2-(2,3-dioxo-2,3-dihydro-1H-indol-1-yl)-N-phenylacetamide derivatives as cytotoxic agents",1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.bmcl.2019.03.036,Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,1
1125,10.1016/j.bmcl.2006.12.010,Identification of arylsulfonamides as Aquaporin 4 inhibitors.,10.1016/j.bmc.2008.06.005,Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.,1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1021/acs.jmedchem.5b01771,"4-Arylbenzenesulfonamides as Human Carbonic Anhydrase Inhibitors (hCAIs): Synthesis by Pd Nanocatalyst-Mediated Suzuki-Miyaura Reaction, Enzyme Inhibition, and X-ray Crystallographic Studies.",1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1016/j.bmc.2013.06.041,"5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies.",1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1021/acsmedchemlett.0c00417,In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2015.06.050,"Inhibition studies of bacterial, fungal and protozoan β-class carbonic anhydrases with Schiff bases incorporating sulfonamide moieties.",1
1125,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1021/acs.jmedchem.6b01389,"Benzenesulfonamides Incorporating Flexible Triazole Moieties Are Highly Effective Carbonic Anhydrase Inhibitors: Synthesis and Kinetic, Crystallographic, Computational, and Intraocular Pressure Lowering Investigations.",1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1021/acs.jmedchem.5b00523,6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.07.024,"Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.04.002,Acetylcholinesterase and carbonic anhydrase inhibitory properties of novel urea and sulfamide derivatives incorporating dopaminergic 2-aminotetralin scaffolds.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.bmcl.2018.02.006,High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,1
71516,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1016/j.neuropharm.2006.07.038,"Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.",1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1016/j.bmcl.2015.02.045,Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.bmcl.2018.06.044,"Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.",1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1021/acs.jmedchem.7b00958,Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1016/j.bmcl.2017.05.058,Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.bmcl.2017.05.058,Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1016/j.bmcl.2019.03.036,Ultra-potent vinblastine analogues improve on-target activity of the parent microtubulin-targeting compound.,1
71516,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1021/jm3014376,Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1021/ml400281w,Potent Vinblastine C20' Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1021/ml400281w,Potent Vinblastine C20' Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line.,1
71516,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1021/ml400281w,Potent Vinblastine C20' Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line.,1
71516,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
72035,10.1016/j.bmc.2006.11.004,Lead discovery and optimization of T-type calcium channel blockers.,10.1016/j.bmcl.2010.09.098,"Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2008.06.037,"Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2011.07.087,Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers.,1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2007.08.070,Discovery of potent T-type calcium channel blocker.,1
72035,10.1016/j.bmc.2006.11.004,Lead discovery and optimization of T-type calcium channel blockers.,10.1021/jm800830n,"Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1021/jm800830n,"Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2010.09.098,"Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists.",1
71516,10.1097/00001813-199607000-00012,Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1016/j.bmcl.2018.02.006,High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.,1
71516,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/acs.jmedchem.8b00986,Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents.,1
71516,10.1016/j.bmcl.2010.09.091,Catharanthine C16 substituent effects on the biomimetic coupling with vindoline: preparation and evaluation of a key series of vinblastine analogues.,10.1016/j.bmcl.2018.02.006,High expression of class III β-tubulin has no impact on functional cancer cell growth inhibition of a series of key vinblastine analogs.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1021/jm3014376,Total synthesis and evaluation of vinblastine analogues containing systematic deep-seated modifications in the vindoline subunit ring system: core redesign.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1016/j.bmcl.2017.05.058,Key analogs of a uniquely potent synthetic vinblastine that contain modifications of the C20' ethyl substituent.,1
71516,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,10.1021/acs.jmedchem.7b00958,Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.,1
71516,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1021/jm3015684,A remarkable series of vinblastine analogues displaying enhanced activity and an unprecedented tubulin binding steric tolerance: C20' urea derivatives.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2019.06.081,Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic/phobic tails for targeting the middle region of human carbonic anhydrases active site: Selective inhibitors of hCA IX.,1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1021/acs.jmedchem.3c00721,"1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities.",1
73548,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
73548,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
73520,10.1021/jm9605905,Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.,10.1021/jm030291x,Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.,1
73520,10.1021/jm00107a008,"Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols.",10.1016/S0960-894X(00)80661-7,Aryl cyanoguanidine potassium channel openers,1
73520,10.1016/j.bmc.2008.11.055,Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.,10.1016/j.bmc.2009.09.041,"New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.",1
73520,10.1021/jm9605905,Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.,10.1021/jm990196h,Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.,1
73520,10.1016/j.bmc.2008.11.055,Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.,10.1016/j.ejmech.2014.04.024,"Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?",1
73520,10.1021/jm00107a008,"Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols.",10.1016/S0960-894X(01)81157-4,Antihypertensive benzopyran-related potassium channel activators: a role for lipophilicity,1
73070,10.1016/j.bmcl.2007.08.053,"Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.",10.1124/dmd.112.044933,"Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2012.12.072,Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers.,1
72035,10.1016/j.bmc.2006.11.004,Lead discovery and optimization of T-type calcium channel blockers.,10.1016/j.bmcl.2007.08.070,Discovery of potent T-type calcium channel blocker.,1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmcl.2010.03.084,"Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers.",1
72035,10.1016/j.bmc.2006.10.013,3D pharmacophore based virtual screening of T-type calcium channel blockers.,10.1016/j.bmc.2011.07.030,Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.,1
72035,10.1016/j.bmc.2006.11.004,Lead discovery and optimization of T-type calcium channel blockers.,10.1016/j.bmc.2011.07.030,Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents.,1
73548,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
73548,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/acs.jmedchem.6b00462,Monothiocarbamates Strongly Inhibit Carbonic Anhydrases in Vitro and Possess Intraocular Pressure Lowering Activity in an Animal Model of Glaucoma.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1016/j.bmc.2013.05.032,"7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.04.019,Discovery of potent carbonic anhydrase and acetylcholine esterase inhibitors: novel sulfamoylcarbamates and sulfamides derived from acetophenones.,1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1016/j.bmc.2016.11.027,"Discovery of 4-sulfamoyl-phenyl-β-lactams as a new class of potent carbonic anhydrase isoforms I, II, IV and VII inhibitors: The first example of subnanomolar CA IV inhibitors.",1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmc.2011.03.061,Synthesis and evaluation of new carbonic anhydrase inhibitors.,1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1021/acsmedchemlett.0c00062,Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2014.12.054,N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmcl.2012.11.102,Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2010.11.031,Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2016.12.040,Dithiocarbamates effectively inhibit the β-carbonic anhydrase from the dandruff-producing fungus Malassezia globosa.,1
1125,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acsmedchemlett.0c00062,Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms.,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2023.115956,"Discovery of C-3 isoxazole substituted thiochromone S,S-dioxide derivatives as potent and selective inhibitors for monoamine oxidase B (MAO-B).",1
75507,10.1016/j.bmcl.2016.09.050,"Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.",10.1021/acs.jmedchem.2c01799,Optimized Ebselen-Based Inhibitors of Bacterial Ureases with Nontypical Mode of Action.,1
75507,10.1016/j.bmcl.2016.09.050,"Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.",10.1016/j.ejmech.2018.06.007,"Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1.",1
75507,10.1016/j.bmcl.2016.09.050,"Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.",10.1016/j.ejmech.2019.06.057,Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.,1
75507,10.1016/j.bmcl.2016.09.050,"Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.",10.1021/acs.jmedchem.0c01140,Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.,1
75507,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.bmc.2016.09.031,Synthesis and evaluation of dihydropyrimidinone-derived selenoesters as multi-targeted directed compounds against Alzheimer's disease.,1
75507,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1021/acs.jmedchem.9b01152,Development and Therapeutic Potential of Selenazo Compounds.,1
75507,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2024.116592,"Novel neuroprotective 5,6-dihydropyrido[2',1':2,3]imidazo[4,5-c]quinoline derivatives acting through cholinesterase inhibition and CB2 signaling modulation.",1
75507,10.1021/acs.jmedchem.9b01492,Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug Discovery.,10.1021/acs.jmedchem.3c00770,NADPH Oxidases: From Molecular Mechanisms to Current Inhibitors.,1
75507,10.1016/j.bmc.2013.12.066,Synthesis and biological evaluation of a new series of ebselen derivatives as glutathione peroxidase (GPx) mimics and cholinesterase inhibitors against Alzheimer's disease.,10.1016/j.ejmech.2015.05.002,"Organoselenocyanates and symmetrical diselenides redox modulators: Design, synthesis and biological evaluation.",1
75302,10.1016/j.bmc.2015.10.036,"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.",10.1016/j.bmc.2016.11.012,"Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.",1
75302,10.1016/j.bmc.2015.10.036,"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.",10.1016/j.ejmech.2021.114035,Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.,1
74911,10.1021/acs.jmedchem.5b01357,A Parallel Synthesis Approach to the Identification of Novel Diheteroarylamide-Based Compounds Blocking HIV Replication: Potential Inhibitors of HIV-1 Pre-mRNA Alternative Splicing.,10.1021/acsmedchemlett.1c00428,2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing.,1
73548,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
73548,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
73548,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
75869,10.1021/acs.jmedchem.8b01527,Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.,10.1016/j.ejmech.2023.115433,Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects.,1
75869,10.1016/j.ejmech.2020.113103,Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease.,10.1016/j.ejmech.2023.115433,Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects.,1
75869,10.1016/j.bmcl.2015.05.098,Identification of dialkyl diacetylene diols with potent cancer chemopreventive activity.,10.1016/j.bmcl.2016.09.018,Systemic structure-activity relationship study of phenyl polyyne diols as potential chemopreventive agents.,1
75869,10.1021/acs.jmedchem.8b01527,Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.,10.1016/j.ejmech.2019.111777,A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model.,1
75869,10.1021/acs.jmedchem.8b01527,Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.,10.1021/acsmedchemlett.9b00163,"Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator.",1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2018.01.029,"Design, synthesis and bioevalucation of novel 2,3-dihydro-1H-inden-1-amine derivatives as potent and selective human monoamine oxidase B inhibitors based on rasagiline.",1
75752,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.ejmech.2017.03.009,MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains.,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
75752,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2019.02.004,"Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.",1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2021.113183,4-Oxoquinolines and monoamine oxidase: When tautomerism matters.,1
75752,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2011.10.049,"Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.",1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2018.07.056,Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.1c00510,Mapping Chromone-3-Phenylcarboxamide Pharmacophore: <i>Quid Est Veritas</i>?,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acsmedchemlett.3c00532,Benzodioxane Carboxamide Derivatives As Novel Monoamine Oxidase B Inhibitors with Antineuroinflammatory Activity.,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1016/j.ejmech.2022.114507,Design and synthesis of chromone-based monoamine oxidase B inhibitors with improved drug-like properties.,1
75752,10.1021/acs.jmedchem.6b00527,Discovery of New Chemical Entities for Old Targets: Insights on the Lead Optimization of Chromone-Based Monoamine Oxidase B (MAO-B) Inhibitors.,10.1021/acs.jmedchem.7b00918,Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?,1
77128,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
76984,10.1016/j.bmcl.2014.07.054,Structure-based optimization of non-peptidic Cathepsin D inhibitors.,10.1021/acs.jmedchem.9b01351,Biomimetic Macrocyclic Inhibitors of Human Cathepsin D: Structure-Activity Relationship and Binding Mode Analysis.,1
76984,10.1016/j.bmcl.2014.07.054,Structure-based optimization of non-peptidic Cathepsin D inhibitors.,10.1016/j.bmc.2020.115879,Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D.,1
76984,10.1021/jm901734u,Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.,10.1016/j.ejmech.2014.07.049,Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.,1
76984,10.1016/j.bmc.2020.115879,Identification and structure-activity relationship studies of small molecule inhibitors of the human cathepsin D.,10.1016/j.bmc.2022.116646,Cathepsin D inhibitors based on tasiamide B derivatives with cell membrane permeability.,1
76984,10.1021/jm901734u,Identification of inhibitors of drug-resistant Candida albicans strains from a library of bicyclic peptidomimetic compounds.,10.1016/j.bmc.2012.09.031,Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype.,1
76538,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
76538,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
76538,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
76538,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
75901,10.1021/acs.jmedchem.1c00994,"Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile.",10.1016/j.ejmech.2024.116351,"Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy.",1
75901,10.18632/oncotarget.4919,The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.,10.1021/acs.jmedchem.1c00994,"Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile.",1
75901,10.18632/oncotarget.4919,The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.,10.1016/j.ejmech.2018.03.075,"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.",1
75901,10.1016/j.bmc.2014.02.007,The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.,10.1016/j.ejmech.2023.115987,Is it still worth renewing nucleoside anticancer drugs nowadays?,1
75901,10.1016/j.bmc.2014.02.007,The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.,10.1016/j.bmcl.2022.128881,"Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor.",1
75869,10.1021/acs.jmedchem.8b01527,Optimization of Vinyl Sulfone Derivatives as Potent Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Activators for Parkinson's Disease Therapy.,10.1016/j.ejmech.2020.113103,Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease.,1
77474,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
77474,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1016/s0167-4889(02)00187-8,Role of human organic anion transporter 4 in the transport of ochratoxin A.,1
77474,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.61.5.982,Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.,1
77474,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
77474,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
77474,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1254/jphs.94.197,Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine.,1
77474,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
77456,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
77129,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2018.09.060,Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.,1
77129,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",10.1016/j.ejmech.2018.09.060,Hemozoin inhibiting 2-phenylbenzimidazoles active against malaria parasites.,1
77129,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1039/C8MD00319J,Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.,1
77129,10.1016/j.ejmech.2016.07.027,Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.,10.1016/j.bmcl.2020.127581,In vitro efficacy of synthesized artemisinin derivatives against Leishmania promastigotes.,1
77129,10.1016/j.ejmech.2012.07.037,"Synthesis and in vitro antimalarial activity of a series of bisquinoline and bispyrrolo[1,2a]quinoxaline compounds.",10.1016/j.bmcl.2021.127855,"Design, synthesis and biological evaluation of mono- and bisquinoline methanamine derivatives as potential antiplasmodial agents.",1
77129,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.ejmech.2016.02.056,Indolyl-3-ethanone-α-thioethers: A promising new class of non-toxic antimalarial agents.,1
77129,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
77129,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",10.1021/acs.jmedchem.1c00354,Antimalarial Benzimidazole Derivatives Incorporating Phenolic Mannich Base Side Chains Inhibit Microtubule and Hemozoin Formation: Structure-Activity Relationship and <i>In Vivo</i> Oral Efficacy Studies.,1
78759,10.1016/j.ejmech.2018.09.054,"Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties.",10.1016/j.ejmech.2021.113521,Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.,1
78306,10.1021/jm00108a002,Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.,10.1016/S0960-894X(00)80096-7,"Structure-activity relationships of a series of glycine antagonists related to 5,7-dichlorokynurenic acid and 3-(2-carboxy-6-chloroindol-3-yl)acetic acid",1
78306,10.1021/jm00108a002,Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor.,10.1016/S0960-894X(00)80093-1,Anticonvulsant activity of glycine-site NMDA antagonists. 2. trans 2-carboxy-4-substituted tetrahydroquinolines.,1
78303,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm901421c,The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.,1
78169,10.1016/j.ejmech.2012.10.050,"Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.",10.1016/j.ejmech.2020.113038,Development of Mcl-1 inhibitors for cancer therapy.,1
78169,10.1016/j.ejmech.2012.12.016,"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.",10.1016/j.ejmech.2020.113038,Development of Mcl-1 inhibitors for cancer therapy.,1
78169,10.1016/j.ejmech.2012.10.050,"Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.",10.1016/j.bmc.2015.02.060,A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.,1
78169,10.1016/j.ejmech.2012.12.016,"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.",10.1016/j.bmc.2020.115851,Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment.,1
78169,10.1016/j.bmcl.2006.10.083,Pharmacophore identification of KSP inhibitors.,10.1016/j.ejmech.2013.01.031,Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.,1
78169,10.1021/jm100009z,Fragment-based deconstruction of Bcl-xL inhibitors.,10.1016/j.bmc.2015.02.060,A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.,1
78108,10.1021/jm070670g,"Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.",10.1016/j.ejmech.2011.01.007,"Synthesis, hypoxia-selective cytotoxicity of new 3-amino-1,2,4-benzotriazine-1,4-dioxide derivatives.",1
78108,10.1021/jm070670g,"Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.",10.1016/j.bmc.2010.03.042,"DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.",1
78108,10.1021/jm070670g,"Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.",10.1016/j.bmc.2008.07.087,"Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.",1
78108,10.1021/jm070670g,"Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.",10.1021/jm800967h,"Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.",1
77652,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
77474,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
78759,10.1016/j.ejmech.2015.07.052,"Ring fusion strategy for synthesis and lead optimization of sulfur-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivatives as promising scaffold of antitumor agents.",10.1016/j.ejmech.2018.02.027,"New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship.",1
78759,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.ejmech.2020.112044,Artemisinin-derived hybrids and their anticancer activity.,1
78759,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.ejmech.2022.114707,Discovery of novel selenium-containing azole derivatives as antifungal agents by exploiting the hydrophobic cleft of CYP51.,1
78759,10.1016/j.ejmech.2020.112550,"Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay.",10.1021/acsmedchemlett.0c00570,Identification of Piperidine-3-carboxamide Derivatives Inducing Senescence-like Phenotype with Antimelanoma Activities.,1
78759,10.1016/j.ejmech.2015.07.052,"Ring fusion strategy for synthesis and lead optimization of sulfur-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivatives as promising scaffold of antitumor agents.",10.1016/j.ejmech.2021.113521,Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.,1
78759,10.1016/j.ejmech.2016.07.049,Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.,10.1016/j.bmc.2019.07.050,Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.,1
78759,10.1021/jm0203377,"Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.",10.1016/j.bmcl.2007.12.053,New insight for fluoroquinophenoxazine derivatives as possibly new potent topoisomerase I inhibitor.,1
78759,10.1021/jm7011479,Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug.,10.1021/acs.jmedchem.5b01956,Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytotoxicity and DNA Cross-Linking in Cancer Cells from Combinations of Doxorubicin and Formaldehyde.,1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
78759,10.1021/np500521v,Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.,10.1016/j.ejmech.2018.02.066,Synthesis and biological evaluation of Schizandrin derivatives as potential anti-cancer agents.,1
78759,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
78759,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
78759,10.1021/jm0612158,"Design, synthesis, and cytotoxic evaluation of a new series of 3-substituted spiro[(dihydropyrazine-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)] derivatives.",10.1021/jm200094h,"Design, synthesis, and cytotoxic evaluation of acyl derivatives of 3-aminonaphtho[2,3-b]thiophene-4,9-dione, a quinone-based system.",1
78759,10.1021/jm020276c,Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.,10.1016/j.bmcl.2008.11.063,Development of dual-acting prodrugs for circumventing multidrug resistance.,1
78759,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2023.115935,HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents.,1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2008.05.051,Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.,1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.bmc.2016.11.039,Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.06.054,Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.,1
78759,10.1016/j.ejmech.2010.05.014,"In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety.",10.1016/j.ejmech.2013.08.048,Synthesis and anticancer activity of some novel trifluoromethylquinolines carrying a biologically active benzenesulfonamide moiety.,1
78759,10.1016/j.ejmech.2019.111974,"Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3).",10.1016/j.ejmech.2021.114070,Synthesis and biological evaluation of celastrol derivatives as potential anti-glioma agents by activating RIP1/RIP3/MLKL pathway to induce necroptosis.,1
78759,10.1016/j.bmcl.2010.05.014,A rapid synthesis of lavendustin-mimetic small molecules by click fragment assembly.,10.1016/j.bmcl.2016.02.073,Design and synthesis of novel 5-aminosalicylate (5-ASA)-4-thiazolinone hybrid derivatives with promising antiproliferative activity.,1
78759,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,10.1016/j.bmc.2024.117654,Target fishing reveals PfPYK-1 and PfRab6 as potential targets of an antiplasmodial 4-anilino-2-trichloromethylquinazoline hit compound.,1
78759,10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
78759,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
78759,10.1016/j.ejmech.2010.11.017,"The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics.",10.1016/j.ejmech.2020.112294,Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.,1
78759,10.1016/j.ejmech.2010.11.017,"The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics.",10.1021/acs.jmedchem.5b00859,"Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD(+)/NADH Ratio and SIRT1.",1
78759,10.1016/j.bmc.2013.03.079,Multidimensional optimization of promising antitumor xanthone derivatives.,10.1016/j.ejmech.2013.09.012,"Pyranoxanthones: Synthesis, growth inhibitory activity on human tumor cell lines and determination of their lipophilicity in two membrane models.",1
78759,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,1
78759,10.1016/j.bmcl.2005.03.082,Identification of antitumor activity of pyrazole oxime ethers.,10.1016/j.ejmech.2013.10.003,Synthesis of some dihydropyrimidine-based compounds bearing pyrazoline moiety and evaluation of their antiproliferative activity.,1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.bmcl.2017.02.042,Biologically active perspective synthesis of heteroannulated 8-nitroquinolines with green chemistry approach.,1
78759,10.1021/jm0612158,"Design, synthesis, and cytotoxic evaluation of a new series of 3-substituted spiro[(dihydropyrazine-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)] derivatives.",10.1021/jm7013056,"Spiro[(dihydropyrazin-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)]-based cytotoxic agents: structure-activity relationship studies on the substituent at N4-position of the diketopiperazine domain.",1
78759,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2018.12.068,"New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.",1
78759,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
78759,10.1021/jm1002414,Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.,10.1021/jm200454y,"Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1021/acs.jmedchem.5b01720,Thioxocoumarins Show an Alternative Carbonic Anhydrase Inhibition Mechanism Compared to Coumarins.,1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm300112w,"Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors.",1
1125,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.bmcl.2019.126874,"Synthesis and evaluation of 4-(1,3,4-oxadiazol-2-yl)-benzenesulfonamides as potent carbonic anhydrase inhibitors.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2016.05.016,"Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/acs.jmedchem.0c01889,"Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations.",1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2021.113486,"Novel benzenesulfonamides aryl and arylsulfone conjugates adopting tail/dual tail approaches: Synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/jm400414j,Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmcl.2014.08.014,Anion inhibition study of the β-class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis.,1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2008.03.023,Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.bmc.2017.08.047,"Development of sulfonamides incorporating phenylacrylamido functionalities as carbonic anhydrase isoforms I, II, IX and XII inhibitors.",1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/acsmedchemlett.0c00417,In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2015.09.022,"Synthesis of novel acridine bis-sulfonamides with effective inhibitory activity against the carbonic anhydrase isoforms I, II, IX and XII.",1
1125,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2016.01.030,Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII.,1
78759,10.1016/j.ejmech.2017.12.023,Part II: New candidates of pyrazole-benzimidazole conjugates as checkpoint kinase 2 (Chk2) inhibitors.,10.1016/j.ejmech.2018.01.072,"Part III: Novel checkpoint kinase 2 (Chk2) inhibitors; design, synthesis and biological evaluation of pyrimidine-benzimidazole conjugates.",1
78759,10.1016/j.bmc.2016.05.043,A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.,10.1016/j.ejmech.2021.113999,Current status of carbazole hybrids as anticancer agents.,1
78759,10.1016/j.ejmech.2010.03.030,"Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides.",10.1016/j.ejmech.2015.01.036,"Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives.",1
78759,10.1016/j.ejmech.2018.09.054,"Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties.",10.1016/j.ejmech.2018.12.068,"New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.",1
78759,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
78759,10.1021/jm020276c,Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.,10.1021/jm300493m,"Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix.",1
78759,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1016/j.bmc.2019.02.002,"Synthesis, antiproliferative and apoptosis induction potential activities of novel bis(indolyl)hydrazide-hydrazone derivatives.",1
78759,10.1016/j.bmc.2007.10.015,Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives.,10.1007/s00044-012-0213-9,Antitumor and antileishmanial evaluation of novel heterocycles derived from quinazoline scaffold: a molecular modeling approach,1
78759,10.1016/j.bmc.2007.10.015,Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives.,10.1016/j.ejmech.2014.11.027,Synthesis and anticancer activity of some 8-substituted-7-methoxy-2H-chromen-2-one derivatives toward hepatocellular carcinoma HepG2 cells.,1
78759,10.1021/jm7011479,Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug.,10.1021/jm900694z,Preclinical efficacy of a carboxylesterase 2-activated prodrug of doxazolidine.,1
78759,10.1021/jm0612158,"Design, synthesis, and cytotoxic evaluation of a new series of 3-substituted spiro[(dihydropyrazine-2,5-dione)-6,3'-(2',3'-dihydrothieno[2,3-b]naphtho-4',9'-dione)] derivatives.",10.1016/j.ejmech.2015.07.044,"Dihydrithieno[2,3-b]naphto-4,9-dione analogues as anticancer agents: Synthesis and in cell pharmacological studies.",1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
78759,10.1021/jm401471v,Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.,10.1021/acs.jmedchem.8b00639,"Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.",1
78759,10.1016/j.ejmech.2010.03.030,"Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides.",10.1016/j.ejmech.2017.07.003,"Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.",1
78759,10.1016/j.ejmech.2018.09.054,"Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties.",10.1021/acs.jnatprod.1c00162,Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.,1
78759,10.1016/j.ejmech.2015.07.052,"Ring fusion strategy for synthesis and lead optimization of sulfur-substituted anthra[1,2-c][1,2,5]thiadiazole-6,11-dione derivatives as promising scaffold of antitumor agents.",10.1016/j.ejmech.2024.116222,"Thiadiazole-, selenadiazole- and triazole-fused anthraquinones as G-quadruplex targeting anticancer compounds.",1
78759,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
78759,10.1016/j.ejmech.2018.04.014,"Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies.",10.1016/j.ejmech.2019.111587,Coumarin-containing hybrids and their anticancer activities.,1
78759,10.1007/s00044-011-9894-8,1-(7-Chloroquinolin-4-yl)-2-[(1H-pyrrol-2-yl)methylene]hydrazine: a potent compound against cancer,10.1016/j.bmcl.2013.12.074,"Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.",1
78759,10.1021/np300266e,Solid-phase total synthesis of cherimolacyclopeptide E and discovery of more potent analogues by alanine screening.,10.1016/j.ejmech.2021.113221,Natural bioeffective cyclooligopeptides from plant seeds of Annona genus.,1
78759,10.1016/j.ejmech.2018.04.014,"Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies.",10.1039/d3md00511a,Latest developments in coumarin-based anticancer agents: mechanism of action and structure-activity relationship studies.,1
78759,10.1021/jm0203377,"Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.",10.1021/acs.jmedchem.9b00726,Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer-Related Targets.,1
78759,10.1016/j.bmc.2007.10.015,Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives.,10.1016/j.ejmech.2010.02.026,"Microwave-assisted synthesis and in-vitro anti-tumor activity of 1,3,4-triaryl-5-N-arylpyrazole-carboxamides.",1
78759,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2023.116103,Synthesis and antitumor activity of cyclopentane-fused anthraquinone derivatives.,1
78759,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1016/j.bmcl.2018.03.033,Synthesis and investigations into the anticancer and antibacterial activity studies of β-carboline chalcones and their bromide salts.,1
78759,10.1016/j.bmc.2007.10.015,Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives.,10.1016/j.ejmech.2011.05.033,Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.,1
78759,10.1016/j.bmcl.2005.03.082,Identification of antitumor activity of pyrazole oxime ethers.,10.1016/j.ejmech.2012.03.056,"Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents.",1
78759,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2018.02.027,"New antitumor anthra[2,3-b]furan-3-carboxamides: Synthesis and structure-activity relationship.",1
78759,10.1021/jm020913z,"Antitumor agents. 1. Synthesis, biological evaluation, and molecular modeling of 5H-pyrido[3,2-a]phenoxazin-5-one, a compound with potent antiproliferative activity.",10.1016/j.ejmech.2019.111960,"Antitumor agents 7. Synthesis, antiproliferative activity and molecular modeling of new l-lysine-conjugated pyridophenoxazinones as potent DNA-binding ligands and topoisomerase IIα inhibitors.",1
78759,10.1016/j.bmc.2020.115674,"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.",10.1016/j.ejmech.2021.113511,"Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.",1
78759,10.1016/j.bmc.2014.12.069,"Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.",10.1016/j.bmc.2020.115935,"Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.",1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
78759,10.1021/jm401471v,Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.,10.1016/j.ejmech.2023.116049,"Camptothecin structure simplification elaborated new imidazo[2,1-b]quinazoline derivative as a human topoisomerase I inhibitor with efficacy against bone cancer cells and colon adenocarcinoma.",1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1039/C8MD00482J,Synthesis and X-ray study of dispiro 8-nitroquinolone analogues and their cytotoxic properties against human cervical cancer HeLa cells.,1
78759,10.1016/j.ejmech.2019.111974,"Synthesis and biological evaluation of some novel 1,2,3-triazole hybrids of myrrhanone B isolated from Commiphora mukul gum resin: Identification of potent antiproliferative leads active against prostate cancer cells (PC-3).",10.1016/j.bmcl.2020.127454,"2H-1,2,3-Triazole-chalcones as novel cytotoxic agents against prostate cancer.",1
78759,10.1016/j.ejmech.2016.07.049,Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.,10.1016/j.ejmech.2016.12.014,"Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors.",1
78759,10.1016/j.bmc.2007.10.034,Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.,10.1016/j.ejmech.2010.11.013,Synthesis and antiproliferative activity of novel symmetrical alkylthio- and alkylseleno-imidocarbamates.,1
78759,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2018.04.005,"Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anti-cancer agents.",1
78759,10.1016/j.ejmech.2012.03.056,"Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents.",10.1016/j.ejmech.2014.03.049,"One-pot, four-component synthesis of novel cytotoxic agents 1-(5-aryl-1,3,4-oxadiazol-2-yl)-1-(1H-pyrrol-2-yl)methanamines.",1
78759,10.1016/j.ejmech.2018.09.054,"Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties.",10.1016/j.ejmech.2020.112294,Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.,1
78759,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2018.03.010,Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.,1
78759,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
78759,10.1016/j.ejmech.2016.07.009,Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents.,10.1016/j.bmcl.2019.126671,Synthesis and evaluation of a novel quinoline-triazole analogs for antitubercular properties via molecular hybridization approach.,1
78759,10.1016/j.bmc.2021.116085,Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.,10.1016/j.ejmech.2023.115879,Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency.,1
78759,10.1016/j.ejmech.2010.05.014,"In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety.",10.1007/s00044-012-0272-y,"Synthesis and antitumor screening of new series of pyrimido-[4,5-b]quinolines and [1,2,4]triazolo[2,3:3,4]pyrimido[6,5-b]quinolines",1
78759,10.1021/np500521v,Identification of key structural characteristics of Schisandra chinensis lignans involved in P-glycoprotein inhibition.,10.1016/j.ejmech.2017.07.076,"Novel Gomisin B analogues as potential cytotoxic agents: Design, synthesis, biological evaluation and docking studies.",1
78759,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
78759,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
78759,10.1021/jm100838z,"Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.",10.1021/jm400311n,"Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.",1
78759,10.1016/j.ejmech.2010.11.017,"The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics.",10.1016/j.ejmech.2014.09.021,"Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones.",1
78759,10.1021/jm100838z,"Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.",10.1021/jm300969t,"Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.",1
78759,10.1021/jm020276c,Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.,10.1021/jm300348r,Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.,1
78759,10.1016/j.bmcl.2010.05.014,A rapid synthesis of lavendustin-mimetic small molecules by click fragment assembly.,10.1016/j.ejmech.2015.02.027,"Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity.",1
78759,10.1016/j.ejmech.2010.05.014,"In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety.",10.1016/j.ejmech.2010.10.024,"Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives.",1
78759,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112558,8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.,1
78759,10.1016/j.ejmech.2013.08.042,"Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.",10.1016/j.ejmech.2021.113609,"Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity.",1
78759,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
78759,10.1016/j.ejmech.2018.09.054,"Tri-armed ligands of G-quadruplex on heteroarene-fused anthraquinone scaffolds: Design, synthesis and pre-screening of biological properties.",10.1016/j.ejmech.2024.116222,"Thiadiazole-, selenadiazole- and triazole-fused anthraquinones as G-quadruplex targeting anticancer compounds.",1
78759,10.1016/j.ejmech.2010.11.017,"The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics.",10.1016/j.ejmech.2014.09.050,"Structure-based hybridization, synthesis and biological evaluation of novel tetracyclic heterocyclic azathioxanthone analogues as potential antitumor agents.",1
78759,10.1016/j.ejmech.2012.06.047,"A series of 2-arylamino-5-(indolyl)-1,3,4-thiadiazoles as potent cytotoxic agents.",10.1016/j.bmcl.2015.07.105,2-(3'-Indolyl)-N-arylthiazole-4-carboxamides: Synthesis and evaluation of antibacterial and anticancer activities.,1
78759,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.bmcl.2018.05.035,"Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.",1
78759,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1021/acs.jmedchem.5b01380,Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents.,1
78759,10.1016/j.ejmech.2014.12.056,Looking for new antileishmanial derivatives in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
78759,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.ejmech.2015.09.021,Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII.,1
1125,10.1021/acsmedchemlett.5b00175,Carbonic Anhydrase Glycoinhibitors belonging to the Aminoxysulfonamide Series.,10.1016/j.ejmech.2016.10.037,New approach of delivering cytotoxic drugs towards CAIX expressing cells: A concept of dual-target drugs.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.bmc.2023.117467,"Design and synthesis of sulfonamides incorporating a biotin moiety: Carbonic anhydrase inhibitory effects, antiproliferative activity and molecular modeling studies.",1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.8b01504,4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.,1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1021/acsmedchemlett.0c00417,In Silico-Guided Identification of New Potent Inhibitors of Carbonic Anhydrases Expressed in Vibrio cholerae.,1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1016/j.ejmech.2019.111702,"Synthesis of coumarin-sulfonamide derivatives and determination of their cytotoxicity, carbonic anhydrase inhibitory and molecular docking studies.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2016.07.034,Anion inhibition profiles of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2015.10.018,New natural product carbonic anhydrase inhibitors incorporating phenol moieties.,1
1125,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,10.1021/acsmedchemlett.3c00032,"Evaluation of 1,3,4-Thiadiazole Carbonic Anhydrase Inhibitors for Gut Decolonization of Vancomycin-Resistant Enterococci.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.ejmech.2019.111600,"Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2013.01.019,Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2020.112219,"Tail approach synthesis of novel benzenesulfonamides incorporating 1,3,4-oxadiazole hybrids as potent inhibitor of carbonic anhydrase I, II, IX, and XII isoenzymes.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1021/acs.jmedchem.5b01771,"4-Arylbenzenesulfonamides as Human Carbonic Anhydrase Inhibitors (hCAIs): Synthesis by Pd Nanocatalyst-Mediated Suzuki-Miyaura Reaction, Enzyme Inhibition, and X-ray Crystallographic Studies.",1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2007.12.022,"Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.",1
1125,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2019.111698,"Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.",1
78759,10.1016/j.bmc.2010.04.028,"Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.",10.1021/jm200511x,Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.,1
78759,10.1016/j.ejmech.2010.11.017,"The first series of 4,11-bis[(2-aminoethyl)amino]anthra[2,3-b]furan-5,10-diones: Synthesis and anti-proliferative characteristics.",10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",1
78759,10.1016/j.ejmech.2010.05.014,"In vitro anticancer screening and radiosensitizing evaluation of some new quinolines and pyrimido[4,5-b]quinolines bearing a sulfonamide moiety.",10.1016/j.bmc.2011.09.033,Cytotoxicity and gene expression profiles of novel synthesized steroid derivatives as chemotherapeutic anti-breast cancer agents.,1
78759,10.1016/j.ejmech.2010.03.030,"Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides.",10.1016/j.ejmech.2010.10.024,"Anti-breast cancer activity of some novel 1,2-dihydropyridine, thiophene and thiazole derivatives.",1
78759,10.1021/jm020276c,Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.,10.1016/j.bmcl.2006.02.066,Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.,1
78759,10.1016/j.ejmech.2012.03.056,"Design, synthesis and biological evaluation of a novel series of 1,3,4-oxadiazole bearing N-methyl-4-(trifluoromethyl)phenyl pyrazole moiety as cytotoxic agents.",10.1016/j.bmcl.2016.03.024,"Synthesis, molecular properties prediction and anticancer, antioxidant evaluation of new edaravone derivatives.",1
78759,10.1021/jm400311n,"Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.",10.1021/acsmedchemlett.5b00011,Discovery of Novel Isatin-Based p53 Inducers.,1
78759,10.1016/j.ejmech.2017.04.078,Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.,10.1016/j.bmcl.2018.07.035,Synthesis and anticancer activity studies of indolylisoxazoline analogues.,1
78759,10.1016/j.ejmech.2021.113337,Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections.,10.1016/j.bmcl.2022.129044,"Design, synthesis and antifungal activities of novel triazole derivatives with selenium-containing hydrophobic side chains.",1
78759,10.1016/j.bmc.2021.116266,From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.,10.1021/acs.jmedchem.2c01668,Ligand-Based Design on the Dog-Bone-Shaped BIBR1532 Pharmacophoric Features and Synthesis of Novel Analogues as Promising Telomerase Inhibitors with In Vitro and In Vivo Evaluations.,1
78759,10.1016/j.bmc.2021.116266,From triazolophthalazines to triazoloquinazolines: A bioisosterism-guided approach toward the identification of novel PCAF inhibitors with potential anticancer activity.,10.1016/j.ejmech.2023.115661,"Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.",1
78759,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.bmcl.2019.08.018,Primaquine homodimers as potential antiplasmodial and anticancer agents.,1
78759,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2021.113521,Thiophene-2-carboxamide derivatives of anthraquinone: A new potent antitumor chemotype.,1
78759,10.1016/j.ejmech.2016.01.050,"Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties.",10.1016/j.ejmech.2020.112294,Amides of pyrrole- and thiophene-fused anthraquinone derivatives: A role of the heterocyclic core in antitumor properties.,1
78759,10.1016/j.bmc.2017.12.022,"Optimization of antimalarial, and anticancer activities of (E)-methyl 2-(7-chloroquinolin-4-ylthio)-3-(4-hydroxyphenyl) acrylate.",10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
78759,10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
78759,10.1021/jm100838z,"Identification of the spiro(oxindole-3,3'-thiazolidine)-based derivatives as potential p53 activity modulators.",10.1016/j.bmcl.2015.08.056,"Synthesis and biological evaluation of spiro[cyclopropane-1,3'-indolin]-2'-ones as potential anticancer agents.",1
82721,10.1021/acs.jmedchem.5b00865,"Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.",10.1016/j.ejmech.2016.09.032,"Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.",1
82721,10.1016/j.bmc.2013.05.019,"Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.",10.1016/j.ejmech.2016.09.032,"Design, synthesis and evaluation of novel 2-amino-3-(naphth-2-yl)propanoic acid derivatives as potent inhibitors of platelet aggregation.",1
82721,10.1021/jm00042a007,Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.,10.1021/jm000022w,Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.,1
82721,10.1021/jm00042a007,Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.,10.1016/0960-894X(96)00473-8,Nonpeptide GPIIb/IIIa inhibitors. 10. Centrally constrained alpha-sulfonamides are potent inhibitors of platelet aggregation,1
81683,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
80965,10.1021/jm970112+,"Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type.",10.1016/j.ejmech.2019.111569,Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.,1
80965,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1016/j.ejmech.2016.11.019,"An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.",1
80965,10.1021/jm970112+,"Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type.",10.1016/j.ejmech.2016.08.059,"Design, synthesis, and biological evaluation of fluorinated imidazo[1,2-a]pyridine derivatives with potential antipsychotic activity.",1
80965,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1021/jm058002n,A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents.,1
80209,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
80209,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
78759,10.1016/j.ejmech.2017.10.055,Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.,10.1021/acs.jnatprod.1c00162,Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.,1
78759,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,10.1016/j.ejmech.2021.113722,Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.,1
78759,10.1016/j.ejmech.2018.04.014,"Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies.",10.1016/j.ejmech.2021.113865,Recent contributions of quinolines to antimalarial and anticancer drug discovery research.,1
78759,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1016/j.ejmech.2021.113765,Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.,1
78759,10.1021/jm400311n,"Synthesis, in vitro, and in cell studies of a new series of [indoline-3,2'-thiazolidine]-based p53 modulators.",10.1016/j.bmcl.2015.08.056,"Synthesis and biological evaluation of spiro[cyclopropane-1,3'-indolin]-2'-ones as potential anticancer agents.",1
85553,10.1016/j.bmcl.2009.09.109,Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.,10.1016/j.bmc.2017.06.009,"Novel 4-acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico studies.",1
85553,10.1016/j.bmcl.2009.09.109,Lead optimization of COX-2 inhibitor nimesulide analogs to overcome aromatase inhibitor resistance in breast cancer cells.,10.1021/jm4004736,Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.,1
84850,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2009.06.060,"The search for potent, small molecule NNRTIs: A review.",1
84850,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
84814,10.1016/S0960-894X(97)00065-6,Design and biological evaluation of a series of thiophene-based 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors,10.1016/j.bmcl.2004.12.042,Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).,1
83772,10.1021/jm500629e,Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.,10.1016/j.bmcl.2020.127577,A guanidinium-based inhibitor of a type I isopentenyl diphosphate isomerase.,1
83772,10.1021/jm400946f,Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.,10.1021/jm500629e,Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.,1
83772,10.1021/jm500629e,Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.,10.1016/j.bmcl.2014.12.089,Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.,1
83245,10.1021/jm970112+,"Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type.",10.1016/j.ejmech.2019.111569,Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.,1
83245,10.1021/jm970112+,"Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new series of high-affinity and selective ligands for the peripheral type.",10.1016/j.ejmech.2020.112924,An update into the medicinal chemistry of translocator protein (TSPO) ligands.,1
82983,10.1021/jm00197a010,Fluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of 5'-deoxy-5-fluoropyrimidine nucleosides.,10.1016/j.bmcl.2014.07.002,Short oligonucleotide prodrug having 5-fluoro and 5-iodouracil inhibits the proliferation of cancer cells in a photo-responsive manner.,1
82721,10.1021/jm00042a007,Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.,10.1021/jm980722p,"Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation.",1
82721,10.1021/jm00042a007,Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.,10.1021/jm970796l,Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes.,1
82721,10.1016/j.bmc.2013.05.019,"Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.",10.1021/acs.jmedchem.5b00865,"Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.",1
82721,10.1021/acs.jmedchem.5b00865,"Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents.",10.1016/j.bmcl.2016.02.011,"Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.",1
82721,10.1021/jm00042a007,Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp.,10.1016/0960-894X(96)00242-9,Non-peptide glycoprotein IIb/IIIa inhibitors. 9. Centrally constrained alpha-sulfonamides are useful tools for exploring platelet receptor function,1
88100,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
88100,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
88100,10.1021/jm021012t,Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.,10.1124/dmd.111.042382,"The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.",1
88100,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
86284,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1016/j.ejmech.2015.04.013,Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.,1
86284,10.1021/acs.jmedchem.7b00437,Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,10.1016/j.ejmech.2017.11.018,Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.,1
86284,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1016/j.ejmech.2014.10.021,Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.,1
86284,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1021/acs.jmedchem.7b00437,Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,1
86284,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1016/j.ejmech.2017.11.018,Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.,1
86284,10.1016/j.ejmech.2015.04.013,Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.,10.1016/j.ejmech.2017.11.018,Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.,1
86284,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1021/jm400240r,Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.,1
86042,10.1021/jm070311l,"Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.",10.1038/s41598-019-48829-3,"Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1",1
86042,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
86042,10.1021/acs.jmedchem.3c01044,Identification of Novel Quinolin-2(1<i>H</i>)-ones as Phosphodiesterase 1 Inhibitors for the Treatment of Inflammatory Bowel Disease.,10.1016/j.ejmech.2024.116710,Discovery of novel N<sup>2</sup>-indazole derivatives as phosphodiesterase 4 inhibitors for the treatment of inflammatory bowel disease.,1
86042,10.1021/jm070311l,"Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibitors.",10.1021/jm101493z,"Nucleoside transport inhibitors: structure-activity relationships for pyrimido[5,4-d]pyrimidine derivatives that potentiate pemetrexed cytotoxicity in the presence of α1-acid glycoprotein.",1
86042,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
88232,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acs.jmedchem.3c01669,Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer.,1
88232,10.1016/j.bmcl.2011.01.137,Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,10.1016/j.ejmech.2016.01.045,Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.,1
88232,10.1021/acs.jmedchem.9b00722,Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.,10.1039/d3md00668a,"Coumarin-furo[2,3-&lt;i&gt;d&lt;/i&gt;]pyrimidone hybrid molecules targeting human liver cancer cells: synthesis, anticancer effect, EGFR inhibition and molecular docking studies.",1
88232,10.1016/j.ejmech.2017.07.005,"Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.",10.1016/j.bmc.2018.12.032,The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.,1
88232,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.ejmech.2022.114533,Recent advances in the development of EGFR degraders: PROTACs and LYTACs.,1
88232,10.1016/j.bmcl.2014.09.056,Optimization of gefitinib analogues with potent anticancer activity.,10.1016/j.bmc.2015.12.001,"Combination of 4-anilinoquinazoline, arylurea and tertiary amine moiety to discover novel anticancer agents.",1
88232,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acsmedchemlett.8b00270,Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.,1
88232,10.1039/C0MD00183J,"[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors",10.1016/j.bmcl.2011.01.137,Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,1
88232,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.ejmech.2019.111888,Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.,1
88232,10.1016/j.bmcl.2006.06.054,Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.,10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",1
88232,10.1016/j.bmcl.2011.01.137,Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.,10.1016/j.ejmech.2020.113016,Therapeutic progression of quinazolines as targeted chemotherapeutic agents.,1
88232,10.1016/j.bmcl.2014.09.056,Optimization of gefitinib analogues with potent anticancer activity.,10.1016/j.bmcl.2016.02.009,Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.,1
88232,10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",10.1016/j.ejmech.2019.03.004,Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.,1
88232,10.1016/j.bmcl.2014.09.056,Optimization of gefitinib analogues with potent anticancer activity.,10.1016/j.bmc.2020.115373,"Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: New class of EGFR-TK inhibitors.",1
88232,10.1039/C0MD00183J,"[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors",10.1016/j.ejmech.2016.01.045,Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.,1
88232,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acs.jmedchem.6b00618,Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer.,1
88232,10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",10.1016/j.ejmech.2021.113173,"Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR mutant cell lines.",1
88232,10.1016/j.ejmech.2017.07.005,"Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.",10.1016/j.bmc.2019.06.001,"Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.",1
88232,10.1016/j.bmcl.2014.09.056,Optimization of gefitinib analogues with potent anticancer activity.,10.1021/acs.jmedchem.8b01612,Design and Evaluation of Potent EGFR Inhibitors through the Incorporation of Macrocyclic Polyamine Moieties into the 4-Anilinoquinazoline Scaffold.,1
88232,10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",10.1016/j.bmcl.2017.02.027,Synthesis and in vitro biological evaluation of novel quinazoline derivatives.,1
88232,10.1016/j.bmc.2014.10.038,Identification of novel 4-anilinoquinazoline derivatives as potent  EGFR inhibitors both under normoxia and hypoxia.,10.1016/j.bmc.2020.115889,Development of a novel acetyl glucose-modified gefitinib derivative to enhance the radiosensitizing effect.,1
88232,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.bmc.2017.03.039,Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.,1
88232,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.bmc.2018.03.025,"Synthesis and evaluation of 2,9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors.",1
88232,10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",10.1016/j.ejmech.2018.03.076,An overview of quinazolines: Pharmacological significance and recent developments.,1
88232,10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",10.1016/j.ejmech.2015.08.027,"Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.",1
88232,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
88232,10.1016/j.ejmech.2017.07.005,"Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.",10.1016/j.ejmech.2020.112640,Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).,1
88232,10.1016/j.bmcl.2006.06.054,Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.,10.1016/j.bmc.2014.09.029,Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity.,1
88232,10.1016/j.ejmech.2017.07.005,"Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.",10.1016/j.ejmech.2020.113016,Therapeutic progression of quinazolines as targeted chemotherapeutic agents.,1
88232,10.1016/j.bmcl.2006.06.054,Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",1
88232,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1016/j.ejmech.2019.03.004,Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.,1
88232,10.1016/j.bmcl.2006.02.025,"Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.",10.1021/jm800829v,"Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies.",1
88317,10.1021/jm100678p,"Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.",10.1021/ml300188t,"Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1021/ml300188t,"Synthesis and antimalarial activity of 3,3-spiroanellated 5,6-disubstituted 1,2,4-trioxanes.",1
88317,10.1016/j.bmcl.2010.06.045,"6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.",10.1016/j.bmcl.2024.129801,"Novel saturated 1,2,4-trioxanes and their antimalarial activity against multidrug resistant Plasmodium yoelii nigeriensis in Swiss mice model via oral route.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.bmcl.2007.05.055,"Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1021/jm301323k,"Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.",1
88317,10.1021/jm100678p,"Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.",10.1021/jm301323k,"Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.",1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1016/j.bmcl.2005.11.108,Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels.,1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1016/s0960-894x(99)00383-2,Synthesis and biological evaluation of conformationally restricted Gabapentin analogues.,1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1016/j.bmcl.2008.10.101,Oxadiazolone bioisosteres of pregabalin and gabapentin.,1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1021/jm060650z,Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain.,1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1016/j.bmcl.2005.05.016,Carboxylate bioisosteres of gabapentin.,1
88316,10.1021/jm970649n,Identification of novel ligands for the gabapentin binding site on the alpha2delta subunit of a calcium channel and their evaluation as anticonvulsant agents.,10.1021/jm049762l,Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.,1
88246,10.1021/jm00170a025,Conformational analysis and structure-activity relationships of selective dopamine D-1 receptor agonists and antagonists of the benzazepine series.,10.1021/jm030614p,"Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists.",1
88232,10.1016/j.bmcl.2006.06.054,Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.,10.1016/j.ejmech.2013.03.013,Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents.,1
88232,10.1016/j.bmc.2014.10.038,Identification of novel 4-anilinoquinazoline derivatives as potent  EGFR inhibitors both under normoxia and hypoxia.,10.1016/j.bmc.2016.01.003,"Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.",1
88232,10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,1
88797,10.1021/acs.jmedchem.6b00547,Discovery and Optimization of N-(4-(3-Aminophenyl)thiazol-2-yl)acetamide as a Novel Scaffold Active against Sensitive and Resistant Cancer Cells.,10.1016/j.bmcl.2018.03.063,Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.,1
88797,10.1021/acs.jmedchem.1c00082,"Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.",10.1016/j.ejmech.2022.114425,"Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.",1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2020.112710,"Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.",1
88797,10.1021/jm4004076,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,10.1016/j.ejmech.2015.09.034,Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.bmcl.2015.07.006,Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/jm301891t,Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.,1
88797,10.1016/j.bmcl.2013.01.113,BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.,10.1016/j.bmcl.2021.128116,Anti-chronic myeloid leukemia activity and quantitative structure-activity relationship of novel thiazole aminobenzamide derivatives.,1
88797,10.1021/jm020143r,"Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.",10.1021/jm0506423,Identification of potent and selective inhibitors of PDGF receptor autophosphorylation.,1
88797,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.bmc.2014.10.030,Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.,1
88317,10.1016/j.bmcl.2007.05.055,"Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.",10.1021/jm301323k,"Bile acid-based 1,2,4-trioxanes: synthesis and antimalarial assessment.",1
88317,10.1016/j.bmcl.2007.05.055,"Orally active antimalarials: synthesis and bioevaluation of a new series of steroid-based 1,2,4-trioxanes against multi-drug resistant malaria in mice.",10.1016/j.bmcl.2008.08.096,"New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.bmcl.2010.06.045,"6-(4'-Aryloxy-phenyl)vinyl-1,2,4-trioxanes: a new series of orally active peroxides effective against multidrug-resistant Plasmodium yoelii in Swiss mice.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1021/jm100678p,"Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.",1
88317,10.1016/j.bmc.2007.11.012,"Orally active 1,2,4-trioxepanes: synthesis and antimalarial activity of a series of 7-arylvinyl-1,2,4-trioxepanes against multidrug-resistant Plasmodium yoelii in Swiss mice.",10.1016/j.bmcl.2008.08.096,"New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice.",1
88317,10.1021/jm100678p,"Synthesis and antimalarial assessment of a new series of orally active amino-functionalized spiro 1,2,4-trioxanes.",10.1016/j.bmcl.2024.129801,"Novel saturated 1,2,4-trioxanes and their antimalarial activity against multidrug resistant Plasmodium yoelii nigeriensis in Swiss mice model via oral route.",1
88317,10.1021/jm051130r,"Orally active 1,2,4-trioxanes: synthesis and antimalarial assessment of a new series of 9-functionalized 3-(1-arylvinyl)-1,2,5-trioxaspiro[5.5]undecanes against multi-drug-resistant plasmodium yoelii nigeriensis in mice.",10.1016/j.bmcl.2008.08.096,"New functionalized 1,2,4-trioxepanes: synthesis and antimalarial activity against multi-drug resistant P. yoelii in mice.",1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.1c00082,"Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.",1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.bmcl.2016.10.007,"Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.",1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
88797,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1021/jm901132v,Selectively nonselective kinase inhibition: striking the right balance.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.5b01618,"Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.",1
88797,10.1016/j.ejmech.2019.05.091,Discovery of novel Bcr-Abl<sup>T315I</sup> inhibitors with flexible linker. Part 1: Confirmation optimization of phenyl-1H-indazol-3-amine as hinge binding moiety.,10.1016/j.ejmech.2022.114425,"Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.",1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2015.09.034,Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.bmc.2014.10.030,Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site.,1
88797,10.1021/jm4004076,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,10.1021/acs.jmedchem.7b00841,Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2022.114442,The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.,1
88797,10.1016/j.bmcl.2013.01.113,BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives.,10.1016/j.bmcl.2019.126758,Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.5b01125,Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.,1
88797,10.1021/jm800988r,"Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2022.114731,Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia.,1
88797,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2018.10.007,Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.,1
88797,10.1016/j.bmcl.2009.02.049,Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.,10.1021/jm201271b,Discovery and development of spleen tyrosine kinase (SYK) inhibitors.,1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2023.115270,Designed multiple ligands for the treatment of type 2 diabetes mellitus and its complications: Discovery of (5-arylidene-4-oxo-2-thioxothiazolidin-3-yl)alkanoic acids active as novel dual-targeted PTP1B/AKR1B1 inhibitors.,1
88882,10.1016/j.bmc.2017.10.005,Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.,10.1021/acs.jmedchem.9b01747,Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.,1
88882,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1016/j.bmcl.2020.127101,"Novel quinolin-4(1H)-one derivatives as multi-effective aldose reductase inhibitors for treatment of diabetic complications: Synthesis, biological evaluation, and molecular modeling studies.",1
88882,10.1016/j.ejmech.2012.02.045,Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.,10.1016/j.bmcl.2017.08.050,"Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.",1
88882,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1016/j.bmcl.2017.08.050,"Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.",1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2021.113630,Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.,1
88882,10.1016/j.ejmech.2012.02.045,Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.,10.1021/jm301124s,"Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.",1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2014.05.003,Structure-activity relationships and molecular modelling of new 5-arylidene-4-thiazolidinone derivatives as aldose reductase inhibitors and potential anti-inflammatory agents.,1
88882,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1016/j.ejmech.2022.114922,Novel rhodanine based inhibitors of aldose reductase of non-acidic nature with p-hydroxybenzylidene functional group.,1
88882,10.1016/j.ejmech.2012.02.045,Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step.,10.1016/j.ejmech.2013.10.043,Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).,1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1021/jm301124s,"Benzofuroxane derivatives as multi-effective agents for the treatment of cardiovascular diabetic complications. Synthesis, functional evaluation, and molecular modeling studies.",1
88882,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1021/acs.jmedchem.9b01747,Development of Novel Oxotriazinoindole Inhibitors of Aldose Reductase: Isosteric Sulfur/Oxygen Replacement in the Thioxotriazinoindole Cemtirestat Markedly Improved Inhibition Selectivity.,1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.bmcl.2018.10.024,"An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications.",1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1021/acs.jmedchem.2c00380,Novel Hydroxychalcone-Based Dual Inhibitors of Aldose Reductase and α-Glucosidase as Potential Therapeutic Agents against Diabetes Mellitus and Its Complications.,1
88882,10.1016/j.bmc.2010.02.050,"Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.",10.1016/j.bmc.2011.10.073,"Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1.",1
88882,10.1021/jm5015814,Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold.,10.1016/j.bmc.2017.10.005,Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2011.10.049,"Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO.",1
94571,10.1021/acs.jmedchem.0c00699,"Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.",10.1016/j.ejmech.2020.112500,"Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.",1
94571,10.1021/acs.jmedchem.0c00699,"Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.",10.1021/acs.jmedchem.1c02102,"Structure-Guided Discovery of the Novel Covalent Allosteric Site and Covalent Inhibitors of Fructose-1,6-Bisphosphate Aldolase to Overcome the Azole Resistance of <i>Candidiasis</i>.",1
94571,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
94571,10.1021/acs.jmedchem.0c00699,"Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction.",10.1021/acs.jmedchem.2c00336,<i>N</i>-Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction.,1
94484,10.1021/jm00378a009,Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.,10.1021/jm040894o,Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.,1
94484,10.1021/jm00378a009,Synthesis and biological evaluation of 14-alkoxymorphinans. 1. Highly potent opioid agonists in the series of (-)-14-methoxy-N-methylmorphinan-6-ones.,10.1021/acs.jmedchem.7b01363,"Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.",1
94484,10.1021/jm00199a018,Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.,10.1016/j.bmcl.2014.05.033,Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.,1
93617,10.1124/dmd.110.035105,Identification of clinically used drugs that activate pregnane X receptors.,10.1021/acs.jmedchem.0c02245,"Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.",1
92458,10.1016/S0960-894X(01)80542-4,Identification and characterisation of the isomers of cyclothiazide responsible for potentiating ampa current.,10.1016/S0960-894X(96)00547-1,"Enantioselective synthesis of a pyrrolo-benzothiadiazine derivative S 18986, a new AMPA receptor positive modulator",1
92412,10.1021/jm0580454,"Synthesis and biological evaluation of a novel series of ""ortho-nitrated"" inhibitors of catechol-O-methyltransferase.",10.1021/jm1001524,"Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.",1
91783,10.1021/jm0495071,"Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist.",10.1016/j.bmcl.2010.09.023,"Discovery and synthesis of 6,7,8,9-tetrahydro-5H-pyrimido-[4,5-d]azepines as novel TRPV1 antagonists.",1
90981,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1016/j.bmc.2017.10.004,Astemizole analogues with reduced hERG inhibition as potent antimalarial compounds.,1
89526,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
88882,10.1016/j.ejmech.2011.03.068,Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications.,10.1016/j.ejmech.2013.10.043,Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acs.jmedchem.0c01504,New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.,1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2009.07.039,Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.,1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1021/jm2004267,"Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2010.07.013,New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.,1
96021,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.bmc.2017.11.036,Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.,1
96021,10.1016/j.bmcl.2019.02.008,"Design, synthesis and biological evaluation of novel human monoamine oxidase B inhibitors based on a fragment in an X-ray crystal structure.",10.1021/acs.jmedchem.0c01663,Computational Fragment-Based Design Facilitates Discovery of Potent and Selective Monoamine Oxidase-B (MAO-B) Inhibitor.,1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2019.04.016,Discovery of coumarin Mannich base derivatives as multifunctional agents against monoamine oxidase B and neuroinflammation for the treatment of Parkinson's disease.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.ejmech.2017.12.013,"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2013.07.005,Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases.,1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1021/acs.jnatprod.6b00391,"Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.",1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1021/jm301014y,Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.,1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2013.09.044,"1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.",1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.bmcl.2014.12.001,Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.05.070,"Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2011.05.074,MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2013.09.010,"Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.",1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.bmc.2013.10.004,Chromenylchalcones with inhibitory effects on monoamine oxidase B.,1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2011.11.020,Hydroxycoumarins as selective MAO-B inhibitors.,1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.bmcl.2015.09.049,Monoamine oxidase inhibitory activities of heterocyclic chalcones.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1039/C7MD00311K,"MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, <i>in vitro</i> study, and docking calculations.",1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2009.11.003,"Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.",1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.02.059,"Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.",1
96021,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.12.013,"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.",1
96021,10.1016/j.bmc.2015.08.012,Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors.,10.1016/j.ejmech.2017.02.059,"Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.",1
96021,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2021.114097,Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.,1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1039/d0md00150c,"Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling",1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2017.10.050,"Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.",1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2021.113800,"Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.",1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2018.07.019,"Discovery of potent anti-convulsant carbonic anhydrase inhibitors: Design, synthesis, in vitro and in vivo appraisal.",1
1125,10.1016/j.bmc.2017.03.017,Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.,10.1016/j.ejmech.2019.111573,"New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.",1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm400414j,Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.,1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.07.045,Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.,1
96021,10.1016/j.ejmech.2013.11.035,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,10.1016/j.ejmech.2017.02.059,"Discovery of highly selective and potent monoamine oxidase B inhibitors: Contribution of additional phenyl rings introduced into 2-aryl-1,3,4-oxadiazin-5(6H)-one.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1039/C1MD00221J,3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer's disease,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.06.007,Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.,1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.bmc.2008.11.068,"New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.",1
96021,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.10.050,"Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents.",1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acs.jnatprod.6b00391,"Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2013.02.009,"Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.",1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.09.045,"2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.",1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.bmcl.2013.06.050,Selected furanochalcones as inhibitors of monoamine oxidase.,1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2011.01.033,"Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.",1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2016.03.081,(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.,1
96021,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm2004267,"Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.",1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2013.02.009,"Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.",1
96021,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2013.11.035,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.11.034,"Inhibition of carbonic anhydrase isoforms I, II, IV, VII and XII with carboxylates and sulfonamides incorporating phthalimide/phthalic anhydride scaffolds.",1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2007.03.008,"Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2019.112021,Pyrrolo and pyrrolopyrimidine sulfonamides act as cytotoxic agents in hypoxia via inhibition of transmembrane carbonic anhydrases.,1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmcl.2015.10.021,"Interaction of carbonic anhydrase isozymes I, II, and IX with some pyridine and phenol hydrazinecarbothioamide derivatives.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2019.111600,"Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2020.115424,"Design, synthesis & biological evaluation of ferulic acid-based small molecule inhibitors against tumor-associated carbonic anhydrase IX.",1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2015.11.104,"Sulfonamide inhibition studies of the α-carbonic anhydrase from the gammaproteobacterium Thiomicrospira crunogena XCL-2, TcruCA.",1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm2000213,"Structural basis for the interaction between carbonic anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides.",1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
1125,10.1016/j.bmcl.2013.04.048,Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening.,10.1039/C8MD00392K,Novel benzoyl thioureido benzene sulfonamides as highly potent and selective inhibitors of carbonic anhydrase IX: optimization and bioactive studies.,1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1021/acsmedchemlett.7b00300,Lucky Switcheroo: Dramatic Potency and Selectivity Improvement of Imidazoline Inhibitors of Human Carbonic Anhydrase VII.,1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.ejmech.2019.111600,"Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.",1
96107,10.1021/jm300630p,Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.,10.1021/jm301848w,On dihydroorotate dehydrogenases and their inhibitors and uses.,1
96107,10.1021/jm300630p,Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.,10.1021/acs.jmedchem.1c01746,Discovery of Orally Available Retinoic Acid Receptor-Related Orphan Receptor γ-t/Dihydroorotate Dehydrogenase Dual Inhibitors for the Treatment of Refractory Inflammatory Bowel Disease.,1
96107,10.1021/jm300630p,Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,1
96107,10.1021/jm300630p,Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.,10.1021/jm501127s,"Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.",1
96107,10.1016/j.ejmech.2022.114489,A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.,10.1016/j.ejmech.2022.114737,Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.,1
96107,10.1021/jm300630p,Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.,10.1016/j.ejmech.2019.111855,"Cerpegin-derived furo[3,4-c]pyridine-3,4(1H,5H)-diones enhance cellular response to interferons by de novo pyrimidine biosynthesis inhibition.",1
96107,10.1021/jm400938g,Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives.,10.1021/jm501127s,"Design, synthesis, X-ray crystallographic analysis, and biological evaluation of thiazole derivatives as potent and selective inhibitors of human dihydroorotate dehydrogenase.",1
96021,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2013.11.035,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm100120s,"Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.",1
96021,10.1016/j.bmcl.2005.07.043,Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.,10.1016/j.ejmech.2017.03.009,MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.12.027,Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.10.032,Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acsmedchemlett.5b00326,Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm801590u,Chalcones: a valid scaffold for monoamine oxidases inhibitors.,1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2017.12.013,"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.",1
96021,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1039/C0MD00014K,"Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.0c00102,Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.111689,Combating fluconazole-resistant fungi with novel β-azole-phenylacetone derivatives.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.03.020,"Current advances of triazole alcohols derived from fluconazole: Design, in vitro and in silico studies.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.05.047,"Design, synthesis, and structure-activity relationship studies of l-amino alcohol derivatives as broad-spectrum antifungal agents.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2012.05.070,Synthesis and biological evaluation of vinyl ether-containing azole derivatives as inhibitors of Trichophyton rubrum.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.4c00652,"Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.11.101,"Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.",1
97867,10.1016/j.ejmech.2018.03.083,"Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives.",10.1021/acs.jmedchem.3c01105,Discovery of Lead 2-Thiazolylhydrazones with Broad-Spectrum and Potent Antifungal Activity.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2012.04.013,"Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains.",1
97246,10.1021/jm300601d,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,10.1016/j.ejmech.2024.116170,pH regulators and their inhibitors in tumor microenvironment.,1
96210,10.1016/j.ejmech.2018.10.067,A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1016/j.bmc.2023.117331,Synthesis and structure-activity relationship studies of naphthoquinones as STAT3 inhibitors.,1
96210,10.1016/j.ejmech.2018.10.067,A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1016/j.ejmech.2024.116448,Exploration of novel isoxazole-fused quinone derivatives as anti-colorectal cancer agents through inhibiting STAT3 and elevating ROS level.,1
96210,10.1016/j.ejmech.2018.10.067,A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1016/j.ejmech.2020.112428,"Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.",1
96210,10.1016/j.ejmech.2018.10.067,A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1016/j.bmc.2020.115347,STAT3 inhibitory activity of naphthoquinones isolated from Tabebuia avellanedae.,1
96210,10.1016/j.ejmech.2018.10.067,A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).,10.1021/acs.jmedchem.0c01897,Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2016.02.013,"Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal agents.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.08.089,"Design of new antifungal agents: synthesis and evaluation of 1-[(1H-indol-5-ylmethyl)amino]-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2021.113715,"Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.01.048,"Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2010.12.006,"New azoles with antifungal activity: Design, synthesis, and molecular docking.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.02.042,"Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2010.03.014,"Structure-based rational design, synthesis and antifungal activity of oxime-containing azole derivatives.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.07.144,Discovery of highly potent novel antifungal azoles by structure-based rational design.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.07.003,"Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2011.06.008,"Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/jm4016284,"Design, synthesis, and structure-activity relationship studies of novel fused heterocycles-linked triazoles with good activity and water solubility.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2012.02.042,"New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.02.027,"Design, synthesis, and evaluation of 1-(N-benzylamino)-2-phenyl-3-(1H-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents.",1
97867,10.1021/acs.jmedchem.1c00883,Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.,10.1016/j.bmc.2023.117543,"Design, synthesis, evaluation and optimization of novel azole analogues as potent antifungal agents.",1
97867,10.1021/acs.jmedchem.1c00883,Identification of Thiazoyl Guanidine Derivatives as Novel Antifungal Agents Inhibiting Ergosterol Biosynthesis for Treatment of Invasive Fungal Infections.,10.1016/j.ejmech.2021.113955,"Broadening antifungal spectrum and improving metabolic stablity based on a scaffold strategy: Design, synthesis, and evaluation of novel 4-phenyl-4,5-dihydrooxazole derivatives as potent fungistatic and fungicidal reagents.",1
97867,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
102584,10.1016/j.ejmech.2013.10.022,"Fragment-based approach to the design of 5-chlorouracil-linked-pyrazolo[1,5-a][1,3,5]triazines as thymidine phosphorylase inhibitors.",10.1016/j.ejmech.2016.10.032,Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.,1
101329,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
99024,10.1016/j.bmcl.2014.07.039,Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum.,10.1039/D0MD00062K,Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?,1
99024,10.1016/j.bmcl.2011.11.108,Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis.,10.1016/j.ejmech.2014.07.007,New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.,1
99024,10.1039/C5MD00596E,The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery,10.1021/acs.jmedchem.5b02038,Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.,1
99024,10.1039/C5MD00596E,The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery,10.1016/j.ejmech.2021.113823,Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.,1
99024,10.1016/j.bmcl.2011.11.108,Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis.,10.1016/j.bmc.2017.04.031,Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.,1
99024,10.1021/jm3009184,"Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.",10.1016/j.ejmech.2021.113823,Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.,1
99024,10.1039/C5MD00596E,The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery,10.1039/D0MD00062K,Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?,1
99024,10.1021/jm3009184,"Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.",10.1039/D0MD00062K,Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?,1
99024,10.1016/j.bmcl.2014.07.039,Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum.,10.1016/j.bmc.2017.04.031,Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.,1
98014,10.1021/jm300601d,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,10.1016/j.ejmech.2024.116170,pH regulators and their inhibitors in tumor microenvironment.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2014.05.079,"Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains.",1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.04.056,Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C3MD20086H,Synthesis and antifungal activity of the novel triazole compounds,1
97867,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.04.022,"Design, synthesis and molecular docking studies of novel triazole as antifungal agent.",1
103658,10.1021/jm801335z,Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.,10.1021/np100373f,Bioactive compounds from the fern Lepisorus contortus.,1
103658,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.bmc.2018.02.048,Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives.,1
103658,10.1021/jm060253o,Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.,10.1016/j.ejmech.2006.12.012,Quinone reductase induction activity of methoxylated analogues of resveratrol.,1
103658,10.1021/np9704819,"Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from vitis vinifera cell cultures",10.1016/j.bmc.2006.09.069,Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.,1
103658,10.1021/jm801335z,Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.,10.1021/np500256w,Spongiapyridine and related spongians isolated from an Indonesian Spongia sp.,1
103658,10.1016/j.ejmech.2006.08.006,Synthesis and cytotoxic evaluation of a series of resveratrol derivatives modified in C2 position.,10.1016/j.bmc.2011.03.001,"Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents.",1
103658,10.1016/j.bmc.2012.10.006,Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1).,10.1021/np500256w,Spongiapyridine and related spongians isolated from an Indonesian Spongia sp.,1
103658,10.1016/j.bmc.2014.01.008,Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators.,10.1021/acs.jnatprod.7b00619,Phenanthrenes: A Promising Group of Plant Secondary Metabolites.,1
103658,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.ejmech.2017.05.041,Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.,1
103658,10.1016/j.bmc.2012.10.006,Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1).,10.1016/j.ejmech.2016.09.033,Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases.,1
103658,10.1016/j.bmc.2010.03.069,"Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents.",10.1016/j.bmc.2013.03.072,Inhibition of VEGF expression in cancer cells and endothelial cell differentiation by synthetic stilbene derivatives.,1
103658,10.1016/j.ejmech.2006.08.006,Synthesis and cytotoxic evaluation of a series of resveratrol derivatives modified in C2 position.,10.1016/j.ejmech.2016.09.033,Development of resveratrol-curcumin hybrids as potential therapeutic agents for inflammatory lung diseases.,1
103029,10.1021/jm400351a,Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.,10.1021/jm500031w,Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).,1
103029,10.1021/jm400351a,Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.,10.1016/j.bmcl.2021.127846,Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.,1
103029,10.1021/jm400351a,Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.,10.1016/j.ejmech.2022.114543,Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.,1
103029,10.1021/jm400351a,Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.,10.1039/C4MD00167B,Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold,1
110803,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1021/jm501086v,Loratadine and analogues: discovery and preliminary structure-activity relationship of inhibitors of the amino acid transporter B(0)AT2.,1
109797,10.1021/jm00037a014,"Non-peptide angiotensin II receptor antagonists: synthesis and biological activity of a series of novel 4,5-dihydro-4-oxo-3H-imidazo[4,5-c]pyridine derivatives.",10.1016/0960-894X(95)00477-B,"4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptor",1
107119,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
105568,10.1021/acs.jmedchem.8b01961,Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,1
104574,10.1021/acs.jmedchem.0c00996,"Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.",10.1021/acs.jmedchem.4c00086,Recent Advances on Small-Molecule Inhibitors of Lipocalin-like Proteins.,1
104385,10.1021/jm00114a018,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,10.1016/j.ejmech.2017.06.068,Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.,1
104385,10.1021/jm00114a018,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,10.1016/j.bmc.2017.12.010,2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.,1
104385,10.1021/jm00114a018,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,10.1016/j.bmc.2010.08.053,Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor.,1
104385,10.1021/jm00114a018,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,10.1021/acs.jmedchem.3c01161,Indazole as a Phenol Bioisostere: Structure-Affinity Relationships of GluN2B-Selective NMDA Receptor Antagonists.,1
103658,10.1016/j.ejmech.2017.03.062,Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.,10.1016/j.ejmech.2018.07.033,Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.,1
103658,10.1021/jm060253o,Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.,10.1016/j.bmc.2011.07.015,Synthesis and antimicrobial activity of (E) stilbene derivatives.,1
103658,10.1021/jm060253o,Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.,10.1016/j.bmc.2010.07.059,Synthesis of heterocycle-based analogs of resveratrol and their antitumor and vasorelaxing properties.,1
103658,10.1021/jm801335z,Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.,10.1016/j.ejmech.2017.05.041,Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.,1
103658,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.bmc.2012.10.006,Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1).,1
103658,10.1016/j.bmc.2010.03.069,"Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents.",10.1016/j.bmcl.2011.04.012,New halogenated phenylcoumarins as tyrosinase inhibitors.,1
103658,10.1021/jm060253o,Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.,10.1016/j.bmcl.2006.10.025,Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2022.115045,"Identification of ""dual-site""-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01885,"Development of Novel Dihydrofuro[3,4-<i>d</i>]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.",1
112651,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
112651,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2021.113654,Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.,1
112258,10.1021/np500905g,HPLC-NMR and HPLC-MS Profiling and Bioassay-Guided Identification of Secondary Metabolites from the Australian Plant Haemodorum spicatum.,10.1021/acs.jnatprod.5b00161,Phytochemical Investigation of the Constituents Derived from the Australian Plant Macropidia fuliginosa.,1
112090,10.1016/j.ejmech.2016.03.014,"Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.",10.1016/j.ejmech.2019.07.031,"Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.",1
112090,10.1016/j.ejmech.2016.03.014,"Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.",10.1021/acs.jmedchem.0c01480,Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities.,1
112090,10.1016/j.ejmech.2016.03.014,"Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.",10.1016/j.bmc.2020.115550,"Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.",1
112090,10.1016/j.ejmech.2016.03.014,"Systematic comparison of the mono-, dimethyl- and trimethyl 3-hydroxy-4(1H)-pyridones - Attempted optimization of the orally active iron chelator, deferiprone.",10.1016/j.ejmech.2023.115945,Novel 3-hydroxypyridin-4(1H)-One derivatives as ferroptosis inhibitors with iron-chelating and reactive oxygen species scavenging activities and therapeutic effect in cisplatin-induced cytotoxicity.,1
110803,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
110803,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1016/j.bmcl.2012.08.041,Synthesis and biological evaluation of cyanoguanidine derivatives of loratadine.,1
110803,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1016/s0960-894x(98)00626-x,"Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.",1
110803,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
110803,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1016/j.bmcl.2012.03.002,"Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.",1
110803,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
110803,10.1021/jm00105a069,"Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.",10.1021/jm058225d,Designed multiple ligands. An emerging drug discovery paradigm.,1
113138,10.1021/acs.jmedchem.2c01875,"Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.",10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.1c01885,"Development of Novel Dihydrofuro[3,4-<i>d</i>]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c01574,Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmc.2013.10.033,"Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.",1
113138,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
113138,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112237,In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmc.2018.12.039,"Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.",1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2020.115927,Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.,1
113138,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2020.112237,In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.2c00576,Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2023.115605,Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
113138,10.1016/j.bmcl.2018.10.010,Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.,10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2021.116531,Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2022.114957,"Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.9b01446,"Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.11.039,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.",1
113138,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2021.116239,Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.,1
113138,10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c00268,"2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.bmc.2023.117484,"In situ click chemistry-based discovery of 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs by exploiting the tolerant region I in binding pocket.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
113138,10.1021/acs.jmedchem.2c01875,"Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.",10.1016/j.bmc.2023.117484,"In situ click chemistry-based discovery of 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs by exploiting the tolerant region I in binding pocket.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.1c00268,"2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.",1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
113138,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.2c01574,Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.,1
113138,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
113138,10.1016/j.bmcl.2005.10.037,Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
113138,10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,1
113138,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.2c01875,"Structure-Based Optimization of 2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Exploiting the Tolerant Regions of the Non-Nucleoside Reverse Transcriptase Inhibitors' Binding Pocket.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113868,Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c00468,Structure-Based Discovery of Novel NH<sub>2</sub>-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH<sub>2</sub>-Naphthyl-Diarylpyrimidine to NH<sub>2</sub>-Biphenyl-Diarylpyrimidine.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2018.03.003,The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.,1
113138,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,1
113138,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2020.112549,Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.,1
113138,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2022.114471,Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.,1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
113138,10.1021/acs.jmedchem.2c00576,Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs.,10.1016/j.ejmech.2024.116708,"Discovery of 2,4,6-trisubstituted pyrimidine derivatives as novel potent HIV-1 NNRTIs by exploiting the tolerant region II of the NNIBP.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
113138,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
113138,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2023.115686,"5-Cyano substituted diarylpyridines as potent HIV-1 NNRTIs: Rational design, synthesis, and activity evaluation.",1
113138,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.2c01574,Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c00576,Lead Optimization and Avoidance of Metabolic-perturbing Motif Developing Novel Diarylpyrimidines as Potent HIV-1 NNRTIs.,1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
113138,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01015,"Discovery of Novel Dihydrothiopyrano[4,3-<i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles.",1
113138,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1016/j.ejmech.2020.113063,"Design, synthesis, and evaluation of ""dual-site""-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2022.116614,Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,1
113138,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmcl.2018.10.010,Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.,1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
113138,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
113138,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
113138,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00361,"Discovery of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP.",1
113138,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
118669,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1016/j.bmcl.2023.129258,"Jozibrevine D from Ancistrocladus ileboensis, the fifth alkaloid in a series of six possible atropo-diastereomeric naphthylisoquinoline dimers, showing antiparasitic and antileukemic activities.",1
118669,10.1021/acs.jnatprod.9b00755,"Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana Ancistrocladus ealaensis, Targeting Pancreatic Cancer Cells.",10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm300508n,"Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.",1
118669,10.1021/jm900629w,On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.,10.1021/jm900946n,Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm0708634,Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.ejmech.2014.09.045,Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.ejmech.2009.02.010,Synthesis of a series of N6-substituted adenosines with activity against trypanosomatid parasites.,1
116949,10.1016/j.ejmech.2020.112258,Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.,10.1016/j.ejmech.2021.113285,Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.,1
116949,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.ejmech.2018.08.082,Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.,1
116949,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.bmcl.2014.01.004,Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPARγ agonists.,1
116949,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.bmcl.2012.11.088,"Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",1
116949,10.1021/jm200409s,"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.",10.1016/j.ejmech.2019.04.030,Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.,1
115369,10.1016/0960-894X(96)00148-5,"Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors",10.1016/s0960-894x(98)00395-3,L-tryptophan urea amides as NK1/NK2 dual antagonists.,1
115369,10.1016/0960-894X(96)00148-5,"Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors",10.1016/s0960-894x(01)00572-8,"Discovery of novel, orally active dual NK1/NK2 antagonists.",1
115369,10.1016/0960-894X(96)00148-5,"Identification and chemical synthesis of MDL 105,212, a non-peptide tachykinin antagonist with high affinity for NK1 and NK2 receptors",10.1016/s0960-894x(00)00463-7,The design and synthesis of novel NK1/NK2 dual antagonists.,1
114423,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2012.06.106,Anion inhibition studies of an α-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2010.06.028,Coumarinyl-substituted sulfonamides strongly inhibit several human carbonic anhydrase isoforms: solution and crystallographic investigations.,1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1016/j.ejmech.2018.11.073,Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2013.03.077,Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine.,1
119288,10.1021/jm00348a019,Synthesis and cardiovascular activity of a new series of cyclohexylaralkylamine derivatives related to perhexiline.,10.1021/acs.jmedchem.6b01592,Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy.,1
118669,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1016/j.ejmech.2011.11.022,New N-methylpiperazinyl derivatives of bicyclic antiprotozoal compounds.,1
118669,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1016/j.bmc.2013.08.022,"Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.",1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm301215e,A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2014.08.005,From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2011.12.018,Quinol derivatives as potential trypanocidal agents.,1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1021/jm201215n,"Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.",1
118669,10.1016/j.bmc.2011.12.053,"Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.",10.1016/j.bmcl.2012.11.072,"Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.",1
118669,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1016/j.ejmech.2014.09.045,Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.,1
118669,10.1021/np0496284,"Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.",10.1016/j.bmc.2009.08.057,"Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.",1
118669,10.1021/acs.jnatprod.9b00589,A Near-Complete Series of Four Atropisomeric Jozimine A2-Type Naphthylisoquinoline Dimers with Antiplasmodial and Cytotoxic Activities and Related Alkaloids from Ancistrocladus abbreviatus.,10.1021/acs.jnatprod.1c00063,"Spirombandakamine A<sub>3</sub> and Cyclombandakamines A<sub>8</sub> and A<sub>9</sub>, Polycyclic Naphthylisoquinoline Dimers, with Antiprotozoal Activity, from a Congolese <i>Ancistrocladus</i> Plant.",1
118669,10.1021/jm050177+,Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.,10.1016/j.bmc.2013.08.022,"Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.",1
119498,10.1021/acsmedchemlett.8b00551,Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.,10.1021/acsmedchemlett.9b00306,A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.,1
119498,10.1039/C8MD00134K,Scaffold hopping from synthetic RXR modulators by virtual screening and <i>de novo</i> design.,10.1021/acs.jmedchem.1c00186,Targeting Nuclear Receptors in Neurodegeneration and Neuroinflammation.,1
119498,10.1016/j.bmcl.2017.01.066,DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.,10.1021/acs.jmedchem.8b01848,"Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.",1
119498,10.1021/acs.jmedchem.9b00995,Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.,10.1021/acsmedchemlett.2c00509,Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.ejmech.2019.111698,"Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.ejmech.2019.111573,"New anthranilic acid-incorporating N-benzenesulfonamidophthalimides as potent inhibitors of carbonic anhydrases I, II, IX, and XII: Synthesis, in vitro testing, and in silico assessment.",1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1016/j.ejmech.2018.03.030,"Synthesis of novel 4-functionalized 1,5-diaryl-1,2,3-triazoles containing benzenesulfonamide moiety as carbonic anhydrase I, II, IV and IX inhibitors.",1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2012.09.065,"Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.0c02077,Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/acs.jmedchem.8b00208,"Discovery of Benzenesulfonamide Derivatives as Carbonic Anhydrase Inhibitors with Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Evaluation.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2016.01.072,Anion inhibition studies of the β-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.,1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1021/acsmedchemlett.8b00170,Targeting Tumor Associated Carbonic Anhydrases IX and XII: Highly Isozyme Selective Coumarin and Psoralen Inhibitors.,1
1125,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2018.03.030,"Synthesis of novel 4-functionalized 1,5-diaryl-1,2,3-triazoles containing benzenesulfonamide moiety as carbonic anhydrase I, II, IV and IX inhibitors.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmcl.2014.01.048,"Substituted benzene sulfonamides incorporating 1,3,5-triazinyl moieties potently inhibit human carbonic anhydrases II, IX and XII.",1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1016/j.bmc.2021.116279,"Design, synthesis and biochemical evaluation of novel carbonic anhydrase inhibitors triggered by structural knowledge on hCA VII.",1
120086,10.1016/j.ejmech.2016.07.027,Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.,10.1016/j.bmcl.2020.127581,In vitro efficacy of synthesized artemisinin derivatives against Leishmania promastigotes.,1
120086,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
120086,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.ejmech.2020.112044,Artemisinin-derived hybrids and their anticancer activity.,1
120086,10.1016/j.bmcl.2009.05.076,Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.,10.1016/j.ejmech.2015.11.003,Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.,1
120086,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.bmc.2021.116131,Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.,1
120086,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
120086,10.1021/acs.jmedchem.0c02104,Discovery of Novel Plasmodium falciparum HDAC1 Inhibitors with Dual-Stage Antimalarial Potency and Improved Safety Based on the Clinical Anticancer Drug Candidate Quisinostat.,10.1021/acs.jmedchem.1c01993,Drug Repurposing of Quisinostat to Discover Novel <i>Plasmodium falciparum</i> HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety.,1
119498,10.1021/np100120c,"Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.",10.1021/np5002016,Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.,1
119498,10.1016/j.bmcl.2017.01.066,DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.,10.1021/acsmedchemlett.8b00551,Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.,1
119498,10.1016/j.bmcl.2017.01.066,DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.,10.1021/acsmedchemlett.9b00306,A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.,1
119498,10.1016/j.bmcl.2017.01.066,DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.,10.1021/acs.jmedchem.0c01354,"Discovery of a ""Gatekeeper"" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.",1
119498,10.1039/C8MD00134K,Scaffold hopping from synthetic RXR modulators by virtual screening and <i>de novo</i> design.,10.1021/acsmedchemlett.9b00306,A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences.,1
119498,10.1021/acsmedchemlett.8b00551,Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.,10.1021/acs.jmedchem.4c01231,Tuning RXR Modulators for PGC1α Recruitment.,1
119498,10.1021/acsmedchemlett.8b00551,Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.,10.1021/acs.jmedchem.1c00235,Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.,1
119498,10.1016/j.bmcl.2017.01.066,DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.,10.1021/acs.jmedchem.1c00235,Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.,1
119498,10.1021/np100120c,"Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.",10.1021/acs.jmedchem.8b00494,Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics.,1
122170,10.1016/j.ejmech.2016.09.012,Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,10.1016/j.bmc.2018.05.049,Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2021.113512,"Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity.",1
122043,10.1016/j.ejmech.2012.08.006,"Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.",10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,1
120086,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
120086,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.ejmech.2017.10.023,"Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.",1
120086,10.1016/j.ejmech.2016.06.035,Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity.,10.1016/j.bmc.2017.05.018,Synthesis of nοvel artemisinin dimers with polyamine linkers and evaluation of their potential as anticancer agents.,1
120086,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm200718m,"Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.",1
120086,10.1016/j.bmcl.2009.05.076,Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.,10.1016/j.ejmech.2017.10.023,"Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin.",1
120086,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
120086,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
120086,10.1016/j.ejmech.2014.01.040,"Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.",10.1016/j.ejmech.2018.03.010,Synthesis of novel ring-contracted artemisinin dimers with potent anticancer activities.,1
120086,10.1016/j.ejmech.2014.01.040,"Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.",10.1016/j.ejmech.2015.11.003,Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.,1
120086,10.1016/j.bmcl.2009.05.076,Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.,10.1016/j.bmc.2021.116131,Cannabidiol-dihydroartemisinin conjugates for ameliorating neuroinflammation with reduced cytotoxicity.,1
120086,10.1016/j.bmcl.2009.05.076,Synthesis of a series of novel dihydroartemisinin derivatives containing a substituted chalcone with greater cytotoxic effects in leukemia cells.,10.1016/j.ejmech.2014.11.016,Synthesis and in vitro biological evaluation of dihydroartemisinyl-chalcone esters.,1
120086,10.1016/j.ejmech.2014.01.040,"Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.",10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
120086,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
122170,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2019.02.015,Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.,1
122170,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2018.11.028,Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2016.09.012,Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.bmc.2018.11.028,Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2022.114269,Nipecotic acid as potential lead molecule for the development of GABA uptake inhibitors; structural insights and design strategies.,1
122170,10.1021/acs.jmedchem.8b01602,Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.,10.1016/j.bmc.2019.05.001,Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2008.01.005,Synthesis and biological evaluation of aminomethylphenol derivatives as inhibitors of the murine GABA transporters mGAT1-mGAT4.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.bmc.2018.05.049,Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with an alkyne spacer as GABA uptake inhibitors.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.ejmech.2010.02.029,"Azetidine derivatives as novel gamma-aminobutyric acid uptake inhibitors: synthesis, biological evaluation, and structure-activity relationship.",1
122170,10.1016/j.ejmech.2016.09.012,Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,10.1016/j.bmc.2019.01.024,Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.,1
122170,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1021/acs.jmedchem.8b01602,Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.,1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.bmc.2015.01.035,"Design, synthesis and SAR studies of GABA uptake inhibitors derived from 2-substituted pyrrolidine-2-yl-acetic acids.",1
122170,10.1021/jm00041a012,"Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3.",10.1016/j.bmc.2019.01.024,Synthesis and biological evaluation of novel N-substituted nipecotic acid derivatives with a cis-alkene spacer as GABA uptake inhibitors.,1
122170,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2016.03.038,Synthesis of 4-substituted nipecotic acid derivatives and their evaluation as potential GABA uptake inhibitors.,1
122170,10.1016/j.ejmech.2016.09.012,Synthesis and biological evaluation of a series of N-alkylated imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.,10.1016/j.bmc.2018.11.028,Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4.,1
122170,10.1021/jm301800j,Focused pseudostatic hydrazone libraries screened by mass spectrometry binding assay: optimizing affinities toward γ-aminobutyric acid transporter 1.,10.1016/j.bmc.2019.05.001,Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).,1
125294,10.1021/ml400014t,Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.,10.1021/jm401812d,Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.,1
125294,10.1021/ml400014t,Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.,10.1016/j.bmcl.2013.07.054,Analogues of the Inhoffen-Lythgoe diol with anti-proliferative activity.,1
124365,10.1021/jm00013a014,Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.,10.1021/jm990418b,"Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308.",1
124365,10.1021/jm00013a014,Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen. (Aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists.,10.1021/jm000022w,Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.,1
122901,10.1021/jm501181z,Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.,10.1016/j.ejmech.2019.04.061,Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.,1
122901,10.1021/ml100192b,Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.,10.1021/jm501181z,Identification and development of biphenyl substituted iminosugars as improved dual glucosylceramide synthase/neutral glucosylceramidase inhibitors.,1
122901,10.1021/ml100192b,Identification of potent and selective glucosylceramide synthase inhibitors from a library of N-alkylated iminosugars.,10.1016/j.ejmech.2019.04.061,Exploring the effect of chirality on the therapeutic potential of N-alkyl-deoxyiminosugars: anti-inflammatory response to Pseudomonas aeruginosa infections for application in CF lung disease.,1
122423,10.1021/jm4011725,Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.,10.1016/j.bmc.2014.12.056,Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.,1
122423,10.1021/jm4011725,Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.,10.1021/acsmedchemlett.7b00533,A BODIPY-Tagged Phosphono Peptide as Activity-Based Probe for Human Leukocyte Elastase.,1
122252,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1021/jm100971t,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,1
122252,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1021/jm4011669,Adenosine A2A receptor as a drug discovery target.,1
122252,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1016/j.ejmech.2017.12.007,Antagonists of the adenosine A2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity.,1
122252,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1021/jm1008659,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",1
122247,10.1016/j.bmcl.2012.05.034,"Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.",10.1016/j.bmcl.2012.08.051,"Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation.",1
122247,10.1016/j.bmcl.2012.05.034,"Discovery, oral pharmacokinetics and in vivo efficacy of a highly selective 5-HT4 receptor agonist: clinical compound TD-2749.",10.1016/j.bmcl.2013.05.018,"Discovery of TD-8954, a clinical stage 5-HT(4) receptor agonist with gastrointestinal prokinetic properties.",1
122170,10.1021/acs.jmedchem.8b01602,Novel Allosteric Ligands of γ-Aminobutyric Acid Transporter 1 (GAT1) by MS Based Screening of Pseudostatic Hydrazone Libraries.,10.1016/j.bmc.2018.11.028,Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4.,1
128763,10.1016/j.bmc.2011.05.009,Generation of 'Unnatural Natural Product' library and identification of a small molecule inhibitor of XIAP.,10.1021/acs.jnatprod.4c00395,"Teleocidin B-4, a PKC Activator, Upregulates Hypoxia-Inducible Factor 1 (HIF-1) Activity by Promoting the Accumulation of HIF-1α Protein via the PKCα/mTORC Signaling Pathway.",1
128645,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
128555,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",1
128555,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
128555,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
128555,10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",10.1016/j.bmc.2020.115728,Next generation quorum sensing inhibitors: Accounts on structure activity relationship studies and biological activities.,1
128555,10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
128555,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
127116,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/acs.jmedchem.6b01309,Structural Analysis of Chemokine Receptor-Ligand Interactions.,1
127116,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",1
127116,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1016/j.ejmech.2018.01.085,Recent updates for designing CCR5 antagonists as anti-retroviral agents.,1
127116,10.1016/j.bmcl.2010.12.109,Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.,10.1016/j.bmc.2011.05.022,"Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.",1
127116,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",10.1016/j.bmc.2020.115923,"Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.",1
127116,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2020.115488,"Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.",1
127116,10.1016/j.bmc.2011.12.055,Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.,10.1016/j.bmc.2015.06.020,Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.,1
125294,10.1021/ml400014t,Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.,10.1016/j.ejmech.2015.01.049,Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors.,1
138562,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1124/dmd.104.002477,"Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.",1
138562,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
138562,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
137532,10.1021/jm060253o,Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells.,10.1016/j.bmc.2011.07.015,Synthesis and antimicrobial activity of (E) stilbene derivatives.,1
136161,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.6b00571,Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.,1
136161,10.1021/jm3007323,"Synthesis and biological evaluation of the 1-arylpyrazole class of σ(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine (S1RA, E-52862).",10.1021/acs.jmedchem.3c00959,Discovery of AD258 as a Sigma Receptor Ligand with Potent Antiallodynic Activity.,1
135248,10.1021/jm030776l,Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.,10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
134571,10.1016/j.bmcl.2013.08.079,Identification of new inhibitors for low molecular weight protein tyrosine phosphatase isoform B.,10.1016/j.bmcl.2020.127342,SAR of non-hydrolysable analogs of pyridoxal 5'-phosphate against low molecular weight protein tyrosine phosphatase isoforms.,1
134571,10.1016/j.bmcl.2008.12.065,Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening.,10.1016/j.bmc.2010.02.053,"'Click chemistry' synthesis of a library of 1,2,3-triazole-substituted galactose derivatives and their evaluation against Trypanosoma cruzi and its cell surface trans-sialidase.",1
134571,10.1016/j.bmcl.2008.12.065,Discovery of novel inhibitors of Trypanosoma cruzi trans-sialidase from in silico screening.,10.1016/j.bmcl.2014.07.088,"Design, synthesis and enzymatic evaluation of 3-O-substituted aryl β-D-galactopyranosides as inhibitors of Trypanosoma cruzi trans-sialidase.",1
132234,10.1021/jm00017a014,"Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol.",10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",1
132234,10.1021/jm070447j,"5-Substituted imidazole-4-acetic acid analogues: synthesis, modeling, and pharmacological characterization of a series of novel gamma-aminobutyric acid(C) receptor agonists.",10.1021/jm301473k,Synthesis and biological evaluation of 4-(aminomethyl)-1-hydroxypyrazole analogues of muscimol as γ-aminobutyric acid(a) receptor agonists.,1
132234,10.1021/jm00017a014,"Partial GABAA receptor agonists. Synthesis and in vitro pharmacology of a series of nonannulated analogs of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol.",10.1021/jm000371q,"A novel class of potent 3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacology.",1
129399,10.1021/jm960133o,"Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.",10.1021/jm3006146,Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.,1
129399,10.1021/jm960133o,"Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.",10.1021/jm980179c,"5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.",1
129399,10.1021/jm960133o,"Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.",10.1021/jm000108p,"Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm801590u,Chalcones: a valid scaffold for monoamine oxidases inhibitors.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmcl.2014.06.015,Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies.,1
139099,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.12.013,"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.09.045,"2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.",1
139099,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
139045,10.1016/S0960-894X(01)81117-3,"Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series",10.1021/jm9504722,Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.,1
139045,10.1016/S0960-894X(01)81117-3,"Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series",10.1016/j.bmc.2012.02.003,Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.,1
139045,10.1016/S0960-894X(01)81117-3,"Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series",10.1016/j.bmc.2010.10.043,Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.,1
138605,10.1021/jm030841r,Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives.,10.1016/j.ejmech.2019.111705,Structure-activity relationships of serotonin 5-HT<sub>7</sub> receptors ligands: A review.,1
138562,10.1021/jm000139k,"A novel series of 4-piperidinopyridine and 4-piperidinopyrimidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase.",10.1021/jm021120f,"Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors.",1
138562,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1016/j.bmcl.2007.05.097,"Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.",1
138562,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1016/j.bmcl.2007.05.096,"Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.",1
138562,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1097/01.fpc.0000170913.73780.5f,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.",1
138562,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
138562,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.10.032,Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acs.jmedchem.0c01504,New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.,1
139099,10.1016/j.ejmech.2013.11.035,A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors.,10.1016/j.bmc.2018.08.024,"Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acsmedchemlett.5b00326,Monoamine Oxidase Inhibitory Activity of Novel Pyrazoline Analogues: Curcumin Based Design and Synthesis.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2013.09.010,"Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.05.070,"Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.",1
139099,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2016.03.081,(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.,1
139099,10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,10.1016/j.ejmech.2021.114097,Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2017.12.013,"Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1039/C0MD00014K,"Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.06.007,Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2009.11.003,"Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.",1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.12.027,Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.,1
139099,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm100120s,"Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.",1
143870,10.1021/jm970819w,"Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.",10.1016/j.bmcl.2010.10.137,Glycosylated nordihydroguaiaretic acids as anti-cancer agents.,1
143870,10.1021/jm970819w,"Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.",10.1016/j.bmcl.2013.09.014,Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.,1
143870,10.1021/jm970819w,"Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation.",10.1016/j.bmc.2017.07.047,meso-Dihydroguaiaretic acid derivatives with antibacterial and antimycobacterial activity.,1
143284,10.1016/j.bmcl.2010.07.094,"Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.",10.1016/j.ejmech.2011.12.021,"Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.",1
142808,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2019.111691,Indole: A privileged scaffold for the design of anti-cancer agents.,1
142808,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2023.115870,The discovery of water-soluble indazole derivatives as potent microtubule polymerization inhibitors.,1
142808,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1016/j.ejmech.2018.11.070,"Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.",1
142808,10.1021/acs.jmedchem.5b01312,"An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.",10.1016/j.ejmech.2020.112359,Current scenario of indole derivatives with potential anti-drug-resistant cancer activity.,1
142808,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
142808,10.1021/ml200236a,10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.,10.1016/j.ejmech.2020.112359,Current scenario of indole derivatives with potential anti-drug-resistant cancer activity.,1
142808,10.1021/jm4016526,Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.,10.1021/acs.jmedchem.0c01345,"SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazoles as Potent Tubulin Polymerization Inhibitors.",1
139286,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
139286,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
139286,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
139241,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
139099,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/acs.jmedchem.0c01109,"Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.ejmech.2019.111600,"Carbonic anhydrase inhibitors based on sorafenib scaffold: Design, synthesis, crystallographic investigation and effects on primary breast cancer cells.",1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2021.113837,Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2009.06.002,The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/j.bmc.2013.05.032,"7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2015.11.031,"Fluorescent sulfonamide carbonic anhydrase inhibitors incorporating 1,2,3-triazole moieties: Kinetic and X-ray crystallographic studies.",1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm031116j,Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/jm400414j,Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/s0960-894x(00)00722-8,Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmcl.2014.02.030,"Synthesis and carbonic anhydrase I, II, IX and XII inhibition studies of 4-N,N-disubstituted sulfanilamides incorporating 4,4,4-trifluoro-3-oxo-but-1-enyl, phenacylthiourea and imidazol-2(3H)-one/thione moieties.",1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/jm1003667,Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2015.06.021,"Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.",1
1125,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2014.07.014,Cyclic tertiary sulfamates: selective inhibition of the tumor-associated carbonic anhydrases IX and XII by N- and O-substituted acesulfame derivatives.,1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2017.02.037,"Synthesis of bulky-tailed sulfonamides incorporating pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-1(5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects.",1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1016/j.bmcl.2006.10.014,Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptors.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1016/j.bmcl.2006.04.084,Discovery of 3-arylpropionic acids as potent agonists of sphingosine-1-phosphate receptor-1 (S1P1) with high selectivity against all other known S1P receptor subtypes.,1
144940,10.1021/ml400194r,Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.,10.1016/j.bmc.2014.05.035,Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.,1
144940,10.1021/ml400194r,Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.,10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/acs.jmedchem.5b01512,Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1016/j.ejmech.2014.07.081,Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1016/j.bmcl.2011.10.085,Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.,1
144940,10.1021/acs.jmedchem.6b00089,Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.,10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/acs.jmedchem.6b00373,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/ml400194r,Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.,1
144940,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",1
144940,10.1021/acs.jmedchem.6b00373,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,1
144940,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",10.1021/acs.jmedchem.1c01979,Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.,1
144940,10.1021/acs.jmedchem.6b00373,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",1
144940,10.1021/acs.jmedchem.6b00089,Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.,10.1021/acs.jmedchem.6b00373,Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1).,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/np2000528,Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2009.07.039,Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors.,1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.bmcl.2014.12.034,"Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.06.007,Investigations on the 2-thiazolylhydrazyne scaffold: synthesis and molecular modeling of selective human monoamine oxidase inhibitors.,1
149457,10.1016/j.bmc.2013.06.022,Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.,10.1016/j.bmcl.2014.05.064,Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein.,1
149095,10.1021/jm00369a007,Synthesis and evaluation of a series of 2'-O-acyl derivatives of 9-beta-D-arabinofuranosyladenine as antiherpes agents.,10.1021/jm901590f,Application of the dipeptidyl peptidase IV (DPPIV/CD26) based prodrug approach to different amine-containing drugs.,1
147981,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
144959,10.1021/jm030115o,Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.,10.1016/j.bmc.2018.07.012,Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.,1
144940,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.1c01979,Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.,1
144940,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.0c01109,"Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.",1
144940,10.1021/ml400194r,Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.,10.1016/j.bmcl.2015.10.026,New fluorinated agonists for targeting the sphingosin-1-phosphate receptor 1 (S1P(1)).,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1124/dmd.110.035378,"CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis.",1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1016/j.bmcl.2010.02.006,Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.,1
144940,10.1021/jm050242f,"Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.",10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",1
144940,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",10.1021/acs.jmedchem.0c01109,"Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.",1
144940,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/acs.jnatprod.6b00391,"Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1021/jm301014y,Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.,1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2020.112475,"Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.",1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2013.02.009,"Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.",1
150743,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2012.11.006,"1,5-Diphenylpenta-2,4-dien-1-ones as potent and selective monoamine oxidase-B inhibitors.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1039/C4MD00437J,Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective monoamine oxidase B inhibitors,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2012.10.032,Recent advances in the development of selective human MAO-B inhibitors: (hetero)arylidene-(4-substituted-thiazol-2-yl)hydrazines.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2023.115091,"8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2023.115091,"8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1021/acs.jmedchem.2c01271,Development of MAO-A and 5-HT<sub>2A</sub>R Dual Inhibitors with Improved Antidepressant Activity.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2013.02.009,"Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study.",1
150743,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1016/j.ejmech.2016.03.081,(E)-3-Heteroarylidenechroman-4-ones as potent and selective monoamine oxidase-B inhibitors.,1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.bmc.2014.05.002,"New coumarin derivatives: design, synthesis and use as inhibitors of hMAO.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2014.03.042,Identification of the stereochemical requirements in the 4-aryl-2-cycloalkylidenhydrazinylthiazole scaffold for the design of selective human monoamine oxidase B inhibitors.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm100120s,"Synthesis, stereochemical separation, and biological evaluation of selective inhibitors of human MAO-B: 1-(4-arylthiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazines.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2017.07.045,Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2010.07.013,New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmc.2014.05.002,"New coumarin derivatives: design, synthesis and use as inhibitors of hMAO.",1
150743,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm2004267,"Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1016/j.ejmech.2015.03.040,Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.09.045,"2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1039/C0MD00014K,"Synthesis and selective inhibition of human monoamine oxidases of a large scaffold of (4,5-substituted-thiazol-2-yl)hydrazones",1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2014.04.060,"New 2H-chromene-3-carboxamide derivatives: design, synthesis and use as inhibitors of hMAO.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.bmc.2010.05.070,"Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors.",1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2011.12.027,Synthesis and biological assessment of novel 2-thiazolylhydrazones and computational analysis of their recognition by monoamine oxidase B.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2011.11.020,Hydroxycoumarins as selective MAO-B inhibitors.,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1021/jm801590u,Chalcones: a valid scaffold for monoamine oxidases inhibitors.,1
150743,10.1016/j.bmc.2009.12.029,"A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors.",10.1021/jm1013709,Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1021/jm2004267,"Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.",1
153330,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c00468,Structure-Based Discovery of Novel NH<sub>2</sub>-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH<sub>2</sub>-Naphthyl-Diarylpyrimidine to NH<sub>2</sub>-Biphenyl-Diarylpyrimidine.,1
153330,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
153330,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
153330,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,1
153330,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
153330,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
153330,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
153330,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
153330,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
150882,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1039/C1MD00221J,3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer's disease,1
150743,10.1021/jm800132g,"Synthesis, stereochemical identification, and selective inhibitory activity against human monoamine oxidase-B of 2-methylcyclohexylidene-(4-arylthiazol-2-yl)hydrazones.",10.1016/j.ejmech.2009.11.003,"Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives.",1
150743,10.1021/jm200716y,Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.,10.1021/acs.jnatprod.6b00391,"Anisucoumaramide, a Bioactive Coumarin from Clausena anisum-olens.",1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.bmcl.2011.05.074,MAO inhibitory activity modulation: 3-Phenylcoumarins versus 3-benzoylcoumarins.,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1039/C4MD00437J,Synthesis and evaluation of 6-methylcoumarin derivatives as potent and selective monoamine oxidase B inhibitors,1
150743,10.1016/j.bmcl.2009.04.085,A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors.,10.1016/j.ejmech.2011.01.033,"Synthesis, human monoamine oxidase inhibitory activity and molecular docking studies of 3-heteroarylcoumarin derivatives.",1
155006,10.1021/acs.jmedchem.1c01353,Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Bitopic Ligands.,10.1021/acs.jmedchem.3c00098,Transformation of a Dopamine D<sub>2</sub> Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/jm5004039,"Functionally selective dopamine D₂, D₃ receptor partial agonists.",1
155006,10.1016/j.ejmech.2017.12.099,Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.,10.1016/j.ejmech.2019.111736,"Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.",1
155006,10.1016/j.bmcl.2016.04.087,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",10.1016/j.bmcl.2018.01.038,Synthesis and biological evaluation of a series of novel pyridinecarboxamides as potential multi-receptor antipsychotic drugs.,1
155006,10.1016/j.ejmech.2017.12.099,Synthesis and biological evaluation of a series of multi-target N-substituted cyclic imide derivatives with potential antipsychotic effect.,10.1016/j.bmcl.2021.127909,Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/jm300603y,Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/acs.jmedchem.1c01353,Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Bitopic Ligands.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1016/j.bmc.2015.04.026,Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1016/j.ejmech.2022.114193,Novel D<sub>2</sub>/5-HT receptor modulators related to cariprazine with potential implication to schizophrenia treatment.,1
154798,10.1016/j.bmc.2009.11.060,Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28.,10.1016/j.bmcl.2014.06.082,Allosteric modulation of the G protein-coupled US28 receptor of human cytomegalovirus: are the small-weight inverse agonist of US28 'camouflaged' agonists?,1
154798,10.1016/j.bmcl.2011.06.120,Identification of novel allosteric modulators for the G-protein coupled US28 receptor of human cytomegalovirus.,10.1016/j.bmcl.2014.06.082,Allosteric modulation of the G protein-coupled US28 receptor of human cytomegalovirus: are the small-weight inverse agonist of US28 'camouflaged' agonists?,1
154798,10.1016/j.bmc.2009.11.060,Identification of novel allosteric nonpeptidergic inhibitors of the human cytomegalovirus-encoded chemokine receptor US28.,10.1016/j.bmcl.2011.06.120,Identification of novel allosteric modulators for the G-protein coupled US28 receptor of human cytomegalovirus.,1
154537,10.1021/jm9706224,"Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.",10.1021/jm040219e,"Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.",1
154537,10.1021/jm9706224,"Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.",10.1016/s0960-894x(98)00504-6,"Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.",1
154537,10.1021/jm9706224,"Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.",10.1016/j.bmcl.2005.01.058,"3-(2,5-Dihydro-1H-pyrrol-2-ylmethoxy)pyridines: synthesis and analgesic activity.",1
154537,10.1021/jm9706224,"Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.",10.1016/j.bmcl.2009.01.099,Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/j.bmc.2013.06.041,"5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmcl.2011.05.071,In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2016.06.005,"Kinetic and X-ray crystallographic investigations of substituted 2-thio-6-oxo-1,6-dihydropyrimidine-benzenesulfonamides acting as carbonic anhydrase inhibitors.",1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1021/acs.jmedchem.0c00733,Sulfonamide Inhibitors of Human Carbonic Anhydrases Designed through a Three-Tails Approach: Improving Ligand/Isoform Matching and Selectivity of Action.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmcl.2009.06.002,The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2021.113351,"Comprehensive study on potent and selective carbonic anhydrase inhibitors: Synthesis, bioactivities and molecular modelling studies of 4-(3-(2-arylidenehydrazine-1-carbonyl)-5-(thiophen-2-yl)-1H-pyrazole-1-yl) benzenesulfonamides.",1
1125,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1021/acsmedchemlett.4c00206,"Novel 2,4-Dichloro-5-sulfamoylbenzoic Acid Oxime Esters: First Studies as Potential Human Carbonic Anhydrase Inhibitors.",1
1125,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2017.01.017,"Novel indolin-2-one-based sulfonamides as carbonic anhydrase inhibitors: Synthesis, in vitro biological evaluation against carbonic anhydrases isoforms I, II, IV and VII and molecular docking studies.",1
1125,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2023.115538,Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/acs.jmedchem.6b00443,"An Unusual Natural Product Primary Sulfonamide: Synthesis, Carbonic Anhydrase Inhibition, and Protein X-ray Structures of Psammaplin C.",1
164035,10.1016/j.bmcl.2008.04.025,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",10.1016/j.bmcl.2024.129654,2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design.,1
164035,10.1016/j.bmcl.2008.04.025,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",10.1016/j.bmcl.2008.04.045,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,1
163574,10.1021/acs.jmedchem.8b01256,"Discovery of Clinical Candidate 2-(4-(2-((1 H-Benzo[ d]imidazol-2-yl)thio)ethyl)piperazin-1-yl)- N-(6-methyl-2,4-bis(methylthio)pyridin-3-yl)acetamide Hydrochloride [K-604], an Aqueous-Soluble Acyl-CoA:Cholesterol O-Acyltransferase-1 Inhibitor.",10.1021/acs.jmedchem.2c01265,Targeting Sterol <i>O</i>-Acyltransferase/Acyl-CoA:Cholesterol Acyltransferase (ACAT): A Perspective on Small-Molecule Inhibitors and Their Therapeutic Potential.,1
155584,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.1c00261,The Medicinal Chemistry of Caffeine.,1
155006,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/jm500457x,Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D₂ receptor.,1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1021/ml500279k,Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2005.10.074,Synthesis and antibacterial activity of 3-O-acyl-6-O-carbamoyl erythromycin A derivatives.,1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2020.112222,"Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.",1
171587,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmcl.2017.02.041,"Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides.",1
167995,10.1021/jm070415w,Discovery and optimization of p38 inhibitors via computer-assisted drug design.,10.1016/j.bmcl.2008.04.043,"Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.",1
167995,10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
167995,10.1016/j.bmcl.2011.09.078,Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).,10.1016/j.ejmech.2020.112721,Selective targeting of the αC and DFG-out pocket in p38 MAPK.,1
167995,10.1021/jm070415w,Discovery and optimization of p38 inhibitors via computer-assisted drug design.,10.1016/j.bmcl.2009.03.104,Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.,1
167995,10.1021/jm070415w,Discovery and optimization of p38 inhibitors via computer-assisted drug design.,10.1016/j.bmcl.2010.06.102,Optimization of alpha-ketoamide based p38 inhibitors through modifications to the region that binds to the allosteric site.,1
167995,10.1016/j.bmcl.2008.04.043,"Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.",10.1016/j.bmcl.2009.03.104,Discovery and characterization of the N-phenyl-N'-naphthylurea class of p38 kinase inhibitors.,1
167326,10.1021/jm970389+,Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonists.,10.1021/jm010852p,Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.,1
1125,10.1016/j.ejmech.2023.115783,Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for μ Opioid receptor for Safer and long-lasting analgesia.,10.1021/acs.jmedchem.3c02254,Novel Carbonic Anhydrase Inhibitors with Dual-Tail Core Sulfonamide Show Potent and Lasting Effects for Glaucoma Therapy.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.1c01906,One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.01.018,"Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII.",1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1016/j.bmc.2017.12.035,"Benzimidazole design, synthesis, and docking to build selective carbonic anhydrase VA inhibitors.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2014.12.054,N-Acylsulfonamides strongly inhibit human carbonic anhydrase isoenzymes I and II.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmc.2010.10.024,Novel hybrids of 15-membered 8a- and 9a-azahomoerythromycin A ketolides and quinolones as potent antibacterials.,1
171587,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmc.2015.08.020,Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmc.2012.08.007,Synthesis and structure-activity relationship of a novel class of 15-membered macrolide antibiotics known as '11a-azalides'.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2006.09.036,Synthesis and antibacterial activity of C6-carbazate ketolides.,1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2019.02.073,"Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.",1
171587,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmcl.2012.12.070,"Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.",1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.bmcl.2022.128761,"Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides.",1
171587,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.ejmech.2019.03.037,"Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.",1
171587,10.1016/j.bmcl.2010.07.072,A new series of macrolide derivatives with 4''-O-saccharide substituents.,10.1016/j.bmcl.2013.09.083,Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities.,1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2024.116630,"Design, synthesis and structure-activity relationships of novel non-ketolides: 9-Oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH.",1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2005.12.097,"Synthesis and antibacterial activity of 6-O-heteroarylcarbamoyl-11,12-lactoketolides.",1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2004.12.067,"Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes.",1
171587,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.bmc.2016.01.055,Synthesis and antibacterial evaluation of novel 4″-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1021/jm100711p,Synthesis and structure-activity relationships of novel 8a-aza-8a-homoerythromycin A ketolides.,1
171587,10.1016/j.bmcl.2004.06.045,"Synthesis and antibacterial activity of C-6 carbamate ketolides, a novel series of orally active ketolide antibiotics.",10.1016/j.bmcl.2007.04.104,"Synthesis and antibacterial activity of 3-keto-6-O-carbamoyl-11,12-cyclic thiocarbamate erythromycin A derivatives.",1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2012.10.103,"Restoring catalytic activity to the human carbonic anhydrase (CA) related proteins VIII, X and XI affords isoforms with high catalytic efficiency and susceptibility to anion inhibition.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.05.016,"Synthesis of 4-(thiazol-2-ylamino)-benzenesulfonamides with carbonic anhydrase I, II and IX inhibitory activity and cytotoxic effects against breast cancer cell lines.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2013.01.019,Novel sulfamides as potential carbonic anhydrase isoenzymes inhibitors.,1
176291,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/jm4019299,"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.",1
175447,10.1016/j.bmc.2009.07.073,Identification and characterization of novel sirtuin inhibitor scaffolds.,10.1039/C1MD00199J,Development of second generation epigenetic agents,1
175447,10.1016/j.bmc.2009.07.073,Identification and characterization of novel sirtuin inhibitor scaffolds.,10.1016/j.ejmech.2016.04.063,How much successful are the medicinal chemists in modulation of SIRT1: A critical review.,1
175447,10.1016/j.bmcl.2009.08.028,Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine.,10.1039/C1MD00199J,Development of second generation epigenetic agents,1
175447,10.1021/jm500777s,Discovery of potent and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach.,10.1021/acs.jmedchem.5b01517,Aminothiazoles as Potent and Selective Sirt2 Inhibitors: A Structure-Activity Relationship Study.,1
175447,10.1016/j.bmc.2021.116328,Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.,10.1016/j.bmc.2022.116999,Discovery of novel compounds as potent activators of Sirt3.,1
175106,10.1016/j.bmc.2013.06.022,Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.,10.1016/j.ejmech.2022.114111,Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.,1
173090,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2006.09.028,"Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.",1
173090,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(01)00649-7,Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.,1
173090,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2010.04.031,Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma).,1
173090,10.1021/jm980413z,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.,10.1007/s00044-011-9818-7,The application of comparative molecular field analysis for the design of -anilino substituted-3-phenyl propanoic acids as novel PPAR/ dual ligands,1
173090,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.ejmech.2007.03.004,QSAR analysis of PPAR-gamma agonists as anti-diabetic agents.,1
171587,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.ejmech.2013.08.023,Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides.,1
176796,10.1016/j.bmcl.2012.08.093,Synthesis and in vitro antitumour screening of 2-(β-D-xylofuranosyl)thiazole-4-carboxamide and two novel tiazofurin analogues with substituted tetrahydrofurodioxol moiety as a sugar mimic.,10.1016/j.ejmech.2016.01.037,Synthesis and in vitro antitumour activity of tiazofurin analogues with nitrogen functionalities at the C-2' position.,1
176796,10.1016/j.bmcl.2012.08.093,Synthesis and in vitro antitumour screening of 2-(β-D-xylofuranosyl)thiazole-4-carboxamide and two novel tiazofurin analogues with substituted tetrahydrofurodioxol moiety as a sugar mimic.,10.1016/j.ejmech.2019.111712,"Structure based design, synthesis and in vitro antitumour activity of tiazofurin stereoisomers with nitrogen functions at the C-2' or C-3' positions.",1
176291,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/jm2004706,Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.,1
1125,10.1021/jm00039a023,Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tight-binding inhibitors.,10.1016/j.bmc.2012.12.037,o-Benzenedisulfonimido-sulfonamides are potent inhibitors of the tumor-associated carbonic anhydrase isoforms CA IX and CA XII.,1
1125,10.1016/j.ejmech.2023.115783,Discovery of a novel series of potent carbonic anhydrase inhibitors with selective affinity for μ Opioid receptor for Safer and long-lasting analgesia.,10.1021/acs.jmedchem.3c02190,Synthetic Approaches to Novel Human Carbonic Anhydrase Isoform Inhibitors Based on Pyrrol-2-one Moiety.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2017.03.026,Inhibition of Malassezia globosa carbonic anhydrase with phenols.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.ejmech.2019.111698,"Continued exploration and tail approach synthesis of benzenesulfonamides containing triazole and dual triazole moieties as carbonic anhydrase I, II, IV and IX inhibitors.",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2011.05.071,In vitro inhibition of α-carbonic anhydrase isozymes by some phenolic compounds.,1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmc.2007.07.044,"Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity.",1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmcl.2016.12.035,Sulfonamide inhibition profile of the γ-carbonic anhydrase identified in the genome of the pathogenic bacterium Burkholderia pseudomallei the etiological agent responsible of melioidosis.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2016.01.012,Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action.,1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1016/j.bmcl.2019.126874,"Synthesis and evaluation of 4-(1,3,4-oxadiazol-2-yl)-benzenesulfonamides as potent carbonic anhydrase inhibitors.",1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1021/acsmedchemlett.0c00062,Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2020.113035,Handling drug-target selectivity: A study on ureido containing Carbonic Anhydrase inhibitors.,1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.ejmech.2022.114793,Development of benzene and benzothiazole-sulfonamide analogues as selective inhibitors of the tumor-associated carbonic anhydrase IX.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmcl.2013.12.124,Anion inhibition studies of two new β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.,1
183934,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/jm500823a,Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors.,1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmc.2008.10.087,Discovery and development of heat shock protein 90 inhibitors.,1
183934,10.1021/jm200784m,"Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.",10.1021/jm401801t,Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologues enable the structure-based discovery of pathogen-selective inhibitors.,1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmcl.2006.01.099,4-Amino derivatives of the Hsp90 inhibitor CCT018159.,1
183934,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.ejmech.2016.05.033,"Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.",1
183934,10.1021/jm200784m,"Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.",10.1016/j.bmcl.2015.01.023,Discovery of novel oxazepine and diazepine carboxamides as two new classes of heat shock protein 90 inhibitors.,1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.ejmech.2016.05.033,"Design and synthesis of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-1,2,3,4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors.",1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmc.2011.08.048,Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.,1
183934,10.1016/j.bmc.2011.08.048,Lead identification of β-lactam and related imine inhibitors of the molecular chaperone heat shock protein 90.,10.1016/j.bmc.2016.12.050,"Design, synthesis and biological evaluation of 7-(aryl)-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline derivatives as potential Hsp90 inhibitors and anticancer agents.",1
183934,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
183934,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2016.11.062,"Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.",1
182921,10.1016/j.bmc.2013.06.022,Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.,10.1016/j.bmcl.2014.05.064,Structure-activity relationships of oxysterol-derived pharmacological chaperones for Niemann-Pick type C1 protein.,1
180370,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
180228,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
179594,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
179594,10.1016/j.bmcl.2009.09.120,Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates.,10.1016/j.bmcl.2013.09.100,"3',4'-Bis-difluoromethoxycinnamoylanthranilate (FT061): an orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy.",1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2013.05.032,"7-Substituted-sulfocoumarins are isoform-selective, potent carbonic anhydrase II inhibitors.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmc.2016.05.029,"Anion inhibition profiles of α-, β- and γ-carbonic anhydrases from the pathogenic bacterium Vibrio cholerae.",1
1125,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,10.1016/j.bmc.2017.03.054,Synthesis of new 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII.,1
187372,10.1021/acs.jmedchem.1c00604,"Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).",10.1021/acs.jmedchem.2c00523,Discovery of a Novel Oral Proteasome Inhibitor to Block NLRP3 Inflammasome Activation with Anti-inflammation Activity.,1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.ejmech.2018.12.072,Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.,1
187372,10.1016/j.ejmech.2014.06.017,Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.,10.1016/j.bmc.2018.01.017,Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.,1
187372,10.1016/j.ejmech.2014.06.017,Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.,10.1016/j.ejmech.2017.01.034,"Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.",1
187372,10.1021/acs.jmedchem.1c00604,"Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).",10.1021/acs.jmedchem.2c00733,Discovery of Highly Selective Inhibitors of the Human Constitutive Proteasome β5c Chymotryptic Subunit.,1
187372,10.1021/acs.jmedchem.1c00604,"Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).",10.1016/j.ejmech.2023.115856,"Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification.",1
187372,10.1021/acs.jmedchem.1c00604,"Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i).",10.1016/j.bmc.2024.117790,Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor.,1
187372,10.1021/jm400351a,Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.,10.1016/j.bmc.2017.05.049,Synthesis and biological activity of peptide proline-boronic acids as proteasome inhibitors.,1
183934,10.1021/jm060836y,Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.,10.1021/jm701018h,"4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.",1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1021/jm9004708,Heat shock protein 90: inhibitors in clinical trials.,1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1021/jm701018h,"4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.",1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmcl.2009.01.003,"5-Aryl-4-(5-substituted-2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone.",1
183934,10.1016/j.bmcl.2005.05.046,"The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.",10.1016/j.bmcl.2005.08.092,Structure-based discovery of a new class of Hsp90 inhibitors.,1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.ejmech.2017.01.034,"Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.",1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.bmc.2018.06.020,"Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.",1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.bmc.2018.01.017,Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.,1
1125,10.1016/j.bmc.2008.11.071,Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors.,10.1016/j.bmcl.2011.02.059,"Virtual screening-driven identification of human carbonic anhydrase inhibitors incorporating an original, new pharmacophore.",1
1125,10.1021/jm00394a021,"Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.",10.1021/jm9900523,"Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: is the tail more important than the ring?",1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmcl.2011.12.069,Synthesis and carbonic anhydrase inhibitory properties of novel cyclohexanonyl bromophenol derivatives.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2018.12.049,"Continued exploration of 1,2,4-oxadiazole periphery for carbonic anhydrase-targeting primary arene sulfonamides: Discovery of subnanomolar inhibitors of membrane-bound hCA IX isoform that selectively kill cancer cells in hypoxic environment.",1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.ejmech.2016.09.035,Synthesis and evaluation of new benzodioxole-based dithiocarbamate derivatives as potential anticancer agents and hCA-I and hCA-II inhibitors.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1021/jm300031j,Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo.,1
1125,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2023.115538,Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer.,1
1125,10.1016/j.ejmech.2019.111896,"Sulfonamide/sulfamate switch with a series of piperazinylureido derivatives: Synthesis, kinetic and in silico evaluation as carbonic anhydrase isoforms I, II, IV, and IX inhibitors.",10.1021/acsmedchemlett.3c00484,Discovery of a New Class of 1-(4-Sulfamoylbenzoyl)piperidine-4-carboxamides as Human Carbonic Anhydrase Inhibitors.,1
1125,10.1016/j.bmcl.2006.12.010,Identification of arylsulfonamides as Aquaporin 4 inhibitors.,10.1016/j.bmc.2007.12.038,Inhibition of aquaporin 4 by antiepileptic drugs.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmcl.2016.07.015,Synthesis and carbonic anhydrase inhibitory effects of new N-glycosylsulfonamides incorporating the phenol moiety.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2011.06.038,Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2013.06.041,"5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies.",1
1125,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1016/j.ejmech.2018.11.073,Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety.,1
190629,10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,10.1016/j.bmc.2017.04.018,Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate.,1
189099,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",1
188815,10.1016/j.bmc.2015.10.036,"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.",10.1016/j.ejmech.2021.114035,Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.,1
188815,10.1016/j.bmc.2015.10.036,"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.",10.1016/j.bmc.2016.11.012,"Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.",1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1021/jm070284z,Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1021/jm990412m,Protease inhibitors: current status and future prospects.,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1039/C1MD00077B,HIV-1 protease inhibitors with a tertiary alcohol containing transition-state mimic and various P2 and P1 substituents,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1021/jm070680h,Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1016/j.bmcl.2012.10.095,Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
188196,10.1021/jm970873c,New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.,10.1021/jm201620t,"Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.",1
187515,10.1016/j.bmc.2008.11.055,Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.,10.1016/j.bmc.2009.09.041,"New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.",1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.ejmech.2016.10.023,Urea-containing peptide boronic acids as potent proteasome inhibitors.,1
187372,10.1021/acs.jmedchem.8b01161,Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.,10.1021/acs.jmedchem.9b00363,Improvement of Asparagine Ethylenediamines as Anti-malarial <i>Plasmodium</i>-Selective Proteasome Inhibitors.,1
187372,10.1021/jm501344n,Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.,10.1016/j.bmc.2016.04.025,"3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.",1
187372,10.1021/acs.jmedchem.0c00499,Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases.,10.1016/j.bmc.2024.117790,Optimization of α-amido boronic acids via cryo-electron microscopy analysis: Discovery of a novel highly selective immunoproteasome subunit LMP7 (β5i)/LMP2 (β1i) dual inhibitor.,1
201200,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.bmcl.2017.07.033,"Design, synthesis and in vitro anticancer activity of novel quinoline and oxadiazole derivatives of ursolic acid.",1
201200,10.1016/j.ejmech.2011.02.053,Identification of pentacyclic triterpenes derivatives as potent inhibitors against glycogen phosphorylase based on 3D-QSAR studies.,10.1021/jm5002293,Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis.,1
201200,10.1016/j.bmcl.2018.12.060,"Design, synthesis, and screening of novel ursolic acid derivatives as potential anti-cancer agents that target the HIF-1α pathway.",10.1016/j.bmcl.2019.04.028,Synthesis and evaluation of the HIF-1α inhibitory activities of novel ursolic acid tetrazole derivatives.,1
198677,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",1
198677,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
198677,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
198677,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
198677,10.1021/acs.jmedchem.0c00182,"Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.",10.1021/acs.jmedchem.1c01014,Discovery of an eIF4A Inhibitor with a Novel Mechanism of Action.,1
198677,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
193962,10.1021/acs.jmedchem.9b00058,A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.,10.1021/acs.jmedchem.0c01773,Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors.,1
192908,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1016/j.bmcl.2010.04.052,"Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reducing ion channel activity.",1
192908,10.1016/j.bmcl.2009.03.054,3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.,10.1021/jm901559e,1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.,1
191924,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm0607247,"NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.",1
191924,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
190629,10.1021/jm300281x,Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator.,10.1021/jm401625b,1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators.,1
190629,10.1021/jm0613976,"Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators.",10.1021/jm900280m,Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit.,1
216457,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm100287t,"Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.",1
213639,10.1021/jm049510k,"Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors.",10.1016/j.ejmech.2011.02.071,Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.,1
211620,10.1016/j.bmcl.2006.05.099,Identification of small-molecule inhibitors of the Abeta-ABAD interaction.,10.1016/j.bmcl.2016.05.087,"Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.",1
211620,10.1016/j.bmcl.2006.05.099,Identification of small-molecule inhibitors of the Abeta-ABAD interaction.,10.1016/j.bmc.2016.12.029,Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer's disease treatment.,1
210852,10.1021/jm00156a009,"Synthesis, antimalarial activity, and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4-quinolinyl)amino]-3-[(alkylamino)methyl] [1,1'-biphenyl]-2-ols and N omega-oxides.",10.1016/0960-894X(96)00040-6,The effect of fluorine substitution on the antimalarial activity of tebuquine,1
208749,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
205165,10.1021/jm020143r,"Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.",10.1182/blood-2009-05-222034,AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).,1
205165,10.1021/jm020143r,"Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.",10.1021/jm300042x,"Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.",1
202259,10.1016/j.bmcl.2008.10.042,Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.,10.1039/c3md20374c,Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.,1
202259,10.1016/j.bmcl.2008.10.042,Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.,10.1021/jm900770h,Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).,1
202259,10.1016/j.bmcl.2005.07.032,Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.,10.1016/j.bmcl.2008.10.042,Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2.,1
202259,10.1016/j.bmcl.2005.07.032,Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.,10.1039/c3md20374c,Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse.,1
201200,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.ejmech.2016.07.045,Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells.,1
201200,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.ejmech.2017.07.013,"Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.",1
201200,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.bmcl.2016.10.008,Discovery of ursolic acid prodrug (NX-201): Pharmacokinetics and in vivo antitumor effects in PANC-1 pancreatic cancer.,1
201200,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.bmcl.2018.12.060,"Design, synthesis, and screening of novel ursolic acid derivatives as potential anti-cancer agents that target the HIF-1α pathway.",1
223819,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
222633,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
222633,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
222203,10.1016/j.bmcl.2014.01.014,Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.,10.1016/j.ejmech.2017.11.029,Recent developments in anti-Trichomonas research: An update review.,1
221962,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/acs.jmedchem.0c01836,Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist.,1
221962,10.1021/jm0201159,Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists.,10.1021/jm401343c,"MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.",1
217548,10.1021/acs.jmedchem.5b01972,Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.,10.1016/j.bmcl.2022.128837,Strategies for targeting the P2Y<sub>12</sub> receptor in the central nervous system.,1
217341,10.1016/j.bmc.2014.12.069,"Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.",10.1021/acs.jmedchem.5b01281,Recent Progress in the Discovery of Next Generation Inhibitors of Aromatase from the Structure-Function Perspective.,1
217341,10.1016/j.bmc.2014.12.069,"Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.",10.1016/j.ejmech.2015.09.038,Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.,1
217341,10.1021/jm00087a013,Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.,10.1016/j.ejmech.2020.112845,Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: Comparative SAR/QSAR assessment on steroidal aromatase inhibitors.,1
217341,10.1016/j.bmc.2014.12.069,"Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.",10.1016/j.bmc.2020.115935,"Synthesis and anticancer potential of novel 5,6-oxygenated and/or halogenated steroidal d-homo lactones.",1
217341,10.1021/jm00087a013,Synthesis and evaluation of a new series of mechanism-based aromatase inhibitors.,10.1016/j.ejmech.2015.09.038,Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.,1
216457,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/jm1016297,"Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.",1
216457,10.1021/acs.jmedchem.5b01972,Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development.,10.1021/acs.jmedchem.7b00854,Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y2 Receptor.,1
216457,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1021/acs.jmedchem.7b01906,"Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-Pα,α-Dithiophosphate Analogues.",1
216457,10.1016/j.ejmech.2008.07.015,Identification of hydrolytically stable and selective P2Y(1) receptor agonists.,10.1016/j.bmc.2012.07.042,"UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.",1
230999,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2019.111841,"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.",1
230999,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
230999,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112085,"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.",1
230999,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
230999,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
230966,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.ejmech.2014.12.027,"Functionalized tetrahydro-1H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity.",1
230966,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
230966,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
230966,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00723,"A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.",1
228354,10.1016/j.ejmech.2021.113929,"Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PA<sub>N</sub> inhibitors.",10.1021/acs.jmedchem.2c00857,Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PA<sub>N</sub> Endonuclease Inhibitors.,1
228121,10.1021/jm800455g,A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.,10.1021/jm901440f,Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai.,1
228121,10.1016/j.ejmech.2022.114711,The current strategies of optimization of oseltamivir against mutant neuraminidases of influenza A：A review.,10.1021/acs.jmedchem.4c00131,Novel Acyl Thiourea-Based Hydrophobic Tagging Degraders Exert Potent Anti-Influenza Activity through Two Distinct Endonuclease Polymerase Acidic-Targeted Degradation Pathways.,1
228121,10.1016/j.bmcl.2015.04.059,"Assessing the oral bioavailability of difluorosialic acid prodrugs, potent viral neuraminidase inhibitors, using a snapshot PK screening assay.",10.1016/j.ejmech.2016.10.061,Prodrug approach: An overview of recent cases.,1
228121,10.1021/ml500236n,Identification and synthesis of quinolizidines with anti-influenza a virus activity.,10.1021/ml500533x,Phenolic diterpenoid derivatives as anti-influenza a virus agents.,1
223819,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm061317y,A high-throughput screen for aggregation-based inhibition in a large compound library.,1
223819,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
237007,10.1016/j.bmcl.2004.11.032,Pharmacophore identification of alpha(1A)-adrenoceptor antagonists.,10.1007/s00044-010-9379-1,3D-QSAR CoMFA and CoMSIA studies on a set of diverse 1a-adrenergic receptor antagonists,1
236507,10.1021/np9704819,"Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from vitis vinifera cell cultures",10.1016/j.bmc.2006.09.069,Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro.,1
236507,10.1021/np9704819,"Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from vitis vinifera cell cultures",10.1021/np800083x,Targeted isolation and structure elucidation of stilbene glycosides from the bark of Lysidice brevicalyx Wei guided by biological and chemical screening.,1
235143,10.1016/j.bmcl.2011.04.092,"Identification of 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors.",10.1016/j.bmc.2012.02.054,Discovery of novel tricyclic compounds as squalene synthase inhibitors.,1
235143,10.1016/j.bmcl.2011.04.092,"Identification of 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors.",10.1021/ml400151c,"Discovery of DF-461, a Potent Squalene Synthase Inhibitor.",1
234877,10.1021/jm030166l,"Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.",10.1021/acs.jmedchem.1c01215,Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design.,1
234707,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.bmcl.2011.06.015,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",1
234541,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1016/j.bmcl.2012.03.107,Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.,1
234541,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
234541,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1016/j.ejmech.2021.113765,Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.,1
234541,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1016/j.bmc.2021.116354,A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.,1
234541,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1021/jm200383j,"Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?",1
234541,10.1016/j.ejmech.2021.113765,Identification and structure-activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
234541,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1021/acs.jmedchem.3c00609,Highly Selective Inhibitors of Dipeptidyl Peptidase 9 (DPP9) Derived from the Clinically Used DPP4-Inhibitor Vildagliptin.,1
234541,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1016/j.ejmech.2017.08.024,Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.,1
231062,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm400813y,Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmc.2011.08.043,The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.11.072,A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.,1
242716,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
242716,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.04.069,Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines.,1
242716,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.04.095,"Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/jm1005989,Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.,1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.04.135,Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.7b00205,Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.0c01195,Recent Advances in β<sub>2</sub>-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.,1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmc.2011.08.043,The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/jm401532g,"Discovery of a rapidly metabolized, long-acting β(2) adrenergic receptor agonist with a short onset time incorporating a sulfone group suitable for once-daily dosing.",1
242303,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
240769,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1021/acs.jmedchem.1c01694,Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.,1
240769,10.1016/j.bmcl.2009.04.149,Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate.,10.1021/acs.jmedchem.1c00308,Crystal Structures of Metallo-β-Lactamase (IMP-1) and Its D120E Mutant in Complexes with Citrate and the Inhibitory Effect of the Benzyl Group in Citrate Monobenzyl Ester.,1
240769,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1016/j.bmc.2019.01.018,Inhibition of a viral prolyl hydroxylase.,1
238731,10.1016/j.bmc.2013.09.004,Acidic biphenyl derivatives: synthesis and biological activity of a new series of potent 5-HT(4) receptor antagonists.,10.1016/j.bmcl.2014.06.083,Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.,1
1125,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2019.111642,From random to rational: A discovery approach to selective subnanomolar inhibitors of human carbonic anhydrase IV based on the Castagnoli-Cushman multicomponent reaction.,1
1125,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
242716,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1021/jm1005989,Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.04.095,"Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.04.135,Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.,1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmc.2018.10.043,"Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β<sub>2</sub>-adrenoceptor agonists.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmc.2018.10.043,"Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β<sub>2</sub>-adrenoceptor agonists.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.ejmech.2021.113697,"8-Hydroxyquinolin-2(1H)-one analogues as potential β<sub>2</sub>-agonists: Design, synthesis and activity study.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmc.2019.115178,"Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β<sub>2</sub>-adrenoceptor agonists.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.3c02074,"Discovery and Identification of Novel 5-Hydroxy-4<i>H</i>-benzo[1,4]oxazin-3-one Derivatives as Potent β<sub>2</sub>-Adrenoceptor Agonists through Structure-Based Design, Synthesis, and Biological Evaluation.",1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.04.069,Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2010.11.064,Inhibition of β-carbonic anhydrases with ureido-substituted benzenesulfonamides.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1016/j.ejmech.2019.112021,Pyrrolo and pyrrolopyrimidine sulfonamides act as cytotoxic agents in hypoxia via inhibition of transmembrane carbonic anhydrases.,1
1125,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmc.2016.01.019,"Kinetic and X-ray crystallographic investigations on carbonic anhydrase isoforms I, II, IX and XII of a thioureido analog of SLC-0111.",1
1125,10.1016/j.bmc.2013.11.042,"Inhibition of carbonic anhydrases from the extremophilic bacteria Sulfurihydrogenibium yellostonense (SspCA) and S. azorense (SazCA) with a new series of sulfonamides incorporating aroylhydrazone-, [1,2,4]triazolo[3,4-b][1,3,4]thiadiazinyl- or 2-(cyanophenylmethylene)-1,3,4-thiadiazol-3(2H)-yl moieties.",10.1016/j.bmcl.2014.03.001,Arylamino bisphosphonates: potent and selective inhibitors of the tumor-associated carbonic anhydrase XII.,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1016/j.bmc.2013.03.077,Synthesis and carbonic anhydrase inhibitory properties of sulfamides structurally related to dopamine.,1
1125,10.1021/jm4009532,Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates.,10.1021/jm501003k,Discovery and characterization of novel selective inhibitors of carbonic anhydrase IX.,1
1125,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2008.06.105,Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies.,1
1125,10.1016/j.bmc.2008.06.013,Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid.,10.1016/j.bmc.2015.03.068,Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action.,1
1125,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/acs.jmedchem.5b00523,6-Substituted sulfocoumarins are selective carbonic anhdydrase IX and XII inhibitors with significant cytotoxicity against colorectal cancer cells.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmcl.2011.04.105,Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium.,1
1125,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2016.10.023,Bortezomib inhibits mammalian carbonic anhydrases.,1
1125,10.1016/j.bmcl.2010.02.042,Inhibition studies of a beta-carbonic anhydrase from Brucella suis with a series of water soluble glycosyl sulfanilamides.,10.1016/j.bmc.2012.07.024,The alpha-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1 is highly susceptible to inhibition by sulfonamides.,1
1125,10.1016/j.bmc.2014.09.021,"Inhibition of carbonic anhydrase isoforms I, II, IX and XII with novel Schiff bases: identification of selective inhibitors for the tumor-associated isoforms over the cytosolic ones.",10.1016/j.ejmech.2017.01.017,"Novel indolin-2-one-based sulfonamides as carbonic anhydrase inhibitors: Synthesis, in vitro biological evaluation against carbonic anhydrases isoforms I, II, IV and VII and molecular docking studies.",1
1125,10.1016/j.ejmech.2017.11.061,Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases.,10.1021/acsmedchemlett.8b00362,Heterocoumarins Are Selective Carbonic Anhydrase IX and XII Inhibitors with Cytotoxic Effects against Cancer Cells Lines.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1016/j.ejmech.2021.113562,Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1016/j.bmc.2014.11.028,Clofazimine analogs with antileishmanial and antiplasmodial activity.,1
255347,10.1016/j.ejmech.2021.113562,Optimization of the clofazimine structure leads to a highly water-soluble C3-aminopyridinyl riminophenazine endowed with improved anti-Wnt and anti-cancer activity in vitro and in vivo.,10.1016/j.ejmech.2022.114209,Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.,1
255221,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
254086,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1016/j.bmcl.2008.12.005,New quinoline NK3 receptor antagonists with CNS activity.,1
254086,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,10.1016/j.bmcl.2013.12.033,Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.,1
254086,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm900948q,Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.,1
254086,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,1
254086,10.1021/jm900948q,Identification of a critical residue in the transmembrane domain 2 of tachykinin neurokinin 3 receptor affecting the dissociation kinetics and antagonism mode of osanetant (SR 142801) and piperidine-based structures.,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,1
254086,10.1021/jm980633c,Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).,10.1021/jm1010012,Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor.,1
250908,10.1016/j.bmcl.2019.126788,Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.,10.1021/acs.jmedchem.1c00300,Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.,1
247418,10.1016/j.bmcl.2014.03.090,"Identification of the first potent, selective and bioavailable PPARα antagonist.",10.1016/j.bmcl.2018.12.045,Discovery of potent and selective PPARα/δ dual antagonists and initial biological studies.,1
244737,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.0c01779,Fragment-like Chloroquinolineamines Activate the Orphan Nuclear Receptor Nurr1 and Elucidate Activation Mechanisms.,1
242716,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmc.2011.05.064,The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.,1
242716,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.05.097,Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.,1
255477,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
255477,10.1021/jm070688r,New series of antiprion compounds: pyrazolone derivatives have the potent activity of inhibiting protease-resistant prion protein accumulation.,10.1016/j.ejmech.2011.04.016,Anti-prion activities and drug-like potential of functionalized quinacrine analogs with basic phenyl residues at the 9-amino position.,1
255477,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c00468,Structure-Based Discovery of Novel NH<sub>2</sub>-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH<sub>2</sub>-Naphthyl-Diarylpyrimidine to NH<sub>2</sub>-Biphenyl-Diarylpyrimidine.,1
255477,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
255477,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
255477,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
255477,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
255477,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
255477,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
255477,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1126/science.1211936,Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.,1
255477,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,1
255347,10.1016/j.ejmech.2015.01.065,"Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.",10.1016/j.ejmech.2019.111778,Combined therapy with Benznidazole and repurposed drugs Clofazimine and Benidipine for chronic Chagas disease.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1016/j.ejmech.2022.114209,Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1016/j.bmc.2014.10.035,Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.,1
255347,10.1021/jm300828h,Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
255904,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1021/jm401067s,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,1
255904,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
255904,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.04.131,"Regioselective synthesis and biological evaluation of bis(indolyl)methane derivatized 1,4-disubstituted 1,2,3-bistriazoles as anti-infective agents.",1
255904,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
255904,10.1021/jm00373a015,Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones.,10.1016/j.bmcl.2005.11.001,Partial structures of ketoconazole as modulators of the large conductance calcium-activated potassium channel (BK(Ca)).,1
255904,10.1021/ml100283h,Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.,10.1016/j.ejmech.2014.10.021,Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.,1
255904,10.1021/acs.jmedchem.6b00989,"Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor.",10.1021/acs.jmedchem.2c01862,"Imidazo[1,2-<i>a</i>]Pyridine Derivatives as Novel Dual-Target Inhibitors of ABCB1 and ABCG2 for Reversing Multidrug Resistance.",1
255904,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2009.01.048,"Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted benzylamino-2-propanols.",1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2011.02.042,"Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.",1
255477,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1016/j.bmc.2012.03.042,Investigating the activity of quinine analogues versus chloroquine resistant Plasmodium falciparum.,1
255477,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
255477,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
255477,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
255477,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
255904,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,1
255904,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
255904,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
255904,10.1021/jm00373a015,Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones.,10.1016/j.ejmech.2017.04.044,An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.2c01451,"Novel Aryl Alkamidazole Derivatives as Multifunctional Antifungal Inhibitors: Design, Synthesis, and Biological Evaluation.",1
255904,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
255904,10.1016/j.bmc.2011.03.038,"Antifungal, cytotoxic and SAR studies of a series of N-alkyl, N-aryl and N-alkylphenyl-1,4-pyrrolediones and related compounds.",10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
255904,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
255904,10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1039/C3MD20086H,Synthesis and antifungal activity of the novel triazole compounds,1
255904,10.1016/j.bmc.2007.10.034,Antifungal and cytotoxic activities of some N-substituted aniline derivatives bearing a hetaryl fragment.,10.1016/j.bmc.2012.08.033,Structure-activity relationship study of nitrosopyrimidines acting as antifungal agents.,1
255904,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
255904,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,1
255904,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
255904,10.1124/mol.112.084152,Structure-based identification of OATP1B1/3 inhibitors.,10.1021/acs.jmedchem.6b01317,Discovery of Competitive and Noncompetitive Ligands of the Organic Cation Transporter 1 (OCT1; SLC22A1).,1
255904,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
1124,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm031116j,Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.,1
1124,10.1021/jm00394a021,"Synthesis and physicochemical properties of thiadiazolo[3,2-a]pyrimidinesulfonamides and thiadiazolo[3,2-a]triazinesulfonamides as candidates for topically effective carbonic anhydrase inhibitors.",10.1021/jm9901879,"Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route.",1
1124,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2008.03.023,Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.,1
255904,10.1021/jm00373a015,Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones.,10.1016/j.bmcl.2011.08.049,Synthesis and biological evaluation of some novel triazol-3-ones as antimicrobial agents.,1
255904,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1021/jm401067s,Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2019.07.003,"Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles.",1
255904,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.bmcl.2019.126869,"Design, synthesis and bio-evaluation of C-1 alkylated tetrahydro-β-carboline derivatives as novel antifungal lead compounds.",1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2008.04.056,Synthesis and SAR studies of biaryloxy-substituted triazoles as antifungal agents.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.bmcl.2012.02.042,"New triazole derivatives as antifungal agents: synthesis via click reaction, in vitro evaluation and molecular docking studies.",1
255904,10.1016/j.bmc.2008.08.034,Screening of herbal constituents for aromatase inhibitory activity.,10.1016/j.bmc.2012.02.042,"Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.",1
255904,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
255904,10.1016/j.ejmech.2008.04.010,"Synthesis and anti-microbial screening of some Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones.",10.1007/s00044-012-0320-7,Synthesis and in vitro antimicrobial activity of some newer quinazolinonesulfonamide linked hybrid heterocyclic entities derived from glycine,1
255904,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
255904,10.1021/acs.jmedchem.0c00564,Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A<sub>2B</sub> Adenosine Receptor Antagonists.,10.1021/acs.jmedchem.2c01768,Exploring the Effect of Halogenation in a Series of Potent and Selective A<sub>2B</sub> Adenosine Receptor Antagonists.,1
255904,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1016/j.bmc.2021.116577,Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.,1
255904,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1021/acs.jmedchem.4c01057,"Design, Synthesis, and Activity Evaluation of Novel Benzazole Bifunctional Antifungal Inhibitors with an LDH Carrier.",1
255904,10.1021/acs.jmedchem.8b01656,"Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.",10.1021/acs.jmedchem.2c00468,Structure-Based Discovery of Novel NH<sub>2</sub>-Biphenyl-Diarylpyrimidines as Potent Non-Nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Safety: From NH<sub>2</sub>-Naphthyl-Diarylpyrimidine to NH<sub>2</sub>-Biphenyl-Diarylpyrimidine.,1
255904,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.0c00841,"Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.",1
1125,10.1016/j.bmcl.2005.02.088,"Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols.",10.1016/j.bmcl.2008.06.024,Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors?,1
1125,10.1016/j.bmc.2009.01.067,Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
1125,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/acsmedchemlett.0c00062,Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms.,1
1124,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2007.07.019,"Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.",1
1124,10.1016/j.ejmech.2012.08.006,"Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.",10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,1
1124,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1124,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/jm0501073,Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.,1
1124,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1124,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2007.12.022,"Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies.",1
1124,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2008.05.051,Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.,1
1124,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm060807n,"Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.",1
1124,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1124,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.06.054,Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.,1
264453,10.1021/jm3011146,Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.,10.1016/j.ejmech.2017.05.033,Novel propanamides as fatty acid amide hydrolase inhibitors.,1
264453,10.1021/jm3011146,Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor.,10.1016/j.bmc.2019.115052,A rational search for discovering potential neutraligands of human complement fragment 5a (<sup>h</sup>C5a).,1
259664,10.1016/j.ejmech.2020.112119,Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.,10.1021/acs.jmedchem.2c02061,Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy.,1
259664,10.1016/j.ejmech.2020.112119,Further exploration of DVD-445 as a lead thioredoxin reductase (TrxR) inhibitor for cancer therapy: Optimization of potency and evaluation of anticancer potential.,10.1039/d4md00136b,Discovery of new tricyclic spiroindole derivatives as potent P-glycoprotein inhibitors for reversing multidrug resistance enabled by a synthetic methodology-based library.,1
259664,10.1021/jm401330r,Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.,10.1016/j.bmc.2015.01.054,Discovery of anthranilamides as a novel class of inhibitors of neurotropic alphavirus replication.,1
255947,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
255947,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
255947,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1038/nchembio.215,Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.,1
255947,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
255947,10.1038/nchembio806,A clinical drug library screen identifies astemizole as an antimalarial agent.,10.1073/pnas.0802982105,In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.,1
255947,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
255947,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
255947,10.1016/j.bmc.2009.01.013,Synthesis and in vitro antitubercular activity of a series of quinoline derivatives.,10.1016/j.ejmech.2012.08.047,"The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.",1
255947,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2022.114161,Synthetic approaches and structural diversity of triazolylbutanols derived from voriconazole in the antifungal drug development.,1
255904,10.1021/jm051211n,"Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking.",10.1016/j.ejmech.2021.113715,"Improving the metabolic stability of antifungal compounds based on a scaffold hopping strategy: Design, synthesis, and structure-activity relationship studies of dihydrooxazole derivatives.",1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/jm200649p,"Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1016/j.bmcl.2012.05.120,Enamino-oxindole HIV protease inhibitors.,1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b00676,"Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1016/j.bmc.2017.07.014,Synthesis and biological evaluation in vitro and in mammalian cells of new heteroaryl carboxyamides as HIV-protease inhibitors.,1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.bmc.2017.04.005,"Design of novel HIV-1 protease inhibitors incorporating isophthalamide-derived P2-P3 ligands: Synthesis, biological evaluation and X-ray structural studies of inhibitor-HIV-1 protease complex.",1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1016/j.bmcl.2019.08.006,"Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.bmcl.2017.09.003,"Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.6b00639,"Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/jm1012374,"Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1021/acsmedchemlett.0c00043,Novel HIV-1 Protease Inhibitors with Morpholine as the P2 Ligand to Enhance Activity against DRV-Resistant Variants.,1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1021/jm8004543,"Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.5b00676,"Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1021/jm900303m,"Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.bmcl.2015.05.052,"Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.",1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1128/aac.01766-09,"Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.",1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.ejmech.2010.02.005,"Design, synthesis, and in vitro antitumor evaluation of novel diaryl ureas derivatives.",1
276734,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.1c00459,"Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.",1
276734,10.1016/j.ejmech.2010.09.002,Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.,10.1016/j.bmc.2020.115872,"Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.",1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2018.11.076,CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors.,1
276734,10.1021/jm900607f,"Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.",10.1016/j.ejmech.2011.02.057,"Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.",1
276734,10.1021/jm101479y,Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.,10.1016/j.ejmech.2012.02.007,"Design, synthesis and biological evaluation of novel (E)-α-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors.",1
267861,10.1021/jm0580454,"Synthesis and biological evaluation of a novel series of ""ortho-nitrated"" inhibitors of catechol-O-methyltransferase.",10.1021/jm1001524,"Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.",1
267825,10.1021/jm0580454,"Synthesis and biological evaluation of a novel series of ""ortho-nitrated"" inhibitors of catechol-O-methyltransferase.",10.1021/jm1001524,"Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.",1
267825,10.1021/acs.jmedchem.8b01126,Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.,10.1021/acsmedchemlett.9b00345,Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol <i>O</i>-Methyltransferase.,1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1016/j.ejmech.2018.09.046,"Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.",1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1016/j.bmc.2020.115623,Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.,1
267163,10.1021/jm070482q,Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1016/j.bmcl.2017.09.003,"Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.",1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/jm1012374,"Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.",1
267163,10.1021/jm050019i,Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.,10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
267163,10.1021/jm900695w,"Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.",10.1021/acs.jmedchem.5b01697,Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.,1
276734,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1016/j.ejmech.2019.06.054,"Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.",1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmc.2011.06.016,"Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).",1
276734,10.1021/jm101479y,Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.,10.1016/j.ejmech.2018.11.033,Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance.,1
276734,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1021/acs.jmedchem.7b01091,Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.,1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1021/acs.jmedchem.7b00901,Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?,1
276734,10.1021/jm101479y,Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.,10.1016/j.ejmech.2017.02.041,"Design, synthesis and evaluation of derivatives based on pyrimidine scaffold as potent Pan-Raf inhibitors to overcome resistance.",1
276734,10.1021/jm101479y,Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.,10.1021/acs.jmedchem.7b01306,Current Insights of BRAF Inhibitors in Cancer.,1
276734,10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.bmcl.2012.09.031,"Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.",1
276734,10.1016/j.bmc.2020.115674,"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.",10.1016/j.ejmech.2021.113768,Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.,1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1021/jm901509a,"BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring.",1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1016/j.bmcl.2009.10.051,"Synthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line.",1
276734,10.1016/j.ejmech.2017.09.018,"Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.",10.1021/acs.jmedchem.3c02319,Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.,1
276734,10.1016/j.ejmech.2020.112461,Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach.,10.1016/j.ejmech.2022.114434,Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.,1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.bmc.2012.03.018,"Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents.",1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.bmc.2018.03.039,"Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafV600E and VEGFR-2.",1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.ejmech.2014.11.008,"Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.",1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2019.01.003,Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.,1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1016/j.bmcl.2013.02.034,Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines.,1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1016/j.bmcl.2010.08.010,Synthesis of aminoquinazoline derivatives and their antiproliferative activities against melanoma cell line.,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/jm301537p,"Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.",1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1016/j.bmcl.2009.08.005,"Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma.",1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmcl.2012.05.116,3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).,1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2024.116547,Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.,1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1016/j.ejmech.2016.02.039,Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2011.02.057,"Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.",1
276734,10.1016/j.ejmech.2019.05.021,Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
276734,10.1021/jm900242c,Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.,10.1007/s00044-012-0400-8,"Thiourea and thioether derivatives of sorafenib: synthesis, crystal structure, and antiproliferative activity",1
276734,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1039/C1MD00175B,Inhibitors of Stat5 protein signalling,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmc.2013.03.083,Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).,1
276734,10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
282509,10.1021/jm400966v,Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,1
282509,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
282509,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
277989,10.1021/jm300601d,Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat.,10.1016/j.ejmech.2024.116170,pH regulators and their inhibitors in tumor microenvironment.,1
276734,10.1016/j.ejmech.2015.02.019,"LEADOPT: an automatic tool for structure-based lead optimization, and its application in structural optimizations of VEGFR2 and SYK inhibitors.",10.1016/j.ejmech.2020.112461,Synthesis and biological evaluation of diaryl urea derivatives designed as potential anticarcinoma agents using de novo structure-based lead optimization approach.,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/acs.jmedchem.1c02079,Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library.,1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2020.112443,"Pyrido[2,3-b][1,5]benzoxazepin-5(6H)-one derivatives as CDK8 inhibitors.",1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2016.02.039,Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.,1
276734,10.1016/j.ejmech.2016.03.015,Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.,10.1016/j.ejmech.2021.113353,"In pursuit of a selective hepatocellular carcinoma therapeutic agent: Novel thalidomide derivatives with antiproliferative, antimigratory and STAT3 inhibitory properties.",1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1016/j.ejmech.2020.113043,Angel or Devil ? - CDK8 as the new drug target.,1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1016/j.bmc.2012.05.051,"Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.",1
276734,10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,10.1021/acs.jmedchem.2c00820,"Discovery of the Novel 1<i>H</i>-Pyrrolo[2,3-<i>b</i>]pyridine Derivative as a Potent Type II CDK8 Inhibitor against Colorectal Cancer.",1
276734,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/acsmedchemlett.6b00044,Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8.,1
276734,10.1016/j.bmc.2020.115674,"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.",10.1016/j.bmcl.2024.129673,"Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation.",1
276734,10.1016/j.ejmech.2008.09.016,Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas.,10.1039/C2MD20275A,"3,3-Dimethyl-1H-pyrrolo[3,2-g]quinolin-2(3H)-one derivatives as novel Raf kinase inhibitors",1
1085,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm060807n,"Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.",1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1021/acs.jmedchem.0c00015,"Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.",1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
296388,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.2c01574,Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.,1
296388,10.1016/j.bmcl.2012.02.055,"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
296388,10.1016/j.bmcl.2012.02.055,"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1016/j.bmcl.2014.07.011,Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
296388,10.1016/j.bmcl.2014.07.011,Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
296388,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
296388,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2022.116614,Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,1
294897,10.1021/jm900448m,Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics.,10.1016/j.ejmech.2019.07.007,Cell-active carbazole derivatives as inhibitors of the zika virus protease.,1
286065,10.1021/acs.jmedchem.1c02177,Discovery and Optimization of 5-Hydroxy-Diclofenac toward a New Class of Ligands with Nanomolar Affinity for the CaMKIIα Hub Domain.,10.1021/acs.jmedchem.2c00805,"Exploring the NCS-382 Scaffold for CaMKIIα Modulation: Synthesis, Biochemical Pharmacology, and Biophysical Characterization of Ph-HTBA as a Novel High-Affinity Brain-Penetrant Stabilizer of the CaMKIIα Hub Domain.",1
283927,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
296388,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
1096,10.1021/acs.jmedchem.0c00734,Optimization of Acetazolamide-Based Scaffold as Potent Inhibitors of Vancomycin-Resistant Enterococcus.,10.1021/acs.jmedchem.4c00740,Development of Penicillin-Based Carbonic Anhydrase Inhibitors Targeting Multidrug-Resistant &lt;i&gt;Neisseria gonorrhoeae&lt;/i&gt;.,1
1096,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1096,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1096,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1096,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2007.07.019,"Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.",1
1096,10.1016/j.bmcl.2006.12.010,Identification of arylsulfonamides as Aquaporin 4 inhibitors.,10.1016/j.bmc.2007.12.038,Inhibition of aquaporin 4 by antiepileptic drugs.,1
1096,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.06.054,Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.,1
1096,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2008.05.051,Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.,1
1096,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.bmc.2015.05.019,"Design and synthesis of benzothiazole-6-sulfonamides acting as highly potent inhibitors of carbonic anhydrase isoforms I, II, IX and XII.",1
1096,10.1016/j.bmcl.2013.04.048,Discovery of new potent inhibitors for carbonic anhydrase IX by structure-based virtual screening.,10.1039/C8MD00392K,Novel benzoyl thioureido benzene sulfonamides as highly potent and selective inhibitors of carbonic anhydrase IX: optimization and bioactive studies.,1
1096,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/jm0501073,Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.,1
1096,10.1016/j.ejmech.2012.08.006,"Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.",10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,1
1096,10.1016/j.bmcl.2006.12.010,Identification of arylsulfonamides as Aquaporin 4 inhibitors.,10.1016/j.bmc.2008.06.005,Lack of aquaporin-4 water transport inhibition by antiepileptics and arylsulfonamides.,1
1090,10.1021/jm000491y,"Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.",10.1021/jm030064v,Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.,1
1090,10.1021/jm000491y,"Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.",10.1016/j.bmc.2008.04.030,'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines.,1
296388,10.1016/j.bmcl.2012.02.055,"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmc.2018.12.039,"Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.",1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
296388,10.1016/j.bmcl.2012.02.055,"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
296388,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
296388,10.1016/j.bmcl.2012.02.055,"Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.",10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1021/acs.jmedchem.2c01900,Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy.,1
296388,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
296388,10.1016/j.bmcl.2014.07.011,Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,1
296388,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
296388,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
296388,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
296388,10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",10.1021/acs.jmedchem.8b00843,The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmcl.2014.07.011,Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
301194,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.7b00584,Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.,1
301194,10.1016/j.ejmech.2018.04.020,Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents.,10.1021/acs.jmedchem.9b00241,Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity.,1
301194,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.6b01194,Design and Discovery of Functionally Selective Serotonin 2C (5-HT) Receptor Agonists.,1
301194,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1021/acs.jmedchem.5b01153,"Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.",1
301194,10.1021/jm5019274,Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents.,10.1016/j.ejmech.2019.111626,Design of fluorinated cyclopropane derivatives of 2-phenylcyclopropylmethylamine leading to identification of a selective serotonin 2C (5-HT<sub>2C</sub>) receptor agonist without 5-HT<sub>2B</sub> agonism.,1
299120,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1016/j.bmcl.2011.12.067,Discovery of novel selective inhibitors for EGFR-T790M/L858R.,1
299120,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1021/acs.jmedchem.0c00870,Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.,1
299120,10.1016/j.bmcl.2015.10.003,"Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.",10.1021/acs.jmedchem.0c01647,"HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.",1
299120,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1016/j.bmcl.2019.04.029,"Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors.",1
299120,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1016/j.bmc.2013.03.053,"Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.",1
297372,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
297372,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
296388,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114939,Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs.,1
296388,10.1021/jm3007678,"Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.",10.1016/j.bmcl.2017.04.068,"Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.",1
296388,10.1021/acs.jmedchem.5b01827,Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.,10.1021/acs.jmedchem.2c01574,Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.,1
296388,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.1c00127,Bispecific Estrogen Receptor α Degraders Incorporating Novel Binders Identified Using DNA-Encoded Chemical Library Screening.,10.1021/acs.jmedchem.3c01186,Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.9b01580,Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.3c01186,Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.0c01163,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2018.12.042,Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.0c02230,Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.7b01682,"Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.",1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1016/j.ejmech.2019.111605,Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.,1
302932,10.1021/acs.jmedchem.9b00995,Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.,10.1021/acsmedchemlett.2c00509,Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN.,1
302932,10.1021/np100120c,"Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor.",10.1021/np5002016,Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.,1
302932,10.1021/acs.jmedchem.9b00995,Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.,10.1021/acs.jmedchem.0c01883,Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.0c02230,Heterodimeric GW7604 Derivatives: Modification of the Pharmacological Profile by Additional Interactions at the Coactivator Binding Site.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2022.128734,"Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).",1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2019.111605,Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2020.112191,Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2020.112191,Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators.,1
304798,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,1
1063,10.1021/jm00374a005,6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.,10.1016/j.ejmech.2009.10.016,"Design, synthesis and docking studies of new furobenzopyranones and pyranobenzopyranones as photoreagent towards DNA and as antimicrobial agents.",1
996,10.1021/jm9603781,A virtual screening approach applied to the search for trypanothione reductase inhibitors.,10.1016/j.bmc.2008.05.074,The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.,1
941,10.1016/j.bmcl.2004.07.085,Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.,10.1021/jm050483n,Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.,1
923,10.1016/j.bmcl.2011.09.035,"Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.",10.1021/acs.jmedchem.7b01402,"Highly Selective, Potent, and Oral mTOR Inhibitor for Treatment of Cancer as Autophagy Inducer.",1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.0c01163,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
304798,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
304798,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.2c00008,"Discovery of Thieno[2,3-<i>e</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.0c00224,Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.2c00008,"Discovery of Thieno[2,3-<i>e</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.0c00913,Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer.,1
1085,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2008.03.023,Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.,1
1085,10.1016/j.ejmech.2012.08.006,"Carbonic anhydrase inhibitors. Regioselective synthesis of novel series 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XII.",10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,1
1085,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1021/jm0501073,Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors.,1
1085,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2007.07.019,"Carbonic anhydrase inhibitors: Selective inhibition of the extracellular, tumor-associated isoforms IX and XII over isozymes I and II with glycosyl-thioureido-sulfonamides.",1
1085,10.1016/j.ejmech.2013.10.081,"Carbonic anhydrase inhibitors. Synthesis, and molecular structure of novel series N-substituted N'-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)guanidines and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1085,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2008.05.051,Carbonic anhydrase inhibitors: design of spin-labeled sulfonamides incorporating TEMPO moieties as probes for cytosolic or transmembrane isozymes.,1
1085,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.06.054,Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.,1
1085,10.1016/j.ejmech.2014.06.074,Synthesis of a new series of N⁴-substituted 4-(2-aminoethyl)benzenesulfonamides and their inhibitory effect on human carbonic anhydrase cytosolic isozymes I and II and transmembrane tumor-associated isozymes IX and XII.,10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1085,10.1016/j.ejmech.2014.05.039,"Carbonic anhydrase inhibitors. Synthesis of a novel series of 5-substituted 2,4-dichlorobenzenesulfonamides and their inhibition of human cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII.",10.1016/j.ejmech.2017.11.005,"Novel 2-(2-arylmethylthio-4-chloro-5-methylbenzenesulfonyl)-1-(1,3,5-triazin-2-ylamino)guanidine derivatives: Inhibition of human carbonic anhydrase cytosolic isozymes I and II and the transmembrane tumor-associated isozymes IX and XII, anticancer activity, and molecular modeling studies.",1
1085,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm031116j,Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.,1
1063,10.1021/jm00374a005,6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.,10.1021/jm960117r,"4'-Methyl derivatives of 5-MOP and 5-MOA: synthesis, photoreactivity, and photobiological activity.",1
1063,10.1021/jm00374a005,6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.,10.1021/jm950585l,"Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01468,Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.2c00008,"Discovery of Thieno[2,3-<i>e</i>]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability.",1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acsmedchemlett.0c00224,Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.0c01163,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1016/j.bmc.2023.117235,A novel selective estrogen receptor degrader induces cell cycle arrest in breast cancer via ERα degradation and the autophagy-lysosome pathway.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acsmedchemlett.0c00224,Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,1
304798,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.3c01186,Discovery of <b>ERD-3111</b> as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,1
304798,10.1021/acs.jmedchem.3c00465,Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.8b00106,New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2021.113543,Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.6b00753,Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acsmedchemlett.8b00106,New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.,1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1021/acs.jmedchem.9b01580,Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.,1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b00753,Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).,1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.2c02032,Discovery of a Novel Class of PROTACs as Potent and Selective Estrogen Receptor α Degraders to Overcome Endocrine-Resistant Breast Cancer <i>In Vitro</i> and <i>In Vivo</i>.,1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1021/acs.jmedchem.3c00465,Identification of Novel Dual-Target Estrogen Receptor α Degraders with Tubulin Inhibitory Activity for the Treatment of Endocrine-Resistant Breast Cancer.,1
304798,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,1
304798,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
304798,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1021/acs.jmedchem.8b01837,Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.,1
304798,10.1021/acs.jmedchem.8b00921,Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.,10.1016/j.ejmech.2019.03.058,Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).,1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acsmedchemlett.0c00224,Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.,1
304798,10.1021/acs.jmedchem.6b01917,Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.,10.1016/j.ejmech.2023.115324,"Design, synthesis and biological evaluation of fluorinated selective estrogen receptor degraders (FSERDs) --- A promising strategy for advanced ER positive breast cancer.",1
304798,10.1021/acsmedchemlett.8b00414,Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927.,10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
305519,10.1007/s00044-011-9752-8,Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives,10.1007/s00044-011-9833-8,"Synthesis, characterization, and antimicrobial evaluation of novel naphthalene-based 1,2,4-triazoles",1
305519,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1021/acs.jmedchem.2c01496,Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.,1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.bmcl.2017.02.042,Biologically active perspective synthesis of heteroannulated 8-nitroquinolines with green chemistry approach.,1
305519,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1021/acs.jmedchem.2c00134,"Design, Synthesis, and Proof-of-Concept of Triple-Site Inhibitors against Aminoacyl-tRNA Synthetases.",1
305519,10.1016/j.ejmech.2017.08.066,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of cyclopenta(hepta)[b]thiophene and fused cyclohepta[b]thiophene analogs.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
305519,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",1
305519,10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",10.1016/j.ejmech.2020.112832,Antibacterial activities with the structure-activity relationship of coumarin derivatives.,1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
305519,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
305519,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.06.071,Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.,1
305519,10.1007/s00044-012-9990-4,"Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus",10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",1
305519,10.1007/s00044-011-9752-8,Antimicrobial screening of novel synthesized benzimidazole nucleus containing 4-oxo-thiazolidine derivatives,10.1007/s00044-012-9988-y,"Synthesis and antimicrobial screening of novel series of imidazo-[1,2-a]pyridine derivatives",1
305519,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
305519,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
305519,10.1007/s00044-010-9328-z,"Synthesis of new series of pyrazolo[4,3-d]pyrimidin-7-ones and pyrido[2,3-d]pyrimidin-4-ones for their bacterial and cyclin-dependent kinases (CDKs) inhibitory activities",10.1016/j.bmc.2017.10.012,"An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.",1
304798,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.0c01163,"Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.",1
305519,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2012.05.004,"New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.",1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0381-7,Microwave-assisted synthesis of novel 4H-chromene derivatives bearing 2-aryloxyquinoline and their antimicrobial activity assessment,1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",1
305519,10.1007/s00044-012-0121-z,"Synthesis of promising antimicrobial agents: a novel series of N-(4-(2,6-dichloroquinolin-3-yl)-6-(aryl)pyrimidin-2-yl)-2-morpholinoacetamides",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,1
305519,10.1016/j.ejmech.2019.111941,Discovery of novel tRNA-amino acid dual-site inhibitors against threonyl-tRNA synthetase by fragment-based target hopping.,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,1
305519,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1016/j.ejmech.2015.02.056,Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.,1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0322-5,"Microwave-assisted synthesis of pyrido[1,2-a]benzimidazole derivatives of -aryloxyquinoline and their antimicrobial and antituberculosis activities",1
305519,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",1
305519,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",1
305519,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
305519,10.1016/j.bmc.2007.05.048,"Identification of antibacterial and antiviral activities of novel fused 1,2,4-triazine esters.",10.1016/j.ejmech.2019.111804,Structure-activity relationships (SAR) of triazine derivatives: Promising antimicrobial agents.,1
305519,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.07.057,"Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.",1
305519,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.05.054,"1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.",1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0301-x,Microwave-induced CAN promoted atom-economic synthesis of 1H-benzo[b]xanthene and 4H-benzo[g]chromene derivatives of N-allyl quinolone and their antimicrobial activity,1
305519,10.1021/np500905g,HPLC-NMR and HPLC-MS Profiling and Bioassay-Guided Identification of Secondary Metabolites from the Australian Plant Haemodorum spicatum.,10.1021/acs.jnatprod.5b00161,Phytochemical Investigation of the Constituents Derived from the Australian Plant Macropidia fuliginosa.,1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0292-7,"Synthesis and in vitro antimicrobial evaluation of novel 2-amino-6-(phenylthio)-4-(2-(phenylthio)quinolin-3-yl)pyridine-3,5-dicarbonitriles",1
305519,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.bmcl.2015.02.056,Studies on antimicrobial effects of four ligands and their transition metal complexes with 8-mercaptoquinoline and pyridine terminal groups.,1
305519,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,10.1021/acs.jmedchem.2c01496,Structure-Guided Design of Halofuginone Derivatives as ATP-Aided Inhibitors Against Bacterial Prolyl-tRNA Synthetase.,1
305519,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",1
305519,10.1007/s00044-013-0489-4,"Synthesis of a new series of 2-(2-oxo-2H-chromen-3-yl)-5H-chromeno[4,3-b]pyridin-5-ones by two facile methods and evaluation of their antimicrobial activity",10.1016/j.ejmech.2020.113034,"A review: Biologically active 3,4-heterocycle-fused coumarins.",1
305519,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2020.112832,Antibacterial activities with the structure-activity relationship of coumarin derivatives.,1
305519,10.1016/j.ejmech.2018.08.008,"Design, synthesis, antimicrobial, antiquorum-sensing and antitumor evaluation of new series of pyrazolopyridine derivatives.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
305519,10.1016/j.ejmech.2020.112848,Structure-guided optimization and mechanistic study of a class of quinazolinone-threonine hybrids as antibacterial ThrRS inhibitors.,10.1021/acs.jmedchem.2c00134,"Design, Synthesis, and Proof-of-Concept of Triple-Site Inhibitors against Aminoacyl-tRNA Synthetases.",1
305519,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2021.113442,A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies.,1
305519,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,10.1016/j.bmcl.2018.01.045,"Synthesis, antimicrobial activity and acid dissociation constants of methyl 5,5-diphenyl-1-(thiazol-2-yl)pyrrolidine-2-carboxylate derivatives.",1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-012-0085-z,"Microwave-assisted CAN-catalyzed solvent-free synthesis of N-allyl quinolone-based pyrano[4,3-b]chromene and benzopyrano[3,2-c]chromene derivatives and their antimicrobial activity",1
305519,10.1016/j.ejmech.2011.06.022,"Synthesis and identification of β-aryloxyquinolines and their pyrano[3,2-c]chromene derivatives as a new class of antimicrobial and antituberculosis agents.",10.1007/s00044-011-9861-4,Microwave-assisted synthesis of 3-indolyl substituted 4H-chromenes catalyzed by DMAP and their antimicrobial activity,1
305519,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2020.113134,Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation.,1
305519,10.1007/s00044-012-9990-4,"Synthesis, characterization and antimicrobial screening of hybrid molecules containing benzimidazole-pyrazole and pyridine nucleus",10.1007/s00044-012-0190-z,Microwave-assisted synthesis and antimicrobial screening of new imidazole derivatives bearing 4-thiazolidinone nucleus,1
305519,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
305519,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.bmcl.2016.04.004,"Design, synthesis and biological evaluation of potent FAAH inhibitors.",1
312994,10.1016/j.bmcl.2016.02.061,"Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties.",10.1039/C6MD00683C,(Indolylalkyl)piperidine carbamates as inhibitors of fatty acid amide hydrolase (FAAH).,1
312994,10.1021/acs.jmedchem.8b01483,Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.,10.1016/j.ejmech.2023.115916,"Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors.",1
312994,10.1021/jm060394q,Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.,10.1021/jm400923s,"Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors.",1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.ejmech.2011.07.021,Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability.,1
312304,10.1021/jm030650o,Validation of automated docking programs for docking and database screening against RNA drug targets.,10.1021/acsmedchemlett.0c00682,Design and Implementation of Synthetic RNA Binders for the Inhibition of miR-21 Biogenesis.,1
312304,10.1016/j.bmc.2008.02.056,Identification of neomycin B-binding site in T box antiterminator model RNA.,10.1021/jm9000659,Design and implementation of an ribonucleic acid (RNA) directed fragment library.,1
312304,10.1021/jm030650o,Validation of automated docking programs for docking and database screening against RNA drug targets.,10.1021/jm9000659,Design and implementation of an ribonucleic acid (RNA) directed fragment library.,1
311899,10.1016/j.bmcl.2009.11.131,Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists.,10.1021/jm4011669,Adenosine A2A receptor as a drug discovery target.,1
310199,10.1016/j.bmcl.2004.07.089,"Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.",10.1016/j.ejmech.2018.10.054,Medicinal chemistry of vicinal diaryl scaffold: A mini review.,1
308355,10.1016/j.ejmech.2019.04.023,The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.,10.1016/j.ejmech.2021.113710,Andrographolide and its derivatives: Current achievements and future perspectives.,1
308355,10.1016/j.ejmech.2019.04.023,The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent.,10.1016/j.ejmech.2022.114110,Discovery and development of labdane-oxindole hybrids as small-molecule inhibitors against chikungunya virus infection.,1
305519,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
305519,10.1007/s00044-012-9980-6,"An efficient, solvent-free microwave-assisted synthesis and antimicrobial screening of 1,6-dihydropyrimidine analogues",10.1007/s00044-013-0840-9,"An efficient synthesis, characterization, and antimicrobial screening of tetrahydropyrimidine derivatives",1
305519,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",1
305519,10.1016/j.ejmech.2018.04.025,"New pyrazolopyridine analogs: Synthesis, antimicrobial, antiquorum-sensing and antitumor screening.",10.1016/j.bmc.2020.115976,"Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.",1
313314,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
312994,10.1021/jm060394q,Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.,10.1021/jm800311k,Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.,1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.ejmech.2012.11.035,An unprecedented reversible mode of action of β-lactams for the inhibition of human fatty acid amide hydrolase (hFAAH).,1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1039/C2MD00307D,2-Amino-5-arylbenzoxazole derivatives as potent inhibitors of fatty acid amide hydrolase (FAAH),1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1021/ml5001239,"Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain.",1
312994,10.1021/jm060394q,Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system.,10.1016/j.ejmech.2013.01.050,(4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).,1
312994,10.1016/j.bmc.2012.11.006,"Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.",10.1021/acs.jmedchem.6b00538,"Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.",1
312994,10.1021/acs.jmedchem.6b01578,"Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase.",10.1021/acs.jmedchem.8b00893,Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit.,1
312994,10.1016/j.bmc.2012.11.006,"Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.bmcl.2016.02.061,"Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties.",1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1039/C2MD20146A,"Discovery of potent, non-carbonyl inhibitors of fatty acid amide hydrolase (FAAH)",1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1021/acs.jmedchem.6b00538,"Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors.",1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.bmcl.2011.06.096,The discovery and development of inhibitors of fatty acid amide hydrolase (FAAH).,1
312994,10.1021/acs.jmedchem.6b01578,"Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase.",10.1016/j.ejmech.2019.111674,Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems.,1
312994,10.1021/acs.jmedchem.8b01483,Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor.,10.1021/acs.jmedchem.1c01806,Reversible Monoacylglycerol Lipase Inhibitors: Discovery of a New Class of Benzylpiperidine Derivatives.,1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1021/jm200723m,SAR and LC/MS studies of β-lactamic inhibitors of human fatty acid amide hydrolase (hFAAH): evidence of a nonhydrolytic process.,1
312994,10.1016/j.bmcl.2011.02.052,"Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.",10.1016/j.ejmech.2017.05.033,Novel propanamides as fatty acid amide hydrolase inhibitors.,1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1016/j.bmcl.2011.11.128,Differential signaling properties at the kappa opioid receptor of 12-epi-salvinorin A and its analogues.,1
316021,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.0c01915,Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.,1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1016/j.bmcl.2010.08.001,Synthesis and biological evaluation of C-2 halogenated analogs of salvinorin A.,1
316021,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1039/d0md00104j,G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9,1
316021,10.1021/acs.jmedchem.6b01235,Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability.,10.1021/acs.jmedchem.7b00148,Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability.,1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1021/jm501521d,Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.,1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1016/j.bmc.2012.02.040,Semisynthetic neoclerodanes as kappa opioid receptor probes.,1
315123,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
315123,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
315123,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
313314,10.1016/j.ejmech.2012.11.007,Identification of novel chromenone derivatives as interleukin-5 inhibitors.,10.1016/j.bmc.2013.02.037,Design and synthesis of novel chromenone derivatives as interleukin-5 inhibitors.,1
313314,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
313314,10.1016/j.ejmech.2012.11.007,Identification of novel chromenone derivatives as interleukin-5 inhibitors.,10.1016/j.ejmech.2017.07.069,Discovery of novel 3-(hydroxyalkoxy)-2-alkylchromen-4-one analogs as interleukin-5 inhibitors.,1
313314,10.1016/j.ejmech.2012.11.007,Identification of novel chromenone derivatives as interleukin-5 inhibitors.,10.1016/j.bmc.2015.03.045,Exploration of benzamidochromenone derivatives with conformational restrictor as interleukin-5 inhibitors.,1
313314,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
313314,10.1016/j.ejmech.2012.11.007,Identification of novel chromenone derivatives as interleukin-5 inhibitors.,10.1016/j.bmc.2017.06.018,Novel analogs of N-acylhydroxyethylaminomethyl-4H-chromen-4-one scaffold as IL-5 inhibitors.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2010.11.030,Design & synthesis of N'-[substituted] pyridine-4-carbohydrazides as potential anticonvulsant agents.,1
316347,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2021.113253,Structure activity refinement of phenylsulfonyl piperazines as antimalarials that block erythrocytic invasion.,1
316347,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
316347,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/acsmedchemlett.7b00030,Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit P. falciparum Dihydroorotate Dehydrogenase.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
316347,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
316347,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/acs.jmedchem.1c00044,"Discovery of Potent and Fast-Acting Antimalarial Bis-1,2,4-triazines.",1
316347,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2023.115694,Triazole hybrid compounds: A new frontier in malaria treatment.,1
316347,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/jm500098s,Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a SoftFocus kinase library: part 1.,1
316347,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
316347,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",10.1021/acs.jmedchem.8b01333,"Antimalarial Lead-Optimization Studies on a 2,6-Imidazopyridine Series within a Constrained Chemical Space To Circumvent Atypical Dose-Response Curves against Multidrug Resistant Parasite Strains.",1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1021/acs.jnatprod.7b00327,"Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.",1
316021,10.1016/j.bmc.2008.12.012,Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor.,10.1021/np1007872,Opioid receptor probes derived from cycloaddition of the hallucinogen natural product salvinorin A.,1
316347,10.1016/j.ejmech.2016.01.015,Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.,10.1021/acs.jmedchem.8b01310,Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of Plasmodium M1 and M17 Aminopeptidases.,1
923,10.1016/j.bmcl.2011.09.035,"Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.",10.1021/jm301389h,"Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.",1
923,10.1016/j.bmc.2021.116041,Identification of madangamine A as a novel lysosomotropic agent to inhibit autophagy.,10.1016/j.ejmech.2023.116117,"Targeting autophagy drug discovery: Targets, indications and development trends.",1
923,10.1016/j.bmcl.2011.09.035,"Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.",10.1016/j.ejmech.2020.112391,Targeting mTOR for fighting diseases: A revisited review of mTOR inhibitors.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2011.11.004,Design and synthesis of novel stiripentol analogues as potential anticonvulsants.,1
921,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,10.1016/j.ejmech.2011.07.027,"Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrrole[1,2-a]pyrazines.",1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmcl.2019.05.007,"Novel benzothiazole hydrazine carboxamide hybrid scaffolds as potential in vitro GABA AT enzyme inhibitors: Synthesis, molecular docking and antiepileptic evaluation.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm9012054,Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.,1
921,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.bmcl.2010.05.059,"Novel semicarbazones based 2,5-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity.",1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm9508705,Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1007/s00044-011-9615-3,New antiepileptic agents: structureactivity relationships,1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmcl.2012.11.051,"Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm100185c,Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm2004305,Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.,1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1007/s00044-012-0169-9,Synthesis and anticonvulsant activity of novel quinazolin-4(3H)-one derived pyrazole analogs,1
316347,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400656s,Novel conjugated quinoline-indoles compromise Plasmodium falciparum mitochondrial function and show promising antimalarial activity.,1
316347,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/jm200592f,Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,1
316347,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2021.113518,Discovery and development of 2-aminobenzimidazoles as potent antimalarials.,1
316347,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2023.115458,Recent developments in antimalarial activities of 4-aminoquinoline derivatives.,1
316347,10.1016/j.ejmech.2014.01.040,"Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.",10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
316347,10.1016/j.ejmech.2009.09.012,A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity.,10.1128/aac.01220-10,Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.,1
316347,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1021/acsmedchemlett.4c00323,Innovative Multistage ML-QSAR Models for Malaria: From Data to Discovery.,1
316347,10.1016/j.ejmech.2020.112941,"Comparative study between the anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine and quinoline derivatives and the identification of new PfDHODH inhibitors.",10.1016/j.ejmech.2024.116163,Discovery of new piperaquine hybrid analogs linked by triazolopyrimidine and pyrazolopyrimidine scaffolds with antiplasmodial and transmission blocking activities.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,1
316347,10.1021/acs.jmedchem.6b01673,Optimization of 2-Anilino 4-Amino Substituted Quinazolines into Potent Antimalarial Agents with Oral in Vivo Activity.,10.1016/j.ejmech.2024.116677,Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3.,1
316347,10.1016/j.ejmech.2014.01.040,"Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.",10.1021/acs.jmedchem.5b01380,Artemisinin-Derived Dimers: Potent Antimalarial and Anticancer Agents.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2016.01.015,Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.,1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1039/d3md00524k,"Novel indolyl 1,2,4-triazole derivatives as potential anti-proliferative agents: &lt;i&gt;in silico&lt;/i&gt; studies, synthesis, and biological evaluation.",1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1016/j.ejmech.2020.112239,"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.",1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1021/acs.jmedchem.1c02019,"Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia.",1
319858,10.1016/j.ejmech.2020.112239,"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.",10.1016/j.bmcl.2022.128991,"Design, synthesis and biological evaluation of pteridine-7(8H)-one derivatives as potent and selective CDK4/6 inhibitors.",1
318173,10.1021/jm0503749,Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.,10.1016/j.ejmech.2017.08.069,Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.,1
318173,10.1021/jm0503749,Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.,10.1016/j.ejmech.2017.04.013,Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.,1
317540,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm101168r,γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.,1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1016/j.ejmech.2020.112674,Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.,1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1016/j.bmcl.2012.04.031,"Wake promoting agents: search for next generation modafinil, lessons learned: part III.",1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.7b01313,"Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.",1
317124,10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",10.1016/j.ejmech.2020.112674,Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.,1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.6b01373,Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.,1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1016/j.bmcl.2011.12.099,Wake-promoting agents: search for next generation modafinil: part I.,1
317124,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/jm401754x,Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues.,1
316347,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2015.07.047,Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1007/s00044-011-9615-3,New antiepileptic agents: structureactivity relationships,1
321696,10.1016/j.bmcl.2013.03.104,Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.,10.1016/j.bmc.2013.09.013,Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.,1
320260,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/acs.jmedchem.8b00986,Synthesis and Pharmacological Evaluation of Noscapine-Inspired 5-Substituted Tetrahydroisoquinolines as Cytotoxic Agents.,1
320260,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/acsmedchemlett.3c00462,Structural Modification of Noscapine via Photoredox/Nickel Dual Catalysis for the Discovery of S-Phase Arresting Agents.,1
320260,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/jm501180v,Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.,1
320260,10.1021/jm050674q,Identification of novel and improved antimitotic agents derived from noscapine.,10.1021/jm200848t,"Tubulin binding, protein-bound conformation in solution, and antimitotic cellular profiling of noscapine and its derivatives.",1
320240,10.1021/jm2002487,Neurosteroid analogues. 16. A new explanation for the lack of anesthetic effects of δ(16)-alphaxalone and identification of a δ(17(20)) analogue with potent anesthetic activity.,10.1021/jm401577c,Neurosteroid analogues. 18. Structure-activity studies of ent-steroid potentiators of γ-aminobutyric acid type A receptors and comparison of their activities with those of alphaxalone and allopregnanolone.,1
320240,10.1021/jm2002487,Neurosteroid analogues. 16. A new explanation for the lack of anesthetic effects of δ(16)-alphaxalone and identification of a δ(17(20)) analogue with potent anesthetic activity.,10.1021/jm3016365,Allopregnanolone and pregnanolone analogues modified in the C ring: synthesis and activity.,1
319898,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",10.1021/jm100762r,Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.,1
319898,10.1016/j.bmcl.2009.08.039,Pyrazole NNRTIs 1: design and initial optimisation of a novel template.,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",1
319858,10.1016/j.ejmech.2020.112239,"Discovery of a novel series of imidazo[1',2':1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors.",10.1016/j.ejmech.2024.116547,Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.,1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
319858,10.1021/acs.jmedchem.2c00947,"Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.",10.1016/j.ejmech.2024.116547,Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.,1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1021/acs.jmedchem.2c00947,"Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.",1
319858,10.1021/acs.jmedchem.6b01670,"Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.",10.1016/j.ejmech.2024.116547,Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.,1
319858,10.1016/j.ejmech.2019.01.011,"Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
321696,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1021/acs.jmedchem.7b01751,"4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.",1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.bmcl.2015.01.004,"Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.",1
921,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm020225f,Design and evaluation of affinity labels of functionalized amino acid anticonvulsants.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm050283b,"Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm020225f,Design and evaluation of affinity labels of functionalized amino acid anticonvulsants.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2010.02.063,"Combating oxidative stress in epilepsy: design, synthesis, quantum chemical studies and anticonvulsant evaluation of 1-(substituted benzylidene/ethylidene)-4-(naphthalen-1-yl)semicarbazides.",1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm100185c,Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm901563p,Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.,1
921,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
921,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
921,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2016.01.009,The importance of triazole scaffold in the development of anticonvulsant agents.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm9012054,Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2007.02.004,"Synthesis and CNS depressant activity of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm901563p,Synthesis and anticonvulsant activities of (R)-N-(4'-substituted)benzyl 2-acetamido-3-methoxypropionamides.,1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
321696,10.1016/j.ejmech.2020.112492,Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.,10.1016/j.ejmech.2024.116386,Opportunities and perspectives of small molecular phosphodiesterase inhibitors in neurodegenerative diseases.,1
321696,10.1016/j.bmcl.2013.03.104,Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.,10.1021/acs.jmedchem.7b01751,"4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.",1
321696,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1016/j.bmcl.2014.07.016,Novel Roflumilast analogs as soft PDE4 inhibitors.,1
321696,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,1
321696,10.1016/j.bmcl.2009.01.045,Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.,10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
321696,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2023.115195,Advances in the development of phosphodiesterase-4 inhibitors.,1
321696,10.1016/j.bmcl.2009.01.045,Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.,10.1021/acs.jmedchem.6b00829,Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.,1
321696,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2022.114631,Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.,1
321696,10.1021/acs.jmedchem.1c02058,Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,1
321696,10.1021/acs.jmedchem.1c02058,Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.,10.1016/j.ejmech.2023.115195,Advances in the development of phosphodiesterase-4 inhibitors.,1
321696,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1021/acs.jmedchem.6b00829,Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.,1
321696,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,1
321696,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
321696,10.1016/j.bmcl.2013.03.104,Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.,10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
321696,10.1021/acs.jmedchem.1c02058,Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,1
321696,10.1016/j.bmcl.2009.01.045,Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",1
328201,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
328201,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,1
328201,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,1
328201,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
328201,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,1
328201,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acs.jmedchem.8b01523,Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,1
327306,10.1021/acs.jmedchem.3c00485,<i>De Novo</i> Design of Nurr1 Agonists <i>via</i> Fragment-Augmented Generative Deep Learning in Low-Data Regime.,10.1021/acs.jmedchem.3c01467,Exploring Fatty Acid Mimetics as NR4A Ligands.,1
325239,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
325239,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",1
325238,10.1021/jm050368c,Glycodiversification for the optimization of the kanamycin class aminoglycosides.,10.1039/c4md00078a,Antifungal Amphiphilic Aminoglycosides.,1
325236,10.1021/jm030650o,Validation of automated docking programs for docking and database screening against RNA drug targets.,10.1021/jm9000659,Design and implementation of an ribonucleic acid (RNA) directed fragment library.,1
322351,10.1016/j.bmcl.2013.02.079,C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome.,10.1016/j.bmcl.2014.01.072,"New C(4)- and C(1)-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform.",1
333370,10.1021/jm060762q,Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation.,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,1
333370,10.1021/jm030453p,"Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes.",10.1016/j.bmcl.2010.11.076,The synthesis and biological evaluation of 2-(3-methyl or 3-phenylisoxazol-5-yl)-3-aryl-8-thiabicyclo[3.2.1]octanes.,1
333370,10.1021/jm980028+,Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton.,10.1016/s0960-894x(01)00443-7,"Rational design and synthesis of novel 2,5-disubstituted cis- and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter.",1
333370,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1016/j.ejmech.2020.112674,Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.,1
333370,10.1021/jm980028+,Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton.,10.1016/s0960-894x(01)00132-9,"Pharmacophore-based discovery of 3,4-disubstituted pyrrolidines as a novel class of monoamine transporter inhibitors.",1
333370,10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",10.1016/j.ejmech.2020.112674,Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.,1
333370,10.1021/jm030453p,"Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes.",10.1016/j.bmc.2009.05.052,"Synthesis and structure-activity relationship of 3beta-(4-alkylthio, -methylsulfinyl, and -methylsulfonylphenyl)tropane and 3beta-(4-alkylthiophenyl)nortropane derivatives for monoamine transporters.",1
333370,10.1021/jm980028+,Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton.,10.1016/s0960-894x(00)00308-5,Synthesis and biological evaluation of 1-azabicyclo-[3.2.1]octanes: new dopamine transporter inhibitors.,1
330785,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1021/acs.jmedchem.7b00978,"Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.",1
330785,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
330785,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.ejmech.2014.03.061,"Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.",1
330785,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.bmcl.2012.07.052,Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90.,1
328601,10.1016/j.ejmech.2023.115636,Coumarins as factor XIIa inhibitors: Potency and selectivity improvements using a fragment-based strategy.,10.1021/acs.jmedchem.4c00475,"Discovery of Highly Selective, Potent, Covalent, and Orally Bioavailable Factor XIIa Inhibitors for the Treatment of Thrombo-Inflammation.",1
328201,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1016/j.bmcl.2016.04.052,Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/jm300806c,Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.,1
328201,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acs.jmedchem.8b01523,Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.,1
333370,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(02)00464-x,Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes.,1
333370,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.3c02037,Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile.,1
333370,10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",10.1021/acs.jmedchem.3c02037,Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile.,1
333370,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.6b01373,Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.,1
333370,10.1021/jm030646c,"Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.",10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,1
333370,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/acs.jmedchem.6b01373,Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.,1
333370,10.1021/jm980028+,Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton.,10.1016/s0960-894x(01)00379-1,Sar studies of piperidine-based analogues of cocaine. Part 3: oxadiazoles.,1
333370,10.1021/jm030646c,"Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.",10.1016/j.bmcl.2005.08.111,N-8-Substituted benztropinamine analogs as selective dopamine transporter ligands.,1
333370,10.1021/jm030646c,"Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.",10.1021/jm060762q,Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogues for in vivo investigation.,1
333370,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/jm030008u,Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.,1
333370,10.1021/jm980028+,Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton.,10.1016/j.bmc.2007.03.069,"Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters.",1
333370,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",1
333370,10.1016/j.ejmech.2020.112674,Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.,10.1021/acs.jmedchem.3c02037,Modifications to 1-(4-(2-Bis(4-fluorophenyl)methyl)sulfinyl)alkyl Alicyclic Amines That Improve Metabolic Stability and Retain an Atypical DAT Inhibitor Profile.,1
333370,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.9b01188,"Structure-Activity Relationships for a Series of (Bis(4-fluorophenyl)methyl)sulfinyl Alkyl Alicyclic Amines at the Dopamine Transporter: Functionalizing the Terminal Nitrogen Affects Affinity, Selectivity, and Metabolic Stability.",1
333370,10.1021/jm9902943,"Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-[3-(cis-3, 5-dimethyl-1-piperazinyl)propyl]carbazole (rimcazole) analogues.",10.1016/s0960-894x(01)00662-x,"[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4'-fluorophenyl)amine analogues as novel probes for the dopamine transporter.",1
333370,10.1021/jm030646c,"Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.",10.1016/j.bmcl.2005.02.012,The role of QSAR in dopamine interactions.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm500739f,Structural basis for rational design of inhibitors targeting Trypanosoma cruzi sterol 14α-demethylase: two regions of the enzyme molecule potentiate its inhibition.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acs.jmedchem.8b00641,"Sterol 14α-Demethylase Structure-Based Design of VNI (( R)- N-(1-(2,4-Dichlorophenyl)-2-(1 H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)benzamide)) Derivatives To Target Fungal Infections: Synthesis, Biological Evaluation, and Crystallographic Analysis.",1
334337,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1016/j.bmcl.2009.10.029,Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.,1
334337,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1021/jm900030h,Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.,1
334337,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",1
334337,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1021/jm501568b,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,1
334337,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1016/j.bmc.2013.01.050,"Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.",1
334337,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acsmedchemlett.9b00218,Discovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruzi.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm401610c,Two analogues of fenarimol show curative activity in an experimental model of Chagas disease.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acs.jmedchem.1c01710,Relaxed Substrate Requirements of Sterol 14α-Demethylase from <i>Naegleria fowleri</i> Are Accompanied by Resistance to Inhibition.,1
334337,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
334337,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1016/j.ejmech.2017.04.044,An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy.,1
334337,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1016/j.bmc.2021.116577,Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.,1
333370,10.1021/jm030646c,"Structure-activity relationships at monoamine transporters for a series of N-substituted 3alpha-(bis[4-fluorophenyl]methoxy)tropanes: comparative molecular field analysis, synthesis, and pharmacological evaluation.",10.1016/j.bmcl.2009.10.087,Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.,1
334866,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1007/s00044-010-9522-z,"An efficient one-pot cyclization of quinoline thiosemicarbazones to quinolines derivatized with 1,3,4-thiadiazole as anticancer and anti-tubercular agents",1
334866,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
334866,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
334866,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2022.114916,Expanding the knowledge around antitubercular 5-(2-aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead optimization and release of a novel antitubercular chemotype via scaffold derivatization.,1
334866,10.1016/j.bmcl.2018.09.021,"1,2,3-Triazole fused with pyridine/pyrimidine as new template for antimicrobial agents: Regioselective synthesis and identification of potent N-heteroarenes.",10.1016/j.ejmech.2020.112832,Antibacterial activities with the structure-activity relationship of coumarin derivatives.,1
334866,10.1016/j.bmcl.2018.09.021,"1,2,3-Triazole fused with pyridine/pyrimidine as new template for antimicrobial agents: Regioselective synthesis and identification of potent N-heteroarenes.",10.1016/j.ejmech.2022.114888,"1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.",1
334866,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
334337,10.1021/jm9013136,Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery.,10.1016/j.bmc.2013.01.050,"Design, structure-activity relationship and in vivo efficacy of piperazine analogues of fenarimol as inhibitors of Trypanosoma cruzi.",1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/jm501568b,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,1
334337,10.1021/jm801313t,Rational modification of a candidate cancer drug for use against Chagas disease.,10.1021/jm501568b,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,1
334337,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
334337,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2020.112082,New azole antifungals with a fused triazinone scaffold.,1
334337,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2023.115506,"Novel antifungal triazoles with alkynyl-methoxyl side chains: Design, synthesis, and biological activity evaluation.",1
334337,10.1021/jm400012e,Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth.,10.1021/acs.jmedchem.7b00463,"Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.",1
334337,10.1016/j.bmcl.2009.10.029,Isoquinoline-based analogs of the cancer drug clinical candidate tipifarnib as anti-Trypanosoma cruzi agents.,10.1021/jm501568b,Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51.,1
334337,10.1016/j.ejmech.2020.112849,Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.,10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1021/acs.jmedchem.9b00940,"Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.",1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.7b00978,"Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.",1
335628,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1021/acs.jmedchem.9b01420,Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1021/acs.jmedchem.5b00197,Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1038/nchembio.2007.10,Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1016/j.bmc.2008.10.087,Discovery and development of heat shock protein 90 inhibitors.,1
335388,10.1021/acs.jmedchem.9b00322,"Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865).",10.1021/acs.jmedchem.9b01312,Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA<sub>A</sub>R) Modulators Acting at the Benzodiazepine Binding Site: An Update.,1
334866,10.1016/j.ejmech.2011.03.041,Urea/thiourea derivatives of quinazolinone-lysine conjugates: synthesis and structure-activity relationships of a new series of antimicrobials.,10.1016/j.ejmech.2014.09.098,"Implications of N-capped urea/thiourea and C-capped 3-(1-piperazinyl)-1,2-benzisothiazole with bridging Gly-Val/Phe-Gly-Val-Pro as therapeutic targets.",1
334866,10.1016/j.ejmech.2011.02.052,Novel dihydropyrimidines and its pyrazole derivatives: synthesis and pharmacological screening.,10.1016/j.ejmech.2023.115701,Heterocyclic pyrimidine derivatives as promising antibacterial agents.,1
334866,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
334866,10.1016/j.bmc.2010.09.006,Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin.,10.1016/j.ejmech.2018.08.002,Pyrrole: An insight into recent pharmacological advances with structure activity relationship.,1
334866,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2013.11.007,"Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.",1
334866,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2012.08.047,"The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.",1
334866,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmcl.2011.06.076,Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.,1
334866,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.ejmech.2019.02.010,"Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.",1
334866,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
340939,10.1021/acsmedchemlett.3c00260,"Synthesis and Optimization of 1-Substituted Imidazo[4,5-&lt;i&gt;c&lt;/i&gt;]quinoline TLR7 Agonists.",10.1021/acs.jmedchem.4c00464,Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist.,1
340939,10.1016/j.bmcl.2019.126788,Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.,10.1039/D1MD00031D,Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.,1
340684,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/acs.jmedchem.5b00159,N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.,1
340684,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1016/j.bmc.2017.09.006,"1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.",1
340684,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/jm400674a,"Inhibiting the HIV integration process: past, present, and the future.",1
338934,10.1021/acs.jmedchem.1c01136,Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.,10.1016/j.bmc.2023.117295,Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,1
337366,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.bmc.2018.02.048,Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1016/j.bmc.2008.05.047,"Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.",1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2019.126809,"Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.",1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1016/j.bmcl.2006.06.025,Synthesis of a red-shifted fluorescence polarization probe for Hsp90.,1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.5b00197,Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.,1
335628,10.1021/jm0508078,Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.,10.1016/j.bmcl.2017.10.036,Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases.,1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.9b01420,Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.,1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2016.11.062,"Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.",1
335628,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acsmedchemlett.1c00213,Design and Synthesis of TRAP1 Selective Inhibitors: H-Bonding with Asn171 Residue in TRAP1 Increases Paralog Selectivity.,1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/ml400247k,Probing the Binding Site of Bile Acids in TGR5.,1
343964,10.1021/acs.jmedchem.1c00851,Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5<sup>H88Y</sup> Mutant Mice.,10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1016/j.bmcl.2011.09.123,"Antibacterial and antitubercular activity of fosmidomycin, FR900098, and their lipophilic analogs.",1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1016/j.ejmech.2012.02.031,"Growth inhibition of Mycobacterium smegmatis by prodrugs of deoxyxylulose phosphate reducto-isomerase inhibitors, promising anti-mycobacterial agents.",1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm5014264,Synthesis and bioactivity of β-substituted fosmidomycin analogues targeting 1-deoxy-D-xylulose-5-phosphate reductoisomerase.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm200694q,Reverse fosmidomycin derivatives against the antimalarial drug target IspC (Dxr).,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm4012559,"IspC as target for antiinfective drug discovery: synthesis, enantiomeric separation, and structural biology of fosmidomycin thia isosters.",1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm100211e,Synthesis and evaluation of alpha-halogenated analogues of 3-(acetylhydroxyamino)propylphosphonic acid (FR900098) as antimalarials.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1016/j.bmc.2016.11.040,Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1016/j.bmcl.2011.07.005,Substitution of the phosphonic acid and hydroxamic acid functionalities of the DXR inhibitor FR900098: an attempt to improve the activity against Mycobacterium tuberculosis.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1016/j.bmcl.2012.09.021,"Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR).",1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm5010978,Development of inhibitors of the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway enzymes as potential anti-infective agents.,1
343725,10.1016/j.bmc.2007.12.001,Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates.,10.1021/jm5019719,Prodrugs of reverse fosmidomycin analogues.,1
343041,10.1124/dmd.111.042457,Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib.,10.1124/dmd.112.047340,Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.,1
341064,10.1021/acs.jmedchem.6b00523,Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.,10.1016/j.ejmech.2023.115601,"Disulfide-incorporated lipid prodrugs of cidofovir: Synthesis, antiviral activity, and release mechanism.",1
346036,10.1016/j.bmcl.2013.12.089,Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
345080,10.1016/j.bmcl.2016.12.032,Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.,10.1016/j.ejmech.2019.05.032,"Triptolide: Medicinal chemistry, chemical biology and clinical progress.",1
345080,10.1021/acs.jmedchem.6b01786,Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.,10.1016/j.bmcl.2017.06.038,"Diverse heterocyclic scaffolds as dCTP pyrophosphatase 1 inhibitors. Part 1: Triazoles, triazolopyrimidines, triazinoindoles, quinoline hydrazones and arylpiperazines.",1
345080,10.1021/acs.jmedchem.6b01786,Identification of Triazolothiadiazoles as Potent Inhibitors of the dCTP Pyrophosphatase 1.,10.1021/acs.jmedchem.7b00182,Piperazin-1-ylpyridazine Derivatives Are a Novel Class of Human dCTP Pyrophosphatase 1 Inhibitors.,1
344658,10.1016/j.bmcl.2023.129130,Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones.,10.1016/j.bmcl.2023.129531,Identification of novel glucocerebrosidase chaperones by unexpected skeletal rearrangement reaction.,1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
343964,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
343964,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
343964,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1016/j.ejmech.2023.115851,Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.,1
343964,10.1021/acs.jmedchem.1c00851,Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5<sup>H88Y</sup> Mutant Mice.,10.1016/j.bmc.2023.117418,Discovery and biological evaluation of cholic acid derivatives as potent TGR5 positive allosteric modulators.,1
343964,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
343964,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1021/ml400247k,Probing the Binding Site of Bile Acids in TGR5.,1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/jm901390p,"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.",1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2023.115851,Chemical exploration of TGR5 functional hot-spots: Synthesis and structure-activity relationships of C7- and C23-Substituted cholic acid derivatives.,1
343964,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.bmcl.2010.08.014,Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5.,1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.11.004,Design and synthesis of novel stiripentol analogues as potential anticonvulsants.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2008.01.036,Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.,1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1016/j.bmcl.2008.04.067,"Design and synthesis of 6-amino-1,4-oxazepane-3,5-dione derivatives as novel broad spectrum anticonvulsants.",1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.07.043,"Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.",1
363589,10.1021/acs.jmedchem.8b01491,Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
363589,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
363589,10.1016/j.bmcl.2014.06.071,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",10.1016/j.bmcl.2015.04.102,"Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.",1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1021/acs.jmedchem.5b00258,Applications of Fluorine in Medicinal Chemistry.,1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1016/j.bmcl.2014.03.009,"Design, synthesis and biological evaluation of novel aminomethyl-piperidones based DPP-IV inhibitors.",1
360720,10.1016/j.bmcl.2014.08.002,Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.,10.1016/j.bmcl.2017.05.001,QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).,1
360720,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1016/j.bmcl.2022.128867,Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.,1
360720,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1016/j.ejmech.2023.115772,Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.,1
360720,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1016/j.ejmech.2022.114596,A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.,1
358192,10.1016/j.bmcl.2006.07.008,The discovery and optimization of pyrimidinone-containing MCH R1 antagonists.,10.1016/j.bmcl.2007.04.012,Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists.,1
346895,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
346036,10.1016/j.bmcl.2011.09.056,Identification of a novel RAMP-independent CGRP receptor antagonist.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
363589,10.1016/j.bmcl.2015.04.102,"Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.",10.1016/j.ejmech.2016.08.023,Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.,1
363589,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1016/j.ejmech.2017.08.024,Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.,1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1021/jm401992e,Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes.,1
363589,10.1016/j.bmc.2019.01.001,Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.,10.1016/j.bmc.2021.116354,A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.,1
921,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2012.11.025,Synthesis and anticonvulsant activity of new phenytoin derivatives.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1007/s00044-011-9739-5,"Synthesis, characterization and pharmacological evaluation of (E)-N-(substituted-benzylidene)isonicotinohydrazide derivatives as potent anticonvulsant agents",1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.bmcl.2011.04.117,"Practical synthesis, anticonvulsant, and antimicrobial activity of N-allyl and N-propargyl di(indolyl)indolin-2-ones.",1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2011.09.003,"Design and synthesis of 2-(1, 3-dioxoisoindolin-2-yl)-N-(4-oxo-2-substitutedthiazolidin-3-yl) acetamide derivatives as potential anticonvulsant agents.",1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm030498q,3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.,1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm9508705,Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1016/j.bmcl.2008.04.067,"Design and synthesis of 6-amino-1,4-oxazepane-3,5-dione derivatives as novel broad spectrum anticonvulsants.",1
921,10.1007/s00044-010-9313-6,"Synthesis, anticonvulsant and toxicity screening of thiazolylthiadiazole derivatives",10.1016/j.bmc.2020.115585,Synthetic and therapeutic perspectives of nitrogen containing heterocycles as anti-convulsants.,1
921,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
921,10.1007/s00044-010-9313-6,"Synthesis, anticonvulsant and toxicity screening of thiazolylthiadiazole derivatives",10.1016/j.ejmech.2013.06.026,"Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.",1
921,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2011.11.004,Design and synthesis of novel stiripentol analogues as potential anticonvulsants.,1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1007/s00044-011-9615-3,New antiepileptic agents: structureactivity relationships,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.5b01222,"Design, Synthesis, and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multitarget-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer's Disease.",1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm401169a,Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.,1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
364520,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
364520,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112423,Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.02.042,"Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.",1
364520,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
363589,10.1021/acs.jmedchem.8b01491,Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.,10.1016/j.bmc.2021.116354,A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.,1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
363589,10.1016/j.bmcl.2014.05.076,Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.,10.1016/j.ejmech.2016.08.023,Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.,1
363589,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1021/jm200383j,"Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?",1
363589,10.1016/j.bmcl.2008.05.080,Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads.,10.1016/j.bmcl.2012.03.107,Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity.,1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1016/j.bmc.2020.115861,"Synthesis, in vitro evaluation, and computational simulations studies of 1,2,3-triazole analogues as DPP-4 inhibitors.",1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1016/j.ejmech.2018.03.041,Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.,1
363589,10.1016/j.bmcl.2013.07.061,"Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2- (2,5-difluorophenyl)-5-(4,6-dihydropyrrolo [3,4-c]pyrazol-5-(1H)-yl)tetrahydro-2H-pyran-3-amine (23) [corrected].",10.1016/j.bmc.2021.116354,A review upon medicinal perspective and designing rationale of DPP-4 inhibitors.,1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
364520,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2021.113567,Discovery of hydrazide-containing oseltamivir analogues as potent inhibitors of influenza A neuraminidase.,1
364520,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2019.111841,"Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.",1
364520,10.1016/j.ejmech.2018.08.097,"Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.",10.1016/j.ejmech.2021.114034,Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.,1
364520,10.1016/j.ejmech.2018.08.097,"Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.",10.1016/j.ejmech.2022.115019,Discovery of novel 5-methoxybenzothiophene hydrazides as metabolically stable Clk1 inhibitors with high potency and unprecedented Clk1 isoenzyme selectivity.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm070836d,"Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.",1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
364520,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2016.09.078,"Design, synthesis and biological evaluation of new phthalimide and saccharin derivatives with alicyclic amines targeting cholinesterases, beta-secretase and amyloid beta aggregation.",1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112085,"Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.",1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.7b01417,"Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline-Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer's Disease.",1
364520,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
364520,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1039/C9MD00286C,Druggability profile of stilbene-derived PPAR agonists: determination of physicochemical properties and PAMPA study.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm060230+,Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
365189,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
365189,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,1
365189,10.1021/acs.jmedchem.2c01064,Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for <i>Mycobacterium tuberculosis</i> Treatment.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
365189,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,1
365189,10.1016/j.bmc.2022.117006,Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.,10.1016/j.ejmech.2023.115571,"Design, synthesis and biological evaluation of 3-substituted-2-thioxothiazolidin-4-one (rhodanine) derivatives as antitubercular agents against Mycobacterium tuberculosis protein tyrosine phosphatase B.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.03.060,"Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety.",1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2016.05.093,"Synthesis and antitubercular activity of new 1,3,4-oxadiazoles bearing pyridyl and thiazolyl scaffolds.",1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.bmcl.2020.127434,"Novel isoniazid embedded triazole derivatives: Synthesis, antitubercular and antimicrobial activity evaluation.",1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
364875,10.1016/j.ejmech.2019.111914,Structural optimization of aminopyrimidine-based CXCR4 antagonists.,10.1016/j.ejmech.2020.112537,"Design, synthesis, and evaluation of pyrrolidine based CXCR4 antagonists with in vivo anti-tumor metastatic activity.",1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2017.07.058,Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.,1
364520,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
364520,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
364520,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1016/j.bmc.2012.04.002,"Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm2004305,Primary amino acid derivatives: compounds with anticonvulsant and neuropathic pain protection activities.,1
892,10.1016/S0960-894X(00)80531-4,"Synthesis, biochemical activity and behavioral effects of a series of 1,4,5,6-tetrahydropyrimidines as novel ligands for M1 receptors",10.1021/jm960467d,"Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.",1
860,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.bmcl.2022.128871,"Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.",1
365189,10.1021/jm00145a020,"4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption.",10.1016/j.bmcl.2015.07.043,The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.07.033,"Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2009.11.036,"New 1,3-oxazolo[4,5-c]quinoline derivatives: synthesis and evaluation of antibacterial and antituberculosis properties.",1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2010.07.003,Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.,1
365189,10.1016/j.bmcl.2004.09.052,In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.,10.1016/j.ejmech.2007.08.003,Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstituted-benzylidene)isonicotinohydrazide derivatives.,1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
365189,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.bmcl.2017.10.071,"Design, synthesis and in vitro anti-tuberculosis activity of benzo[6,7]cyclohepta[1,2-b]pyridine-1,2,3-triazole derivatives.",1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1039/C5MD00057B,"1,2,3-Triazole derivatives as antitubercular agents: synthesis, biological evaluation and molecular docking study",1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1021/acs.jmedchem.0c01374,"2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F)-Dependent Nitroreductase (Ddn).",1
365189,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1021/ml400088y,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1039/C3MD00366C,"Synthesis and biological evaluation of substituted N-alkylphenyl-3,5-dinitrobenzamide analogs as anti-TB agents",1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1021/jm200759t,"Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain-attenuating properties.",1
921,10.1021/jm00165a006,Preparation and anticonvulsant activity of a series of functionalized alpha-aromatic and alpha-heteroaromatic amino acids.,10.1016/0960-894X(96)00220-X,Synthesis and anticonvulsant evaluation of a series of (R)- and (S)-N-Cbz--aminoglutarimide and succinimide,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.ejmech.2011.07.043,"Synthesis and anticonvulsant properties of new acetamide derivatives of phthalimide, and its saturated cyclohexane and norbornene analogs.",1
921,10.1016/j.ejmech.2010.02.031,"Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives.",10.1016/j.ejmech.2011.10.020,"Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.",1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1016/j.bmc.2012.04.002,"Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides.",1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm100508m,The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.,1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1016/j.bmcl.2019.06.001,"Synthesis and pharmacological evaluation of novel N-Mannich bases derived from 5,5-diphenyl and 5,5-di(propan-2-yl)imidazolidine-2,4-dione core.",1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm061431g,Discovery of 4-aminobutyric acid derivatives possessing anticonvulsant and antinociceptive activities: a hybrid pharmacophore approach.,1
921,10.1021/jm00112a020,Preparation and anticonvulsant activity of a series of functionalized alpha-heteroatom-substituted amino acids.,10.1021/jm200759t,"Primary amino acid derivatives: substitution of the 4'-N'-benzylamide site in (R)-N'-benzyl 2-amino-3-methylbutanamide, (R)-N'-benzyl 2-amino-3,3-dimethylbutanamide, and (R)-N'-benzyl 2-amino-3-methoxypropionamide provides potent anticonvulsants with pain-attenuating properties.",1
921,10.1021/jm9603025,(Aryloxy)aryl semicarbazones and related compounds: a novel class of anticonvulsant agents possessing high activity in the maximal electroshock screen.,10.1021/jm000155h,Medicinal chemistry of neuronal voltage-gated sodium channel blockers.,1
921,10.1016/j.ejmech.2009.12.062,"Triazole incorporated thiazoles as a new class of anticonvulsants: design, synthesis and in vivo screening.",10.1016/j.ejmech.2012.10.002,"Design, synthesis and evaluation of N-(substituted benzothiazol-2-yl)amides as anticonvulsant and neuroprotective.",1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2015.11.071,Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent.,1
365189,10.1124/dmd.110.035105,Identification of clinically used drugs that activate pregnane X receptors.,10.1021/acs.jmedchem.0c02245,"Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.",1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2015.05.048,"Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.",1
365189,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2017.01.024,"Synthesis, antimycobacterial and cytotoxic activity of α,β-unsaturated amides and 2,4-disubstituted oxazoline derivatives.",1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2013.09.061,Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2012.08.047,"The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2011.12.119,Camphorsulfonic acid catalysed facile tandem double Friedlander annulation protocol for the synthesis of phenoxy linked bisquinoline derivatives and discovery of antitubercular agents.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.07.049,"Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.",1
365189,10.1016/j.bmc.2006.12.027,N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.,10.1039/c5md00340g,Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents.,1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2016.09.043,Identification and optimization of a new series of anti-tubercular quinazolinones.,1
365189,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
365189,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.bmcl.2019.06.055,Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.,1
822,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
822,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
822,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
822,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
822,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
822,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
822,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
822,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,1
822,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
822,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
365189,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmc.2015.10.021,"Aminopyrazolo[1,5-a]pyrimidines as potential inhibitors of Mycobacterium tuberculosis: Structure activity relationships and ADME characterization.",1
365189,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.ejmech.2018.09.049,"Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids.",1
365189,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1007/s00044-011-9662-9,"Isonicotinic acid hydrazide derivatives: synthesis, antimicrobial activity, and QSAR studies",1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
365189,10.1016/j.bmcl.2016.03.066,Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.,10.1039/d4md00221k,"Expanding the chemical space of ester of quinoxaline-7-carboxylate 1,4-di-&lt;i&gt;N&lt;/i&gt;-oxide derivatives as potential antitubercular agents.",1
365189,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1039/d3md00079f,"Synthesis and pharmacological evaluation of 1,3-diaryl substituted pyrazole based (thio)urea derivatives as potent antimicrobial agents against multi-drug resistant <i>Staphylococcus aureus</i> and <i>Mycobacterium tuberculosis</i>.",1
365189,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
365189,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
365189,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.bmc.2021.116529,"Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
365189,10.1016/j.bmcl.2005.06.010,Identification of heteroarylenamines as a new class of antituberculosis lead molecules.,10.1016/j.ejmech.2013.06.010,Synthesis and antimycobacterial activity of analogues of the bioactive natural products sampangine and cleistopholine.,1
365189,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
365189,10.1021/jm901235p,"Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
365189,10.1021/jm300123s,Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2014.05.069,"1-Substituted-5-[(3,5-dinitrobenzyl)sulfanyl]-1H-tetrazoles and their isosteric analogs: A new class of selective antitubercular agents active against drug-susceptible and multidrug-resistant mycobacteria.",1
365189,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
365189,10.1021/acs.jmedchem.9b01032,Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy.,10.1021/acs.jmedchem.0c02245,"Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.",1
365189,10.1021/jm00145a020,"4-Deoxypyrido[1',2':1,2]imidazo[5,4-c]rifamycin SV derivatives. A new series of semisynthetic rifamycins with high antibacterial activity and low gastroenteric absorption.",10.1021/jm400887j,Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?,1
365189,10.1021/jm901235p,"Identification, synthesis, and pharmacological evaluation of tetrahydroindazole based ligands as novel antituberculosis agents.",10.1016/j.bmcl.2020.127655,Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.,1
365189,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
365189,10.1016/j.bmcl.2004.09.052,In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones.,10.1007/s00044-011-9948-y,Isoniazid: the magic molecule,1
365189,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2019.01.002,Synthesis and evaluation of α-aminoacyl amides as antitubercular agents effective on drug resistant tuberculosis.,1
365189,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,10.1016/j.bmcl.2020.127655,Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
365189,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.3c02061,"Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens.",1
365189,10.1021/acs.jmedchem.0c02153,"Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens.",10.1021/acs.jmedchem.4c00441,"Design, Synthesis, and Evaluation of the Antitubercular Activity of 5-Phenyl Substituted-5, 6-dihydropyrido[2, 3-<i>d</i>]pyrimidine-4, 7(<i>3H</i>, <i>8H</i>)-dione Compounds.",1
365189,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmcl.2018.11.002,"Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.",1
365189,10.1016/j.bmc.2022.117006,Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2015.12.080,Natural product-based synthesis of novel anti-infective isothiocyanate- and isoselenocyanate-functionalized amphilectane diterpenes.,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1128/aac.00749-08,"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.",1
365189,10.1016/j.bmc.2015.11.018,"Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2018.11.002,"Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
365189,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.bmc.2018.02.049,"Design, synthesis and biological evaluation of benzofuran appended benzothiazepine derivatives as inhibitors of butyrylcholinesterase and antimicrobial agents.",1
365189,10.1016/j.ejmech.2010.05.035,"Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs.",10.1016/j.bmc.2019.04.017,Benzofuran-isatin hybrids tethered via different length alkyl linkers and their in vitro anti-mycobacterial activities.,1
365189,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acsmedchemlett.7b00356,Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid.,1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,1
365189,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.06.071,Ultrasound-assisted one-pot four-component synthesis of novel 2-amino-3-cyanopyridine derivatives bearing 5-imidazopyrazole scaffold and their biological broadcast.,1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
365189,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2023.115539,"Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.06.053,"hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents.",1
365189,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1039/d1md00387a,Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant <i>Mycobacterium tuberculosis</i> demonstrating bactericidal efficacy.,1
365189,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1021/acs.jmedchem.0c01833,"Tuberculosis: An Overview of the Immunogenic Response, Disease Progression, and Medicinal Chemistry Efforts in the Last Decade toward the Development of Potential Drugs for Extensively Drug-Resistant Tuberculosis Strains.",1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmc.2021.116529,"Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.",1
365189,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.11.032,"Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.",1
365189,10.1016/j.bmcl.2016.03.066,Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.,10.1016/j.ejmech.2021.113657,"Discovery of novel nitrogenous heterocyclic-containing quinoxaline-1,4-di-N-oxides as potent activator of autophagy in M.tb-infected macrophages.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmcl.2018.07.005,"Design, synthesis and antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2017.01.004,Quinolidene based monocarbonyl curcumin analogues as promising antimycobacterial agents: Synthesis and molecular docking study.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2013.06.076,Synthesis and binary QSAR study of antitubercular quinolylhydrazides.,1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2016.11.056,"New bithiazolyl hydrazones: Novel synthesis, characterization and antitubercular evaluation.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2018.03.004,"Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.",1
365189,10.1016/j.ejmech.2022.114145,Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1021/acs.jmedchem.9b00912,"Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.",1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2014.05.062,"Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.",1
365189,10.1016/j.bmcl.2012.10.060,Development of 5-nitrothiazole derivatives: identification of leads against both replicative and latent Mycobacterium tuberculosis.,10.1016/j.bmcl.2019.03.020,Thiazolyl-pyrazole derivatives as potential antimycobacterial agents.,1
365189,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.bmcl.2018.11.036,"Synthesis and biological evaluation of 1H-pyrrolo[2,3-d]pyrimidine-1,2,3-triazole derivatives as novel anti-tubercular agents.",1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2017.05.026,"QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.",1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2018.09.049,"Design, synthesis and anti-mycobacterial activity evaluation of benzofuran-isatin hybrids.",1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2009.12.045,Design and synthesis of some new quinoline-3-carbohydrazone derivatives as potential antimycobacterial agents.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2021.113603,Identification of novel benzothiopyranones with ester and amide motifs derived from active metabolite as promising leads against Mycobacterium tuberculosis.,1
365189,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
365189,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2016.07.068,Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties.,1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.1c00263,Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.ejmech.2017.05.044,"Design, synthesis and antimycobacterial activity of novel imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
365189,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.ejmech.2015.10.054,Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.,1
365189,10.1021/acs.jmedchem.8b00172,"Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.",10.1016/j.ejmech.2022.114105,A new strategy for hit generation: Novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen).,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1021/acsmedchemlett.5b00202,Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents.,1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2020.112996,Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and Mycobacterium tuberculosis.,1
365189,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
365189,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2018.07.047,Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.,1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2017.04.002,Isoniazid derivatives and their anti-tubercular activity.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2021.113580,Synthesis and structure-activity relationship of new chalcone linked 5-phenyl-3-isoxazolecarboxylic acid methyl esters potentially active against drug resistant Mycobacterium tuberculosis.,1
365189,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1016/j.ejmech.2018.07.047,Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
365189,10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,10.1016/j.ejmech.2023.115409,Comprehensive coverage on anti-mycobacterial endeavour reported during 2022.,1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
365189,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2022.114454,Emerging impact of triazoles as anti-tubercular agent.,1
822,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
822,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
822,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
789,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
789,10.1021/jm00389a008,"Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.",10.1021/acs.jmedchem.5b00201,Volume of Distribution in Drug Design.,1
789,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
789,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2009.11.039,Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay.,1
789,10.1021/jm00389a008,"Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases.",10.1021/acs.jmedchem.6b00472,"The ""Cyclopropyl Fragment"" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.",1
789,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
365189,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,10.1016/j.bmcl.2019.03.020,Thiazolyl-pyrazole derivatives as potential antimycobacterial agents.,1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1016/j.bmc.2018.03.004,"Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901112f,"Searching for new cures for tuberculosis: design, synthesis, and biological evaluation of 2-methylbenzothiazoles.",1
365189,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2020.112075,"Design, synthesis, and biological evaluation of novel 4H-chromen-4-one derivatives as antituberculosis agents against multidrug-resistant tuberculosis.",1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.ejmech.2014.10.079,"Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.",1
365189,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmc.2016.01.011,Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors.,1
365189,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
365189,10.1016/j.bmcl.2016.07.039,"A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.",10.1016/j.ejmech.2017.06.051,Triazole derivatives and their anti-tubercular activity.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmcl.2018.12.053,Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmc.2022.116777,Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.,1
365189,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmcl.2011.06.076,Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2011.03.039,"New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2012.05.004,"New N-arylamino biquinoline derivatives: synthesis, antimicrobial, antituberculosis, and antimalarial evaluation.",1
365189,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.05.025,"Synthesis, characterization and antitubercular activities of novel pyrrolyl hydrazones and their Cu-complexes.",1
365189,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm900513a,"Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/ml200157f,Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/acsmedchemlett.5b00324,2-(Quinolin-4-yloxy)acetamides Are Active against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.ejmech.2009.12.074,Structure-activity relationship of new anti-tuberculosis agents derived from oxazoline and oxazole benzyl esters.,1
365189,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
365189,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmc.2014.06.012,"Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.",1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
365189,10.1021/jm900003c,Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.,10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",1
365189,10.1016/j.bmc.2010.09.006,Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmc.2018.03.004,"Synthesis, evaluation and CoMFA/CoMSIA study of nitrofuranyl methyl N-heterocycles as novel antitubercular agents.",1
365189,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2013.11.007,"Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.",1
365189,10.1016/j.bmc.2010.09.006,Identification of a novel pyrrole derivative endowed with antimycobacterial activity and protection index comparable to that of the current antitubercular drugs streptomycin and rifampin.,10.1016/j.ejmech.2018.08.002,Pyrrole: An insight into recent pharmacological advances with structure activity relationship.,1
365189,10.1021/acsmedchemlett.5b00141,"Nitrofuranyl Methyl Piperazines as New Anti-TB Agents: Identification, Validation, Medicinal Chemistry, and PK Studies.",10.1016/j.bmcl.2018.07.046,"Design, synthesis and evaluation of oxime-functionalized nitrofuranylamides as novel antitubercular agents.",1
365189,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.bmcl.2016.10.082,"Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.",1
365189,10.1016/j.bmcl.2007.09.096,Synthesis and biological evaluation of N-(aryl)-2-thiophen-2-ylacetamides series as a new class of antitubercular agents.,10.1016/j.bmcl.2017.05.032,"Synthesis, SAR and molecular docking studies of benzo[d]thiazole-hydrazones as potential antibacterial and antifungal agents.",1
365189,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.ejmech.2017.06.005,Drug development against tuberculosis: Impact of alkaloids.,1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",1
365189,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.ejmech.2009.11.036,"New 1,3-oxazolo[4,5-c]quinoline derivatives: synthesis and evaluation of antibacterial and antituberculosis properties.",1
365189,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
365189,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmc.2012.08.041,"1,3-Azoles from ortho-naphthoquinones: synthesis of aryl substituted imidazoles and oxazoles and their potent activity against Mycobacterium tuberculosis.",1
365189,10.1021/jm400887j,Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?,10.1016/j.bmcl.2016.06.075,Synthesis and antibacterial evaluation of macrocyclic diarylheptanoid derivatives.,1
365189,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.bmcl.2015.08.006,Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents.,1
365189,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
365189,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2021.113472,"Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis.",1
365189,10.1021/acsmedchemlett.6b00330,"Identification of N-(2-Phenoxyethyl)imidazo[1,2-a]pyridine-3-carboxamides as New Antituberculosis Agents.",10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",1
365189,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2020.112538,"Design, synthesis and biological evaluation of diamino substituted cyclobut-3-ene-1,2-dione derivatives for the treatment of drug-resistant tuberculosis.",1
365189,10.1016/j.ejmech.2017.12.088,Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors.,10.1021/acs.jnatprod.9b00475,"Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.",1
365189,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
365189,10.1016/j.bmcl.2016.03.066,Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis.,10.1016/j.bmcl.2021.127784,Synthesis of novel quinoxaline-alkynyl derivatives and their anti-Mycobacterium tuberculosis activity.,1
365189,10.1016/j.ejmech.2015.06.032,"4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation.",10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
365189,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2017.07.059,Recent advances of pyrazole-containing derivatives as anti-tubercular agents.,1
789,10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2022.114563,"Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.",1
789,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
789,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
789,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
789,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
789,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
789,10.1021/jm7014809,High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.,10.1021/jm9003945,Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.,1
789,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
789,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1023/a:1025032511040,pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jf102525e,Importance of physicochemical properties for the design of new pesticides.,1
789,10.1021/acs.jmedchem.8b02032,Optimization of Blood-Brain Barrier Permeability with Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibitors Having a 2-Aminopyridine Scaffold.,10.1021/acs.jmedchem.3c00782,"Potent, Selective, and Membrane Permeable 2-Amino-4-Substituted Pyridine-Based Neuronal Nitric Oxide Synthase Inhibitors.",1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1073/pnas.0705517104,Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2010.07.125,Discovery of quinolines as selective glucocorticoid receptor agonists.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm901551w,"Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.",1
365281,10.1016/j.bmc.2009.10.035,"Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents.",10.1016/j.bmc.2010.06.046,"Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.",1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2016.11.007,"Synthesis of novel steroidal agonists, partial agonists, and antagonists for the glucocorticoid receptor.",1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.bmcl.2022.128871,"Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.",1
365195,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
365195,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.bmcl.2019.06.055,Discovery and evaluation of novel nitrodihydroimidazooxazoles as promising anti-tuberculosis agents.,1
365195,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.bmcl.2017.03.069,"6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.",1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1128/aac.00749-08,"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.",1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1021/acsmedchemlett.5b00202,Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents.,1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.bmcl.2017.03.069,"6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases.",1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",1
365195,10.1021/jm060957y,"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.",10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
365189,10.1016/j.ejmech.2017.03.065,Synthesis and antimycobacterial screening of new thiazolyl-oxazole derivatives.,10.1016/j.ejmech.2018.02.067,"Synthesis and antimycobacterial activity of 1-(β-d-Ribofuranosyl)-4-coumarinyloxymethyl- / -coumarinyl-1,2,3-triazole.",1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1021/jm100957a,Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2009.06.020,"Highly tractable, sub-nanomolar non-steroidal glucocorticoid receptor agonists.",1
365281,10.1021/ml2001196,Optimization of the Central Core of Indolinone-Acetic Acid-Based CRTH2 (DP2) Receptor Antagonists.,10.1021/jm200866y,"Discovery of potent, selective, and orally bioavailable alkynylphenoxyacetic acid CRTH2 (DP2) receptor antagonists for the treatment of allergic inflammatory diseases.",1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2011.09.018,Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2013.06.089,Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2007.06.066,Non-steroidal glucocorticoid agonists: the discovery of aryl pyrazoles as A-ring mimetics.,1
365281,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/s0960-894x(02)00105-1,"A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.",1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2011.09.018,Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2013.06.089,Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.,1
365281,10.1016/j.bmcl.2020.127298,Discovery of the potent non-steroidal glucocorticoid receptor modulator BAY 1003803 as clinical candidate.,10.1039/d4md00301b,Development of new dehydrocostuslactone derivatives for treatment of atopic dermatitis &lt;i&gt;via&lt;/i&gt; inhibition of the NF-κB signaling pathway.,1
365281,10.1016/j.bmc.2009.10.035,"Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents.",10.1016/j.bmc.2009.11.066,"Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, anti-inflammatory and antioxidant agents.",1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2013.06.085,Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm070778w,Nonsteroidal glucocorticoid agonists: tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) efficacy selectivity.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm100447c,Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2010.04.012,5-Functionalized indazoles as glucocorticoid receptor agonists.,1
365281,10.1016/j.bmcl.2014.09.053,Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.,10.1016/j.bmcl.2020.127205,Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.,1
365284,10.1021/jm00081a014,"Synthesis, antiproliferative, and antiviral activity of certain 4-aminopyrrolo[2,3-d]pyridazine nucleosides: an entry into a novel series of adenosine analogues.",10.1021/jm960631x,"Synthesis and antiproliferative and antiviral activity of carbohydrate-modified pyrrolo[2,3-d]pyridazin-7-one nucleosides.",1
365284,10.1016/j.bmcl.2006.06.066,Discovery of a novel series of inhibitors of human cytomegalovirus primase.,10.1016/j.bmcl.2007.01.109,SAR studies on a novel series of human cytomegalovirus primase inhibitors.,1
365281,10.1016/j.bmcl.2010.12.121,Discovery of a potent series of non-steroidal non α-trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity.,10.1016/j.bmcl.2013.10.052,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,1
365281,10.1016/j.bmcl.2010.12.121,Discovery of a potent series of non-steroidal non α-trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity.,10.1016/j.bmcl.2011.09.018,Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2010.04.012,5-Functionalized indazoles as glucocorticoid receptor agonists.,1
365281,10.1016/j.bmc.2009.10.035,"Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents.",10.1016/j.bmc.2009.12.077,"Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.",1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2010.07.125,Discovery of quinolines as selective glucocorticoid receptor agonists.,1
365281,10.1016/j.bmcl.2014.09.053,Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt.,10.1016/j.ejmech.2019.111984,Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1021/jm100751q,Nonsteroidal dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2013.06.085,Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.,1
365281,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,1
365281,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm101445p,Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1016/j.bmcl.2013.10.052,Function-regulating pharmacophores in a sulfonamide class of glucocorticoid receptor agonists.,1
365281,10.1016/j.bmc.2009.12.077,"Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.",10.1016/j.bmc.2010.06.046,"Synthesis of novel 3,5-diaryl pyrazole derivatives using combinatorial chemistry as inhibitors of tyrosinase as well as potent anticancer, anti-inflammatory agents.",1
365281,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
365281,10.1016/j.bmcl.2007.07.031,Identification of dissociated non-steroidal glucocorticoid receptor agonists.,10.1021/jm901551w,"Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.",1
365538,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
365538,10.1016/j.ejmech.2015.10.002,"Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.",10.1016/j.ejmech.2016.03.080,A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems.,1
365538,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2008.09.027,"Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.",1
365538,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm901421c,The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.,1
365538,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
365538,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1016/j.ejmech.2022.114618,Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.,1
365538,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm991171l,The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.,1
365284,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2013.05.009,Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof.,1
365284,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2007.03.061,"Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).",1
365284,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1021/jm981051y,"Synthesis of imidazo[1,2-a]pyridines as antiviral agents.",1
365284,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1016/j.ejmech.2022.114618,Synthesis and antiviral properties of biomimetic iminosugar-based nucleosides.,1
365284,10.1016/j.bmcl.2020.127514,Structural hybridization as a facile approach to new drug candidates.,10.1016/j.ejmech.2021.113193,Exploration of artemisinin derivatives and synthetic peroxides in antimalarial drug discovery research.,1
365284,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2008.09.027,"Influence of 6- or 8-substitution on the antiviral activity of 3-arylalkylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (CMV) and varicella-zoster virus (VZV): part II.",1
365284,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
365284,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1016/S0960-894X(96)00244-2,"Synthesis and antiviral activity of 2-deoxy-1,5-anhydro-D-mannitol nucleosides containing a pyrimidine base moiety",1
365284,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm991171l,The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.,1
366279,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,1
366274,10.1021/jm049692i,Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.,10.1016/j.bmcl.2005.06.054,Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowering activity in a rabbit model of glaucoma.,1
366274,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1016/j.bmcl.2008.03.023,Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors.,1
366274,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm060807n,"Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue.",1
366274,10.1021/jm011112j,Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation.,10.1021/jm031116j,Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity.,1
365916,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm401549m,Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases.,1
365916,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
365538,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1021/jm981051y,"Synthesis of imidazo[1,2-a]pyridines as antiviral agents.",1
365538,10.1021/jm00063a008,3-Quinolinecarboxamides. A series of novel orally-active antiherpetic agents.,10.1016/S0960-894X(97)00117-0,Synthesis and biological activities of truncated acridone: Structure-activity relationship studies of cytotoxic 5-hydroxy-4-quinolone,1
365538,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
365538,10.1016/j.bmc.2007.09.032,"SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b]pyrazolo[3,4-h]-1,6-naphthyridine series.",10.1007/s00044-007-9035-6,"Synthesis and antiviral activity of new 4-(phenylamino)/4-[(methylpyridin-2-yl)amino]-1-phenyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acids derivatives",1
365538,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1016/S0960-894X(96)00244-2,"Synthesis and antiviral activity of 2-deoxy-1,5-anhydro-D-mannitol nucleosides containing a pyrimidine base moiety",1
365538,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm070836d,"Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.",1
365538,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm980287z,"5-Substituted pyrimidines with a 1,5-anhydro-2, 3-dideoxy-D-arabino-hexitol moiety at N-1: synthesis, antiviral activity, conformational analysis, and interaction with viral thymidine kinase.",1
365538,10.1021/jm9507901,"Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.",10.1016/j.bmc.2007.03.061,"Influence of 6 or 8-substitution on the antiviral activity of 3-phenethylthiomethylimidazo[1,2-a]pyridine against human cytomegalovirus (HCMV) and varicella-zoster virus (VZV).",1
365538,10.1021/jm00005a010,"Synthesis, biological evaluation, and structure analysis of a series of new 1,5-anhydrohexitol nucleosides.",10.1021/jm9904194,Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.,1
366712,10.1016/j.ejmech.2012.12.016,"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.",10.1021/acs.jmedchem.5b01888,Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.,1
366712,10.1016/j.ejmech.2018.01.100,Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.,10.1021/acs.jmedchem.3c01998,Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.,1
366712,10.1016/j.ejmech.2012.12.016,"Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.",10.1016/j.ejmech.2018.01.076,Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.,1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2010.11.030,Synthesis of a novel human PPARδ selective agonist and its stimulatory effect on oligodendrocyte differentiation.,1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2007.11.053,"Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.",1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmc.2011.03.053,Biological evaluation of novel benzisoxazole derivatives as PPARδ agonists.,1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2018.03.010,Structure-guided evolution of a 2-phenyl-4-carboxyquinoline chemotype into PPARα selective agonists: New leads for oculovascular conditions.,1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1021/jm101360s,Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.,1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1021/acs.jmedchem.9b01189,"Evolution of a 4-Benzyloxy-benzylamino Chemotype to Provide Efficacious, Potent, and Isoform Selective PPARα Agonists as Leads for Retinal Disorders.",1
366667,10.1021/jm058056x,Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.,10.1016/j.bmcl.2008.09.094,The discovery of equipotent PPARalpha/gamma dual activators.,1
366279,10.1016/j.bmc.2009.11.021,Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library.,10.1021/jm1013242,Natural product-based phenols as novel probes for mycobacterial and fungal carbonic anhydrases.,1
366279,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm300112w,"Synthesis, structure-activity relationship studies, and X-ray crystallographic analysis of arylsulfonamides as potent carbonic anhydrase inhibitors.",1
366279,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1016/j.ejmech.2018.11.073,Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety.,1
366279,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1016/j.ejmech.2018.11.073,Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety.,1
366279,10.1016/j.ejmech.2013.10.071,Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors.,10.1016/j.bmc.2021.116279,"Design, synthesis and biochemical evaluation of novel carbonic anhydrase inhibitors triggered by structural knowledge on hCA VII.",1
366279,10.1021/jm9014026,"Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as potent carbonic anhydrase inhibitors: synthesis, biological evaluation, and enzyme--ligand X-ray studies.",10.1021/jm2000213,"Structural basis for the interaction between carbonic anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/acs.jmedchem.7b01135,"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
366712,10.1021/jm100009z,Fragment-based deconstruction of Bcl-xL inhibitors.,10.1016/j.bmc.2015.02.060,A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.,1
789,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
789,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
789,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,1
789,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1016/j.bmcl.2010.12.079,"Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.",1
789,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm049661n,In silico prediction of membrane permeability from calculated molecular parameters.,1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1002/jps.20373,"Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.",1
789,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
721,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1039/d4md00060a,Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.,1
721,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm0309001,Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.,1
721,10.1124/dmd.110.036095,Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.,10.1021/jm401963n,A high-throughput cell-based method to predict the unbound drug fraction in the brain.,1
721,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
721,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1039/d2md00192f,"Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-<i>a</i>]pyrimidine scaffold.",1
367860,10.1016/j.bmc.2016.10.011,Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.,10.1016/j.bmc.2018.04.005,"Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.bmc.2013.12.033,Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/acs.jmedchem.8b00510,"Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.bmcl.2014.09.031,Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,1
367860,10.1021/acs.jmedchem.8b00571,"Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.",10.1021/acs.jmedchem.8b01153,Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.,1
367860,10.1021/acs.jmedchem.0c00359,Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,10.1016/j.ejmech.2023.115848,Synthesis and clinical application of small-molecule inhibitors of Janus kinase.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.bmc.2015.05.028,"Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/acs.jmedchem.5b00710,Development of Selective Covalent Janus Kinase 3 Inhibitors.,1
367860,10.1016/j.bmcl.2013.03.015,"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.",10.1021/acs.jmedchem.5b00710,Development of Selective Covalent Janus Kinase 3 Inhibitors.,1
367860,10.1016/j.bmcl.2013.03.015,"Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.",10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
721,10.1021/jm9600609,Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands.,10.1021/jm991131h,"3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.4049/jimmunol.1201348,"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1016/j.bmc.2018.01.021,"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.",1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/acs.jmedchem.8b00667,Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.,1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
367860,10.1021/jm400266t,"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.",10.1016/j.bmcl.2015.07.037,Discovery of Tyk2 inhibitors via the virtual site-directed fragment-based drug design.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/jm501262q,Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/jm400266t,"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.",1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmc.2015.05.028,"Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.",1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.bmcl.2016.02.035,Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/acs.jmedchem.2c00922,"Discovery of Hexahydrofuro[3,2-<i>b</i>]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",1
367860,10.1021/acs.jmedchem.8b00510,"Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.",10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",1
367860,10.1021/acs.jmedchem.6b01634,Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.,10.1021/acs.jmedchem.8b00667,Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/acs.jmedchem.8b00510,"Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/jm301646k,3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.,1
721,10.1021/jm030946u,"New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.",10.1016/j.bmc.2007.05.017,"7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.",1
721,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2013.12.001,"Synthesis, anticonvulsant activity and molecular properties prediction of dialkyl 1-(di(ethoxycarbonyl)methyl)-2,6-dimethyl-4-substituted-1,4-dihydropyridine-3,5-dicarboxylates.",1
721,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1016/j.ejmech.2016.11.019,"An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.",1
721,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm3011433,Ion channels as therapeutic targets: a drug discovery perspective.,1
721,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1016/j.bmc.2017.02.013,"Synthesis and pharmacological evaluation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as potential GABAA-R ligands.",1
721,10.1021/np9702446,"Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine.",10.1021/jm200186n,Modulation of GABAA-receptors by honokiol and derivatives: subtype selectivity and structure-activity relationship.,1
721,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
721,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
721,10.1021/jm9001154,Identification of anxiolytic/nonsedative agents among indol-3-ylglyoxylamides acting as functionally selective agonists at the gamma-aminobutyric acid-A (GABAA) alpha2 benzodiazepine receptor.,10.1021/acs.jmedchem.0c01808,The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.,1
721,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1021/acs.jmedchem.7b01151,"Identification of a New Pyrazolo[1,5-a]quinazoline Ligand Highly Affine to γ-Aminobutyric Type A (GABAA) Receptor Subtype with Anxiolytic-Like and Antihyperalgesic Activity.",1
721,10.1021/jm020999w,"Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands.",10.1021/jm058002n,A novel selective GABA(A) alpha1 receptor agonist displaying sedative and anxiolytic-like properties in rodents.,1
721,10.1016/j.ejmech.2007.04.009,Computational aqueous solubility prediction for drug-like compounds in congeneric series.,10.1016/j.bmc.2009.08.022,Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.,1
721,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.bmcl.2017.01.050,DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.,1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.bmc.2015.05.028,"Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.",1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.bmcl.2015.09.020,"Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.",1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/acs.jmedchem.7b01135,"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1016/j.bmcl.2013.02.012,Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.,1
367860,10.1016/j.bmcl.2015.09.020,"Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.",10.1016/j.bmcl.2016.02.035,Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.,1
367860,10.1016/j.bmc.2016.10.011,Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.,10.1016/j.bmc.2019.03.048,"Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.",1
367860,10.1021/acs.jmedchem.6b01634,Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.,10.1021/acs.jmedchem.3c00554,Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmc.2018.04.005,"Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.",1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/acs.jmedchem.7b01135,"The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,1
367860,10.1021/acs.jmedchem.0c00359,Fragment-Based Discovery of Pyrazolopyridones as JAK1 Inhibitors with Excellent Subtype Selectivity.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",1
367860,10.1016/j.bmcl.2015.09.020,"Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.",10.1186/s41927-018-0031-x,In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1016/j.bmcl.2019.04.008,Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/acs.jmedchem.9b01439,Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.,1
368538,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2019.06.016,"Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.",1
368538,10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",10.1039/C7MD00578D,"Design, synthesis and biological evaluation of 3',4',5'-trimethoxy flavonoid benzimidazole derivatives as potential anti-tumor agents.",1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2019.04.005,"Synthesis, and evaluation of in vitro and in vivo anticancer activity of 14-substituted oridonin analogs: A novel and potent cell cycle arrest and apoptosis inducer through the p53-MDM2 pathway.",1
368538,10.1016/j.bmc.2014.02.028,"Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.",10.1039/d3md00560g,Research status of indole-modified natural products.,1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2017.11.009,"Design, synthesis and preliminary biological evaluation of 5,8-dihydropteridine-6,7-diones that induce apoptosis and suppress cell migration.",1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2017.05.018,Nitric oxide-releasing derivatives of brefeldin A as potent and highly selective anticancer agents.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1016/j.chembiol.2016.10.008,Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.,1
367860,10.1021/jm4004895,Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmc.2013.12.033,Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group.,1
367860,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmcl.2014.09.031,Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/jm200911r,Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.,1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/acs.jmedchem.8b00571,"Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.",1
367860,10.1021/acs.jmedchem.8b00571,"Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.",10.1021/acs.jmedchem.2c00922,"Discovery of Hexahydrofuro[3,2-<i>b</i>]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.",1
367860,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/acs.jmedchem.0c01952,"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.",1
367860,10.1021/jm101157q,Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.,10.1021/acs.jmedchem.8b01823,Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor.,1
368538,10.1016/j.ejmech.2018.05.028,"Synthesis, cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain at C2 position.",10.1021/acs.jmedchem.2c00432,"A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62.",1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2022.114805,"Design, synthesis and biological evaluation of 3-aryl-7-hydroxy scopoletin derivatives as autophagy activators against tumorigenesis.",1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2018.04.009,Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties.,1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2018.01.031,"Design, synthesis and in vitro biological evaluation of novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing a thiosemicarbazide moiety.",1
368538,10.1016/j.ejmech.2019.03.046,"Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.",10.1016/j.ejmech.2021.113361,Design and synthesis of diosgenin derivatives as apoptosis inducers through mitochondria-related pathways.,1
368538,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.05.064,"Synthesis, antimicrobial, antiquorum-sensing and antitumor activities of new benzimidazole analogs.",1
368538,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2019.06.016,"Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.",1
368538,10.1016/j.bmcl.2016.12.032,Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.,10.1039/d2md00363e,"Novel triphenylphosphonium amphiphilic conjugates of glycerolipid type: synthesis, cytotoxic and antibacterial activity, and targeted cancer cell delivery.",1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.bmcl.2017.08.021,"Design, synthesis and preliminary antiproliferative activity studies of new diheteroaryl thioether derivatives.",1
368538,10.1016/j.bmcl.2008.06.097,Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,1
368538,10.1016/j.ejmech.2015.03.058,Synthesis and pharmacological evaluation of novel bisindole derivatives bearing oximes moiety: identification of novel proapoptotic agents.,10.1016/j.bmc.2018.02.021,Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.,1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,1
368538,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2018.09.047,Synthesis of scutellarein derivatives with antiproliferative activity and selectivity through the intrinsic pathway.,1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2019.03.046,"Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.",1
368538,10.1016/j.ejmech.2013.03.011,"Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: design, synthesis and biological screening.",10.1016/j.ejmech.2019.01.017,Quinolone hybrids and their anti-cancer activities: An overview.,1
368538,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2019.03.046,"Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.",1
368538,10.1021/acs.jmedchem.6b01652,A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway.,10.1016/j.ejmech.2022.114141,One-pot synthesis of oxoaporphines as potent antitumor agents and investigation of their mechanisms of actions.,1
368538,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2017.12.070,Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.,1
368538,10.1016/j.bmc.2014.02.028,"Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.",10.1016/j.ejmech.2017.07.040,"Design, synthesis and biological evaluation of 4-anilinoquinoline derivatives as novel potent tubulin depolymerization agents.",1
368538,10.1021/jm9014394,A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.,10.1021/jm200235u,N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.,1
368538,10.1016/j.ejmech.2013.02.010,"Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles.",10.1016/j.ejmech.2017.03.018,"Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.",1
368538,10.1016/j.bmc.2012.07.016,A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.,10.1039/C4MD00306C,3-Propionyl-thiazolidine-4-carboxylic acid ethyl esters: a family of antiproliferative thiazolidines,1
368538,10.1016/j.bmcl.2009.04.014,"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads.",10.1007/s00044-012-0424-0,"Synthesis, cytotoxic evaluation, and in silico studies of substituted N-alkylbromo-benzothiazoles",1
368538,10.1016/j.bmcl.2009.04.014,"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads.",10.1016/j.ejmech.2011.09.049,Synthesis and cytotoxic activity of novel 3-(1H-indol-3-yl)-1H-pyrazole-5-carbohydrazide derivatives.,1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1039/C7MD00165G,"Design, synthesis, and biological evaluation of new thiazolo[5,4-<i>d</i>]pyrimidine derivatives as potent antiproliferative agents.",1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2017.10.037,Synthesis and preliminary antiproliferative activity of new pteridin-7(8H)-one derivatives.,1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2018.03.084,"Discovery of 6-chloro-2-(propylthio)-8,9-dihydro-7H-purines containing a carboxamide moiety as potential selective anti-lung cancer agents.",1
368538,10.1016/j.bmc.2014.02.028,"Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.",10.1039/C8MD00284C,Novel hybrids derived from aspirin and chalcones potently suppress colorectal cancer <i>in vitro</i> and <i>in vivo</i>.,1
368538,10.1016/j.bmcl.2009.04.014,"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads.",10.1016/j.bmcl.2012.02.007,Scaffold hybridization in generation of indenoindolones as anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase.,1
368538,10.1016/j.bmcl.2009.04.014,"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads.",10.1007/s00044-012-0407-1,"Antitumour activity of 5-[(2E)-1-(1H-benzimidazol-2-yl)-3-substituted phenylprop-2-en-1-ylidene] pyrimidine-2,4,6(1H,3H,5H)-triones against Daltons ascitic lymphoma in mice",1
368538,10.1021/jm401574p,Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.,10.1021/acs.jmedchem.0c02107,Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.,1
368538,10.1016/j.bmcl.2016.12.032,Identification of a diverse synthetic abietane diterpenoid library for anticancer activity.,10.1016/j.ejmech.2017.07.049,"Click chemistry-based synthesis and anticancer activity evaluation of novel C-14 1,2,3-triazole dehydroabietic acid hybrids.",1
368538,10.1021/jm401574p,Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.,10.1021/jm501397h,Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells.,1
368538,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2016.08.015,Synthesis and cytotoxicity of novel artemisinin derivatives containing sulfur atoms.,1
368538,10.1021/jm401574p,Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth.,10.1021/acs.jmedchem.7b01699,Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.,1
368538,10.1016/j.bmcl.2020.127470,Novel anticancer Hsp90 inhibitor disubstituted pyrazolyl 2-aminopyrimidine compound 7t induces cell cycle arrest and apoptosis via mitochondrial pathway in MCF-7 cells.,10.1016/j.bmcl.2021.128213,"Design, synthesis and antiproliferative activity of novel 2,4-diamino-5-methyleneaminopyrimidine derivatives as potential anticancer agents.",1
368538,10.1016/j.ejmech.2018.01.069,Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics.,10.1016/j.ejmech.2018.04.009,Antiproliferative hydrogen sulfide releasing evodiamine derivatives and their apoptosis inducing properties.,1
368538,10.1016/j.ejmech.2018.10.058,"Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric cancer agents: Design, synthesis and structural optimization.",10.1016/j.bmc.2022.116705,"Isolation, synthesis and bioactivity evaluation of isoquinoline alkaloids from Corydalis hendersonii Hemsl. against gastric cancer in vitro and in vivo.",1
368538,10.1016/j.ejmech.2018.08.036,Novel antitumor compound optimized from natural saponin Albiziabioside A induced caspase-dependent apoptosis and ferroptosis as a p53 activator through the mitochondrial pathway.,10.1021/acs.jmedchem.9b00644,Natural Product Albiziabioside A Conjugated with Pyruvate Dehydrogenase Kinase Inhibitor Dichloroacetate To Induce Apoptosis-Ferroptosis-M2-TAMs Polarization for Combined Cancer Therapy.,1
368538,10.1021/jm9014394,A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.,10.1016/j.bmcl.2012.12.063,Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents.,1
368538,10.1016/j.bmcl.2013.11.032,Synthesis of a novel series of artemisinin dimers with potent anticancer activity involving Sonogashira cross-coupling reaction.,10.1016/j.ejmech.2015.11.003,Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives.,1
368538,10.1016/j.bmc.2012.07.016,A novel thiazolidine compound induces caspase-9 dependent apoptosis in cancer cells.,10.1016/j.ejmech.2017.04.069,"Design, synthesis and biological evaluation of some novel sulfonamide derivatives as apoptosis inducers.",1
368538,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2024.129775,"Synthesis and cytotoxicity of novel 6,8,9-trisubstituted purine analogs against liver cancer cells.",1
368538,10.1016/j.bmcl.2008.06.097,Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.,10.1016/j.ejmech.2019.06.016,"Hydrogen sulfide donating ent-kaurane and spirolactone-type 6,7-seco-ent-kaurane derivatives: Design, synthesis and antiproliferative properties.",1
368538,10.1016/j.bmcl.2008.06.097,Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.,10.1016/j.ejmech.2019.03.046,"Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.",1
368538,10.1021/jm9014394,A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.,10.1016/j.bmcl.2012.03.002,"Design and synthesis of thiourea derivatives containing a benzo[5,6]cyclohepta[1,2-b]pyridine moiety as potential antitumor and anti-inflammatory agents.",1
368538,10.1016/j.ejmech.2016.01.026,Synthesis and screening of ursolic acid-benzylidine derivatives as potential anti-cancer agents.,10.1016/j.ejmech.2017.07.013,"Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.",1
368538,10.1016/j.ejmech.2017.04.056,"Identification of thiazolo[5,4-d]pyrimidine derivatives as potent antiproliferative agents through the drug repurposing strategy.",10.1016/j.ejmech.2018.10.058,"Novel 3-(2,6,9-trisubstituted-9H-purine)-8-chalcone derivatives as potent anti-gastric cancer agents: Design, synthesis and structural optimization.",1
372438,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
372428,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
372385,10.1016/j.bmc.2007.11.028,A novel series of parenteral cephalosporins exhibiting potent activities against both Pseudomonas aeruginosa and other gram-negative pathogens. Part 2: Synthesis and structure-activity relationships.,10.1016/j.ejmech.2018.06.014,"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.",1
372385,10.1016/j.bmc.2007.08.001,A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.,10.1016/j.bmcl.2018.01.006,Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.,1
372385,10.1016/j.bmc.2007.08.001,A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.,10.1021/jm400560z,Pyridone-conjugated monobactam antibiotics with gram-negative activity.,1
372385,10.1016/j.bmc.2007.08.001,A novel series of parenteral cephalosporins exhibiting potent activities against Pseudomonas aeruginosa and other Gram-negative pathogens: synthesis and structure-activity relationships.,10.1016/j.ejmech.2018.06.014,"Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.",1
371110,10.1016/j.bmc.2007.10.060,Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.,10.1021/jm8009876,Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.,1
370546,10.1021/jm060870c,Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.,10.1021/jm100146h,Factor Xa inhibitors: next-generation antithrombotic agents.,1
370546,10.1021/jm060870c,Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.,10.1016/j.bmcl.2011.01.131,Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with aminoindane and phenylpyrrolidine P4 motifs.,1
370546,10.1021/jm060870c,Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.,10.1016/j.bmcl.2009.11.077,Structure and property based design of factor Xa inhibitors: pyrrolidin-2-ones with monoaryl P4 motifs.,1
370546,10.1021/jm060870c,Factor Xa inhibitors: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides.,10.1016/j.bmcl.2007.03.080,Selective and dual action orally active inhibitors of thrombin and factor Xa.,1
369464,10.1021/acs.jmedchem.1c01509,"Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.",10.1016/j.ejmech.2023.115219,Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.,1
369464,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
369464,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
369464,10.1007/s00044-012-0007-0,Identification of ZINC02765569: a potent inhibitor of PTP1B by vHTS,10.1007/s00044-012-0165-0,Molecular modeling and synthesis of ZINC02765569 derivatives as protein tyrosine phosphatase 1B inhibitors: lead optimization study,1
369464,10.1021/jm501175v,"Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.",10.1016/j.bmc.2018.06.035,"Design and synthesis of novel pyrimido[5,4-d]pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes.",1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/s0960-894x(02)00328-1,Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1021/jm000468c,"Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.",1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1021/acs.jmedchem.7b01574,Selective Inhibitors of Human Neuraminidase 3.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2019.111940,"Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.",1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1016/j.ejmech.2023.115410,Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.,1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1039/C4MD00168K,Conformational analysis of peramivir reveals critical differences between free and enzyme-bound states,1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1039/C4MD00089G,Inhibitors of the human neuraminidase enzymes,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2023.115275,Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.,1
373806,10.1021/acs.jmedchem.2c00857,Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PA<sub>N</sub> Endonuclease Inhibitors.,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.113097,Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.112147,"Discovery of novel ""Dual-site"" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.",1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2020.113097,Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1016/s0960-894x(01)00019-1,Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.,1
373798,10.1021/acs.jmedchem.1c01527,Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.,10.1016/j.ejmech.2024.116737,"Optimization of potent, broad-spectrum, and specific anti-influenza compounds targeting RNA polymerase PA-PB1 heterodimerization.",1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/s0960-894x(01)00019-1,Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,1
373806,10.1021/jm8001197,Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.,10.1016/j.ejmech.2014.04.082,Tamiphosphor monoesters as effective anti-influenza agents.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1021/jm0002679,"BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.",1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2023.115275,Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.,1
373806,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1016/j.ejmech.2023.115275,Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.,1
373806,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,10.1016/j.ejmech.2023.115410,Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2023.115410,Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1016/j.ejmech.2019.111940,"Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity.",1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2023.115410,Conformationally locked sugar derivatives and analogues as potential neuraminidase inhibitors.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/j.bmcl.2006.07.047,Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/s0960-894x(99)00031-1,Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.,1
373806,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112147,"Discovery of novel ""Dual-site"" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.",1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1016/s0960-894x(99)00031-1,Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.,1
373806,10.1021/acs.jmedchem.8b00929,"Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.",10.1021/acs.jmedchem.1c01531,Zanamivir-Cholesterol Conjugate: A Long-Acting Neuraminidase Inhibitor with Potent Efficacy against Drug-Resistant Influenza Viruses.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1016/j.bmcl.2006.07.047,Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/j.bmcl.2009.04.067,Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/s0960-894x(02)01039-9,Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/j.bmc.2013.05.054,"Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop.",1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1021/acs.jmedchem.2c01258,Sialidase Inhibitors with Different Mechanisms.,1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1016/j.bmc.2018.05.035,Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1021/jm100621s,Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1016/j.bmcl.2011.07.071,3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase.,1
373806,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,10.1016/j.ejmech.2023.115275,Discovery of N-substituted oseltamivir derivatives as novel neuraminidase inhibitors with improved drug resistance profiles and favorable drug-like properties.,1
373806,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1021/acs.jmedchem.1c01970,Iterative Optimization and Structure-Activity Relationship Studies of Oseltamivir Amino Derivatives as Potent and Selective Neuraminidase Inhibitors <i>via</i> Targeting 150-Cavity.,1
373806,10.1021/jm8001197,Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.,10.1021/jm3009713,Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.,1
373806,10.1021/jm8001197,Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.,10.1021/acs.jmedchem.6b00029,Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.,1
373806,10.1021/jm9703754,Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.,10.1021/jm010528u,Structural studies of the resistance of influenza virus neuramindase to inhibitors.,1
373985,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
373985,10.1016/j.ejmech.2008.07.009,Regioselective synthesis and antimicrobial screening of novel ketocarbazolodispiropyrrolidine derivatives.,10.1016/j.ejmech.2010.11.039,Synthesis and antimicrobial activity of highly functionalised novel β-lactam grafted spiropyrrolidines and pyrrolizidines.,1
373985,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
373985,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/acs.jmedchem.6b01903,"Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.",1
373985,10.1016/j.ejmech.2008.07.009,Regioselective synthesis and antimicrobial screening of novel ketocarbazolodispiropyrrolidine derivatives.,10.1016/j.bmcl.2010.04.084,Synthesis of novel beta-lactam fused spiroisoxazolidine chromanones and tetralones as potent antimicrobial agent for human and plant pathogens.,1
373981,10.1039/C6MD00236F,SAR and identification of 2-(quinolin-4-yloxy)acetamides as <i>Mycobacterium tuberculosis</i> cytochrome <i>bc</i><sub>1</sub> inhibitors.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
373981,10.1021/acsmedchemlett.8b00410,"Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
373981,10.1016/j.ejmech.2020.112175,Repurposed drug candidates for antituberculosis therapy.,10.1016/j.ejmech.2021.114066,Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.,1
373970,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/acs.jmedchem.5b00262,"Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.",1
373970,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/jm201465w,"Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.",1
373970,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/acs.jmedchem.6b01903,"Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.",1
373928,10.1021/jm101266s,Identifying chelators for metalloprotein inhibitors using a fragment-based approach.,10.1016/j.bmcl.2014.06.016,Inhibition of the lymphoid tyrosine phosphatase: the effect of zinc(II) ions and chelating ligand fragments on enzymatic activity.,1
373806,10.1021/acs.jmedchem.1c01366,Identification of C5-NH<sub>2</sub> Modified Oseltamivir Derivatives as Novel Influenza Neuraminidase Inhibitors with Highly Improved Antiviral Activities and Favorable Druggability.,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,1
373806,10.1021/ml400080t,"Identification of Selective Nanomolar Inhibitors of the Human Neuraminidase, NEU4.",10.1021/acs.jmedchem.1c01612,Human Neuraminidases: Structures and Stereoselective Inhibitors.,1
373806,10.1021/jm8001197,Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.,10.1021/jm100822f,Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles.,1
373806,10.1021/jm970374b,"Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.",10.1016/s0960-894x(02)00330-x,Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.,1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm501787c,"Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1016/j.bmc.2020.115544,"Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.3c00763,Structure-Based Design of Transport-Specific Multitargeted One-Carbon Metabolism Inhibitors in Cytosol and Mitochondria.,1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm501113m,"Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm501113m,"Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
374007,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.7b01708,"Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.",1
374007,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm501113m,"Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.",1
374007,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
374007,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
373985,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
373985,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/jm201465w,"Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.",1
373985,10.1016/j.ejmech.2011.03.041,Urea/thiourea derivatives of quinazolinone-lysine conjugates: synthesis and structure-activity relationships of a new series of antimicrobials.,10.1016/j.ejmech.2019.03.018,4(3H)-Quinazolinone derivatives: Promising antibacterial drug leads.,1
373985,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
373985,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/acs.jmedchem.5b00262,"Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.",1
373985,10.1016/j.bmc.2009.10.035,"Synthesis and biological evaluation of a novel series of pyrazole chalcones as anti-inflammatory, antioxidant and antimicrobial agents.",10.1016/j.bmc.2009.12.077,"Synthesis and biological screening of a combinatorial library of beta-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.5b00801,"6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401139z,"Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.5b00801,"6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm401328u,"Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.3c00763,Structure-Based Design of Transport-Specific Multitargeted One-Carbon Metabolism Inhibitors in Cytosol and Mitochondria.,1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.7b01708,"Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm501787c,"Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.bmc.2021.116093,"Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.7b01708,"Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1016/j.bmc.2021.116093,"Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor expressing human tumors.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.6b00594,"Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1016/j.bmc.2020.115544,"Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.",1
374008,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2019.06.013,"Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.",1
721,10.1016/j.bmc.2014.01.008,Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators.,10.1021/acs.jnatprod.7b00619,Phenanthrenes: A Promising Group of Plant Secondary Metabolites.,1
721,10.1021/acs.jmedchem.5b00599,Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",1
721,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1021/jm1001887,"New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.",1
721,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.bmc.2011.12.039,Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor-5-HT1A/5-HT2A/5-HT7 and D2/D3/D4-agents: the synthesis and pharmacological evaluation.,1
721,10.1021/jm00147a034,"Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.",10.1021/jm991131h,"3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.",1
721,10.1021/jm960401i,High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracyclic imidazoquinoxalines.,10.1021/acs.jmedchem.6b00034,"Design, Synthesis, and Biological Evaluation of Imidazo[1,5-a]quinoline as Highly Potent Ligands of Central Benzodiazepine Receptors.",1
721,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
721,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.ejmech.2015.11.040,"Towards new 5-HT7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties.",1
721,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.bmc.2014.11.008,"Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.",1
721,10.1016/j.ejmech.2009.09.014,"Design, synthesis and pharmacological screening of potential anticonvulsant agents using hybrid approach.",10.1016/j.bmcl.2014.11.016,Microwave assisted synthesis and docking study of N-(2-oxo-2-(4-oxo-2-substituted thiazolidin-3ylamino)ethyl)benzamide derivatives as anticonvulsant agents.,1
721,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1016/j.bmc.2013.02.027,"Synthesis of novel cognition enhancers with pyrazolo[5,1-c][1,2,4]benzotriazine core acting at γ-aminobutyric acid type A (GABA(A)) receptor.",1
721,10.1038/nchembio.307,Rapid behavior-based identification of neuroactive small molecules in the zebrafish.,10.1021/acs.jnatprod.7b00081,HPLC-Based Activity Profiling for GABAA Receptor Modulators in Extracts: Validation of an Approach Utilizing a Larval Zebrafish Locomotor Assay.,1
721,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm040883v,"Discovery of functionally selective 7,8,9,10-tetrahydro-7,10-ethano-1,2,4-triazolo[3,4-a]phthalazines as GABA A receptor agonists at the alpha3 subunit.",1
721,10.1021/acs.jmedchem.9b00322,"Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865).",10.1021/acs.jmedchem.9b01312,Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA<sub>A</sub>R) Modulators Acting at the Benzodiazepine Binding Site: An Update.,1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.8b00408,"Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
374182,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2022.114682,Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.,1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2024.116327,Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.,1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2022.114682,Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.,1
374182,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c01480,Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout.,1
374182,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2024.116753,"Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.",1
374052,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
374052,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm101445p,Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.,1
374052,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
374052,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acsmedchemlett.3c00326,Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport.,1
374008,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2016.03.032,"Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.",1
374008,10.1021/jm8011323,"Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transporter for cellular entry.",10.1021/acs.jmedchem.8b00408,"Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acsmedchemlett.3c00326,Discovery of Tumor-Targeted 6-Methyl Substituted Pemetrexed and Related Antifolates with Selective Loss of RFC Transport.,1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm201688n,"Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier.",1
374008,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
374008,10.1016/j.ejmech.2015.01.055,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.",10.1016/j.ejmech.2017.08.032,"Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.",1
374548,10.1016/j.bmcl.2012.01.076,"New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.",10.1039/d2md00352j,Pyridine based dual binding site aromatase (CYP19A1) inhibitors.,1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1016/j.ejmech.2011.05.074,"Synthesis and structure-activity relationship of 1- and 2-substituted-1,2,3-triazole letrozole-based analogues as aromatase inhibitors.",1
374548,10.1016/j.bmcl.2012.01.076,"New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.",10.1016/j.bmcl.2017.11.010,Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.,1
374548,10.1016/j.bmcl.2012.01.076,"New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.",10.1039/C3MD00166K,Flavans from Desmos cochinchinensis as potent aromatase inhibitors,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1021/jm300930n,Novel aromatase inhibitors by structure-guided design.,1
374548,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,10.1021/acs.jmedchem.4c00196,Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.,1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1016/j.bmcl.2010.03.113,Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).,1
374548,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.ejmech.2021.114097,Synthesis of novel thiazolyl hydrazone derivatives as potent dual monoamine oxidase-aromatase inhibitors.,1
374182,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
374182,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
374182,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
374182,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.bmc.2022.117073,"Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.",1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2024.116753,"Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.",1
374182,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c01480,Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout.,1
374553,10.1016/j.bmc.2013.03.044,"2-(2-Methylfuran-3-carboxamido)-3-phenylpropanoic acid, a potential CYP26A1 inhibitor to enhance all-trans retinoic acid-induced leukemia cell differentiation based on virtual screening and biological evaluation.",10.1016/j.bmc.2014.11.036,Synthesis and biological evaluation of 3-phenyl-3-aryl carboxamido propanoic acid derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26A1).,1
374553,10.1016/j.bmc.2013.03.044,"2-(2-Methylfuran-3-carboxamido)-3-phenylpropanoic acid, a potential CYP26A1 inhibitor to enhance all-trans retinoic acid-induced leukemia cell differentiation based on virtual screening and biological evaluation.",10.1016/j.bmc.2015.08.019,"Design, synthesis, and biological evaluation of amide imidazole derivatives as novel metabolic enzyme CYP26A1 inhibitors.",1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.bmcl.2016.04.078,Synthesis and biological characterization of 3-(imidazol-1-ylmethyl)piperidine sulfonamides as aromatase inhibitors.,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.bmcl.2017.11.010,Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.ejmech.2021.113737,"Synthesis, structure-activity relationships and molecular docking studies of phenyldiazenyl sulfonamides as aromatase inhibitors.",1
374548,10.1016/j.ejmech.2011.03.043,Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors.,10.1016/j.bmcl.2013.01.045,"Design, synthesis and aromatase inhibitory activities of novel indole-imidazole derivatives.",1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1021/acsmedchemlett.9b00591,Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors.,1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1016/j.ejmech.2017.10.057,"Synthesis, molecular docking, and QSAR study of sulfonamide-based indoles as aromatase inhibitors.",1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1016/j.ejmech.2017.11.057,Potent aromatase inhibitors and molecular mechanism of inhibitory action.,1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.ejmech.2019.111815,"Synthesis, biological evaluation, and docking study of indole aryl sulfonamides as aromatase inhibitors.",1
374548,10.1021/jm800945c,Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors.,10.1016/j.bmc.2015.04.036,"Synthesis and molecular docking of 1,2,3-triazole-based sulfonamides as aromatase inhibitors.",1
374548,10.1016/j.ejmech.2023.115328,Structure-guided identification of novel dual-targeting estrogen receptor α degraders with aromatase inhibitory activity for the treatment of endocrine-resistant breast cancer.,10.1016/j.ejmech.2023.116111,Targeting aromatase to restrain oestrogen production and developing efficacious interventions against ER-positive cancer.,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.bmc.2019.08.001,"Synthesis, molecular docking, and QSAR study of bis-sulfonamide derivatives as potential aromatase inhibitors.",1
374548,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.bmcl.2017.11.010,Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1.,1
374548,10.1021/jm2000689,Structure-based design of potent aromatase inhibitors by high-throughput docking.,10.1016/j.ejmech.2019.02.045,Rational design of allosteric modulators of the aromatase enzyme: An unprecedented therapeutic strategy to fight breast cancer.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
374719,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2020.112549,Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.,1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmcl.2006.03.080,Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm500284x,Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.,1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.08.007,Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.,1
374719,10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.9b01769,Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2021.116531,Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV‑1 non-nucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
374719,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112237,In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.,1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1016/j.bmc.2010.03.007,Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.,1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmc.2010.03.007,Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.,1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/acs.jmedchem.8b01238,Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.,1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2022.115042,Development of novel S-N<sub>3</sub>-DABO derivatives as potent non-nucleoside reverse transcriptase inhibitors with improved potency and selectivity.,1
374719,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1039/C3MD00247K,Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm101626c,"Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.bmc.2020.115927,Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.,1
374719,10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2017.07.012,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.",1
374719,10.1021/jm0407658,"4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.",10.1021/jm0408621,"4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2019.111603,Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2017.02.047,Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.,1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1021/jm070683u,From docking false-positive to active anti-HIV agent.,1
374719,10.1016/j.bmcl.2008.06.072,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm201134m,Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.,1
374719,10.1016/j.bmcl.2008.06.072,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/jm800527x,Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.,1
374719,10.1016/j.bmcl.2009.08.039,Pyrazole NNRTIs 1: design and initial optimisation of a novel template.,10.1016/j.bmcl.2009.08.043,Pyrazole NNRTIs 3: optimisation of physicochemical properties.,1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
374719,10.1016/j.ejmech.2015.10.002,"Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives.",10.1016/j.ejmech.2017.12.083,Quinoxaline derivatives as new inhibitors of coxsackievirus B5.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
374719,10.1016/j.bmcl.2009.08.043,Pyrazole NNRTIs 3: optimisation of physicochemical properties.,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",1
374719,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmcl.2013.06.093,Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.,1
374719,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1016/j.ejmech.2023.115586,Fluorine in anti-HIV drugs approved by FDA from 1981 to 2023.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2018.03.003,The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1021/acs.jmedchem.8b01729,Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles.,1
374719,10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",10.1016/j.bmc.2017.12.033,Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2020.112811,Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.,1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",1
374719,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",10.1128/aac.01455-09,"Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.",1
374719,10.1016/j.bmcl.2009.08.039,Pyrazole NNRTIs 1: design and initial optimisation of a novel template.,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",1
374719,10.1016/j.bmcl.2006.10.082,Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity.,10.1021/jm900802y,Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.,1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2018.01.016,Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.,1
374719,10.1016/j.bmcl.2008.06.072,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1039/C0MD00009D,Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.bmc.2011.05.024,"Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.",1
374719,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2023.115605,Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1016/j.bmc.2012.12.049,Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.,1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1016/j.ejmech.2022.114512,Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.,1
374719,10.1016/j.bmcl.2008.06.072,Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113868,Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.bmcl.2018.03.012,First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,1
374719,10.1016/j.ejmech.2018.10.029,Novel natural non-nucleoside inhibitors of HIV-1 reverse transcriptase identified by shape- and structure-based virtual screening techniques.,10.1021/acs.jmedchem.1c00535,Quinolinonyl Non-Diketo Acid Derivatives as Inhibitors of HIV-1 Ribonuclease H and Polymerase Functions of Reverse Transcriptase.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.8b00054,Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.,1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.bmc.2021.116239,Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.11.039,"Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.",1
374719,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
717,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1021/jm050293c,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",1
374719,10.1016/j.bmcl.2006.08.037,Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.,10.1016/j.bmc.2013.09.051,"Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.",1
374719,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,10.1016/j.ejmech.2020.113051,Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1021/jm801330n,Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.,1
374719,10.1016/j.bmcl.2010.09.034,"Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.",10.1016/j.ejmech.2012.02.019,Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
374719,10.1016/j.ejmech.2020.112071,"Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root.",10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2016.06.026,"Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2016.07.047,"2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.",1
374719,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1016/j.ejmech.2024.116772,"Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acsmedchemlett.7b00524,"Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the ""NNRTI Adjacent"" Binding Site.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2018.03.059,"Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.",1
374719,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.2c02055,"<i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine as a New Class of HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor.",1
374719,10.1016/j.bmcl.2018.10.010,Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.,10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2024.116668,"Structure-based discovery of novel piperidine-biphenyl-DAPY derivatives as non-nucleoside reverse transcriptase inhibitors featuring improved potency, safety, and selectivity: From piperazine-biphenyl-DAPYs to piperidine-biphenyl-DAPYs.",1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1021/acs.jmedchem.6b00738,"Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.",1
721,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.ejmech.2015.04.046,"Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.",1
721,10.1021/acs.jmedchem.6b00562,"Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.",10.1016/j.ejmech.2018.10.016,Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors.,1
721,10.1016/j.bmc.2014.01.008,Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators.,10.1021/acs.jnatprod.7b00081,HPLC-Based Activity Profiling for GABAA Receptor Modulators in Extracts: Validation of an Approach Utilizing a Larval Zebrafish Locomotor Assay.,1
721,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1016/j.bmc.2017.02.013,"Synthesis and pharmacological evaluation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as potential GABAA-R ligands.",1
721,10.1021/jm030946u,"New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.",10.1016/j.bmc.2007.02.018,"Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.",1
721,10.1021/np9702446,"Identification of magnolol and honokiol as anxiolytic agents in extracts of saiboku-to, an oriental herbal medicine.",10.1021/acs.jnatprod.7b00081,HPLC-Based Activity Profiling for GABAA Receptor Modulators in Extracts: Validation of an Approach Utilizing a Larval Zebrafish Locomotor Assay.,1
721,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1016/j.bmc.2011.10.047,Development of ligands at γ-aminobutyrric acid type A (GABAA) receptor subtype as new agents for pain relief.,1
717,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
717,10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
717,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,1
717,10.1016/j.bmcl.2006.09.086,The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
717,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/jm501792c,Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.,1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1016/j.ejmech.2022.114957,"Disubstituted pyrimidine-5-carboxamide derivatives as novel HIV-1 NNRTIs: Crystallographic overlay-based molecular design, synthesis, and biological evaluation.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.0c00117,Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.bmc.2015.09.020,"A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.",1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/ml5003713,Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.,1
374719,10.1021/jm0407658,"4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.",10.1021/jm900802y,Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.,1
374719,10.1016/j.ejmech.2021.113204,Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
374719,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01015,"Discovery of Novel Dihydrothiopyrano[4,3-<i>d</i>]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles.",1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
374719,10.1021/jm001095i,"Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.",10.1016/j.bmc.2007.09.015,Synthesis and antiviral activity of new dimeric inhibitors against HIV-1.,1
374719,10.1016/j.bmcl.2004.04.008,5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1021/acs.jmedchem.1c00987,"Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.",1
374719,10.1021/acs.jmedchem.1c00708,Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.,10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1016/j.bmc.2013.08.040,"Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.",1
374719,10.1021/acs.jmedchem.7b00332,"Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.",10.1021/acs.jmedchem.1c01758,Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2022.114742,"A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives.",1
378216,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
378216,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
378216,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.7b01581,"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.",1
378216,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.8b01578,"Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.",1
374719,10.1016/j.ejmech.2014.05.059,Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.,10.1016/j.ejmech.2018.09.013,Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.,1
374719,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2019.111619,Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.,1
374719,10.1016/j.bmcl.2013.06.091,Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.,10.1016/j.ejmech.2016.05.054,Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.,1
374719,10.1016/j.bmcl.2012.11.115,Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.,10.1016/j.bmc.2016.07.039,Computer-aided discovery of anti-HIV agents.,1
374719,10.1021/jm800340w,"5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.",10.1039/C3MD00225J,Structure-activity evaluation of new uracil-based non-nucleoside inhibitors of HIV reverse transcriptase,1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1016/j.bmc.2012.04.030,"Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.",1
374719,10.1016/j.ejmech.2019.111874,Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.,10.1021/acs.jmedchem.1c01676,"Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.",1
374719,10.1021/jm040829e,"Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.",10.1016/j.bmc.2011.08.060,"Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs).",1
374719,10.1016/j.ejmech.2016.10.009,Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement.,10.1016/j.ejmech.2022.114471,Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm200377r,"Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm101288t,"Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00749-08,"New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.",1
378216,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.2c00972,Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",1
378216,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b01581,"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.",1
378216,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1021/jm4003878,Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.,1
378216,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b01581,"Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis.",1
378216,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",1
378216,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00055-06,Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2008.03.011,"Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.",1
378216,10.1021/acs.jmedchem.5b01699,"Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm801374t,Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.,1
378216,10.1021/acs.jmedchem.7b00034,"7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.",10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
378216,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,10.1016/j.bmcl.2015.12.002,Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,1
378216,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1021/ml400088y,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2014.08.066,SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2010.11.093,The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00550-09,"Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2015.07.084,Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2015.12.002,Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.,1
378216,10.1021/jm901273n,Rational design of 5-phenyl-3-isoxazolecarboxylic acid ethyl esters as growth inhibitors of Mycobacterium tuberculosis. a potent and selective series for further drug development.,10.1016/j.ejmech.2013.11.007,"Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2013.07.006,A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/ml200036r,"Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.00849-10,PA-824 exhibits time-dependent activity in a murine model of tuberculosis.,1
378216,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",10.1016/j.bmcl.2014.05.062,"Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm901378u,Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains.,1
378216,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.0c01372,Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1126/science.1164571,PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmcl.2013.01.101,Small molecule modulators of Wnt/β-catenin signaling.,1
378218,10.1016/j.bmcl.2018.11.022,Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.,10.1016/j.ejmech.2020.113149,A perspective on medicinal chemistry approaches towards adenomatous polyposis coli and Wnt signal based colorectal cancer inhibitors.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.ejmech.2013.01.023,"Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.",1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmcl.2019.03.032,Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/ml400088y,"Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm901207n,"Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.01389-08,Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1128/aac.49.6.2153-2163.2005,New small-molecule synthetic antimycobacterials.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm801246z,Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm1010644,"Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
378216,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1021/acs.jmedchem.8b01578,"Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity.",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1021/jm2012276,"Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).",1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.ejmech.2021.114066,Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmcl.2015.06.060,Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs.,1
378216,10.1038/35016103,A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.,10.1016/j.bmc.2012.02.025,"Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds.",1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1073/pnas.1118370109,Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.,1
378315,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.1c00748,"Total Synthesis and Antimalarial Activity of 2-(<i>p</i>-Hydroxybenzyl)-prodigiosins, Isoheptylprodigiosin, and Geometric Isomers of Tambjamine MYP1 Isolated from Marine Bacteria.",1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.ejmech.2021.113362,Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide.,1
378218,10.1016/j.bmc.2015.07.001,Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.,10.1016/j.bmcl.2018.11.022,Identification of novel triazole inhibitors of Wnt/β-catenin signaling based on the Niclosamide chemotype.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1021/acs.jmedchem.9b01950,Structure-Activity Relationship Studies on Diversified Salicylamide Derivatives as Potent Inhibitors of Human Adenovirus Infection.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmcl.2019.06.023,SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmc.2017.01.046,Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.,1
378218,10.1016/j.bmc.2015.07.001,Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.,10.1016/j.bmc.2018.09.016,"Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.",1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1021/ml3003082,Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmcl.2022.128870,Synthesis and biological evaluation of niclosamide PROTACs.,1
378218,10.1016/j.bmc.2015.07.001,Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.,10.1016/j.bmc.2017.01.046,Benzimidazole inhibitors from the Niclosamide chemotype inhibit Wnt/β-catenin signaling with selectivity over effects on ATP homeostasis.,1
378218,10.1016/j.bmc.2015.07.001,Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.,10.1016/j.bmcl.2021.127906,Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.bmc.2015.07.001,Structure-activity studies of Wnt/β-catenin inhibition in the Niclosamide chemotype: Identification of derivatives with improved drug exposure.,1
378218,10.1021/ml100146z,Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.,10.1016/j.ejmech.2019.111922,Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?,1
378315,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
378315,10.1021/jm200265b,Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.,10.1021/jm301848w,On dihydroorotate dehydrogenases and their inhibitors and uses.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm201095h,Targeting the liver stage of malaria parasites: a yet unmet goal.,1
378315,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1016/j.bmcl.2018.03.036,"One-pot, multicomponent synthesis of 2,3-disubstituted quinazolin-ones with potent and selective activity against Toxoplasma gondii.",1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
378315,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/acsmedchemlett.8b00371,Potent Antimalarial 2-Pyrazolyl Quinolone <i>bc</i> <sub>1</sub> (Q<sub>i</sub>) Inhibitors with Improved Drug-like Properties.,1
378315,10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1021/acs.jmedchem.8b01961,Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.,10.1021/acs.jmedchem.0c00539,Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.,1
378315,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1021/acsmedchemlett.8b00371,Potent Antimalarial 2-Pyrazolyl Quinolone <i>bc</i> <sub>1</sub> (Q<sub>i</sub>) Inhibitors with Improved Drug-like Properties.,1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1021/jm400246e,Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.5b00678,"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.",1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.0c02022,Novel Antimalarial Tetrazoles and Amides Active against the Hemoglobin Degradation Pathway in <i>Plasmodium falciparum</i>.,1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/acs.jmedchem.0c01152,"Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4-b]pyridines.",1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
378315,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1039/C5MD00062A,2-Pyridylquinoloneantimalarials with improved antimalarial activity and physicochemical properties,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1039/C1MD00183C,The development of quinoloneesters as novel antimalarial agents targeting the Plasmodium falciparum bc1protein complex,1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/jm301848w,On dihydroorotate dehydrogenases and their inhibitors and uses.,1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm200718m,"Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.",1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2015.07.047,Exploring the 3-piperidin-4-yl-1H-indole scaffold as a novel antimalarial chemotype.,1
378315,10.1021/jm500147k,"Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethers.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500715u,"N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.",1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm200718m,"Synthesis, antimalarial activity, and structure-activity relationship of 7-(2-phenoxyethoxy)-4(1H)-quinolones.",1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1021/jm201184h,"Identification, design and biological evaluation of heterocyclic quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",1
378315,10.1021/jm201179h,"Identification, design and biological evaluation of bisaryl quinolones targeting Plasmodium falciparum type II NADH:quinone oxidoreductase (PfNDH2).",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/jm400246e,Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm500535j,"Aminoazabenzimidazoles, a novel class of orally active antimalarial agents.",1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.5b01485,Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.,1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/acs.jmedchem.7b00738,Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies.,1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
380567,10.1021/jm061401d,"Design, synthesis, and structure-activity relationships of a novel series of 5-alkylidenepyridazin-3(2H)-ones with a non-cAMP-based antiplatelet activity.",10.1016/j.bmcl.2010.09.031,New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities.,1
380567,10.1021/jm00122a011,"Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.",10.1016/j.bmcl.2007.11.034,"2-Substituted 4-, 5-, and 6-[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones and 2-substituted 4,5-bis[(1E)-3-oxo-3-phenylprop-1-en-1-yl]pyridazin-3(2H)-ones as potent platelet aggregation inhibitors: design, synthesis, and SAR studies.",1
378616,10.1016/j.bmcl.2008.01.042,Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.,10.1016/j.bmcl.2008.10.118,Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.,1
378616,10.1016/j.bmcl.2008.01.042,Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.,10.1021/jm9009857,"Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.",1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1021/jm400246e,Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria.,1
378315,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.8b00143,Discovery of Marinoquinolines as Potent and Fast-Acting Plasmodium falciparum Inhibitors with in Vivo Activity.,1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2011.12.096,"Benzoxaborole antimalarial agents. Part 2: Discovery of fluoro-substituted 7-(2-carboxyethyl)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.",1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.7b00621,Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.,1
378315,10.1021/jm201642z,Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.,10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1016/j.ejmech.2016.09.029,Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold.,10.1016/j.ejmech.2021.113722,Antiplasmodial 2-thiophenoxy-3-trichloromethyl quinoxalines target the apicoplast of Plasmodium falciparum.,1
378315,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.2c02092,"Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4.",1
378315,10.1021/jm1007903,Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity.,10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1016/j.ejmech.2018.01.039,Antiplasmodial and antimalarial activities of quinolone derivatives: An overview.,1
378315,10.1021/jm200015a,"Optimization of 1,2,3,4-tetrahydroacridin-9(10H)-ones as antimalarials utilizing structure-activity and structure-property relationships.",10.1021/jm500942v,Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.,1
378315,10.1021/acs.jmedchem.6b00759,"ICI 56,780 Optimization: Structure-Activity Relationship Studies of 7-(2-Phenoxyethoxy)-4(1H)-quinolones with Antimalarial Activity.",10.1021/acs.jmedchem.0c01104,"Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1<i>H</i>)-Quinolones with Single Dose Cures.",1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1016/j.bmcl.2007.09.080,Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility.,1
717,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1016/j.bmc.2014.03.018,Preliminary investigations into triazole derived androgen receptor antagonists.,1
717,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1021/jm201059s,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,1
717,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,1
717,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/acs.jmedchem.1c00681,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",1
717,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/jm501239f,Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/j.bmcl.2007.01.007,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,1
717,10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,10.1021/jm501995n,Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(00)00010-x,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(99)00118-3,"Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one.",1
717,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
717,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1021/jm501995n,Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/j.bmcl.2006.03.047,Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands.,1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1021/jm100051g,"Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.",1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1021/jm7014638,Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.,1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1021/jm070191h,Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.,1
391374,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
390877,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.ejmech.2015.02.022,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.",1
390877,10.1016/j.ejmech.2015.01.042,"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.",10.1016/j.bmc.2017.06.022,Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.,1
389718,10.1016/j.bmc.2008.05.076,Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.,10.1016/j.bmc.2020.115710,Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs.,1
389718,10.1016/j.bmc.2008.05.076,Antileishmanial activity screening of 5-nitro-2-heterocyclic benzylidene hydrazides.,10.1016/j.bmc.2014.03.044,"Exploring 5-nitrofuran derivatives against nosocomial pathogens: synthesis, antimicrobial activity and chemometric analysis.",1
384165,10.1016/j.bmcl.2007.05.007,Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.,10.1021/acs.jmedchem.9b01701,The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.,1
383750,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/ml400422a,Iron chelators in photodynamic therapy revisited: synergistic effect by novel highly active thiosemicarbazones.,1
383750,10.1016/j.ejmech.2019.111764,Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent.,10.1016/j.ejmech.2020.112349,Thiosemicarbazone-based lead optimization to discover high-efficiency and low-toxicity anti-gastric cancer agents.,1
383750,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/acs.jmedchem.6b01050,"Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.",1
383750,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm301691s,Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.,1
383750,10.1016/j.ejmech.2020.112349,Thiosemicarbazone-based lead optimization to discover high-efficiency and low-toxicity anti-gastric cancer agents.,10.1016/j.ejmech.2020.112970,"Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells.",1
383750,10.1016/j.ejmech.2019.111764,Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent.,10.1016/j.ejmech.2020.112970,"Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells.",1
383750,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm900552r,Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.,1
383750,10.1021/jm070445z,"Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.",10.1021/jm7012562,Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.,1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1016/j.bmcl.2008.07.112,Substituted aryl pyrimidines as potent and soluble TRPV1 antagonists.,1
382857,10.1021/jm070190p,Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.,10.1016/j.bmcl.2008.02.022,4-Aminopyrimidine tetrahydronaphthols: a series of novel vanilloid receptor-1 antagonists with improved solubility properties.,1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2017.11.071,Xanthine oxidase inhibitory activity of natural and hemisynthetic flavonoids from Gardenia oudiepe (Rubiaceae) in vitro and molecular docking studies.,1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",1
394996,10.1016/j.bmc.2015.07.032,Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro.,10.1016/j.bmcl.2017.05.001,QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).,1
394996,10.1016/j.bmcl.2014.08.002,Structure-based design of a novel series of azetidine inhibitors of the hepatitis C virus NS3/4A serine protease.,10.1016/j.bmcl.2017.05.001,QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).,1
394231,10.1016/j.bmcl.2006.09.015,In silico identification and biochemical characterization of novel inhibitors of NQO1.,10.1021/jm9011609,Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).,1
394231,10.1021/jm070472p,"Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.",10.1016/j.ejmech.2016.10.062,"Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.",1
394231,10.1016/j.bmcl.2006.09.015,In silico identification and biochemical characterization of novel inhibitors of NQO1.,10.1021/jm070472p,"Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.",1
394231,10.1021/jm070472p,"Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.",10.1021/jm9011609,Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).,1
394231,10.1021/jm070472p,"Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.",10.1021/acs.jmedchem.8b00124,NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.,1
394165,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2009.03.039,Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.,1
394165,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2009.07.043,Fluorinated pyridinium oximes as potential reactivators for acetylcholinesterases inhibited by paraoxon organophosphorus agent.,1
394165,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm7012826,New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin.,1
394165,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
394165,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
394165,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
394165,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/acs.jmedchem.7b01537,4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(98)00107-3,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",1
717,10.1016/j.bmcl.2006.09.086,The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.,10.1016/j.bmcl.2006.11.047,"2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.",1
717,10.1016/j.bmcl.2011.08.118,Tetrahydroquinolines as a novel series of nonsteroidal selective androgen receptor modulators: structural requirements for better physicochemical and biological properties.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
717,10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,10.1016/j.bmcl.2016.02.088,7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.,1
717,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/j.bmcl.2011.01.073,Design and synthesis of tricyclic tetrahydroquinolines as a new series of nonsteroidal selective androgen receptor modulators (SARMs).,1
717,10.1016/j.bmcl.2008.03.062,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
717,10.1016/j.bmcl.2008.03.085,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,10.1016/j.ejmech.2022.114119,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,1
717,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1016/j.bmcl.2004.10.085,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",1
666,10.1021/jm980414r,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent.,10.1016/s0960-894x(99)00603-4,Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.,1
666,10.1016/j.ejmech.2014.06.015,Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.,10.1016/j.ejmech.2019.111939,New desulfured troglitazone derivatives: Improved synthesis and biological evaluation.,1
666,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/j.bmcl.2006.09.028,"Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.",1
666,10.1124/dmd.110.035105,Identification of clinically used drugs that activate pregnane X receptors.,10.1021/acs.jmedchem.0c02245,"Designing Out PXR Activity on Drug Discovery Projects: A Review of Structure-Based Methods, Empirical and Computational Approaches.",1
666,10.1021/jm9804127,N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.,10.1016/s0960-894x(99)00603-4,Synthesis and biological activity of a novel series of indole-derived PPARgamma agonists.,1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1039/d3md00316g,"Past, present and future of xanthine oxidase inhibitors: design strategies, structural and pharmacological insights, patents and clinical trials.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2017.06.059,"Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors.",1
635,10.1021/jm00147a034,"Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.",10.1021/jm960240i,"Synthesis, structure-activity relationships, and molecular modeling studies of N-(indol-3-ylglyoxylyl)benzylamine derivatives acting at the benzodiazepine receptor.",1
635,10.1021/jm00147a034,"Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.",10.1021/jm9800301,"N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological action on brain benzodiazepine receptors.",1
635,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1021/acs.jmedchem.7b01151,"Identification of a New Pyrazolo[1,5-a]quinazoline Ligand Highly Affine to γ-Aminobutyric Type A (GABAA) Receptor Subtype with Anxiolytic-Like and Antihyperalgesic Activity.",1
635,10.1021/jm00147a034,"Benzodiazepine receptor binding and anticonflict activity in a series of 3,6-disubstituted pyridazino[4,3-c]isoquinolines devoid of anticonvulsant properties.",10.1021/jm991131h,"3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands.",1
605,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.ejmech.2019.111736,"Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.",1
605,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
605,10.1016/j.bmc.2009.05.079,"Tetrahydroisoquinolines as dopaminergic ligands: 1-Butyl-7-chloro-6-hydroxy-tetrahydroisoquinoline, a new compound with antidepressant-like activity in mice.",10.1016/j.bmcl.2013.08.062,"Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.",1
605,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2016.09.061,"Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2020.112077,"Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.bmc.2018.02.013,Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout.,1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2021.113928,"Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2017.09.051,"Design, synthesis and biological evaluation of N-(4-alkoxy-3-cyanophenyl)isonicotinamide/nicotinamide derivatives as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2017.09.051,"Design, synthesis and biological evaluation of N-(4-alkoxy-3-cyanophenyl)isonicotinamide/nicotinamide derivatives as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2017.01.049,"Discovery and biological evaluation of some (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,1
717,10.1016/j.bmcl.2004.10.051,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",10.1021/acsmedchemlett.5b00173,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",1
399340,10.1021/acs.jmedchem.1c02179,Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.,10.1021/acsmedchemlett.3c00449,MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3.,1
398458,10.1053/gast.2002.36591,The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.,10.1124/dmd.111.040758,In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.,1
397074,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1039/C8MD00512E,Benzoflavone derivatives as potent antihyperuricemic agents.,1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2015.12.055,Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.,1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2019.07.062,"Targeting the subpocket in xanthine oxidase: Design, synthesis, and biological evaluation of 2-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2020.112077,"Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",1
395607,10.1016/j.bmc.2007.03.010,The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors.,10.1016/j.bmc.2012.03.019,Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.,1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,1
395607,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,1
395607,10.1016/j.bmc.2007.03.010,The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors.,10.1016/j.bmc.2012.09.060,"Trisubstituted thiophene analogues of 1-thiazolyl-2-pyrazoline, super oxidase inhibitors and free radical scavengers.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",1
395607,10.1016/j.ejmech.2017.03.002,"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor.",10.1016/j.bmcl.2017.06.059,"Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors.",1
635,10.1021/jm801599a,"Synthesis, in vivo evaluation, and molecular modeling studies of new pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide derivatives. Identification of a bifunctional hydrogen bond area related to the inverse agonism.",10.1021/jm1001887,"New fluoro derivatives of the pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide system: evaluation of fluorine binding properties in the benzodiazepine site on γ-aminobutyrric acid type A (GABA(A)) receptor. Design, synthesis, biological, and molecular modeling investigation.",1
402280,10.1016/j.bmcl.2009.09.066,Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
402280,10.1016/j.bmcl.2013.12.089,Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
402280,10.1016/j.bmcl.2009.09.066,Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.,10.1016/j.bmcl.2010.12.054,Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.,1
401141,10.1021/jm00048a008,"Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates.",10.1021/jm800279t,X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/jm0109558,"An orally active, water-soluble neurokinin-1 receptor antagonist suitable for both intravenous and oral clinical administration.",1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/jm800219f,The many roles for fluorine in medicinal chemistry.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/acsmedchemlett.1c00264,Discovery of the First Non-cGMP Mimetic Small Molecule Activators of cGMP-Dependent Protein Kinase 1 α (PKG1α).,1
399361,10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,10.1016/j.bmcl.2013.12.033,Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1016/j.bmcl.2007.08.028,Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/acs.jmedchem.1c00790,"Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.",1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1016/j.bmcl.2018.09.016,Methyl-containing pharmaceuticals: Methylation in drug design.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1016/j.bmcl.2006.06.035,Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/jm2017072,Identification of a crucial amino acid in the helix position 6.51 of human tachykinin neurokinin 1 and 3 receptors contributing to the insurmountable mode of antagonism by dual NK₁/NK₃ antagonists.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1021/acs.jmedchem.1c00793,Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity.,1
399361,10.1021/jm980299k,"Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.",10.1016/j.bmcl.2006.06.044,"Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivatives.",1
399340,10.1021/acs.jmedchem.1c02179,Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells.,10.1039/d2md00199c,A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acsmedchemlett.8b00423,Novel Isoxazole Derivatives with Potent FXR Agonistic Activity Prevent Acetaminophen-Induced Liver Injury.,1
404691,10.1016/j.bmcl.2008.09.027,"Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
404691,10.1016/j.bmcl.2006.05.084,Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.,10.1016/j.bmc.2011.09.039,Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.,1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/jm070633p,"Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.",1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/jm201004p,"Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2016.06.039,Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.,1
404691,10.1016/j.bmc.2011.09.039,Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.,10.1039/C8MD00272J,Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm500889f,Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).,1
404691,10.1021/jm3002718,"Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.",10.1021/acs.jmedchem.6b01287,Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmcl.2012.03.057,"Nelumal A, the active principle from Ligularia nelumbifolia, is a novel farnesoid X receptor agonist.",1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/jm501273r,Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/ml400247k,Probing the Binding Site of Bile Acids in TGR5.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm0707931,"Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.",1
403465,10.1021/jm070849r,"Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.",10.1021/jm800001n,"(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.",1
403465,10.1124/jpet.105.085589,"Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.",10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
402280,10.1016/j.bmcl.2011.09.056,Identification of a novel RAMP-independent CGRP receptor antagonist.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
404691,10.1016/j.bmcl.2008.09.027,"Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.",10.1039/C8MD00272J,Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmcl.2006.03.075,Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acs.jmedchem.7b00903,Nonacidic Farnesoid X Receptor Modulators.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm201004p,"Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.",1
404691,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm500937v,Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1074/jbc.m109326200,"Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor.",1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acs.jmedchem.9b01701,The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.,1
404691,10.1039/C8MD00272J,Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.,10.1021/acs.jmedchem.1c01017,Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2015.04.035,Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.ejmech.2023.115307,Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm201004p,"Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm901390p,"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acsmedchemlett.0c00647,A New FXR Ligand Chemotype with Agonist/Antagonist Switch.,1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1016/j.bmcl.2008.09.027,"Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",1
404691,10.1021/jm3002718,"Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.",10.1016/j.ejmech.2017.02.037,"Synthesis and biological evaluations of chalcones, flavones and chromenes as farnesoid x receptor (FXR) antagonists.",1
404691,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1021/ml400247k,Probing the Binding Site of Bile Acids in TGR5.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm0582221,Farnesoid X receptor: from structure to potential clinical applications.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2012.03.016,Discovery and structural development of small molecules that enhance transport activity of bile salt export pump mutant associated with progressive familial intrahepatic cholestasis type 2.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1016/j.bmc.2008.07.046,New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines.,1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.bmc.2015.01.048,"Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists.",1
404691,10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,10.1021/acs.jmedchem.9b00770,7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1039/C9MD00264B,Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.,1
404691,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1039/C8MD00272J,Discovery of new FXR agonists based on 6-ECDCA binding properties by virtual screening and molecular docking.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmcl.2018.07.026,"Lipid accumulation inhibitory activities of novel isoxazole-based chenodeoxycholic acids: Design, synthesis and preliminary mechanism study.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmcl.2008.09.027,"Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acs.jmedchem.7b00398,A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.,1
404691,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1021/acs.jmedchem.7b00295,Synthesis and Biological Evaluation of Bile Acid Analogues Inhibitory to Clostridium difficile Spore Germination.,1
404691,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.9b00770,7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.,1
404691,10.1016/j.bmcl.2008.09.027,"Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.",10.1021/jm201004p,"Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2007.01.046,"Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.",1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm101336m,Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm070633p,"Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.",1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
405786,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/jm5004039,"Functionally selective dopamine D₂, D₃ receptor partial agonists.",1
405366,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
405365,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
405365,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
405365,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
405365,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/jm025529g,"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.",1
404691,10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,10.1016/j.bmc.2015.01.048,"Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists.",1
404691,10.1016/j.bmcl.2006.05.084,Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.,10.1016/j.bmc.2011.09.056,Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmcl.2012.04.099,E297G mutated bile salt export pump (BSEP) function enhancers derived from GW4064: structural development study and separation from farnesoid X receptor-agonistic activity.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/jm901390p,"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.",1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1016/j.bmc.2011.09.039,Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidum.,1
404691,10.1021/jm0002127,Identification of a chemical tool for the orphan nuclear receptor FXR.,10.1021/acs.jmedchem.1c01017,Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.,1
404691,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/ml200256d,Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.,1
404691,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
407949,10.1016/j.bmcl.2007.01.059,Optimization of halopemide for phospholipase D2 inhibition.,10.1016/j.bmcl.2018.10.033,"Isoform selective PLD inhibition by novel, chiral 2,8-diazaspiro[4.5]decan-1-one derivatives.",1
407949,10.1016/j.bmcl.2007.01.059,Optimization of halopemide for phospholipase D2 inhibition.,10.1021/jm301782e,"Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-Triazaspiro[4.5]decane Core: discovery of Ml298 and Ml299 that decrease invasive migration in U87-MG glioblastoma cells.",1
407949,10.1016/j.bmcl.2007.01.059,Optimization of halopemide for phospholipase D2 inhibition.,10.1038/nchembio.140,Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.,1
407549,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/acs.jmedchem.9b00258,Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.,1
407549,10.1021/jm030191r,Identification and prediction of promiscuous aggregating inhibitors among known drugs.,10.1021/jm801605r,Promiscuous aggregate-based inhibitors promote enzyme unfolding.,1
407549,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
407549,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
406787,10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
406787,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1021/acs.jmedchem.3c01431,Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis.,1
406787,10.1021/acs.jmedchem.2c00386,"Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.",10.1016/j.ejmech.2023.115713,Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.,1
406787,10.1016/j.ejmech.2017.05.058,"Synthesis, antiprotozoal activity, and chemoinformatic analysis of 2-(methylthio)-1H-benzimidazole-5-carboxamide derivatives: Identification of new selective giardicidal and trichomonicidal compounds.",10.1021/acs.jmedchem.0c00910,Anti-Giardia Drug Discovery: Current Status and Gut Feelings.,1
405786,10.1021/acs.jmedchem.1c01353,Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Bitopic Ligands.,10.1021/acs.jmedchem.3c00417,Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D<sub>3</sub> (D<sub>3</sub>R) and μ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics.,1
405786,10.1016/j.ejmech.2021.113190,Pharmacological characterization of a new series of carbamoylguanidines reveals potent agonism at the H<sub>2</sub>R and D<sub>3</sub>R.,10.1021/acs.jmedchem.1c00692,Abolishing Dopamine D<sub>2long</sub>/D<sub>3</sub> Receptor Affinity of Subtype-Selective Carbamoylguanidine-Type Histamine H<sub>2</sub> Receptor Agonists.,1
405786,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/acs.jmedchem.9b00412,Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D<sub>3</sub> Receptor (D<sub>3</sub>R) Ligand Promiscuity across Highly Conserved Aminergic G-Protein-Coupled Receptors (GPCRs).,1
405786,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/jm300482h,Molecular determinants of selectivity and efficacy at the dopamine D3 receptor.,1
405786,10.1016/j.bmc.2011.04.021,Synthesis and characterization of selective dopamine D₂ receptor ligands using aripiprazole as the lead compound.,10.1021/acs.jmedchem.1c01353,Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D<sub>2</sub>/D<sub>3</sub> Receptor Bitopic Ligands.,1
605,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.ejmech.2011.08.002,Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.,1
605,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.bmc.2014.11.008,"Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.",1
605,10.1021/jm030946u,"New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.",10.1016/j.bmc.2007.05.017,"7-Arylpiperazinylalkyl and 7-tetrahydroisoquinolinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and some of their purine-2,6,8-trione analogs as 5-HT(1A), 5-HT(2A), and 5-HT(7) serotonin receptor ligands.",1
605,10.1021/jm070524a,Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.,10.1016/j.ejmech.2017.09.021,NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation.,1
605,10.1016/j.bmc.2007.07.029,The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.,10.1016/j.bmc.2011.05.056,Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.,1
605,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm048980b,Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).,1
605,10.1021/jm030946u,"New arylpiperazine 5-HT(1A) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation.",10.1016/j.bmc.2007.02.018,"Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.",1
605,10.1021/jm200020a,"Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.",10.1016/j.bmcl.2014.11.036,Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.,1
601,10.1021/jm00147a022,"Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives.",10.1016/j.bmcl.2009.09.002,"Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.",1
601,10.1021/jm00006a015,Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.,10.1021/jm000339w,Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.,1
601,10.1021/jm00006a015,Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.,10.1021/jm960199j,"Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups.",1
601,10.1021/jm030064v,Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.,10.1016/j.bmc.2008.04.050,"High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.",1
601,10.1021/jm00006a015,Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.,10.1021/jm020153s,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",1
601,10.1021/jm00006a015,Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes.,10.1021/jm030064v,Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.,1
573,10.1016/j.ejmech.2017.05.047,Synthesis of a new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT1A affinities.,10.1016/j.bmc.2017.12.016,"5-HT1A and 5-HT2A receptors affinity, docking studies and pharmacological evaluation of a series of 8-acetyl-7-hydroxy-4-methylcoumarin derivatives.",1
407949,10.1016/j.bmcl.2007.01.059,Optimization of halopemide for phospholipase D2 inhibition.,10.1016/j.bmcl.2009.02.057,Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.,1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1016/j.bmcl.2005.03.102,"Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.",1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1021/jm025545d,Pyrimidinylpyrroloquinolones as highly potent and selective PDE5 inhibitors for treatment of erectile dysfunction.,1
410802,10.1021/jm060113e,A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.,10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01132,"Discovery of Novel Pyrazolo[3,4-b] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.",1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1021/jm301159y,"Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.",1
410802,10.1016/j.bmcl.2005.02.083,Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.,10.1016/j.bmcl.2005.05.090,Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.,1
410802,10.1021/acs.jmedchem.8b01209,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01120,From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.,1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1016/j.bmcl.2003.12.027,SAR development of polycyclic guanine derivatives targeted to the discovery of a selective PDE5 inhibitor for treatment of erectile dysfunction.,1
410802,10.1021/jm060113e,A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.,10.1016/j.bmcl.2018.11.043,"Design, synthesis and evaluation of N<sup>2</sup>,N<sup>4</sup>-diaminoquinazoline based inhibitors of phosphodiesterase type 5.",1
410802,10.1021/jm200644r,Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.,10.1021/acs.jmedchem.5b01813,PDEStrIAn: A Phosphodiesterase Structure and Ligand Interaction Annotated Database As a Tool for Structure-Based Drug Design.,1
410123,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1021/jm4011669,Adenosine A2A receptor as a drug discovery target.,1
410123,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1016/j.ejmech.2017.12.007,Antagonists of the adenosine A2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity.,1
410123,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1016/j.bmcl.2013.11.051,Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.,1
410123,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1021/jm1008659,"Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.",1
410123,10.1021/jm070623o,"Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.",10.1016/j.bmcl.2008.11.075,"Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.",1
408410,10.1016/j.bmc.2015.05.008,Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity.,10.1021/acs.jmedchem.8b01226,"Evaluation of Amides, Carbamates, Sulfonamides, and Ureas of 4-Prop-2-ynylidenecycloalkylamine as Potent, Selective, and Bioavailable Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5.",1
410802,10.1016/j.bmcl.2005.02.083,Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.,10.1016/j.bmc.2008.07.022,"In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.",1
410802,10.1021/jm200644r,Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.,10.1021/jm301159y,"Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5.",1
410802,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c00983,Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.,1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1016/j.bmcl.2008.09.108,Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction.,1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/j.bmcl.2014.09.082,"Design and synthesis of novel 5-(3,4,5-trimethoxybenzoyl)-4-aminopyrimidine derivatives as potent and selective phosphodiesterase 5 inhibitors: scaffold hopping using a pseudo-ring by intramolecular hydrogen bond formation.",1
410802,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
410802,10.1021/jm060113e,A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.,10.1016/j.ejmech.2019.05.026,Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model.,1
410802,10.1016/j.bmcl.2004.03.021,Identification of purine inhibitors of phosphodiesterase 7 (PDE7).,10.1016/j.bmcl.2005.02.025,Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.,1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1016/j.ejmech.2018.09.028,Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect.,1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/s0960-894x(03)00440-2,"1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.",1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c01120,From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.,1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/j.bmcl.2020.127097,Novel PDE5 inhibitors derived from rutaecarpine for the treatment of Alzheimer's disease.,1
410802,10.1016/j.bmcl.2005.02.083,Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.,10.1021/acs.jmedchem.1c00261,The Medicinal Chemistry of Caffeine.,1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",1
410802,10.1021/jm060113e,A novel series of potent and selective PDE5 inhibitors with potential for high and dose-independent oral bioavailability.,10.1039/d2md00206j,"Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.",1
418483,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
418414,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm040760a,Contribution of ionization and lipophilicity to drug binding to albumin: a preliminary step toward biodistribution prediction.,1
418414,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
417226,10.1021/np0200360,"Isolation and structure of a 20,21-epoxybufenolide series from ""Ch'an Su"".",10.1021/np049950e,Inhibitory effects of bufadienolides on interleukin-6 in MH-60 cells.,1
416772,10.1021/jm300771j,Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.,10.1021/jm400820m,Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.,1
416772,10.1021/jm300771j,Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.,10.1016/j.bmcl.2016.04.030,State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.,1
416772,10.1021/acs.jmedchem.2c01632,Discovery of a Series of 5-Amide-1<i>H</i>-pyrazole-3-carboxyl Derivatives as Potent P2Y<sub>14</sub>R Antagonists with Anti-Inflammatory Characters.,10.1021/acs.jmedchem.4c00699,Discovery of a Series of 4-Amide-thiophene-2-carboxyl Derivatives as Highly Potent P2Y<sub>14</sub> Receptor Antagonists for Inflammatory Bowel Disease Treatment.,1
416772,10.1021/jm300771j,Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.,10.1016/j.bmcl.2022.128837,Strategies for targeting the P2Y<sub>12</sub> receptor in the central nervous system.,1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.1c00862,Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.,1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/s0960-894x(02)01036-3,Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.,1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/s0960-894x(02)00401-8,"A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5.",1
410802,10.1021/jm000336j,Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors.,10.1016/j.bmcl.2003.12.090,Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.,1
410802,10.1021/acs.jmedchem.7b00523,"Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.8b01209,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",1
410802,10.1021/jm000558h,"Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.",10.1016/j.ejmech.2012.12.009,Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.,1
410802,10.1021/acs.jmedchem.8b01209,"Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.",10.1021/acs.jmedchem.0c00983,Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.,1
410802,10.1021/jm200644r,Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors.,10.1021/acs.jmedchem.9b00123,"Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.",1
419596,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
419032,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.7b00978,"Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.",1
419032,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
419032,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2013.11.036,Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.,1
418845,10.1021/jm070849r,"Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.",10.1016/j.bmcl.2010.11.103,Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.,1
418845,10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,10.1021/acs.jmedchem.0c01033,Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.,1
418845,10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,10.1016/j.bmcl.2013.10.057,Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.,1
418845,10.1021/jm070849r,"Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.",10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,1
418845,10.1021/jm070849r,"Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.",10.1021/jm800001n,"(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.",1
418623,10.1021/jm701007g,"Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.",10.1016/j.bmcl.2020.127548,Discovery of 1-(1H-indazol-4-yl)-3-((1-phenyl-1H-pyrazol-5-yl)methyl) ureas as potent and thermoneutral TRPV1 antagonists.,1
418623,10.1021/jm701007g,"Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.",10.1021/jm100051g,"Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.",1
418623,10.1021/jm701007g,"Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.",10.1021/jm500916t,"Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.",1
418623,10.1021/jm701007g,"Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.",10.1016/j.bmcl.2010.04.047,Discovery of TRPV1 antagonist ABT-116.,1
418487,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,1
418485,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1016/j.bmcl.2022.128841,Development of an automated screen for Kv7.2 potassium channels and discovery of a new agonist chemotype.,1
418485,10.1021/acsmedchemlett.9b00097,Synthesis and Optimization of K<sub>v</sub>7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity.,10.1021/acs.jmedchem.9b00796,Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.,1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1021/jm020138n,Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists.,1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1021/jm049548x,Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics.,1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1021/jm9504722,Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.,1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1021/jm9904147,"Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists.",1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1016/j.bmc.2010.10.043,Angiotensin II receptor type 1 (AT1) selective nonpeptidic antagonists--a perspective.,1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1021/jm010457z,"Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.",1
421066,10.1021/jm00074a018,A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.,10.1016/S0960-894X(01)80526-6,Imidazolinones as nonpeptide angiotensin II receptor antagonists,1
421007,10.1021/jm1005034,"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.",10.1021/jm4014136,"Design and synthesis of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (citalopram) analogues as novel probes for the serotonin transporter S1 and S2 binding sites.",1
421007,10.1021/jm1005034,"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.",10.1016/j.bmcl.2018.09.029,Clickable photoaffinity ligands for the human serotonin transporter based on the selective serotonin reuptake inhibitor (S)-citalopram.,1
421007,10.1021/jm1005034,"Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.",10.1021/acs.jmedchem.5b00682,Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram.,1
419601,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
419601,10.1016/j.bmcl.2017.11.007,Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.,10.1016/j.bmcl.2019.126703,Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7.,1
419601,10.1016/j.bmcl.2014.01.014,Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.,10.1016/j.ejmech.2017.11.029,Recent developments in anti-Trichomonas research: An update review.,1
419601,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
419596,10.1021/jm000407e,Property-based design: optimization of drug absorption and pharmacokinetics.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
419596,10.1021/jm00164a019,"Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.",10.1021/jm070681+,"Imidazo[2,1-b]thiazole system: a scaffold endowing dihydropyridines with selective cardiodepressant activity.",1
422253,10.1016/j.bmc.2017.09.006,"1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.",10.1016/j.ejmech.2018.06.036,"5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.",1
422175,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1021/acs.jmedchem.2c01164,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",1
573,10.1016/j.ejmech.2017.05.047,Synthesis of a new series of aryl/heteroarylpiperazinyl derivatives of 8-acetyl-7-hydroxy-4-methylcoumarin with low nanomolar 5-HT1A affinities.,10.1039/C7MD00281E,Development of selective agents targeting serotonin 5HT<sub>1A</sub> receptors with subnanomolar activities based on a coumarin core.,1
556,10.1021/jm701491k,Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.,10.1021/jm300106z,"Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.",1
322,10.1021/acs.jmedchem.6b01840,Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.,10.1021/acs.jmedchem.8b00185,Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.,1
322,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2023.117468,"Design, synthesis and antiplasmodial evaluation of new amide-, carbamate-, and ureido-type harmicines.",1
322,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmcl.2021.127952,Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents.,1
322,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.ejmech.2021.113687,"Further investigation of harmicines as novel antiplasmodial agents: Synthesis, structure-activity relationship and insight into the mechanism of action.",1
322,10.1021/acs.jmedchem.6b01840,Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.,10.1016/j.ejmech.2021.114062,DYRK1A inhibitors for disease therapy: Current status and perspectives.,1
322,10.1021/acs.jmedchem.6b01840,Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.,10.1016/j.ejmech.2018.07.050,"Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.",1
322,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.bmc.2024.117734,"Discovery of harmiprims, harmine-primaquine hybrids, as potent and selective anticancer and antimalarial compounds.",1
322,10.1016/j.ejmech.2019.111927,Harmicines - harmine and cinnamic acid hybrids as novel antiplasmodial hits.,10.1016/j.ejmech.2022.114408,"Design and synthesis of harmiquins, harmine and chloroquine hybrids as potent antiplasmodial agents.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2023.115454,3-Hydroxy-pyridin-4(1H)-ones as siderophores mediated delivery of isobavachalcone enhances antibacterial activity against pathogenic Pseudomonas aeruginosa.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C6MD00357E,,1
246,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.07.057,"Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2022.114521,Discovery of novel phenylhydrazone-based oxindole-thiolazoles as potent antibacterial agents toward Pseudomonas aeruginosa.,1
426152,10.1016/j.bmc.2008.12.057,Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens.,10.1021/jm100062h,Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.,1
426110,10.1016/j.ejmech.2016.06.048,Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.,10.1016/j.ejmech.2018.09.057,"Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs.",1
426110,10.1016/j.ejmech.2016.06.048,Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening.,10.1021/acsmedchemlett.9b00609,Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs).,1
425372,10.1016/j.bmc.2012.01.047,Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol.,10.1016/j.bmc.2012.10.006,Optimization of thiazole analogues of resveratrol for induction of NAD(P)H:quinone reductase 1 (QR1).,1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1016/j.ejmech.2018.06.036,"5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/ml400009t,"4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.",1
422253,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1016/j.bmc.2017.09.006,"1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/jm501799k,Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.,1
422253,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.bmc.2017.09.006,"1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/jm400674a,"Inhibiting the HIV integration process: past, present, and the future.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/jm401040b,"6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",1
422253,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1021/acsmedchemlett.5b00230,"Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase Inhibitors.",1
422253,10.1021/jm8007085,"Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.",10.1021/acs.jmedchem.5b00159,N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase.,1
427379,10.1016/j.bmcl.2008.04.045,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,10.1021/jm8009537,"Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",1
427379,10.1016/j.bmcl.2008.04.025,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",10.1016/j.bmcl.2008.04.045,Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors.,1
427379,10.1016/j.bmcl.2008.04.025,"Identification of 1S,2R-milnacipran analogs as potent norepinephrine and serotonin transporter inhibitors.",10.1021/jm8009537,"Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain.",1
426660,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.1c00082,"Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.",1
426660,10.1021/jm301824k,"Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.",10.1016/j.bmc.2020.115876,"Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.",1
426660,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.5b01618,"Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.",1
426660,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.bmcl.2015.07.006,Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.,1
426660,10.1021/jm301824k,"Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.",10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
426660,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
426660,10.1021/jm301824k,"Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.",10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,1
426660,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2022.114442,The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.,1
426660,10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
426660,10.1021/jm301824k,"Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.",10.1021/acsmedchemlett.5b00143,Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.,1
426660,10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,10.1021/acsmedchemlett.5b00143,Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors.,1
426660,10.1016/j.vascn.2014.07.002,Prediction of Thorough QT study results using action potential simulations based on ion channel screens.,10.1021/acs.jmedchem.8b01040,"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.",1
426152,10.1016/j.bmcl.2013.09.016,Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists.,10.1021/acs.jmedchem.6b00305,Transient Receptor Potential Melastatin 8 Channel (TRPM8) Modulation: Cool Entryway for Treating Pain and Cancer.,1
433015,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1016/j.bmcl.2020.127465,Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres.,1
433015,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1053/gast.2001.24804,"LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.",1
433015,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,1
433015,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
433015,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
433015,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1016/s0014-5793(00)01596-9,Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver.,1
433015,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1074/jbc.m300909200,Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.,1
433015,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/acs.jmedchem.2c00144,Discovery of a Highly Selective and H435R-Sensitive Thyroid Hormone Receptor β Agonist.,1
433015,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
433015,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
430012,10.1021/jm500109z,"Investigation of a novel series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as human immunodeficiency virus type 1 integrase inhibitors.",10.1016/j.ejmech.2016.03.083,"2-hydroxyisoquinoline-1,3(2H,4H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4.",1
430009,10.1021/jm7014815,Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases.,10.1021/jm201292w,"Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A₂B adenosine receptor antagonists.",1
430009,10.1021/jm7014815,Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases.,10.1021/jm900413e,1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.,1
429475,10.1021/jm701191z,Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.,10.1016/j.ejmech.2017.06.045,Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).,1
429350,10.1016/j.bmcl.2019.126930,Discovery and optimization of novel pyridines as highly potent and selective glycogen synthase kinase 3 inhibitors.,10.1016/j.bmc.2023.117406,Glycogen synthase kinase-3: A potential target for diabetes.,1
427670,10.1016/j.ejmech.2022.114122,Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model.,10.1016/j.bmcl.2023.129383,Discovery of 5-((1H-indazol-3-yl) methylene)-2-thioxoimidazolidin-4-one derivatives as a new class of AHR agonists with anti-psoriasis activity in a mouse model.,1
436277,10.1016/j.bmcl.2008.01.068,"Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.",10.1021/jm1000198,Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification.,1
436277,10.1016/j.bmc.2018.11.006,"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors.",10.1016/j.bmc.2020.115351,"Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.",1
436277,10.1021/jm4006059,Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.,10.1016/j.ejmech.2016.08.026,Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.,1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2009.04.136,The discovery of the potent aurora inhibitor MK-0457 (VX-680).,1
436277,10.1021/jm4006059,Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.,10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
436277,10.1016/j.bmcl.2008.01.068,"Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.",10.1021/jm4006059,Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor.,1
436277,10.1016/j.bmc.2018.11.006,"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors.",10.1016/j.bmcl.2019.01.034,Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.,1
435188,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.bmcl.2011.06.015,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",1
434834,10.1016/j.bmc.2013.09.023,The discovery and optimization of novel dual inhibitors of topoisomerase II and histone deacetylase.,10.1016/j.ejmech.2015.03.035,"Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.",1
434834,10.1021/jm200388e,Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.,10.1016/j.bmcl.2011.06.015,"The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.",1
433015,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/acs.jmedchem.2c01669,Discovery of Highly Potent and Selective Thyroid Hormone Receptor β Agonists for the Treatment of Nonalcoholic Steatohepatitis.,1
433015,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,1
433015,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1074/jbc.m300909200,Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.,1
433015,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1210/en.2004-0058,"Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.",1
433015,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/jm4019299,"Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.",1
433015,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,10.1210/en.2004-0058,"Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.",1
436278,10.1021/jm060897w,"1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.",10.1016/j.bmcl.2008.01.068,"Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.",1
436278,10.1021/jm060897w,"1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.",10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
436278,10.1021/jm060897w,"1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.",10.1021/jm8012129,Discovery and development of aurora kinase inhibitors as anticancer agents.,1
436278,10.1021/jm060897w,"1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.",10.1016/j.ejmech.2012.07.038,The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.,1
436278,10.1016/j.bmcl.2008.01.068,"Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.",10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
436278,10.1016/j.ejmech.2012.07.038,The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.,10.1039/c4md00045e,Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.,1
436278,10.1021/jm060897w,"1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.",10.1016/j.ejmech.2020.112108,"Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition.",1
436277,10.1016/j.bmcl.2008.01.068,"Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.",10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2020.127556,The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors.,1
436277,10.1016/j.bmc.2018.11.006,"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors.",10.1016/j.bmcl.2020.127556,The synthesis and anti-tumour properties of novel 4-substituted phthalazinones as Aurora B kinase inhibitors.,1
436277,10.1021/jm5005336,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",10.1016/j.ejmech.2022.114424,"Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.",1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2016.08.026,Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design.,1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2013.04.039,"Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.",1
436277,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2012.04.066,"Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.",1
436277,10.1021/jm5005336,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",10.1016/j.ejmech.2022.114714,"Structure-based discovery of 1-(3-fluoro-5-(5-(3-(methylsulfonyl)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)phenyl)-3-(pyrimidin-5-yl)urea as a potent and selective nanomolar type-II PLK4 inhibitor.",1
442013,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jnatprod.0c01327,Marine Bile Natural Products as Agonists of the TGR5 Receptor.,1
442013,10.1021/jm00399a007,"Bile acids with a cyclopropyl-containing side chain. 3. Separation, identification, and properties of all four stereoisomers of 3 alpha,7 beta-dihydroxy-22,23-methylene-5 beta-cholan-24-oic acid.",10.1021/jm9508503,"Synthesis and physicochemical, biological, and pharmacological properties of new bile acids amidated with cyclic amino acids.",1
442013,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
438618,10.1016/j.bmc.2007.10.060,Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.,10.1016/j.bmc.2009.05.027,Benzhydrylquinazolinediones: novel cytosolic phospholipase A2alpha inhibitors with improved physicochemical properties.,1
438618,10.1016/j.bmc.2007.10.060,Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.,10.1021/jm8009876,Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors.,1
438486,10.1016/j.bmc.2007.10.021,Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors.,10.1021/jm301755q,Novel inhibitors of protein arginine deiminase with potential activity in multiple sclerosis animal model.,1
437583,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1016/j.ejmech.2018.01.085,Recent updates for designing CCR5 antagonists as anti-retroviral agents.,1
437583,10.1016/j.bmcl.2007.12.058,Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.,10.1016/j.bmcl.2010.03.095,"Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.",1
437583,10.1016/j.bmcl.2007.12.058,Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.,10.1016/j.ejmech.2018.01.085,Recent updates for designing CCR5 antagonists as anti-retroviral agents.,1
437583,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/acs.jmedchem.6b01309,Structural Analysis of Chemokine Receptor-Ligand Interactions.,1
437583,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/acs.jmedchem.8b01077,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",1
437583,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/acs.jmedchem.2c01383,Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.,1
437583,10.1021/acs.jmedchem.8b01077,"Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists.",10.1021/acs.jmedchem.2c01383,Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability.,1
437583,10.1016/j.bmcl.2007.12.058,Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",1
437583,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/jm401101p,Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.,1
437583,10.1016/j.bmcl.2007.12.058,Anti-HIV-1 entry optimization of novel imidazopiperidine-tropane CCR5 antagonists.,10.1021/acs.jmedchem.6b01309,Structural Analysis of Chemokine Receptor-Ligand Interactions.,1
443348,10.1016/j.ejmech.2007.08.005,"Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.",10.1016/j.bmc.2015.05.026,"Synthesis, molecular docking and biological evaluation of 3-arylfuran-2(5H)-ones as anti-gastric ulcer agent.",1
442830,10.1016/j.ejmech.2016.03.057,Multi-target screening mines hesperidin as a multi-potent inhibitor: Implication in Alzheimer's disease therapeutics.,10.1016/j.bmc.2023.117536,Hesperidin Methyl Chalcone reduces extracellular Aβ<sub>(25-35)</sub> peptide aggregation and fibrillation and also protects Neuro 2a cells from Aβ<sub>(25-35)</sub> induced neuronal dysfunction.,1
442573,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1021/acs.jmedchem.6b01217,"Design, Synthesis, and Biological Evaluation of Novel Tetrahydroprotoberberine Derivatives (THPBs) as Selective α1A-Adrenoceptor Antagonists.",1
442573,10.1016/j.bmc.2012.12.016,"Asymmetric total synthesis and identification of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D(1), D(2) and serotonin 5-HT(1A) multi-action profile.",10.1016/j.bmc.2019.04.014,"Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.",1
442375,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/jm501273r,Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.,1
442375,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
442375,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jmedchem.9b00770,7-Methylation of Chenodeoxycholic Acid Derivatives Yields a Substantial Increase in TGR5 Receptor Potency.,1
442375,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1039/d0md00425a,Structural modifications that increase gut restriction of bile acid derivatives,1
442373,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2015.09.024,Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.,1
442342,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2015.09.024,Mutational mapping of the transmembrane binding site of the G-protein coupled receptor TGR5 and binding mode prediction of TGR5 agonists.,1
442313,10.1053/gast.2002.36591,The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.,10.1152/ajpgi.00360.2003,Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump.,1
442313,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
442077,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/acs.jnatprod.0c01327,Marine Bile Natural Products as Agonists of the TGR5 Receptor.,1
442077,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.ejmech.2024.116462,Update on the development of TGR5 agonists for human diseases.,1
442013,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1021/jm501273r,Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.,1
442013,10.1021/jm7015864,"Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.",10.1016/j.bmc.2015.01.048,"Stereoselective synthesis, biological evaluation, and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1 (GP-BAR1, TGR5) agonists.",1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2016.04.036,"Design, synthesis and biological evaluation of 5-fluorouracil-derived benzimidazoles as novel type of potential antimicrobial agents.",1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2019.04.043,"Antibacterial activity study of 1,2,4-triazole derivatives.",1
246,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1016/j.ejmech.2024.116626,Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2016.04.070,Discovery of novel berberine imidazoles as safe antimicrobial agents by down regulating ROS generation.,1
444750,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
444750,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
444750,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,10.1016/j.bmc.2020.115437,"A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening.",1
444750,10.1016/j.bmc.2020.115902,Structure-guided optimization of D-captopril for discovery of potent NDM-1 inhibitors.,10.1016/j.ejmech.2024.116140,Fluorinated captopril analogues inhibit metallo-β-lactamases and facilitate structure determination of NDM-1 binding pose.,1
443348,10.1016/j.ejmech.2018.08.098,"Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.",10.1021/acsmedchemlett.9b00193,"Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase.",1
443348,10.1016/j.bmcl.2013.06.042,"Novel pyrazoline amidoxime and their 1,2,4-oxadiazole analogues: synthesis and pharmacological screening.",10.1016/j.ejmech.2018.07.007,Current progress on antioxidants incorporating the pyrazole core.,1
443348,10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,10.1016/j.bmcl.2016.06.005,Synthesis of lignan conjugates via cyclopropanation: Antimicrobial and antioxidant studies.,1
443348,10.1016/j.ejmech.2007.08.005,"Synthesis and biological activities of a series of 4,5-diaryl-3-hydroxy-2(5H)-furanones.",10.1016/j.ejmech.2019.03.021,Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.,1
443348,10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,10.1007/s00044-012-0269-6,"Synthesis of some new glutamine linked 2,3-disubstituted quinazolinone derivatives as potent antimicrobial and antioxidant agents",1
443348,10.1016/j.ejmech.2011.02.052,Novel dihydropyrimidines and its pyrazole derivatives: synthesis and pharmacological screening.,10.1016/j.ejmech.2018.07.007,Current progress on antioxidants incorporating the pyrazole core.,1
443348,10.1016/j.bmcl.2015.01.010,Schiff's bases of quinazolinone derivatives: Synthesis and SAR studies of a novel series of potential anti-inflammatory and antioxidants.,10.1016/j.bmcl.2021.128002,Novel iodinated quinazolinones bearing sulfonamide as new scaffold targeting radiation induced oxidative stress.,1
443348,10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,10.1016/j.bmcl.2015.11.038,Synthesis of novel coumarin appended bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities.,1
444750,10.1016/j.bmcl.2016.03.004,Fragment-based discovery of inhibitor scaffolds targeting the metallo-β-lactamases NDM-1 and VIM-2.,10.1021/acs.jmedchem.7b00407,Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-β-lactamase-1.,1
444750,10.1016/j.bmcl.2018.02.025,Virtual target screening reveals rosmarinic acid and salvianolic acid A inhibiting metallo- and serine-β-lactamases.,10.1021/acs.jmedchem.9b00735,"Structure-Based Development of (1-(3'-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-β-lactamases.",1
444750,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
444750,10.1016/j.bmcl.2012.08.040,"Chiral separation, configurational identification and antihypertensive evaluation of (±)-7,8-dihydroxy-3-methyl-isochromanone-4.",10.1016/j.bmc.2012.09.043,Novel nitric oxide-releasing isochroman-4-one derivatives: Synthesis and evaluation of antihypertensive activity.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116293,"Design, synthesis and antibacterial evaluation of low toxicity amphiphilic-cephalosporin derivatives.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,1
246,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2024.116392,Discovery of indolylacryloyl-derived oxacins as novel potential broad-spectrum antibacterial candidates.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2022.114891,Novel coumarin aminophosphonates as potential multitargeting antibacterial agents against Staphylococcus aureus.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116626,Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1021/acs.jmedchem.4c00238,Cyanomethylquinolones as a New Class of Potential Multitargeting Broad-Spectrum Antibacterial Agents.,1
246,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.11.032,"Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2023.115452,Thiazolyl hydrazineylidenyl indolones as unique potential multitargeting broad-spectrum antimicrobial agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.2c00001,Unique Carbazole-Oxadiazole Derivatives as New Potential Antibiotics for Combating Gram-Positive and -Negative Bacteria.,1
246,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",1
451253,10.1021/jm030776l,Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.,10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
451253,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm300514y,"Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.",1
449724,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/jm4004279,Approaches to protozoan drug discovery: phenotypic screening.,1
449724,10.1038/nature09107,Thousands of chemical starting points for antimalarial lead identification.,10.1021/jm500191u,Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei.,1
447948,10.1016/j.bmcl.2008.05.064,Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.,10.1021/jm801252w,"Discovery of begacestat, a Notch-1-sparing gamma-secretase inhibitor for the treatment of Alzheimer's disease.",1
447948,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm301741t,"Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.",1
447948,10.1016/j.bmcl.2008.05.064,Discovery of a novel series of Notch-sparing gamma-secretase inhibitors.,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,1
446786,10.1021/jm800824d,Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs.,10.1021/jm2004706,Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia.,1
446784,10.1021/jm991165p,"Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.",10.1021/jm301543e,Orvinols with mixed kappa/mu opioid receptor agonist activity.,1
446784,10.1021/jm991165p,"Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.",10.1021/acs.jmedchem.5b00130,"C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors.",1
446784,10.1021/jm991165p,"Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.",10.1021/jm401964y,Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity.,1
446784,10.1021/jm991165p,"Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.",10.1021/jm2003238,Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine.,1
446784,10.1021/jm991165p,"Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.",10.1021/jm070255o,"Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.",1
446432,10.1021/acs.jmedchem.9b00995,Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.,10.1021/acs.jmedchem.0c01883,Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343.,1
445395,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
445395,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
453548,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
453228,10.1016/j.bmcl.2013.02.028,Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.,10.1016/j.bmcl.2015.11.004,Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.,1
452533,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2017.12.070,Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.,1
452533,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2024.129775,"Synthesis and cytotoxicity of novel 6,8,9-trisubstituted purine analogs against liver cancer cells.",1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1016/j.bmcl.2012.10.075,Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.,1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1016/j.ejmech.2023.115172,Application and synthesis of thiazole ring in clinically approved drugs.,1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1021/jm401507s,"Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor.",1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1128/aac.01058-08,"In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.",1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1128/aac.01452-09,In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.,1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1021/jm401396p,"Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.",1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1016/j.bmcl.2010.10.071,Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.,1
451744,10.1016/j.bmcl.2008.07.088,Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.,10.1016/j.bmc.2010.05.027,Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.,1
451253,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1016/j.bmcl.2014.07.063,"Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.",1
451253,10.1021/jm0110340,Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.,10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
451253,10.1021/jm030776l,Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.,10.1021/jm040217u,The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.,1
451253,10.1021/jm060904g,"SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.",10.1021/jm800582j,Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.,1
457258,10.1016/j.bmcl.2009.01.024,The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.,10.1016/j.bmcl.2014.06.033,The discovery of indole full agonists of the neurotensin receptor 1 (NTSR1).,1
457258,10.1016/j.bmcl.2009.01.024,The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.,10.1016/j.bmcl.2013.11.026,Imidazole-derived agonists for the neurotensin 1 receptor.,1
457258,10.1016/j.bmcl.2009.01.024,The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.,10.1021/jm5003843,Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.,1
457258,10.1016/j.bmcl.2009.01.024,The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.,10.1021/acs.jmedchem.9b00340,"Discovery of β-Arrestin Biased, Orally Bioavailable, and CNS Penetrant Neurotensin Receptor 1 (NTR1) Allosteric Modulators.",1
456580,10.1021/jm101554k,Identification of inhibitors that block vaccinia virus infection by targeting the DNA synthesis processivity factor D4.,10.1021/acs.jmedchem.3c00069,An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses.,1
455596,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1021/acs.jmedchem.6b00608,"4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.",1
455596,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1021/ml4003309,Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.,1
455596,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1016/j.ejmech.2013.10.037,New aminopyrimidine derivatives as inhibitors of the TAM family.,1
455243,10.1021/jm901650u,Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates.,10.1016/j.bmcl.2010.12.123,Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.,1
455140,10.1016/j.bmc.2014.08.034,"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.",10.1021/acs.jmedchem.5b00832,Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,1
454842,10.1021/jm801332q,"Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.",10.1016/j.bmcl.2022.128554,"Discovery of DS-3801b, a non-macrolide GPR38 agonist with N-methylanilide structure.",1
454374,10.1021/acs.jmedchem.7b00472,"Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells.",10.1021/acs.jmedchem.0c01561,"Design, Synthesis, and Biological Evaluation of a Series of Oxazolone Carboxamides as a Novel Class of Acid Ceramidase Inhibitors.",1
454365,10.1016/j.ejmech.2020.113041,"Structural modifications in the distal, regulatory region of histamine H receptor antagonists leading to the identification of a potent anti-obesity agent.",10.1021/acs.jmedchem.3c00430,Dual Piperidine-Based Histamine H<sub>3</sub> and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain.,1
454365,10.1016/j.ejmech.2020.112743,Rational design of new multitarget histamine H receptor ligands as potential candidates for treatment of Alzheimer's disease.,10.1021/acs.jmedchem.3c00430,Dual Piperidine-Based Histamine H<sub>3</sub> and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain.,1
453827,10.1016/j.ejmech.2017.03.062,Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease.,10.1016/j.bmcl.2022.128602,"Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors.",1
453570,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmcl.2013.12.050,Synthesis and evaluation of 4-(2-pyrimidinylamino) benzamides inhibitors of hedgehog signaling pathway.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmcl.2014.05.066,"Five-membered heteroaromatic ring fused-pyrimidine derivatives: design, synthesis, and hedgehog signaling pathway inhibition study.",1
460092,10.1021/ml300172p,Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.,10.1016/j.bmcl.2016.03.013,Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmcl.2015.06.049,Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.ejmech.2018.02.034,Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmc.2013.12.055,"Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.",1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1021/acs.jmedchem.7b00794,Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmcl.2013.10.022,The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors.,1
460092,10.1016/j.bmcl.2015.06.049,Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.,10.1016/j.ejmech.2019.03.057,Structural optimization on a virtual screening hit of smoothened receptor.,1
460092,10.1016/j.bmcl.2014.03.079,Scaffold hopping approach to a new series of smoothened antagonists.,10.1016/j.ejmech.2018.05.035,Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.,1
459679,10.1016/j.ejmech.2015.03.052,"Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.",10.1016/j.bmc.2018.09.012,"Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.",1
459679,10.1016/j.ejmech.2015.03.052,"Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.",10.1016/j.ejmech.2016.09.055,"Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.",1
459205,10.1016/j.bmcl.2009.02.049,Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.,10.1021/jm201271b,Discovery and development of spleen tyrosine kinase (SYK) inhibitors.,1
458773,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1016/j.ejmech.2022.114631,Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.,1
458773,10.1021/acs.jmedchem.0c00060,Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.,10.1021/acs.jmedchem.3c02087,Discovery of 4-Ethoxy-6-chloro-5-azaindazoles as Novel PDE4 Inhibitors for the Treatment of Alcohol Use Disorder and Alcoholic Liver Diseases.,1
457258,10.1016/j.bmcl.2009.01.024,The identification of nonpeptide neurotensin receptor partial agonists from the potent antagonist SR48692 using a calcium mobilization assay.,10.1016/j.ejmech.2011.01.047,The many faces of the adamantyl group in drug design.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2022.114657,An unanticipated discovery of novel naphthalimidopropanediols as potential broad-spectrum antibacterial members.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2024.116219,Novel aminothiazoximone-corbelled ethoxycarbonylpyrimidones with antibiofilm activity to conquer Gram-negative bacteria through potential multitargeting effects.,1
246,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1021/acs.jmedchem.4c00238,Cyanomethylquinolones as a New Class of Potential Multitargeting Broad-Spectrum Antibacterial Agents.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.bmcl.2015.06.041,Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.,1
460481,10.1021/jm1013264,"Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.",10.1016/j.bmc.2013.09.001,"Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.",1
460144,10.1016/j.bmcl.2009.02.049,Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.,10.1021/jm201271b,Discovery and development of spleen tyrosine kinase (SYK) inhibitors.,1
460092,10.1021/jm1008924,"Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).",10.1016/j.bmc.2019.115227,"Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).",1
460092,10.1016/j.bmcl.2015.06.049,Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.,10.1016/j.ejmech.2017.09.002,Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.,1
460092,10.1021/ml400014t,Identification of vitamin d3-based hedgehog pathway inhibitors that incorporate an aromatic a-ring isostere.,10.1021/jm401812d,Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors.,1
460092,10.1016/j.ejmech.2018.05.035,Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.,10.1016/j.bmc.2020.115584,"Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.",1
460092,10.1016/j.bmcl.2017.06.030,Introduction of fluorine to phenyl group of 4-(2-pyrimidinylamino)benzamides leading to a series of potent hedgehog signaling pathway inhibitors.,10.1016/j.bmc.2018.08.037,Novel 4-(2-pyrimidinylamino)benzamide derivatives as potent hedgehog signaling pathway inhibitors.,1
460092,10.1016/j.bmcl.2014.03.079,Scaffold hopping approach to a new series of smoothened antagonists.,10.1016/j.bmcl.2015.06.049,Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.,1
460092,10.1016/j.bmcl.2014.03.079,Scaffold hopping approach to a new series of smoothened antagonists.,10.1016/j.ejmech.2019.03.057,Structural optimization on a virtual screening hit of smoothened receptor.,1
460092,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.ejmech.2018.05.035,Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.,1
460092,10.1016/j.ejmech.2018.05.035,Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.,10.1016/j.ejmech.2022.114867,Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy.,1
460092,10.1016/j.ejmech.2018.05.035,Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.,10.1016/j.ejmech.2019.03.057,Structural optimization on a virtual screening hit of smoothened receptor.,1
468830,10.1021/jm8001235,"Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.",10.1021/jm901420x,"Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.",1
467361,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2024.129775,"Synthesis and cytotoxicity of novel 6,8,9-trisubstituted purine analogs against liver cancer cells.",1
467361,10.1016/j.ejmech.2014.10.080,Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.,10.1016/j.bmcl.2017.12.070,Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.,1
461225,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.,1
246,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2021.113442,A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies.,1
246,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.05.054,"1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.bmcl.2022.129012,Unique iminotetrahydroberberine-corbelled metronidazoles as potential membrane active broad-spectrum antibacterial agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2022.114192,Discovery of unique thiazolidinone-conjugated coumarins as novel broad spectrum antibacterial agents.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2017.11.027,"Novel aminopyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.bmcl.2021.128198,A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents.,1
246,10.1016/j.bmcl.2010.02.060,"Design, synthesis, and biological evaluation of a novel series of quercetin diacylglucosides as potent anti-MRSA and anti-VRE agents.",10.1021/jm200010x,Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2024.116449,Novel natural osthole-inspired amphiphiles as membrane targeting antibacterials against methicillin-resistant Staphylococcus aureus (MRSA).,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C5MD00574D,Synthesis and biological evaluation of Schiff base-linked imidazolyl naphthalimides as novel potential anti-MRSA agents,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.bmcl.2022.128885,Pyrimidine-conjugated fluoroquinolones as new potential broad-spectrum antibacterial agents.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116392,Discovery of indolylacryloyl-derived oxacins as novel potential broad-spectrum antibacterial candidates.,1
469313,10.1021/jm8004527,"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.",10.1016/j.ejmech.2024.116698,"Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy.",1
469313,10.1021/jm8004527,"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.",10.1016/j.bmc.2013.11.022,"Design, synthesis and evaluation of novel indole derivatives as AKT inhibitors.",1
469313,10.1021/jm8004527,"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.",10.1016/j.bmcl.2009.01.002,Aminofurazans as potent inhibitors of AKT kinase.,1
469313,10.1021/jm8004527,"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.",10.1039/C8MD00197A,"Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.",1
469313,10.1021/jm8004527,"Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.",10.1021/acs.jmedchem.0c01901,Furazans in Medicinal Chemistry.,1
469114,10.1021/jm800416m,"Synthesis, ex vivo evaluation, and radiolabeling of potent 1,5-diphenylpyrrolidin-2-one cannabinoid subtype-1 receptor ligands as candidates for in vivo imaging.",10.1021/jm2000536,"N-(4-cyanotetrahydro-2H-pyran-4-yl) and N-(1-cyanocyclohexyl) derivatives of 1,5-diarylpyrazole-3-carboxamides showing high affinity for 18 kDa translocator protein and/or cannabinoid receptors.",1
468830,10.1021/jm8001235,"Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.",10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",1
468830,10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",10.1021/acsmedchemlett.1c00613,"Discovery of Novel Indole Derivatives as Fructose-1,6-bisphosphatase Inhibitors and X-ray Cocrystal Structures Analysis.",1
468830,10.1021/jm901420x,"Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.",10.1021/acs.jmedchem.0c00726,"Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.",1
468830,10.1021/jm901420x,"Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.",10.1016/j.ejmech.2017.09.029,"Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.",1
468830,10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",10.1021/acs.jmedchem.0c00726,"Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis.",1
468830,10.1021/jm901420x,"Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.",10.1039/C0MD00269K,"Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity",1
468830,10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",10.1039/C0MD00269K,"Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity",1
468830,10.1021/jm901420x,"Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.",10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",1
468830,10.1021/jm8001235,"Discovery of phosphonic diamide prodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors.",10.1039/C0MD00269K,"Oxazole phosphonic acids as fructose 1,6-bisphosphatase inhibitors with potent glucose-lowering activity",1
468830,10.1021/jm101035x,"Discovery of a series of phosphonic acid-containing thiazoles and orally bioavailable diamide prodrugs that lower glucose in diabetic animals through inhibition of fructose-1,6-bisphosphatase.",10.1016/j.ejmech.2017.09.029,"Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus.",1
469690,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1016/s0014-5793(00)01596-9,Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver.,1
469690,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1074/jbc.m300909200,Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.,1
469690,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
469690,10.1006/bbrc.1998.9974,Identification of thyroid hormone transporters.,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,1
469690,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/acs.jmedchem.3c01026,Targeting Glial Cells by Organic Anion-Transporting Polypeptide 1C1 (OATP1C1)-Utilizing l-Thyroxine-Derived Prodrugs.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1016/s0014-5793(00)01596-9,Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver.,1
469690,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
469690,10.1210/endo.142.5.8115,Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner.,10.1210/en.2004-0058,"Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.",1
469690,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,1
469690,10.1074/jbc.274.52.37161,A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
469690,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1074/jbc.m300909200,Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter.,1
469690,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1210/en.2004-0058,"Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.",1
469866,10.1016/j.bmcl.2020.127710,"Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.",10.1039/d3md00751k,Design and synthesis of novel chloropyridazine hybrids as promising anticancer agents acting by apoptosis induction and PARP-1 inhibition through a molecular hybridization strategy.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.bmc.2013.12.031,7-Azaindole-1-carboxamides as a new class of PARP-1 inhibitors.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2021.113357,Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2022.114574,"Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone.",1
469866,10.1016/j.ejmech.2023.115709,"Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.",10.1021/acs.jmedchem.3c02460,Design of Selective PARP-1 Inhibitors and Antitumor Studies.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2023.115709,"Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1021/acs.jmedchem.3c02460,Design of Selective PARP-1 Inhibitors and Antitumor Studies.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1021/acs.jmedchem.9b00622,Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2018.01.018,"Design and synthesis of 2-(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carboxamides as novel orally efficacious Poly(ADP-ribose)polymerase (PARP) inhibitors.",1
469866,10.1016/j.bmcl.2020.127710,"Identification of 2-substituted pyrrolo[1,2-b]pyridazine derivatives as new PARP-1 inhibitors.",10.1016/j.ejmech.2024.116535,"Poly (ADP-ribose) polymerase (PARP) inhibitors as anticancer agents: An outlook on clinical progress, synthetic strategies, biological activity, and structure-activity relationship.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2017.06.053,"Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.bmcl.2016.06.045,"Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1021/acs.jmedchem.0c01346,"Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.",1
469866,10.1021/jm400211f,Fragment-based ligand design of novel potent inhibitors of tankyrases.,10.1021/jm401356t,"Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors.",1
469690,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
469690,10.1074/jbc.274.24.17159,Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1.,10.1073/pnas.0304987101,Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acsmedchemlett.7b00222,Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1158/0008-5472.can-11-1515,Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acsmedchemlett.9b00378,Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2018.07.036,Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.6b01801,"Design and Elaboration of a Tractable Tricyclic Scaffold To Synthesize Druglike Inhibitors of Dipeptidyl Peptidase-4 (DPP-4), Antagonists of the C-C Chemokine Receptor Type 5 (CCR5), and Highly Potent and Selective Phosphoinositol-3 Kinase δ (PI3Kδ) Inhibitors.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1021/jm2007084,Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.7b01465,"Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.8b01857,Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1038/aps.2010.150,"ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2020.112913,"Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1021/acs.jmedchem.8b01946,Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1021/acs.jmedchem.5b01498,"Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.",1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.ejmech.2023.115943,Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer.,1
469866,10.1021/jm301825t,"Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.",10.1016/j.bmcl.2014.04.061,Synthesis of isoquinolinone-based tricycles as novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.,1
469866,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1016/j.ejmech.2023.116054,Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1039/C2MD20044A,Small molecules targeting phosphoinositide 3-kinases,1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.bmcl.2011.04.124,Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.,1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2014.10.022,"Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmcl.2013.02.102,Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.,1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1021/jm300867c,The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.,1
470511,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
470511,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm300867c,The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1021/jm2009327,"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2014.07.099,"Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1021/acs.jmedchem.7b00357,"Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmcl.2020.127194,"Design, synthesis and antiproliferative activity evaluation of a series of pyrrolo[2,1-f][1,2,4]triazine derivatives.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2020.112913,"Identification of methyl (5-(6-((4-(methylsulfonyl)piperazin-1-yl)methyl)-4-morpholinopyrrolo[2,1-f][1,2,4]triazin-2-yl)-4-(trifluoromethyl)pyridin-2-yl)carbamate (CYH33) as an orally bioavailable, highly potent, PI3K alpha inhibitor for the treatment of advanced solid tumors.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm3003747,Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1042/bj20140889,"Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm901284w,"Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2014.10.022,"Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2012.09.002,"Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2012.09.002,"Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno[3,2-d]pyrimidine derivatives as potential antitumor agents.",1
470511,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm2009327,"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmcl.2012.01.074,"Imidazo[1,2-a]pyrazines as novel PI3K inhibitors.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm300847w,PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmc.2016.06.032,"Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2016.03.033,"Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3Kα/mTOR inhibitors.",1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1039/C2MD20044A,Small molecules targeting phosphoinositide 3-kinases,1
470511,10.1021/jm300403a,Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.,10.1016/j.ejmech.2019.111718,Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1038/nchembio.293,The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm4003632,"Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2015.04.037,Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2020.112904,Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.6b00963,Class II Phosphoinositide 3-Kinases as Novel Drug Targets.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/ml3003132,Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/ml900028r,"Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.7b00357,"Design, Synthesis, and Biological Evaluation of Dimorpholine Substituted Thienopyrimidines as Potential Class I PI3K/mTOR Dual Inhibitors.",1
470511,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.8b01262,"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.bmcl.2011.04.124,Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm3008745,Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1016/j.ejmech.2014.07.099,"Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.",1
470511,10.1021/jm300403a,Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.,10.1021/jm300847w,PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases.,1
470511,10.1016/j.bmcl.2010.03.046,"Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
470511,10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm2007084,Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm300403a,Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/jm300717c,Potent and highly selective benzimidazole inhibitors of PI3-kinase delta.,1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1016/j.ejmech.2017.06.015,Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.,1
485738,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2020.112147,"Discovery of novel ""Dual-site"" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.",1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1016/j.ejmech.2018.08.032,Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.,1
485738,10.1016/j.bmcl.2006.02.023,Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.,10.1016/j.bmcl.2008.04.026,Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication.,1
480746,10.1016/j.bmcl.2009.11.066,Optimization of orally bioavailable alkyl amine renin inhibitors.,10.1021/acsmedchemlett.2c00280,Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.,1
480746,10.1016/j.bmc.2016.09.030,Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.,10.1021/acsmedchemlett.6b00251,"Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor.",1
480746,10.1016/j.bmc.2016.09.030,Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.,10.1016/j.bmc.2018.04.051,"Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.",1
480746,10.1016/j.bmcl.2009.11.066,Optimization of orally bioavailable alkyl amine renin inhibitors.,10.1021/ml200137x,"Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.",1
480746,10.1016/j.bmcl.2009.04.140,Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.,10.1016/j.bmcl.2009.11.066,Optimization of orally bioavailable alkyl amine renin inhibitors.,1
480746,10.1016/j.bmcl.2009.11.066,Optimization of orally bioavailable alkyl amine renin inhibitors.,10.1021/acs.jmedchem.2c00834,"Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.",1
480746,10.1016/j.bmcl.2009.04.140,Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.,10.1021/jm901885s,Direct renin inhibitors as a new therapy for hypertension.,1
480746,10.1016/j.bmcl.2009.04.140,Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.,10.1021/ml200137x,"Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.",1
480746,10.1016/j.bmcl.2009.11.066,Optimization of orally bioavailable alkyl amine renin inhibitors.,10.1021/jm901885s,Direct renin inhibitors as a new therapy for hypertension.,1
474361,10.1016/j.bmcl.2009.07.001,N-substituted bis-C-alkyloxadiazolones as dual effectors: efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials.,10.1016/j.bmcl.2010.07.124,"Reverse-benzamidine antimalarial agents: design, synthesis, and biological evaluation.",1
474361,10.1016/j.bmcl.2009.07.001,N-substituted bis-C-alkyloxadiazolones as dual effectors: efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials.,10.1016/j.bmcl.2019.06.045,Evaluation of amidoxime derivatives as prodrug candidates of potent bis-cationic antimalarials.,1
470511,10.1021/jm800295d,"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .",10.1021/acs.jmedchem.9b01499,Free-Wilson Analysis of Comprehensive Data on Phosphoinositide-3-kinase (PI3K) Inhibitors Reveals Importance of N-Methylation for PI3Kδ Activity.,1
485955,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1074/jbc.m203803200,Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice.,1
485902,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
485902,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
485738,10.1016/j.bmcl.2006.02.023,Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.,10.1016/j.bmcl.2010.10.141,Bitriazolyl acyclonucleosides synthesized via Huisgen reaction using internal alkynes show antiviral activity against tobacco mosaic virus.,1
485738,10.1021/jm401330r,Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.,10.1021/acs.jmedchem.7b00180,"Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.",1
485738,10.1021/jm401330r,Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.,10.1021/acs.jmedchem.5b01047,"Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.",1
485738,10.1021/jm401330r,Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.,10.1016/j.bmc.2015.12.008,Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.,1
485738,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,10.1016/j.ejmech.2023.115678,Rational design and optimization of acylthioureas as novel potent influenza virus non-nucleoside polymerase inhibitors.,1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1016/j.ejmech.2020.112944,"Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.",1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1021/acs.jmedchem.8b01065,Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.,1
485738,10.1016/j.bmcl.2015.05.039,"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.",10.1016/j.bmc.2020.115757,COVID-19 therapy: What weapons do we bring into battle?,1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1021/acs.jmedchem.5b00012,A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.,1
485738,10.1016/j.bmcl.2015.02.059,"Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.",10.1021/acs.jmedchem.5b01653,The Medicinal Chemistry of Dengue Virus.,1
485738,10.1016/j.bmcl.2006.02.023,Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.,10.1021/jm800927r,Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.,1
485738,10.1021/jm500300r,Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.,10.1021/acs.jmedchem.5b01935,"4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.",1
485738,10.1021/jm051229y,Identification of compounds with anti-West Nile Virus activity.,10.1021/acs.jmedchem.5b01047,"Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.",1
485955,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/mol.61.5.982,Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus.,1
485955,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/acs.jmedchem.3c01026,Targeting Glial Cells by Organic Anion-Transporting Polypeptide 1C1 (OATP1C1)-Utilizing l-Thyroxine-Derived Prodrugs.,1
485955,10.1124/jpet.105.085589,"Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.",10.1124/dmd.112.049452,Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans.,1
485955,10.1124/jpet.105.085589,"Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.",10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1039/C6MD00235H,,1
485955,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1210/en.2004-0058,"Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier.",1
485955,10.1124/jpet.105.085589,"Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.",10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
485955,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
485955,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1124/jpet.103.060194,Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1124/jpet.103.051300,Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1211/0022357021440,"Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin.",1
485955,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
485955,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1124/jpet.103.060194,Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1124/dmd.112.049452,Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans.,1
485955,10.1124/jpet.105.085589,"Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.",10.1038/nrd3028,Membrane transporters in drug development.,1
486594,10.1021/jm800043g,Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.,10.1016/j.ejmech.2011.05.031,Combined SVM-based and docking-based virtual screening for retrieving novel inhibitors of c-Met.,1
486594,10.1021/jm800043g,Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.,10.1021/jm501913a,Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.,1
486594,10.1021/jm800043g,Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.,10.1016/j.ejmech.2017.08.044,Recent advances in the discovery of small molecule c-Met Kinase inhibitors.,1
486594,10.1021/jm800043g,Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.,10.1016/j.bmcl.2009.09.096,Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.,1
486421,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1016/0016-5085(95)90588-x,Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver.,1
486421,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
486421,10.1126/science.7754369,Identification and characterization of a prostaglandin transporter.,10.1016/s0014-5793(98)00585-7,Identification of multispecific organic anion transporter 2 expressed predominantly in the liver.,1
486421,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
486353,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1124/dmd.32.3.291,Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1053/gast.2001.21176,Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1023/a:1013077609227,Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C.,1
485955,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1021/acs.jmedchem.3c01026,Targeting Glial Cells by Organic Anion-Transporting Polypeptide 1C1 (OATP1C1)-Utilizing l-Thyroxine-Derived Prodrugs.,1
485955,10.1006/bbrc.2000.2922,Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.,10.1124/dmd.104.002337,Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B.,1
485955,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1124/dmd.112.047910,Identification of multiple binding sites for substrate transport in bovine organic anion transporting polypeptide 1a2.,1
485955,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2020.112934,"Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors.",1
494066,10.1021/acsmedchemlett.7b00153,Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.,10.1021/acs.jmedchem.3c00926,Progress on the Pharmacological Targeting of Janus Pseudokinases.,1
490644,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1016/j.ejmech.2020.112426,Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.,1
490644,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1021/acsmedchemlett.9b00243,Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold.,1
490644,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1021/acs.jmedchem.9b01094,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,1
490644,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1016/j.ejmech.2020.112152,"Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.",1
490644,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,1
490151,10.1016/j.bmc.2011.01.052,"Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.",10.1016/j.bmcl.2011.02.109,"Biological evaluation of 3'-O-alkylated analogs of salacinol, the role of hydrophobic alkyl group at 3' position in the side chain on the α-glucosidase inhibitory activity.",1
490151,10.1016/j.bmc.2011.01.052,"Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.",10.1016/j.bmc.2016.06.013,"Hydrophobic substituents increase the potency of salacinol, a potent α-glucosidase inhibitor from Ayurvedic traditional medicine 'Salacia'.",1
490151,10.1016/j.bmc.2011.01.052,"Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.",10.1016/j.bmcl.2020.127751,"Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine ""Salacia,"" against human intestinal maltase.",1
490151,10.1016/j.bmc.2011.01.052,"Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.",10.1016/j.ejmech.2016.01.029,"Design, synthesis and biological evaluation of 3'-benzylated analogs of 3'-epi-neoponkoranol as potent α-glucosidase inhibitors.",1
490151,10.1016/j.bmc.2011.01.052,"Isolation, structure identification and SAR studies on thiosugar sulfonium salts, neosalaprinol and neoponkoranol, as potent α-glucosidase inhibitors.",10.1021/acs.jmedchem.2c01984,Design and Synthesis of Sulfonium Derivatives: A Novel Class of α-Glucosidase Inhibitors with Potent In Vivo Antihyperglycemic Activities.,1
489525,10.1021/jm500167q,Identification of type II and III DDR2 inhibitors.,10.1021/jm5012319,Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,1
486977,10.1124/dmd.110.035493,"Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.",10.1016/j.ejmech.2024.116593,The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective.,1
486789,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
486789,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1021/acs.jmedchem.2c01785,<i>N</i>'-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile.,1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1016/j.ejmech.2021.113654,Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.,1
495109,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,10.1021/acs.jmedchem.4c01267,"Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood-Brain Barrier-Permeable Ebola Virus Entry Inhibitors.",1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1021/acs.jmedchem.4c00527,N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.,1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acs.jmedchem.4c00527,N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.,1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2021.113654,Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.,1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acsmedchemlett.0c00298,"Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.",1
495109,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acs.jmedchem.8b00350,Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1021/acsmedchemlett.7b00153,Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2022.128950,"Targeting non-alcoholic fatty liver disease: Design, X-ray co-crystal structure and synthesis of 'first-in-kind' inhibitors of serine/threonine kinase25.",1
494066,10.1021/acsmedchemlett.7b00153,Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.,10.1016/j.ejmech.2023.115198,A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.bmcl.2013.04.039,"Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors.",1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2022.114551,Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.,1
494066,10.1021/jm800984v,"Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.",10.1016/j.ejmech.2020.112155,Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders.,1
495617,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2016.11.062,"Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.",1
495617,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.7b00978,"Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors.",1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acs.jmedchem.2c01785,<i>N</i>'-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile.,1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1021/acs.jmedchem.4c01267,"Discovery of Thiophene Derivatives as Potent, Orally Bioavailable, and Blood-Brain Barrier-Permeable Ebola Virus Entry Inhibitors.",1
495109,10.1021/acs.jmedchem.8b01328,Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.,10.1021/acsmedchemlett.0c00298,"Toward the Target: Tilorone, Quinacrine, and Pyronaridine Bind to Ebola Virus Glycoprotein.",1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1016/j.ejmech.2024.116596,(+)-fenchol and (-)-isopinocampheol derivatives targeting the entry process of filoviruses.,1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acs.jmedchem.8b01328,Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.,1
495109,10.1021/acs.jmedchem.8b01328,Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.,10.1021/acs.jmedchem.4c00527,N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.,1
495109,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,10.1021/acs.jmedchem.2c01785,<i>N</i>'-Phenylacetohydrazide Derivatives as Potent Ebola Virus Entry Inhibitors with an Improved Pharmacokinetic Profile.,1
495109,10.1021/acs.jmedchem.7b01249,Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection.,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,1
495109,10.1021/acs.jmedchem.8b01328,Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.,10.1016/j.ejmech.2022.114608,"Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.",1
495109,10.1021/acs.jmedchem.8b01328,Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library.,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,1
495109,10.1021/acs.jmedchem.0c00463,Discovery and Structural Optimization of 4-(Aminomethyl)benzamides as Potent Entry Inhibitors of Ebola and Marburg Virus Infections.,10.1016/j.ejmech.2024.116596,(+)-fenchol and (-)-isopinocampheol derivatives targeting the entry process of filoviruses.,1
495109,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,10.1021/acs.jmedchem.4c00527,N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.,1
246,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.bmcl.2024.129709,Hydrazyl hydroxycoumarins as new potential conquerors towards Pseudomonas aeruginosa.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.bmcl.2022.128695,Natural aloe emodin-hybridized sulfonamide aminophosphates as novel potential membrane-perturbing and DNA-intercalating agents against Enterococcus faecalis.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.4c00238,Cyanomethylquinolones as a New Class of Potential Multitargeting Broad-Spectrum Antibacterial Agents.,1
246,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1016/j.ejmech.2024.116392,Discovery of indolylacryloyl-derived oxacins as novel potential broad-spectrum antibacterial candidates.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2022.114188,Dihydropyrimidinone imidazoles as unique structural antibacterial agents for drug-resistant gram-negative pathogens.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1016/j.ejmech.2022.114192,Discovery of unique thiazolidinone-conjugated coumarins as novel broad spectrum antibacterial agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.2c00818,<i>N</i>-Arylimidazoliums as Highly Selective Biomimetic Antimicrobial Agents.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.2c02042,Azolylpyrimidinediols as Novel Structural Scaffolds of DNA-Groove Binders against Intractable <i>Acinetobacter baumannii</i>.,1
246,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
246,10.1016/j.ejmech.2024.116392,Discovery of indolylacryloyl-derived oxacins as novel potential broad-spectrum antibacterial candidates.,10.1021/acs.jmedchem.4c00238,Cyanomethylquinolones as a New Class of Potential Multitargeting Broad-Spectrum Antibacterial Agents.,1
499179,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2024.116782,Development of peptoid-based heteroaryl-decorated histone deacetylase (HDAC) inhibitors with dual-stage antiplasmodial activity.,1
499179,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1021/acs.jmedchem.6b01595,"Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.",1
499179,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1016/j.ejmech.2018.09.018,"One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.",1
499179,10.1021/jm801654y,Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.,10.1038/nchembio.313,Chemical phylogenetics of histone deacetylases.,1
495617,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2013.11.036,Correlation between chemotype-dependent binding conformations of HSP90α/β and isoform selectivity-Implications for the structure-based design of HSP90α/β selective inhibitors for treating neurodegenerative diseases.,1
517610,10.1016/j.ejmech.2008.12.016,"Synthesis, pharmacological and in silico evaluation of 1-(4-di-hydroxy-3,5-dioxa-4-borabicyclo[4.4.0]deca-7,9,11-trien-9-yl)-2-(tert-butylamino)ethanol, a compound designed to act as a beta2 adrenoceptor agonist.",10.1016/j.bmcl.2014.12.077,Insights on the role of boron containing moieties in the design of new potent and efficient agonists targeting the β2 adrenoceptor.,1
516838,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1021/acs.jmedchem.1c01694,Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.,1
516838,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1016/j.bmc.2019.01.018,Inhibition of a viral prolyl hydroxylase.,1
515833,10.1021/jm100034x,Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.,10.1016/j.ejmech.2020.112240,Discovery of new LXRβ agonists as glioblastoma inhibitors.,1
515421,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm301306c,Effect of helical conformation and side chain structure on γ-secretase inhibition by β-peptide foldamers: insight into substrate recognition.,1
515421,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm301741t,"Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.",1
511261,10.1021/acsmedchemlett.3c00082,Examination of the Impact of Triazole Position within Linkers on Solubility and Lipophilicity of a CDK9 Degrader Series.,10.1021/acs.jmedchem.4c00652,"Triazoles in Medicinal Chemistry: Physicochemical Properties, Bioisosterism, and Application.",1
511261,10.1016/j.bmcl.2019.05.024,Synthesis and structure activity relationships of a series of 4-amino-1H-pyrazoles as covalent inhibitors of CDK14.,10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
510462,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
508147,10.1021/jm8000373,Recent developments in fragment-based drug discovery.,10.1021/jm100009z,Fragment-based deconstruction of Bcl-xL inhibitors.,1
508147,10.1021/acs.jmedchem.7b00717,Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.,10.1021/acs.jmedchem.8b01732,Why Some Targets Benefit from beyond Rule of Five Drugs.,1
246,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1016/j.bmcl.2024.129709,Hydrazyl hydroxycoumarins as new potential conquerors towards Pseudomonas aeruginosa.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2021.114050,An unanticipated discovery towards novel naphthalimide corbelled aminothiazoximes as potential anti-MRSA agents and allosteric modulators for PBP2a.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,1
246,10.1016/j.ejmech.2024.116392,Discovery of indolylacryloyl-derived oxacins as novel potential broad-spectrum antibacterial candidates.,10.1016/j.ejmech.2024.116626,Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116219,Novel aminothiazoximone-corbelled ethoxycarbonylpyrimidones with antibiofilm activity to conquer Gram-negative bacteria through potential multitargeting effects.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,1
556755,10.1021/jm200536d,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",10.1021/jm3002372,Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer.,1
556755,10.1021/jm200536d,"Synthesis, in vivo occupancy, and radiolabeling of potent phosphodiesterase subtype-10 inhibitors as candidates for positron emission tomography imaging.",10.1021/jm3004976,Current landscape of phosphodiesterase 10A (PDE10A) inhibition.,1
555040,10.1016/j.ejmech.2010.01.046,Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.,10.1016/j.ejmech.2012.02.033,Tuberculosis: the drug development pipeline at a glance.,1
555040,10.1016/j.ejmech.2010.01.046,Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.,10.1021/jm300208p,Head-to-head prenyl tranferases: anti-infective drug targets.,1
555040,10.1016/j.ejmech.2010.01.046,Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
554892,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
528559,10.1016/j.bmcl.2011.12.001,Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.,10.1016/j.ejmech.2017.09.035,"1,3,5-Triazines: A promising scaffold for anticancer drugs development.",1
522730,10.1021/acs.jmedchem.1c01066,Discovery and Optimization of Orally Bioavailable Phthalazone and Cinnolone Carboxylic Acid Derivatives as S1P2 Antagonists against Fibrotic Diseases.,10.1016/j.ejmech.2023.115762,"Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.",1
521768,10.1016/j.bmcl.2009.02.054,Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.,10.1016/j.bmcl.2009.08.066,Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.,1
520269,10.1021/acs.jmedchem.1c02058,Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis.,10.1021/acs.jmedchem.3c02424,Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model.,1
520121,10.1016/j.bmc.2018.11.006,"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors.",10.1016/j.bmc.2020.115351,"Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.",1
520053,10.1016/j.bmc.2018.11.006,"Synthesis and identification of 2,4-bisanilinopyrimidines bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential Aurora A inhibitors.",10.1016/j.bmc.2020.115351,"Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors.",1
520053,10.1021/acsmedchemlett.2c00098,Discovery and Optimization of Seven-Membered Lactam-Based Compounds to Phenocopy the Inhibition of the Aurora Kinase B.,10.1016/j.ejmech.2022.114904,"2-Phenoxy-3, 4'-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization.",1
520053,10.1021/acs.jmedchem.6b00709,Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening.,10.1021/acs.jmedchem.9b00353,Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents.,1
559790,10.1021/jm9006559,"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.",10.1016/j.ejmech.2020.112524,Structure-activity relationships of Wee1 inhibitors: A review.,1
558931,10.1021/jm2013997,Update on the development of antagonists of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2). From lead optimization to clinical proof-of-concept in asthma and allergic rhinitis.,10.1016/j.bmcl.2013.03.093,2-(1H-Pyrazol-4-yl)acetic acids as CRTh2 antagonists.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C4MD00281D,Synthesis and biological evaluation of a new class of quinazolinoneazoles as potential antimicrobial agents and their interactions with calf thymus DNA and human serum albumin,1
246,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2019.06.093,Indole-nitroimidazole conjugates as efficient manipulators to decrease the genes expression of methicillin-resistant Staphylococcus aureus.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2024.116626,Synthesis and antibacterial medicinal evaluation of carbothioamido hydrazonyl thiazolylquinolone with multitargeting antimicrobial potential to combat increasingly global resistance.,1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.1c01592,Natural Berberine-derived Azolyl Ethanols as New Structural Antibacterial Agents against Drug-Resistant <i>Escherichia coli</i>.,1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116657,"Quaternized antimicrobial peptide mimics based on harmane as potent anti-MRSA agents by multi-target mechanism covering cell wall, cell membrane and intracellular targets.",1
246,10.1016/j.ejmech.2023.115773,Identification of unique indolylcyanoethylenyl sulfonylanilines as novel structural scaffolds of potential antibacterial agents.,10.1016/j.ejmech.2024.116215,Effective ciprofloxacin cationic antibacterial agent against persister bacteria with low hemolytic toxicity.,1
246,10.1016/j.ejmech.2023.116107,Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates.,10.1016/j.ejmech.2024.116219,Novel aminothiazoximone-corbelled ethoxycarbonylpyrimidones with antibiofilm activity to conquer Gram-negative bacteria through potential multitargeting effects.,1
246,10.1016/j.bmcl.2014.05.029,Synthesis and bioactive evaluation of a novel series of coumarinazoles.,10.1039/C5MD00186B,"Design, synthesis, and antibacterial evaluation of novel azolylthioether quinolones as MRSA DNA intercalators",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1016/j.ejmech.2023.115088,Benzenesulfonyl thiazoloimines as unique multitargeting antibacterial agents towards Enterococcus faecalis.,1
246,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
246,10.1021/acs.jmedchem.1c00334,Identification of Unique Quinazolone Thiazoles as Novel Structural Scaffolds for Potential Gram-Negative Bacterial Conquerors.,10.1021/acs.jmedchem.2c01674,Membrane-Targeting Neolignan-Antimicrobial Peptide Mimic Conjugates to Combat Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Infections.,1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/acs.jmedchem.2c01214,Lectin-Targeted Prodrugs Activated by <i>Pseudomonas aeruginosa</i> for Self-Destructive Antibiotic Release.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2021.127984,Microwave assisted regioselective synthesis of quinoline appended triazoles as potent anti-tubercular and antifungal agents via copper (I) catalyzed cycloaddition.,1
570147,10.1016/j.bmcl.2010.07.094,"Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.",10.1016/j.ejmech.2021.113669,A review on the structures and biological activities of anti-Helicobacter pylori agents.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2010.07.072,A new series of macrolide derivatives with 4''-O-saccharide substituents.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2019.03.037,"Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2012.01.023,Structure-activity relationships of novel alkylides: 3-O-arylalkyl clarithromycin derivatives with improved antibacterial activities.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2007.03.107,Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides.,1
561520,10.1016/j.bmc.2015.10.036,"Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.",10.1016/j.bmc.2016.11.012,"Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.",1
560078,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1016/j.bmcl.2015.02.045,Synthesis and biological evaluation of C-13' substituted 7'-homo-anhydrovinblastine derivatives.,1
560078,10.1016/j.bmcl.2011.10.114,Ceric ammonium nitrate-promoted oxidative coupling reaction for the synthesis and evaluation of a series of anti-tumor amide anhydrovinblastine analogs.,10.1016/j.bmcl.2012.10.024,Synthesis and structure-activity relationship studies of cytotoxic vinorelbine amide analogues.,1
560078,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1021/acs.jmedchem.6b00525,Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.,1
560078,10.1016/j.bmcl.2011.10.114,Ceric ammonium nitrate-promoted oxidative coupling reaction for the synthesis and evaluation of a series of anti-tumor amide anhydrovinblastine analogs.,10.1016/j.bmcl.2012.03.082,The effect of vindoline C-16 substituents on the biomimetic coupling reaction: synthesis and cytotoxicity evaluation of the corresponding vinorelbine analogues.,1
560078,10.1021/jm4004347,Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives.,10.1021/jm500530v,One-pot synthesis of vinca alkaloids-phomopsin hybrids.,1
559790,10.1021/jm9006559,"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.",10.1021/acs.jmedchem.7b00996,Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.,1
559790,10.1021/jm9006559,"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.",10.1021/acs.jmedchem.8b01469,Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.,1
559790,10.1039/C8MD00319J,Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.,10.1039/d2md00104g,Interrogation of the Pathogen Box reveals small molecule ligands against the mycobacterial trehalose transporter LpqY-SugABC.,1
559790,10.1021/jm9006559,"Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.",10.1021/acs.jmedchem.8b00049,How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?,1
570147,10.1016/j.bmcl.2013.03.057,Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives.,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2017.02.041,"Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2012.10.054,"Synthesis, antibacterial activity and docking of 14-membered 9-O-(3-arylalkyl) oxime 11,12-cyclic carbonate ketolides.",1
570147,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.bmc.2020.115729,"Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmc.2015.08.020,Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,1
570147,10.1016/j.bmcl.2010.07.094,"Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.",10.1016/j.ejmech.2011.12.021,"Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.",1
570147,10.1016/j.bmcl.2010.07.072,A new series of macrolide derivatives with 4''-O-saccharide substituents.,10.1016/j.bmcl.2013.09.083,Synthesis of 4″-O-desosaminyl clarithromycin derivatives and their anti-bacterial activities.,1
570147,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.bmcl.2021.128330,"Design, synthesis and antibacterial evaluation of novel 3-O-substituted 15-membered azalides possessing 1,2,3-triazole side chains.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2024.116630,"Design, synthesis and structure-activity relationships of novel non-ketolides: 9-Oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2012.12.070,"Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.",1
570147,10.1016/j.bmcl.2013.03.057,Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives.,10.1016/j.bmcl.2021.128110,"Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2009.06.023,"Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity.",1
570147,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmc.2015.08.020,Synthesis and structure-activity relationships of novel 9-oxime acylides with improved bactericidal activity.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2010.11.035,Synthesis and antibacterial evaluation of novel clarithromycin derivatives with C-4″ elongated arylalkyl groups against macrolide-resistant strains.,1
570147,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.ejmech.2022.114888,"1,2,3-Triazole-containing hybrids with potential antibacterial activity against ESKAPE pathogens.",1
571772,10.1021/jm900722z,Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",1
571772,10.1021/jm900722z,Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.,10.1039/C8MD00624E,Identification and biological evaluation of novel benzothiazole derivatives bearing a pyridine-semicarbazone moiety as apoptosis inducers <i>via</i> activation of procaspase-3 to caspase-3.,1
571772,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2016.02.003,"Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.",1
571772,10.1021/jm900722z,Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.,10.1021/acs.jmedchem.5b00413,Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.,1
571201,10.1016/j.bmc.2009.10.063,Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.,10.1016/j.bmcl.2013.09.071,Gallic acid is the major component of grape seed extract that inhibits amyloid fibril formation.,1
570962,10.1016/j.bmcl.2010.07.045,"Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.",10.1074/jbc.m113.505032,A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor.,1
570147,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.ejmech.2019.03.037,"Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.",1
570147,10.1016/j.bmcl.2019.126850,"A novel series of 11-O-carbamoyl-3-O-descladinosyl clarithromycin derivatives bearing 1,2,3-triazole group: Design, synthesis and antibacterial evaluation.",10.1016/j.bmcl.2021.128110,"Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives.",1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.ejmech.2009.11.032,"Synthesis and antibacterial activity of novel 3-O-carbamoyl derivatives of clarithromycin and 11,12-cyclic carbonate azithromycin.",1
570147,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmcl.2012.12.070,"Synthesis and antibacterial activity of 9-oxime ether non-ketolides, and novel binding mode of alkylides with bacterial rRNA.",1
570147,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.ejmech.2013.08.023,Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2013.01.067,Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2005.12.033,Synthesis and biological investigation of new 4''-malonyl tethered derivatives of erythromycin and clarithromycin.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2018.09.012,Synthesis and antibacterial activity of novel 3-O-arylalkylcarbamoyl-3-O-descladinosyl-9-O-(2-chlorobenzyl)oxime clarithromycin derivatives.,1
570147,10.1021/jm020568d,Synthesis and antibacterial activity of a novel series of acylides: 3-O-(3-pyridyl)acetylerythromycin A derivatives.,10.1016/j.bmcl.2010.03.038,Synthesis and antibacterial activities of a novel alkylide: 3-O-(3-aryl-2-propargyl) and 3-O-(3-aryl-2-propenyl)clarithromycin derivatives.,1
570147,10.1016/j.bmcl.2011.10.101,Synthesis and antibacterial activity of a novel series of acylides active against community acquired respiratory pathogens.,10.1016/j.bmcl.2017.02.041,"Design, synthesis and structure-bactericidal activity relationships of novel 9-oxime ketolides and reductive epimers of acylides.",1
573133,10.1021/acsmedchemlett.6b00468,Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach.,10.1021/acsmedchemlett.0c00216,"Identification and Development of 1,4-Diaryl-1,2,3-triazolo-Based Ureas as Novel FLT3 Inhibitors.",1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/jm100189a,Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmcl.2012.05.116,3-Phenyl-1H-5-pyrazolylamine-based derivatives as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).,1
573133,10.1021/acs.jmedchem.1c00459,"Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.",10.1016/j.ejmech.2022.114292,"Synthesis of 2H-Imidazo[2',1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations.",1
573133,10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",10.1021/acs.jmedchem.1c00459,"Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.",1
573133,10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",10.1016/j.ejmech.2020.112232,A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",1
573133,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.1c01196,Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations.,1
573133,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1016/j.ejmech.2020.112232,A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.,1
573133,10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
573133,10.1016/j.ejmech.2020.112232,A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.,10.1021/acs.jmedchem.1c00459,"Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.",1
573133,10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",10.1021/acs.jmedchem.1c01196,Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations.,1
573120,10.1016/j.ejmech.2020.112175,Repurposed drug candidates for antituberculosis therapy.,10.1016/j.ejmech.2021.114066,Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.,1
571772,10.1021/jm900722z,Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.,10.1016/j.ejmech.2014.08.058,"Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents.",1
571772,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2015.04.018,"Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.",1
571772,10.1021/jm900722z,Procaspase-3 activation as an anti-cancer strategy: structure-activity relationship of procaspase-activating compound 1 (PAC-1) and its cellular co-localization with caspase-3.,10.1016/j.bmc.2016.02.003,"Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.",1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/jm301433m,"Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters.",1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.5b01982,Tweaking Subtype Selectivity and Agonist Efficacy at (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) Receptors in a Small Series of BnTetAMPA Analogues.,1
573408,10.1021/acs.jmedchem.5b01124,"Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist.",10.1021/acs.jmedchem.3c01811,"Design, Synthesis, Pharmacology, and In Silico Studies of (1<i>S</i>,2<i>S</i>,3<i>S</i>)-2-((<i>S</i>)-Amino(carboxy)methyl)-3-(carboxymethyl)cyclopropane-1-carboxylic Acid (LBG30300): A Picomolar Potency Subtype-Selective mGlu<sub>2</sub> Receptor Agonist.",1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/acs.jmedchem.5b01333,New 4-Functionalized Glutamate Analogues Are Selective Agonists at Metabotropic Glutamate Receptor Subtype 2 or Selective Agonists at Metabotropic Glutamate Receptor Group III.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
573133,10.1021/acs.jmedchem.9b00223,"Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.",10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmc.2015.06.033,Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N'-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1039/d3md00597f,Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.,1
573133,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.bmc.2023.117155,"Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors.",1
573133,10.1021/acsmedchemlett.6b00468,Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
573133,10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
573133,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.1c00459,"Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.",1
573133,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2020.112232,A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.,1
573133,10.1021/jm9007533,"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor.",10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1016/j.ejmech.2023.115170,Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.,1
573926,10.1016/j.ejmech.2016.07.027,Synthesis and biological evaluation of a series of non-hemiacetal ester derivatives of artemisinin.,10.1016/j.bmcl.2020.127581,In vitro efficacy of synthesized artemisinin derivatives against Leishmania promastigotes.,1
573926,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
573926,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/jm060822s,"Stereoselective chemoenzymatic synthesis of the four stereoisomers of l-2-(2-carboxycyclobutyl)glycine and pharmacological characterization at human excitatory amino acid transporter subtypes 1, 2, and 3.",1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/acs.jmedchem.8b00700,Chemoenzymatic Synthesis and Pharmacological Characterization of Functionalized Aspartate Analogues As Novel Excitatory Amino Acid Transporter Inhibitors.,1
573408,10.1021/jm800865a,"1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of potent and Selective iGluR5 modulators.",10.1021/jm2004078,"Selective kainate receptor (GluK1) ligands structurally based upon 1H-cyclopentapyrimidin-2,4(1H,3H)-dione: synthesis, molecular modeling, and pharmacological and biostructural characterization.",1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.8b01986,Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands.,1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/jm301433m,"Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters.",1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/jm800091e,"Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human excitatory amino acid transporter subtype 2.",1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/jm800091e,"Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human excitatory amino acid transporter subtype 2.",1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.5b01333,New 4-Functionalized Glutamate Analogues Are Selective Agonists at Metabotropic Glutamate Receptor Subtype 2 or Selective Agonists at Metabotropic Glutamate Receptor Group III.,1
573408,10.1021/jm050597z,Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3.,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",1
573408,10.1021/acs.jmedchem.5b01982,Tweaking Subtype Selectivity and Agonist Efficacy at (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) Receptors in a Small Series of BnTetAMPA Analogues.,10.1021/acs.jmedchem.8b01986,Use of the 4-Hydroxytriazole Moiety as a Bioisosteric Tool in the Development of Ionotropic Glutamate Receptor Ligands.,1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/jm900565c,"The glutamate receptor GluR5 agonist (S)-2-amino-3-(3-hydroxy-7,8-dihydro-6H-cyclohepta[d]isoxazol-4-yl)propionic acid and the 8-methyl analogue: synthesis, molecular pharmacology, and biostructural characterization.",1
573408,10.1021/jm800092x,"Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotropic glutamate receptor subtypes 5, 6, and 7.",10.1021/acs.jmedchem.8b00700,Chemoenzymatic Synthesis and Pharmacological Characterization of Functionalized Aspartate Analogues As Novel Excitatory Amino Acid Transporter Inhibitors.,1
241,10.1016/j.bmc.2006.12.027,N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.,10.1016/j.bmcl.2012.04.056,"Synthesis and antimicrobial activities of structurally novel S,S'-bis(heterosubstituted) disulfides.",1
241,10.1016/j.bmcl.2009.06.006,The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents.,10.1016/j.ejmech.2019.02.055,"Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids.",1
573927,10.1021/acs.jmedchem.3c01406,"Synthesis, Optimization, and Structure-Activity Relationships of Nicotinamide Phosphoribosyltransferase (NAMPT) Positive Allosteric Modulators (N-PAMs).",10.1021/acs.jmedchem.3c02112,Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.6b00697,Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.,1
573927,10.1039/C5MD00261C,Identification of a novel NAMPT inhibitor by combinatorial click chemistry and chemical refinement,10.1016/j.ejmech.2019.111576,"Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.",1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4015108,Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.6b00324,Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1016/j.bmcl.2017.06.018,SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.7b00467,Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.,1
573927,10.1016/j.bmcl.2016.04.039,Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.,10.1016/j.bmc.2019.115217,Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.,1
573927,10.1016/j.ejmech.2019.111576,"Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.",10.1021/acs.jmedchem.4c00193,Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.2c01990,Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4008664,Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/acs.jmedchem.3c02112,Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death.,1
573927,10.1016/j.ejmech.2022.114504,Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.,10.1016/j.ejmech.2023.115170,Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1021/jm4001049,Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors.,1
573927,10.1021/acs.jmedchem.6b01392,Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.,10.1016/j.ejmech.2023.115170,Synthesis and structure-activity relationship of new nicotinamide phosphoribosyltransferase inhibitors with antitumor activity on solid and haematological cancer.,1
573927,10.1021/acs.jmedchem.6b01392,Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.,10.1016/j.ejmech.2019.111576,"Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.",1
573927,10.1021/acs.jmedchem.6b01392,Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity.,10.1016/j.ejmech.2022.114504,Identification of new FK866 analogues with potent anticancer activity against pancreatic cancer.,1
241,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.ejmech.2023.115930,New broad-spectrum and potent antibacterial agents with dual-targeting mechanism: Promoting FtsZ polymerization and disrupting bacterial membranes.,1
241,10.1007/s00044-010-9427-x,"Synthesis, spectral, theoretical, and antimicrobial screening of some heterocyclic oximes",10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,1
241,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
241,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2021.113442,A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies.,1
241,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.ejmech.2010.09.045,The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains.,1
241,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2013.05.003,Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.,1
241,10.1016/j.bmcl.2014.10.039,Identification and characterization of an anti-pseudomonal  dichlorocarbazol derivative displaying anti-biofilm activity.,10.1016/j.ejmech.2023.115627,Antimicrobial activity of natural and semi-synthetic carbazole alkaloids.,1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2017.09.050,4-Quinolone hybrids and their antibacterial activities.,1
241,10.1016/j.ejmech.2011.09.011,"Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.",10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
241,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2021.113266,Antitubercular properties of thiazolidin-4-ones - A review.,1
241,10.1016/j.ejmech.2008.04.010,"Synthesis and anti-microbial screening of some Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones.",10.1016/j.ejmech.2016.01.052,Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.ejmech.2010.03.002,"Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1002/jps.20373,"Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.",1
574221,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1016/j.ejmech.2023.115143,The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists.,1
574221,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/jm070633p,"Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.",1
574221,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1016/j.bmcl.2010.06.084,Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.,1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
574221,10.1016/j.bmcl.2010.06.084,Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.,10.1016/j.bmc.2011.03.004,"Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.",1
574221,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm070633p,"Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.",1
574221,10.1016/j.bmcl.2010.06.084,Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.,10.1021/acs.jmedchem.7b00907,"Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH).",1
574221,10.1016/j.bmcl.2010.06.084,Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.,10.1021/acs.jmedchem.0c01065,Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.,1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
574221,10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,10.1016/j.bmc.2021.116280,"Discovery of novel ketoxime ether derivatives with potent FXR agonistic activity, oral effectiveness and high liver/blood ratio.",1
574221,10.1021/jm060294k,"Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.",10.1021/acs.jmedchem.6b01126,"Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.",1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm0582221,Farnesoid X receptor: from structure to potential clinical applications.,1
573927,10.1021/jm400186h,Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors.,10.1016/j.bmc.2019.115217,Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening.,1
581814,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
581814,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
581767,10.1016/j.ejmech.2020.112373,Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.,10.1016/j.ejmech.2021.113967,"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.",1
581767,10.1016/j.bmc.2017.05.017,"Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.",10.1021/acs.jmedchem.0c00925,"Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.",1
581767,10.1039/C7MD00642J,"Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.",10.1021/acs.jmedchem.0c00925,"Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.",1
581767,10.1016/j.ejmech.2020.112373,Discovery of indoximod prodrugs and characterization of clinical candidate NLG802.,10.1021/acs.jmedchem.0c00925,"Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.",1
581767,10.1016/j.bmc.2017.05.017,"Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.ejmech.2017.11.088,"Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.",1
579824,10.1021/jm901525b,Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance.,10.1021/acs.jmedchem.8b00164,Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361).,1
579689,10.1021/jm00078a011,"Synthesis and pharmacological activity of a series of dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-diones, a novel class of potent cognition enhancers.",10.1021/jm991170t,"Design, synthesis, and preliminary pharmacological evaluation of 1, 4-diazabicyclo[4.3.0]nonan-9-ones as a new class of highly potent nootropic agents.",1
578235,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1021/acs.jmedchem.7b01751,"4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships.",1
578235,10.1016/j.bmcl.2009.04.012,Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.,10.1021/jm5001216,Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.,1
577488,10.1021/jm030650o,Validation of automated docking programs for docking and database screening against RNA drug targets.,10.1021/jm9000659,Design and implementation of an ribonucleic acid (RNA) directed fragment library.,1
577488,10.1016/j.ejmech.2018.08.022,Broad-spectrum antibacterial amphiphilic aminoglycosides: A new focus on the structure of the lipophilic groups extends the series of active dialkyl neamines.,10.1039/d3md00602f,Application of tobramycin benzyl ether as an antibiotic adjuvant capable of sensitizing multidrug-resistant Gram-negative bacteria to rifampicin.,1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/acsmedchemlett.7b00318,Synthesis and Biological Evaluation of a Series of Bile Acid Derivatives as FXR Agonists for Treatment of NASH.,1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1021/jm901390p,"Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.",1
574221,10.1021/jm049904b,"Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.",10.1016/j.ejmech.2022.114652,"Development of 3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-sulfate sodium salt (INT-767): Process optimization, synthesis and characterization of metabolites.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2019.126846,"The bioisosteric modification of pyrazinamide derivatives led to potent antitubercular agents: Synthesis via click approach and molecular docking of pyrazine-1,2,3-triazoles.",1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1021/jm900028n,"Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics.",1
241,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
241,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,10.1016/j.ejmech.2019.111977,One-pot synthesis and molecular docking of some new spiropyranindol-2-one derivatives as immunomodulatory agents and in vitro antimicrobial potential with DNA gyrase inhibitor.,1
241,10.1007/s00044-012-0224-6,5-Nitro-heteroarylidene analogs of 2-thiazolylimino-4-thiazolidinones as a novel series of antibacterial agents,10.1016/j.ejmech.2019.06.068,Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.,1
241,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/D1MD00230A,"Design, synthesis, and antibacterial activity of <i>N</i>-(trifluoromethyl)phenyl substituted pyrazole derivatives.",1
241,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.02.016,"Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.",1
241,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.bmc.2019.06.033,"Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids.",1
241,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.bmcl.2020.127655,Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.,1
241,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.bmcl.2014.05.002,"Studies on molecular properties prediction, antitubercular and antimicrobial activities of novel quinoline based pyrimidine motifs.",1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmcl.2006.12.005,"Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors.",1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
581814,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
581814,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,1
581814,10.1210/me.2001-0309,Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter.,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
581814,10.1021/ml300286h,Identification of Potent and Selective Diphenylpropanamide RORγ Inhibitors.,10.1021/jm401901d,Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).,1
596528,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.bmc.2021.115997,"Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.",1
596528,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2021.114055,Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.,1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1021/jm501026z,Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.,1
596408,10.1021/jm901818u,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,10.1016/j.ejmech.2014.08.045,Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors.,1
596408,10.1021/jm901818u,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,10.1021/jm100481d,"6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor.",1
596408,10.1021/jm901818u,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,10.1021/acs.jmedchem.6b01827,Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges.,1
583322,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,1
583322,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
583322,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1021/jm901421c,The permeation of amphoteric drugs through artificial membranes--an in combo absorption model based on paracellular and transmembrane permeability.,1
583322,10.1021/jm049711o,Exploring the role of different drug transport routes in permeability screening.,10.1016/j.ejmech.2009.11.034,Neural computational prediction of oral drug absorption based on CODES 2D descriptors.,1
582652,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",10.1128/aac.01455-09,"Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.",1
582652,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",10.1021/jm200990c,Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.,1
582652,10.1016/j.bmcl.2009.08.080,"Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate.",10.1021/jm100762r,Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.,1
581859,10.1021/acs.jmedchem.2c01275,Identification and Biochemical Characterization of Pyrrolidinediones as Novel Inhibitors of the Bacterial Enzyme MurA.,10.1016/j.ejmech.2023.115789,"Discovery of 1,2-diaryl-3-oxopyrazolidin-4-carboxamides as a new class of MurA enzyme inhibitors and characterization of their antibacterial activity.",1
581843,10.1021/acs.jmedchem.5b01485,Antimalarial Chemotherapy: Natural Product Inspired Development of Preclinical and Clinical Candidates with Diverse Mechanisms of Action.,10.1016/j.ejmech.2016.11.025,Comprehensive review on various strategies for antimalarial drug discovery.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1128/aac.00330-08,"Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.",1
598402,10.1016/j.ejmech.2014.05.017,Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation.,10.1016/j.ejmech.2016.01.019,Synthesis and evaluation of dual antiplatelet activity of bispidine derivatives of N-substituted pyroglutamic acids.,1
598402,10.1021/acs.jmedchem.8b01971,Optimization of P2Y<sub>12</sub> Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties.,10.1016/j.ejmech.2021.113924,"P2Y<sub>12</sub> antagonists: Approved drugs, potential naturally isolated and synthesised compounds, and related in-silico studies.",1
598402,10.1016/j.bmcl.2014.01.066,"Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.",10.1021/jm5006226,Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.,1
596528,10.1016/j.bmcl.2011.06.063,Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.,10.1039/C2MD20044A,Small molecules targeting phosphoinositide 3-kinases,1
596528,10.1016/j.bmcl.2011.06.063,Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.,10.1021/jm501026z,Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: importance of the morpholine ring.,1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
596528,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1016/j.ejmech.2021.114055,Synthesis and bioevaluation of diaryl urea derivatives as potential antitumor agents for the treatment of human colorectal cancer.,1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1016/j.bmc.2021.115997,"Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.",1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1039/C2MD20044A,Small molecules targeting phosphoinositide 3-kinases,1
596528,10.1016/j.bmcl.2011.06.063,Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1016/j.ejmech.2021.114039,Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.,1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1021/acs.jmedchem.4c00173,"Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.",1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1016/j.bmcl.2011.06.063,Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.,1
596528,10.1021/jm901830p,"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.",10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",1
596528,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2021.114039,Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.,1
602271,10.1016/j.bmc.2014.06.020,Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.,10.1016/j.ejmech.2016.06.056,"Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1.",1
241,10.1016/j.bmc.2007.07.009,"Identification, biological activity, and mechanism of the anti-ischemic quinolone analog.",10.1016/j.ejmech.2018.01.078,Ciprofloxacin derivatives and their antibacterial activities.,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2009.06.006,The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents.,1
241,10.1016/j.bmc.2022.116938,Drug screening approach against mycobacterial fatty acyl-AMP ligase FAAL32 renews the interest of the salicylanilide pharmacophore in the fight against tuberculosis.,10.1016/j.ejmech.2023.115646,Discovery of new diaryl ether inhibitors against Mycobacterium tuberculosis targeting the minor portal of InhA.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm0497895,A prodrug approach toward the development of water soluble fluoroquinolones and structure--activity relationships of quinoline-3-carboxylic acids.,1
241,10.1016/j.bmcl.2009.06.006,The synthesis and biological evaluation of a novel series of C7 non-basic substituted fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2010.03.044,"4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: novel C7 moieties of fluoroquinolones as antibacterial agents.",1
241,10.1016/j.bmcl.2016.05.088,Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.,10.1016/j.ejmech.2018.08.068,Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.,1
241,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2020.112666,Recent advancements in the development of bioactive pyrazoline derivatives.,1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,1
241,10.1016/j.ejmech.2008.07.024,"Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides.",10.1016/j.ejmech.2017.09.050,4-Quinolone hybrids and their antibacterial activities.,1
241,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2019.02.004,An optimised series of substituted N-phenylpyrrolamides as DNA gyrase B inhibitors.,1
241,10.1016/j.bmc.2015.02.016,Identification of Bacillus anthracis PurE inhibitors with antimicrobial activity.,10.1016/j.ejmech.2021.113442,A key review on oxadiazole analogs as potential methicillin-resistant Staphylococcus aureus (MRSA) activity: Structure-activity relationship studies.,1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2017.09.050,4-Quinolone hybrids and their antibacterial activities.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2019.111977,One-pot synthesis and molecular docking of some new spiropyranindol-2-one derivatives as immunomodulatory agents and in vitro antimicrobial potential with DNA gyrase inhibitor.,1
241,10.1021/acs.jmedchem.6b01834,Discovery and Optimization of Isoquinoline Ethyl Ureas as Antibacterial Agents.,10.1016/j.ejmech.2018.06.023,"N-(1,3,4-oxadiazol-2-yl)benzamide analogs, bacteriostatic agents against methicillin- and vancomycin-resistant bacteria.",1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
614499,10.1021/jm201301h,Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,10.1021/jm401937a,Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.,1
608601,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c02247,Discovery of a Potent and Selective FLT3 Inhibitor (<i>Z</i>)-<i>N</i>-(5-((5-Fluoro-2-oxoindolin-3-ylidene)methyl)-4-methyl-1<i>H</i>-pyrrol-3-yl)-3-(pyrrolidin-1-yl)propanamide with Improved Drug-like Properties and Superior Efficacy in FLT3-ITD-Positive Acute Myeloid Leukemia.,1
608601,10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
608601,10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,10.1021/acs.jmedchem.8b01594,Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.,1
608601,10.1016/j.ejmech.2015.05.008,Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.,10.1021/acs.jmedchem.9b01229,Identification of a Multitargeted Tyrosine Kinase Inhibitor for the Treatment of Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia.,1
608601,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
604615,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1021/acs.jmedchem.6b00883,"Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family.",1
604615,10.1021/jm040159c,"Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.",10.1016/j.bmc.2010.08.004,Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: synthesis and biological evaluation.,1
603308,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/jm200739e,"Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase.",1
603308,10.1021/jm9015729,"Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduced folate carrier for cellular entry.",10.1021/acs.jmedchem.8b00408,"Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.",1
602271,10.1021/acs.jmedchem.7b01039,Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.,10.1021/acs.jmedchem.2c01621,From (Tool)Bench to Bedside: The Potential of Necroptosis Inhibitors.,1
602271,10.1016/j.bmc.2014.06.020,Structure-based optimization and biological evaluation of trisubstituted pyrazole as a core structure of potent ROS1 kinase inhibitors.,10.1016/j.ejmech.2014.11.023,Synthesis and biological evaluation of new pyrazol-4-ylpyrimidine derivatives as potential ROS1 kinase inhibitors.,1
602271,10.1016/j.ejmech.2017.11.073,"Discovery, optimization and biological evaluation for novel c-Met kinase inhibitors.",10.1016/j.ejmech.2018.03.049,"Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.",1
602271,10.1016/j.ejmech.2018.07.071,Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease.,10.1021/acs.jmedchem.0c01944,Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.,1
602271,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1016/j.ejmech.2024.116475,Recent discovery and development of AXL inhibitors as antitumor agents.,1
602271,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1021/ml4003309,Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.,1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.0c01195,Recent Advances in β<sub>2</sub>-Agonists for Treatment of Chronic Respiratory Diseases and Heart Failure.,1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
624199,10.1016/j.bmcl.2009.05.027,SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.,10.1021/jm201461q,Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.,1
622556,10.1016/j.bmcl.2010.02.091,Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.,10.1016/j.ejmech.2017.08.045,A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies.,1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.bmcl.2010.02.007,"2-Cyano-3,10-dioxooleana-1,9(11)-dien-28-oic acid anhydride. A novel and highly potent anti-inflammatory and cytoprotective agent.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm101445p,Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.,1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.bmcl.2011.03.018,"Synthesis and biological evaluation of 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.bmcl.2006.09.012,"Design, synthesis, and anti-inflammatory activity both in vitro and in vivo of new betulinic acid analogues having an enone functionality in ring A.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.bmcl.2005.03.031,"Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/s0960-894x(02)00105-1,"A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm3003922,"Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.",1
620237,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm400224q,"Keap calm, and carry on covalently.",1
619010,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm200893p,Metabolism-directed design of oxetane-containing arylsulfonamide derivatives as γ-secretase inhibitors.,1
619010,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm300094u,Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.,1
619010,10.1021/jm900188z,Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.,10.1021/jm301741t,"Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitors that selectively inhibit the production of amyloid-β over Notch.",1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acs.jmedchem.8b01523,Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1016/j.bmc.2014.07.038,Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/jm300806c,Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acs.jmedchem.7b01515,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",1
626299,10.1016/j.bmcl.2010.03.087,"Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III.",10.1016/j.ejmech.2019.06.002,Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.,1
626299,10.1016/j.bmcl.2010.03.087,"Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III.",10.1016/j.bmc.2022.116922,The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.,1
625589,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
625589,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,1
625589,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
625589,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.7b00205,Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR.,1
625589,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.9b00761,The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/ml4002858,"Pharmacokinetics, metabolism, and in vivo efficacy of the antimalarial natural product bromophycolide A.",1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2019.05.043,New dimensions in the field of antimalarial research against malaria resurgence.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2023.115247,Current development of β-carboline derived potential antimalarial scaffolds.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/acs.jmedchem.4c01241,Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2022.114324,Discovery of spirooxadiazoline oxindoles with dual-stage antimalarial activity.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400325j,Using genetic methods to define the targets of compounds with antimalarial activity.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/acs.jmedchem.6b01065,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,1
626453,10.1021/jm2011645,"Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists.",10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acs.jmedchem.8b01523,Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.,1
626453,10.1021/acs.jmedchem.7b01515,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",10.1021/acs.jmedchem.8b01523,Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection.,1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acsmedchemlett.5b00010,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1021/acs.jmedchem.7b01515,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",1
626453,10.1021/jm500206r,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",10.1016/j.bmcl.2016.04.052,Discovery of novel non-steroidal reverse indole mineralocorticoid receptor antagonists.,1
630886,10.1021/acs.jmedchem.8b00103,Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).,10.1016/j.bmc.2024.117634,"1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells.",1
630886,10.1021/acsmedchemlett.6b00180,Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor.,10.1016/j.ejmech.2019.01.036,Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.,1
630886,10.1021/acs.jmedchem.8b00103,Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).,10.1021/acs.jmedchem.9b00327,"Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.",1
630886,10.1016/j.ejmech.2018.01.087,Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.,10.1021/acs.jmedchem.3c02124,Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.,1
630886,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/acs.jmedchem.1c00681,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",1
630886,10.1016/j.ejmech.2018.01.087,Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.,10.1021/acs.jmedchem.9b00327,"Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.",1
630886,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/acs.jmedchem.2c00716,Therapeutic Strategies to Target the Androgen Receptor.,1
630553,10.1016/j.bmcl.2011.12.026,"Discovery of 7-arylsulfonyl-1,2,3,4, 4a,9a-hexahydro-benzo[4,5]furo[2,3-c]pyridines: identification of a potent and selective 5-HT₆ receptor antagonist showing activity in rat social recognition test.",10.1021/jm5003952,Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease.,1
630553,10.1021/acs.jmedchem.1c00224,"Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptor Antagonist with Antipsychotic and Procognitive Properties.",10.1021/acs.jmedchem.3c02148,First-in-Class Selenium-Containing Potent Serotonin Receptor 5-HT&lt;sub&gt;6&lt;/sub&gt; Agents with a Beneficial Neuroprotective Profile against Alzheimer's Disease.,1
630553,10.1021/acs.jmedchem.1c00224,"Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT<sub>3</sub> and 5-HT<sub>6</sub> Receptor Antagonist with Antipsychotic and Procognitive Properties.",10.1021/acs.jmedchem.3c01482,Superiority of the Triple-Acting 5-HT<sub>6</sub>R/5-HT<sub>3</sub>R Antagonist and MAO-B Reversible Inhibitor <b>PZ-1922</b> over 5-HT<sub>6</sub>R Antagonist Intepirdine in Alleviation of Cognitive Deficits in Rats.,1
630356,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1021/acs.jmedchem.1c01547,Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.,1
630322,10.1016/j.bmc.2014.08.034,"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.",10.1016/j.bmcl.2015.05.012,Recent trends in orexin research--2010 to 2015.,1
630322,10.1016/j.bmc.2014.08.034,"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.",10.1021/acs.jmedchem.5b00832,Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1021/jm400314m,"Cell-based medicinal chemistry optimization of high-throughput screening (HTS) hits for orally active antimalarials. Part 1: challenges in potency and absorption, distribution, metabolism, excretion/pharmacokinetics (ADME/PK).",1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.ejmech.2014.03.055,Synthetic indole and melatonin derivatives exhibit antimalarial activity on the cell cycle of the human malaria parasite Plasmodium falciparum.,1
630274,10.1126/science.1193225,"Spiroindolones, a potent compound class for the treatment of malaria.",10.1016/j.bmcl.2013.03.067,Recent advances in malaria drug discovery.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm980448z,Artificial neural network applied to prediction of fluorquinolone antibacterial activity by topological methods.,1
241,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1039/d3md00204g,"Design, synthesis and evaluation of halogenated phenazine antibacterial prodrugs targeting nitroreductase enzymes for activation.",1
241,10.1016/j.ejmech.2015.10.047,"Synthesis, antimycobacterial screening and ligand-based molecular docking studies on novel pyrrole derivatives bearing pyrazoline, isoxazole and phenyl thiourea moieties.",10.1016/j.ejmech.2016.11.032,"Synthesis, biological evaluation and in silico molecular modeling of pyrrolyl benzohydrazide derivatives as enoyl ACP reductase inhibitors.",1
630975,10.1021/acs.jmedchem.7b00313,Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.,10.1021/acs.jmedchem.0c01686,Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.,1
630886,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1016/j.ejmech.2021.113376,Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.,1
630886,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/jm500684r,Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3).,1
630886,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,1
630886,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1021/acs.jmedchem.2c01164,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",1
630886,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/jm301714s,Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators.,1
630886,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/jm501792c,Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenografts in mice.,1
630886,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1021/acs.jmedchem.7b00105,"1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment.",1
630886,10.1016/j.ejmech.2021.113376,Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.,10.1021/acs.jmedchem.3c00585,"Discovery of <b>BWA-522</b>, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.",1
630886,10.1021/acs.jmedchem.8b00103,Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).,10.1016/j.ejmech.2022.114982,1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells.,1
630886,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1016/j.ejmech.2019.111608,Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.,1
630886,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/acs.jmedchem.2c01164,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",1
630886,10.1021/jm3015712,Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.,10.1021/acs.jmedchem.2c00912,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2012.09.108,"POMA analyses as new efficient bioinformatics' platform to predict and optimise bioactivity of synthesized 3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide/carbothioamide analogues.",1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmc.2021.116117,Synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenylpyrimidine derivatives with 4-amino or 4-hydroxy as a pharmacophore element binding with xanthine oxidase active site.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2019.07.061,"Design, synthesis and biological evaluation of 2-(4-alkoxy-3-cyano)phenyl-6-oxo-1,6-dihydropyrimidine-5-carboxylic acid derivatives as novel xanthine oxidase inhibitors.",1
241,10.1016/j.bmcl.2016.05.088,Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.,10.1016/j.bmcl.2020.127655,Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.,1
241,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
241,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1016/j.ejmech.2018.08.061,Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA).,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.ejmech.2010.11.023,Synthesis and in vitro antimycobacterial activity of 8-OCH(3) ciprofloxacin methylene and ethylene isatin derivatives.,1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.bmcl.2007.01.038,"Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.",1
241,10.1007/s00044-012-0369-3,Antibacterial and antifungal screening of newly synthesized benzimidazole-clubbed chalcone derivatives,10.1007/s00044-013-0791-1,"Synthesis and antimicrobial evaluation of 1,3,4-oxadiazole-based chalcone derivatives",1
241,10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,10.1016/j.bmcl.2015.11.038,Synthesis of novel coumarin appended bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities.,1
241,10.1016/j.ejmech.2011.09.011,"Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.",10.1016/j.ejmech.2018.01.078,Ciprofloxacin derivatives and their antibacterial activities.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s00044-011-9876-x,"New thiazolidine-2,4-diones as antimicrobial and cytotoxic agent",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1021/jm101510d,"Design, synthesis, and biological evaluation of new cinnamic derivatives as antituberculosis agents.",1
241,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.05.054,"1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.",1
241,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2020.112245,Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA).,1
241,10.1007/s00044-011-9702-5,Antioxidant potential and antimicrobial screening of some novel imidazole derivatives: greenway efficient one pot synthesis,10.1016/j.bmcl.2016.06.005,Synthesis of lignan conjugates via cyclopropanation: Antimicrobial and antioxidant studies.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2021.114086,"Intramolecular hydrogen bond interruption and scaffold hopping of TMC-5 led to 2-(4-alkoxy-3-cyanophenyl)pyrimidine-4/5-carboxylic acids and 6-(4-alkoxy-3-cyanophenyl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-ones as potent pyrimidine-based xanthine oxidase inhibitors.",1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2024.116443,"Design, synthesis, and biological evaluation of 5-(1H-indol-5-yl)isoxazole-3-carboxylic acids as novel xanthine oxidase inhibitors.",1
241,10.1016/j.ejmech.2013.03.017,"Synthesis and identification of β-aryloxyquinoline based diversely fluorine substituted N-aryl quinolone derivatives as a new class of antimicrobial, antituberculosis and antioxidant agents.",10.1016/j.ejmech.2014.03.069,"Investigation of Ugi-4CC derived 1H-tetrazol-5-yl-(aryl) methyl piperazinyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid: synthesis, biology and 3D-QSAR analysis.",1
241,10.1016/j.ejmech.2008.07.024,"Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides.",10.1016/j.bmcl.2016.02.057,"Novel amalgamation of phthalazine-quinolines as biofilm inhibitors: One-pot synthesis, biological evaluation and in silico ADME prediction with favorable metabolic fate.",1
241,10.1016/j.ejmech.2011.09.011,"Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.",10.1016/j.ejmech.2017.09.050,4-Quinolone hybrids and their antibacterial activities.,1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1128/aac.01649-07,"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.",1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1021/acs.jmedchem.4c00558,Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of &lt;i&gt;Clostridioides difficile&lt;/i&gt; Infection.,1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.bmc.2016.01.055,Synthesis and antibacterial evaluation of novel 4″-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens.,1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1128/aac.01311-05,Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.,1
241,10.1007/s00044-012-0376-4,"Synthesis, molecular docking studies, and in vitro screening of sulfanilamide-thiourea hybrids as antimicrobial and urease inhibitors",10.1016/j.ejmech.2016.08.039,Hybrid molecules: The privileged scaffolds for various pharmaceuticals.,1
241,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1016/j.ejmech.2020.113002,Installation of an aryl boronic acid function into the external section of N-aryl-oxazolidinones: Synthesis and antimicrobial evaluation.,1
241,10.1021/jm401808n,First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.,10.1016/j.ejmech.2015.02.056,Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.,1
241,10.1016/j.ejmech.2018.05.011,New N-phenylpyrrolamide DNA gyrase B inhibitors: Optimization of efficacy and antibacterial activity.,10.1016/j.ejmech.2020.112326,Recent advances in DNA gyrase-targeted antimicrobial agents.,1
241,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.ejmech.2021.113723,Modification of 5-methylphenanthridium from benzothiazoles to indoles as potent FtsZ inhibitors: Broadening the antibacterial spectrum toward vancomycin-resistant enterococci.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2014.01.035,"Synthesis, antileishmanial activity and docking study of N'-substitutedbenzylidene-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetohydrazides.",1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2013.04.074,The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.,1
650126,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.bmc.2013.09.049,"Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.",1
650126,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1021/acs.jmedchem.5b00840,Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/jm301891t,Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.5b00270,"Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.",1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.2c01361,Targeting Gatekeeper Mutations for Kinase Drug Discovery.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2016.10.003,Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.,1
649637,10.1021/acs.jmedchem.1c00082,"Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.",10.1016/j.ejmech.2022.114425,"Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.",1
649637,10.1021/jm4004076,Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.,10.1021/acs.jmedchem.7b00841,Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.bmcl.2015.07.006,Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1021/acs.jmedchem.1c00082,"Discovery of a Candidate Containing an (<i>S</i>)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1<i>H</i>-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.",1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2022.114442,The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.,1
649637,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2023.115475,Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2015.01.055,Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.ejmech.2015.08.056,Synthesis and evaluation of 1-hydroxy/methoxy-4-methyl-2-phenyl-1H-imidazole-5-carboxylic acid derivatives as non-purine xanthine oxidase inhibitors.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2014.01.050,HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.,1
647206,10.1016/j.bmcl.2012.11.057,Lead optimization of isocytosine-derived xanthine oxidase inhibitors.,10.1016/j.bmcl.2015.12.055,Structure-based design and biological evaluation of novel 2-(indol-2-yl) thiazole derivatives as xanthine oxidase inhibitors.,1
685974,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1021/acsmedchemlett.3c00335,"Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors.",1
683540,10.1016/j.bmcl.2010.06.094,"Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.",10.1016/j.bmcl.2012.12.004,Synthesis and evaluation against hepatitis C virus of 7-deaza analogues of 2'-C-methyl-6-O-methyl guanosine nucleoside and L-Alanine ester phosphoramidates.,1
683540,10.1016/j.bmcl.2010.06.094,"Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.",10.1021/jm2011673,Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents.,1
683540,10.1016/j.bmcl.2010.06.094,"Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.",10.1016/j.bmcl.2011.06.013,Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.,1
675254,10.1021/acs.jmedchem.9b01252,Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation.,10.1021/acs.jmedchem.0c01799,Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.,1
675143,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.6b01373,Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.,1
675143,10.1021/ml1002025,Structure-Activity Relationships at the Monoamine Transporters for a Novel Series of Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) Analogues.,10.1021/acs.jmedchem.9b01938,Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters.,1
674643,10.1124/dmd.111.041475,Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.,10.1016/j.bmcl.2012.12.090,Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.,1
674389,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1016/j.ejmech.2014.06.078,"Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.",1
656664,10.1021/jm5005623,"Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.",10.1016/j.bmcl.2018.05.010,"Design, synthesis and evaluation of photoactivatable derivatives of microtubule (MT)-active [1,2,4]triazolo[1,5-a]pyrimidines.",1
651088,10.1016/j.bmcl.2015.08.060,"Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation.",10.1016/j.bmcl.2016.06.045,"Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.",1
650126,10.1021/acs.jmedchem.3c00606,Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis.,10.1021/acs.jmedchem.4c00291,Discovery of a Covalent Inhibitor That Overcame Resistance to Venetoclax in AML Cells Overexpressing BFL-1.,1
650126,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1021/acs.jmedchem.1c02208,Discovery of Pteridine-7(8<i>H</i>)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).,1
650126,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1016/j.ejmech.2019.03.004,Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.,1
650126,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.ejmech.2022.114533,Recent advances in the development of EGFR degraders: PROTACs and LYTACs.,1
650126,10.1021/jm301365e,"Structural optimization and structure-activity relationships of N2-(4-(4-Methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations.",10.1016/j.bmc.2014.01.035,"Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.",1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1016/j.bmcl.2007.01.038,"Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones.",1
241,10.1016/S0960-894X(97)00054-1,"Synthesis and structural optimization of 7-(3,3-disubstituted-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acids as antibacterial agents",10.1016/s0960-894x(98)00355-2,Synthesis and structure-activity relationships of 2-pyridones: II. 8-(Fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1007/s11095-013-1232-z,Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm0402061,"Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin.",1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.ejmech.2020.113030,Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors.,1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
686684,10.1021/acs.jmedchem.9b01659,Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.,10.1016/j.ejmech.2021.113604,Design and synthesis of Grp94 selective inhibitors based on Phe199 induced fit mechanism and their anti-inflammatory effects.,1
686684,10.1021/acs.jmedchem.9b01659,Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.,10.1021/acs.jmedchem.4c00722,Allosteric Activation of Protein Phosphatase 5 with Small Molecules.,1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.ejmech.2023.115690,Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer.,1
686684,10.1021/acs.jmedchem.9b01659,Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.,10.1021/acs.jmedchem.4c00966,Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects.,1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1021/acs.jmedchem.6b00912,"Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.",1
686037,10.1016/j.ejmech.2023.115474,Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases.,10.1039/d3md00737e,<i>N</i>-Arylsulfonamide-based adenosine analogues to target RNA cap <i>N</i>7-methyltransferase nsp14 of SARS-CoV-2.,1
685974,10.1021/acsmedchemlett.1c00326,Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.,10.1016/j.ejmech.2023.115979,Development of de-novo coronavirus 3-chymotrypsin-like protease (3CL<sup>pro</sup>) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection.,1
685974,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1016/j.ejmech.2023.115979,Development of de-novo coronavirus 3-chymotrypsin-like protease (3CL<sup>pro</sup>) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection.,1
685974,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1021/acsmedchemlett.1c00326,Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.,1
685974,10.1021/acsmedchemlett.1c00326,Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.,10.1021/acsmedchemlett.3c00335,"Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M<sup>pro</sup> Inhibitors.",1
689324,10.1016/j.bmcl.2010.07.033,Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.,10.1021/acs.jmedchem.0c02249,Synthesis and Characterization of the Novel Rodent-Active and CNS-Penetrant P2X7 Receptor Antagonist Lu AF27139.,1
689324,10.1016/j.bmcl.2010.09.101,Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor.,10.1021/acs.jmedchem.9b00584,Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease.,1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.ejmech.2014.03.061,"Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.",1
686684,10.1021/jm100060b,"Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.",10.1016/j.ejmech.2018.04.019,"Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.",1
241,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
241,10.1016/j.bmc.2006.12.027,N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.,10.1016/j.bmcl.2016.10.002,Allicin-inspired thiolated fluoroquinolones as antibacterials against ESKAPE pathogens.,1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
241,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1016/j.bmc.2011.03.011,QSAR-based permeability model for drug-like compounds.,1
241,10.1016/j.bmcl.2012.08.073,Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.,10.1016/j.bmcl.2014.05.051,One pot three components microwave assisted and conventional synthesis of new 3-(4-chloro-2-hydroxyphenyl)-2-(substituted) thiazolidin-4-one as antimicrobial agents.,1
241,10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",10.1016/j.bmc.2017.07.057,"Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.",1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2020.112222,"Design, synthesis and structure-activity relationships of novel 15-membered macrolides: Quinolone/quinoline-containing sidechains tethered to the C-6 position of azithromycin acylides.",1
241,10.1016/j.bmc.2007.07.009,"Identification, biological activity, and mechanism of the anti-ischemic quinolone analog.",10.1016/j.bmcl.2011.07.060,Preparation and antibacterial evaluation of decarboxylated fluoroquinolones.,1
241,10.1021/jm001101a,Experimental and computational screening models for the prediction of intestinal drug absorption.,10.1021/jm901371v,Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2011.10.057,"Molecular properties prediction and synthesis of novel 1,3,4-oxadiazole analogues as potent antimicrobial and antitubercular agents.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2021.128381,"Synthesis, anti-microbial, toxicity and molecular docking studies of N-nitroso-N-phenylhydroxylamine (cupferron) and its derivatives.",1
241,10.1016/j.bmcl.2003.07.028,Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action.,10.1016/j.ejmech.2011.07.049,"Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2016.12.002,"Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2017.12.078,"Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2016.04.035,"Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2014.09.037,"Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.",1
692959,10.1016/j.ejmech.2014.09.095,Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.,10.1016/j.ejmech.2016.07.059,"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.",1
692559,10.1016/j.bmcl.2010.07.054,The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life.,10.1021/ml500299q,Synthesis of Deuterated Benzopyran Derivatives as Selective COX-2 Inhibitors with Improved Pharmacokinetic Properties.,1
692515,10.1021/acs.jmedchem.8b01766,2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.,10.1021/acs.jmedchem.2c01523,"Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.",1
692515,10.1021/acs.jmedchem.8b01765,2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.,10.1021/acs.jmedchem.2c01523,"Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.",1
692515,10.1021/acs.jmedchem.8b01766,2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.,10.1021/acs.jmedchem.8b01765,2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action.,1
692515,10.1021/acs.jmedchem.8b01766,2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site.,10.1021/acs.jmedchem.1c00063,"Molecular Plasticity of Crystalline CK2α' Leads to KN2, a Bivalent Inhibitor of Protein Kinase CK2 with Extraordinary Selectivity.",1
691867,10.1016/j.bmc.2016.03.055,Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.,10.1021/acs.jmedchem.8b00499,N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers.,1
691867,10.1016/j.bmc.2016.03.055,Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.,10.1016/j.bmc.2020.115493,"Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting <sup>V600E</sup>BRAF.",1
691867,10.1016/j.bmc.2016.03.055,Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.,10.1016/j.ejmech.2019.06.042,Light-controlled inhibition of BRAFV600E kinase.,1
691867,10.1016/j.bmc.2016.03.055,Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.,10.1021/acs.jmedchem.7b01306,Current Insights of BRAF Inhibitors in Cancer.,1
689324,10.1016/j.bmcl.2010.07.033,Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.,10.1021/acs.jmedchem.9b00584,Pyroglutamide-Based P2X7 Receptor Antagonists Targeting Inflammatory Bowel Disease.,1
689324,10.1016/j.bmcl.2010.07.033,Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor.,10.1016/j.bmcl.2010.09.101,Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X(7) receptor.,1
693510,10.1016/j.ejmech.2017.03.076,Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening.,10.1016/j.bmcl.2019.126791,"Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells.",1
693510,10.1016/j.ejmech.2017.11.101,Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.,10.1016/j.ejmech.2020.112964,Development of novel benzimidazole-derived neddylation inhibitors for suppressing tumor growth invitro and invivo.,1
693510,10.1016/j.ejmech.2017.03.076,Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening.,10.1016/j.ejmech.2019.111848,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,1
693510,10.1016/j.ejmech.2017.03.076,Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening.,10.1016/j.ejmech.2022.114156,NAE modulators: A potential therapy for gastric carcinoma.,1
693510,10.1016/j.ejmech.2017.11.101,Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.,10.1016/j.ejmech.2019.111848,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2016.02.003,"Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2016.04.062,"Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2014.05.013,"Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.",1
692959,10.1016/j.ejmech.2014.09.095,Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.,10.1016/j.ejmech.2016.04.062,"Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2014.09.095,Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.,1
692959,10.1016/j.ejmech.2014.09.095,Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.,10.1016/j.ejmech.2018.09.050,"Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2016.07.059,"Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2015.04.018,"Design, synthesis, biological evaluation and preliminary mechanism study of novel benzothiazole derivatives bearing indole-based moiety as potent antitumor agents.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.bmc.2014.01.014,"Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.",1
692959,10.1016/j.ejmech.2014.09.095,Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.,10.1016/j.bmcl.2019.126630,"Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia.",1
692959,10.1016/j.bmc.2013.06.026,"Discovery and optimization of novel 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazones as c-Met kinase inhibitors.",10.1016/j.ejmech.2014.04.059,"Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents.",1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.bmcl.2022.128761,"Design and synthesis of novel macrolones bridged with linkers from 11,12-positions of macrolides.",1
241,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2020.112245,Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA).,1
241,10.1016/j.ejmech.2008.04.010,"Synthesis and anti-microbial screening of some Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones.",10.1016/j.bmcl.2014.09.062,"Synthesis, antimicrobial and anti-biofilm activities of novel Schiff base analogues derived from methyl-12-aminooctadec-9-enoate.",1
241,10.1016/j.ejmech.2011.09.011,"Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study.",10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm060844e,"Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.",1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1021/jm101604v,Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1128/aac.00330-08,"Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.",1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2024.116630,"Design, synthesis and structure-activity relationships of novel non-ketolides: 9-Oxime clarithromycin featured with seven-to thirteen-atom-length diamine linkers at 3-OH.",1
241,10.1039/C3MD00387F,Synthesis and synergistic antimycobacterial screening of chlorpromazine and its metabolites,10.1016/j.ejmech.2019.02.010,"Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.",1
241,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.bmc.2020.115729,"Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.",1
694811,10.1016/j.bmcl.2018.08.039,Discovery and lead identification of quinazoline-based BRD4 inhibitors.,10.1016/j.bmcl.2019.03.014,Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.,1
693510,10.1016/j.ejmech.2017.03.076,Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening.,10.1016/j.bmcl.2024.129647,Identification of novel benzothiazole derivatives as inhibitors of NEDDylation pathway to inhibit the progression of gastric cancer.,1
693510,10.1021/ml2000615,Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity.,10.1016/j.ejmech.2022.114156,NAE modulators: A potential therapy for gastric carcinoma.,1
693510,10.1016/j.ejmech.2017.11.101,Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.,10.1016/j.ejmech.2022.114156,NAE modulators: A potential therapy for gastric carcinoma.,1
693510,10.1021/ml2000615,Identification of NAE Inhibitors Exhibiting Potent Activity in Leukemia Cells: Exploring the Structural Determinants of NAE Specificity.,10.1021/acs.jmedchem.1c00242,Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.,1
693510,10.1016/j.ejmech.2017.11.101,Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.,10.1021/acs.jmedchem.1c00242,Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.,1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2019.02.051,"Design, synthesis and biological evaluation of novel α-acyloxy carboxamides via Passerini reaction as caspase 3/7 activators.",1
241,10.1021/jm00022a013,"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents.",10.1021/jm0205090,"A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2010.07.069,"Molecular properties prediction, synthesis and antimicrobial activity of some newer oxadiazole derivatives.",1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1016/j.bmc.2018.11.020,"Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.",1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1021/acs.jmedchem.5b00613,Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.,1
694811,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",10.1021/acs.jmedchem.5b00613,Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.,1
694811,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1021/acs.jmedchem.7b00193,"Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.",1
694811,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",10.1021/acs.jmedchem.5b01511,"Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.",1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1016/j.bmcl.2019.03.014,Lead optimization and efficacy evaluation of quinazoline-based BET family inhibitors for potential treatment of cancer and inflammatory diseases.,1
241,10.1016/j.ejmech.2018.09.053,"Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators.",10.1016/j.bmc.2019.02.024,Antibacterial activity of indolyl-quinolinium derivatives and study their mode of action.,1
241,10.1021/acs.jmedchem.9b00394,Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.,10.1021/acsmedchemlett.2c00111,"1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum.",1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2010.03.044,"4-Substituted 4-(1H-1,2,3-triazol-1-yl)piperidine: novel C7 moieties of fluoroquinolones as antibacterial agents.",1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
241,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2019.02.073,"Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.",1
173,10.1007/s00044-012-9975-3,"Synthesis, molecular modeling and anti-inflammatory screening of new 1,2,3-benzotriazinone derivatives",10.1016/j.ejmech.2018.11.027,Anti-inflammatory activity of triazine derivatives: A systematic review.,1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1039/C8MD00198G,Targeting Brd4 for cancer therapy: inhibitors and degraders.,1
694811,10.1021/jm301588r,"Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands.",10.1021/acs.jmedchem.5b01514,Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.,1
694811,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",10.1021/jm501504k,Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization.,1
241,10.1016/j.ejmech.2018.10.008,"Novel indole-thiazolidinone conjugates: Design, synthesis and whole-cell phenotypic evaluation as a novel class of antimicrobial agents.",10.1016/j.ejmech.2023.115689,Thiazole-based analogues as potential antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA) and their SAR elucidation.,1
241,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2020.113134,Pyrazole-based analogs as potential antibacterial agents against methicillin-resistance staphylococcus aureus (MRSA) and its SAR elucidation.,1
241,10.1016/j.ejmech.2018.11.012,Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections.,10.1016/j.ejmech.2020.112832,Antibacterial activities with the structure-activity relationship of coumarin derivatives.,1
241,10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",10.1016/j.ejmech.2016.12.016,"Synthesis and biological screening of novel 2-morpholinoquinoline nucleus clubbed with 1,2,4-oxadiazole motifs.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmc.2016.05.051,"Bacterial Peptide deformylase inhibition of cyano substituted biaryl analogs: Synthesis, in vitro biological evaluation, molecular docking study and in silico ADME prediction.",1
241,10.1021/acs.jmedchem.1c00168,A Modular Synthetic Route Involving <i>N</i>-Aryl-2-nitrosoaniline Intermediates Leads to a New Series of 3-Substituted Halogenated Phenazine Antibacterial Agents.,10.1021/acs.jmedchem.1c02034,Mechanistic Studies and <i>In Vivo</i> Efficacy of an Oxadiazole-Containing Antibiotic.,1
241,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1016/j.ejmech.2014.03.010,Emergence of pyrido quinoxalines as new family of antimalarial agents.,1
241,10.1016/j.ejmech.2008.07.024,"Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides.",10.1007/s00044-012-0020-3,Synthesis of novel optically pure -amino acid functionalised-7-trifluoromethyl substituted quinolone derivatives and their antibacterial activity,1
241,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2018.03.016,Recent advances of imidazole-containing derivatives as anti-tubercular agents.,1
241,10.1016/j.ejmech.2014.02.015,"Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.",10.1016/j.ejmech.2014.07.008,"Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.bmcl.2014.12.063,"Biofilm inhibition of linezolid-like Schiff bases: synthesis, biological activity, molecular docking and in silico ADME prediction.",1
241,10.1021/jm000942e,Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties.,10.1016/j.ejmech.2018.09.067,1-(2-Hydroxybenzoyl)-thiosemicarbazides are promising antimicrobial agents targeting d-alanine-d-alanine ligase in bacterio.,1
696704,10.1016/j.bmcl.2013.02.020,"Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.",10.1016/j.bmcl.2013.12.112,"Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.",1
694811,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1016/j.ejmech.2018.02.070,Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups.,1
694811,10.1021/ml4001485,"Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors.",10.1021/acs.jmedchem.7b00193,"Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.",1
241,10.1016/j.bmcl.2005.11.064,Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.,10.1128/aac.01315-06,In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.bmcl.2015.07.044,Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.,1
241,10.1016/j.bmcl.2009.05.061,Optimization of the central linker of dicationic bis-benzimidazole anti-MRSA and anti-VRE agents.,10.1016/j.ejmech.2020.112245,Indole-based derivatives as potential antibacterial activity against methicillin-resistance Staphylococcus aureus (MRSA).,1
241,10.1021/acs.jmedchem.9b00394,Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.,10.1021/acsmedchemlett.0c00428,Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.,1
241,10.1016/j.ejmech.2008.07.024,"Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides.",10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
241,10.1016/j.bmcl.2016.05.088,Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.,10.1016/j.bmc.2017.02.003,New nitrofurans amenable by isocyanide multicomponent chemistry are active against multidrug-resistant and poly-resistant Mycobacterium tuberculosis.,1
241,10.1016/j.bmcl.2005.11.065,Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
241,10.1016/j.bmcl.2007.01.090,The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents.,10.1016/j.ejmech.2017.11.082,4-Quinolone derivatives and their activities against Gram positive pathogens.,1
241,10.1016/j.bmc.2007.07.009,"Identification, biological activity, and mechanism of the anti-ischemic quinolone analog.",10.1016/j.bmcl.2012.12.045,Synthesis and antibacterial evaluation of a novel tricyclic oxaborole-fused fluoroquinolone.,1
173,10.1021/jm980570y,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.",10.1016/j.bmcl.2015.02.004,Synthesis and biological evaluation of pyrazolylthiazole carboxylic acids as potent anti-inflammatory-antimicrobial agents.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(00)00329-2,"Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(01)00670-9,4-Aryl/cycloalkyl-5-phenyloxazole derivatives as selective COX-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm049121q,"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.",1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/jm1005989,Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.,1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmc.2011.05.064,The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating hydantoin or uracil rings.,1
705778,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1021/jm1005989,Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.,1
705778,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.04.135,Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.,1
704774,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1016/j.ejmech.2018.01.085,Recent updates for designing CCR5 antagonists as anti-retroviral agents.,1
704774,10.1021/jm100978n,"An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).",10.1021/acs.jmedchem.6b01309,Structural Analysis of Chemokine Receptor-Ligand Interactions.,1
701078,10.1038/nchembio826,Probing cell-division phenotype space and Polo-like kinase function using small molecules.,10.1016/j.cub.2006.12.037,"BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.",1
699395,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
699312,10.1016/j.ejmech.2016.06.030,"Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
699312,10.1016/j.ejmech.2016.06.030,"Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.",10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
696704,10.1016/j.bmcl.2013.02.020,"Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.",10.1016/j.ejmech.2021.114039,Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.,1
696704,10.1016/j.bmcl.2013.02.020,"Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.",10.1016/j.bmcl.2014.07.073,"Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.",1
696704,10.1021/acs.jmedchem.8b00416,Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment.,10.1021/acs.jmedchem.2c01070,"Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.",1
696704,10.1016/j.bmcl.2014.07.073,"Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.",10.1016/j.bmc.2017.12.025,Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors.,1
706046,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.bmc.2022.116614,Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.,1
706046,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.3c01040,Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives.,1
706046,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1016/j.ejmech.2024.116326,Recent advances in the exploration of oxazolidinone scaffolds from compound development to antibacterial agents and other bioactivities.,1
705778,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1021/ml4005232,"Discovery of AZD3199, An Inhaled Ultralong Acting β2 Receptor Agonist with Rapid Onset of Action.",1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1021/acs.jmedchem.7b00205,Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR.,1
705778,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
705778,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.04.069,Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines.,1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.04.095,"Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.",1
705778,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.05.097,Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.,1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
705778,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2014.06.014,"The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist.",1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2014.04.069,Multivalent design of long-acting β(2)-adrenoceptor agonists incorporating biarylamines.,1
705778,10.1016/j.bmcl.2010.06.136,A physical properties based approach for the exploration of a 4-hydroxybenzothiazolone series of beta2-adrenoceptor agonists as inhaled long-acting bronchodilators.,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,1
705778,10.1021/jm100068m,The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist.,10.1016/j.bmcl.2011.04.135,Design driven HtL: The discovery and synthesis of new high efficacy β₂-agonists.,1
705778,10.1016/j.bmcl.2011.10.049,From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.,10.1016/j.bmcl.2014.04.095,"Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.",1
712273,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(01)00554-6,Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones.,1
712273,10.1016/j.bmcl.2006.11.062,Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.,10.1016/j.bmcl.2011.12.110,Synthesis and antihormonal properties of novel 11β-benzoxazole-substituted steroids.,1
712273,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm100447c,Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists.,1
712273,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
712273,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm801512v,"Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.",1
712273,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1021/jm070778w,Nonsteroidal glucocorticoid agonists: tetrahydronaphthalenes with alternative steroidal A-ring mimetics possessing dissociated (transrepression/transactivation) efficacy selectivity.,1
712273,10.1016/j.bmcl.2006.11.062,Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.,10.1016/j.bmcl.2008.05.070,Insight from molecular modeling into different conformation and SAR of natural steroids and unnatural 7-oxa-steroids.,1
712090,10.1021/acs.jmedchem.7b00324,Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.,10.1016/j.ejmech.2021.113652,"Anticancer potential of indirubins in medicinal chemistry: Biological activity, structural modification, and structure-activity relationship.",1
712090,10.1021/acs.jmedchem.7b00324,Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.,10.1021/acs.jmedchem.1c01311,Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer.,1
712090,10.1021/acs.jmedchem.7b00324,Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.,10.1016/j.ejmech.2023.115829,Discovery and optimization of indirubin derivatives as novel ferroptosis inducers for the treatment of colon cancer.,1
711568,10.1016/j.bmc.2014.08.034,"Design, synthesis, and structure-activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists.",10.1021/acs.jmedchem.5b00832,Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,1
708075,10.1016/j.bmcl.2017.10.024,Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.,10.1016/j.bmc.2019.115208,Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.,1
708075,10.1016/j.bmcl.2017.10.024,Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.,10.1021/acs.jmedchem.8b01300,"Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.",1
708075,10.1021/acs.jmedchem.8b01300,"Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.",10.1016/j.bmc.2019.115208,Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.,1
708075,10.1016/j.bmcl.2017.10.024,Synthesis and anti-HCV activity of a series of β-d-2'-deoxy-2'-dibromo nucleosides and their corresponding phosphoramidate prodrugs.,10.1016/j.bmc.2019.01.005,Synthesis and anti-HCV activity of β-d-2'-deoxy-2'-α-chloro-2'-β-fluoro and β-d-2'-deoxy-2'-α-bromo-2'-β-fluoro nucleosides and their phosphoramidate prodrugs.,1
706046,10.1021/jm4000598,Solubility-driven optimization of (pyridin-3-yl) benzoxazinyl-oxazolidinones leading to a promising antibacterial agent.,10.1021/acs.jmedchem.1c00480,Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs.,1
935964,10.1021/jm049147h,Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents.,10.1021/acs.jmedchem.3c00069,An Overview of Antivirals against Monkeypox Virus and Other Orthopoxviruses.,1
915223,10.1021/ml500131a,Optimization of Rutaecarpine as ABCA1 Up-Regulator for Treating Atherosclerosis.,10.1016/j.ejmech.2019.01.012,"Searching for new agents active against Candida albicans biofilm: A series of indole derivatives, design, synthesis and biological evaluation.",1
899136,10.1016/j.bmcl.2012.10.010,"Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.",10.1021/acs.jmedchem.2c00263,Discovery of the First Selective IDO2 Inhibitor As Novel Immunotherapeutic Avenues for Rheumatoid Arthritis.,1
879381,10.1021/jm301583m,Reporter ligand NMR screening method for 2-oxoglutarate oxygenase inhibitors.,10.1021/acs.jmedchem.1c01694,Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.,1
744023,10.1016/j.ejmech.2017.10.055,Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.,10.1016/j.bmcl.2020.127100,Simplistic perylene-related compounds as inhibitors of tick-borne encephalitis virus reproduction.,1
744023,10.1016/j.ejmech.2017.10.055,Aminomethylation of heliomycin: Preparation and anticancer characterization of the first series of semi-synthetic derivatives.,10.1021/acs.jnatprod.1c00162,Water-Soluble Heliomycin Derivatives to Target i-Motif DNA.,1
716337,10.1021/jm5005336,"The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.",10.1016/j.ejmech.2015.03.020,Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: success and challenges.,1
712273,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1021/jm0105530,"Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists.",1
712273,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1073/pnas.0705517104,Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.,1
712273,10.1016/j.bmcl.2006.11.062,Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.,10.1016/j.bmcl.2007.02.013,Parallel synthesis and SAR study of novel oxa-steroids as potent and selective progesterone receptor antagonists.,1
712273,10.1016/j.bmcl.2006.11.062,Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.,10.1016/j.bmcl.2009.01.095,Synthesis and SAR study of novel pseudo-steroids as potent and selective progesterone receptor antagonists.,1
712273,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
712273,10.1016/j.bmcl.2007.08.064,"Synthesis and identification of novel 11beta-aryl-4',5'-dihydrospiro[estra-4,9-diene-17beta,4'-oxazole] analogs with dissociated antiprogesterone activities.",10.1016/j.bmcl.2011.12.110,Synthesis and antihormonal properties of novel 11β-benzoxazole-substituted steroids.,1
712273,10.1016/j.bmcl.2006.11.062,Synthesis and identification of novel oxa-steroids as progesterone receptor antagonists.,10.1016/j.bmcl.2007.08.064,"Synthesis and identification of novel 11beta-aryl-4',5'-dihydrospiro[estra-4,9-diene-17beta,4'-oxazole] analogs with dissociated antiprogesterone activities.",1
712273,10.1021/jm970699s,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",10.1016/s0960-894x(02)00746-1,"New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles.",1
712273,10.1021/jm060302x,Dissociated nonsteroidal glucocorticoid receptor modulators; discovery of the agonist trigger in a tetrahydronaphthalene-benzoxazine series.,10.1016/j.bmcl.2007.06.066,Non-steroidal glucocorticoid agonists: the discovery of aryl pyrazoles as A-ring mimetics.,1
1038292,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2024.116527,"A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments.",1
1038292,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2023.115538,Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2021.114008,Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acsmedchemlett.0c00062,Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.bmc.2023.117467,"Design and synthesis of sulfonamides incorporating a biotin moiety: Carbonic anhydrase inhibitory effects, antiproliferative activity and molecular modeling studies.",1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.0c02077,Inhibition of Carbonic Anhydrase Using SLC-149: Support for a Noncatalytic Function of CAIX in Breast Cancer.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.1c01906,One-Pot Procedure for the Synthesis of Asymmetric Substituted Ureido Benzene Sulfonamides as Effective Inhibitors of Carbonic Anhydrase Enzymes.,1
1038292,10.1016/j.ejmech.2019.111843,"Synthesis, biological and molecular dynamics investigations with a series of triazolopyrimidine/triazole-based benzenesulfonamides as novel carbonic anhydrase inhibitors.",10.1016/j.ejmech.2020.112923,Recent advances in the medicinal chemistry of carbonic anhydrase inhibitors.,1
1038292,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2021.114008,Natural inspired ligustrazine-based SLC-0111 analogues as novel carbonic anhydrase inhibitors.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.bmc.2019.03.001,"Discovery of new ureido benzenesulfonamides incorporating 1,3,5-triazine moieties as carbonic anhydrase I, II, IX and XII inhibitors.",1
1037718,10.1021/acs.jmedchem.1c01509,"Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.",10.1016/j.ejmech.2023.115219,Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.,1
1037718,10.1021/acs.jmedchem.1c01509,"Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.",10.1021/acs.jmedchem.1c01934,Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.,1
1037718,10.1021/acs.jmedchem.1c01934,Multiparameter Optimization of Oxidative Phosphorylation Inhibitors for the Treatment of Pancreatic Cancer.,10.1016/j.ejmech.2023.115219,Recent advances of mitochondrial complex I inhibitors for cancer therapy: Current status and future perspectives.,1
1037712,10.1016/j.bmcl.2013.02.028,Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.,10.1016/j.bmcl.2015.11.004,Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.,1
986663,10.1021/np500856u,Design and Synthesis of a Screening Library Using the Natural Product Scaffold 3-Chloro-4-hydroxyphenylacetic Acid.,10.1021/acs.jnatprod.7b00929,Identification of Gibberellic Acid Derivatives That Deregulate Cholesterol Metabolism in Prostate Cancer Cells.,1
954312,10.1016/j.ejmech.2017.07.068,"Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.",10.1016/j.bmcl.2018.11.016,Synthesis and biological evaluation of Ginsenoside Compound K analogues as a novel class of anti-asthmatic agents.,1
1054485,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
1054485,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2018.07.064,"8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.",1
1054485,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,1
1054485,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2018.06.001,"Novel 8-nitroquinolin-2(1H)-ones as NTR-bioactivated antikinetoplastid molecules: Synthesis, electrochemical and SAR study.",1
1054485,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1016/j.ejmech.2020.112558,8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.,1
1054485,10.1016/j.bmcl.2017.10.067,"Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides.",10.1016/j.ejmech.2020.112849,Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.,1
1054485,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1016/j.ejmech.2020.112668,Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties.,1
1054485,10.1016/j.ejmech.2011.01.071,"1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.",10.1021/acs.jmedchem.7b00143,Nitroimidazoles: Molecular Fireworks That Combat a Broad Spectrum of Infectious Diseases.,1
1054485,10.1016/j.bmc.2015.03.064,Antileishmanial pharmacomodulation in 8-nitroquinolin-2(1H)-one series.,10.1021/acsmedchemlett.9b00566,New 8-Nitroquinolinone Derivative Displaying Submicromolar in Vitro Activities against Both Trypanosoma brucei and cruzi.,1
1044548,10.1021/jm400966v,Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.,10.1021/acs.jmedchem.2c01075,Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2021.113800,"Natural inspired piperine-based sulfonamides and carboxylic acids as carbonic anhydrase inhibitors: Design, synthesis and biological evaluation.",1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.8b01504,4-Hydroxy-3-nitro-5-ureido-benzenesulfonamides Selectively Target the Tumor-Associated Carbonic Anhydrase Isoforms IX and XII Showing Hypoxia-Enhanced Antiproliferative Profiles.,1
1038292,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2022.114412,Development of 4-((3-oxo-3-phenylpropyl)amino)benzenesulfonamide derivatives utilizing tail/dual-tail approaches as novel carbonic anhydrase inhibitors.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1016/j.ejmech.2024.116170,pH regulators and their inhibitors in tumor microenvironment.,1
1038292,10.1016/j.bmc.2017.03.027,Synthesis and carbonic anhydrase inhibition of a series of SLC-0111 analogs.,10.1021/acs.jmedchem.8b00770,Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 Analogues for the Treatment of Hypoxic Tumors Overexpressing Carbonic Anhydrase IX.,1
1038292,10.1016/j.ejmech.2021.113360,Identification of N-phenyl-2-(phenylsulfonyl)acetamides/propanamides as new SLC-0111 analogues: Synthesis and evaluation of the carbonic anhydrase inhibitory activities.,10.1016/j.ejmech.2023.115538,Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm101445p,Tricyclic compounds containing nonenolizable cyano enones. A novel class of highly potent anti-inflammatory and cytoprotective agents.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/acs.jnatprod.7b00271,Electrophilic Triterpenoid Enones: A Comparative Thiol-Trapping and Bioactivity Study.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.ejmech.2018.02.062,"Design and synthesis of new hybrids from 2-cyano-3,12-dioxooleana- 9-dien-28-oic acid and O2-(2,4-dinitrophenyl) diazeniumdiolate for intervention of drug-resistant lung cancer.",1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm3003922,"Synthesis, chemical reactivity as Michael acceptors, and biological potency of monocyclic cyanoenones, novel and highly potent anti-inflammatory and cytoprotective agents.",1
1139916,10.1021/acs.jmedchem.6b00228,Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.,10.1016/j.bmc.2018.12.026,Discovery of a crystalline sulforaphane analog with good solid-state stability and engagement of the Nrf2 pathway in vitro and in vivo.,1
1139916,10.1021/acs.jmedchem.5b01292,Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.,10.1016/j.ejmech.2024.116408,Modulators for palmitoylation of proteins and small molecules.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/j.ejmech.2017.07.013,"Oleanane-, ursane-, and quinone methide friedelane-type triterpenoid derivatives: Recent advances in cancer treatment.",1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/jm5019302,Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1021/acs.jmedchem.5b01292,Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.,1
1139916,10.1021/acs.jmedchem.6b00228,Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.,10.1021/acs.jmedchem.2c00457,Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein-Protein Interaction Inhibitors with an Alternative Binding Mode.,1
1139916,10.1021/acs.jmedchem.6b00228,Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.,10.1021/acs.jmedchem.9b01074,Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.,1
1139916,10.1021/jm0002230,Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages.,10.1016/s0960-894x(02)00105-1,"A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production.",1
1069144,10.1021/jm1013264,"Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.",10.1016/j.bmc.2013.09.001,"Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.",1
1066153,10.1016/j.bmc.2017.11.018,"A novel series of enoyl reductase inhibitors targeting the ESKAPE pathogens, Staphylococcus aureus and Acinetobacter baumannii.",10.1016/j.ejmech.2020.112757,FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitors.,1
1062164,10.1021/acs.jmedchem.8b01491,Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
1054485,10.1016/j.bmc.2013.09.002,"Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.",10.1021/acsmedchemlett.8b00347,"Nongenotoxic 3-Nitroimidazo[1,2-<i>a</i>]pyridines Are NTR1 Substrates That Display Potent <i>in Vitro</i> Antileishmanial Activity.",1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2019.05.051,"Chalcone derivatives bearing chromen or benzo[f]chromen moieties: Design, synthesis, and evaluations of anti-inflammatory, analgesic, selective COX-2 inhibitory activities.",1
1153572,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/acs.jmedchem.0c01952,"Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.",1
1153572,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.ejmech.2024.116210,"Design, synthesis and evaluation of C-5 substituted pyrrolopyridine derivatives as potent Janus Kinase 1 inhibitors with excellent selectivity.",1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/acs.jmedchem.7b01598,"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.",1
1153572,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
1150404,10.1016/j.bmcl.2009.04.107,Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.,10.1039/C1MD00116G,"Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus",1
1150404,10.1021/ml400027y,"Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.",10.1021/acs.jmedchem.5b01594,Structure-Activity Relationship of Azaindole-Based Glucokinase Activators.,1
1144723,10.1021/acs.jmedchem.9b01547,"Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-<i>trans</i>-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid.",10.1016/j.ejmech.2021.113431,"Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy.",1
1144723,10.1021/acs.jmedchem.9b01547,"Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-<i>trans</i>-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid.",10.1021/acs.jmedchem.0c00807,2-Arylbenzo[<i>d</i>]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy.,1
1143222,10.1016/j.bmcl.2010.12.118,"Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.",10.1016/j.ejmech.2024.116124,Synthesis and clinical application of new drugs approved by FDA in 2023.,1
1143222,10.1016/j.bmcl.2010.12.118,"Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as γ-secretase inhibitors: discovery of PF-3084014.",10.1021/acs.jmedchem.5b01516,Notch Antagonists: Potential Modulators of Cancer and Inflammatory Diseases.,1
1142547,10.1021/jm200049r,Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.,10.1021/acs.jmedchem.1c00790,"Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.",1
1142547,10.1021/jm200049r,Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.,10.1124/dmd.112.049551,"Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.",1
1142547,10.1021/jm200049r,Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.,10.1021/acs.jmedchem.6b01818,"Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.",1
1142547,10.1021/jm200049r,Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.,10.1016/j.ejmech.2019.111773,Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.,1
1139916,10.1021/acs.jmedchem.5b01292,Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification of Pharmacologically Relevant Targets and Interaction Sites.,10.1021/acs.jmedchem.4c01160,New CDDO Arylboronate Ester Derivatives with High Selectivity and Low Toxicity.,1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm3012239,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,1
173,10.1016/j.bmcl.2016.12.069,"Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening.",10.1016/j.ejmech.2021.113493,Contemporary advances of cyclic molecules proposed for inflammation.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.8b00922,"Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.",1
173,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1097/00004647-200304000-00007,Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.,1
173,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1016/j.ejmech.2015.06.011,"Molecular docking design and one-pot expeditious synthesis of novel 2,5-diarylpyrazolo[1,5-a]pyrimidin-7-amines as anti-inflammatory agents.",1
173,10.1021/np020023m,Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.,10.1021/np040130b,Lanostane triterpenoids and triterpene glycosides from the fruit body of Fomitopsis pinicola and their inhibitory activity against COX-1 and COX-2.,1
173,10.1021/jm980570y,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.",10.1016/j.ejmech.2010.10.035,"Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.",1
173,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.ejmech.2016.01.055,"An integrated overview on pyrrolizines as potential anti-inflammatory, analgesic and antipyretic agents.",1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1007/s00044-009-9163-2,"Lonazolac analogues: molecular modeling, synthesis, and in vivo anti-inflammatory activity",1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2015.02.004,Synthesis and biological evaluation of pyrazolylthiazole carboxylic acids as potent anti-inflammatory-antimicrobial agents.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm701191z,Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm200973j,Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs.,1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2017.06.002,"Synthesis, potential anti-inflammatory and analgesic activities study of (S)-N-substituted-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxamides.",1
173,10.1021/np020023m,Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.,10.1021/np0504311,Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2.,1
173,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1016/s0167-4889(02)00187-8,Role of human organic anion transporter 4 in the transport of ochratoxin A.,1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2010.10.001,Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.,1
1162276,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1021/acs.jmedchem.7b01019,Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy.,1
1162276,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1021/jm501778s,"Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.",1
1162276,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1016/j.ejmech.2017.02.015,"Design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine derivatives as mTOR inhibitors.",1
1162276,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1016/j.bmc.2018.06.025,"Design and synthesis of alkyl substituted pyridino[2,3-D]pyrimidine compounds as PI3Kα/mTOR dual inhibitors with improved pharmacokinetic properties and potent in vivo antitumor activity.",1
1161875,10.1016/j.ejmech.2016.09.098,Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors.,10.1016/j.bmcl.2019.126824,"Synthesis, biological evaluation and SAR studies of ursolic acid 3β-ester derivatives as novel CETP inhibitors.",1
1161875,10.1016/j.ejmech.2016.09.098,Fragment-based discovery of novel pentacyclic triterpenoid derivatives as cholesteryl ester transfer protein inhibitors.,10.1016/j.ejmech.2017.08.012,Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.,1
1153672,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
1153672,10.1021/jm001020e,High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.,10.1016/j.bmc.2007.03.040,QSAR study on permeability of hydrophobic compounds with artificial membranes.,1
1153672,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
1153672,10.1016/j.bmcl.2010.08.117,Property based optimization of δ-lactam HDAC inhibitors for metabolic stability.,10.1016/j.bmcl.2010.12.079,"Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors.",1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/acs.jmedchem.0c02111,"Discovery of Novel Pyrrolo[2,3-<i>d</i>]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors.",1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm401490p,Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.,1
1153572,10.1021/jm300438j,Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,1
1153572,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1021/jm3012239,Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.,1
1153572,10.1021/jm300628c,Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.,10.1016/j.bmcl.2014.01.001,Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.8b00281,Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acsmedchemlett.5b00424,"Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043.",1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acsmedchemlett.9b00343,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,1
1172957,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1172957,10.1021/jm3008882,Identification of antitubercular benzothiazinone compounds by ligand-based design.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1172957,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1172957,10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1172957,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1172957,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1016/j.ejmech.2018.03.020,Drug discovery in tuberculosis. New drug targets and antimycobacterial agents.,1
1172957,10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1172957,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1172957,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1172957,10.1021/acs.jmedchem.0c00107,Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.,10.1016/j.ejmech.2023.115611,"2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.ejmech.2023.115267,"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.",1
1175867,10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",10.1016/j.ejmech.2023.115990,Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.,1
1175867,10.1016/j.bmc.2017.12.030,Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.,10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.bmc.2017.12.030,Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.,1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.ejmech.2016.02.040,"Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.",1
1175867,10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",10.1016/j.ejmech.2023.115267,"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1021/acs.jmedchem.6b00202,Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.,1
1175867,10.1016/j.bmcl.2018.07.048,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.bmc.2015.09.010,"Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.bmc.2016.03.014,Discovery of novel pyrrole-based scaffold as potent and orally bioavailable free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.,1
1175867,10.1021/acs.jmedchem.0c00843,Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.,10.1016/j.ejmech.2023.115267,"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.bmcl.2019.01.014,"Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine.",1
1175867,10.1016/j.bmc.2017.12.030,Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.,10.1016/j.ejmech.2023.115990,Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.,1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.ejmech.2019.06.087,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.",1
1175867,10.1021/acs.jmedchem.0c00843,Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.,10.1016/j.ejmech.2023.115990,Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.,1
1172957,10.1021/acs.jmedchem.8b01356,Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.,10.1021/acs.jmedchem.9b02075,Molecule Property Analyses of Active Compounds for <i>Mycobacterium tuberculosis</i>.,1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.bmc.2016.08.068,Discovery of novel free fatty acid receptor 1 agonists bearing triazole core via click chemistry.,1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.ejmech.2016.02.040,"Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.",1
1175867,10.1016/j.bmcl.2018.07.048,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",10.1016/j.ejmech.2021.113810,Discovery and development of CPL207280 as new GPR40/FFA1 agonist.,1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.ejmech.2019.06.087,"Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1021/acsmedchemlett.7b00460,SAR Studies of Indole-5-propanoic Acid Derivatives To Develop Novel GPR40 Agonists.,1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1021/acs.jmedchem.6b01357,Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.,1
1175867,10.1016/j.bmc.2017.12.030,Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.,10.1016/j.ejmech.2022.114883,"Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.ejmech.2016.03.054,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.ejmech.2022.114883,"Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.",1
1175867,10.1021/jm2005699,Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.,10.1016/j.ejmech.2016.03.054,"Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.",1
1175867,10.1016/j.bmcl.2018.07.048,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",10.1016/j.ejmech.2023.115267,"Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1021/acs.jmedchem.6b01357,Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.,1
1175867,10.1021/acs.jmedchem.0c00843,Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.,10.1016/j.ejmech.2022.114883,"Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes.",1
1175867,10.1021/acs.jmedchem.0c00843,Design and Identification of a GPR40 Full Agonist (SCO-267) Possessing a 2-Carbamoylphenyl Piperidine Moiety.,10.1016/j.bmcl.2021.127969,"FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.bmc.2017.12.030,Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold.,1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.bmc.2015.10.011,"Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.",1
1214046,10.1016/j.ejmech.2018.12.055,"Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.",10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,1
1214046,10.1021/acs.jmedchem.7b01075,In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.,10.1021/acs.jmedchem.1c01559,"Discovery of 1-Amino-1<i>H</i>-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.",1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2019.06.035,Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.,1
1214046,10.1016/j.ejmech.2018.12.055,"Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.",10.1016/j.ejmech.2020.112339,Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2020.112339,Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.bmc.2019.115254,"Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.",1
1176030,10.1016/j.bmcl.2011.06.108,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",10.1016/j.ejmech.2015.03.054,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",1
1176030,10.1016/j.bmcl.2011.06.108,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",10.1016/j.bmcl.2014.01.061,"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",1
1176030,10.1021/jm201295j,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.",10.1016/j.ejmech.2015.03.054,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",1
1176030,10.1021/jm201295j,"Optimization of 5-pyridazin-3-one phenoxypropylamines as potent, selective histamine H₃ receptor antagonists with potent cognition enhancing activity.",10.1016/j.bmcl.2014.01.061,"Discovery of (1R,6S)-5-[4-(1-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2-one (R,S-4a): histamine H(3) receptor inverse agonist demonstrating potent cognitive enhancing and wake promoting activity.",1
1176030,10.1016/j.bmcl.2011.06.108,"Identification of pyridazin-3-one derivatives as potent, selective histamine H₃ receptor inverse agonists with robust wake activity.",10.1016/j.bmcl.2011.08.104,Synthesis and evaluation of pyridazinone-phenethylamine derivatives as selective and orally bioavailable histamine H3 receptor antagonists with robust wake-promoting activity.,1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.bmc.2020.115574,"Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents.",1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.bmc.2018.10.019,"Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.",1
1175867,10.1016/j.bmcl.2018.07.048,"Design, synthesis and biological evaluation of a series of novel GPR40 agonists containing nitrogen heterocyclic rings.",10.1016/j.ejmech.2023.115990,Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.,1
1175867,10.1021/jm300170m,"Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.",10.1016/j.ejmech.2021.113810,Discovery and development of CPL207280 as new GPR40/FFA1 agonist.,1
1214046,10.1021/acs.jmedchem.7b01290,Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.,10.1021/acs.jmedchem.9b01346,Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.bmc.2018.07.007,Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1021/acs.jmedchem.2c00030,Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2017.09.024,Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.bmc.2019.115236,Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1039/C8MD00413G,"Design, synthesis and biological evaluation of novel 2-phenyl pyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.",1
1214046,10.1016/j.ejmech.2018.12.055,"Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.",10.1021/acs.jmedchem.2c00030,Medicinal Chemistry Strategies for the Development of Bruton's Tyrosine Kinase Inhibitors against Resistance.,1
1214046,10.1016/j.bmcl.2018.09.033,Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.,10.1016/j.bmcl.2018.09.018,Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.bmc.2018.07.007,Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2017.04.037,Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.,1
1214046,10.1016/j.ejmech.2018.12.055,"Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ.",10.1016/j.ejmech.2022.114232,Recent development of BTK-based dual inhibitors in the treatment of cancers.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.bmc.2021.116358,Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.,1
1214046,10.1016/j.bmcl.2018.09.033,Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.,10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1021/acs.jmedchem.8b00441,"Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.",1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.bmc.2021.116358,Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.,1
1220034,10.1016/j.ejmech.2013.06.052,"Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.",10.1016/j.bmcl.2016.08.015,"Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors.",1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2017.09.024,Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,1
1214046,10.1016/j.bmcl.2018.09.018,Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.,10.1016/j.ejmech.2021.113329,Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2021.114009,Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2017.06.016,Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.ejmech.2017.04.037,Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.,1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.bmc.2018.07.007,Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1021/acsmedchemlett.6b00235,"Discovery of Novel Bruton's Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold.",1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.bmc.2016.11.054,Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.,1
1214046,10.1016/j.ejmech.2016.11.047,Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.,10.1016/j.bmc.2021.116358,Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.,1
1214046,10.1021/acs.jmedchem.7b01290,Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma.,10.1016/j.bmc.2018.01.008,Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.,1
1214046,10.1021/jm4017762,"Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.",10.1016/j.ejmech.2017.03.001,"Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.",1
1214046,10.1016/j.ejmech.2017.10.080,Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.,10.1016/j.ejmech.2022.114232,Recent development of BTK-based dual inhibitors in the treatment of cancers.,1
1270807,10.1016/j.bmcl.2013.03.014,The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.,10.1016/j.bmcl.2015.07.092,Recent progress in the development of small-molecule glucagon receptor antagonists.,1
1265685,10.1021/acsmedchemlett.6b00005,"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.",10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
1265685,10.1021/acsmedchemlett.6b00005,"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1265685,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
1265685,10.1021/jm300867c,The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α.,10.1021/acsmedchemlett.6b00005,"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.",1
1265685,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1250535,10.1016/j.bmcl.2011.09.056,Identification of a novel RAMP-independent CGRP receptor antagonist.,10.1021/jm500364u,Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.,1
1220034,10.1016/j.ejmech.2013.06.052,"Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.",10.1016/j.bmc.2015.11.027,Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.,1
1220034,10.1016/j.bmc.2018.06.022,"Design, synthesis and biological evaluation of novel series of 2H-benzo[b][1,4]oxazin-3(4H)-one and 2H-benzo[b][1,4]oxazine scaffold derivatives as PI3Kα inhibitors.",10.1016/j.ejmech.2019.06.021,"Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.",1
1220034,10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
1220034,10.1016/j.ejmech.2013.06.052,"Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.",10.1016/j.bmc.2015.08.013,Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity.,1
1220034,10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1220034,10.1016/j.ejmech.2017.01.016,Discovery of a series of N-(5-(quinolin-6-yl)pyridin-3-yl)benzenesulfonamides as PI3K/mTOR dual inhibitors.,10.1016/j.ejmech.2019.06.021,"Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.",1
1220034,10.1021/ml5005014,Discovery of a Novel Series of Thienopyrimidine as Highly Potent and Selective PI3K Inhibitors.,10.1021/acsmedchemlett.7b00222,Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.,1
1220034,10.1016/j.ejmech.2013.06.052,"Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.",10.1016/j.bmc.2014.04.064,Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents.,1
1220034,10.1016/j.ejmech.2013.06.052,"Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.",10.1016/j.bmc.2015.07.017,"Modification of N-(6-(2-methoxy-3-(4-fluorophenylsulfonamido)pyridin-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)acetamide as PI3Ks inhibitor by replacement of the acetamide group with alkylurea.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm2001376,Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase.,1
1281325,10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",10.1016/j.bmcl.2018.05.054,"Discovery and evaluation of 3,5-disubstituted indole derivatives as Pim kinase inhibitors.",1
1281325,10.1021/ml400307j,"Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.",10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",1
1281325,10.1021/ml400307j,"Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.",10.1016/j.bmc.2020.115724,"Aminothiazolones as potent, selective and cell active inhibitors of the PIM kinase family.",1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1016/j.bmc.2017.07.036,Structure based drug design of Pim-1 kinase followed by pharmacophore guided synthesis of quinolone-based inhibitors.,1
1280078,10.1021/jm201467r,Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.,10.1021/jm201465w,"Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.",1
1280015,10.1016/j.bmcl.2014.06.071,"Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.",10.1016/j.bmcl.2015.04.102,"Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.",1
1277569,10.1021/jm801400g,"Use of acetylcholine binding protein in the search for novel alpha7 nicotinic receptor ligands. In silico docking, pharmacological screening, and X-ray analysis.",10.1016/j.bmcl.2011.12.008,"Structure-based design, synthesis and structure-activity relationships of dibenzosuberyl- and benzoate-substituted tropines as ligands for acetylcholine-binding protein.",1
1277553,10.1016/j.ejmech.2020.112643,Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer.,10.1016/j.ejmech.2022.114561,"Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent.",1
1276066,10.1021/jm400887j,Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?,10.1039/d3md00457k,Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules.,1
1270808,10.1016/j.bmcl.2011.10.113,A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.,10.1016/j.bmcl.2013.03.014,The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.,1
1270808,10.1016/j.bmcl.2013.03.014,The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.,10.1016/j.bmcl.2015.07.092,Recent progress in the development of small-molecule glucagon receptor antagonists.,1
1270808,10.1016/j.bmcl.2011.10.113,A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.,10.1016/j.bmcl.2015.07.092,Recent progress in the development of small-molecule glucagon receptor antagonists.,1
1270807,10.1016/j.bmcl.2011.10.113,A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.,10.1016/j.bmcl.2015.07.092,Recent progress in the development of small-molecule glucagon receptor antagonists.,1
1270807,10.1016/j.bmcl.2011.10.113,A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.,10.1021/jm300579z,"Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes.",1
1270807,10.1016/j.bmcl.2011.10.113,A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.,10.1016/j.bmcl.2013.03.014,The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.,1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1016/j.bmcl.2016.01.032,"Design and synthesis of substituted pyrido[3,2-d]-1,2,3-triazines as potential Pim-1 inhibitors.",1
173,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.ejmech.2014.10.056,Synthesis and evaluation of new indole-based chalcones as potential antiinflammatory agents.,1
173,10.1007/s00044-011-9901-0,"Pharmacological screening for anti-inflammatory, analgesic activity of pyrazolyl derivatives along with molecular docking studies",10.1016/j.ejmech.2021.113493,Contemporary advances of cyclic molecules proposed for inflammation.,1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2007.11.010,"1-Toluene-sulfonyl-3-[(3'-hydroxy-5'-substituted)-gamma-butyrolactone]-indoles: synthesis, COX-2 inhibition and anti-cancer activities.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.9b00823,Engineered Substrate for Cyclooxygenase-2: A Pentapeptide Isoconformational to Arachidonic Acid for Managing Inflammation.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2012.01.130,N-1 and C-3 substituted indole Schiff bases as selective COX-2 inhibitors: synthesis and biological evaluation.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2012.01.034,Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.07.023,"Potent, orally available, selective COX-2 inhibitors based on 2-imidazoline core.",1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2020.127376,Synthesis and evaluations of selective COX-2 inhibitory effects: Benzo[d]thiazol analogs.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2013.03.005,"Synthesis of novel 1,3,4-trisubstituted pyrazoles as anti-inflammatory and analgesic agents.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2013.09.052,"Synthesis, biological evaluation and molecular modeling study of 5-trifluoromethyl-Δ²-pyrazoline and isomeric 5/3-trifluoromethylpyrazole derivatives as anti-inflammatory agents.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm070821f,New celecoxib derivatives as anti-inflammatory agents.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2008.04.007,"Novel anti-inflammatory agents based on pyridazinone scaffold; design, synthesis and in vivo activity.",1
173,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1021/jm020545z,"In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-012-0253-1,"Synthesis of some new 2,6-disubstituted-3(2H)-pyridazinone derivatives and investigation of their analgesic, anti-inflammatory and antimicrobial activities",1
1334474,10.1021/acs.jmedchem.6b00523,Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.,10.1021/acs.jmedchem.7b00734,The ProTide Prodrug Technology: From the Concept to the Clinic.,1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1021/acs.jmedchem.1c00071,"Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine <i>C</i>-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV.",1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1021/acs.jmedchem.0c01929,Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.,1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1021/acs.jmedchem.6b01594,"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.",1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1021/acs.jmedchem.3c00750,"Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.",1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1016/j.bmc.2021.116364,Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.,1
1334397,10.1016/j.bmcl.2012.09.025,Identification of a novel and orally available benzimidazole derivative as an NPY Y5 receptor antagonist with in vivo efficacy.,10.1016/j.bmcl.2012.11.005,Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.,1
1326477,10.1016/j.bmcl.2020.127474,"Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.",10.1021/acs.jmedchem.2c01753,Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives.,1
1281325,10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",10.1021/acsmedchemlett.6b00518,Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket.,1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1016/j.ejmech.2019.03.050,PIM kinase inhibitors: Structural and pharmacological perspectives.,1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1021/acs.jmedchem.1c01084,"Optimization of 4,6-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth.",1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1016/j.ejmech.2019.02.022,"Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.",1
1281325,10.1021/acs.jmedchem.1c01084,"Optimization of 4,6-Disubstituted Pyrido[3,2-<i>d</i>]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth.",10.1021/acs.jmedchem.3c01802,Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.,1
1281325,10.1021/ml400307j,"Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors.",10.1016/j.bmc.2017.02.056,Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.,1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1021/jm3009234,Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.,1
1281325,10.1016/j.bmcl.2011.12.130,"Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.",10.1016/j.bmcl.2013.05.072,Identification of potent Yes1 kinase inhibitors using a library screening approach.,1
1335704,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1016/j.ejmech.2015.04.037,Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.,1
1335704,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
1335704,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1016/j.bmcl.2015.02.067,"Design, synthesis and antiproliferative activity evaluation of m-(4-morpholinyl-1,3,5-triazin-2-yl)benzamides in vitro.",1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1016/j.ejmech.2019.111718,Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acs.jmedchem.9b00622,Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1016/j.ejmech.2017.09.002,Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",1
1335704,10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acsmedchemlett.7b00222,Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acsmedchemlett.8b00167,Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acs.jmedchem.8b01262,"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.",1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1016/j.ejmech.2020.113101,Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents.,1
1334474,10.1016/j.bmcl.2012.02.105,"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides.",10.1021/acsmedchemlett.1c00624,"Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2.",1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1021/acsmedchemlett.1c00391,The Discovery of Conformationally Constrained Bicyclic Peptidomimetics as Potent Hepatitis C NS5A Inhibitors.,1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1016/j.ejmech.2015.06.033,Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors.,1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1016/j.bmcl.2015.06.031,"Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.",1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1021/acs.jmedchem.9b02176,"GSK2818713, a Novel Biphenylene Scaffold-Based Hepatitis C NS5A Replication Complex Inhibitor with Broad Genotype Coverage.",1
1339281,10.1021/acs.jmedchem.9b01562,Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate.,10.1016/j.ejmech.2021.114034,Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.,1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1016/j.bmcl.2014.10.057,Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.,1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1021/acs.jmedchem.1c00790,"Geminal Diheteroatomic Motifs: Some Applications of Acetals, Ketals, and Their Sulfur and Nitrogen Homologues in Medicinal Chemistry and Drug Design.",1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1016/j.bmcl.2014.10.056,Potent bisimidazole-based HCV NS5A inhibitors bearing annulated tricyclic motifs.,1
1338342,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1039/d2md00153e,"Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.",1
1338342,10.1021/ml200198x,"Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.",10.1016/j.ejmech.2024.116475,Recent discovery and development of AXL inhibitors as antitumor agents.,1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1021/acs.jmedchem.6b00235,"Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors.",1
1335704,10.1021/ml200156t,"Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.",10.1039/C2MD20044A,Small molecules targeting phosphoinositide 3-kinases,1
1335704,10.1021/acs.jmedchem.2c00267,Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.,10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
1335704,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.2c01070,"Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.",1
1335704,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.8b01262,"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.",1
1348407,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.8b00329,Plasmodial Kinase Inhibitors: License to Cure?,1
1348407,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
1348407,10.1021/acs.jmedchem.8b00382,"Identification of Fast-Acting 2,6-Disubstituted Imidazopyridines That Are Efficacious in the in Vivo Humanized Plasmodium falciparum NODscidIL2Rγ null Mouse Model of Malaria.",10.1021/acs.jmedchem.0c01411,"Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and In Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model.",1
1348407,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/acs.jmedchem.9b00761,The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.,1
1348407,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1021/jm4014778,"Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.",1
1348407,10.1021/jm3001373,"3,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.",10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
1348359,10.1021/jm300025r,Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.,10.1016/j.ejmech.2018.03.075,"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.",1
1348359,10.1021/jm300025r,Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.,10.1016/j.bmc.2014.06.044,"Design, synthesis and biological evaluation of thienopyridinones as Chk1 inhibitors.",1
1348359,10.1021/jm300025r,Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.,10.1021/acs.jmedchem.7b01490,Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.,1
1344984,10.1016/j.bmc.2012.04.033,"Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.",10.1016/j.ejmech.2018.07.063,Novel selenadiazole derivatives as selective antitumor and radical scavenging agents.,1
1344984,10.1016/j.bmc.2012.04.033,"Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy.",10.1016/j.bmcl.2016.01.017,"Synthesis and antiproliferative evaluation of novel 1,2,4-triazole derivatives incorporating benzisoselenazolone scaffold.",1
1342038,10.1021/jm2009925,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",10.1021/acs.jmedchem.0c02167,Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.,1
1342038,10.1021/jm2009925,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",10.1021/acs.jmedchem.7b00794,Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.,1
1342038,10.1021/jm2009925,"Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.",10.1016/j.ejmech.2022.114226,Design and development of photoswitchable DFG-Out RET kinase inhibitors.,1
1340894,10.1016/j.bmc.2016.03.055,Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.,10.1021/acs.jmedchem.7b01306,Current Insights of BRAF Inhibitors in Cancer.,1
1339281,10.1021/jm4013104,Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound.,10.1021/jm501291c,Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.,1
173,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmcl.2014.11.088,"Synthesis, analgesic, anti-inflammatory and anti-ulcerogenic activities of certain novel Schiff's bases as fenamate isosteres.",1
173,10.1016/j.ejmech.2009.06.035,"Design, synthesis and pharmacological screening of novel nitric oxide donors containing 1,5-diarylpyrazolin-3-one as nontoxic NSAIDs.",10.1016/j.ejmech.2010.10.001,Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",1
1376110,10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",10.1016/j.ejmech.2020.112571,A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.,1
1376110,10.1021/acsmedchemlett.1c00161,Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.,10.1021/acs.jmedchem.4c00312,Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.,1
1376107,10.1021/acs.jmedchem.0c00996,"Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.",10.1021/acs.jmedchem.1c00099,"Identification of Transthyretin Tetramer Kinetic Stabilizers That Are Capable of Inhibiting the Retinol-Dependent Retinol Binding Protein 4-Transthyretin Interaction: Potential Novel Therapeutics for Macular Degeneration, Transthyretin Amyloidosis, and Their Common Age-Related Comorbidities.",1
1376107,10.1016/j.ejmech.2016.08.003,Systemic optimization and structural evaluation of quinoline derivatives as transthyretin amyloidogenesis inhibitors.,10.1021/acs.jmedchem.2c01926,Novel Strategy To Inhibit Transthyretin Amyloidosis via the Synergetic Effect of Chemoselective Acylation and Noncovalent Inhibitor Release.,1
1376098,10.1021/jm300771j,Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.,10.1016/j.bmcl.2022.128837,Strategies for targeting the P2Y<sub>12</sub> receptor in the central nervous system.,1
1376098,10.1021/jm300771j,Identification of high-affinity P2Y₁₂ antagonists based on a phenylpyrazole glutamic acid piperazine backbone.,10.1016/j.bmcl.2016.04.030,State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.,1
1354598,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1016/j.ejmech.2020.112955,An insight into the recent development of the clinical candidates for the treatment of malaria and their target proteins.,1
1354598,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/acs.jmedchem.9b00761,The Development Process for Discovery and Clinical Advancement of Modern Antimalarials.,1
1354598,10.1021/jm300041e,Imidazolopiperazines: lead optimization of the second-generation antimalarial agents.,10.1021/acs.jmedchem.1c00034,Identification and Profiling of a Novel Diazaspiro[3.4]octane Chemical Series Active against Multiple Stages of the Human Malaria Parasite Plasmodium falciparum and Optimization Efforts.,1
1352913,10.1016/j.ejmech.2021.113396,Synthesis and in vivo screening of isosteviol derivatives as new cardioprotective agents.,10.1021/acs.jmedchem.4c00345,"Design, Synthesis, and In Vivo Evaluation of Isosteviol Derivatives as New SIRT3 Activators with Highly Potent Cardioprotective Effects.",1
1349462,10.1016/j.bmcl.2012.04.113,Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.,10.1021/jm401396p,"Discovery and early development of TMC647055, a non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase.",1
1348407,10.1021/acs.jmedchem.6b01641,"Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.",10.1021/acs.jmedchem.8b00648,"Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.",1
1376140,10.1021/acs.jmedchem.5b00771,"Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.",10.1016/j.ejmech.2017.12.030,Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.,1
1376140,10.1021/acs.jmedchem.5b00771,"Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.",10.1016/j.ejmech.2019.07.037,An overview on chemical structures as ΔF508-CFTR correctors.,1
1376110,10.1021/acs.jmedchem.1c02069,Discovery and Optimization of Highly Selective Inhibitors of CDK5.,10.1021/acs.jmedchem.3c00566,Novel Medicinal Chemistry Strategies Targeting CDK5 for Drug Discovery.,1
1376110,10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",10.1016/j.ejmech.2016.01.011,"5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.",1
173,10.1016/j.ejmech.2012.08.046,"Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.",10.1016/j.ejmech.2014.03.001,"1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.",1
173,10.1021/jm9805081,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.",10.1016/j.bmc.2006.11.029,"Preparation of 5-aryl-3-alkylthio-l,2,4-triazoles and corresponding sulfones with antiinflammatory-analgesic activity.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",1
173,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.ejmech.2023.115724,Magic shotgun approach to anti-inflammatory pharmacotherapy: Synthesis of novel thienopyrimidine monomers/heterodimer as dual COX-2 and 15-LOX inhibitors endowed with potent antioxidant activity.,1
173,10.1021/np970343j,Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.,10.1021/acsmedchemlett.5b00286,Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents.,1
173,10.1021/jm990965x,"1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole derivatives: a new series of potent and selective COX-2 inhibitors in which a sulfonyl group is not a structural requisite.",10.1016/j.ejmech.2018.04.060,Functionalized spirooxindole-indolizine hybrids: Stereoselective green synthesis and evaluation of anti-inflammatory effect involving TNF-α and nitrite inhibition.,1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.ejmech.2008.10.039,"Synthesis and biological evaluation of 4,5-diphenyloxazolone derivatives on route towards selective COX-2 inhibitors.",1
173,10.1021/jm0009383,"Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.",10.1039/d2md00192f,"Insights into the medicinal chemistry of heterocycles integrated with a pyrazolo[1,5-<i>a</i>]pyrimidine scaffold.",1
173,10.1016/j.bmcl.2009.04.014,"Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads.",10.1016/j.bmcl.2013.11.080,Rationally designed hybrid molecules with appreciable COX-2 inhibitory and anti-nociceptive activities.,1
173,10.1016/j.bmcl.2016.02.008,"Synthesis and anti-inflammatory activity evaluation of a novel series of 6-phenoxy-[1,2,4]triazolo[3,4-a]phthalazine-3-carboxamide derivatives.",10.1016/j.bmcl.2017.08.014,"Design, synthesis, anti-inflammatory activity, and molecular docking studies of perimidine derivatives containing triazole.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.12.063,"Design, synthesis and biological evaluation of novel 4-hydroxybenzene acrylic acid derivatives.",1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2022.114682,Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.,1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2022.114682,Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents.,1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2024.116327,Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.,1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2024.116753,"Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.",1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2023.115532,Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase.,1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2022.114816,"Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.",1
1377990,10.1016/j.ejmech.2023.115532,Identification of 5-[5-cyano-1-(pyridin-2-ylmethyl)-1H-indole-3-carboxamido] thiazole-4-carboxylic acid as a promising dual inhibitor of urate transporter 1 and xanthine oxidase.,10.1016/j.ejmech.2024.116327,Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities.,1
1377665,10.1021/acs.jmedchem.0c01001,Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors.,10.1021/acs.jmedchem.4c00527,N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.,1
1377263,10.1016/j.bmcl.2017.11.007,Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.,10.1016/j.bmcl.2019.126703,Synthesis and antidepressant effect of novel aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT1A/5-HT7.,1
1377263,10.1016/j.bmcl.2017.11.007,Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT1A/5-HT7.,10.1016/j.bmc.2024.117698,"Design, synthesis, and biological evaluation of aralkyl piperazine and piperidine derivatives targeting SSRI/5-HT<sub>1A</sub>/5-HT<sub>7</sub>.",1
1376149,10.1021/jm5010144,"Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90.",10.1021/acs.jmedchem.9b01420,Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.,1
1376149,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1016/j.bmcl.2019.126809,"Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1.",1
1376149,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.9b01420,Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.,1
1376149,10.1021/jm400619b,Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.,10.1021/acs.jmedchem.5b01106,Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.,1
1378032,10.1021/acs.jmedchem.0c00374,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
1378032,10.1021/acs.jmedchem.8b01491,Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.,10.1021/acs.jmedchem.0c00374,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",1
1378029,10.1016/j.bmcl.2015.09.020,"Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.",10.1021/acs.jmedchem.3c00050,Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.,1
1378008,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1021/acs.jmedchem.2c01164,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",1
1378008,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/jm501239f,Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.,1
1378008,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,1
1378008,10.1021/acsmedchemlett.6b00137,Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.,10.1021/acs.jmedchem.2c01487,A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives.,1
1378008,10.1021/jm400048v,Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.,10.1021/acs.jmedchem.2c01164,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",1
1378007,10.1016/j.bmc.2012.09.030,Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.,10.1016/j.bmcl.2013.10.022,The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors.,1
1378005,10.1016/j.bmcl.2016.12.013,Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus.,10.1016/j.bmcl.2017.11.005,The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.,1
1377998,10.1021/acs.jmedchem.8b01714,Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
1377998,10.1021/acsmedchemlett.6b00468,Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach.,10.1021/acs.jmedchem.0c00696,Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.,1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1021/acs.jmedchem.4c00136,Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability.,1
1377990,10.1021/acs.jmedchem.0c00223,Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.,10.1016/j.ejmech.2022.114890,Recent advances in gout drugs.,1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2022.114816,"Design, synthesis and activity evaluation of novel lesinurad analogues containing thienopyrimidinone or pyridine substructure as human urate transporter 1 inhibitors.",1
1377990,10.1021/acs.jmedchem.1c02057,Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability.,10.1016/j.ejmech.2024.116753,"Design, synthesis and bioactivity evaluation of isobavachin derivatives as hURAT1 inhibitors for hyperuricemia agents.",1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1016/j.ejmech.2021.113164,Rational design of SphK inhibitors using crystal structures aided by computer.,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1016/j.bmc.2016.05.047,Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice.,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1021/jm501760d,Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors.,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1021/acs.jmedchem.7b00233,"Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.",1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1016/j.ejmech.2020.113121,Probing the substitution pattern of indole-based scaffold reveals potent and selective sphingosine kinase 2 inhibitors.,1
1422105,10.1016/j.bmcl.2013.01.070,Discovery of a novel series of quinolone α7 nicotinic acetylcholine receptor agonists.,10.1016/j.bmcl.2017.10.009,"Design and synthesis of a novel series of (1'S,2R,4'S)-3H-4'-azaspiro[benzo[4,5]imidazo[2,1-b]oxazole-2,2'-bicyclo[2.2.2]octanes] with high affinity for the α7 neuronal nicotinic receptor.",1
1420377,10.1021/ml300049d,Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).,10.1016/j.ejmech.2023.115236,Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents.,1
1420377,10.1021/ml300049d,Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).,10.1021/acs.jmedchem.0c02085,Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor.,1
1420377,10.1021/ml300049d,Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973).,10.1016/j.ejmech.2023.115758,A review: FDA-approved fluorine-containing small molecules from 2015 to 2022.,1
1414543,10.1039/C7MD00104E,A structurally guided dissection-then-evolution strategy for ligand optimization of smoothened receptor.,10.1016/j.bmc.2022.117051,"Design, synthesis and biological evaluation of novel 4-aminopiperidine derivatives as SMO/ERK dual inhibitors.",1
1414543,10.1039/C7MD00104E,A structurally guided dissection-then-evolution strategy for ligand optimization of smoothened receptor.,10.1016/j.bmc.2018.04.058,Synthesis and evaluation of novel dimethylpyridazine derivatives as hedgehog signaling pathway inhibitors.,1
1412359,10.1021/acsmedchemlett.2c00098,Discovery and Optimization of Seven-Membered Lactam-Based Compounds to Phenocopy the Inhibition of the Aurora Kinase B.,10.1016/j.ejmech.2022.114904,"2-Phenoxy-3, 4'-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization.",1
1383600,10.1021/jm00199a018,Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.,10.1016/j.bmcl.2014.05.033,Opioids and efflux transporters. Part 4: influence of N-substitution on P-glycoprotein substrate activity of noroxymorphone analogues.,1
1380095,10.1016/j.bmc.2010.03.041,"Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.",10.1021/acs.jmedchem.6b01260,Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.,1
1380095,10.1016/j.bmc.2010.03.041,"Discovery of GS-9131: Design, synthesis and optimization of amidate prodrugs of the novel nucleoside phosphonate HIV reverse transcriptase (RT) inhibitor GS-9148.",10.1021/acs.jmedchem.7b00416,Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.,1
1378032,10.1021/acs.jmedchem.8b01491,Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes.,10.1021/acs.jmedchem.3c00412,Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.,1
1448219,10.1021/acs.jmedchem.7b00618,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",10.1016/j.ejmech.2023.115331,"Application of an ""inhalation by design"" approach to the identification and in-vitro evaluation of novel purine based PI3Kδ inhibitors.",1
1448219,10.1021/acs.jmedchem.7b00618,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",10.1021/acs.jmedchem.0c01544,"Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.",1
1448219,10.1021/acs.jmedchem.7b00618,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",10.1021/acs.jmedchem.3c00508,Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.,1
1448219,10.1021/acs.jmedchem.1c00004,"Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.",10.1021/acs.jmedchem.1c01520,Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma.,1
1442605,10.1016/j.bmcl.2014.12.078,"Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.",10.1016/j.ejmech.2022.114595,Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.,1
1439374,10.1021/acs.jmedchem.5b01840,A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease.,10.1016/j.ejmech.2019.111805,Discovery of small-molecule candidates against inflammatory bowel disease.,1
1439374,10.1021/acs.jmedchem.5b01840,A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease.,10.1021/acs.jmedchem.6b01309,Structural Analysis of Chemokine Receptor-Ligand Interactions.,1
1439374,10.1021/acs.jmedchem.5b01840,A New Series of Orally Bioavailable Chemokine Receptor 9 (CCR9) Antagonists; Possible Agents for the Treatment of Inflammatory Bowel Disease.,10.1016/j.bmcl.2019.06.042,Small-molecule agents for the treatment of inflammatory bowel disease.,1
1429059,10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,10.1016/j.bmcl.2013.10.057,Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.,1
1429059,10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,10.1021/acs.jmedchem.0c01033,Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.,1
1429054,10.1021/jm2014887,Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.,10.1016/j.ejmech.2017.07.051,"Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.",1
1428839,10.1016/j.ejmech.2018.07.020,"Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui.",10.1021/acs.jnatprod.9b00088,Potent Anti-HIV Ingenane Diterpenoids from Euphorbia ebracteolata.,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1021/acs.jmedchem.5b01439,From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II).,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1016/j.ejmech.2020.112713,"Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors.",1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1021/acs.jmedchem.9b00162,Topographical Mapping of Isoform-Selectivity Determinants for J-Channel-Binding Inhibitors of Sphingosine Kinases 1 and 2.,1
1425224,10.1016/j.bmcl.2013.06.030,Structure guided design of a series of sphingosine kinase (SphK) inhibitors.,10.1021/jm4011687,Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.,1
1515670,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2021.113205,Recent advances of dual FGFR inhibitors as a novel therapy for cancer.,1
1515670,10.1021/jm301581y,Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib.,10.1016/j.ejmech.2023.115475,Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives.,1
1481484,10.1021/acs.jmedchem.1c01711,"Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment.",10.1016/j.ejmech.2022.114489,A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.,1
1481484,10.1016/j.ejmech.2022.114489,A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.,10.1016/j.ejmech.2022.114737,Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.,1
1481484,10.1021/acs.jmedchem.1c01711,"Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment.",10.1016/j.ejmech.2022.114737,Discovery of potent human dihydroorotate dehydrogenase inhibitors based on a benzophenone scaffold.,1
1450297,10.1016/j.ejmech.2018.05.005,"Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.",10.1016/j.ejmech.2021.113205,Recent advances of dual FGFR inhibitors as a novel therapy for cancer.,1
1448219,10.1021/acs.jmedchem.8b02014,"Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.",10.1021/acs.jmedchem.0c01544,"Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease.",1
1448219,10.1021/acsmedchemlett.7b00222,Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity.,10.1016/j.ejmech.2021.113661,"Bioisosteric replacements of the indole moiety for the development of a potent and selective PI3Kδ inhibitor: Design, synthesis and biological evaluation.",1
1448219,10.1021/acs.jmedchem.8b02014,"Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.",10.1021/acs.jmedchem.1c00004,"Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.",1
1448219,10.1021/acs.jmedchem.7b00618,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
1448219,10.1021/acs.jmedchem.1c00004,"Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases.",10.1021/acs.jmedchem.3c00508,Discovery of Highly Selective and Orally Bioavailable PI3Kδ Inhibitors with Anti-Inflammatory Activity for Treatment of Acute Lung Injury.,1
1448219,10.1016/j.bmcl.2017.01.077,Identification of highly potent and selective PI3Kδ inhibitors.,10.1021/acs.jmedchem.7b00618,"Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological Disorders.",1
1448219,10.1016/j.bmc.2022.117028,Identification of PI3K/HDAC Dual-targeted inhibitors with subtype selectivity as potential therapeutic agents against solid Tumors: Building HDAC6 potency in a Quinazolinone-based PI3Kδ-selective template.,10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
1448219,10.1021/acsmedchemlett.6b00209,"Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.",10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
1448219,10.1021/acsmedchemlett.6b00209,"Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.",10.1016/j.ejmech.2018.09.033,Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.,1
1448219,10.1016/j.bmcl.2017.01.077,Identification of highly potent and selective PI3Kδ inhibitors.,10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
173,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.bmc.2022.116633,Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2006.06.036,Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/C8MD00022K,"Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2011.06.019,"Analogue-based design, synthesis and molecular docking analysis of 2,3-diaryl quinazolinones as non-ulcerogenic anti-inflammatory agents.",1
173,10.1016/j.ejmech.2009.12.078,"Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1'- cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents.",10.1016/j.ejmech.2019.03.042,"Novel benzenesulfonamide and 1,2-benzisothiazol-3(2H)-one-1,1-dioxide derivatives as potential selective COX-2 inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(01)00212-8,Thiazole analogues of the NSAID indomethacin as selective COX-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2010.07.132,"Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1,2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2017.08.023,Synthesis and biological evaluations of new nitric oxide-anti-inflammatory drug hybrids.,1
173,10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",10.1016/j.bmcl.2004.01.048,A prodrug approach to COX-2 inhibitors with methylsulfone.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00559-4,A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.08.013,"Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(00)00634-x,"2,2-Dimethyl-4,5-diaryl-3(2H)furanone derivatives as selective cyclo-oxygenase-2 inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2016.12.030,"Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC.",1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1039/d4md00135d,"New pyrazole-pyridazine hybrids as selective COX-2 inhibitors: design, synthesis, molecular docking, &lt;i&gt;in silico&lt;/i&gt; studies and investigation of their anti-inflammatory potential by evaluation of TNF-α, IL-6, PGE-2 and NO in LPS-induced RAW264.7 macrophages.",1
173,10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,10.1016/j.bmc.2010.01.021,"Synthesis and biological evaluation of novel pyrazolyl-2,4-thiazolidinediones as anti-inflammatory and neuroprotective agents.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2023.115496,"Synthesis and anti-inflammatory activity evaluation of NO-releasing furoxan/1,2,4-triazole hybrid derivatives.",1
1566719,10.1021/acs.jmedchem.0c00035,"Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.",10.1016/j.ejmech.2021.113853,Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.,1
1566719,10.1016/j.ejmech.2013.03.062,"In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208).",10.1016/j.ejmech.2021.113953,"Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.",1
1563853,10.1021/acs.jmedchem.5b01483,"The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).",10.1021/acs.jmedchem.2c01422,"Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.",1
1529535,10.1021/jm400349k,"Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.",10.1021/acs.jmedchem.8b01365,Improvement of Aqueous Solubility of Lapatinib-Derived Analogues: Identification of a Quinolinimine Lead for Human African Trypanosomiasis Drug Development.,1
1528018,10.1021/acs.jmedchem.0c01161,"Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.",10.1016/j.ejmech.2022.114479,Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia.,1
1528018,10.1021/acs.jmedchem.0c01161,"Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.",10.1021/acs.jmedchem.3c00231,Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.,1
1525993,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1021/acs.jmedchem.8b01262,"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.",1
1525993,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1021/acs.jmedchem.0c00620,"4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.",1
1525993,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1021/jm501778s,"Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2.",1
1525993,10.1016/j.bmcl.2013.01.019,Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.,10.1039/C5MD00493D,"eCF309: a potent, selective and cell-permeable mTOR inhibitor",1
1525737,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.6b01575,Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives.,1
1523585,10.1021/acs.jmedchem.8b00246,"Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.",10.1021/acs.jmedchem.1c00489,"Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.",1
1523585,10.1021/jm501833t,"Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.",10.1021/acs.jmedchem.7b00393,BACE-1 Inhibitors: From Recent Single-Target Molecules to Multitarget Compounds for Alzheimer's Disease.,1
1523585,10.1021/acs.jmedchem.8b00246,"Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.",10.1016/j.bmcl.2018.12.049,New evolutions in the BACE1 inhibitor field from 2014 to 2018.,1
1523585,10.1021/jm501833t,"Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.",10.1016/j.bmcl.2018.12.049,New evolutions in the BACE1 inhibitor field from 2014 to 2018.,1
1519608,10.1021/jm4006274,Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism.,10.1021/jm401071u,Resistance by allostery: a novel perspective for eg5-targeted drug design.,1
1592320,10.1021/acs.jmedchem.2c00568,"Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.",10.1021/acs.jmedchem.4c00817,"Discovery of Pyrazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.",1
1592320,10.1021/acs.jmedchem.8b02014,"Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.",10.1021/acs.jmedchem.2c00568,"Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.",1
1588448,10.1016/j.bmcl.2013.09.016,Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists.,10.1021/acs.jmedchem.6b00305,Transient Receptor Potential Melastatin 8 Channel (TRPM8) Modulation: Cool Entryway for Treating Pain and Cancer.,1
1583828,10.1021/jm400732v,Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,10.1021/jm400731m,Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.,1
1583828,10.1021/jm400732v,Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.,10.1021/acs.jmedchem.8b01668,Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.,1
1570706,10.1016/j.ejmech.2021.113259,"Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.",10.1016/j.bmc.2021.116396,Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects.,1
1570706,10.1021/acs.jmedchem.7b01039,Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design.,10.1016/j.bmcl.2022.128990,Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I<sup>1/2</sup> ALK inhibitors with promising antitumor effects.,1
1570706,10.1016/j.bmc.2020.115719,"Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.",10.1016/j.ejmech.2023.115477,Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy.,1
1570706,10.1016/j.ejmech.2021.113259,"Structure-based optimization identified novel furyl-containing 2,4-diarylaminopyrimidine analogues as ALK/ROS1 dual inhibitors with anti-mutation effects.",10.1016/j.ejmech.2023.115477,Recent advances in the development of dual ALK/ROS1 inhibitors for non-small cell lung cancer therapy.,1
1570706,10.1016/j.bmc.2020.115715,"Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.",10.1016/j.bmc.2021.116108,"Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects.",1
1566719,10.1016/j.ejmech.2013.03.062,"In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208).",10.1016/j.bmcl.2019.06.028,"Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208.",1
1566719,10.1021/acs.jmedchem.0c00035,"Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.",10.1021/acs.jmedchem.1c01851,"Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.",1
1566719,10.1016/j.ejmech.2016.05.057,"Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.",10.1016/j.ejmech.2022.114423,"Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.",1
1566719,10.1021/acs.jmedchem.0c00035,"Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.",10.1016/j.ejmech.2022.114423,"Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.",1
1566719,10.1016/j.ejmech.2016.05.057,"Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.",10.1021/acs.jmedchem.6b01761,Drug Discovery Targeting Bromodomain-Containing Protein 4.,1
1566719,10.1021/acs.jmedchem.0c00035,"Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation.",10.1021/acs.jmedchem.3c01837,Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2012.09.069,"Analogue-based design, synthesis and docking of non-steroidal anti-inflammatory agents. Part 2: methyl sulfanyl/methyl sulfonyl substituted 2,3-diaryl-2,3-dihydro-1H-quinazolin-4-ones.",1
173,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.bmcl.2014.11.088,"Synthesis, analgesic, anti-inflammatory and anti-ulcerogenic activities of certain novel Schiff's bases as fenamate isosteres.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-011-9823-x,"Synthesis of 1-(4-aminosulfonylphenyl)-3,5-diarylpyrazoline derivatives as potent antiinflammatory and antimicrobial agents",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-009-9163-2,"Lonazolac analogues: molecular modeling, synthesis, and in vivo anti-inflammatory activity",1
1606934,10.1021/acs.jmedchem.7b00807,"Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.",10.1021/acs.jmedchem.7b01466,"Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.",1
1606934,10.1021/acs.jmedchem.7b00807,"Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.",10.1021/acs.jmedchem.1c00115,Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.,1
1606934,10.1021/acs.jmedchem.7b00709,"Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.",10.1021/acs.jmedchem.1c00115,Advances in Cyclic Nucleotide Phosphodiesterase-Targeted PET Imaging and Drug Discovery.,1
1606934,10.1021/acs.jmedchem.7b00709,"Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.",10.1021/acs.jmedchem.7b00807,"Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.",1
1604993,10.1021/acs.jmedchem.5b00892,Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile).,10.1016/j.bmcl.2015.11.087,7TM X-ray structures for class C GPCRs as new drug-discovery tools. 1. mGluR5.,1
1592320,10.1021/acs.jmedchem.8b02014,"Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.",10.1016/j.ejmech.2023.115768,"Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.",1
1592320,10.1021/acs.jmedchem.8b02014,"Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.",10.1021/acs.jmedchem.4c00817,"Discovery of Pyrazolo[1,5-<i>a</i>]pyridine Derivatives as Potent and Selective PI3Kγ/δ Inhibitors.",1
1592320,10.1016/j.bmc.2023.117261,"Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.",10.1021/acs.jmedchem.4c00347,Designing Small Molecule PI3Kγ Inhibitors: A Review of Structure-Based Methods and Computational Approaches.,1
1592320,10.1021/acs.jmedchem.2c00568,"Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.",10.1016/j.ejmech.2023.115768,"Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.",1
1592320,10.1021/acsmedchemlett.6b00209,"Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.",10.1016/j.ejmech.2018.09.033,Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.,1
1592320,10.1021/acsmedchemlett.6b00209,"Discovery of a Series of 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.",10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
1592320,10.1021/acs.jmedchem.6b00799,"Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.",10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
1622615,10.1021/acs.jmedchem.6b00523,Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates.,10.1021/acs.jmedchem.7b00734,The ProTide Prodrug Technology: From the Concept to the Clinic.,1
1615006,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1615006,10.1021/jm500571f,"Lead optimization of 1,4-azaindoles as antimycobacterial agents.",10.1021/acsmedchemlett.9b00343,Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity.,1
1610476,10.1021/acs.jmedchem.7b00437,Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.,10.1021/acs.jmedchem.2c01037,"Design, Synthesis, and Biological Evaluations of Pyridyl 4,5,6,7-Tetrahydro-4,7-Methanobenzo[<i>d</i>]isoxazoles as Potent and Selective Inhibitors of 11β-Hydroxylase.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm9906015,"Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2004.01.053,"Methanesulfonamide group at position-4 of the C-5-phenyl ring of 1,5-diarylpyrazole affords a potent class of cyclooxygenase-2 (COX-2) inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2013.05.029,Synthesis of novel celecoxib analogues by bioisosteric replacement of sulfonamide as potent anti-inflammatory agents and cyclooxygenase inhibitors.,1
173,10.1021/jm9805081,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.",10.1016/j.ejmech.2010.09.016,"Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.",1
173,10.1021/jm701191z,Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.,10.1021/jm201528b,Cyclooxygenase-1-selective inhibitors based on the (E)-2'-des-methyl-sulindac sulfide scaffold.,1
173,10.1016/j.ejmech.2009.12.078,"Synthesis, biological evaluation and molecular docking of novel series of spiro [(2H,3H) quinazoline-2,1'- cyclohexan]-4(1H)- one derivatives as anti-inflammatory and analgesic agents.",10.1039/C9MD00228F,Discovery of new non-acidic lonazolac analogues with COX-2 selectivity as potent anti-inflammatory agents.,1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2015.02.043,Rapid 'one-pot' synthesis of a novel benzimidazole-5-carboxylate and its hydrazone derivatives as potential anti-inflammatory and antimicrobial agents.,1
173,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.ejmech.2013.12.023,Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.,1
173,10.1016/j.ejmech.2021.113731,"Identification, semisynthesis, and anti-inflammatory evaluation of 2,3-seco-clavine-type ergot alkaloids from human intestinal fungus Aspergillus fumigatus CY018.",10.1016/j.ejmech.2022.114497,Novel quinoline-based derivatives: A new class of PDE4B inhibitors for adjuvant-induced arthritis.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2022.116633,Synthetic methodology-enabled discovery of a tunable indole template for COX-1 inhibition and anti-cancer activity.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020545z,"In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2012.11.046,"Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.",1
1761965,10.1016/j.bmcl.2020.126969,"Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains.",10.1016/j.ejmech.2024.116313,Recent advances in developing modified C14 side chain pleuromutilins as novel antibacterial agents.,1
1758265,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1021/acs.jmedchem.3c00504,Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.,1
1758265,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1016/j.ejmech.2023.116054,Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.,1
1744850,10.1021/acs.jmedchem.9b01681,Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors.,10.1021/acs.jmedchem.1c02169,"Design, Synthesis, and Preclinical Profiling of GSK3739936 (BMS-986180), an Allosteric Inhibitor of HIV-1 Integrase with Broad-Spectrum Activity toward 124/125 Polymorphs.",1
1724957,10.1021/acs.jmedchem.8b01492,Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.,10.1021/acs.jmedchem.9b01736,"Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.",1
1724957,10.1021/acs.jmedchem.8b01492,Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.,10.1016/j.ejmech.2022.115030,"Function-oriented synthesis of Imidazo[1,2-a]pyrazine and Imidazo[1,2-b]pyridazine derivatives as potent PI3K/mTOR dual inhibitors.",1
1724957,10.1021/acs.jmedchem.8b01492,Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective.,10.1016/j.ejmech.2019.111718,Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer.,1
1677842,10.1021/acsmedchemlett.0c00095,Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif.,10.1021/acs.jmedchem.2c01070,"Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.",1
1677677,10.1021/acs.jmedchem.7b00662,Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.,10.1016/j.ejmech.2024.116408,Modulators for palmitoylation of proteins and small molecules.,1
1677677,10.1021/acs.jmedchem.7b00662,Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.,10.1021/acs.jmedchem.0c01799,Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.,1
1677677,10.1021/acs.jmedchem.7b00662,Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.,10.1016/j.ejmech.2018.02.034,Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.,1
1626740,10.1016/j.ejmech.2018.01.100,Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.,10.1016/j.ejmech.2020.112446,Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy.,1
1626740,10.1016/j.ejmech.2018.01.100,Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.,10.1016/j.bmcl.2021.128215,"Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.",1
1626740,10.1021/acs.jmedchem.7b00717,Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.,10.1021/acs.jmedchem.8b00180,Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations.,1
1626740,10.1021/acs.jmedchem.1c00690,Structure-Based Optimization of 3-Phenyl-<i>N</i>-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors.,10.1021/acs.jmedchem.4c00643,Discovery of Novel Mcl-1 Inhibitors with a 3-Substituted-1<i>H</i>-indole-1-yl Moiety Binding to the P1-P3 Pockets to Induce Apoptosis in Acute Myeloid Leukemia Cells.,1
1623950,10.1016/j.ejmech.2018.02.025,"Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.",10.1021/acs.jmedchem.0c00082,Discovery of a Silicon-Containing Pan-Genotype Hepatitis C Virus NS5A Inhibitor.,1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.ejmech.2023.115443,"Synthesis of new multitarget-directed ligands containing thienopyrimidine nucleus for inhibition of 15-lipoxygenase, cyclooxygenases, and pro-inflammatory cytokines.",1
173,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.ejmech.2006.09.001,"Non-carboxylic analogues of arylpropionic acids: synthesis, anti-inflammatory activity and ulcerogenic potential.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm0000719,"Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2019.03.036,Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-011-9853-4,Synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatoryantibacterial agents,1
173,10.1016/j.ejmech.2013.03.011,"Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: design, synthesis and biological screening.",10.1016/j.bmcl.2016.12.069,"Novel 2,4-dichlorophenoxy acetic acid substituted thiazolidin-4-ones as anti-inflammatory agents: Design, synthesis and biological screening.",1
173,10.1021/jm9805081,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.",10.1016/j.ejmech.2010.10.035,"Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.",1
173,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1016/j.ejmech.2010.10.005,"Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/acs.jmedchem.1c00880,"Design, Synthesis, and Activity Evaluation of Stereoconfigured Tartarate Derivatives as Potential Anti-inflammatory Agents <i>In Vitro</i> and <i>In Vivo</i>.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2018.10.014,"Design, synthesis and biological evaluation of novel 2-sulfonylindoles as potential anti-inflammatory therapeutic agents for treatment of acute lung injury.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",1
173,10.1016/j.ejmech.2014.03.003,"Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.",10.1016/j.ejmech.2018.04.004,Indolyl-isoxazolidines attenuate LPS-stimulated pro-inflammatory cytokines and increase survival in a mouse model of sepsis: Identification of potent lead.,1
173,10.1021/jm9805081,"Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.",10.1016/j.ejmech.2010.10.001,Synthesis and biological evaluation of some thiazolylpyrazole derivatives as dual anti-inflammatory antimicrobial agents.,1
173,10.1016/j.ejmech.2012.08.046,"Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.",10.1016/j.bmcl.2014.08.062,Synthesis of novel pyrazole–thiadiazole hybrid as potential potent and selective cyclooxygenase-2 (COX-2) inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2014.08.050,"Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.",1
1763252,10.1021/acs.jmedchem.8b00172,"Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1782648,10.1016/j.bmcl.2015.03.013,Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.,10.1016/j.bmcl.2019.04.042,"Discovery of 5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors.",1
1782495,10.1021/acs.jmedchem.9b00394,Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.,10.1021/acsmedchemlett.0c00428,Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.,1
1782495,10.1021/acs.jmedchem.9b00394,Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.,10.1021/acsmedchemlett.1c00345,Structurally Optimized Potent Dual-Targeting NBTI Antibacterials with an Enhanced Bifurcated Halogen-Bonding Propensity.,1
1780336,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",1
1780336,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1016/j.ejmech.2023.115658,"Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.",1
1780336,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
1780336,10.1016/j.bmcl.2017.06.037,"Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors.",10.1021/acs.jmedchem.3c02188,Discovery of a Novel Potent Tetrazole Antifungal Candidate with High Selectivity and Broad Spectrum.,1
1780336,10.1016/j.bmcl.2014.05.068,Design and optimization of highly-selective fungal CYP51 inhibitors.,10.1016/j.ejmech.2023.115658,"Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.",1
1763582,10.1016/j.ejmech.2018.04.062,Structure-based lead optimization to improve antiviral potency and ADMET properties of phenyl-1H-pyrrole-carboxamide entry inhibitors targeted to HIV-1 gp120.,10.1021/acs.jmedchem.9b02149,"Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.",1
1763572,10.1016/j.ejmech.2015.12.023,"Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.",10.1021/acs.jmedchem.8b00049,How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?,1
1763569,10.1021/acs.jmedchem.2c01550,Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.,10.1021/acs.jmedchem.3c01712,Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.,1
1763563,10.1021/acs.jmedchem.8b00246,"Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.",10.1021/acs.jmedchem.1c00359,Discovery of Extremely Selective Fused Pyridine-Derived β-Site Amyloid Precursor Protein-Cleaving Enzyme (BACE1) Inhibitors with High In Vivo Efficacy through 10s Loop Interactions.,1
1763563,10.1021/acs.jmedchem.8b00246,"Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.",10.1016/j.bmcl.2018.12.049,New evolutions in the BACE1 inhibitor field from 2014 to 2018.,1
1763563,10.1021/acs.jmedchem.8b00246,"Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation.",10.1021/acs.jmedchem.0c01858,Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2.,1
1763252,10.1021/acs.jmedchem.8b00172,"Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.",10.1016/j.ejmech.2020.113139,Small organic molecules targeting the energy metabolism of Mycobacterium tuberculosis.,1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.bmcl.2014.08.062,Synthesis of novel pyrazole–thiadiazole hybrid as potential potent and selective cyclooxygenase-2 (COX-2) inhibitors.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",1
1789220,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acs.jmedchem.1c01049,Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acsmedchemlett.1c00652,Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.06.053,"hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents.",1
1789220,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.bmc.2021.116529,"Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.",1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.1c00263,Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities.,1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.03.060,"Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety.",1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,1
1782648,10.1016/j.bmcl.2015.03.013,Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.,10.1016/j.ejmech.2018.11.015,"Design, synthesis and biological evaluation of novel, orally bioavailable pyrimidine-fused heterocycles as influenza PB2 inhibitors.",1
1782648,10.1016/j.bmcl.2015.03.013,Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors.,10.1016/j.ejmech.2023.115185,Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acsmedchemlett.8b00634,Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties.,1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2019.06.038,"Design, synthesis and biological activity of N-(2-phenoxy)ethyl imidazo[1,2-a]pyridine-3-carboxamides as new antitubercular agents.",1
1789220,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1789220,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
1789220,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",10.1016/j.ejmech.2023.115545,"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety.",1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2022.114993,Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis.,1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1021/acsmedchemlett.8b00634,Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties.,1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1021/acs.jmedchem.9b00912,"Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.",1
1789220,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2023.117212,Targeting mycobacterial membranes and membrane proteins: Progress and limitations.,1
1789220,10.1021/acsmedchemlett.8b00177,"Identification of N-Benzyl 3,5-Dinitrobenzamides Derived from PBTZ169 as Antitubercular Agents.",10.1016/j.ejmech.2022.114946,Pyrimidine derivatives with antitubercular activity.,1
1789220,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1789220,10.1016/j.ejmech.2018.09.042,Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2021.113398,"Design, synthesis and biological activity of N-(amino)piperazine-containing benzothiazinones against Mycobacterium tuberculosis.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1021/acs.jmedchem.2c00227,Tuberculosis Drug Discovery: Challenges and New Horizons.,1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1016/j.ejmech.2019.111709,The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer.,1
1817518,10.1021/acs.jmedchem.0c02005,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",10.1021/acs.jmedchem.3c00027,"Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.",1
1817518,10.1021/acs.jmedchem.3c00027,"Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.",10.1021/acs.jmedchem.3c01934,"Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR<sup>L858R/T790M</sup>/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers.",1
1797457,10.1016/j.ejmech.2020.112990,"Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).",10.1016/j.ejmech.2024.116415,"Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.",1
1797457,10.1021/acs.jmedchem.9b00510,"Discovery and Development of a Series of Pyrazolo[3,4-<i>d</i>]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design.",10.1021/acs.jmedchem.2c01507,Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.,1
1797457,10.1016/j.ejmech.2018.05.005,"Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.",10.1016/j.ejmech.2024.116415,"Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.",1
1797457,10.1016/j.ejmech.2020.112990,"Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).",10.1016/j.bmcl.2022.128982,Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.,1
1797457,10.1021/acs.jmedchem.9b00510,"Discovery and Development of a Series of Pyrazolo[3,4-<i>d</i>]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design.",10.1021/acs.jmedchem.1c00174,"Discovery and Optimization of a Novel 2<i>H</i>-Pyrazolo[3,4-d]pyrimidine Derivative as a Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitor.",1
1793370,10.1021/acs.jmedchem.5b00742,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",10.1021/acs.jmedchem.5b00832,Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.,1
1793370,10.1021/acs.jmedchem.5b00742,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",10.1039/d3md00573a,"Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2020.112409,"Identification of benzothiazinones containing 2-benzyl-2,7-diazaspiro[3.5]nonane moieties as new antitubercular agents.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmcl.2018.07.005,"Design, synthesis and antimycobacterial activity of 3,5-dinitrobenzamide derivatives containing fused ring moieties.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2019.111595,Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.,1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.bmc.2019.01.022,"Design, synthesis and antimycobacterial activity of less lipophilic Q203 derivatives containing alkaline fused ring moieties.",1
1789220,10.1021/acsmedchemlett.7b00106,Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.,10.1016/j.ejmech.2018.12.071,"Synthesis and antitubercular evaluation of reduced lipophilic imidazo[1,2-a]pyridine-3-carboxamide derivatives.",1
1817518,10.1021/acs.jmedchem.1c01827,Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.,10.1021/acs.jmedchem.4c00107,"Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.",1
1817518,10.1021/acs.jmedchem.1c01827,Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.,10.1016/j.ejmech.2024.116489,Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.,1
1817518,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1021/acsmedchemlett.2c00514,Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.,1
1817518,10.1016/j.ejmech.2022.114856,Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.,10.1016/j.bmcl.2023.129575,"Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation.",1
1817518,10.1016/j.ejmech.2022.114856,Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.,10.1016/j.ejmech.2023.116074,Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC.,1
1817518,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1016/j.ejmech.2024.116590,Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.,1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1016/j.bmc.2018.05.039,"Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.",1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1016/j.ejmech.2020.112199,Design and synthesis of selective degraders of EGFR mutant.,1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1021/acs.jmedchem.1c00876,Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.,1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1039/C7MD00571G,Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors.,1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1016/j.bmc.2018.05.039,"Synthesis and biological evaluation of irreversible EGFR tyrosine kinase inhibitors containing pyrido[3,4-d]pyrimidine scaffold.",1
1817518,10.1021/acs.jmedchem.9b00722,Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer.,10.1021/acs.jmedchem.2c01434,Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.,1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1021/acsmedchemlett.8b00373,Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.,1
1817518,10.1016/j.ejmech.2022.114381,Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.,10.1016/j.ejmech.2024.116711,Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer.,1
1817518,10.1016/j.ejmech.2022.114381,Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment.,10.1016/j.ejmech.2022.114900,Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.,1
1817518,10.1021/acs.jmedchem.0c02005,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",10.1021/acs.jmedchem.3c00277,Discovery of Potent and Wild-Type-Sparing Fourth-Generation EGFR Inhibitors for Treatment of Osimertinib-Resistance NSCLC.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm020563g,"Synthesis and cyclooxygenase-2 inhibiting property of 1,5-diarylpyrazoles with substituted benzenesulfonamide moiety as pharmacophore: Preparation of sodium salt for injectable formulation.",1
173,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1016/j.bmc.2018.07.024,"Synthesis, in vitro and in vivo biological evaluation, COX-1/2 inhibition and molecular docking study of indole-N-acylhydrazone derivatives.",1
1837803,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1016/j.ejmech.2023.116054,Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy.,1
1835710,10.1021/jm5005336,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",10.1016/j.ejmech.2015.03.020,Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: success and challenges.,1
1835710,10.1021/jm5005336,"The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.",10.1016/j.ejmech.2022.114424,"Design, synthesis, and biological evaluation of novel pyrazolo [3,4-d]pyrimidine derivatives as potent PLK4 inhibitors for the treatment of TRIM37-amplified breast cancer.",1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1021/acsmedchemlett.1c00651,Proteome-wide Identification of Off-Targets of a Potent EGFR<sup>L858R/T790M</sup> Mutant Inhibitor.,1
1817518,10.1021/acs.jmedchem.3c00027,"Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer.",10.1016/j.ejmech.2023.116106,"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.",1
1817518,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1016/j.ejmech.2022.114900,Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.,1
1817518,10.1016/j.ejmech.2022.114856,Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.,10.1016/j.ejmech.2024.116590,Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.,1
1817518,10.1016/j.ejmech.2022.114889,"Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.",10.1016/j.ejmech.2023.116106,"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.",1
1817518,10.1021/acs.jmedchem.0c02005,"Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer.",10.1016/j.ejmech.2022.114889,"Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.",1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1021/acs.jmedchem.8b00346,"Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1016/j.ejmech.2023.116106,"Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.",1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1016/j.ejmech.2018.02.051,"Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs.",1
1817518,10.1016/j.ejmech.2016.12.006,"A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties.",10.1021/acs.jmedchem.2c01246,Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.,1
1817518,10.1021/acs.jmedchem.6b00403,"Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.",10.1016/j.ejmech.2017.08.061,"Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC.",1
1837803,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1021/acs.jmedchem.3c00504,Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.,1
1837803,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1016/j.ejmech.2023.115461,Recent advances in EZH2-based dual inhibitors in the treatment of cancers.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1007/s00044-011-9898-4,"Heteroaromatic analogues of 1,5-diarylpyrazole class as anti-inflammatory agents",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm000004e,"Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00365-0,"SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm9700225,"1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflammatory agents.",1
173,10.1021/jm701191z,Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.,10.1016/j.bmc.2016.11.037,"Design, synthesis and analgesic/anti-inflammatory evaluation of novel diarylthiazole and diarylimidazole derivatives towards selective COX-1 inhibitors with better gastric profile.",1
173,10.1016/S0960-894X(96)00582-3,"A new series of selective COX-2 inhibitors: 5,6-diarylthiazolo[3,2-b][1,2,4]triazoles",10.1016/s0960-894x(99)00264-4,2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(02)00739-4,Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2007.03.006,"Synthesis, docking studies and anti-inflammatory activity of 4,5,6,7-tetrahydro-2H-indazole derivatives.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00288-7,"The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1039/d1md00280e,Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm010458r,Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.,1
173,10.1021/jm030765s,"Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.",10.1021/jm049121q,"1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and highly selective cyclooxygenase-2 inhibitors.",1
173,10.1021/jm701191z,Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor.,10.1016/j.bmcl.2010.11.062,Design of novel N-phenylnicotinamides as selective cyclooxygenase-1 inhibitors.,1
173,10.1016/j.ejmech.2009.10.025,Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.,10.1021/jm100194a,Development and characterization of new inhibitors of the human and mouse hematopoietic prostaglandin D(2) synthases.,1
1927218,10.1021/acs.jmedchem.9b01809,"Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity.",10.1016/j.ejmech.2021.113967,"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.",1
1927218,10.1021/acsmedchemlett.7b00488,"Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.",10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",1
1927218,10.1021/acs.jmedchem.9b01799,"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.",10.1016/j.ejmech.2020.112703,"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).",1
1927218,10.1021/acs.jmedchem.9b01809,"Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity.",10.1021/acs.jmedchem.1c00679,"Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.",1
1927160,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1016/j.ejmech.2022.114900,Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.,1
1927160,10.1016/j.ejmech.2022.114856,Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors.,10.1016/j.ejmech.2024.116590,Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.,1
1927160,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1016/j.ejmech.2024.116590,Discovery of new cyclopropane sulfonamide derivatives as EGFR inhibitors to overcome C797S-mediated resistance and EGFR double mutation.,1
1927160,10.1021/acsmedchemlett.1c00555,Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR<sup>T790M/C797S</sup> Mutants.,10.1021/acsmedchemlett.2c00514,Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.,1
1926959,10.1016/j.bmcl.2017.06.041,"Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.",10.1016/j.ejmech.2019.03.064,"Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.",1
1926959,10.1016/j.bmcl.2017.06.041,"Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate.",10.1016/j.ejmech.2019.07.038,Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.,1
1926946,10.1021/acsmedchemlett.9b00401,Impact of Minor Structural Modifications on Properties of a Series of mTOR Inhibitors.,10.1039/d0md00227e,"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold",1
1926946,10.1016/j.bmc.2019.115215,Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway.,10.1039/d0md00227e,"Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold",1
1837808,10.1021/acsmedchemlett.6b00519,"Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.",10.1016/j.bmcl.2017.10.019,Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L.,1
1837808,10.1021/acsmedchemlett.6b00519,"Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.",10.1021/acsmedchemlett.9b00452,New Potent DOT1L Inhibitors for <i>in Vivo</i> Evaluation in Mouse.,1
1837808,10.1021/acsmedchemlett.6b00519,"Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.",10.1021/acs.jmedchem.1c02228,Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.,1
1837803,10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,10.1016/j.bmcl.2024.129726,"Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.",1
1947706,10.1016/j.ejmech.2017.05.049,Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.,10.1021/acs.jmedchem.9b01094,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,1
1947706,10.1021/acs.jmedchem.9b01094,Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.,10.1016/j.ejmech.2021.113953,"Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy.",1
1927218,10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.ejmech.2020.112703,"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).",1
1927218,10.1021/acs.jmedchem.9b01799,"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.",10.1021/acs.jmedchem.1c01305,Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.,1
1927218,10.1021/acs.jmedchem.9b01809,"Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity.",10.1021/acs.jmedchem.1c00303,"X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.",1
1927218,10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.ejmech.2023.115217,"Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.",1
1927218,10.1021/acsmedchemlett.7b00488,"Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.",10.1016/j.ejmech.2019.111985,"Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.",1
1927218,10.1021/acs.jmedchem.9b01799,"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.",10.1021/acs.jmedchem.1c00303,"X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.",1
1927218,10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.ejmech.2021.113967,"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.",1
1927218,10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",10.1021/acs.jmedchem.2c01954,"Dual Nicotinamide Phosphoribosyltransferase (NAMPT) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors for the Treatment of Drug-Resistant Nonsmall-Cell Lung Cancer.",1
1927218,10.1021/acsmedchemlett.7b00488,"Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.",10.1016/j.ejmech.2021.113967,"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.",1
1927218,10.1021/acsmedchemlett.7b00488,"Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.",10.1016/j.ejmech.2020.112703,"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).",1
1927218,10.1016/j.ejmech.2019.06.037,"Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors.",10.1016/j.bmcl.2020.127038,"Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy.",1
1927218,10.1021/acs.jmedchem.9b01799,"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.",10.1016/j.bmcl.2021.128373,Discovery of novel IDO1 inhibitors targeting the protein's apo form through scaffold hopping from holo-IDO1 inhibitor.,1
1927218,10.1021/acs.jmedchem.9b01809,"Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity.",10.1016/j.ejmech.2020.112703,"Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).",1
1927218,10.1021/acs.jmedchem.9b01799,"DNA-Encoded Library Technology-Based Discovery, Lead Optimization, and Prodrug Strategy toward Structurally Unique Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors.",10.1016/j.ejmech.2021.113967,"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.",1
1966980,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acs.jmedchem.1c01968,Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.,1
1966980,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1016/j.ejmech.2018.08.031,"Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.",1
1966691,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
1966691,10.1021/acsmedchemlett.9b00370,Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.,10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
1966691,10.1021/acs.jmedchem.5b00984,"Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.",10.1021/acsmedchemlett.9b00370,Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.,1
1965665,10.1021/acs.jmedchem.3c00525,Discovery of (<i>S</i>)-<i>N</i>-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6<i>H</i>)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.,10.1016/j.ejmech.2024.116315,Discovery of novel itaconimide-based derivatives as potent HDAC inhibitors for the efficient treatment of prostate cancer.,1
1959536,10.1021/acsmedchemlett.5b00117,Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).,10.1016/j.ejmech.2023.115486,Synthesis and evaluation of piperazinotriazoles. Discovery of a potent and orally bioavailable neurokinin-3 receptor inhibitor.,1
1954930,10.1021/acs.jmedchem.5b00742,"Novel Octahydropyrrolo[3,4-c]pyrroles Are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.",10.1039/d3md00573a,"Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.",1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.3c00136,Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges.,1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2022.128734,"Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD).",1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2015.09.074,Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.,1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.1c00847,GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer.,1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.6b01355,Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.,1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acs.jmedchem.7b01682,"Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.",1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1016/j.bmcl.2018.12.042,Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograft.,1
1947752,10.1021/acs.jmedchem.5b00054,"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.",10.1021/acsmedchemlett.0c00224,Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/s0960-894x(99)00264-4,2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm010484p,"4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a fluorine atom and identification of a potent, highly selective, and orally active COX-2 inhibitor JTE-522(1).",1
173,10.1016/j.ejmech.2012.08.046,"Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.",10.1016/j.bmc.2013.12.002,"Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(metylthio)-1,2,4-triazine as selective cyclooxygenase-2 inhibitors.",1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2015.04.023,Synthesis and QSAR study of novel anti-inflammatory active mesalazine-metronidazole conjugates.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmc.2019.115246,Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.,1
173,10.1016/j.bmcl.2020.127173,"Screening of chalcone analogs with anti-depressant, anti-inflammatory, analgesic, and COX-2-inhibiting effects.",10.1039/d1md00280e,Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1021/jm991106b,"Synthesis and biological evaluation of 3,4-diaryloxazolones: A new class of orally active cyclooxygenase-2 inhibitors.",1
173,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
173,10.1016/j.ejmech.2012.06.040,"Indole based cyclooxygenase inhibitors: synthesis, biological evaluation, docking and NMR screening.",10.1016/j.ejmech.2017.09.056,Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.,1
173,10.1016/j.bmcl.2012.08.073,Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.,10.1016/j.ejmech.2016.04.028,"2-Aryl-3-(2-morpholinoethyl)thiazolidin-4-ones: Synthesis, anti-inflammatory in vivo, cytotoxicity in vitro and molecular docking studies.",1
173,10.1016/j.ejmech.2011.10.029,"Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.",10.1016/j.ejmech.2016.04.028,"2-Aryl-3-(2-morpholinoethyl)thiazolidin-4-ones: Synthesis, anti-inflammatory in vivo, cytotoxicity in vitro and molecular docking studies.",1
173,10.1016/j.bmc.2010.06.002,Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.,10.1016/j.ejmech.2018.01.066,"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates.",1
154,10.1016/j.bmcl.2013.03.062,Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",1
1971064,10.1021/acs.jmedchem.7b00662,Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.,10.1016/j.ejmech.2024.116408,Modulators for palmitoylation of proteins and small molecules.,1
1971064,10.1021/acs.jmedchem.7b00662,Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.,10.1021/acs.jmedchem.0c01799,Small-Molecule Inhibitors Targeting the Canonical WNT Signaling Pathway for the Treatment of Cancer.,1
1966980,10.1021/acs.jmedchem.5b01073,"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.",10.1021/acsmedchemlett.8b00270,Acrylamide Functional Group Incorporation Improves Drug-like Properties: An Example with EGFR Inhibitors.,1
2077668,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1021/acs.jmedchem.3c02133,Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.,1
2077668,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115999,Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment.,1
2039216,10.1021/acs.jmedchem.8b00808,"Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.",10.1016/j.ejmech.2024.116759,A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.,1
2039216,10.1021/acs.jmedchem.8b00808,"Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.",10.1016/j.ejmech.2021.113842,"Drugs for the treatment of glaucoma: Targets, structure-activity relationships and clinical research.",1
2013100,10.1021/acs.jmedchem.9b00260,Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.,10.1021/acs.jmedchem.0c02044,Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site.,1
2013100,10.1021/acs.jmedchem.9b00260,Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.,10.1021/acsmedchemlett.3c00375,Targeting the Subpocket Enables the Discovery of Thiadiazole-Pyridazine Derivatives as Glutaminase C Inhibitors.,1
2013100,10.1021/acs.jmedchem.9b00260,Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.,10.1016/j.ejmech.2022.115014,"Design, synthesis, and biological evaluation of novel glutaminase 1 allosteric inhibitors with an alkane chain tail group.",1
2013100,10.1021/acs.jmedchem.9b00260,Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.,10.1021/acs.jmedchem.0c01398,"Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.",1
2013100,10.1021/acs.jmedchem.9b00260,Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models.,10.1016/j.ejmech.2022.114337,Discovery of novel glutaminase 1 allosteric inhibitor with 4-piperidinamine linker and aromatic heterocycles.,1
1984780,10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",10.1021/acs.jmedchem.0c01279,Synthesis and Structure-Activity Relationship of Tetra-Substituted Cyclohexyl Diol Inhibitors of Proviral Insertion of Moloney Virus (PIM) Kinases.,1
1984780,10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",10.1016/j.bmcl.2016.03.037,"Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.",1
1984780,10.1021/acs.jmedchem.5b01275,"Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.",10.1016/j.ejmech.2023.116016,Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors.,1
1980306,10.1021/acs.jmedchem.9b00322,"Design and Identification of a Novel, Functionally Subtype Selective GABA<sub>A</sub> Positive Allosteric Modulator (PF-06372865).",10.1021/acs.jmedchem.9b01312,Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABA<sub>A</sub>R) Modulators Acting at the Benzodiazepine Binding Site: An Update.,1
173,10.1124/mol.59.5.1277,Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.,10.1124/jpet.103.063370,Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.,1
173,10.1021/jm960803q,"Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).",10.1016/j.bmcl.2015.02.004,Synthesis and biological evaluation of pyrazolylthiazole carboxylic acids as potent anti-inflammatory-antimicrobial agents.,1
173,10.1016/j.ejmech.2012.08.046,"Molecular modeling, synthesis and screening of some new 4-thiazolidinone derivatives with promising selective COX-2 inhibitory activity.",10.1016/j.bmcl.2017.05.017,Synthesis of methanesulphonamido-benzimidazole derivatives as gastro-sparing antiinflammatory agents with antioxidant effect.,1
2095838,10.1021/acs.jmedchem.8b00854,"Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).",10.1021/acs.jmedchem.2c01618,"Synthesis, Structure-Activity Relationships, and <i>In Vivo</i> Evaluation of Novel C-17 Amine Derivatives Based on GSK3640254 as HIV-1 Maturation Inhibitors with Broad Spectrum Activity.",1
2095838,10.1021/acs.jmedchem.8b00854,"Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).",10.1016/j.bmcl.2021.127823,Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition.,1
2095838,10.1021/acs.jmedchem.8b00854,"Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).",10.1021/acsmedchemlett.3c00279,Sub-stoichiometric Modulation of Viral Targets-Potent Antiviral Agents That Exploit Target Vulnerability.,1
2095675,10.1016/j.ejmech.2021.113951,Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.,10.1016/j.ejmech.2023.115762,"Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.",1
2095675,10.1021/acs.jmedchem.0c00688,Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.,10.1016/j.ejmech.2023.115762,"Emerging opportunities to treat idiopathic pulmonary fibrosis: Design, discovery, and optimizations of small-molecule drugs targeting fibrogenic pathways.",1
2095675,10.1016/j.ejmech.2021.113951,Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.,10.1016/j.ejmech.2022.114307,"Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.",1
2089439,10.1021/acsmedchemlett.6b00005,"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
2089439,10.1021/acsmedchemlett.6b00005,"Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR.",10.1016/j.ejmech.2022.114971,Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents.,1
2085515,10.1039/C6MD00539J,Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators.,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",1
2085515,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1039/C6MD00539J,Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators.,1
2085515,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acsmedchemlett.0c00333,"Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety Profiles.",1
2085515,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",1
2085515,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.6b01433,"Asymmetric Hydroboration Approach to the Scalable Synthesis of ((1R,3S)-1-Amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) as a Potent S1P Receptor Modulator.",1
2085515,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",10.1021/acsmedchemlett.0c00333,"Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety Profiles.",1
2085515,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",10.1021/acs.jmedchem.0c01109,"Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.",1
2085515,10.1021/acsmedchemlett.5b00448,Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.,10.1021/acs.jmedchem.0c01109,"Bicyclic Ligand-Biased Agonists of S1P: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles.",1
2126088,10.1016/j.ejmech.2020.112277,Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).,10.1016/j.ejmech.2023.115889,Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,1
2126088,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,10.1016/j.ejmech.2021.113482,"Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.",1
2126088,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,10.1016/j.ejmech.2023.115889,Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1.,1
2126088,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,10.1021/acsmedchemlett.9b00611,Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.,1
2109780,10.1021/acs.jmedchem.6b01127,Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).,10.1021/acs.jmedchem.1c00104,Discovery and <i>In Vivo</i> Anti-inflammatory Activity Evaluation of a Novel Non-peptidyl Non-covalent Cathepsin C Inhibitor.,1
2109780,10.1021/acs.jmedchem.6b01127,Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).,10.1016/j.ejmech.2022.114368,"Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: Design, structure-activity relationship and anti-inflammatory activity in vivo.",1
2109780,10.1021/acs.jmedchem.6b01127,Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).,10.1021/acs.jmedchem.0c00776,Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?,1
2109780,10.1021/acs.jmedchem.6b01127,Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).,10.1016/j.bmcl.2021.128202,Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy.,1
2099025,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2023.115618,Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.,1
2099025,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2022.114654,"Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.",1
2099025,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1021/acs.jmedchem.2c00308,Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.,1
2099025,10.1016/j.ejmech.2022.114601,Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor.,10.1016/j.ejmech.2023.115618,Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.,1
2099025,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2022.114899,Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.,1
2095838,10.1021/acs.jmedchem.8b00854,"Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).",10.1021/acs.jmedchem.2c00879,"The Discovery of GSK3640254, a Next-Generation Inhibitor of HIV-1 Maturation.",1
2095838,10.1021/acs.jmedchem.8b00854,"Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 R,3a S,5a R,5b R,7a R,11a S,11b R,13a R,13b R)-3a-((2-(1,1-Dioxidothiomorpholino)ethyl)amino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1 H-cyclopenta[ a]chrysen-9-yl)benzoic Acid (GSK3532795, BMS-955176).",10.1021/acsmedchemlett.8b00656,Second Generation Inhibitors of HIV-1 Maturation.,1
2196387,10.1021/acsmedchemlett.0c00294,"Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer.",10.1016/j.ejmech.2022.114519,Design and development of a novel series of oral bivalent BET inhibitors with potent anticancer activities.,1
2193796,10.1021/acsmedchemlett.6b00238,Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.,10.1016/j.ejmech.2018.11.072,Targeting the immunity protein kinases for immuno-oncology.,1
2193796,10.1021/acsmedchemlett.6b00238,Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate.,10.1021/acs.jmedchem.8b01298,Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.,1
2141043,10.1016/j.bmcl.2020.127004,Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B.,10.1016/j.ejmech.2022.114595,Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective.,1
2141043,10.1016/j.bmcl.2020.127004,Multi-step parallel synthesis enabled optimization of benzofuran derivatives as pan-genotypic non-nucleoside inhibitors of HCV NS5B.,10.1016/j.bmc.2022.116699,Recent advancement in small molecules as HCV inhibitors.,1
2133503,10.1021/acs.jmedchem.8b00690,"Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).",10.1016/j.ejmech.2023.115334,"Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.",1
2133503,10.1021/acs.jmedchem.8b00690,"Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).",10.1021/acs.jmedchem.3c00963,Development of MPS1 Inhibitors: Recent Advances and Perspectives.,1
2133503,10.1021/acs.jmedchem.8b00690,"Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4 H-1,2,4-triazol-3-yl)phenyl)-6-methyl- N8-neopentylpyrido[3,4- d]pyrimidine-2,8-diamine (BOS172722).",10.1016/j.ejmech.2024.116504,Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1021/acsmedchemlett.9b00611,Discovery of CNS-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1016/j.ejmech.2020.113114,Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1016/j.bmcl.2017.12.026,Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1016/j.ejmech.2020.112277,Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1039/d3md00663h,Discovery of benzoheterocyclic-substituted amide derivatives as apoptosis signal-regulating kinase 1 (ASK1) inhibitors.,1
2126088,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,10.1016/j.ejmech.2020.113114,Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis.,1
2126088,10.1016/j.bmcl.2017.02.079,Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy.,10.1016/j.ejmech.2023.115889,Small-molecule inhibitors targeting apoptosis signal-regulated kinase 1.,1
2126088,10.1021/acs.jmedchem.9b01206,Rational Design and Optimization of a Novel Class of Macrocyclic Apoptosis Signal-Regulating Kinase 1 Inhibitors.,10.1016/j.ejmech.2020.112277,Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal-regulating kinase 1 (ASK1).,1
2205527,10.1016/j.ejmech.2021.113622,Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.,10.1016/j.ejmech.2023.115292,Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.,1
2205527,10.1016/j.ejmech.2020.112527,A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.,10.1016/j.ejmech.2021.113157,The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.,1
2205527,10.1021/acsmedchemlett.0c00521,Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.,10.1021/acsmedchemlett.1c00326,Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.,1
2205527,10.1016/j.ejmech.2021.113863,Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.,10.1016/j.ejmech.2022.114857,Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2.,1
2205527,10.1016/j.ejmech.2021.113863,Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.,10.1016/j.ejmech.2024.116128,"Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.",1
2197829,10.1021/acs.jmedchem.9b00362,"Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.",10.1016/j.ejmech.2023.115464,Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.,1
2197829,10.1021/acs.jmedchem.1c00019,Discovery and Optimization of 2<i>H</i>-1λ<sup>2</sup>-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer.,10.1016/j.ejmech.2023.115464,Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.,1
2197822,10.1021/acs.jmedchem.9b00662,"Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.",10.1021/acsmedchemlett.0c00004,"Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.",1
2197822,10.1021/acs.jmedchem.9b00662,"Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1.",10.1016/j.ejmech.2022.114524,"Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.",1
2197775,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2016.09.022,Synthesis of novel 15-membered 8a-azahomoerythromycin A acylides: Consequences of structural modification at the C-3 and C-6 position on antibacterial activity.,1
2197775,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.ejmech.2019.02.073,"Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.",1
2197775,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1016/j.bmc.2016.01.055,Synthesis and antibacterial evaluation of novel 4″-glycyl linked quinolyl-azithromycins with potent activity against macrolide-resistant pathogens.,1
2197775,10.1021/ml100253p,Discovery of 4''-ether linked azithromycin-quinolone hybrid series: influence of the central linker on the antibacterial activity.,10.1021/ml500279k,Synthesis and Structure-Activity Relationships of α-Amino-γ-lactone Ketolides: A Novel Class of Macrolide Antibiotics.,1
2197741,10.1021/acs.jmedchem.9b00426,"Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.",10.1016/j.ejmech.2022.114187,Discovery of a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase: Structural activity relationship and antitumor activity both in vitro and in vivo.,1
2197356,10.1021/acs.jmedchem.1c01123,A Novel Anticancer Stem Cell Compound Derived from Pleuromutilin Induced Necroptosis of Melanoma Cells.,10.1016/j.ejmech.2022.114643,Discovery of a novel Pleuromutilin derivative as anti-IPF lead compound via high-throughput assay.,1
2196387,10.1021/acsmedchemlett.9b00474,"Pharmacokinetics-Driven Optimization of 7-Methylimidazo[1,5-<i>a</i>]pyrazin-8(7H)-one as Novel BRD4 Inhibitors.",10.1016/j.bmc.2021.116133,"Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family.",1
2213203,10.1021/acs.jmedchem.7b01171,Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).,10.1021/acs.jmedchem.8b00173,Factor XIa Inhibitors as New Anticoagulants.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.ejmech.2024.116304,Scaffold hopping derived novel benzoxazepinone receptor-interacting protein kinase 1 (RIP1) inhibitors as anti-necroptosis agents: Anti-inflammatory effect in systemic inflammatory response syndrome (SIRS) and epilepsy.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1021/acs.jmedchem.7b01647,"Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships.",1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.bmcl.2024.129643,"Design, synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors.",1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1021/acsmedchemlett.9b00108,Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.bmc.2023.117385,Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.ejmech.2021.113484,Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1021/acs.jmedchem.3c02102,From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.bmc.2022.116686,"Discovery of novel 2,8-diazaspiro[4.5]decan-1-one derivatives as potent RIPK1 kinase inhibitors.",1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.ejmech.2024.116269,Small-molecule agents for treating skin diseases.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.ejmech.2023.116076,"Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.",1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1021/acs.jmedchem.2c02067,Structure-Based Design of Novel Alkynyl Thio-Benzoxazepinone Receptor-Interacting Protein Kinase-1 Inhibitors: Extending the Chemical Space from the Allosteric to ATP Binding Pockets.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.ejmech.2022.114345,Investigation on the chemical space of the substituted triazole thio-benzoxazepinone RIPK1 inhibitors.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1016/j.bmc.2024.117611,Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors.,1
2211775,10.1021/acs.jmedchem.6b01751,Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.,10.1021/acs.jmedchem.2c01518,Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.,1
2205527,10.1016/j.ejmech.2020.112527,A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.,10.1016/j.ejmech.2023.115831,"Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.2c01070,"Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.",1
2224818,10.1021/acs.jmedchem.9b00972,A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.,10.1021/acs.jmedchem.2c01070,"Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions.",1
2219973,10.1021/acs.jmedchem.5b01582,A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.,10.1021/acs.jmedchem.7b01731,"The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.",1
2213203,10.1021/acs.jmedchem.7b01171,Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).,10.1021/acs.jmedchem.2c02130,Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.,1
154,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",10.1021/acs.jmedchem.6b00212,Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening.,1
154,10.1016/j.bmcl.2013.03.062,Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.,10.1021/acs.jmedchem.5b01930,Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,1
154,10.1016/j.bmcl.2013.03.062,Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.,10.1016/j.bmcl.2017.12.052,Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.,1
154,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",10.1021/acs.jmedchem.7b01530,"Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.",1
154,10.1021/acs.jmedchem.6b01427,Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).,10.1021/acs.jmedchem.7b01530,"Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.",1
154,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",10.1021/acs.jmedchem.6b01427,Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2).,1
154,10.1016/j.bmcl.2013.03.062,Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors.,10.1021/acs.jmedchem.6b00282,Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.,1
154,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",10.1021/acs.jmedchem.5b01930,Discovery of Potent and Orally Active Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors as a Potential Therapy for Diabetic Macular Edema.,1
154,10.1016/j.bmcl.2017.12.052,Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis.,10.1021/acs.jmedchem.0c00372,Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.,1
154,10.1021/acs.jmedchem.5b01024,"Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors.",10.1021/acs.jmedchem.6b00282,Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.,1
148,10.1016/j.bmc.2010.01.076,Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids.,10.1016/j.bmc.2012.07.021,Natural product coumarins that inhibit human carbonic anhydrases.,1
148,10.1021/np000306j,"In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.",10.1128/aac.01175-08,In vitro and in vivo properties of ellagic acid in malaria treatment.,1
2265783,10.1021/acs.jmedchem.0c01161,"Discovery of Clinical Candidate (5-(3-(4-Chlorophenoxy)prop-1-yn-1-yl)-3-hydroxypicolinoyl)glycine, an Orally Bioavailable Prolyl Hydroxylase Inhibitor for the Treatment of Anemia.",10.1021/acs.jmedchem.3c00231,Preferred Conformation-Guided Discovery of Potent and Orally Active HIF Prolyl Hydroxylase 2 Inhibitors for the Treatment of Anemia.,1
2260709,10.1021/acs.jmedchem.9b00058,A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.,10.1021/acs.jmedchem.0c01773,Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors.,1
2226054,10.1021/acs.jmedchem.7b00974,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",10.1021/acs.jmedchem.1c01305,Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy.,1
2226054,10.1021/acs.jmedchem.7b00974,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",10.1021/acs.jmedchem.9b01549,"Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors.",1
2226054,10.1021/acs.jmedchem.7b00974,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",10.1021/acs.jmedchem.4c01360,Structural Insights into Protein-Inhibitor Interactions in Human Tryptophan Dioxygenase.,1
2226054,10.1021/acs.jmedchem.7b00974,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",10.1021/acs.jmedchem.1c00679,"Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.",1
2226054,10.1021/acs.jmedchem.7b00974,"Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate.",10.1021/acsmedchemlett.0c00004,"Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.",1
2225368,10.1021/acs.jmedchem.8b01308,Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.,10.1016/j.bmcl.2022.128680,"Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.",1
2225368,10.1021/acs.jmedchem.8b01308,Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.,10.1021/acs.jmedchem.2c00922,"Discovery of Hexahydrofuro[3,2-<i>b</i>]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.8b01262,"Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acsmedchemlett.9b00333,"Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.",1
2224818,10.1021/acs.jmedchem.9b00972,A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.,10.1021/acsmedchemlett.9b00333,"Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2023.116109,"Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1016/j.ejmech.2021.114039,Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review.,1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.9b00525,"(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.",1
2224818,10.1021/acs.jmedchem.7b00930,"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.",10.1021/acs.jmedchem.9b00972,A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor.,1
146,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
2323131,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.bmc.2024.117651,Research progress of LSD1-based dual-target agents for cancer therapy.,1
2323131,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1021/acs.jmedchem.3c02133,Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.,1
2323131,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115367,"Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors.",1
2323131,10.1021/acs.jmedchem.1c00966,"Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.",10.1016/j.ejmech.2023.115999,Exploring the potential of histone demethylase inhibition in multi-therapeutic approaches for cancer treatment.,1
2297579,10.1021/acs.jmedchem.8b00588,Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses.,10.1016/j.ejmech.2021.114065,Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists.,1
2297579,10.1021/acs.jmedchem.8b00588,Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses.,10.1016/j.ejmech.2024.116269,Small-molecule agents for treating skin diseases.,1
2297579,10.1021/acs.jmedchem.8b00588,Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses.,10.1021/acs.jmedchem.1c01436,"Discovery of Chromane-6-Sulfonamide Derivative as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.",1
2289800,10.1021/acs.jmedchem.7b01714,Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.,10.1016/j.ejmech.2018.11.072,Targeting the immunity protein kinases for immuno-oncology.,1
2289800,10.1021/acs.jmedchem.7b01714,Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.,10.1016/j.bmc.2021.116186,"Design, synthesis and biological evaluation of imidazopyridazine derivatives containing isoquinoline group as potent MNK1/2 inhibitors.",1
2289800,10.1021/acs.jmedchem.7b01714,Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.,10.1039/d3md00121k,Medicinal chemistry approaches to target the MNK-eIF4E axis in cancer.,1
2289800,10.1021/acs.jmedchem.7b01714,Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.,10.1021/acsmedchemlett.2c00442,"Using Imidazo[2,1-<i>b</i>][1,3,4]thiadiazol Skeleton to Design and Synthesize Novel MNK Inhibitors.",1
2289800,10.1021/acs.jmedchem.7b01714,Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.,10.1021/acs.jmedchem.3c02008,Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.,1
2285640,10.1039/C7MD00637C,Recent updates in the discovery and development of novel antimalarial drug candidates.,10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
2272109,10.18632/oncotarget.4919,The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.,10.1016/j.ejmech.2018.03.075,"Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors.",1
2272109,10.18632/oncotarget.4919,The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.,10.1021/acs.jmedchem.5b01938,Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).,1
2335281,10.1021/acs.jmedchem.1c02071,Discovery of a Novel Series of Imipridone Compounds as <i>Homo sapiens</i> Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.,10.1021/acs.jmedchem.4c00798,Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.,1
2335186,10.1021/acs.jmedchem.2c00857,Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PA<sub>N</sub> Endonuclease Inhibitors.,10.1016/j.ejmech.2024.116639,Design and synthesis of 7-membered lactam fused hydroxypyridinones as potent metal binding pharmacophores (MBPs) for inhibiting influenza virus PA<sub>N</sub> endonuclease.,1
2335186,10.1021/acs.jmedchem.1c01527,Lead Optimization of Influenza Virus RNA Polymerase Inhibitors Targeting PA-PB1 Interaction.,10.1021/acs.jmedchem.2c00857,Identification of N- and C-3-Modified Laudanosoline Derivatives as Novel Influenza PA<sub>N</sub> Endonuclease Inhibitors.,1
2323895,10.1039/C7MD00637C,Recent updates in the discovery and development of novel antimalarial drug candidates.,10.1016/j.bmc.2023.117339,Recent developments in antimalarial drug discovery.,1
148,10.1021/jm00040a015,Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors.,10.1016/s0960-894x(97)10197-4,DNA gyrase inhibitory activity of ellagic acid derivatives.,1
148,10.1016/j.ejmech.2016.07.073,Inhibitor screening and enzymatic activity determination for autophagy target Atg4B using a gel electrophoresis-based assay.,10.1016/j.ejmech.2019.05.086,Identification of benzo[cd]indol-2(1H)-ones as novel Atg4B inhibitors via a structure-based virtual screening and a novel AlphaScreen assay.,1
148,10.1021/np000306j,"In vitro antiplasmodial activity of extracts of Tristaniopsis species and identification of the active constituents: ellagic acid and 3,4,5-trimethoxyphenyl-(6'-O-galloyl)-O-beta-D-glucopyranoside.",10.1128/aac.00544-08,Compounds structurally related to ellagic acid show improved antiplasmodial activity.,1
146,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2023.115502,Sulfur-fluoride exchange (SuFEx)-enabled lead discovery of AChE inhibitors by fragment linking strategies.,1
146,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2016.08.034,Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB.,1
146,10.1016/j.ejmech.2021.113735,Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.,10.1016/j.ejmech.2022.114333,"Novel benzothiazole‒urea hybrids: Design, synthesis and biological activity as potent anti-bacterial agents against MRSA.",1
146,10.1021/jm00070a005,Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
146,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
146,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
146,10.1021/acs.jmedchem.9b00010,Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.,10.1016/j.ejmech.2021.113202,Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules.,1
146,10.1021/jm00073a014,Synthesis and antibacterial activity of a new series of tetracyclic pyridone carboxylic acids.,10.1016/j.ejmech.2018.08.095,Recent developments of quinolone-based derivatives and their activities against Escherichia coli.,1
146,10.1016/j.bmc.2014.10.016,An efficient synthesis and biological screening of benzofuran  and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis  DNA GyrB inhibition.,10.1016/j.ejmech.2020.112967,An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.,1
2335581,10.1021/acs.jmedchem.9b01423,"Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.",10.1016/j.ejmech.2023.115464,Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.,1
2335581,10.1021/acs.jmedchem.9b01423,"Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.",10.1016/j.ejmech.2024.116759,A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.,1
2335453,10.1021/acs.jmedchem.1c00690,Structure-Based Optimization of 3-Phenyl-<i>N</i>-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors.,10.1021/acs.jmedchem.3c01998,Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.,1
2335434,10.1021/acs.jmedchem.6b01315,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",10.1021/acs.jmedchem.2c00047,Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.,1
2335434,10.1021/acs.jmedchem.6b01315,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",10.1016/j.ejmech.2024.116470,Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships.,1
2335434,10.1021/acs.jmedchem.6b01315,"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.",10.1021/acsmedchemlett.0c00045,"Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time.",1
2335429,10.1021/acsmedchemlett.2c00219,Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic Properties.,10.1016/j.ejmech.2023.115254,"Recent updates on 1,2,3-triazole-containing hybrids with in vivo therapeutic potential against cancers: A mini-review.",1
2335425,10.1021/acs.jmedchem.2c00100,"Structure-Based Discovery and Optimization of Furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.",10.1021/acs.jmedchem.3c01028,Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.,1
2335425,10.1021/acs.jmedchem.2c00100,"Structure-Based Discovery and Optimization of Furo[3,2-<i>c</i>]pyridin-4(5<i>H</i>)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors.",10.1021/acs.jmedchem.3c02104,Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.,1
2335413,10.1021/acs.jmedchem.2c00660,Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,10.1021/acs.jmedchem.3c01787,Discovery of Selective and Orally Available Galectin-1 Inhibitors.,1
2335413,10.1021/acs.jmedchem.2c00660,Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,10.1021/acsmedchemlett.3c00261,Discovery of <i>N</i>-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Galectin-3 and Galectin-8 C-Terminal Domain Inhibitors.,1
2335413,10.1021/acs.jmedchem.2c00660,Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,10.1021/acs.jmedchem.4c00485,Discovery of the Selective and Orally Available Galectin-1 Inhibitor GB1908 as a Potential Treatment for Lung Cancer.,1
2335413,10.1021/acs.jmedchem.2c00660,Discovery and Optimization of the First Highly Effective and Orally Available Galectin-3 Inhibitors for Treatment of Fibrotic Disease.,10.1016/j.bmc.2024.117638,"Identification of benzothiazole derived monosaccharides as potent, selective, and orally bioavailable inhibitors of human and mouse galectin-3; a rare example of using a S···O binding interaction for drug design.",1
2335281,10.1021/acs.jmedchem.1c02071,Discovery of a Novel Series of Imipridone Compounds as <i>Homo sapiens</i> Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.,10.1021/acs.jmedchem.4c00338,Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.,1
2335281,10.1021/acs.jmedchem.3c01950,Discovery of a Novel Series of <i>Homo sapiens</i> Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.,10.1021/acs.jmedchem.4c00798,Discovery of Dehydrogenated Imipridone Derivatives as Activators of Human Caseinolytic Protease P.,1
2335281,10.1021/acs.jmedchem.1c02071,Discovery of a Novel Series of Imipridone Compounds as <i>Homo sapiens</i> Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo.,10.1021/acs.jmedchem.3c01950,Discovery of a Novel Series of <i>Homo sapiens</i> Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1021/acs.jmedchem.2c00308,Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.,1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1021/acs.jmedchem.3c00899,"Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.",1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2024.116640,Discovery of novel indazole derivatives as second-generation TRK inhibitors.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2022.114899,Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1021/acs.jmedchem.2c01361,Targeting Gatekeeper Mutations for Kinase Drug Discovery.,1
2335598,10.1021/acs.jmedchem.3c00899,"Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.",10.1016/j.ejmech.2024.116640,Discovery of novel indazole derivatives as second-generation TRK inhibitors.,1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1016/j.ejmech.2023.115618,Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2022.114451,Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects in vitro and in vivo.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2023.115291,"Design, synthesis and biological evaluation of novel indolin-2-one derivatives as potent second-generation TRKs inhibitors.",1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1021/acs.jmedchem.3c00899,"Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.",1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1016/j.ejmech.2022.114899,Switch type I to type II TRK inhibitors for combating clinical resistance induced by xDFG mutation for cancer therapy.,1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1021/acs.jmedchem.1c01539,Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.,1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2023.115618,Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.,1
2335598,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1016/j.ejmech.2022.114654,"Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.",1
2335598,10.1021/acs.jmedchem.1c01597,"Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6<i>H</i>-pyrimido[5,4-<i>b</i>][1,4]oxazin-7(8<i>H</i>)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants.",10.1016/j.ejmech.2022.114654,"Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance.",1
2377594,10.1021/acsmedchemlett.9b00274,Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).,10.1021/acs.jmedchem.9b01247,Discovery of GSK3527497: A Candidate for the Inhibition of Transient Receptor Potential Vanilloid-4 (TRPV4).,1
2377594,10.1021/acsmedchemlett.9b00274,Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).,10.1021/acsmedchemlett.1c00406,"Identification, Synthesis, and Characterization of a Major Circulating Human Metabolite of TRPV4 Antagonist GSK2798745.",1
2376423,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1016/j.ejmech.2023.115334,"Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.",1
2376423,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1021/acs.jmedchem.3c00963,Development of MPS1 Inhibitors: Recent Advances and Perspectives.,1
2363094,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1016/j.ejmech.2023.115334,"Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.",1
2363094,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1021/acs.jmedchem.1c01165,Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.,1
2363094,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1021/acs.jmedchem.3c00963,Development of MPS1 Inhibitors: Recent Advances and Perspectives.,1
2363094,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1016/j.ejmech.2024.116504,Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents.,1
2346268,10.1021/acs.jmedchem.3c01338,"Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies.",10.1021/acs.jmedchem.4c01120,"Identification of 6-Anilino Imidazo[4,5-<i>c</i>]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.",1
2346268,10.1021/acsmedchemlett.2c00172,Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8<i>H</i>-purin-8-one Inhibitors of DNA-PK.,10.1021/acs.jmedchem.4c01120,"Identification of 6-Anilino Imidazo[4,5-<i>c</i>]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.",1
2341613,10.1021/acs.jmedchem.0c00182,"Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.",10.1016/j.ejmech.2020.112653,Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses.,1
2341112,10.1021/acs.jmedchem.9b02035,"Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.",10.1021/acs.jmedchem.3c00963,Development of MPS1 Inhibitors: Recent Advances and Perspectives.,1
2336109,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1021/acs.jmedchem.1c01539,Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.,1
2336109,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1016/j.ejmech.2023.115618,Recent advances in the discovery of tropomyosin receptor kinases TRKs inhibitors: A mini review.,1
2336109,10.1016/j.ejmech.2021.113673,Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization.,10.1021/acs.jmedchem.3c00899,"Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.",1
2335637,10.1021/acs.jmedchem.8b00808,"Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.",10.1016/j.ejmech.2024.116759,A comprehensive review of new small molecule drugs approved by the FDA in 2022: Advance and prospect.,1
115,10.1021/acs.jmedchem.5b00904,"Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.",10.1016/j.bmcl.2016.10.078,Novel 5-substituted 3-hydroxyphenyl and 3-nitrophenyl ethers of S-prolinol as α4β2-nicotinic acetylcholine receptor ligands.,1
2486781,10.1021/acs.jmedchem.0c01170,"Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.",10.1016/j.ejmech.2024.116830,Discovery of novel substituted pyridine carboxamide derivatives as potent allosteric SHP2 inhibitors.,1
2486008,10.1021/acs.jmedchem.8b01695,"Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P) Modulator Advanced into Clinical Trials.",10.1021/acsmedchemlett.0c00333,"Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P<sub>1</sub>) Modulators: Optimization of the PK, PD, and Safety Profiles.",1
2483061,10.1021/acs.jmedchem.0c00374,"Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes.",10.1016/j.ejmech.2024.116464,Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).,1
97,10.1016/j.bmcl.2014.02.066,Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.,10.1016/j.bmcl.2015.10.012,Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1021/jm0704696,Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine.,1
115,10.1021/acs.jmedchem.5b00904,"Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.",10.1021/acs.jmedchem.0c01150,"Modifications at C(5) of 2-(2-Pyrrolidinyl)-Substituted 1,4-Benzodioxane Elicit Potent α4β2 Nicotinic Acetylcholine Receptor Partial Agonism with High Selectivity over the α3β4 Subtype.",1
115,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm300212s,Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1021/jm201301h,Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,1
115,10.1021/acs.jmedchem.5b00904,"Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.",10.1016/j.ejmech.2016.10.048,"From pyrrolidinyl-benzodioxane to pyrrolidinyl-pyridodioxanes, or from unselective antagonism to selective partial agonism at α4β2 nicotinic acetylcholine receptor.",1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1021/jm3006542,"Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders.",1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1016/j.bmcl.2005.06.053,3-(2-Aminoethyl)pyridine analogs as alpha4beta2 nicotinic cholinergic receptor ligands.,1
115,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
97,10.1021/jm0307842,Alpha1-adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety.,10.1016/j.bmc.2008.04.058,"Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin.",1
97,10.1021/jm980285e,"Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.",10.1016/j.ejmech.2011.04.032,"Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-adrenergic receptor blocking properties.",1
2755078,10.1021/acs.jmedchem.2c00117,"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.",10.1016/j.ejmech.2023.115491,The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm400408r,Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.,1
2261,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1021/jm0104825,"New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.",1
2261,10.1021/jm9704457,Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.,10.1021/jm991005d,New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.,1
2261,10.1021/jm0309811,"Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.",10.1021/jm058225d,Designed multiple ligands. An emerging drug discovery paradigm.,1
2261,10.1016/j.bmc.2008.06.030,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",10.1016/j.bmc.2011.12.019,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,1
2261,10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,10.1021/acs.jmedchem.8b01096,Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics.,1
2261,10.1016/j.bmcl.2020.127053,Identification of C10 nitrogen-containing aporphines with dopamine D<sub>1</sub> versus D<sub>5</sub> receptor selectivity.,10.1016/j.bmc.2020.115578,Structural manipulation of aporphines via C10 nitrogenation leads to the identification of new 5-HT<sub>7A</sub>R ligands.,1
2261,10.1021/jm401958n,Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,10.1016/j.bmcl.2015.09.045,Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics.,1
97,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1021/jm8003152,Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.,1
2464781,10.1016/j.ejmech.2022.114907,"Identification of novel Pyrrolo[2,3-d]Pyrimidine-based KRAS G12C inhibitors with anticancer effects.",10.1016/j.ejmech.2023.115698,Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways.,1
2453082,10.1016/j.bmcl.2021.128149,Discovery and optimization of selective RET inhibitors via scaffold hopping.,10.1021/acs.jmedchem.3c02319,Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.,1
2453082,10.1016/j.bmcl.2021.128149,Discovery and optimization of selective RET inhibitors via scaffold hopping.,10.1016/j.ejmech.2022.114862,1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.,1
97,10.1021/jm0307842,Alpha1-adrenoceptor antagonists. 6. Structural optimization of pyridazinone-arylpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moiety.,10.1016/j.bmcl.2008.07.084,Synthesis and biological affinity of new imidazo- and indol-arylpiperazine derivatives: further validation of a pharmacophore model for alpha(1)-adrenoceptor antagonists.,1
97,10.1021/jm7015683,Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).,10.1093/toxsci/kft176,A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.,1
115,10.1021/jm9910627,"Improving the nicotinic pharmacophore with a series of (Isoxazole)methylene-1-azacyclic compounds: synthesis, structure-activity relationship, and molecular modeling.",10.1021/jm025613w,"Synthesis, nicotinic acetylcholine receptor binding affinities, and molecular modeling of constrained epibatidine analogues.",1
115,10.1021/jm201301h,Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,10.1021/ml3002715,From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.,1
